bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
Perfusion is an umlsterm, Peptids is an umlsterm, Endothelin-1 is an umlsterm, ANP is an umlsterm, Haemodynamik is an umlsterm, Patienten is an umlsterm, angeborenen is an umlsterm, pulmonaler Hypertension is an umlsterm, Stickstoffmonoxid is an umlsterm, NO - Synthase is an umlsterm, ANP is an umlsterm, Guanosinmonophosphat is an umlsterm, Sauerstoff is an umlsterm, Patienten is an umlsterm, pulmonaler Hypertension is an umlsterm, Patienten is an umlsterm, pulmonaler Hypertension is an umlsterm, Feedback - Mechanismus is an umlsterm, ANP is an umlsterm, ET-1 is an umlsterm, ANP is an umlsterm, Vasodilatation is an umlsterm, Sauerstoff is an umlsterm	ZfuerKardiologie.00890100.ger.abstr_task1	Sentence: Die pulmonale Perfusion wird von vasokonstriktorischen und vasodilatatorischen Faktoren reguliert . Ziel der Studie war es , den Einfluss des vasokonstriktorischen Peptids Endothelin-1 ( ET-1) und des vasodilatatorischen atrialen natriuretischen Peptis ( ANP ) auf die pulmonale Haemodynamik bei Patienten mit angeborenen Shuntvitien und konsekutiver pulmonaler Hypertension zu untersuchen . Sowohl Stickstoffmonoxid ( NO ) , das von einer konstitutiven endothelialen NO-Synthase ( eNOS ) gebildet wird , als auch ANP entfalten ihre vasodilatatorische Wirkung durch den intrazellulaeren Botenstoff ( second messenger zyklisches Guanosinmonophosphat ( ) cGMP ) . Sauerstoff ist ein Kofaktor der eNOS und ein bedeutsamer pulmonaler Vasodilatator bei Patienten mit pulmonaler Hypertension . Es wurde ueberprueft , ob bei Patienten mit pulmonaler Hypertension ein Feedback-Mechanismus zwischen ANP und ET-1 besteht und inwieweit die cGMP-Produktion von der Stimulation durch ANP abhaengt . Darueber hinaus sollte untersucht werden , ob das Phaenomen einer pulmonalen Vasodilatation durch Sauerstoff mit Aenderungen der ET-1- oder cGMP-Plasmaspiegel einhergeht . Instructions: please typing these entity words according to sentence: Perfusion, Peptids, Endothelin-1, ANP, Haemodynamik, Patienten, angeborenen, pulmonaler Hypertension, Stickstoffmonoxid, NO - Synthase, ANP, Guanosinmonophosphat, Sauerstoff, Patienten, pulmonaler Hypertension, Patienten, pulmonaler Hypertension, Feedback - Mechanismus, ANP, ET-1, ANP, Vasodilatation, Sauerstoff Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die pulmonale Perfusion wird von vasokonstriktorischen und vasodilatatorischen Faktoren reguliert . Ziel der Studie war es , den Einfluss des vasokonstriktorischen Peptids Endothelin-1 ( ET-1) und des vasodilatatorischen atrialen natriuretischen Peptis ( ANP ) auf die pulmonale Haemodynamik bei Patienten mit angeborenen Shuntvitien und konsekutiver pulmonaler Hypertension zu untersuchen . Sowohl Stickstoffmonoxid ( NO ) , das von einer konstitutiven endothelialen NO-Synthase ( eNOS ) gebildet wird , als auch ANP entfalten ihre vasodilatatorische Wirkung durch den intrazellulaeren Botenstoff ( second messenger zyklisches Guanosinmonophosphat ( ) cGMP ) . Sauerstoff ist ein Kofaktor der eNOS und ein bedeutsamer pulmonaler Vasodilatator bei Patienten mit pulmonaler Hypertension . Es wurde ueberprueft , ob bei Patienten mit pulmonaler Hypertension ein Feedback-Mechanismus zwischen ANP und ET-1 besteht und inwieweit die cGMP-Produktion von der Stimulation durch ANP abhaengt . Darueber hinaus sollte untersucht werden , ob das Phaenomen einer pulmonalen Vasodilatation durch Sauerstoff mit Aenderungen der ET-1- oder cGMP-Plasmaspiegel einhergeht .	[ "Die", "pulmonale", "Perfusion", "wird", "von", "vasokonstriktorischen", "und", "vasodilatatorischen", "Faktoren", "reguliert", ".", "Ziel", "der", "Studie", "war", "es", ",", "den", "Einfluss", "des", "vasokonstriktorischen", "Peptids", "Endothelin-1", "(", "ET-1", ")", "und", "des", "vasodilatatorischen", "atrialen", "natriuretischen", "Peptis", "(", "ANP", ")", "auf", "die", "pulmonale", "Haemodynamik", "bei", "Patienten", "mit", "angeborenen", "Shuntvitien", "und", "konsekutiver", "pulmonaler", "Hypertension", "zu", "untersuchen", ".", "Sowohl", "Stickstoffmonoxid", "(", "NO", ")", ",", "das", "von", "einer", "konstitutiven", "endothelialen", "NO", "-", "Synthase", "(", "eNOS", ")", "gebildet", "wird", ",", "als", "auch", "ANP", "entfalten", "ihre", "vasodilatatorische", "Wirkung", "durch", "den", "intrazellulaeren", "Botenstoff", "(", "second", "messenger", "zyklisches", "Guanosinmonophosphat", "(", ")", "cGMP", ")", ".", "Sauerstoff", "ist", "ein", "Kofaktor", "der", "eNOS", "und", "ein", "bedeutsamer", "pulmonaler", "Vasodilatator", "bei", "Patienten", "mit", "pulmonaler", "Hypertension", ".", "Es", "wurde", "ueberprueft", ",", "ob", "bei", "Patienten", "mit", "pulmonaler", "Hypertension", "ein", "Feedback", "-", "Mechanismus", "zwischen", "ANP", "und", "ET-1", "besteht", "und", "inwieweit", "die", "cGMP", "-", "Produktion", "von", "der", "Stimulation", "durch", "ANP", "abhaengt", ".", "Darueber", "hinaus", "sollte", "untersucht", "werden", ",", "ob", "das", "Phaenomen", "einer", "pulmonalen", "Vasodilatation", "durch", "Sauerstoff", "mit", "Aenderungen", "der", "ET-1-", "oder", "cGMP", "-", "Plasmaspiegel", "einhergeht", "." ]	[ "umlsterm" ]
Perfusion, Peptids, Endothelin-1, ANP, Haemodynamik, Patienten, angeborenen, pulmonaler Hypertension, Stickstoffmonoxid, NO - Synthase, ANP, Guanosinmonophosphat, Sauerstoff, Patienten, pulmonaler Hypertension, Patienten, pulmonaler Hypertension, Feedback - Mechanismus, ANP, ET-1, ANP, Vasodilatation, Sauerstoff	ZfuerKardiologie.00890100.ger.abstr_task2	Sentence: Die pulmonale Perfusion wird von vasokonstriktorischen und vasodilatatorischen Faktoren reguliert . Ziel der Studie war es , den Einfluss des vasokonstriktorischen Peptids Endothelin-1 ( ET-1) und des vasodilatatorischen atrialen natriuretischen Peptis ( ANP ) auf die pulmonale Haemodynamik bei Patienten mit angeborenen Shuntvitien und konsekutiver pulmonaler Hypertension zu untersuchen . Sowohl Stickstoffmonoxid ( NO ) , das von einer konstitutiven endothelialen NO-Synthase ( eNOS ) gebildet wird , als auch ANP entfalten ihre vasodilatatorische Wirkung durch den intrazellulaeren Botenstoff ( second messenger zyklisches Guanosinmonophosphat ( ) cGMP ) . Sauerstoff ist ein Kofaktor der eNOS und ein bedeutsamer pulmonaler Vasodilatator bei Patienten mit pulmonaler Hypertension . Es wurde ueberprueft , ob bei Patienten mit pulmonaler Hypertension ein Feedback-Mechanismus zwischen ANP und ET-1 besteht und inwieweit die cGMP-Produktion von der Stimulation durch ANP abhaengt . Darueber hinaus sollte untersucht werden , ob das Phaenomen einer pulmonalen Vasodilatation durch Sauerstoff mit Aenderungen der ET-1- oder cGMP-Plasmaspiegel einhergeht . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Die pulmonale Perfusion wird von vasokonstriktorischen und vasodilatatorischen Faktoren reguliert . Ziel der Studie war es , den Einfluss des vasokonstriktorischen Peptids Endothelin-1 ( ET-1) und des vasodilatatorischen atrialen natriuretischen Peptis ( ANP ) auf die pulmonale Haemodynamik bei Patienten mit angeborenen Shuntvitien und konsekutiver pulmonaler Hypertension zu untersuchen . Sowohl Stickstoffmonoxid ( NO ) , das von einer konstitutiven endothelialen NO-Synthase ( eNOS ) gebildet wird , als auch ANP entfalten ihre vasodilatatorische Wirkung durch den intrazellulaeren Botenstoff ( second messenger zyklisches Guanosinmonophosphat ( ) cGMP ) . Sauerstoff ist ein Kofaktor der eNOS und ein bedeutsamer pulmonaler Vasodilatator bei Patienten mit pulmonaler Hypertension . Es wurde ueberprueft , ob bei Patienten mit pulmonaler Hypertension ein Feedback-Mechanismus zwischen ANP und ET-1 besteht und inwieweit die cGMP-Produktion von der Stimulation durch ANP abhaengt . Darueber hinaus sollte untersucht werden , ob das Phaenomen einer pulmonalen Vasodilatation durch Sauerstoff mit Aenderungen der ET-1- oder cGMP-Plasmaspiegel einhergeht .	[ "Die", "pulmonale", "Perfusion", "wird", "von", "vasokonstriktorischen", "und", "vasodilatatorischen", "Faktoren", "reguliert", ".", "Ziel", "der", "Studie", "war", "es", ",", "den", "Einfluss", "des", "vasokonstriktorischen", "Peptids", "Endothelin-1", "(", "ET-1", ")", "und", "des", "vasodilatatorischen", "atrialen", "natriuretischen", "Peptis", "(", "ANP", ")", "auf", "die", "pulmonale", "Haemodynamik", "bei", "Patienten", "mit", "angeborenen", "Shuntvitien", "und", "konsekutiver", "pulmonaler", "Hypertension", "zu", "untersuchen", ".", "Sowohl", "Stickstoffmonoxid", "(", "NO", ")", ",", "das", "von", "einer", "konstitutiven", "endothelialen", "NO", "-", "Synthase", "(", "eNOS", ")", "gebildet", "wird", ",", "als", "auch", "ANP", "entfalten", "ihre", "vasodilatatorische", "Wirkung", "durch", "den", "intrazellulaeren", "Botenstoff", "(", "second", "messenger", "zyklisches", "Guanosinmonophosphat", "(", ")", "cGMP", ")", ".", "Sauerstoff", "ist", "ein", "Kofaktor", "der", "eNOS", "und", "ein", "bedeutsamer", "pulmonaler", "Vasodilatator", "bei", "Patienten", "mit", "pulmonaler", "Hypertension", ".", "Es", "wurde", "ueberprueft", ",", "ob", "bei", "Patienten", "mit", "pulmonaler", "Hypertension", "ein", "Feedback", "-", "Mechanismus", "zwischen", "ANP", "und", "ET-1", "besteht", "und", "inwieweit", "die", "cGMP", "-", "Produktion", "von", "der", "Stimulation", "durch", "ANP", "abhaengt", ".", "Darueber", "hinaus", "sollte", "untersucht", "werden", ",", "ob", "das", "Phaenomen", "einer", "pulmonalen", "Vasodilatation", "durch", "Sauerstoff", "mit", "Aenderungen", "der", "ET-1-", "oder", "cGMP", "-", "Plasmaspiegel", "einhergeht", "." ]	[ "umlsterm" ]
nanocrystalline hydroxyapatite paste is a Intervention_Pharmacological, nanocrystalline hydroxyapatite ( nano - HA ) bone graft substitute is a Intervention_Pharmacological, Probing bone levels ( PBL ) is a Outcome_Physical, probing pocket depths ( PPD ) is a Outcome_Physical, Healing is a Outcome_Physical, in mean PPD is a Outcome_Physical, PPD reduction is a Outcome_Physical	41534_task0	Sentence: Clinical effects of nanocrystalline hydroxyapatite paste in the treatment of intrabony periodontal defects : a randomized controlled clinical study . The purpose of the present randomized controlled clinical study was to compare the clinical outcomes of papilla preservation flap surgery with or without the application of a novel nanocrystalline hydroxyapatite ( nano-HA ) bone graft substitute . Fourteen patients with paired intrabony periodontal defects of ≥ 4 mm participated in this split-mouth design study . The defects in each subject were randomly selected to receive nano-HA paste in conjunction with papilla preservation flaps or papilla preservation flaps alone . Probing bone levels ( PBL ) from a customized acrylic stent and probing pocket depths ( PPD ) were measured at baseline and again 6 months following surgery . No differences in any of the investigated parameters were observed at baseline between the two groups . Healing was uneventful in all patients . Both treatments resulted in significant improvements between baseline and 6 months ( p < 0.05 ) . At 6 months after therapy , the sites treated with nano-HA paste showed a reduction in mean PPD from 8.3 ± 1.2 to 4.0 ± 1.1 mm and a gain in PBL of 4.3 ± 1.4 mm , whereas in the control group , the mean PPD changed from 7.9 ± 1.2 mm to 5.0 ± 1.2 mm and PBL gain was 2.6 ± 1.4 mm . Results demonstrated statistically greater PPD reduction and PBL gain ( p < 0.05 ) in the test group as compared with the control group . In conclusion , after 6 months , the treatment of intrabony periodontal defects with a nano-HA paste leads to significantly improved clinical outcomes when compared with papilla preservation flap surgery alone . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Physical	[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Clinical effects of nanocrystalline hydroxyapatite paste in the treatment of intrabony periodontal defects : a randomized controlled clinical study . The purpose of the present randomized controlled clinical study was to compare the clinical outcomes of papilla preservation flap surgery with or without the application of a novel nanocrystalline hydroxyapatite ( nano-HA ) bone graft substitute . Fourteen patients with paired intrabony periodontal defects of ≥ 4 mm participated in this split-mouth design study . The defects in each subject were randomly selected to receive nano-HA paste in conjunction with papilla preservation flaps or papilla preservation flaps alone . Probing bone levels ( PBL ) from a customized acrylic stent and probing pocket depths ( PPD ) were measured at baseline and again 6 months following surgery . No differences in any of the investigated parameters were observed at baseline between the two groups . Healing was uneventful in all patients . Both treatments resulted in significant improvements between baseline and 6 months ( p < 0.05 ) . At 6 months after therapy , the sites treated with nano-HA paste showed a reduction in mean PPD from 8.3 ± 1.2 to 4.0 ± 1.1 mm and a gain in PBL of 4.3 ± 1.4 mm , whereas in the control group , the mean PPD changed from 7.9 ± 1.2 mm to 5.0 ± 1.2 mm and PBL gain was 2.6 ± 1.4 mm . Results demonstrated statistically greater PPD reduction and PBL gain ( p < 0.05 ) in the test group as compared with the control group . In conclusion , after 6 months , the treatment of intrabony periodontal defects with a nano-HA paste leads to significantly improved clinical outcomes when compared with papilla preservation flap surgery alone .	[ "Clinical", "effects", "of", "nanocrystalline", "hydroxyapatite", "paste", "in", "the", "treatment", "of", "intrabony", "periodontal", "defects", ":", "a", "randomized", "controlled", "clinical", "study", ".", "The", "purpose", "of", "the", "present", "randomized", "controlled", "clinical", "study", "was", "to", "compare", "the", "clinical", "outcomes", "of", "papilla", "preservation", "flap", "surgery", "with", "or", "without", "the", "application", "of", "a", "novel", "nanocrystalline", "hydroxyapatite", "(", "nano", "-", "HA", ")", "bone", "graft", "substitute", ".", "Fourteen", "patients", "with", "paired", "intrabony", "periodontal", "defects", "of", "≥", "4", "mm", "participated", "in", "this", "split", "-", "mouth", "design", "study", ".", "The", "defects", "in", "each", "subject", "were", "randomly", "selected", "to", "receive", "nano", "-", "HA", "paste", "in", "conjunction", "with", "papilla", "preservation", "flaps", "or", "papilla", "preservation", "flaps", "alone", ".", "Probing", "bone", "levels", "(", "PBL", ")", "from", "a", "customized", "acrylic", "stent", "and", "probing", "pocket", "depths", "(", "PPD", ")", "were", "measured", "at", "baseline", "and", "again", "6", "months", "following", "surgery", ".", "No", "differences", "in", "any", "of", "the", "investigated", "parameters", "were", "observed", "at", "baseline", "between", "the", "two", "groups", ".", "Healing", "was", "uneventful", "in", "all", "patients", ".", "Both", "treatments", "resulted", "in", "significant", "improvements", "between", "baseline", "and", "6", "months", "(", "p", "<", "0.05", ")", ".", "At", "6", "months", "after", "therapy", ",", "the", "sites", "treated", "with", "nano", "-", "HA", "paste", "showed", "a", "reduction", "in", "mean", "PPD", "from", "8.3", "±", "1.2", "to", "4.0", "±", "1.1", "mm", "and", "a", "gain", "in", "PBL", "of", "4.3", "±", "1.4", "mm", ",", "whereas", "in", "the", "control", "group", ",", "the", "mean", "PPD", "changed", "from", "7.9", "±", "1.2", "mm", "to", "5.0", "±", "1.2", "mm", "and", "PBL", "gain", "was", "2.6", "±", "1.4", "mm", ".", "Results", "demonstrated", "statistically", "greater", "PPD", "reduction", "and", "PBL", "gain", "(", "p", "<", "0.05", ")", "in", "the", "test", "group", "as", "compared", "with", "the", "control", "group", ".", "In", "conclusion", ",", "after", "6", "months", ",", "the", "treatment", "of", "intrabony", "periodontal", "defects", "with", "a", "nano", "-", "HA", "paste", "leads", "to", "significantly", "improved", "clinical", "outcomes", "when", "compared", "with", "papilla", "preservation", "flap", "surgery", "alone", "." ]	[ "Intervention_Pharmacological", "Outcome_Physical" ]
nanocrystalline hydroxyapatite paste is a Intervention_Pharmacological, nanocrystalline hydroxyapatite ( nano - HA ) bone graft substitute is a Intervention_Pharmacological, Probing bone levels ( PBL ) is a Outcome_Physical, probing pocket depths ( PPD ) is a Outcome_Physical, Healing is a Outcome_Physical, in mean PPD is a Outcome_Physical, PPD reduction is a Outcome_Physical	41534_task1	Sentence: Clinical effects of nanocrystalline hydroxyapatite paste in the treatment of intrabony periodontal defects : a randomized controlled clinical study . The purpose of the present randomized controlled clinical study was to compare the clinical outcomes of papilla preservation flap surgery with or without the application of a novel nanocrystalline hydroxyapatite ( nano-HA ) bone graft substitute . Fourteen patients with paired intrabony periodontal defects of ≥ 4 mm participated in this split-mouth design study . The defects in each subject were randomly selected to receive nano-HA paste in conjunction with papilla preservation flaps or papilla preservation flaps alone . Probing bone levels ( PBL ) from a customized acrylic stent and probing pocket depths ( PPD ) were measured at baseline and again 6 months following surgery . No differences in any of the investigated parameters were observed at baseline between the two groups . Healing was uneventful in all patients . Both treatments resulted in significant improvements between baseline and 6 months ( p < 0.05 ) . At 6 months after therapy , the sites treated with nano-HA paste showed a reduction in mean PPD from 8.3 ± 1.2 to 4.0 ± 1.1 mm and a gain in PBL of 4.3 ± 1.4 mm , whereas in the control group , the mean PPD changed from 7.9 ± 1.2 mm to 5.0 ± 1.2 mm and PBL gain was 2.6 ± 1.4 mm . Results demonstrated statistically greater PPD reduction and PBL gain ( p < 0.05 ) in the test group as compared with the control group . In conclusion , after 6 months , the treatment of intrabony periodontal defects with a nano-HA paste leads to significantly improved clinical outcomes when compared with papilla preservation flap surgery alone . Instructions: please typing these entity words according to sentence: nanocrystalline hydroxyapatite paste, nanocrystalline hydroxyapatite ( nano - HA ) bone graft substitute, Probing bone levels ( PBL ), probing pocket depths ( PPD ), Healing, in mean PPD, PPD reduction Options: Intervention_Pharmacological, Outcome_Physical	[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Clinical effects of nanocrystalline hydroxyapatite paste in the treatment of intrabony periodontal defects : a randomized controlled clinical study . The purpose of the present randomized controlled clinical study was to compare the clinical outcomes of papilla preservation flap surgery with or without the application of a novel nanocrystalline hydroxyapatite ( nano-HA ) bone graft substitute . Fourteen patients with paired intrabony periodontal defects of ≥ 4 mm participated in this split-mouth design study . The defects in each subject were randomly selected to receive nano-HA paste in conjunction with papilla preservation flaps or papilla preservation flaps alone . Probing bone levels ( PBL ) from a customized acrylic stent and probing pocket depths ( PPD ) were measured at baseline and again 6 months following surgery . No differences in any of the investigated parameters were observed at baseline between the two groups . Healing was uneventful in all patients . Both treatments resulted in significant improvements between baseline and 6 months ( p < 0.05 ) . At 6 months after therapy , the sites treated with nano-HA paste showed a reduction in mean PPD from 8.3 ± 1.2 to 4.0 ± 1.1 mm and a gain in PBL of 4.3 ± 1.4 mm , whereas in the control group , the mean PPD changed from 7.9 ± 1.2 mm to 5.0 ± 1.2 mm and PBL gain was 2.6 ± 1.4 mm . Results demonstrated statistically greater PPD reduction and PBL gain ( p < 0.05 ) in the test group as compared with the control group . In conclusion , after 6 months , the treatment of intrabony periodontal defects with a nano-HA paste leads to significantly improved clinical outcomes when compared with papilla preservation flap surgery alone .	[ "Clinical", "effects", "of", "nanocrystalline", "hydroxyapatite", "paste", "in", "the", "treatment", "of", "intrabony", "periodontal", "defects", ":", "a", "randomized", "controlled", "clinical", "study", ".", "The", "purpose", "of", "the", "present", "randomized", "controlled", "clinical", "study", "was", "to", "compare", "the", "clinical", "outcomes", "of", "papilla", "preservation", "flap", "surgery", "with", "or", "without", "the", "application", "of", "a", "novel", "nanocrystalline", "hydroxyapatite", "(", "nano", "-", "HA", ")", "bone", "graft", "substitute", ".", "Fourteen", "patients", "with", "paired", "intrabony", "periodontal", "defects", "of", "≥", "4", "mm", "participated", "in", "this", "split", "-", "mouth", "design", "study", ".", "The", "defects", "in", "each", "subject", "were", "randomly", "selected", "to", "receive", "nano", "-", "HA", "paste", "in", "conjunction", "with", "papilla", "preservation", "flaps", "or", "papilla", "preservation", "flaps", "alone", ".", "Probing", "bone", "levels", "(", "PBL", ")", "from", "a", "customized", "acrylic", "stent", "and", "probing", "pocket", "depths", "(", "PPD", ")", "were", "measured", "at", "baseline", "and", "again", "6", "months", "following", "surgery", ".", "No", "differences", "in", "any", "of", "the", "investigated", "parameters", "were", "observed", "at", "baseline", "between", "the", "two", "groups", ".", "Healing", "was", "uneventful", "in", "all", "patients", ".", "Both", "treatments", "resulted", "in", "significant", "improvements", "between", "baseline", "and", "6", "months", "(", "p", "<", "0.05", ")", ".", "At", "6", "months", "after", "therapy", ",", "the", "sites", "treated", "with", "nano", "-", "HA", "paste", "showed", "a", "reduction", "in", "mean", "PPD", "from", "8.3", "±", "1.2", "to", "4.0", "±", "1.1", "mm", "and", "a", "gain", "in", "PBL", "of", "4.3", "±", "1.4", "mm", ",", "whereas", "in", "the", "control", "group", ",", "the", "mean", "PPD", "changed", "from", "7.9", "±", "1.2", "mm", "to", "5.0", "±", "1.2", "mm", "and", "PBL", "gain", "was", "2.6", "±", "1.4", "mm", ".", "Results", "demonstrated", "statistically", "greater", "PPD", "reduction", "and", "PBL", "gain", "(", "p", "<", "0.05", ")", "in", "the", "test", "group", "as", "compared", "with", "the", "control", "group", ".", "In", "conclusion", ",", "after", "6", "months", ",", "the", "treatment", "of", "intrabony", "periodontal", "defects", "with", "a", "nano", "-", "HA", "paste", "leads", "to", "significantly", "improved", "clinical", "outcomes", "when", "compared", "with", "papilla", "preservation", "flap", "surgery", "alone", "." ]	[ "Intervention_Pharmacological", "Outcome_Physical" ]
nanocrystalline hydroxyapatite paste, nanocrystalline hydroxyapatite ( nano - HA ) bone graft substitute, Probing bone levels ( PBL ), probing pocket depths ( PPD ), Healing, in mean PPD, PPD reduction	41534_task2	Sentence: Clinical effects of nanocrystalline hydroxyapatite paste in the treatment of intrabony periodontal defects : a randomized controlled clinical study . The purpose of the present randomized controlled clinical study was to compare the clinical outcomes of papilla preservation flap surgery with or without the application of a novel nanocrystalline hydroxyapatite ( nano-HA ) bone graft substitute . Fourteen patients with paired intrabony periodontal defects of ≥ 4 mm participated in this split-mouth design study . The defects in each subject were randomly selected to receive nano-HA paste in conjunction with papilla preservation flaps or papilla preservation flaps alone . Probing bone levels ( PBL ) from a customized acrylic stent and probing pocket depths ( PPD ) were measured at baseline and again 6 months following surgery . No differences in any of the investigated parameters were observed at baseline between the two groups . Healing was uneventful in all patients . Both treatments resulted in significant improvements between baseline and 6 months ( p < 0.05 ) . At 6 months after therapy , the sites treated with nano-HA paste showed a reduction in mean PPD from 8.3 ± 1.2 to 4.0 ± 1.1 mm and a gain in PBL of 4.3 ± 1.4 mm , whereas in the control group , the mean PPD changed from 7.9 ± 1.2 mm to 5.0 ± 1.2 mm and PBL gain was 2.6 ± 1.4 mm . Results demonstrated statistically greater PPD reduction and PBL gain ( p < 0.05 ) in the test group as compared with the control group . In conclusion , after 6 months , the treatment of intrabony periodontal defects with a nano-HA paste leads to significantly improved clinical outcomes when compared with papilla preservation flap surgery alone . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Clinical effects of nanocrystalline hydroxyapatite paste in the treatment of intrabony periodontal defects : a randomized controlled clinical study . The purpose of the present randomized controlled clinical study was to compare the clinical outcomes of papilla preservation flap surgery with or without the application of a novel nanocrystalline hydroxyapatite ( nano-HA ) bone graft substitute . Fourteen patients with paired intrabony periodontal defects of ≥ 4 mm participated in this split-mouth design study . The defects in each subject were randomly selected to receive nano-HA paste in conjunction with papilla preservation flaps or papilla preservation flaps alone . Probing bone levels ( PBL ) from a customized acrylic stent and probing pocket depths ( PPD ) were measured at baseline and again 6 months following surgery . No differences in any of the investigated parameters were observed at baseline between the two groups . Healing was uneventful in all patients . Both treatments resulted in significant improvements between baseline and 6 months ( p < 0.05 ) . At 6 months after therapy , the sites treated with nano-HA paste showed a reduction in mean PPD from 8.3 ± 1.2 to 4.0 ± 1.1 mm and a gain in PBL of 4.3 ± 1.4 mm , whereas in the control group , the mean PPD changed from 7.9 ± 1.2 mm to 5.0 ± 1.2 mm and PBL gain was 2.6 ± 1.4 mm . Results demonstrated statistically greater PPD reduction and PBL gain ( p < 0.05 ) in the test group as compared with the control group . In conclusion , after 6 months , the treatment of intrabony periodontal defects with a nano-HA paste leads to significantly improved clinical outcomes when compared with papilla preservation flap surgery alone .	[ "Clinical", "effects", "of", "nanocrystalline", "hydroxyapatite", "paste", "in", "the", "treatment", "of", "intrabony", "periodontal", "defects", ":", "a", "randomized", "controlled", "clinical", "study", ".", "The", "purpose", "of", "the", "present", "randomized", "controlled", "clinical", "study", "was", "to", "compare", "the", "clinical", "outcomes", "of", "papilla", "preservation", "flap", "surgery", "with", "or", "without", "the", "application", "of", "a", "novel", "nanocrystalline", "hydroxyapatite", "(", "nano", "-", "HA", ")", "bone", "graft", "substitute", ".", "Fourteen", "patients", "with", "paired", "intrabony", "periodontal", "defects", "of", "≥", "4", "mm", "participated", "in", "this", "split", "-", "mouth", "design", "study", ".", "The", "defects", "in", "each", "subject", "were", "randomly", "selected", "to", "receive", "nano", "-", "HA", "paste", "in", "conjunction", "with", "papilla", "preservation", "flaps", "or", "papilla", "preservation", "flaps", "alone", ".", "Probing", "bone", "levels", "(", "PBL", ")", "from", "a", "customized", "acrylic", "stent", "and", "probing", "pocket", "depths", "(", "PPD", ")", "were", "measured", "at", "baseline", "and", "again", "6", "months", "following", "surgery", ".", "No", "differences", "in", "any", "of", "the", "investigated", "parameters", "were", "observed", "at", "baseline", "between", "the", "two", "groups", ".", "Healing", "was", "uneventful", "in", "all", "patients", ".", "Both", "treatments", "resulted", "in", "significant", "improvements", "between", "baseline", "and", "6", "months", "(", "p", "<", "0.05", ")", ".", "At", "6", "months", "after", "therapy", ",", "the", "sites", "treated", "with", "nano", "-", "HA", "paste", "showed", "a", "reduction", "in", "mean", "PPD", "from", "8.3", "±", "1.2", "to", "4.0", "±", "1.1", "mm", "and", "a", "gain", "in", "PBL", "of", "4.3", "±", "1.4", "mm", ",", "whereas", "in", "the", "control", "group", ",", "the", "mean", "PPD", "changed", "from", "7.9", "±", "1.2", "mm", "to", "5.0", "±", "1.2", "mm", "and", "PBL", "gain", "was", "2.6", "±", "1.4", "mm", ".", "Results", "demonstrated", "statistically", "greater", "PPD", "reduction", "and", "PBL", "gain", "(", "p", "<", "0.05", ")", "in", "the", "test", "group", "as", "compared", "with", "the", "control", "group", ".", "In", "conclusion", ",", "after", "6", "months", ",", "the", "treatment", "of", "intrabony", "periodontal", "defects", "with", "a", "nano", "-", "HA", "paste", "leads", "to", "significantly", "improved", "clinical", "outcomes", "when", "compared", "with", "papilla", "preservation", "flap", "surgery", "alone", "." ]	[ "Intervention_Pharmacological", "Outcome_Physical" ]
antifungal agents is a GROUP, ketoconazole is a DRUG, itraconazole is a DRUG, Nafazodone is a DRUG, fluvoxamine is a DRUG, cimetidine is a DRUG, Xanax is a BRAND, Fluoxetine is a DRUG, OCs is a GROUP, sertraline is a DRUG, diltiazem is a DRUG, macrolide antibiotics is a GROUP	Adinazolam_ddi_task0	Sentence: Co-administration with antifungal agents such as ketoconazole or itraconazole is not recommended. Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction). Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics (exercise caution). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, BRAND, DRUG	[ "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-BRAND", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O" ]	Co-administration with antifungal agents such as ketoconazole or itraconazole is not recommended. Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction). Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics (exercise caution).	[ "Co", "-", "administration", "with", "antifungal", "agents", "such", "as", "ketoconazole", "or", "itraconazole", "is", "not", "recommended", ".", "Nafazodone", ",", "fluvoxamine", ",", "cimetidine", "(", "consider", "Xanax", "dose", "reduction", ")", ".", "Fluoxetine", ",", "OCs", ",", "sertraline", ",", "diltiazem", ",", "macrolide", "antibiotics", "(", "exercise", "caution", ")", "." ]	[ "GROUP", "DRUG", "BRAND" ]
antifungal agents is a GROUP, ketoconazole is a DRUG, itraconazole is a DRUG, Nafazodone is a DRUG, fluvoxamine is a DRUG, cimetidine is a DRUG, Xanax is a BRAND, Fluoxetine is a DRUG, OCs is a GROUP, sertraline is a DRUG, diltiazem is a DRUG, macrolide antibiotics is a GROUP	Adinazolam_ddi_task1	Sentence: Co-administration with antifungal agents such as ketoconazole or itraconazole is not recommended. Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction). Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics (exercise caution). Instructions: please typing these entity words according to sentence: antifungal agents, ketoconazole, itraconazole, Nafazodone, fluvoxamine, cimetidine, Xanax, Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics Options: GROUP, BRAND, DRUG	[ "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-BRAND", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O" ]	Co-administration with antifungal agents such as ketoconazole or itraconazole is not recommended. Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction). Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics (exercise caution).	[ "Co", "-", "administration", "with", "antifungal", "agents", "such", "as", "ketoconazole", "or", "itraconazole", "is", "not", "recommended", ".", "Nafazodone", ",", "fluvoxamine", ",", "cimetidine", "(", "consider", "Xanax", "dose", "reduction", ")", ".", "Fluoxetine", ",", "OCs", ",", "sertraline", ",", "diltiazem", ",", "macrolide", "antibiotics", "(", "exercise", "caution", ")", "." ]	[ "GROUP", "DRUG", "BRAND" ]
antifungal agents, ketoconazole, itraconazole, Nafazodone, fluvoxamine, cimetidine, Xanax, Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics	Adinazolam_ddi_task2	Sentence: Co-administration with antifungal agents such as ketoconazole or itraconazole is not recommended. Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction). Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics (exercise caution). Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-BRAND", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O" ]	Co-administration with antifungal agents such as ketoconazole or itraconazole is not recommended. Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction). Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics (exercise caution).	[ "Co", "-", "administration", "with", "antifungal", "agents", "such", "as", "ketoconazole", "or", "itraconazole", "is", "not", "recommended", ".", "Nafazodone", ",", "fluvoxamine", ",", "cimetidine", "(", "consider", "Xanax", "dose", "reduction", ")", ".", "Fluoxetine", ",", "OCs", ",", "sertraline", ",", "diltiazem", ",", "macrolide", "antibiotics", "(", "exercise", "caution", ")", "." ]	[ "GROUP", "DRUG", "BRAND" ]
modulation of the soleus H - reflex is a Outcome_Physical, rhythmical arm swing is a Intervention_Physical, rhythmic arm swing is a Intervention_Physical, depression of the soleus H - reflex is a Outcome_Physical, ipsilateral is a Participant_Condition, soleus H - reflex depression is a Outcome_Physical, ipsilateral backward arm swing is a Intervention_Physical, ipsilateral arm forward swing is a Intervention_Physical, ipsilateral arm swing is a Intervention_Physical	5688_task0	Sentence: Phase-dependent modulation of the soleus H-reflex during rhythmical arm swing in humans . The purpose of this study is to investigate modulation of the soleus H-reflex during rhythmic arm swing in humans . Significant depression of the soleus H-reflex was observed when subjects swung their ipsilateral arms or both arms reciprocally during testing . The degree of soleus H-reflex depression appeared directly proportional to the speed of the arm swing . This depression was observed in the conditioning-testing intervals of 400 , 500 , and 600 msec during the ipsilateral backward arm swing and at the onset of the ipsilateral arm forward swing . This phase of depression partially overlapped the phase of depression of the soleus H-reflex during walking . However , the pattern of modulation during arm swing was not exactly the same as that during walking . Therefore , we concluded that the ipsilateral arm swing may partially affect the depression of the soleus H-reflex during the arm swing phase of walking but is not responsible for depression of the soleus H-reflex throughout the entire walking cycle . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Outcome_Physical, Participant_Condition	[ "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Phase-dependent modulation of the soleus H-reflex during rhythmical arm swing in humans . The purpose of this study is to investigate modulation of the soleus H-reflex during rhythmic arm swing in humans . Significant depression of the soleus H-reflex was observed when subjects swung their ipsilateral arms or both arms reciprocally during testing . The degree of soleus H-reflex depression appeared directly proportional to the speed of the arm swing . This depression was observed in the conditioning-testing intervals of 400 , 500 , and 600 msec during the ipsilateral backward arm swing and at the onset of the ipsilateral arm forward swing . This phase of depression partially overlapped the phase of depression of the soleus H-reflex during walking . However , the pattern of modulation during arm swing was not exactly the same as that during walking . Therefore , we concluded that the ipsilateral arm swing may partially affect the depression of the soleus H-reflex during the arm swing phase of walking but is not responsible for depression of the soleus H-reflex throughout the entire walking cycle .	[ "Phase", "-", "dependent", "modulation", "of", "the", "soleus", "H", "-", "reflex", "during", "rhythmical", "arm", "swing", "in", "humans", ".", "The", "purpose", "of", "this", "study", "is", "to", "investigate", "modulation", "of", "the", "soleus", "H", "-", "reflex", "during", "rhythmic", "arm", "swing", "in", "humans", ".", "Significant", "depression", "of", "the", "soleus", "H", "-", "reflex", "was", "observed", "when", "subjects", "swung", "their", "ipsilateral", "arms", "or", "both", "arms", "reciprocally", "during", "testing", ".", "The", "degree", "of", "soleus", "H", "-", "reflex", "depression", "appeared", "directly", "proportional", "to", "the", "speed", "of", "the", "arm", "swing", ".", "This", "depression", "was", "observed", "in", "the", "conditioning", "-", "testing", "intervals", "of", "400", ",", "500", ",", "and", "600", "msec", "during", "the", "ipsilateral", "backward", "arm", "swing", "and", "at", "the", "onset", "of", "the", "ipsilateral", "arm", "forward", "swing", ".", "This", "phase", "of", "depression", "partially", "overlapped", "the", "phase", "of", "depression", "of", "the", "soleus", "H", "-", "reflex", "during", "walking", ".", "However", ",", "the", "pattern", "of", "modulation", "during", "arm", "swing", "was", "not", "exactly", "the", "same", "as", "that", "during", "walking", ".", "Therefore", ",", "we", "concluded", "that", "the", "ipsilateral", "arm", "swing", "may", "partially", "affect", "the", "depression", "of", "the", "soleus", "H", "-", "reflex", "during", "the", "arm", "swing", "phase", "of", "walking", "but", "is", "not", "responsible", "for", "depression", "of", "the", "soleus", "H", "-", "reflex", "throughout", "the", "entire", "walking", "cycle", "." ]	[ "Outcome_Physical", "Intervention_Physical", "Participant_Condition" ]
modulation of the soleus H - reflex is a Outcome_Physical, rhythmical arm swing is a Intervention_Physical, rhythmic arm swing is a Intervention_Physical, depression of the soleus H - reflex is a Outcome_Physical, ipsilateral is a Participant_Condition, soleus H - reflex depression is a Outcome_Physical, ipsilateral backward arm swing is a Intervention_Physical, ipsilateral arm forward swing is a Intervention_Physical, ipsilateral arm swing is a Intervention_Physical	5688_task1	Sentence: Phase-dependent modulation of the soleus H-reflex during rhythmical arm swing in humans . The purpose of this study is to investigate modulation of the soleus H-reflex during rhythmic arm swing in humans . Significant depression of the soleus H-reflex was observed when subjects swung their ipsilateral arms or both arms reciprocally during testing . The degree of soleus H-reflex depression appeared directly proportional to the speed of the arm swing . This depression was observed in the conditioning-testing intervals of 400 , 500 , and 600 msec during the ipsilateral backward arm swing and at the onset of the ipsilateral arm forward swing . This phase of depression partially overlapped the phase of depression of the soleus H-reflex during walking . However , the pattern of modulation during arm swing was not exactly the same as that during walking . Therefore , we concluded that the ipsilateral arm swing may partially affect the depression of the soleus H-reflex during the arm swing phase of walking but is not responsible for depression of the soleus H-reflex throughout the entire walking cycle . Instructions: please typing these entity words according to sentence: modulation of the soleus H - reflex, rhythmical arm swing, rhythmic arm swing, depression of the soleus H - reflex, ipsilateral, soleus H - reflex depression, ipsilateral backward arm swing, ipsilateral arm forward swing, ipsilateral arm swing Options: Intervention_Physical, Outcome_Physical, Participant_Condition	[ "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Phase-dependent modulation of the soleus H-reflex during rhythmical arm swing in humans . The purpose of this study is to investigate modulation of the soleus H-reflex during rhythmic arm swing in humans . Significant depression of the soleus H-reflex was observed when subjects swung their ipsilateral arms or both arms reciprocally during testing . The degree of soleus H-reflex depression appeared directly proportional to the speed of the arm swing . This depression was observed in the conditioning-testing intervals of 400 , 500 , and 600 msec during the ipsilateral backward arm swing and at the onset of the ipsilateral arm forward swing . This phase of depression partially overlapped the phase of depression of the soleus H-reflex during walking . However , the pattern of modulation during arm swing was not exactly the same as that during walking . Therefore , we concluded that the ipsilateral arm swing may partially affect the depression of the soleus H-reflex during the arm swing phase of walking but is not responsible for depression of the soleus H-reflex throughout the entire walking cycle .	[ "Phase", "-", "dependent", "modulation", "of", "the", "soleus", "H", "-", "reflex", "during", "rhythmical", "arm", "swing", "in", "humans", ".", "The", "purpose", "of", "this", "study", "is", "to", "investigate", "modulation", "of", "the", "soleus", "H", "-", "reflex", "during", "rhythmic", "arm", "swing", "in", "humans", ".", "Significant", "depression", "of", "the", "soleus", "H", "-", "reflex", "was", "observed", "when", "subjects", "swung", "their", "ipsilateral", "arms", "or", "both", "arms", "reciprocally", "during", "testing", ".", "The", "degree", "of", "soleus", "H", "-", "reflex", "depression", "appeared", "directly", "proportional", "to", "the", "speed", "of", "the", "arm", "swing", ".", "This", "depression", "was", "observed", "in", "the", "conditioning", "-", "testing", "intervals", "of", "400", ",", "500", ",", "and", "600", "msec", "during", "the", "ipsilateral", "backward", "arm", "swing", "and", "at", "the", "onset", "of", "the", "ipsilateral", "arm", "forward", "swing", ".", "This", "phase", "of", "depression", "partially", "overlapped", "the", "phase", "of", "depression", "of", "the", "soleus", "H", "-", "reflex", "during", "walking", ".", "However", ",", "the", "pattern", "of", "modulation", "during", "arm", "swing", "was", "not", "exactly", "the", "same", "as", "that", "during", "walking", ".", "Therefore", ",", "we", "concluded", "that", "the", "ipsilateral", "arm", "swing", "may", "partially", "affect", "the", "depression", "of", "the", "soleus", "H", "-", "reflex", "during", "the", "arm", "swing", "phase", "of", "walking", "but", "is", "not", "responsible", "for", "depression", "of", "the", "soleus", "H", "-", "reflex", "throughout", "the", "entire", "walking", "cycle", "." ]	[ "Outcome_Physical", "Intervention_Physical", "Participant_Condition" ]
modulation of the soleus H - reflex, rhythmical arm swing, rhythmic arm swing, depression of the soleus H - reflex, ipsilateral, soleus H - reflex depression, ipsilateral backward arm swing, ipsilateral arm forward swing, ipsilateral arm swing	5688_task2	Sentence: Phase-dependent modulation of the soleus H-reflex during rhythmical arm swing in humans . The purpose of this study is to investigate modulation of the soleus H-reflex during rhythmic arm swing in humans . Significant depression of the soleus H-reflex was observed when subjects swung their ipsilateral arms or both arms reciprocally during testing . The degree of soleus H-reflex depression appeared directly proportional to the speed of the arm swing . This depression was observed in the conditioning-testing intervals of 400 , 500 , and 600 msec during the ipsilateral backward arm swing and at the onset of the ipsilateral arm forward swing . This phase of depression partially overlapped the phase of depression of the soleus H-reflex during walking . However , the pattern of modulation during arm swing was not exactly the same as that during walking . Therefore , we concluded that the ipsilateral arm swing may partially affect the depression of the soleus H-reflex during the arm swing phase of walking but is not responsible for depression of the soleus H-reflex throughout the entire walking cycle . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Phase-dependent modulation of the soleus H-reflex during rhythmical arm swing in humans . The purpose of this study is to investigate modulation of the soleus H-reflex during rhythmic arm swing in humans . Significant depression of the soleus H-reflex was observed when subjects swung their ipsilateral arms or both arms reciprocally during testing . The degree of soleus H-reflex depression appeared directly proportional to the speed of the arm swing . This depression was observed in the conditioning-testing intervals of 400 , 500 , and 600 msec during the ipsilateral backward arm swing and at the onset of the ipsilateral arm forward swing . This phase of depression partially overlapped the phase of depression of the soleus H-reflex during walking . However , the pattern of modulation during arm swing was not exactly the same as that during walking . Therefore , we concluded that the ipsilateral arm swing may partially affect the depression of the soleus H-reflex during the arm swing phase of walking but is not responsible for depression of the soleus H-reflex throughout the entire walking cycle .	[ "Phase", "-", "dependent", "modulation", "of", "the", "soleus", "H", "-", "reflex", "during", "rhythmical", "arm", "swing", "in", "humans", ".", "The", "purpose", "of", "this", "study", "is", "to", "investigate", "modulation", "of", "the", "soleus", "H", "-", "reflex", "during", "rhythmic", "arm", "swing", "in", "humans", ".", "Significant", "depression", "of", "the", "soleus", "H", "-", "reflex", "was", "observed", "when", "subjects", "swung", "their", "ipsilateral", "arms", "or", "both", "arms", "reciprocally", "during", "testing", ".", "The", "degree", "of", "soleus", "H", "-", "reflex", "depression", "appeared", "directly", "proportional", "to", "the", "speed", "of", "the", "arm", "swing", ".", "This", "depression", "was", "observed", "in", "the", "conditioning", "-", "testing", "intervals", "of", "400", ",", "500", ",", "and", "600", "msec", "during", "the", "ipsilateral", "backward", "arm", "swing", "and", "at", "the", "onset", "of", "the", "ipsilateral", "arm", "forward", "swing", ".", "This", "phase", "of", "depression", "partially", "overlapped", "the", "phase", "of", "depression", "of", "the", "soleus", "H", "-", "reflex", "during", "walking", ".", "However", ",", "the", "pattern", "of", "modulation", "during", "arm", "swing", "was", "not", "exactly", "the", "same", "as", "that", "during", "walking", ".", "Therefore", ",", "we", "concluded", "that", "the", "ipsilateral", "arm", "swing", "may", "partially", "affect", "the", "depression", "of", "the", "soleus", "H", "-", "reflex", "during", "the", "arm", "swing", "phase", "of", "walking", "but", "is", "not", "responsible", "for", "depression", "of", "the", "soleus", "H", "-", "reflex", "throughout", "the", "entire", "walking", "cycle", "." ]	[ "Outcome_Physical", "Intervention_Physical", "Participant_Condition" ]
Protein - tyrosine kinase activation is an other_name, lipopolysaccharide induction is an other_name, interleukin 1beta is a protein_molecule, NFkappaB activation is an other_name, NFkappaB nuclear translocation is an other_name	20977_task0	Sentence: Protein-tyrosine kinase activation is required for lipopolysaccharide induction of interleukin 1beta and NFkappaB activation, but not NFkappaB nuclear translocation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_molecule, other_name	[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "B-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]	Protein-tyrosine kinase activation is required for lipopolysaccharide induction of interleukin 1beta and NFkappaB activation, but not NFkappaB nuclear translocation.	[ "Protein", "-", "tyrosine", "kinase", "activation", "is", "required", "for", "lipopolysaccharide", "induction", "of", "interleukin", "1beta", "and", "NFkappaB", "activation", ",", "but", "not", "NFkappaB", "nuclear", "translocation", "." ]	[ "other_name", "protein_molecule", "cell_line", "protein_family_or_group", "lipid", "cell_type", "protein_complex", "amino_acid_monomer" ]
Protein - tyrosine kinase activation is an other_name, lipopolysaccharide induction is an other_name, interleukin 1beta is a protein_molecule, NFkappaB activation is an other_name, NFkappaB nuclear translocation is an other_name	20977_task1	Sentence: Protein-tyrosine kinase activation is required for lipopolysaccharide induction of interleukin 1beta and NFkappaB activation, but not NFkappaB nuclear translocation. Instructions: please typing these entity words according to sentence: Protein - tyrosine kinase activation, lipopolysaccharide induction, interleukin 1beta, NFkappaB activation, NFkappaB nuclear translocation Options: protein_molecule, other_name	[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "B-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]	Protein-tyrosine kinase activation is required for lipopolysaccharide induction of interleukin 1beta and NFkappaB activation, but not NFkappaB nuclear translocation.	[ "Protein", "-", "tyrosine", "kinase", "activation", "is", "required", "for", "lipopolysaccharide", "induction", "of", "interleukin", "1beta", "and", "NFkappaB", "activation", ",", "but", "not", "NFkappaB", "nuclear", "translocation", "." ]	[ "other_name", "protein_molecule", "cell_line", "protein_family_or_group", "lipid", "cell_type", "protein_complex", "amino_acid_monomer" ]
Protein - tyrosine kinase activation, lipopolysaccharide induction, interleukin 1beta, NFkappaB activation, NFkappaB nuclear translocation	20977_task2	Sentence: Protein-tyrosine kinase activation is required for lipopolysaccharide induction of interleukin 1beta and NFkappaB activation, but not NFkappaB nuclear translocation. Instructions: please extract entity words from the input sentence	[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "B-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]	Protein-tyrosine kinase activation is required for lipopolysaccharide induction of interleukin 1beta and NFkappaB activation, but not NFkappaB nuclear translocation.	[ "Protein", "-", "tyrosine", "kinase", "activation", "is", "required", "for", "lipopolysaccharide", "induction", "of", "interleukin", "1beta", "and", "NFkappaB", "activation", ",", "but", "not", "NFkappaB", "nuclear", "translocation", "." ]	[ "other_name", "protein_molecule", "cell_line", "protein_family_or_group", "lipid", "cell_type", "protein_complex", "amino_acid_monomer" ]
SST is an intervention, labeling anger is an outcome, LA is an intervention	1041_task0	Sentence: After the 6-month training period , the SST Group made fewer errors in labeling anger on adult faces , whereas error rates in the LA Group remained stable . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: intervention, outcome	[ "O", "O", "O", "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O" ]	After the 6-month training period , the SST Group made fewer errors in labeling anger on adult faces , whereas error rates in the LA Group remained stable .	[ "After", "the", "6-month", "training", "period", ",", "the", "SST", "Group", "made", "fewer", "errors", "in", "labeling", "anger", "on", "adult", "faces", ",", "whereas", "error", "rates", "in", "the", "LA", "Group", "remained", "stable", "." ]	[ "outcome", "intervention" ]
SST is an intervention, labeling anger is an outcome, LA is an intervention	1041_task1	Sentence: After the 6-month training period , the SST Group made fewer errors in labeling anger on adult faces , whereas error rates in the LA Group remained stable . Instructions: please typing these entity words according to sentence: SST, labeling anger, LA Options: intervention, outcome	[ "O", "O", "O", "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O" ]	After the 6-month training period , the SST Group made fewer errors in labeling anger on adult faces , whereas error rates in the LA Group remained stable .	[ "After", "the", "6-month", "training", "period", ",", "the", "SST", "Group", "made", "fewer", "errors", "in", "labeling", "anger", "on", "adult", "faces", ",", "whereas", "error", "rates", "in", "the", "LA", "Group", "remained", "stable", "." ]	[ "outcome", "intervention" ]
SST, labeling anger, LA	1041_task2	Sentence: After the 6-month training period , the SST Group made fewer errors in labeling anger on adult faces , whereas error rates in the LA Group remained stable . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O" ]	After the 6-month training period , the SST Group made fewer errors in labeling anger on adult faces , whereas error rates in the LA Group remained stable .	[ "After", "the", "6-month", "training", "period", ",", "the", "SST", "Group", "made", "fewer", "errors", "in", "labeling", "anger", "on", "adult", "faces", ",", "whereas", "error", "rates", "in", "the", "LA", "Group", "remained", "stable", "." ]	[ "outcome", "intervention" ]
aim is an umlsterm, patients is an umlsterm, preeclampsia is an umlsterm, t - PA is an umlsterm, PAI-1 is an umlsterm, human is an umlsterm, cells is an umlsterm, human is an umlsterm, endothelium is an umlsterm, cells is an umlsterm, umbilical veins is an umlsterm, patients is an umlsterm, HELLP syndrome is an umlsterm, patients is an umlsterm, preeclampsia is an umlsterm, patients is an umlsterm, women is an umlsterm, controls is an umlsterm, t - PA is an umlsterm, PAI-1 is an umlsterm, ELISA is an umlsterm, cell cultures is an umlsterm, t - PA is an umlsterm, patients is an umlsterm, preeclampsia is an umlsterm, HELLP syndrome is an umlsterm, control group is an umlsterm, PAI-1 is an umlsterm, cell cultures is an umlsterm, t - PA is an umlsterm, PAI-1 is an umlsterm, patients is an umlsterm, preeclampsia is an umlsterm, HELLP syndrome is an umlsterm, t - PA is an umlsterm, PAI-1 is an umlsterm, human is an umlsterm, endothelium is an umlsterm, cells is an umlsterm, patients is an umlsterm, sign is an umlsterm, cell is an umlsterm	PerinatalMedizin.60080079.eng.abstr_task0	Sentence: The aim of our study was to investigate the influence that serum of patients with preeclampsia has on t-PA and PAI-1 expression from human endothelial cells . For this purpose , we cultured human endothelium cells , gained from umbilical veins , for 24 h with sera of 7 patients with HELLP syndrome and 12 patients with preeclampsia . The sera of 12 normotensive pregnant patients and 9 non-pregnant women were used as controls . We then determined t-PA and PAI-1 levels by ELISA , both in the maternal serum and in the supernatant of the endothelial cell cultures . While t-PA levels were significantly higher in the serum of patients with preeclampsia and HELLP syndrome than in the control group ( median : 8.0 ng/ml and 6.2 ng/ml vs 3.9 ng/ml and 3.1 ng/ml ) , levels of PAI-1 did not show any significant disparity among the different groups . The supernatant of the endothelial cell cultures demonstrated significantly elevated levels of both t-PA ( P 0.001 ) and PAI-1 ( P 0.01 ) when stimulated with serum gained from patients with preeclampsia or HELLP syndrome . The increased expression of t-PA and PAI-1 from human endothelium cells after stimulation with the serum of preeclamptic patients must be considered as a sign of increased endothelial cell activation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O" ]	The aim of our study was to investigate the influence that serum of patients with preeclampsia has on t-PA and PAI-1 expression from human endothelial cells . For this purpose , we cultured human endothelium cells , gained from umbilical veins , for 24 h with sera of 7 patients with HELLP syndrome and 12 patients with preeclampsia . The sera of 12 normotensive pregnant patients and 9 non-pregnant women were used as controls . We then determined t-PA and PAI-1 levels by ELISA , both in the maternal serum and in the supernatant of the endothelial cell cultures . While t-PA levels were significantly higher in the serum of patients with preeclampsia and HELLP syndrome than in the control group ( median : 8.0 ng/ml and 6.2 ng/ml vs 3.9 ng/ml and 3.1 ng/ml ) , levels of PAI-1 did not show any significant disparity among the different groups . The supernatant of the endothelial cell cultures demonstrated significantly elevated levels of both t-PA ( P 0.001 ) and PAI-1 ( P 0.01 ) when stimulated with serum gained from patients with preeclampsia or HELLP syndrome . The increased expression of t-PA and PAI-1 from human endothelium cells after stimulation with the serum of preeclamptic patients must be considered as a sign of increased endothelial cell activation .	[ "The", "aim", "of", "our", "study", "was", "to", "investigate", "the", "influence", "that", "serum", "of", "patients", "with", "preeclampsia", "has", "on", "t", "-", "PA", "and", "PAI-1", "expression", "from", "human", "endothelial", "cells", ".", "For", "this", "purpose", ",", "we", "cultured", "human", "endothelium", "cells", ",", "gained", "from", "umbilical", "veins", ",", "for", "24", "h", "with", "sera", "of", "7", "patients", "with", "HELLP", "syndrome", "and", "12", "patients", "with", "preeclampsia", ".", "The", "sera", "of", "12", "normotensive", "pregnant", "patients", "and", "9", "non", "-", "pregnant", "women", "were", "used", "as", "controls", ".", "We", "then", "determined", "t", "-", "PA", "and", "PAI-1", "levels", "by", "ELISA", ",", "both", "in", "the", "maternal", "serum", "and", "in", "the", "supernatant", "of", "the", "endothelial", "cell", "cultures", ".", "While", "t", "-", "PA", "levels", "were", "significantly", "higher", "in", "the", "serum", "of", "patients", "with", "preeclampsia", "and", "HELLP", "syndrome", "than", "in", "the", "control", "group", "(", "median", ":", "8.0", "ng", "/", "ml", "and", "6.2", "ng", "/", "ml", "vs", "3.9", "ng", "/", "ml", "and", "3.1", "ng", "/", "ml", ")", ",", "levels", "of", "PAI-1", "did", "not", "show", "any", "significant", "disparity", "among", "the", "different", "groups", ".", "The", "supernatant", "of", "the", "endothelial", "cell", "cultures", "demonstrated", "significantly", "elevated", "levels", "of", "both", "t", "-", "PA", "(", "P", "0.001", ")", "and", "PAI-1", "(", "P", "0.01", ")", "when", "stimulated", "with", "serum", "gained", "from", "patients", "with", "preeclampsia", "or", "HELLP", "syndrome", ".", "The", "increased", "expression", "of", "t", "-", "PA", "and", "PAI-1", "from", "human", "endothelium", "cells", "after", "stimulation", "with", "the", "serum", "of", "preeclamptic", "patients", "must", "be", "considered", "as", "a", "sign", "of", "increased", "endothelial", "cell", "activation", "." ]	[ "umlsterm" ]
aim is an umlsterm, patients is an umlsterm, preeclampsia is an umlsterm, t - PA is an umlsterm, PAI-1 is an umlsterm, human is an umlsterm, cells is an umlsterm, human is an umlsterm, endothelium is an umlsterm, cells is an umlsterm, umbilical veins is an umlsterm, patients is an umlsterm, HELLP syndrome is an umlsterm, patients is an umlsterm, preeclampsia is an umlsterm, patients is an umlsterm, women is an umlsterm, controls is an umlsterm, t - PA is an umlsterm, PAI-1 is an umlsterm, ELISA is an umlsterm, cell cultures is an umlsterm, t - PA is an umlsterm, patients is an umlsterm, preeclampsia is an umlsterm, HELLP syndrome is an umlsterm, control group is an umlsterm, PAI-1 is an umlsterm, cell cultures is an umlsterm, t - PA is an umlsterm, PAI-1 is an umlsterm, patients is an umlsterm, preeclampsia is an umlsterm, HELLP syndrome is an umlsterm, t - PA is an umlsterm, PAI-1 is an umlsterm, human is an umlsterm, endothelium is an umlsterm, cells is an umlsterm, patients is an umlsterm, sign is an umlsterm, cell is an umlsterm	PerinatalMedizin.60080079.eng.abstr_task1	Sentence: The aim of our study was to investigate the influence that serum of patients with preeclampsia has on t-PA and PAI-1 expression from human endothelial cells . For this purpose , we cultured human endothelium cells , gained from umbilical veins , for 24 h with sera of 7 patients with HELLP syndrome and 12 patients with preeclampsia . The sera of 12 normotensive pregnant patients and 9 non-pregnant women were used as controls . We then determined t-PA and PAI-1 levels by ELISA , both in the maternal serum and in the supernatant of the endothelial cell cultures . While t-PA levels were significantly higher in the serum of patients with preeclampsia and HELLP syndrome than in the control group ( median : 8.0 ng/ml and 6.2 ng/ml vs 3.9 ng/ml and 3.1 ng/ml ) , levels of PAI-1 did not show any significant disparity among the different groups . The supernatant of the endothelial cell cultures demonstrated significantly elevated levels of both t-PA ( P 0.001 ) and PAI-1 ( P 0.01 ) when stimulated with serum gained from patients with preeclampsia or HELLP syndrome . The increased expression of t-PA and PAI-1 from human endothelium cells after stimulation with the serum of preeclamptic patients must be considered as a sign of increased endothelial cell activation . Instructions: please typing these entity words according to sentence: aim, patients, preeclampsia, t - PA, PAI-1, human, cells, human, endothelium, cells, umbilical veins, patients, HELLP syndrome, patients, preeclampsia, patients, women, controls, t - PA, PAI-1, ELISA, cell cultures, t - PA, patients, preeclampsia, HELLP syndrome, control group, PAI-1, cell cultures, t - PA, PAI-1, patients, preeclampsia, HELLP syndrome, t - PA, PAI-1, human, endothelium, cells, patients, sign, cell Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O" ]	The aim of our study was to investigate the influence that serum of patients with preeclampsia has on t-PA and PAI-1 expression from human endothelial cells . For this purpose , we cultured human endothelium cells , gained from umbilical veins , for 24 h with sera of 7 patients with HELLP syndrome and 12 patients with preeclampsia . The sera of 12 normotensive pregnant patients and 9 non-pregnant women were used as controls . We then determined t-PA and PAI-1 levels by ELISA , both in the maternal serum and in the supernatant of the endothelial cell cultures . While t-PA levels were significantly higher in the serum of patients with preeclampsia and HELLP syndrome than in the control group ( median : 8.0 ng/ml and 6.2 ng/ml vs 3.9 ng/ml and 3.1 ng/ml ) , levels of PAI-1 did not show any significant disparity among the different groups . The supernatant of the endothelial cell cultures demonstrated significantly elevated levels of both t-PA ( P 0.001 ) and PAI-1 ( P 0.01 ) when stimulated with serum gained from patients with preeclampsia or HELLP syndrome . The increased expression of t-PA and PAI-1 from human endothelium cells after stimulation with the serum of preeclamptic patients must be considered as a sign of increased endothelial cell activation .	[ "The", "aim", "of", "our", "study", "was", "to", "investigate", "the", "influence", "that", "serum", "of", "patients", "with", "preeclampsia", "has", "on", "t", "-", "PA", "and", "PAI-1", "expression", "from", "human", "endothelial", "cells", ".", "For", "this", "purpose", ",", "we", "cultured", "human", "endothelium", "cells", ",", "gained", "from", "umbilical", "veins", ",", "for", "24", "h", "with", "sera", "of", "7", "patients", "with", "HELLP", "syndrome", "and", "12", "patients", "with", "preeclampsia", ".", "The", "sera", "of", "12", "normotensive", "pregnant", "patients", "and", "9", "non", "-", "pregnant", "women", "were", "used", "as", "controls", ".", "We", "then", "determined", "t", "-", "PA", "and", "PAI-1", "levels", "by", "ELISA", ",", "both", "in", "the", "maternal", "serum", "and", "in", "the", "supernatant", "of", "the", "endothelial", "cell", "cultures", ".", "While", "t", "-", "PA", "levels", "were", "significantly", "higher", "in", "the", "serum", "of", "patients", "with", "preeclampsia", "and", "HELLP", "syndrome", "than", "in", "the", "control", "group", "(", "median", ":", "8.0", "ng", "/", "ml", "and", "6.2", "ng", "/", "ml", "vs", "3.9", "ng", "/", "ml", "and", "3.1", "ng", "/", "ml", ")", ",", "levels", "of", "PAI-1", "did", "not", "show", "any", "significant", "disparity", "among", "the", "different", "groups", ".", "The", "supernatant", "of", "the", "endothelial", "cell", "cultures", "demonstrated", "significantly", "elevated", "levels", "of", "both", "t", "-", "PA", "(", "P", "0.001", ")", "and", "PAI-1", "(", "P", "0.01", ")", "when", "stimulated", "with", "serum", "gained", "from", "patients", "with", "preeclampsia", "or", "HELLP", "syndrome", ".", "The", "increased", "expression", "of", "t", "-", "PA", "and", "PAI-1", "from", "human", "endothelium", "cells", "after", "stimulation", "with", "the", "serum", "of", "preeclamptic", "patients", "must", "be", "considered", "as", "a", "sign", "of", "increased", "endothelial", "cell", "activation", "." ]	[ "umlsterm" ]
aim, patients, preeclampsia, t - PA, PAI-1, human, cells, human, endothelium, cells, umbilical veins, patients, HELLP syndrome, patients, preeclampsia, patients, women, controls, t - PA, PAI-1, ELISA, cell cultures, t - PA, patients, preeclampsia, HELLP syndrome, control group, PAI-1, cell cultures, t - PA, PAI-1, patients, preeclampsia, HELLP syndrome, t - PA, PAI-1, human, endothelium, cells, patients, sign, cell	PerinatalMedizin.60080079.eng.abstr_task2	Sentence: The aim of our study was to investigate the influence that serum of patients with preeclampsia has on t-PA and PAI-1 expression from human endothelial cells . For this purpose , we cultured human endothelium cells , gained from umbilical veins , for 24 h with sera of 7 patients with HELLP syndrome and 12 patients with preeclampsia . The sera of 12 normotensive pregnant patients and 9 non-pregnant women were used as controls . We then determined t-PA and PAI-1 levels by ELISA , both in the maternal serum and in the supernatant of the endothelial cell cultures . While t-PA levels were significantly higher in the serum of patients with preeclampsia and HELLP syndrome than in the control group ( median : 8.0 ng/ml and 6.2 ng/ml vs 3.9 ng/ml and 3.1 ng/ml ) , levels of PAI-1 did not show any significant disparity among the different groups . The supernatant of the endothelial cell cultures demonstrated significantly elevated levels of both t-PA ( P 0.001 ) and PAI-1 ( P 0.01 ) when stimulated with serum gained from patients with preeclampsia or HELLP syndrome . The increased expression of t-PA and PAI-1 from human endothelium cells after stimulation with the serum of preeclamptic patients must be considered as a sign of increased endothelial cell activation . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O" ]	The aim of our study was to investigate the influence that serum of patients with preeclampsia has on t-PA and PAI-1 expression from human endothelial cells . For this purpose , we cultured human endothelium cells , gained from umbilical veins , for 24 h with sera of 7 patients with HELLP syndrome and 12 patients with preeclampsia . The sera of 12 normotensive pregnant patients and 9 non-pregnant women were used as controls . We then determined t-PA and PAI-1 levels by ELISA , both in the maternal serum and in the supernatant of the endothelial cell cultures . While t-PA levels were significantly higher in the serum of patients with preeclampsia and HELLP syndrome than in the control group ( median : 8.0 ng/ml and 6.2 ng/ml vs 3.9 ng/ml and 3.1 ng/ml ) , levels of PAI-1 did not show any significant disparity among the different groups . The supernatant of the endothelial cell cultures demonstrated significantly elevated levels of both t-PA ( P 0.001 ) and PAI-1 ( P 0.01 ) when stimulated with serum gained from patients with preeclampsia or HELLP syndrome . The increased expression of t-PA and PAI-1 from human endothelium cells after stimulation with the serum of preeclamptic patients must be considered as a sign of increased endothelial cell activation .	[ "The", "aim", "of", "our", "study", "was", "to", "investigate", "the", "influence", "that", "serum", "of", "patients", "with", "preeclampsia", "has", "on", "t", "-", "PA", "and", "PAI-1", "expression", "from", "human", "endothelial", "cells", ".", "For", "this", "purpose", ",", "we", "cultured", "human", "endothelium", "cells", ",", "gained", "from", "umbilical", "veins", ",", "for", "24", "h", "with", "sera", "of", "7", "patients", "with", "HELLP", "syndrome", "and", "12", "patients", "with", "preeclampsia", ".", "The", "sera", "of", "12", "normotensive", "pregnant", "patients", "and", "9", "non", "-", "pregnant", "women", "were", "used", "as", "controls", ".", "We", "then", "determined", "t", "-", "PA", "and", "PAI-1", "levels", "by", "ELISA", ",", "both", "in", "the", "maternal", "serum", "and", "in", "the", "supernatant", "of", "the", "endothelial", "cell", "cultures", ".", "While", "t", "-", "PA", "levels", "were", "significantly", "higher", "in", "the", "serum", "of", "patients", "with", "preeclampsia", "and", "HELLP", "syndrome", "than", "in", "the", "control", "group", "(", "median", ":", "8.0", "ng", "/", "ml", "and", "6.2", "ng", "/", "ml", "vs", "3.9", "ng", "/", "ml", "and", "3.1", "ng", "/", "ml", ")", ",", "levels", "of", "PAI-1", "did", "not", "show", "any", "significant", "disparity", "among", "the", "different", "groups", ".", "The", "supernatant", "of", "the", "endothelial", "cell", "cultures", "demonstrated", "significantly", "elevated", "levels", "of", "both", "t", "-", "PA", "(", "P", "0.001", ")", "and", "PAI-1", "(", "P", "0.01", ")", "when", "stimulated", "with", "serum", "gained", "from", "patients", "with", "preeclampsia", "or", "HELLP", "syndrome", ".", "The", "increased", "expression", "of", "t", "-", "PA", "and", "PAI-1", "from", "human", "endothelium", "cells", "after", "stimulation", "with", "the", "serum", "of", "preeclamptic", "patients", "must", "be", "considered", "as", "a", "sign", "of", "increased", "endothelial", "cell", "activation", "." ]	[ "umlsterm" ]
loxapine is a DRUG, lorazepam is a DRUG, loxapine is a DRUG, loxapine is a DRUG	Loxapine_ddi_task0	Sentence: There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam. The risk of using loxapine in combination with CNS-active drugs has not been systematically evaluated. Therefore, caution is advised if the concomitant administration of loxapine and CNS-active drugs is required. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DRUG	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O" ]	There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam. The risk of using loxapine in combination with CNS-active drugs has not been systematically evaluated. Therefore, caution is advised if the concomitant administration of loxapine and CNS-active drugs is required.	[ "There", "have", "been", "rare", "reports", "of", "significant", "respiratory", "depression", ",", "stupor", "and", "/", "or", "hypotension", "with", "the", "concomitant", "use", "of", "loxapine", "and", "lorazepam", ".", "The", "risk", "of", "using", "loxapine", "in", "combination", "with", "CNS", "-", "active", "drugs", "has", "not", "been", "systematically", "evaluated", ".", "Therefore", ",", "caution", "is", "advised", "if", "the", "concomitant", "administration", "of", "loxapine", "and", "CNS", "-", "active", "drugs", "is", "required", "." ]	[ "DRUG" ]
loxapine is a DRUG, lorazepam is a DRUG, loxapine is a DRUG, loxapine is a DRUG	Loxapine_ddi_task1	Sentence: There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam. The risk of using loxapine in combination with CNS-active drugs has not been systematically evaluated. Therefore, caution is advised if the concomitant administration of loxapine and CNS-active drugs is required. Instructions: please typing these entity words according to sentence: loxapine, lorazepam, loxapine, loxapine Options: DRUG	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O" ]	There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam. The risk of using loxapine in combination with CNS-active drugs has not been systematically evaluated. Therefore, caution is advised if the concomitant administration of loxapine and CNS-active drugs is required.	[ "There", "have", "been", "rare", "reports", "of", "significant", "respiratory", "depression", ",", "stupor", "and", "/", "or", "hypotension", "with", "the", "concomitant", "use", "of", "loxapine", "and", "lorazepam", ".", "The", "risk", "of", "using", "loxapine", "in", "combination", "with", "CNS", "-", "active", "drugs", "has", "not", "been", "systematically", "evaluated", ".", "Therefore", ",", "caution", "is", "advised", "if", "the", "concomitant", "administration", "of", "loxapine", "and", "CNS", "-", "active", "drugs", "is", "required", "." ]	[ "DRUG" ]
loxapine, lorazepam, loxapine, loxapine	Loxapine_ddi_task2	Sentence: There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam. The risk of using loxapine in combination with CNS-active drugs has not been systematically evaluated. Therefore, caution is advised if the concomitant administration of loxapine and CNS-active drugs is required. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O" ]	There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam. The risk of using loxapine in combination with CNS-active drugs has not been systematically evaluated. Therefore, caution is advised if the concomitant administration of loxapine and CNS-active drugs is required.	[ "There", "have", "been", "rare", "reports", "of", "significant", "respiratory", "depression", ",", "stupor", "and", "/", "or", "hypotension", "with", "the", "concomitant", "use", "of", "loxapine", "and", "lorazepam", ".", "The", "risk", "of", "using", "loxapine", "in", "combination", "with", "CNS", "-", "active", "drugs", "has", "not", "been", "systematically", "evaluated", ".", "Therefore", ",", "caution", "is", "advised", "if", "the", "concomitant", "administration", "of", "loxapine", "and", "CNS", "-", "active", "drugs", "is", "required", "." ]	[ "DRUG" ]
biopterin is a CHEMICAL	10464780_task0	Sentence: [The relation between metabolism of biopterin and dystonia-parkinsonism]. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O" ]	[The relation between metabolism of biopterin and dystonia-parkinsonism].	[ "[", "The", "relation", "between", "metabolism", "of", "biopterin", "and", "dystonia", "-", "parkinsonism", "]", "." ]	[ "GENE-Y", "CHEMICAL" ]
biopterin is a CHEMICAL	10464780_task1	Sentence: [The relation between metabolism of biopterin and dystonia-parkinsonism]. Instructions: please typing these entity words according to sentence: biopterin Options: CHEMICAL	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O" ]	[The relation between metabolism of biopterin and dystonia-parkinsonism].	[ "[", "The", "relation", "between", "metabolism", "of", "biopterin", "and", "dystonia", "-", "parkinsonism", "]", "." ]	[ "GENE-Y", "CHEMICAL" ]
biopterin	10464780_task2	Sentence: [The relation between metabolism of biopterin and dystonia-parkinsonism]. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O" ]	[The relation between metabolism of biopterin and dystonia-parkinsonism].	[ "[", "The", "relation", "between", "metabolism", "of", "biopterin", "and", "dystonia", "-", "parkinsonism", "]", "." ]	[ "GENE-Y", "CHEMICAL" ]
Tumor is a MORFOLOGIA_NEOPLASIA, carcinoma intraductal de alto grado is a MORFOLOGIA_NEOPLASIA, metástasis de acenocarcinoma is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, Carcinoma intraductal is a MORFOLOGIA_NEOPLASIA, cT4dNxM0 is a MORFOLOGIA_NEOPLASIA, carcinoma is a MORFOLOGIA_NEOPLASIA, metastásicas is a MORFOLOGIA_NEOPLASIA	81_task0	Sentence: Anamnesis Mujer de 51 años, sin alergias medicamentosas conocidas. No antecedentes médicos de interés. Intervenida de lesión benigna de la mama derecha y quistectomía en la trompa de Falopio. Fumadora de 1 paquete/día. No embarazos. Menarquia a los 10 años y menopausia a los 46 años. Acude a su médico de cabecera por una lesión eritematosa e inflamatoria en la mama izquierda, orientada como mastitis, para la que se pauta tratamiento antibiótico. Exploración física Estable hemodinámicamente. ECOG 0. ACP: dentro de la normalidad. Tumor inflamatorio que ocupa los cuatro cuadrantes de la mama izquierda, con mayor afectación inflamatoria en ambos cuadrantes inferiores. No adenopatías palpables axilares ni supraclaviculares. Pruebas complementarias Se inicia estudio de manera ambulatoria, con la realización de las siguientes pruebas complementarias: » Mamografía (27/6/14): engrosamiento difuso de la piel de la mama izquierda. Marcado aumento de la reticulación del tejido graso subcutáneo. BIRADS 0. » Resonancia magnética (RM) (3/7/14): notable asimetría. Mama izquierda con engrosamiento de la piel, el pezón y la areola. Presencia de un ganglio linfático de 14 mm en la axila izquierda. » Biopsia ecodirigida con resultado anatomopatológico: carcinoma intraductal de alto grado, con necrosis y microcalcificaciones. Receptores hormonales (RH) negativos, HER2 positivo, Ki-67 27% » PAAF axilar: compatible con metástasis de acenocarcinoma » Se solicitan una TC toracoabdominal (TC TA) y una gamagrafía ósea (GGO), que descartan metástasis. » Se solicita una ventriculografía isotópica para la valoración de la función cardíaca previa al tratamiento con antraciclina (FEV 62%). Diagnóstico Carcinoma intraductal de mama izquierda, cT4dNxM0 (estadio III), RH-, HER2+, Ki-67 27%. Tratamiento Paciente candidata a quimioterapia neoadyuvante; se inicia en agosto de 2014 con esquema antraciclina + taxanos + trastuzumab + pertuzumab. Evolución La paciente realiza cuatro ciclos de quimioterapia con el esquema arriba indicado, presentando como complicación durante este período neutropenia grado 3. El 28 de octubre de 2014 acude a consulta para continuar el tratamiento. Clínicamente, presenta astenia grado 3, con aparición de eritema en el surco intermamario. Se solicita punch de la lesión, con positividad para carcinoma de origen mamario, RH-, HER2+, por lo tanto se trata de una progresión local en el curso de la neoadyuvancia. Valorada por Cirugía, que descarta cirugía de rescate por extensa afectación cutánea, se realiza un nuevo estudio de estadificación con TC TA y GGO, sin lesiones metastásicas. Valorado el caso en comité de mama, se decide cambio a segunda línea con capecitabina + lapatinib. Actualmente, la paciente ha realizado seis ciclos, con total desaparición de la lesión inflamatoria en la mama, y con RM sin captaciones patológicas nodulares focales ni adenopatías de tamaño patológico a nivel axilar, ni en las cadenas mamarias internas. Actualmente está en espera de mastectomía radical y posterior tratamiento con radioterapia local. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Mujer de 51 años, sin alergias medicamentosas conocidas. No antecedentes médicos de interés. Intervenida de lesión benigna de la mama derecha y quistectomía en la trompa de Falopio. Fumadora de 1 paquete/día. No embarazos. Menarquia a los 10 años y menopausia a los 46 años. Acude a su médico de cabecera por una lesión eritematosa e inflamatoria en la mama izquierda, orientada como mastitis, para la que se pauta tratamiento antibiótico. Exploración física Estable hemodinámicamente. ECOG 0. ACP: dentro de la normalidad. Tumor inflamatorio que ocupa los cuatro cuadrantes de la mama izquierda, con mayor afectación inflamatoria en ambos cuadrantes inferiores. No adenopatías palpables axilares ni supraclaviculares. Pruebas complementarias Se inicia estudio de manera ambulatoria, con la realización de las siguientes pruebas complementarias: » Mamografía (27/6/14): engrosamiento difuso de la piel de la mama izquierda. Marcado aumento de la reticulación del tejido graso subcutáneo. BIRADS 0. » Resonancia magnética (RM) (3/7/14): notable asimetría. Mama izquierda con engrosamiento de la piel, el pezón y la areola. Presencia de un ganglio linfático de 14 mm en la axila izquierda. » Biopsia ecodirigida con resultado anatomopatológico: carcinoma intraductal de alto grado, con necrosis y microcalcificaciones. Receptores hormonales (RH) negativos, HER2 positivo, Ki-67 27% » PAAF axilar: compatible con metástasis de acenocarcinoma » Se solicitan una TC toracoabdominal (TC TA) y una gamagrafía ósea (GGO), que descartan metástasis. » Se solicita una ventriculografía isotópica para la valoración de la función cardíaca previa al tratamiento con antraciclina (FEV 62%). Diagnóstico Carcinoma intraductal de mama izquierda, cT4dNxM0 (estadio III), RH-, HER2+, Ki-67 27%. Tratamiento Paciente candidata a quimioterapia neoadyuvante; se inicia en agosto de 2014 con esquema antraciclina + taxanos + trastuzumab + pertuzumab. Evolución La paciente realiza cuatro ciclos de quimioterapia con el esquema arriba indicado, presentando como complicación durante este período neutropenia grado 3. El 28 de octubre de 2014 acude a consulta para continuar el tratamiento. Clínicamente, presenta astenia grado 3, con aparición de eritema en el surco intermamario. Se solicita punch de la lesión, con positividad para carcinoma de origen mamario, RH-, HER2+, por lo tanto se trata de una progresión local en el curso de la neoadyuvancia. Valorada por Cirugía, que descarta cirugía de rescate por extensa afectación cutánea, se realiza un nuevo estudio de estadificación con TC TA y GGO, sin lesiones metastásicas. Valorado el caso en comité de mama, se decide cambio a segunda línea con capecitabina + lapatinib. Actualmente, la paciente ha realizado seis ciclos, con total desaparición de la lesión inflamatoria en la mama, y con RM sin captaciones patológicas nodulares focales ni adenopatías de tamaño patológico a nivel axilar, ni en las cadenas mamarias internas. Actualmente está en espera de mastectomía radical y posterior tratamiento con radioterapia local.	[ "Anamnesis", "\n", "Mujer", "de", "51", "años", ",", "sin", "alergias", "medicamentosas", "conocidas", ".", "No", "antecedentes", "médicos", "de", "interés", ".", "\n", "Intervenida", "de", "lesión", "benigna", "de", "la", "mama", "derecha", "y", "quistectomía", "en", "la", "trompa", "de", "Falopio", ".", "Fumadora", "de", "1", "paquete", "/", "día", ".", "No", "embarazos", ".", "Menarquia", "a", "los", "10", "años", "y", "menopausia", "a", "los", "46", "años", ".", "\n\n", "Acude", "a", "su", "médico", "de", "cabecera", "por", "una", "lesión", "eritematosa", "e", "inflamatoria", "en", "la", "mama", "izquierda", ",", "orientada", "como", "mastitis", ",", "para", "la", "que", "se", "pauta", "tratamiento", "antibiótico", ".", "\n\n", "Exploración", "física", "\n", "Estable", "hemodinámicamente", ".", "ECOG", "0", ".", "ACP", ":", "dentro", "de", "la", "normalidad", ".", "Tumor", "inflamatorio", "que", "ocupa", "los", "cuatro", "cuadrantes", "de", "la", "mama", "izquierda", ",", "con", "mayor", "afectación", "inflamatoria", "en", "ambos", "cuadrantes", "inferiores", ".", "No", "adenopatías", "palpables", "axilares", "ni", "supraclaviculares", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "inicia", "estudio", "de", "manera", "ambulatoria", ",", "con", "la", "realización", "de", "las", "siguientes", "pruebas", "complementarias", ":", "\n", "»", "Mamografía", "(", "27/6/14", "):", "engrosamiento", "difuso", "de", "la", "piel", "de", "la", "mama", "izquierda", ".", "Marcado", "aumento", "de", "la", "reticulación", "del", "tejido", "graso", "subcutáneo", ".", "BIRADS", "0", ".", "\n", "»", "Resonancia", "magnética", "(", "RM", ")", "(", "3/7/14", "):", "notable", "asimetría", ".", "Mama", "izquierda", "con", "engrosamiento", "de", "la", "piel", ",", "el", "pezón", "y", "la", "areola", ".", "Presencia", "de", "un", "ganglio", "linfático", "de", "14", "mm", "en", "la", "axila", "izquierda", ".", "\n", "»", "Biopsia", "ecodirigida", "con", "resultado", "anatomopatológico", ":", "carcinoma", "intraductal", "de", "alto", "grado", ",", "con", "necrosis", "y", "microcalcificaciones", ".", "Receptores", "hormonales", "(", "RH", ")", "negativos", ",", "HER2", "positivo", ",", "Ki-67", "27", "%", "\n", "»", "PAAF", "axilar", ":", "compatible", "con", "metástasis", "de", "acenocarcinoma", "\n", "»", "Se", "solicitan", "una", "TC", "toracoabdominal", "(", "TC", "TA", ")", "y", "una", "gamagrafía", "ósea", "(", "GGO", ")", ",", "que", "descartan", "metástasis", ".", "\n", "»", "Se", "solicita", "una", "ventriculografía", "isotópica", "para", "la", "valoración", "de", "la", "función", "cardíaca", "previa", "al", "tratamiento", "con", "antraciclina", "(", "FEV", "62", "%", ")", ".", "\n\n", "Diagnóstico", "\n", "Carcinoma", "intraductal", "de", "mama", "izquierda", ",", "cT4dNxM0", "(", "estadio", "III", ")", ",", "RH-", ",", "HER2", "+", ",", "Ki-67", "27", "%", ".", "\n\n", "Tratamiento", "\n", "Paciente", "candidata", "a", "quimioterapia", "neoadyuvante", ";", "se", "inicia", "en", "agosto", "de", "2014", "con", "esquema", "antraciclina", "+", "taxanos", "+", "trastuzumab", "+", "pertuzumab", ".", "\n\n", "Evolución", "\n", "La", "paciente", "realiza", "cuatro", "ciclos", "de", "quimioterapia", "con", "el", "esquema", "arriba", "indicado", ",", "presentando", "como", "complicación", "durante", "este", "período", "neutropenia", "grado", "3", ".", "El", "28", "de", "octubre", "de", "2014", "acude", "a", "consulta", "para", "continuar", "el", "tratamiento", ".", "Clínicamente", ",", "presenta", "astenia", "grado", "3", ",", "con", "aparición", "de", "eritema", "en", "el", "surco", "intermamario", ".", "Se", "solicita", "punch", "de", "la", "lesión", ",", "con", "positividad", "para", "carcinoma", "de", "origen", "mamario", ",", "RH-", ",", "HER2", "+", ",", "por", "lo", "tanto", "se", "trata", "de", "una", "progresión", "local", "en", "el", "curso", "de", "la", "neoadyuvancia", ".", "Valorada", "por", "Cirugía", ",", "que", "descarta", "cirugía", "de", "rescate", "por", "extensa", "afectación", "cutánea", ",", "se", "realiza", "un", "nuevo", "estudio", "de", "estadificación", "con", "TC", "TA", "y", "GGO", ",", "sin", "lesiones", "metastásicas", ".", "Valorado", "el", "caso", "en", "comité", "de", "mama", ",", "se", "decide", "cambio", "a", "segunda", "línea", "con", "capecitabina", "+", "lapatinib", ".", "Actualmente", ",", "la", "paciente", "ha", "realizado", "seis", "ciclos", ",", "con", "total", "desaparición", "de", "la", "lesión", "inflamatoria", "en", "la", "mama", ",", "y", "con", "RM", "sin", "captaciones", "patológicas", "nodulares", "focales", "ni", "adenopatías", "de", "tamaño", "patológico", "a", "nivel", "axilar", ",", "ni", "en", "las", "cadenas", "mamarias", "internas", ".", "Actualmente", "está", "en", "espera", "de", "mastectomía", "radical", "y", "posterior", "tratamiento", "con", "radioterapia", "local", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
Tumor is a MORFOLOGIA_NEOPLASIA, carcinoma intraductal de alto grado is a MORFOLOGIA_NEOPLASIA, metástasis de acenocarcinoma is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, Carcinoma intraductal is a MORFOLOGIA_NEOPLASIA, cT4dNxM0 is a MORFOLOGIA_NEOPLASIA, carcinoma is a MORFOLOGIA_NEOPLASIA, metastásicas is a MORFOLOGIA_NEOPLASIA	81_task1	Sentence: Anamnesis Mujer de 51 años, sin alergias medicamentosas conocidas. No antecedentes médicos de interés. Intervenida de lesión benigna de la mama derecha y quistectomía en la trompa de Falopio. Fumadora de 1 paquete/día. No embarazos. Menarquia a los 10 años y menopausia a los 46 años. Acude a su médico de cabecera por una lesión eritematosa e inflamatoria en la mama izquierda, orientada como mastitis, para la que se pauta tratamiento antibiótico. Exploración física Estable hemodinámicamente. ECOG 0. ACP: dentro de la normalidad. Tumor inflamatorio que ocupa los cuatro cuadrantes de la mama izquierda, con mayor afectación inflamatoria en ambos cuadrantes inferiores. No adenopatías palpables axilares ni supraclaviculares. Pruebas complementarias Se inicia estudio de manera ambulatoria, con la realización de las siguientes pruebas complementarias: » Mamografía (27/6/14): engrosamiento difuso de la piel de la mama izquierda. Marcado aumento de la reticulación del tejido graso subcutáneo. BIRADS 0. » Resonancia magnética (RM) (3/7/14): notable asimetría. Mama izquierda con engrosamiento de la piel, el pezón y la areola. Presencia de un ganglio linfático de 14 mm en la axila izquierda. » Biopsia ecodirigida con resultado anatomopatológico: carcinoma intraductal de alto grado, con necrosis y microcalcificaciones. Receptores hormonales (RH) negativos, HER2 positivo, Ki-67 27% » PAAF axilar: compatible con metástasis de acenocarcinoma » Se solicitan una TC toracoabdominal (TC TA) y una gamagrafía ósea (GGO), que descartan metástasis. » Se solicita una ventriculografía isotópica para la valoración de la función cardíaca previa al tratamiento con antraciclina (FEV 62%). Diagnóstico Carcinoma intraductal de mama izquierda, cT4dNxM0 (estadio III), RH-, HER2+, Ki-67 27%. Tratamiento Paciente candidata a quimioterapia neoadyuvante; se inicia en agosto de 2014 con esquema antraciclina + taxanos + trastuzumab + pertuzumab. Evolución La paciente realiza cuatro ciclos de quimioterapia con el esquema arriba indicado, presentando como complicación durante este período neutropenia grado 3. El 28 de octubre de 2014 acude a consulta para continuar el tratamiento. Clínicamente, presenta astenia grado 3, con aparición de eritema en el surco intermamario. Se solicita punch de la lesión, con positividad para carcinoma de origen mamario, RH-, HER2+, por lo tanto se trata de una progresión local en el curso de la neoadyuvancia. Valorada por Cirugía, que descarta cirugía de rescate por extensa afectación cutánea, se realiza un nuevo estudio de estadificación con TC TA y GGO, sin lesiones metastásicas. Valorado el caso en comité de mama, se decide cambio a segunda línea con capecitabina + lapatinib. Actualmente, la paciente ha realizado seis ciclos, con total desaparición de la lesión inflamatoria en la mama, y con RM sin captaciones patológicas nodulares focales ni adenopatías de tamaño patológico a nivel axilar, ni en las cadenas mamarias internas. Actualmente está en espera de mastectomía radical y posterior tratamiento con radioterapia local. Instructions: please typing these entity words according to sentence: Tumor, carcinoma intraductal de alto grado, metástasis de acenocarcinoma, metástasis, Carcinoma intraductal, cT4dNxM0, carcinoma, metastásicas Options: MORFOLOGIA_NEOPLASIA	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Mujer de 51 años, sin alergias medicamentosas conocidas. No antecedentes médicos de interés. Intervenida de lesión benigna de la mama derecha y quistectomía en la trompa de Falopio. Fumadora de 1 paquete/día. No embarazos. Menarquia a los 10 años y menopausia a los 46 años. Acude a su médico de cabecera por una lesión eritematosa e inflamatoria en la mama izquierda, orientada como mastitis, para la que se pauta tratamiento antibiótico. Exploración física Estable hemodinámicamente. ECOG 0. ACP: dentro de la normalidad. Tumor inflamatorio que ocupa los cuatro cuadrantes de la mama izquierda, con mayor afectación inflamatoria en ambos cuadrantes inferiores. No adenopatías palpables axilares ni supraclaviculares. Pruebas complementarias Se inicia estudio de manera ambulatoria, con la realización de las siguientes pruebas complementarias: » Mamografía (27/6/14): engrosamiento difuso de la piel de la mama izquierda. Marcado aumento de la reticulación del tejido graso subcutáneo. BIRADS 0. » Resonancia magnética (RM) (3/7/14): notable asimetría. Mama izquierda con engrosamiento de la piel, el pezón y la areola. Presencia de un ganglio linfático de 14 mm en la axila izquierda. » Biopsia ecodirigida con resultado anatomopatológico: carcinoma intraductal de alto grado, con necrosis y microcalcificaciones. Receptores hormonales (RH) negativos, HER2 positivo, Ki-67 27% » PAAF axilar: compatible con metástasis de acenocarcinoma » Se solicitan una TC toracoabdominal (TC TA) y una gamagrafía ósea (GGO), que descartan metástasis. » Se solicita una ventriculografía isotópica para la valoración de la función cardíaca previa al tratamiento con antraciclina (FEV 62%). Diagnóstico Carcinoma intraductal de mama izquierda, cT4dNxM0 (estadio III), RH-, HER2+, Ki-67 27%. Tratamiento Paciente candidata a quimioterapia neoadyuvante; se inicia en agosto de 2014 con esquema antraciclina + taxanos + trastuzumab + pertuzumab. Evolución La paciente realiza cuatro ciclos de quimioterapia con el esquema arriba indicado, presentando como complicación durante este período neutropenia grado 3. El 28 de octubre de 2014 acude a consulta para continuar el tratamiento. Clínicamente, presenta astenia grado 3, con aparición de eritema en el surco intermamario. Se solicita punch de la lesión, con positividad para carcinoma de origen mamario, RH-, HER2+, por lo tanto se trata de una progresión local en el curso de la neoadyuvancia. Valorada por Cirugía, que descarta cirugía de rescate por extensa afectación cutánea, se realiza un nuevo estudio de estadificación con TC TA y GGO, sin lesiones metastásicas. Valorado el caso en comité de mama, se decide cambio a segunda línea con capecitabina + lapatinib. Actualmente, la paciente ha realizado seis ciclos, con total desaparición de la lesión inflamatoria en la mama, y con RM sin captaciones patológicas nodulares focales ni adenopatías de tamaño patológico a nivel axilar, ni en las cadenas mamarias internas. Actualmente está en espera de mastectomía radical y posterior tratamiento con radioterapia local.	[ "Anamnesis", "\n", "Mujer", "de", "51", "años", ",", "sin", "alergias", "medicamentosas", "conocidas", ".", "No", "antecedentes", "médicos", "de", "interés", ".", "\n", "Intervenida", "de", "lesión", "benigna", "de", "la", "mama", "derecha", "y", "quistectomía", "en", "la", "trompa", "de", "Falopio", ".", "Fumadora", "de", "1", "paquete", "/", "día", ".", "No", "embarazos", ".", "Menarquia", "a", "los", "10", "años", "y", "menopausia", "a", "los", "46", "años", ".", "\n\n", "Acude", "a", "su", "médico", "de", "cabecera", "por", "una", "lesión", "eritematosa", "e", "inflamatoria", "en", "la", "mama", "izquierda", ",", "orientada", "como", "mastitis", ",", "para", "la", "que", "se", "pauta", "tratamiento", "antibiótico", ".", "\n\n", "Exploración", "física", "\n", "Estable", "hemodinámicamente", ".", "ECOG", "0", ".", "ACP", ":", "dentro", "de", "la", "normalidad", ".", "Tumor", "inflamatorio", "que", "ocupa", "los", "cuatro", "cuadrantes", "de", "la", "mama", "izquierda", ",", "con", "mayor", "afectación", "inflamatoria", "en", "ambos", "cuadrantes", "inferiores", ".", "No", "adenopatías", "palpables", "axilares", "ni", "supraclaviculares", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "inicia", "estudio", "de", "manera", "ambulatoria", ",", "con", "la", "realización", "de", "las", "siguientes", "pruebas", "complementarias", ":", "\n", "»", "Mamografía", "(", "27/6/14", "):", "engrosamiento", "difuso", "de", "la", "piel", "de", "la", "mama", "izquierda", ".", "Marcado", "aumento", "de", "la", "reticulación", "del", "tejido", "graso", "subcutáneo", ".", "BIRADS", "0", ".", "\n", "»", "Resonancia", "magnética", "(", "RM", ")", "(", "3/7/14", "):", "notable", "asimetría", ".", "Mama", "izquierda", "con", "engrosamiento", "de", "la", "piel", ",", "el", "pezón", "y", "la", "areola", ".", "Presencia", "de", "un", "ganglio", "linfático", "de", "14", "mm", "en", "la", "axila", "izquierda", ".", "\n", "»", "Biopsia", "ecodirigida", "con", "resultado", "anatomopatológico", ":", "carcinoma", "intraductal", "de", "alto", "grado", ",", "con", "necrosis", "y", "microcalcificaciones", ".", "Receptores", "hormonales", "(", "RH", ")", "negativos", ",", "HER2", "positivo", ",", "Ki-67", "27", "%", "\n", "»", "PAAF", "axilar", ":", "compatible", "con", "metástasis", "de", "acenocarcinoma", "\n", "»", "Se", "solicitan", "una", "TC", "toracoabdominal", "(", "TC", "TA", ")", "y", "una", "gamagrafía", "ósea", "(", "GGO", ")", ",", "que", "descartan", "metástasis", ".", "\n", "»", "Se", "solicita", "una", "ventriculografía", "isotópica", "para", "la", "valoración", "de", "la", "función", "cardíaca", "previa", "al", "tratamiento", "con", "antraciclina", "(", "FEV", "62", "%", ")", ".", "\n\n", "Diagnóstico", "\n", "Carcinoma", "intraductal", "de", "mama", "izquierda", ",", "cT4dNxM0", "(", "estadio", "III", ")", ",", "RH-", ",", "HER2", "+", ",", "Ki-67", "27", "%", ".", "\n\n", "Tratamiento", "\n", "Paciente", "candidata", "a", "quimioterapia", "neoadyuvante", ";", "se", "inicia", "en", "agosto", "de", "2014", "con", "esquema", "antraciclina", "+", "taxanos", "+", "trastuzumab", "+", "pertuzumab", ".", "\n\n", "Evolución", "\n", "La", "paciente", "realiza", "cuatro", "ciclos", "de", "quimioterapia", "con", "el", "esquema", "arriba", "indicado", ",", "presentando", "como", "complicación", "durante", "este", "período", "neutropenia", "grado", "3", ".", "El", "28", "de", "octubre", "de", "2014", "acude", "a", "consulta", "para", "continuar", "el", "tratamiento", ".", "Clínicamente", ",", "presenta", "astenia", "grado", "3", ",", "con", "aparición", "de", "eritema", "en", "el", "surco", "intermamario", ".", "Se", "solicita", "punch", "de", "la", "lesión", ",", "con", "positividad", "para", "carcinoma", "de", "origen", "mamario", ",", "RH-", ",", "HER2", "+", ",", "por", "lo", "tanto", "se", "trata", "de", "una", "progresión", "local", "en", "el", "curso", "de", "la", "neoadyuvancia", ".", "Valorada", "por", "Cirugía", ",", "que", "descarta", "cirugía", "de", "rescate", "por", "extensa", "afectación", "cutánea", ",", "se", "realiza", "un", "nuevo", "estudio", "de", "estadificación", "con", "TC", "TA", "y", "GGO", ",", "sin", "lesiones", "metastásicas", ".", "Valorado", "el", "caso", "en", "comité", "de", "mama", ",", "se", "decide", "cambio", "a", "segunda", "línea", "con", "capecitabina", "+", "lapatinib", ".", "Actualmente", ",", "la", "paciente", "ha", "realizado", "seis", "ciclos", ",", "con", "total", "desaparición", "de", "la", "lesión", "inflamatoria", "en", "la", "mama", ",", "y", "con", "RM", "sin", "captaciones", "patológicas", "nodulares", "focales", "ni", "adenopatías", "de", "tamaño", "patológico", "a", "nivel", "axilar", ",", "ni", "en", "las", "cadenas", "mamarias", "internas", ".", "Actualmente", "está", "en", "espera", "de", "mastectomía", "radical", "y", "posterior", "tratamiento", "con", "radioterapia", "local", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
Tumor, carcinoma intraductal de alto grado, metástasis de acenocarcinoma, metástasis, Carcinoma intraductal, cT4dNxM0, carcinoma, metastásicas	81_task2	Sentence: Anamnesis Mujer de 51 años, sin alergias medicamentosas conocidas. No antecedentes médicos de interés. Intervenida de lesión benigna de la mama derecha y quistectomía en la trompa de Falopio. Fumadora de 1 paquete/día. No embarazos. Menarquia a los 10 años y menopausia a los 46 años. Acude a su médico de cabecera por una lesión eritematosa e inflamatoria en la mama izquierda, orientada como mastitis, para la que se pauta tratamiento antibiótico. Exploración física Estable hemodinámicamente. ECOG 0. ACP: dentro de la normalidad. Tumor inflamatorio que ocupa los cuatro cuadrantes de la mama izquierda, con mayor afectación inflamatoria en ambos cuadrantes inferiores. No adenopatías palpables axilares ni supraclaviculares. Pruebas complementarias Se inicia estudio de manera ambulatoria, con la realización de las siguientes pruebas complementarias: » Mamografía (27/6/14): engrosamiento difuso de la piel de la mama izquierda. Marcado aumento de la reticulación del tejido graso subcutáneo. BIRADS 0. » Resonancia magnética (RM) (3/7/14): notable asimetría. Mama izquierda con engrosamiento de la piel, el pezón y la areola. Presencia de un ganglio linfático de 14 mm en la axila izquierda. » Biopsia ecodirigida con resultado anatomopatológico: carcinoma intraductal de alto grado, con necrosis y microcalcificaciones. Receptores hormonales (RH) negativos, HER2 positivo, Ki-67 27% » PAAF axilar: compatible con metástasis de acenocarcinoma » Se solicitan una TC toracoabdominal (TC TA) y una gamagrafía ósea (GGO), que descartan metástasis. » Se solicita una ventriculografía isotópica para la valoración de la función cardíaca previa al tratamiento con antraciclina (FEV 62%). Diagnóstico Carcinoma intraductal de mama izquierda, cT4dNxM0 (estadio III), RH-, HER2+, Ki-67 27%. Tratamiento Paciente candidata a quimioterapia neoadyuvante; se inicia en agosto de 2014 con esquema antraciclina + taxanos + trastuzumab + pertuzumab. Evolución La paciente realiza cuatro ciclos de quimioterapia con el esquema arriba indicado, presentando como complicación durante este período neutropenia grado 3. El 28 de octubre de 2014 acude a consulta para continuar el tratamiento. Clínicamente, presenta astenia grado 3, con aparición de eritema en el surco intermamario. Se solicita punch de la lesión, con positividad para carcinoma de origen mamario, RH-, HER2+, por lo tanto se trata de una progresión local en el curso de la neoadyuvancia. Valorada por Cirugía, que descarta cirugía de rescate por extensa afectación cutánea, se realiza un nuevo estudio de estadificación con TC TA y GGO, sin lesiones metastásicas. Valorado el caso en comité de mama, se decide cambio a segunda línea con capecitabina + lapatinib. Actualmente, la paciente ha realizado seis ciclos, con total desaparición de la lesión inflamatoria en la mama, y con RM sin captaciones patológicas nodulares focales ni adenopatías de tamaño patológico a nivel axilar, ni en las cadenas mamarias internas. Actualmente está en espera de mastectomía radical y posterior tratamiento con radioterapia local. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Anamnesis Mujer de 51 años, sin alergias medicamentosas conocidas. No antecedentes médicos de interés. Intervenida de lesión benigna de la mama derecha y quistectomía en la trompa de Falopio. Fumadora de 1 paquete/día. No embarazos. Menarquia a los 10 años y menopausia a los 46 años. Acude a su médico de cabecera por una lesión eritematosa e inflamatoria en la mama izquierda, orientada como mastitis, para la que se pauta tratamiento antibiótico. Exploración física Estable hemodinámicamente. ECOG 0. ACP: dentro de la normalidad. Tumor inflamatorio que ocupa los cuatro cuadrantes de la mama izquierda, con mayor afectación inflamatoria en ambos cuadrantes inferiores. No adenopatías palpables axilares ni supraclaviculares. Pruebas complementarias Se inicia estudio de manera ambulatoria, con la realización de las siguientes pruebas complementarias: » Mamografía (27/6/14): engrosamiento difuso de la piel de la mama izquierda. Marcado aumento de la reticulación del tejido graso subcutáneo. BIRADS 0. » Resonancia magnética (RM) (3/7/14): notable asimetría. Mama izquierda con engrosamiento de la piel, el pezón y la areola. Presencia de un ganglio linfático de 14 mm en la axila izquierda. » Biopsia ecodirigida con resultado anatomopatológico: carcinoma intraductal de alto grado, con necrosis y microcalcificaciones. Receptores hormonales (RH) negativos, HER2 positivo, Ki-67 27% » PAAF axilar: compatible con metástasis de acenocarcinoma » Se solicitan una TC toracoabdominal (TC TA) y una gamagrafía ósea (GGO), que descartan metástasis. » Se solicita una ventriculografía isotópica para la valoración de la función cardíaca previa al tratamiento con antraciclina (FEV 62%). Diagnóstico Carcinoma intraductal de mama izquierda, cT4dNxM0 (estadio III), RH-, HER2+, Ki-67 27%. Tratamiento Paciente candidata a quimioterapia neoadyuvante; se inicia en agosto de 2014 con esquema antraciclina + taxanos + trastuzumab + pertuzumab. Evolución La paciente realiza cuatro ciclos de quimioterapia con el esquema arriba indicado, presentando como complicación durante este período neutropenia grado 3. El 28 de octubre de 2014 acude a consulta para continuar el tratamiento. Clínicamente, presenta astenia grado 3, con aparición de eritema en el surco intermamario. Se solicita punch de la lesión, con positividad para carcinoma de origen mamario, RH-, HER2+, por lo tanto se trata de una progresión local en el curso de la neoadyuvancia. Valorada por Cirugía, que descarta cirugía de rescate por extensa afectación cutánea, se realiza un nuevo estudio de estadificación con TC TA y GGO, sin lesiones metastásicas. Valorado el caso en comité de mama, se decide cambio a segunda línea con capecitabina + lapatinib. Actualmente, la paciente ha realizado seis ciclos, con total desaparición de la lesión inflamatoria en la mama, y con RM sin captaciones patológicas nodulares focales ni adenopatías de tamaño patológico a nivel axilar, ni en las cadenas mamarias internas. Actualmente está en espera de mastectomía radical y posterior tratamiento con radioterapia local.	[ "Anamnesis", "\n", "Mujer", "de", "51", "años", ",", "sin", "alergias", "medicamentosas", "conocidas", ".", "No", "antecedentes", "médicos", "de", "interés", ".", "\n", "Intervenida", "de", "lesión", "benigna", "de", "la", "mama", "derecha", "y", "quistectomía", "en", "la", "trompa", "de", "Falopio", ".", "Fumadora", "de", "1", "paquete", "/", "día", ".", "No", "embarazos", ".", "Menarquia", "a", "los", "10", "años", "y", "menopausia", "a", "los", "46", "años", ".", "\n\n", "Acude", "a", "su", "médico", "de", "cabecera", "por", "una", "lesión", "eritematosa", "e", "inflamatoria", "en", "la", "mama", "izquierda", ",", "orientada", "como", "mastitis", ",", "para", "la", "que", "se", "pauta", "tratamiento", "antibiótico", ".", "\n\n", "Exploración", "física", "\n", "Estable", "hemodinámicamente", ".", "ECOG", "0", ".", "ACP", ":", "dentro", "de", "la", "normalidad", ".", "Tumor", "inflamatorio", "que", "ocupa", "los", "cuatro", "cuadrantes", "de", "la", "mama", "izquierda", ",", "con", "mayor", "afectación", "inflamatoria", "en", "ambos", "cuadrantes", "inferiores", ".", "No", "adenopatías", "palpables", "axilares", "ni", "supraclaviculares", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "inicia", "estudio", "de", "manera", "ambulatoria", ",", "con", "la", "realización", "de", "las", "siguientes", "pruebas", "complementarias", ":", "\n", "»", "Mamografía", "(", "27/6/14", "):", "engrosamiento", "difuso", "de", "la", "piel", "de", "la", "mama", "izquierda", ".", "Marcado", "aumento", "de", "la", "reticulación", "del", "tejido", "graso", "subcutáneo", ".", "BIRADS", "0", ".", "\n", "»", "Resonancia", "magnética", "(", "RM", ")", "(", "3/7/14", "):", "notable", "asimetría", ".", "Mama", "izquierda", "con", "engrosamiento", "de", "la", "piel", ",", "el", "pezón", "y", "la", "areola", ".", "Presencia", "de", "un", "ganglio", "linfático", "de", "14", "mm", "en", "la", "axila", "izquierda", ".", "\n", "»", "Biopsia", "ecodirigida", "con", "resultado", "anatomopatológico", ":", "carcinoma", "intraductal", "de", "alto", "grado", ",", "con", "necrosis", "y", "microcalcificaciones", ".", "Receptores", "hormonales", "(", "RH", ")", "negativos", ",", "HER2", "positivo", ",", "Ki-67", "27", "%", "\n", "»", "PAAF", "axilar", ":", "compatible", "con", "metástasis", "de", "acenocarcinoma", "\n", "»", "Se", "solicitan", "una", "TC", "toracoabdominal", "(", "TC", "TA", ")", "y", "una", "gamagrafía", "ósea", "(", "GGO", ")", ",", "que", "descartan", "metástasis", ".", "\n", "»", "Se", "solicita", "una", "ventriculografía", "isotópica", "para", "la", "valoración", "de", "la", "función", "cardíaca", "previa", "al", "tratamiento", "con", "antraciclina", "(", "FEV", "62", "%", ")", ".", "\n\n", "Diagnóstico", "\n", "Carcinoma", "intraductal", "de", "mama", "izquierda", ",", "cT4dNxM0", "(", "estadio", "III", ")", ",", "RH-", ",", "HER2", "+", ",", "Ki-67", "27", "%", ".", "\n\n", "Tratamiento", "\n", "Paciente", "candidata", "a", "quimioterapia", "neoadyuvante", ";", "se", "inicia", "en", "agosto", "de", "2014", "con", "esquema", "antraciclina", "+", "taxanos", "+", "trastuzumab", "+", "pertuzumab", ".", "\n\n", "Evolución", "\n", "La", "paciente", "realiza", "cuatro", "ciclos", "de", "quimioterapia", "con", "el", "esquema", "arriba", "indicado", ",", "presentando", "como", "complicación", "durante", "este", "período", "neutropenia", "grado", "3", ".", "El", "28", "de", "octubre", "de", "2014", "acude", "a", "consulta", "para", "continuar", "el", "tratamiento", ".", "Clínicamente", ",", "presenta", "astenia", "grado", "3", ",", "con", "aparición", "de", "eritema", "en", "el", "surco", "intermamario", ".", "Se", "solicita", "punch", "de", "la", "lesión", ",", "con", "positividad", "para", "carcinoma", "de", "origen", "mamario", ",", "RH-", ",", "HER2", "+", ",", "por", "lo", "tanto", "se", "trata", "de", "una", "progresión", "local", "en", "el", "curso", "de", "la", "neoadyuvancia", ".", "Valorada", "por", "Cirugía", ",", "que", "descarta", "cirugía", "de", "rescate", "por", "extensa", "afectación", "cutánea", ",", "se", "realiza", "un", "nuevo", "estudio", "de", "estadificación", "con", "TC", "TA", "y", "GGO", ",", "sin", "lesiones", "metastásicas", ".", "Valorado", "el", "caso", "en", "comité", "de", "mama", ",", "se", "decide", "cambio", "a", "segunda", "línea", "con", "capecitabina", "+", "lapatinib", ".", "Actualmente", ",", "la", "paciente", "ha", "realizado", "seis", "ciclos", ",", "con", "total", "desaparición", "de", "la", "lesión", "inflamatoria", "en", "la", "mama", ",", "y", "con", "RM", "sin", "captaciones", "patológicas", "nodulares", "focales", "ni", "adenopatías", "de", "tamaño", "patológico", "a", "nivel", "axilar", ",", "ni", "en", "las", "cadenas", "mamarias", "internas", ".", "Actualmente", "está", "en", "espera", "de", "mastectomía", "radical", "y", "posterior", "tratamiento", "con", "radioterapia", "local", "." ]	[ "MORFOLOGIA_NEOPLASIA" ]
Blind versus open approach to laparoscopic cholecystectomy : is a Intervention_Surgical, 150 is a Participant_Sample-size, gallbladder lithiasis is a Participant_Condition, laparoscopy is a Participant_Condition, rate of complications is a Outcome_Adverse-effects, mortality is a Outcome_Mortality, Major complications is a Outcome_Adverse-effects, Minor complications is a Outcome_Adverse-effects, achievement of pneumoperitoneum is a Outcome_Physical, open laparoscopic technique is a Intervention_Surgical, blind approach is a Intervention_Physical	92964_task0	Sentence: Blind versus open approach to laparoscopic cholecystectomy : a randomized study . Intraabdominal structures may be damaged during blind introduction of the first trocar for laparoscopic operations . In this study , 150 patients with gallbladder lithiasis who underwent laparoscopy were randomly assigned to two groups , a blind ( V group ) or an open ( H group ) , in order to compare the results and the rate of complications . No mortality was observed . Major complications occurred in 3/75 ( 4 % ) patients of the V group and in 1/75 ( 1.3 % ) patient of the H group ( p < 0.05 ) . Minor complications occurred in 5/75 ( 6.7 % ) patients of either group . The achievement of pneumoperitoneum required 4.5+/-0.4 min in the V group and 3.2+/-0.2 min in the H group ( p < 0.05 ) . The open laparoscopic technique is safer and faster than the blind approach ; therefore , it is proposed that this approach be routinely used in all laparoscopic procedures . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Adverse-effects, Intervention_Physical, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Intervention_Surgical	[ "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Blind versus open approach to laparoscopic cholecystectomy : a randomized study . Intraabdominal structures may be damaged during blind introduction of the first trocar for laparoscopic operations . In this study , 150 patients with gallbladder lithiasis who underwent laparoscopy were randomly assigned to two groups , a blind ( V group ) or an open ( H group ) , in order to compare the results and the rate of complications . No mortality was observed . Major complications occurred in 3/75 ( 4 % ) patients of the V group and in 1/75 ( 1.3 % ) patient of the H group ( p < 0.05 ) . Minor complications occurred in 5/75 ( 6.7 % ) patients of either group . The achievement of pneumoperitoneum required 4.5+/-0.4 min in the V group and 3.2+/-0.2 min in the H group ( p < 0.05 ) . The open laparoscopic technique is safer and faster than the blind approach ; therefore , it is proposed that this approach be routinely used in all laparoscopic procedures .	[ "Blind", "versus", "open", "approach", "to", "laparoscopic", "cholecystectomy", ":", "a", "randomized", "study", ".", "Intraabdominal", "structures", "may", "be", "damaged", "during", "blind", "introduction", "of", "the", "first", "trocar", "for", "laparoscopic", "operations", ".", "In", "this", "study", ",", "150", "patients", "with", "gallbladder", "lithiasis", "who", "underwent", "laparoscopy", "were", "randomly", "assigned", "to", "two", "groups", ",", "a", "blind", "(", "V", "group", ")", "or", "an", "open", "(", "H", "group", ")", ",", "in", "order", "to", "compare", "the", "results", "and", "the", "rate", "of", "complications", ".", "No", "mortality", "was", "observed", ".", "Major", "complications", "occurred", "in", "3/75", "(", "4", "%", ")", "patients", "of", "the", "V", "group", "and", "in", "1/75", "(", "1.3", "%", ")", "patient", "of", "the", "H", "group", "(", "p", "<", "0.05", ")", ".", "Minor", "complications", "occurred", "in", "5/75", "(", "6.7", "%", ")", "patients", "of", "either", "group", ".", "The", "achievement", "of", "pneumoperitoneum", "required", "4.5+/-0.4", "min", "in", "the", "V", "group", "and", "3.2+/-0.2", "min", "in", "the", "H", "group", "(", "p", "<", "0.05", ")", ".", "The", "open", "laparoscopic", "technique", "is", "safer", "and", "faster", "than", "the", "blind", "approach", ";", "therefore", ",", "it", "is", "proposed", "that", "this", "approach", "be", "routinely", "used", "in", "all", "laparoscopic", "procedures", "." ]	[ "Intervention_Surgical", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Condition", "Intervention_Physical", "Outcome_Mortality", "Participant_Sample-size" ]
Blind versus open approach to laparoscopic cholecystectomy : is a Intervention_Surgical, 150 is a Participant_Sample-size, gallbladder lithiasis is a Participant_Condition, laparoscopy is a Participant_Condition, rate of complications is a Outcome_Adverse-effects, mortality is a Outcome_Mortality, Major complications is a Outcome_Adverse-effects, Minor complications is a Outcome_Adverse-effects, achievement of pneumoperitoneum is a Outcome_Physical, open laparoscopic technique is a Intervention_Surgical, blind approach is a Intervention_Physical	92964_task1	Sentence: Blind versus open approach to laparoscopic cholecystectomy : a randomized study . Intraabdominal structures may be damaged during blind introduction of the first trocar for laparoscopic operations . In this study , 150 patients with gallbladder lithiasis who underwent laparoscopy were randomly assigned to two groups , a blind ( V group ) or an open ( H group ) , in order to compare the results and the rate of complications . No mortality was observed . Major complications occurred in 3/75 ( 4 % ) patients of the V group and in 1/75 ( 1.3 % ) patient of the H group ( p < 0.05 ) . Minor complications occurred in 5/75 ( 6.7 % ) patients of either group . The achievement of pneumoperitoneum required 4.5+/-0.4 min in the V group and 3.2+/-0.2 min in the H group ( p < 0.05 ) . The open laparoscopic technique is safer and faster than the blind approach ; therefore , it is proposed that this approach be routinely used in all laparoscopic procedures . Instructions: please typing these entity words according to sentence: Blind versus open approach to laparoscopic cholecystectomy :, 150, gallbladder lithiasis, laparoscopy, rate of complications, mortality, Major complications, Minor complications, achievement of pneumoperitoneum, open laparoscopic technique, blind approach Options: Outcome_Adverse-effects, Intervention_Physical, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Intervention_Surgical	[ "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Blind versus open approach to laparoscopic cholecystectomy : a randomized study . Intraabdominal structures may be damaged during blind introduction of the first trocar for laparoscopic operations . In this study , 150 patients with gallbladder lithiasis who underwent laparoscopy were randomly assigned to two groups , a blind ( V group ) or an open ( H group ) , in order to compare the results and the rate of complications . No mortality was observed . Major complications occurred in 3/75 ( 4 % ) patients of the V group and in 1/75 ( 1.3 % ) patient of the H group ( p < 0.05 ) . Minor complications occurred in 5/75 ( 6.7 % ) patients of either group . The achievement of pneumoperitoneum required 4.5+/-0.4 min in the V group and 3.2+/-0.2 min in the H group ( p < 0.05 ) . The open laparoscopic technique is safer and faster than the blind approach ; therefore , it is proposed that this approach be routinely used in all laparoscopic procedures .	[ "Blind", "versus", "open", "approach", "to", "laparoscopic", "cholecystectomy", ":", "a", "randomized", "study", ".", "Intraabdominal", "structures", "may", "be", "damaged", "during", "blind", "introduction", "of", "the", "first", "trocar", "for", "laparoscopic", "operations", ".", "In", "this", "study", ",", "150", "patients", "with", "gallbladder", "lithiasis", "who", "underwent", "laparoscopy", "were", "randomly", "assigned", "to", "two", "groups", ",", "a", "blind", "(", "V", "group", ")", "or", "an", "open", "(", "H", "group", ")", ",", "in", "order", "to", "compare", "the", "results", "and", "the", "rate", "of", "complications", ".", "No", "mortality", "was", "observed", ".", "Major", "complications", "occurred", "in", "3/75", "(", "4", "%", ")", "patients", "of", "the", "V", "group", "and", "in", "1/75", "(", "1.3", "%", ")", "patient", "of", "the", "H", "group", "(", "p", "<", "0.05", ")", ".", "Minor", "complications", "occurred", "in", "5/75", "(", "6.7", "%", ")", "patients", "of", "either", "group", ".", "The", "achievement", "of", "pneumoperitoneum", "required", "4.5+/-0.4", "min", "in", "the", "V", "group", "and", "3.2+/-0.2", "min", "in", "the", "H", "group", "(", "p", "<", "0.05", ")", ".", "The", "open", "laparoscopic", "technique", "is", "safer", "and", "faster", "than", "the", "blind", "approach", ";", "therefore", ",", "it", "is", "proposed", "that", "this", "approach", "be", "routinely", "used", "in", "all", "laparoscopic", "procedures", "." ]	[ "Intervention_Surgical", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Condition", "Intervention_Physical", "Outcome_Mortality", "Participant_Sample-size" ]
Blind versus open approach to laparoscopic cholecystectomy :, 150, gallbladder lithiasis, laparoscopy, rate of complications, mortality, Major complications, Minor complications, achievement of pneumoperitoneum, open laparoscopic technique, blind approach	92964_task2	Sentence: Blind versus open approach to laparoscopic cholecystectomy : a randomized study . Intraabdominal structures may be damaged during blind introduction of the first trocar for laparoscopic operations . In this study , 150 patients with gallbladder lithiasis who underwent laparoscopy were randomly assigned to two groups , a blind ( V group ) or an open ( H group ) , in order to compare the results and the rate of complications . No mortality was observed . Major complications occurred in 3/75 ( 4 % ) patients of the V group and in 1/75 ( 1.3 % ) patient of the H group ( p < 0.05 ) . Minor complications occurred in 5/75 ( 6.7 % ) patients of either group . The achievement of pneumoperitoneum required 4.5+/-0.4 min in the V group and 3.2+/-0.2 min in the H group ( p < 0.05 ) . The open laparoscopic technique is safer and faster than the blind approach ; therefore , it is proposed that this approach be routinely used in all laparoscopic procedures . Instructions: please extract entity words from the input sentence	[ "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Blind versus open approach to laparoscopic cholecystectomy : a randomized study . Intraabdominal structures may be damaged during blind introduction of the first trocar for laparoscopic operations . In this study , 150 patients with gallbladder lithiasis who underwent laparoscopy were randomly assigned to two groups , a blind ( V group ) or an open ( H group ) , in order to compare the results and the rate of complications . No mortality was observed . Major complications occurred in 3/75 ( 4 % ) patients of the V group and in 1/75 ( 1.3 % ) patient of the H group ( p < 0.05 ) . Minor complications occurred in 5/75 ( 6.7 % ) patients of either group . The achievement of pneumoperitoneum required 4.5+/-0.4 min in the V group and 3.2+/-0.2 min in the H group ( p < 0.05 ) . The open laparoscopic technique is safer and faster than the blind approach ; therefore , it is proposed that this approach be routinely used in all laparoscopic procedures .	[ "Blind", "versus", "open", "approach", "to", "laparoscopic", "cholecystectomy", ":", "a", "randomized", "study", ".", "Intraabdominal", "structures", "may", "be", "damaged", "during", "blind", "introduction", "of", "the", "first", "trocar", "for", "laparoscopic", "operations", ".", "In", "this", "study", ",", "150", "patients", "with", "gallbladder", "lithiasis", "who", "underwent", "laparoscopy", "were", "randomly", "assigned", "to", "two", "groups", ",", "a", "blind", "(", "V", "group", ")", "or", "an", "open", "(", "H", "group", ")", ",", "in", "order", "to", "compare", "the", "results", "and", "the", "rate", "of", "complications", ".", "No", "mortality", "was", "observed", ".", "Major", "complications", "occurred", "in", "3/75", "(", "4", "%", ")", "patients", "of", "the", "V", "group", "and", "in", "1/75", "(", "1.3", "%", ")", "patient", "of", "the", "H", "group", "(", "p", "<", "0.05", ")", ".", "Minor", "complications", "occurred", "in", "5/75", "(", "6.7", "%", ")", "patients", "of", "either", "group", ".", "The", "achievement", "of", "pneumoperitoneum", "required", "4.5+/-0.4", "min", "in", "the", "V", "group", "and", "3.2+/-0.2", "min", "in", "the", "H", "group", "(", "p", "<", "0.05", ")", ".", "The", "open", "laparoscopic", "technique", "is", "safer", "and", "faster", "than", "the", "blind", "approach", ";", "therefore", ",", "it", "is", "proposed", "that", "this", "approach", "be", "routinely", "used", "in", "all", "laparoscopic", "procedures", "." ]	[ "Intervention_Surgical", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Condition", "Intervention_Physical", "Outcome_Mortality", "Participant_Sample-size" ]
PSA is a PROTEINAS, marlex is a NORMALIZABLES	8_task0	Sentence: Varón de 65 años que consultaba por un síndrome obstructivo infravesical junto con una tumoración blanda en el hemiescroto derecho, que disminuía de tamaño durante la micción. A la exploración física destacaba la presencia de una bolsa escrotal derecha aumentada de tamaño y de una hernia inguinal reductible. Al tacto rectal destacaba una próstata de tamaño medio, bilobulada y de características adenomatosas. Dentro de las exploraciones complementarias se realizó un PSA total que fue normal, una ecografía vesico-prostática que puso de manifiesto una próstata de 57 gramos y una ecografía testicular con una imagen sugestiva de herniación vesical. Finalmente, la cistografía retrógrada nos mostró la presencia de una hernia vesical masiva en hemiescroto derecho. El tratamiento fue quirúrgico y consistió en la resección de la porción herniada de la vejiga que era para peritoneal y una corrección de la hernia inguinal con malla de marlex. En un segundo tiempo se realizo una RTU de próstata. Controlado a los seis meses el paciente permanece asintomático. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: NORMALIZABLES, PROTEINAS	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Varón de 65 años que consultaba por un síndrome obstructivo infravesical junto con una tumoración blanda en el hemiescroto derecho, que disminuía de tamaño durante la micción. A la exploración física destacaba la presencia de una bolsa escrotal derecha aumentada de tamaño y de una hernia inguinal reductible. Al tacto rectal destacaba una próstata de tamaño medio, bilobulada y de características adenomatosas. Dentro de las exploraciones complementarias se realizó un PSA total que fue normal, una ecografía vesico-prostática que puso de manifiesto una próstata de 57 gramos y una ecografía testicular con una imagen sugestiva de herniación vesical. Finalmente, la cistografía retrógrada nos mostró la presencia de una hernia vesical masiva en hemiescroto derecho. El tratamiento fue quirúrgico y consistió en la resección de la porción herniada de la vejiga que era para peritoneal y una corrección de la hernia inguinal con malla de marlex. En un segundo tiempo se realizo una RTU de próstata. Controlado a los seis meses el paciente permanece asintomático.	[ "Varón", "de", "65", "años", "que", "consultaba", "por", "un", "síndrome", "obstructivo", "infravesical", "junto", "con", "una", "tumoración", "blanda", "en", "el", "hemiescroto", "derecho", ",", "que", "disminuía", "de", "tamaño", "durante", "la", "micción", ".", "\n", "A", "la", "exploración", "física", "destacaba", "la", "presencia", "de", "una", "bolsa", "escrotal", "derecha", "aumentada", "de", "tamaño", "y", "de", "una", "hernia", "inguinal", "reductible", ".", "Al", "tacto", "rectal", "destacaba", "una", "próstata", "de", "tamaño", "medio", ",", "bilobulada", "y", "de", "características", "adenomatosas", ".", "\n", "Dentro", "de", "las", "exploraciones", "complementarias", "se", "realizó", "un", "PSA", "total", "que", "fue", "normal", ",", "una", "ecografía", "vesico", "-", "prostática", "que", "puso", "de", "manifiesto", "una", "próstata", "de", "57", "gramos", "y", "una", "ecografía", "testicular", "con", "una", "imagen", "sugestiva", "de", "herniación", "vesical", ".", "\n\n", "Finalmente", ",", "la", "cistografía", "retrógrada", "nos", "mostró", "la", "presencia", "de", "una", "hernia", "vesical", "masiva", "en", "hemiescroto", "derecho", ".", "\n\n", "El", "tratamiento", "fue", "quirúrgico", "y", "consistió", "en", "la", "resección", "de", "la", "porción", "herniada", "de", "la", "vejiga", "que", "era", "para", "peritoneal", "y", "una", "corrección", "de", "la", "hernia", "inguinal", "con", "malla", "de", "marlex", ".", "En", "un", "segundo", "tiempo", "se", "realizo", "una", "RTU", "de", "próstata", ".", "\n", "Controlado", "a", "los", "seis", "meses", "el", "paciente", "permanece", "asintomático", ".", "\n" ]	[ "NORMALIZABLES", "PROTEINAS" ]
PSA is a PROTEINAS, marlex is a NORMALIZABLES	8_task1	Sentence: Varón de 65 años que consultaba por un síndrome obstructivo infravesical junto con una tumoración blanda en el hemiescroto derecho, que disminuía de tamaño durante la micción. A la exploración física destacaba la presencia de una bolsa escrotal derecha aumentada de tamaño y de una hernia inguinal reductible. Al tacto rectal destacaba una próstata de tamaño medio, bilobulada y de características adenomatosas. Dentro de las exploraciones complementarias se realizó un PSA total que fue normal, una ecografía vesico-prostática que puso de manifiesto una próstata de 57 gramos y una ecografía testicular con una imagen sugestiva de herniación vesical. Finalmente, la cistografía retrógrada nos mostró la presencia de una hernia vesical masiva en hemiescroto derecho. El tratamiento fue quirúrgico y consistió en la resección de la porción herniada de la vejiga que era para peritoneal y una corrección de la hernia inguinal con malla de marlex. En un segundo tiempo se realizo una RTU de próstata. Controlado a los seis meses el paciente permanece asintomático. Instructions: please typing these entity words according to sentence: PSA, marlex Options: NORMALIZABLES, PROTEINAS	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Varón de 65 años que consultaba por un síndrome obstructivo infravesical junto con una tumoración blanda en el hemiescroto derecho, que disminuía de tamaño durante la micción. A la exploración física destacaba la presencia de una bolsa escrotal derecha aumentada de tamaño y de una hernia inguinal reductible. Al tacto rectal destacaba una próstata de tamaño medio, bilobulada y de características adenomatosas. Dentro de las exploraciones complementarias se realizó un PSA total que fue normal, una ecografía vesico-prostática que puso de manifiesto una próstata de 57 gramos y una ecografía testicular con una imagen sugestiva de herniación vesical. Finalmente, la cistografía retrógrada nos mostró la presencia de una hernia vesical masiva en hemiescroto derecho. El tratamiento fue quirúrgico y consistió en la resección de la porción herniada de la vejiga que era para peritoneal y una corrección de la hernia inguinal con malla de marlex. En un segundo tiempo se realizo una RTU de próstata. Controlado a los seis meses el paciente permanece asintomático.	[ "Varón", "de", "65", "años", "que", "consultaba", "por", "un", "síndrome", "obstructivo", "infravesical", "junto", "con", "una", "tumoración", "blanda", "en", "el", "hemiescroto", "derecho", ",", "que", "disminuía", "de", "tamaño", "durante", "la", "micción", ".", "\n", "A", "la", "exploración", "física", "destacaba", "la", "presencia", "de", "una", "bolsa", "escrotal", "derecha", "aumentada", "de", "tamaño", "y", "de", "una", "hernia", "inguinal", "reductible", ".", "Al", "tacto", "rectal", "destacaba", "una", "próstata", "de", "tamaño", "medio", ",", "bilobulada", "y", "de", "características", "adenomatosas", ".", "\n", "Dentro", "de", "las", "exploraciones", "complementarias", "se", "realizó", "un", "PSA", "total", "que", "fue", "normal", ",", "una", "ecografía", "vesico", "-", "prostática", "que", "puso", "de", "manifiesto", "una", "próstata", "de", "57", "gramos", "y", "una", "ecografía", "testicular", "con", "una", "imagen", "sugestiva", "de", "herniación", "vesical", ".", "\n\n", "Finalmente", ",", "la", "cistografía", "retrógrada", "nos", "mostró", "la", "presencia", "de", "una", "hernia", "vesical", "masiva", "en", "hemiescroto", "derecho", ".", "\n\n", "El", "tratamiento", "fue", "quirúrgico", "y", "consistió", "en", "la", "resección", "de", "la", "porción", "herniada", "de", "la", "vejiga", "que", "era", "para", "peritoneal", "y", "una", "corrección", "de", "la", "hernia", "inguinal", "con", "malla", "de", "marlex", ".", "En", "un", "segundo", "tiempo", "se", "realizo", "una", "RTU", "de", "próstata", ".", "\n", "Controlado", "a", "los", "seis", "meses", "el", "paciente", "permanece", "asintomático", ".", "\n" ]	[ "NORMALIZABLES", "PROTEINAS" ]
PSA, marlex	8_task2	Sentence: Varón de 65 años que consultaba por un síndrome obstructivo infravesical junto con una tumoración blanda en el hemiescroto derecho, que disminuía de tamaño durante la micción. A la exploración física destacaba la presencia de una bolsa escrotal derecha aumentada de tamaño y de una hernia inguinal reductible. Al tacto rectal destacaba una próstata de tamaño medio, bilobulada y de características adenomatosas. Dentro de las exploraciones complementarias se realizó un PSA total que fue normal, una ecografía vesico-prostática que puso de manifiesto una próstata de 57 gramos y una ecografía testicular con una imagen sugestiva de herniación vesical. Finalmente, la cistografía retrógrada nos mostró la presencia de una hernia vesical masiva en hemiescroto derecho. El tratamiento fue quirúrgico y consistió en la resección de la porción herniada de la vejiga que era para peritoneal y una corrección de la hernia inguinal con malla de marlex. En un segundo tiempo se realizo una RTU de próstata. Controlado a los seis meses el paciente permanece asintomático. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Varón de 65 años que consultaba por un síndrome obstructivo infravesical junto con una tumoración blanda en el hemiescroto derecho, que disminuía de tamaño durante la micción. A la exploración física destacaba la presencia de una bolsa escrotal derecha aumentada de tamaño y de una hernia inguinal reductible. Al tacto rectal destacaba una próstata de tamaño medio, bilobulada y de características adenomatosas. Dentro de las exploraciones complementarias se realizó un PSA total que fue normal, una ecografía vesico-prostática que puso de manifiesto una próstata de 57 gramos y una ecografía testicular con una imagen sugestiva de herniación vesical. Finalmente, la cistografía retrógrada nos mostró la presencia de una hernia vesical masiva en hemiescroto derecho. El tratamiento fue quirúrgico y consistió en la resección de la porción herniada de la vejiga que era para peritoneal y una corrección de la hernia inguinal con malla de marlex. En un segundo tiempo se realizo una RTU de próstata. Controlado a los seis meses el paciente permanece asintomático.	[ "Varón", "de", "65", "años", "que", "consultaba", "por", "un", "síndrome", "obstructivo", "infravesical", "junto", "con", "una", "tumoración", "blanda", "en", "el", "hemiescroto", "derecho", ",", "que", "disminuía", "de", "tamaño", "durante", "la", "micción", ".", "\n", "A", "la", "exploración", "física", "destacaba", "la", "presencia", "de", "una", "bolsa", "escrotal", "derecha", "aumentada", "de", "tamaño", "y", "de", "una", "hernia", "inguinal", "reductible", ".", "Al", "tacto", "rectal", "destacaba", "una", "próstata", "de", "tamaño", "medio", ",", "bilobulada", "y", "de", "características", "adenomatosas", ".", "\n", "Dentro", "de", "las", "exploraciones", "complementarias", "se", "realizó", "un", "PSA", "total", "que", "fue", "normal", ",", "una", "ecografía", "vesico", "-", "prostática", "que", "puso", "de", "manifiesto", "una", "próstata", "de", "57", "gramos", "y", "una", "ecografía", "testicular", "con", "una", "imagen", "sugestiva", "de", "herniación", "vesical", ".", "\n\n", "Finalmente", ",", "la", "cistografía", "retrógrada", "nos", "mostró", "la", "presencia", "de", "una", "hernia", "vesical", "masiva", "en", "hemiescroto", "derecho", ".", "\n\n", "El", "tratamiento", "fue", "quirúrgico", "y", "consistió", "en", "la", "resección", "de", "la", "porción", "herniada", "de", "la", "vejiga", "que", "era", "para", "peritoneal", "y", "una", "corrección", "de", "la", "hernia", "inguinal", "con", "malla", "de", "marlex", ".", "En", "un", "segundo", "tiempo", "se", "realizo", "una", "RTU", "de", "próstata", ".", "\n", "Controlado", "a", "los", "seis", "meses", "el", "paciente", "permanece", "asintomático", ".", "\n" ]	[ "NORMALIZABLES", "PROTEINAS" ]
benzenesulfonamide is a CHEMICAL, carbonic anhydrase IX is a GENE-Y	23234246_task0	Sentence: Synthesis and SAR of novel Re/99mTc-labeled benzenesulfonamide carbonic anhydrase IX inhibitors for molecular imaging of tumor hypoxia. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]	Synthesis and SAR of novel Re/99mTc-labeled benzenesulfonamide carbonic anhydrase IX inhibitors for molecular imaging of tumor hypoxia.	[ "Synthesis", "and", "SAR", "of", "novel", "Re/99mTc", "-", "labeled", "benzenesulfonamide", "carbonic", "anhydrase", "IX", "inhibitors", "for", "molecular", "imaging", "of", "tumor", "hypoxia", "." ]	[ "CHEMICAL", "GENE-Y" ]
benzenesulfonamide is a CHEMICAL, carbonic anhydrase IX is a GENE-Y	23234246_task1	Sentence: Synthesis and SAR of novel Re/99mTc-labeled benzenesulfonamide carbonic anhydrase IX inhibitors for molecular imaging of tumor hypoxia. Instructions: please typing these entity words according to sentence: benzenesulfonamide, carbonic anhydrase IX Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]	Synthesis and SAR of novel Re/99mTc-labeled benzenesulfonamide carbonic anhydrase IX inhibitors for molecular imaging of tumor hypoxia.	[ "Synthesis", "and", "SAR", "of", "novel", "Re/99mTc", "-", "labeled", "benzenesulfonamide", "carbonic", "anhydrase", "IX", "inhibitors", "for", "molecular", "imaging", "of", "tumor", "hypoxia", "." ]	[ "CHEMICAL", "GENE-Y" ]
benzenesulfonamide, carbonic anhydrase IX	23234246_task2	Sentence: Synthesis and SAR of novel Re/99mTc-labeled benzenesulfonamide carbonic anhydrase IX inhibitors for molecular imaging of tumor hypoxia. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]	Synthesis and SAR of novel Re/99mTc-labeled benzenesulfonamide carbonic anhydrase IX inhibitors for molecular imaging of tumor hypoxia.	[ "Synthesis", "and", "SAR", "of", "novel", "Re/99mTc", "-", "labeled", "benzenesulfonamide", "carbonic", "anhydrase", "IX", "inhibitors", "for", "molecular", "imaging", "of", "tumor", "hypoxia", "." ]	[ "CHEMICAL", "GENE-Y" ]
dystonia is an umlsterm, panic attacks is an umlsterm, treatment is an umlsterm, pathology is an umlsterm, medication is an umlsterm, objective is an umlsterm, analysis is an umlsterm, movement disorder is an umlsterm, myoclonus is an umlsterm, medication is an umlsterm, Nefadozone is an umlsterm, myoclonus is an umlsterm, frequency is an umlsterm, panic attacks is an umlsterm	DerNervenarzt.00710839.eng.abstr_task0	Sentence: We report a case of autosomal dominantly inherited dystonia and panic attacks to discuss successful treatment of a common serotonergic pathology with medication . The objective analysis of the movement disorder was done by Optotrak©. First we demonstrate a reduction of the myoclonus by L-5-hydroxytryptophan, which inhibits after 11 months . After changing the medication to Nefadozone , the myoclonus and the frequency of panic attacks were reduced . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]	We report a case of autosomal dominantly inherited dystonia and panic attacks to discuss successful treatment of a common serotonergic pathology with medication . The objective analysis of the movement disorder was done by Optotrak©. First we demonstrate a reduction of the myoclonus by L-5-hydroxytryptophan, which inhibits after 11 months . After changing the medication to Nefadozone , the myoclonus and the frequency of panic attacks were reduced .	[ "We", "report", "a", "case", "of", "autosomal", "dominantly", "inherited", "dystonia", "and", "panic", "attacks", "to", "discuss", "successful", "treatment", "of", "a", "common", "serotonergic", "pathology", "with", "medication", ".", "The", "objective", "analysis", "of", "the", "movement", "disorder", "was", "done", "by", "Optotrak", "©", ".", "First", "we", "demonstrate", "a", "reduction", "of", "the", "myoclonus", "by", "L-5-hydroxytryptophan", ",", "which", "inhibits", "after", "11", "months", ".", "After", "changing", "the", "medication", "to", "Nefadozone", ",", "the", "myoclonus", "and", "the", "frequency", "of", "panic", "attacks", "were", "reduced", "." ]	[ "umlsterm" ]
dystonia is an umlsterm, panic attacks is an umlsterm, treatment is an umlsterm, pathology is an umlsterm, medication is an umlsterm, objective is an umlsterm, analysis is an umlsterm, movement disorder is an umlsterm, myoclonus is an umlsterm, medication is an umlsterm, Nefadozone is an umlsterm, myoclonus is an umlsterm, frequency is an umlsterm, panic attacks is an umlsterm	DerNervenarzt.00710839.eng.abstr_task1	Sentence: We report a case of autosomal dominantly inherited dystonia and panic attacks to discuss successful treatment of a common serotonergic pathology with medication . The objective analysis of the movement disorder was done by Optotrak©. First we demonstrate a reduction of the myoclonus by L-5-hydroxytryptophan, which inhibits after 11 months . After changing the medication to Nefadozone , the myoclonus and the frequency of panic attacks were reduced . Instructions: please typing these entity words according to sentence: dystonia, panic attacks, treatment, pathology, medication, objective, analysis, movement disorder, myoclonus, medication, Nefadozone, myoclonus, frequency, panic attacks Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]	We report a case of autosomal dominantly inherited dystonia and panic attacks to discuss successful treatment of a common serotonergic pathology with medication . The objective analysis of the movement disorder was done by Optotrak©. First we demonstrate a reduction of the myoclonus by L-5-hydroxytryptophan, which inhibits after 11 months . After changing the medication to Nefadozone , the myoclonus and the frequency of panic attacks were reduced .	[ "We", "report", "a", "case", "of", "autosomal", "dominantly", "inherited", "dystonia", "and", "panic", "attacks", "to", "discuss", "successful", "treatment", "of", "a", "common", "serotonergic", "pathology", "with", "medication", ".", "The", "objective", "analysis", "of", "the", "movement", "disorder", "was", "done", "by", "Optotrak", "©", ".", "First", "we", "demonstrate", "a", "reduction", "of", "the", "myoclonus", "by", "L-5-hydroxytryptophan", ",", "which", "inhibits", "after", "11", "months", ".", "After", "changing", "the", "medication", "to", "Nefadozone", ",", "the", "myoclonus", "and", "the", "frequency", "of", "panic", "attacks", "were", "reduced", "." ]	[ "umlsterm" ]
dystonia, panic attacks, treatment, pathology, medication, objective, analysis, movement disorder, myoclonus, medication, Nefadozone, myoclonus, frequency, panic attacks	DerNervenarzt.00710839.eng.abstr_task2	Sentence: We report a case of autosomal dominantly inherited dystonia and panic attacks to discuss successful treatment of a common serotonergic pathology with medication . The objective analysis of the movement disorder was done by Optotrak©. First we demonstrate a reduction of the myoclonus by L-5-hydroxytryptophan, which inhibits after 11 months . After changing the medication to Nefadozone , the myoclonus and the frequency of panic attacks were reduced . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]	We report a case of autosomal dominantly inherited dystonia and panic attacks to discuss successful treatment of a common serotonergic pathology with medication . The objective analysis of the movement disorder was done by Optotrak©. First we demonstrate a reduction of the myoclonus by L-5-hydroxytryptophan, which inhibits after 11 months . After changing the medication to Nefadozone , the myoclonus and the frequency of panic attacks were reduced .	[ "We", "report", "a", "case", "of", "autosomal", "dominantly", "inherited", "dystonia", "and", "panic", "attacks", "to", "discuss", "successful", "treatment", "of", "a", "common", "serotonergic", "pathology", "with", "medication", ".", "The", "objective", "analysis", "of", "the", "movement", "disorder", "was", "done", "by", "Optotrak", "©", ".", "First", "we", "demonstrate", "a", "reduction", "of", "the", "myoclonus", "by", "L-5-hydroxytryptophan", ",", "which", "inhibits", "after", "11", "months", ".", "After", "changing", "the", "medication", "to", "Nefadozone", ",", "the", "myoclonus", "and", "the", "frequency", "of", "panic", "attacks", "were", "reduced", "." ]	[ "umlsterm" ]
phosphodiesterase-5 is a GENE-Y, vardenafil is a CHEMICAL, sildenafil is a CHEMICAL	17959709_task0	Sentence: Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O" ]	Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil.	[ "Conformational", "variations", "of", "both", "phosphodiesterase-5", "and", "inhibitors", "provide", "the", "structural", "basis", "for", "the", "physiological", "effects", "of", "vardenafil", "and", "sildenafil", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
phosphodiesterase-5 is a GENE-Y, vardenafil is a CHEMICAL, sildenafil is a CHEMICAL	17959709_task1	Sentence: Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Instructions: please typing these entity words according to sentence: phosphodiesterase-5, vardenafil, sildenafil Options: GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O" ]	Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil.	[ "Conformational", "variations", "of", "both", "phosphodiesterase-5", "and", "inhibitors", "provide", "the", "structural", "basis", "for", "the", "physiological", "effects", "of", "vardenafil", "and", "sildenafil", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
phosphodiesterase-5, vardenafil, sildenafil	17959709_task2	Sentence: Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O" ]	Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil.	[ "Conformational", "variations", "of", "both", "phosphodiesterase-5", "and", "inhibitors", "provide", "the", "structural", "basis", "for", "the", "physiological", "effects", "of", "vardenafil", "and", "sildenafil", "." ]	[ "GENE-N", "GENE-Y", "CHEMICAL" ]
Tissue - type plasminogen activator is a GENE-Y, cytokine is a GENE-N, matrix metalloproteinase-9 is a GENE-Y, Tissue - type plasminogen activator is a GENE-Y, tPA is a GENE-Y, serine protease is a GENE-N, plasmin is a GENE-Y, matrix metalloproteinase-9 is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, tPA is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, tPA is a GENE-Y, low density lipoprotein receptor - related protein-1 is a GENE-Y, LRP-1 is a GENE-Y, LRP-1 is a GENE-Y, LRP-1 is a GENE-Y, tPA is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, tyrosine is a CHEMICAL, LRP-1 is a GENE-Y, Mek1 is a GENE-Y, Erk-1 and -2 is a GENE-N, Erk-1/2 is a GENE-N, Mek1 is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, constitutively activated Mek1 is a GENE-Y, Erk-1/2 is a GENE-N, MMP-9 is a GENE-Y, tPA is a GENE-Y, LRP-1 is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, cytokine is a GENE-N, LRP-1 is a GENE-Y, tyrosine is a CHEMICAL	25458_task0	Sentence: Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. Tissue-type plasminogen activator (tPA), a serine protease well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts. However, exactly how tPA transduces its signal into the nucleus to control gene expression is unknown. This study investigated the mechanism by which tPA induces MMP-9 gene expression. Both wild-type and non-enzymatic mutant tPA were found to induce MMP-9 expression in rat kidney interstitial fibroblasts (NRK-49F), indicating that the actions of tPA are independent of its proteolytic activity. tPA bound to the low density lipoprotein receptor-related protein-1 (LRP-1) in NRK-49F cells, and this binding was competitively abrogated by the LRP-1 antagonist, the receptor-associated protein. In mouse embryonic fibroblasts (PEA-13) lacking LRP-1, tPA failed to induce MMP-9 expression. Furthermore, tPA induced rapid tyrosine phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream Erk-1 and -2. Blockade of Erk-1/2 activation by the Mek1 inhibitor abolished MMP-9 induction by tPA in NRK-49F cells. Conversely, overexpression of constitutively activated Mek1 induced Erk-1/2 phosphorylation and MMP-9 expression. In mouse obstructed kidney, tPA, LRP-1, and MMP-9 were concomitantly induced in the renal interstitium. Collectively, these results suggest that besides its classical proteolytic activity, tPA acts as a cytokine that binds to the cell membrane receptor LRP-1, induces its tyrosine phosphorylation, and triggers intracellular signal transduction, thereby inducing specific gene expression in renal interstitial fibroblasts. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL, GENE-Y, GENE-N	[ "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. Tissue-type plasminogen activator (tPA), a serine protease well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts. However, exactly how tPA transduces its signal into the nucleus to control gene expression is unknown. This study investigated the mechanism by which tPA induces MMP-9 gene expression. Both wild-type and non-enzymatic mutant tPA were found to induce MMP-9 expression in rat kidney interstitial fibroblasts (NRK-49F), indicating that the actions of tPA are independent of its proteolytic activity. tPA bound to the low density lipoprotein receptor-related protein-1 (LRP-1) in NRK-49F cells, and this binding was competitively abrogated by the LRP-1 antagonist, the receptor-associated protein. In mouse embryonic fibroblasts (PEA-13) lacking LRP-1, tPA failed to induce MMP-9 expression. Furthermore, tPA induced rapid tyrosine phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream Erk-1 and -2. Blockade of Erk-1/2 activation by the Mek1 inhibitor abolished MMP-9 induction by tPA in NRK-49F cells. Conversely, overexpression of constitutively activated Mek1 induced Erk-1/2 phosphorylation and MMP-9 expression. In mouse obstructed kidney, tPA, LRP-1, and MMP-9 were concomitantly induced in the renal interstitium. Collectively, these results suggest that besides its classical proteolytic activity, tPA acts as a cytokine that binds to the cell membrane receptor LRP-1, induces its tyrosine phosphorylation, and triggers intracellular signal transduction, thereby inducing specific gene expression in renal interstitial fibroblasts.	[ "Tissue", "-", "type", "plasminogen", "activator", "acts", "as", "a", "cytokine", "that", "triggers", "intracellular", "signal", "transduction", "and", "induces", "matrix", "metalloproteinase-9", "gene", "expression", ".", "\n", "Tissue", "-", "type", "plasminogen", "activator", "(", "tPA", ")", ",", "a", "serine", "protease", "well", "known", "for", "generating", "plasmin", ",", "has", "been", "demonstrated", "to", "induce", "matrix", "metalloproteinase-9", "(", "MMP-9", ")", "gene", "expression", "and", "protein", "secretion", "in", "renal", "interstitial", "fibroblasts", ".", "However", ",", "exactly", "how", "tPA", "transduces", "its", "signal", "into", "the", "nucleus", "to", "control", "gene", "expression", "is", "unknown", ".", "This", "study", "investigated", "the", "mechanism", "by", "which", "tPA", "induces", "MMP-9", "gene", "expression", ".", "Both", "wild", "-", "type", "and", "non", "-", "enzymatic", "mutant", "tPA", "were", "found", "to", "induce", "MMP-9", "expression", "in", "rat", "kidney", "interstitial", "fibroblasts", "(", "NRK-49F", ")", ",", "indicating", "that", "the", "actions", "of", "tPA", "are", "independent", "of", "its", "proteolytic", "activity", ".", "tPA", "bound", "to", "the", "low", "density", "lipoprotein", "receptor", "-", "related", "protein-1", "(", "LRP-1", ")", "in", "NRK-49F", "cells", ",", "and", "this", "binding", "was", "competitively", "abrogated", "by", "the", "LRP-1", "antagonist", ",", "the", "receptor", "-", "associated", "protein", ".", "In", "mouse", "embryonic", "fibroblasts", "(", "PEA-13", ")", "lacking", "LRP-1", ",", "tPA", "failed", "to", "induce", "MMP-9", "expression", ".", "Furthermore", ",", "tPA", "induced", "rapid", "tyrosine", "phosphorylation", "on", "the", "beta", "subunit", "of", "LRP-1", ",", "which", "was", "followed", "by", "the", "activation", "of", "Mek1", "and", "its", "downstream", "Erk-1", "and", "-2", ".", "Blockade", "of", "Erk-1/2", "activation", "by", "the", "Mek1", "inhibitor", "abolished", "MMP-9", "induction", "by", "tPA", "in", "NRK-49F", "cells", ".", "Conversely", ",", "overexpression", "of", "constitutively", "activated", "Mek1", "induced", "Erk-1/2", "phosphorylation", "and", "MMP-9", "expression", ".", "In", "mouse", "obstructed", "kidney", ",", "tPA", ",", "LRP-1", ",", "and", "MMP-9", "were", "concomitantly", "induced", "in", "the", "renal", "interstitium", ".", "Collectively", ",", "these", "results", "suggest", "that", "besides", "its", "classical", "proteolytic", "activity", ",", "tPA", "acts", "as", "a", "cytokine", "that", "binds", "to", "the", "cell", "membrane", "receptor", "LRP-1", ",", "induces", "its", "tyrosine", "phosphorylation", ",", "and", "triggers", "intracellular", "signal", "transduction", ",", "thereby", "inducing", "specific", "gene", "expression", "in", "renal", "interstitial", "fibroblasts", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Tissue - type plasminogen activator is a GENE-Y, cytokine is a GENE-N, matrix metalloproteinase-9 is a GENE-Y, Tissue - type plasminogen activator is a GENE-Y, tPA is a GENE-Y, serine protease is a GENE-N, plasmin is a GENE-Y, matrix metalloproteinase-9 is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, tPA is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, tPA is a GENE-Y, low density lipoprotein receptor - related protein-1 is a GENE-Y, LRP-1 is a GENE-Y, LRP-1 is a GENE-Y, LRP-1 is a GENE-Y, tPA is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, tyrosine is a CHEMICAL, LRP-1 is a GENE-Y, Mek1 is a GENE-Y, Erk-1 and -2 is a GENE-N, Erk-1/2 is a GENE-N, Mek1 is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, constitutively activated Mek1 is a GENE-Y, Erk-1/2 is a GENE-N, MMP-9 is a GENE-Y, tPA is a GENE-Y, LRP-1 is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, cytokine is a GENE-N, LRP-1 is a GENE-Y, tyrosine is a CHEMICAL	25458_task1	Sentence: Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. Tissue-type plasminogen activator (tPA), a serine protease well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts. However, exactly how tPA transduces its signal into the nucleus to control gene expression is unknown. This study investigated the mechanism by which tPA induces MMP-9 gene expression. Both wild-type and non-enzymatic mutant tPA were found to induce MMP-9 expression in rat kidney interstitial fibroblasts (NRK-49F), indicating that the actions of tPA are independent of its proteolytic activity. tPA bound to the low density lipoprotein receptor-related protein-1 (LRP-1) in NRK-49F cells, and this binding was competitively abrogated by the LRP-1 antagonist, the receptor-associated protein. In mouse embryonic fibroblasts (PEA-13) lacking LRP-1, tPA failed to induce MMP-9 expression. Furthermore, tPA induced rapid tyrosine phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream Erk-1 and -2. Blockade of Erk-1/2 activation by the Mek1 inhibitor abolished MMP-9 induction by tPA in NRK-49F cells. Conversely, overexpression of constitutively activated Mek1 induced Erk-1/2 phosphorylation and MMP-9 expression. In mouse obstructed kidney, tPA, LRP-1, and MMP-9 were concomitantly induced in the renal interstitium. Collectively, these results suggest that besides its classical proteolytic activity, tPA acts as a cytokine that binds to the cell membrane receptor LRP-1, induces its tyrosine phosphorylation, and triggers intracellular signal transduction, thereby inducing specific gene expression in renal interstitial fibroblasts. Instructions: please typing these entity words according to sentence: Tissue - type plasminogen activator, cytokine, matrix metalloproteinase-9, Tissue - type plasminogen activator, tPA, serine protease, plasmin, matrix metalloproteinase-9, MMP-9, tPA, tPA, MMP-9, tPA, MMP-9, tPA, tPA, low density lipoprotein receptor - related protein-1, LRP-1, LRP-1, LRP-1, tPA, MMP-9, tPA, tyrosine, LRP-1, Mek1, Erk-1 and -2, Erk-1/2, Mek1, MMP-9, tPA, constitutively activated Mek1, Erk-1/2, MMP-9, tPA, LRP-1, MMP-9, tPA, cytokine, LRP-1, tyrosine Options: CHEMICAL, GENE-Y, GENE-N	[ "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. Tissue-type plasminogen activator (tPA), a serine protease well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts. However, exactly how tPA transduces its signal into the nucleus to control gene expression is unknown. This study investigated the mechanism by which tPA induces MMP-9 gene expression. Both wild-type and non-enzymatic mutant tPA were found to induce MMP-9 expression in rat kidney interstitial fibroblasts (NRK-49F), indicating that the actions of tPA are independent of its proteolytic activity. tPA bound to the low density lipoprotein receptor-related protein-1 (LRP-1) in NRK-49F cells, and this binding was competitively abrogated by the LRP-1 antagonist, the receptor-associated protein. In mouse embryonic fibroblasts (PEA-13) lacking LRP-1, tPA failed to induce MMP-9 expression. Furthermore, tPA induced rapid tyrosine phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream Erk-1 and -2. Blockade of Erk-1/2 activation by the Mek1 inhibitor abolished MMP-9 induction by tPA in NRK-49F cells. Conversely, overexpression of constitutively activated Mek1 induced Erk-1/2 phosphorylation and MMP-9 expression. In mouse obstructed kidney, tPA, LRP-1, and MMP-9 were concomitantly induced in the renal interstitium. Collectively, these results suggest that besides its classical proteolytic activity, tPA acts as a cytokine that binds to the cell membrane receptor LRP-1, induces its tyrosine phosphorylation, and triggers intracellular signal transduction, thereby inducing specific gene expression in renal interstitial fibroblasts.	[ "Tissue", "-", "type", "plasminogen", "activator", "acts", "as", "a", "cytokine", "that", "triggers", "intracellular", "signal", "transduction", "and", "induces", "matrix", "metalloproteinase-9", "gene", "expression", ".", "\n", "Tissue", "-", "type", "plasminogen", "activator", "(", "tPA", ")", ",", "a", "serine", "protease", "well", "known", "for", "generating", "plasmin", ",", "has", "been", "demonstrated", "to", "induce", "matrix", "metalloproteinase-9", "(", "MMP-9", ")", "gene", "expression", "and", "protein", "secretion", "in", "renal", "interstitial", "fibroblasts", ".", "However", ",", "exactly", "how", "tPA", "transduces", "its", "signal", "into", "the", "nucleus", "to", "control", "gene", "expression", "is", "unknown", ".", "This", "study", "investigated", "the", "mechanism", "by", "which", "tPA", "induces", "MMP-9", "gene", "expression", ".", "Both", "wild", "-", "type", "and", "non", "-", "enzymatic", "mutant", "tPA", "were", "found", "to", "induce", "MMP-9", "expression", "in", "rat", "kidney", "interstitial", "fibroblasts", "(", "NRK-49F", ")", ",", "indicating", "that", "the", "actions", "of", "tPA", "are", "independent", "of", "its", "proteolytic", "activity", ".", "tPA", "bound", "to", "the", "low", "density", "lipoprotein", "receptor", "-", "related", "protein-1", "(", "LRP-1", ")", "in", "NRK-49F", "cells", ",", "and", "this", "binding", "was", "competitively", "abrogated", "by", "the", "LRP-1", "antagonist", ",", "the", "receptor", "-", "associated", "protein", ".", "In", "mouse", "embryonic", "fibroblasts", "(", "PEA-13", ")", "lacking", "LRP-1", ",", "tPA", "failed", "to", "induce", "MMP-9", "expression", ".", "Furthermore", ",", "tPA", "induced", "rapid", "tyrosine", "phosphorylation", "on", "the", "beta", "subunit", "of", "LRP-1", ",", "which", "was", "followed", "by", "the", "activation", "of", "Mek1", "and", "its", "downstream", "Erk-1", "and", "-2", ".", "Blockade", "of", "Erk-1/2", "activation", "by", "the", "Mek1", "inhibitor", "abolished", "MMP-9", "induction", "by", "tPA", "in", "NRK-49F", "cells", ".", "Conversely", ",", "overexpression", "of", "constitutively", "activated", "Mek1", "induced", "Erk-1/2", "phosphorylation", "and", "MMP-9", "expression", ".", "In", "mouse", "obstructed", "kidney", ",", "tPA", ",", "LRP-1", ",", "and", "MMP-9", "were", "concomitantly", "induced", "in", "the", "renal", "interstitium", ".", "Collectively", ",", "these", "results", "suggest", "that", "besides", "its", "classical", "proteolytic", "activity", ",", "tPA", "acts", "as", "a", "cytokine", "that", "binds", "to", "the", "cell", "membrane", "receptor", "LRP-1", ",", "induces", "its", "tyrosine", "phosphorylation", ",", "and", "triggers", "intracellular", "signal", "transduction", ",", "thereby", "inducing", "specific", "gene", "expression", "in", "renal", "interstitial", "fibroblasts", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Tissue - type plasminogen activator, cytokine, matrix metalloproteinase-9, Tissue - type plasminogen activator, tPA, serine protease, plasmin, matrix metalloproteinase-9, MMP-9, tPA, tPA, MMP-9, tPA, MMP-9, tPA, tPA, low density lipoprotein receptor - related protein-1, LRP-1, LRP-1, LRP-1, tPA, MMP-9, tPA, tyrosine, LRP-1, Mek1, Erk-1 and -2, Erk-1/2, Mek1, MMP-9, tPA, constitutively activated Mek1, Erk-1/2, MMP-9, tPA, LRP-1, MMP-9, tPA, cytokine, LRP-1, tyrosine	25458_task2	Sentence: Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. Tissue-type plasminogen activator (tPA), a serine protease well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts. However, exactly how tPA transduces its signal into the nucleus to control gene expression is unknown. This study investigated the mechanism by which tPA induces MMP-9 gene expression. Both wild-type and non-enzymatic mutant tPA were found to induce MMP-9 expression in rat kidney interstitial fibroblasts (NRK-49F), indicating that the actions of tPA are independent of its proteolytic activity. tPA bound to the low density lipoprotein receptor-related protein-1 (LRP-1) in NRK-49F cells, and this binding was competitively abrogated by the LRP-1 antagonist, the receptor-associated protein. In mouse embryonic fibroblasts (PEA-13) lacking LRP-1, tPA failed to induce MMP-9 expression. Furthermore, tPA induced rapid tyrosine phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream Erk-1 and -2. Blockade of Erk-1/2 activation by the Mek1 inhibitor abolished MMP-9 induction by tPA in NRK-49F cells. Conversely, overexpression of constitutively activated Mek1 induced Erk-1/2 phosphorylation and MMP-9 expression. In mouse obstructed kidney, tPA, LRP-1, and MMP-9 were concomitantly induced in the renal interstitium. Collectively, these results suggest that besides its classical proteolytic activity, tPA acts as a cytokine that binds to the cell membrane receptor LRP-1, induces its tyrosine phosphorylation, and triggers intracellular signal transduction, thereby inducing specific gene expression in renal interstitial fibroblasts. Instructions: please extract entity words from the input sentence	[ "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. Tissue-type plasminogen activator (tPA), a serine protease well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts. However, exactly how tPA transduces its signal into the nucleus to control gene expression is unknown. This study investigated the mechanism by which tPA induces MMP-9 gene expression. Both wild-type and non-enzymatic mutant tPA were found to induce MMP-9 expression in rat kidney interstitial fibroblasts (NRK-49F), indicating that the actions of tPA are independent of its proteolytic activity. tPA bound to the low density lipoprotein receptor-related protein-1 (LRP-1) in NRK-49F cells, and this binding was competitively abrogated by the LRP-1 antagonist, the receptor-associated protein. In mouse embryonic fibroblasts (PEA-13) lacking LRP-1, tPA failed to induce MMP-9 expression. Furthermore, tPA induced rapid tyrosine phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream Erk-1 and -2. Blockade of Erk-1/2 activation by the Mek1 inhibitor abolished MMP-9 induction by tPA in NRK-49F cells. Conversely, overexpression of constitutively activated Mek1 induced Erk-1/2 phosphorylation and MMP-9 expression. In mouse obstructed kidney, tPA, LRP-1, and MMP-9 were concomitantly induced in the renal interstitium. Collectively, these results suggest that besides its classical proteolytic activity, tPA acts as a cytokine that binds to the cell membrane receptor LRP-1, induces its tyrosine phosphorylation, and triggers intracellular signal transduction, thereby inducing specific gene expression in renal interstitial fibroblasts.	[ "Tissue", "-", "type", "plasminogen", "activator", "acts", "as", "a", "cytokine", "that", "triggers", "intracellular", "signal", "transduction", "and", "induces", "matrix", "metalloproteinase-9", "gene", "expression", ".", "\n", "Tissue", "-", "type", "plasminogen", "activator", "(", "tPA", ")", ",", "a", "serine", "protease", "well", "known", "for", "generating", "plasmin", ",", "has", "been", "demonstrated", "to", "induce", "matrix", "metalloproteinase-9", "(", "MMP-9", ")", "gene", "expression", "and", "protein", "secretion", "in", "renal", "interstitial", "fibroblasts", ".", "However", ",", "exactly", "how", "tPA", "transduces", "its", "signal", "into", "the", "nucleus", "to", "control", "gene", "expression", "is", "unknown", ".", "This", "study", "investigated", "the", "mechanism", "by", "which", "tPA", "induces", "MMP-9", "gene", "expression", ".", "Both", "wild", "-", "type", "and", "non", "-", "enzymatic", "mutant", "tPA", "were", "found", "to", "induce", "MMP-9", "expression", "in", "rat", "kidney", "interstitial", "fibroblasts", "(", "NRK-49F", ")", ",", "indicating", "that", "the", "actions", "of", "tPA", "are", "independent", "of", "its", "proteolytic", "activity", ".", "tPA", "bound", "to", "the", "low", "density", "lipoprotein", "receptor", "-", "related", "protein-1", "(", "LRP-1", ")", "in", "NRK-49F", "cells", ",", "and", "this", "binding", "was", "competitively", "abrogated", "by", "the", "LRP-1", "antagonist", ",", "the", "receptor", "-", "associated", "protein", ".", "In", "mouse", "embryonic", "fibroblasts", "(", "PEA-13", ")", "lacking", "LRP-1", ",", "tPA", "failed", "to", "induce", "MMP-9", "expression", ".", "Furthermore", ",", "tPA", "induced", "rapid", "tyrosine", "phosphorylation", "on", "the", "beta", "subunit", "of", "LRP-1", ",", "which", "was", "followed", "by", "the", "activation", "of", "Mek1", "and", "its", "downstream", "Erk-1", "and", "-2", ".", "Blockade", "of", "Erk-1/2", "activation", "by", "the", "Mek1", "inhibitor", "abolished", "MMP-9", "induction", "by", "tPA", "in", "NRK-49F", "cells", ".", "Conversely", ",", "overexpression", "of", "constitutively", "activated", "Mek1", "induced", "Erk-1/2", "phosphorylation", "and", "MMP-9", "expression", ".", "In", "mouse", "obstructed", "kidney", ",", "tPA", ",", "LRP-1", ",", "and", "MMP-9", "were", "concomitantly", "induced", "in", "the", "renal", "interstitium", ".", "Collectively", ",", "these", "results", "suggest", "that", "besides", "its", "classical", "proteolytic", "activity", ",", "tPA", "acts", "as", "a", "cytokine", "that", "binds", "to", "the", "cell", "membrane", "receptor", "LRP-1", ",", "induces", "its", "tyrosine", "phosphorylation", ",", "and", "triggers", "intracellular", "signal", "transduction", ",", "thereby", "inducing", "specific", "gene", "expression", "in", "renal", "interstitial", "fibroblasts", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Kraniofaziale Fehlbildungen is an umlsterm, Schaedelnaehten is an umlsterm, Hirn- is an umlsterm, Gesichtsschaedels is an umlsterm, Therapieansaetze is an umlsterm, Technik is an umlsterm, Operationstechnik is an umlsterm, Operationstechniken is an umlsterm, Techniken is an umlsterm, Tumorchirurgie is an umlsterm, Traumatologie is an umlsterm	MundKieferGesichtschirurgie.0004s068.ger.abstr_task0	Sentence: Kraniofaziale Fehlbildungen entstehen ueberwiegend durch die vorzeitige Verknoecherung von Schaedelnaehten . Je nach Nahtbefall resultieren daraus mehr oder weniger ausgepraegte Deformationen des Hirn- und Gesichtsschaedels , die sowohl zu einer funktionellen als auch zu einer aesthetischen Beeintraechtigung fuehren . Die Aetiopathogenese ist noch weitgehend ungeklaert . In den vergangenen 100 Jahren wurden verschiedene Therapieansaetze entwickelt , wobei Tessier mit der Technik des frontoorbitalen Advancements der entscheidende Fortschritt gelang . Aufbauend auf dieser Operationstechnik wurden bis heute zahlreiche Verbesserungen eingebracht . Mit den heutigen Operationstechniken ist es moeglich , praktisch alle Schaedelfehlbildungen zu therapieren . Gleichzeitig konnten durch diese Techniken auch Fortschritte in der Tumorchirurgie und der Traumatologie erzielt werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]	Kraniofaziale Fehlbildungen entstehen ueberwiegend durch die vorzeitige Verknoecherung von Schaedelnaehten . Je nach Nahtbefall resultieren daraus mehr oder weniger ausgepraegte Deformationen des Hirn- und Gesichtsschaedels , die sowohl zu einer funktionellen als auch zu einer aesthetischen Beeintraechtigung fuehren . Die Aetiopathogenese ist noch weitgehend ungeklaert . In den vergangenen 100 Jahren wurden verschiedene Therapieansaetze entwickelt , wobei Tessier mit der Technik des frontoorbitalen Advancements der entscheidende Fortschritt gelang . Aufbauend auf dieser Operationstechnik wurden bis heute zahlreiche Verbesserungen eingebracht . Mit den heutigen Operationstechniken ist es moeglich , praktisch alle Schaedelfehlbildungen zu therapieren . Gleichzeitig konnten durch diese Techniken auch Fortschritte in der Tumorchirurgie und der Traumatologie erzielt werden .	[ "Kraniofaziale", "Fehlbildungen", "entstehen", "ueberwiegend", "durch", "die", "vorzeitige", "Verknoecherung", "von", "Schaedelnaehten", ".", "Je", "nach", "Nahtbefall", "resultieren", "daraus", "mehr", "oder", "weniger", "ausgepraegte", "Deformationen", "des", "Hirn-", "und", "Gesichtsschaedels", ",", "die", "sowohl", "zu", "einer", "funktionellen", "als", "auch", "zu", "einer", "aesthetischen", "Beeintraechtigung", "fuehren", ".", "Die", "Aetiopathogenese", "ist", "noch", "weitgehend", "ungeklaert", ".", "In", "den", "vergangenen", "100", "Jahren", "wurden", "verschiedene", "Therapieansaetze", "entwickelt", ",", "wobei", "Tessier", "mit", "der", "Technik", "des", "frontoorbitalen", "Advancements", "der", "entscheidende", "Fortschritt", "gelang", ".", "Aufbauend", "auf", "dieser", "Operationstechnik", "wurden", "bis", "heute", "zahlreiche", "Verbesserungen", "eingebracht", ".", "Mit", "den", "heutigen", "Operationstechniken", "ist", "es", "moeglich", ",", "praktisch", "alle", "Schaedelfehlbildungen", "zu", "therapieren", ".", "Gleichzeitig", "konnten", "durch", "diese", "Techniken", "auch", "Fortschritte", "in", "der", "Tumorchirurgie", "und", "der", "Traumatologie", "erzielt", "werden", "." ]	[ "umlsterm" ]
Kraniofaziale Fehlbildungen is an umlsterm, Schaedelnaehten is an umlsterm, Hirn- is an umlsterm, Gesichtsschaedels is an umlsterm, Therapieansaetze is an umlsterm, Technik is an umlsterm, Operationstechnik is an umlsterm, Operationstechniken is an umlsterm, Techniken is an umlsterm, Tumorchirurgie is an umlsterm, Traumatologie is an umlsterm	MundKieferGesichtschirurgie.0004s068.ger.abstr_task1	Sentence: Kraniofaziale Fehlbildungen entstehen ueberwiegend durch die vorzeitige Verknoecherung von Schaedelnaehten . Je nach Nahtbefall resultieren daraus mehr oder weniger ausgepraegte Deformationen des Hirn- und Gesichtsschaedels , die sowohl zu einer funktionellen als auch zu einer aesthetischen Beeintraechtigung fuehren . Die Aetiopathogenese ist noch weitgehend ungeklaert . In den vergangenen 100 Jahren wurden verschiedene Therapieansaetze entwickelt , wobei Tessier mit der Technik des frontoorbitalen Advancements der entscheidende Fortschritt gelang . Aufbauend auf dieser Operationstechnik wurden bis heute zahlreiche Verbesserungen eingebracht . Mit den heutigen Operationstechniken ist es moeglich , praktisch alle Schaedelfehlbildungen zu therapieren . Gleichzeitig konnten durch diese Techniken auch Fortschritte in der Tumorchirurgie und der Traumatologie erzielt werden . Instructions: please typing these entity words according to sentence: Kraniofaziale Fehlbildungen, Schaedelnaehten, Hirn-, Gesichtsschaedels, Therapieansaetze, Technik, Operationstechnik, Operationstechniken, Techniken, Tumorchirurgie, Traumatologie Options: umlsterm	[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]	Kraniofaziale Fehlbildungen entstehen ueberwiegend durch die vorzeitige Verknoecherung von Schaedelnaehten . Je nach Nahtbefall resultieren daraus mehr oder weniger ausgepraegte Deformationen des Hirn- und Gesichtsschaedels , die sowohl zu einer funktionellen als auch zu einer aesthetischen Beeintraechtigung fuehren . Die Aetiopathogenese ist noch weitgehend ungeklaert . In den vergangenen 100 Jahren wurden verschiedene Therapieansaetze entwickelt , wobei Tessier mit der Technik des frontoorbitalen Advancements der entscheidende Fortschritt gelang . Aufbauend auf dieser Operationstechnik wurden bis heute zahlreiche Verbesserungen eingebracht . Mit den heutigen Operationstechniken ist es moeglich , praktisch alle Schaedelfehlbildungen zu therapieren . Gleichzeitig konnten durch diese Techniken auch Fortschritte in der Tumorchirurgie und der Traumatologie erzielt werden .	[ "Kraniofaziale", "Fehlbildungen", "entstehen", "ueberwiegend", "durch", "die", "vorzeitige", "Verknoecherung", "von", "Schaedelnaehten", ".", "Je", "nach", "Nahtbefall", "resultieren", "daraus", "mehr", "oder", "weniger", "ausgepraegte", "Deformationen", "des", "Hirn-", "und", "Gesichtsschaedels", ",", "die", "sowohl", "zu", "einer", "funktionellen", "als", "auch", "zu", "einer", "aesthetischen", "Beeintraechtigung", "fuehren", ".", "Die", "Aetiopathogenese", "ist", "noch", "weitgehend", "ungeklaert", ".", "In", "den", "vergangenen", "100", "Jahren", "wurden", "verschiedene", "Therapieansaetze", "entwickelt", ",", "wobei", "Tessier", "mit", "der", "Technik", "des", "frontoorbitalen", "Advancements", "der", "entscheidende", "Fortschritt", "gelang", ".", "Aufbauend", "auf", "dieser", "Operationstechnik", "wurden", "bis", "heute", "zahlreiche", "Verbesserungen", "eingebracht", ".", "Mit", "den", "heutigen", "Operationstechniken", "ist", "es", "moeglich", ",", "praktisch", "alle", "Schaedelfehlbildungen", "zu", "therapieren", ".", "Gleichzeitig", "konnten", "durch", "diese", "Techniken", "auch", "Fortschritte", "in", "der", "Tumorchirurgie", "und", "der", "Traumatologie", "erzielt", "werden", "." ]	[ "umlsterm" ]
Kraniofaziale Fehlbildungen, Schaedelnaehten, Hirn-, Gesichtsschaedels, Therapieansaetze, Technik, Operationstechnik, Operationstechniken, Techniken, Tumorchirurgie, Traumatologie	MundKieferGesichtschirurgie.0004s068.ger.abstr_task2	Sentence: Kraniofaziale Fehlbildungen entstehen ueberwiegend durch die vorzeitige Verknoecherung von Schaedelnaehten . Je nach Nahtbefall resultieren daraus mehr oder weniger ausgepraegte Deformationen des Hirn- und Gesichtsschaedels , die sowohl zu einer funktionellen als auch zu einer aesthetischen Beeintraechtigung fuehren . Die Aetiopathogenese ist noch weitgehend ungeklaert . In den vergangenen 100 Jahren wurden verschiedene Therapieansaetze entwickelt , wobei Tessier mit der Technik des frontoorbitalen Advancements der entscheidende Fortschritt gelang . Aufbauend auf dieser Operationstechnik wurden bis heute zahlreiche Verbesserungen eingebracht . Mit den heutigen Operationstechniken ist es moeglich , praktisch alle Schaedelfehlbildungen zu therapieren . Gleichzeitig konnten durch diese Techniken auch Fortschritte in der Tumorchirurgie und der Traumatologie erzielt werden . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]	Kraniofaziale Fehlbildungen entstehen ueberwiegend durch die vorzeitige Verknoecherung von Schaedelnaehten . Je nach Nahtbefall resultieren daraus mehr oder weniger ausgepraegte Deformationen des Hirn- und Gesichtsschaedels , die sowohl zu einer funktionellen als auch zu einer aesthetischen Beeintraechtigung fuehren . Die Aetiopathogenese ist noch weitgehend ungeklaert . In den vergangenen 100 Jahren wurden verschiedene Therapieansaetze entwickelt , wobei Tessier mit der Technik des frontoorbitalen Advancements der entscheidende Fortschritt gelang . Aufbauend auf dieser Operationstechnik wurden bis heute zahlreiche Verbesserungen eingebracht . Mit den heutigen Operationstechniken ist es moeglich , praktisch alle Schaedelfehlbildungen zu therapieren . Gleichzeitig konnten durch diese Techniken auch Fortschritte in der Tumorchirurgie und der Traumatologie erzielt werden .	[ "Kraniofaziale", "Fehlbildungen", "entstehen", "ueberwiegend", "durch", "die", "vorzeitige", "Verknoecherung", "von", "Schaedelnaehten", ".", "Je", "nach", "Nahtbefall", "resultieren", "daraus", "mehr", "oder", "weniger", "ausgepraegte", "Deformationen", "des", "Hirn-", "und", "Gesichtsschaedels", ",", "die", "sowohl", "zu", "einer", "funktionellen", "als", "auch", "zu", "einer", "aesthetischen", "Beeintraechtigung", "fuehren", ".", "Die", "Aetiopathogenese", "ist", "noch", "weitgehend", "ungeklaert", ".", "In", "den", "vergangenen", "100", "Jahren", "wurden", "verschiedene", "Therapieansaetze", "entwickelt", ",", "wobei", "Tessier", "mit", "der", "Technik", "des", "frontoorbitalen", "Advancements", "der", "entscheidende", "Fortschritt", "gelang", ".", "Aufbauend", "auf", "dieser", "Operationstechnik", "wurden", "bis", "heute", "zahlreiche", "Verbesserungen", "eingebracht", ".", "Mit", "den", "heutigen", "Operationstechniken", "ist", "es", "moeglich", ",", "praktisch", "alle", "Schaedelfehlbildungen", "zu", "therapieren", ".", "Gleichzeitig", "konnten", "durch", "diese", "Techniken", "auch", "Fortschritte", "in", "der", "Tumorchirurgie", "und", "der", "Traumatologie", "erzielt", "werden", "." ]	[ "umlsterm" ]
N - acetyl cysteine is a CHEMICAL, NAC is a CHEMICAL, organosulfur is a CHEMICAL	23578993_task0	Sentence: Effect of N-acetyl cysteine (NAC), an organosulfur compound from Allium plants, on experimentally induced hepatic prefibrogenic events in wistar rat. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of N-acetyl cysteine (NAC), an organosulfur compound from Allium plants, on experimentally induced hepatic prefibrogenic events in wistar rat.	[ "Effect", "of", "N", "-", "acetyl", "cysteine", "(", "NAC", ")", ",", "an", "organosulfur", "compound", "from", "Allium", "plants", ",", "on", "experimentally", "induced", "hepatic", "prefibrogenic", "events", "in", "wistar", "rat", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
N - acetyl cysteine is a CHEMICAL, NAC is a CHEMICAL, organosulfur is a CHEMICAL	23578993_task1	Sentence: Effect of N-acetyl cysteine (NAC), an organosulfur compound from Allium plants, on experimentally induced hepatic prefibrogenic events in wistar rat. Instructions: please typing these entity words according to sentence: N - acetyl cysteine, NAC, organosulfur Options: CHEMICAL	[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of N-acetyl cysteine (NAC), an organosulfur compound from Allium plants, on experimentally induced hepatic prefibrogenic events in wistar rat.	[ "Effect", "of", "N", "-", "acetyl", "cysteine", "(", "NAC", ")", ",", "an", "organosulfur", "compound", "from", "Allium", "plants", ",", "on", "experimentally", "induced", "hepatic", "prefibrogenic", "events", "in", "wistar", "rat", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
N - acetyl cysteine, NAC, organosulfur	23578993_task2	Sentence: Effect of N-acetyl cysteine (NAC), an organosulfur compound from Allium plants, on experimentally induced hepatic prefibrogenic events in wistar rat. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of N-acetyl cysteine (NAC), an organosulfur compound from Allium plants, on experimentally induced hepatic prefibrogenic events in wistar rat.	[ "Effect", "of", "N", "-", "acetyl", "cysteine", "(", "NAC", ")", ",", "an", "organosulfur", "compound", "from", "Allium", "plants", ",", "on", "experimentally", "induced", "hepatic", "prefibrogenic", "events", "in", "wistar", "rat", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
CG beta is a protein, subunit is a protein, CG beta alpha is a protein, FSH beta is a protein	HPRD50.d2_task0	Sentence: We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "B-protein", "O", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "I-protein", "O" ]	We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer	[ "We", "tested", "this", "point", "by", "cotransfecting", "CHO", "cells", "with", "the", "genes", "encoding", "F", "beta", "alpha", "and", "the", "CG", "beta", "subunit", "or", "the", "CG", "beta", "alpha", "and", "FSH", "beta", "monomer" ]	[ "protein" ]
CG beta is a protein, subunit is a protein, CG beta alpha is a protein, FSH beta is a protein	HPRD50.d2_task1	Sentence: We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer Instructions: please typing these entity words according to sentence: CG beta, subunit, CG beta alpha, FSH beta Options: protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "B-protein", "O", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "I-protein", "O" ]	We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer	[ "We", "tested", "this", "point", "by", "cotransfecting", "CHO", "cells", "with", "the", "genes", "encoding", "F", "beta", "alpha", "and", "the", "CG", "beta", "subunit", "or", "the", "CG", "beta", "alpha", "and", "FSH", "beta", "monomer" ]	[ "protein" ]
CG beta, subunit, CG beta alpha, FSH beta	HPRD50.d2_task2	Sentence: We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "B-protein", "O", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "I-protein", "O" ]	We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer	[ "We", "tested", "this", "point", "by", "cotransfecting", "CHO", "cells", "with", "the", "genes", "encoding", "F", "beta", "alpha", "and", "the", "CG", "beta", "subunit", "or", "the", "CG", "beta", "alpha", "and", "FSH", "beta", "monomer" ]	[ "protein" ]
carbon is a CHEMICAL	23301860_task0	Sentence: Single-walled carbon nanotube surface control of complement recognition and activation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL	[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Single-walled carbon nanotube surface control of complement recognition and activation.	[ "Single", "-", "walled", "carbon", "nanotube", "surface", "control", "of", "complement", "recognition", "and", "activation", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
carbon is a CHEMICAL	23301860_task1	Sentence: Single-walled carbon nanotube surface control of complement recognition and activation. Instructions: please typing these entity words according to sentence: carbon Options: CHEMICAL	[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Single-walled carbon nanotube surface control of complement recognition and activation.	[ "Single", "-", "walled", "carbon", "nanotube", "surface", "control", "of", "complement", "recognition", "and", "activation", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
carbon	23301860_task2	Sentence: Single-walled carbon nanotube surface control of complement recognition and activation. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Single-walled carbon nanotube surface control of complement recognition and activation.	[ "Single", "-", "walled", "carbon", "nanotube", "surface", "control", "of", "complement", "recognition", "and", "activation", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
adult is an umlsterm, hyperkinetic syndrome is an umlsterm, attention is an umlsterm, disorder is an umlsterm, Germany is an umlsterm, children is an umlsterm, symptoms is an umlsterm, adults is an umlsterm, syndrome is an umlsterm, symptoms is an umlsterm, hyperactivity is an umlsterm, Retrospective is an umlsterm, diagnosis is an umlsterm, emotional disturbances is an umlsterm, stress is an umlsterm, adults is an umlsterm, symptoms is an umlsterm, learning disorders is an umlsterm, dyslexia is an umlsterm, dysgraphia is an umlsterm, differential diagnosis is an umlsterm, anxiety is an umlsterm, antisocial personality disorders is an umlsterm, comorbidity is an umlsterm, transmission is an umlsterm, findings is an umlsterm, neurotransmitters is an umlsterm, treatment is an umlsterm, pemoline is an umlsterm, tricyclic antidepressants is an umlsterm, beta blockers is an umlsterm, bupropion is an umlsterm, fluoxetine is an umlsterm, venlafaxine is an umlsterm	DerNervenarzt.80690543.eng.abstr_task0	Sentence: The clinical picture of adult hyperkinetic syndrome ( HKS ) or attention deficit/hyperactivity disorder is nearly unknown in Germany . It can be estimated , that approximately one third of affected children also show symptoms as adults . In the combined type of the syndrome symptoms of inattention as well as of hyperactivity and impulsivity are present , a predominantly inattentive or hyperactive-impulsive type is possible . Retrospective diagnosis of HKS in childhood can be difficult . Disorganization , emotional disturbances and stress intolerance are common in adults with HKS as well as residual symptoms of learning disorders like dyslexia , dyscalculia and dysgraphia . In differential diagnosis especially affective , anxiety and antisocial personality disorders have to be considered , for which on the other side a frequent comorbidity with HKS is known . There is strong evidence for genetic transmission . Neurobiological findings revealed dysregulation of neurotransmitters . For treatment stimulants as pemoline and methamphetamin are effective , in addition tricyclic antidepressants or beta blockers ; positive effects are probable for moclobemide , bupropion , fluoxetine and venlafaxine . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	The clinical picture of adult hyperkinetic syndrome ( HKS ) or attention deficit/hyperactivity disorder is nearly unknown in Germany . It can be estimated , that approximately one third of affected children also show symptoms as adults . In the combined type of the syndrome symptoms of inattention as well as of hyperactivity and impulsivity are present , a predominantly inattentive or hyperactive-impulsive type is possible . Retrospective diagnosis of HKS in childhood can be difficult . Disorganization , emotional disturbances and stress intolerance are common in adults with HKS as well as residual symptoms of learning disorders like dyslexia , dyscalculia and dysgraphia . In differential diagnosis especially affective , anxiety and antisocial personality disorders have to be considered , for which on the other side a frequent comorbidity with HKS is known . There is strong evidence for genetic transmission . Neurobiological findings revealed dysregulation of neurotransmitters . For treatment stimulants as pemoline and methamphetamin are effective , in addition tricyclic antidepressants or beta blockers ; positive effects are probable for moclobemide , bupropion , fluoxetine and venlafaxine .	[ "The", "clinical", "picture", "of", "adult", "hyperkinetic", "syndrome", "(", "HKS", ")", "or", "attention", "deficit", "/", "hyperactivity", "disorder", "is", "nearly", "unknown", "in", "Germany", ".", "It", "can", "be", "estimated", ",", "that", "approximately", "one", "third", "of", "affected", "children", "also", "show", "symptoms", "as", "adults", ".", "In", "the", "combined", "type", "of", "the", "syndrome", "symptoms", "of", "inattention", "as", "well", "as", "of", "hyperactivity", "and", "impulsivity", "are", "present", ",", "a", "predominantly", "inattentive", "or", "hyperactive", "-", "impulsive", "type", "is", "possible", ".", "Retrospective", "diagnosis", "of", "HKS", "in", "childhood", "can", "be", "difficult", ".", "Disorganization", ",", "emotional", "disturbances", "and", "stress", "intolerance", "are", "common", "in", "adults", "with", "HKS", "as", "well", "as", "residual", "symptoms", "of", "learning", "disorders", "like", "dyslexia", ",", "dyscalculia", "and", "dysgraphia", ".", "In", "differential", "diagnosis", "especially", "affective", ",", "anxiety", "and", "antisocial", "personality", "disorders", "have", "to", "be", "considered", ",", "for", "which", "on", "the", "other", "side", "a", "frequent", "comorbidity", "with", "HKS", "is", "known", ".", "There", "is", "strong", "evidence", "for", "genetic", "transmission", ".", "Neurobiological", "findings", "revealed", "dysregulation", "of", "neurotransmitters", ".", "For", "treatment", "stimulants", "as", "pemoline", "and", "methamphetamin", "are", "effective", ",", "in", "addition", "tricyclic", "antidepressants", "or", "beta", "blockers", ";", "positive", "effects", "are", "probable", "for", "moclobemide", ",", "bupropion", ",", "fluoxetine", "and", "venlafaxine", "." ]	[ "umlsterm" ]
adult is an umlsterm, hyperkinetic syndrome is an umlsterm, attention is an umlsterm, disorder is an umlsterm, Germany is an umlsterm, children is an umlsterm, symptoms is an umlsterm, adults is an umlsterm, syndrome is an umlsterm, symptoms is an umlsterm, hyperactivity is an umlsterm, Retrospective is an umlsterm, diagnosis is an umlsterm, emotional disturbances is an umlsterm, stress is an umlsterm, adults is an umlsterm, symptoms is an umlsterm, learning disorders is an umlsterm, dyslexia is an umlsterm, dysgraphia is an umlsterm, differential diagnosis is an umlsterm, anxiety is an umlsterm, antisocial personality disorders is an umlsterm, comorbidity is an umlsterm, transmission is an umlsterm, findings is an umlsterm, neurotransmitters is an umlsterm, treatment is an umlsterm, pemoline is an umlsterm, tricyclic antidepressants is an umlsterm, beta blockers is an umlsterm, bupropion is an umlsterm, fluoxetine is an umlsterm, venlafaxine is an umlsterm	DerNervenarzt.80690543.eng.abstr_task1	Sentence: The clinical picture of adult hyperkinetic syndrome ( HKS ) or attention deficit/hyperactivity disorder is nearly unknown in Germany . It can be estimated , that approximately one third of affected children also show symptoms as adults . In the combined type of the syndrome symptoms of inattention as well as of hyperactivity and impulsivity are present , a predominantly inattentive or hyperactive-impulsive type is possible . Retrospective diagnosis of HKS in childhood can be difficult . Disorganization , emotional disturbances and stress intolerance are common in adults with HKS as well as residual symptoms of learning disorders like dyslexia , dyscalculia and dysgraphia . In differential diagnosis especially affective , anxiety and antisocial personality disorders have to be considered , for which on the other side a frequent comorbidity with HKS is known . There is strong evidence for genetic transmission . Neurobiological findings revealed dysregulation of neurotransmitters . For treatment stimulants as pemoline and methamphetamin are effective , in addition tricyclic antidepressants or beta blockers ; positive effects are probable for moclobemide , bupropion , fluoxetine and venlafaxine . Instructions: please typing these entity words according to sentence: adult, hyperkinetic syndrome, attention, disorder, Germany, children, symptoms, adults, syndrome, symptoms, hyperactivity, Retrospective, diagnosis, emotional disturbances, stress, adults, symptoms, learning disorders, dyslexia, dysgraphia, differential diagnosis, anxiety, antisocial personality disorders, comorbidity, transmission, findings, neurotransmitters, treatment, pemoline, tricyclic antidepressants, beta blockers, bupropion, fluoxetine, venlafaxine Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	The clinical picture of adult hyperkinetic syndrome ( HKS ) or attention deficit/hyperactivity disorder is nearly unknown in Germany . It can be estimated , that approximately one third of affected children also show symptoms as adults . In the combined type of the syndrome symptoms of inattention as well as of hyperactivity and impulsivity are present , a predominantly inattentive or hyperactive-impulsive type is possible . Retrospective diagnosis of HKS in childhood can be difficult . Disorganization , emotional disturbances and stress intolerance are common in adults with HKS as well as residual symptoms of learning disorders like dyslexia , dyscalculia and dysgraphia . In differential diagnosis especially affective , anxiety and antisocial personality disorders have to be considered , for which on the other side a frequent comorbidity with HKS is known . There is strong evidence for genetic transmission . Neurobiological findings revealed dysregulation of neurotransmitters . For treatment stimulants as pemoline and methamphetamin are effective , in addition tricyclic antidepressants or beta blockers ; positive effects are probable for moclobemide , bupropion , fluoxetine and venlafaxine .	[ "The", "clinical", "picture", "of", "adult", "hyperkinetic", "syndrome", "(", "HKS", ")", "or", "attention", "deficit", "/", "hyperactivity", "disorder", "is", "nearly", "unknown", "in", "Germany", ".", "It", "can", "be", "estimated", ",", "that", "approximately", "one", "third", "of", "affected", "children", "also", "show", "symptoms", "as", "adults", ".", "In", "the", "combined", "type", "of", "the", "syndrome", "symptoms", "of", "inattention", "as", "well", "as", "of", "hyperactivity", "and", "impulsivity", "are", "present", ",", "a", "predominantly", "inattentive", "or", "hyperactive", "-", "impulsive", "type", "is", "possible", ".", "Retrospective", "diagnosis", "of", "HKS", "in", "childhood", "can", "be", "difficult", ".", "Disorganization", ",", "emotional", "disturbances", "and", "stress", "intolerance", "are", "common", "in", "adults", "with", "HKS", "as", "well", "as", "residual", "symptoms", "of", "learning", "disorders", "like", "dyslexia", ",", "dyscalculia", "and", "dysgraphia", ".", "In", "differential", "diagnosis", "especially", "affective", ",", "anxiety", "and", "antisocial", "personality", "disorders", "have", "to", "be", "considered", ",", "for", "which", "on", "the", "other", "side", "a", "frequent", "comorbidity", "with", "HKS", "is", "known", ".", "There", "is", "strong", "evidence", "for", "genetic", "transmission", ".", "Neurobiological", "findings", "revealed", "dysregulation", "of", "neurotransmitters", ".", "For", "treatment", "stimulants", "as", "pemoline", "and", "methamphetamin", "are", "effective", ",", "in", "addition", "tricyclic", "antidepressants", "or", "beta", "blockers", ";", "positive", "effects", "are", "probable", "for", "moclobemide", ",", "bupropion", ",", "fluoxetine", "and", "venlafaxine", "." ]	[ "umlsterm" ]
adult, hyperkinetic syndrome, attention, disorder, Germany, children, symptoms, adults, syndrome, symptoms, hyperactivity, Retrospective, diagnosis, emotional disturbances, stress, adults, symptoms, learning disorders, dyslexia, dysgraphia, differential diagnosis, anxiety, antisocial personality disorders, comorbidity, transmission, findings, neurotransmitters, treatment, pemoline, tricyclic antidepressants, beta blockers, bupropion, fluoxetine, venlafaxine	DerNervenarzt.80690543.eng.abstr_task2	Sentence: The clinical picture of adult hyperkinetic syndrome ( HKS ) or attention deficit/hyperactivity disorder is nearly unknown in Germany . It can be estimated , that approximately one third of affected children also show symptoms as adults . In the combined type of the syndrome symptoms of inattention as well as of hyperactivity and impulsivity are present , a predominantly inattentive or hyperactive-impulsive type is possible . Retrospective diagnosis of HKS in childhood can be difficult . Disorganization , emotional disturbances and stress intolerance are common in adults with HKS as well as residual symptoms of learning disorders like dyslexia , dyscalculia and dysgraphia . In differential diagnosis especially affective , anxiety and antisocial personality disorders have to be considered , for which on the other side a frequent comorbidity with HKS is known . There is strong evidence for genetic transmission . Neurobiological findings revealed dysregulation of neurotransmitters . For treatment stimulants as pemoline and methamphetamin are effective , in addition tricyclic antidepressants or beta blockers ; positive effects are probable for moclobemide , bupropion , fluoxetine and venlafaxine . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	The clinical picture of adult hyperkinetic syndrome ( HKS ) or attention deficit/hyperactivity disorder is nearly unknown in Germany . It can be estimated , that approximately one third of affected children also show symptoms as adults . In the combined type of the syndrome symptoms of inattention as well as of hyperactivity and impulsivity are present , a predominantly inattentive or hyperactive-impulsive type is possible . Retrospective diagnosis of HKS in childhood can be difficult . Disorganization , emotional disturbances and stress intolerance are common in adults with HKS as well as residual symptoms of learning disorders like dyslexia , dyscalculia and dysgraphia . In differential diagnosis especially affective , anxiety and antisocial personality disorders have to be considered , for which on the other side a frequent comorbidity with HKS is known . There is strong evidence for genetic transmission . Neurobiological findings revealed dysregulation of neurotransmitters . For treatment stimulants as pemoline and methamphetamin are effective , in addition tricyclic antidepressants or beta blockers ; positive effects are probable for moclobemide , bupropion , fluoxetine and venlafaxine .	[ "The", "clinical", "picture", "of", "adult", "hyperkinetic", "syndrome", "(", "HKS", ")", "or", "attention", "deficit", "/", "hyperactivity", "disorder", "is", "nearly", "unknown", "in", "Germany", ".", "It", "can", "be", "estimated", ",", "that", "approximately", "one", "third", "of", "affected", "children", "also", "show", "symptoms", "as", "adults", ".", "In", "the", "combined", "type", "of", "the", "syndrome", "symptoms", "of", "inattention", "as", "well", "as", "of", "hyperactivity", "and", "impulsivity", "are", "present", ",", "a", "predominantly", "inattentive", "or", "hyperactive", "-", "impulsive", "type", "is", "possible", ".", "Retrospective", "diagnosis", "of", "HKS", "in", "childhood", "can", "be", "difficult", ".", "Disorganization", ",", "emotional", "disturbances", "and", "stress", "intolerance", "are", "common", "in", "adults", "with", "HKS", "as", "well", "as", "residual", "symptoms", "of", "learning", "disorders", "like", "dyslexia", ",", "dyscalculia", "and", "dysgraphia", ".", "In", "differential", "diagnosis", "especially", "affective", ",", "anxiety", "and", "antisocial", "personality", "disorders", "have", "to", "be", "considered", ",", "for", "which", "on", "the", "other", "side", "a", "frequent", "comorbidity", "with", "HKS", "is", "known", ".", "There", "is", "strong", "evidence", "for", "genetic", "transmission", ".", "Neurobiological", "findings", "revealed", "dysregulation", "of", "neurotransmitters", ".", "For", "treatment", "stimulants", "as", "pemoline", "and", "methamphetamin", "are", "effective", ",", "in", "addition", "tricyclic", "antidepressants", "or", "beta", "blockers", ";", "positive", "effects", "are", "probable", "for", "moclobemide", ",", "bupropion", ",", "fluoxetine", "and", "venlafaxine", "." ]	[ "umlsterm" ]
tobacco is a Plant, esophageal cancer is a Disease, esophageal cancer is a Disease, cancer is a Disease, esophageal cancer is a Disease, esophageal cancer is a Disease	8357273_task0	Sentence: Alcohol and tobacco habits have been identified as strong risk factors for esophageal cancer. Increased risks of esophageal cancer have also been reported to be associated with occupational exposure to asbestos and various metals, among vulcanization workers, asphalt workers, and workers in the petrochemical industry. Mortality and cancer incidence were investigated in a series of studies of workers exposed to combustion by-products, i.e., chimney sweeps, waste incinerator workers, gas workers, and bus garage workers exposed to diesel exhausts. The SMRs for esophageal cancer ranged from 150-386 in these cohorts, and a combined SMR of 289 (95% C.I. 174-452) was obtained. Available data on smoking habits and indirect indicators of alcohol consumption show that the excess cannot be attributed solely to these factors. It seems likely that occupational exposure to combustion products is associated with an increased risk of esophageal cancer. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Disease, Plant	[ "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O" ]	Alcohol and tobacco habits have been identified as strong risk factors for esophageal cancer. Increased risks of esophageal cancer have also been reported to be associated with occupational exposure to asbestos and various metals, among vulcanization workers, asphalt workers, and workers in the petrochemical industry. Mortality and cancer incidence were investigated in a series of studies of workers exposed to combustion by-products, i.e., chimney sweeps, waste incinerator workers, gas workers, and bus garage workers exposed to diesel exhausts. The SMRs for esophageal cancer ranged from 150-386 in these cohorts, and a combined SMR of 289 (95% C.I. 174-452) was obtained. Available data on smoking habits and indirect indicators of alcohol consumption show that the excess cannot be attributed solely to these factors. It seems likely that occupational exposure to combustion products is associated with an increased risk of esophageal cancer.	[ "Alcohol", "and", "tobacco", "habits", "have", "been", "identified", "as", "strong", "risk", "factors", "for", "esophageal", "cancer", ".", "Increased", "risks", "of", "esophageal", "cancer", "have", "also", "been", "reported", "to", "be", "associated", "with", "occupational", "exposure", "to", "asbestos", "and", "various", "metals", ",", "among", "vulcanization", "workers", ",", "asphalt", "workers", ",", "and", "workers", "in", "the", "petrochemical", "industry", ".", "Mortality", "and", "cancer", "incidence", "were", "investigated", "in", "a", "series", "of", "studies", "of", "workers", "exposed", "to", "combustion", "by", "-", "products", ",", "i.e", ".", ",", "chimney", "sweeps", ",", "waste", "incinerator", "workers", ",", "gas", "workers", ",", "and", "bus", "garage", "workers", "exposed", "to", "diesel", "exhausts", ".", "The", "SMRs", "for", "esophageal", "cancer", "ranged", "from", "150", "-", "386", "in", "these", "cohorts", ",", "and", "a", "combined", "SMR", "of", "289", "(", "95", "%", "C.I.", "174", "-", "452", ")", "was", "obtained", ".", "Available", "data", "on", "smoking", "habits", "and", "indirect", "indicators", "of", "alcohol", "consumption", "show", "that", "the", "excess", "cannot", "be", "attributed", "solely", "to", "these", "factors", ".", "It", "seems", "likely", "that", "occupational", "exposure", "to", "combustion", "products", "is", "associated", "with", "an", "increased", "risk", "of", "esophageal", "cancer", "." ]	[ "Disease", "Plant" ]
tobacco is a Plant, esophageal cancer is a Disease, esophageal cancer is a Disease, cancer is a Disease, esophageal cancer is a Disease, esophageal cancer is a Disease	8357273_task1	Sentence: Alcohol and tobacco habits have been identified as strong risk factors for esophageal cancer. Increased risks of esophageal cancer have also been reported to be associated with occupational exposure to asbestos and various metals, among vulcanization workers, asphalt workers, and workers in the petrochemical industry. Mortality and cancer incidence were investigated in a series of studies of workers exposed to combustion by-products, i.e., chimney sweeps, waste incinerator workers, gas workers, and bus garage workers exposed to diesel exhausts. The SMRs for esophageal cancer ranged from 150-386 in these cohorts, and a combined SMR of 289 (95% C.I. 174-452) was obtained. Available data on smoking habits and indirect indicators of alcohol consumption show that the excess cannot be attributed solely to these factors. It seems likely that occupational exposure to combustion products is associated with an increased risk of esophageal cancer. Instructions: please typing these entity words according to sentence: tobacco, esophageal cancer, esophageal cancer, cancer, esophageal cancer, esophageal cancer Options: Disease, Plant	[ "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O" ]	Alcohol and tobacco habits have been identified as strong risk factors for esophageal cancer. Increased risks of esophageal cancer have also been reported to be associated with occupational exposure to asbestos and various metals, among vulcanization workers, asphalt workers, and workers in the petrochemical industry. Mortality and cancer incidence were investigated in a series of studies of workers exposed to combustion by-products, i.e., chimney sweeps, waste incinerator workers, gas workers, and bus garage workers exposed to diesel exhausts. The SMRs for esophageal cancer ranged from 150-386 in these cohorts, and a combined SMR of 289 (95% C.I. 174-452) was obtained. Available data on smoking habits and indirect indicators of alcohol consumption show that the excess cannot be attributed solely to these factors. It seems likely that occupational exposure to combustion products is associated with an increased risk of esophageal cancer.	[ "Alcohol", "and", "tobacco", "habits", "have", "been", "identified", "as", "strong", "risk", "factors", "for", "esophageal", "cancer", ".", "Increased", "risks", "of", "esophageal", "cancer", "have", "also", "been", "reported", "to", "be", "associated", "with", "occupational", "exposure", "to", "asbestos", "and", "various", "metals", ",", "among", "vulcanization", "workers", ",", "asphalt", "workers", ",", "and", "workers", "in", "the", "petrochemical", "industry", ".", "Mortality", "and", "cancer", "incidence", "were", "investigated", "in", "a", "series", "of", "studies", "of", "workers", "exposed", "to", "combustion", "by", "-", "products", ",", "i.e", ".", ",", "chimney", "sweeps", ",", "waste", "incinerator", "workers", ",", "gas", "workers", ",", "and", "bus", "garage", "workers", "exposed", "to", "diesel", "exhausts", ".", "The", "SMRs", "for", "esophageal", "cancer", "ranged", "from", "150", "-", "386", "in", "these", "cohorts", ",", "and", "a", "combined", "SMR", "of", "289", "(", "95", "%", "C.I.", "174", "-", "452", ")", "was", "obtained", ".", "Available", "data", "on", "smoking", "habits", "and", "indirect", "indicators", "of", "alcohol", "consumption", "show", "that", "the", "excess", "cannot", "be", "attributed", "solely", "to", "these", "factors", ".", "It", "seems", "likely", "that", "occupational", "exposure", "to", "combustion", "products", "is", "associated", "with", "an", "increased", "risk", "of", "esophageal", "cancer", "." ]	[ "Disease", "Plant" ]
tobacco, esophageal cancer, esophageal cancer, cancer, esophageal cancer, esophageal cancer	8357273_task2	Sentence: Alcohol and tobacco habits have been identified as strong risk factors for esophageal cancer. Increased risks of esophageal cancer have also been reported to be associated with occupational exposure to asbestos and various metals, among vulcanization workers, asphalt workers, and workers in the petrochemical industry. Mortality and cancer incidence were investigated in a series of studies of workers exposed to combustion by-products, i.e., chimney sweeps, waste incinerator workers, gas workers, and bus garage workers exposed to diesel exhausts. The SMRs for esophageal cancer ranged from 150-386 in these cohorts, and a combined SMR of 289 (95% C.I. 174-452) was obtained. Available data on smoking habits and indirect indicators of alcohol consumption show that the excess cannot be attributed solely to these factors. It seems likely that occupational exposure to combustion products is associated with an increased risk of esophageal cancer. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O" ]	Alcohol and tobacco habits have been identified as strong risk factors for esophageal cancer. Increased risks of esophageal cancer have also been reported to be associated with occupational exposure to asbestos and various metals, among vulcanization workers, asphalt workers, and workers in the petrochemical industry. Mortality and cancer incidence were investigated in a series of studies of workers exposed to combustion by-products, i.e., chimney sweeps, waste incinerator workers, gas workers, and bus garage workers exposed to diesel exhausts. The SMRs for esophageal cancer ranged from 150-386 in these cohorts, and a combined SMR of 289 (95% C.I. 174-452) was obtained. Available data on smoking habits and indirect indicators of alcohol consumption show that the excess cannot be attributed solely to these factors. It seems likely that occupational exposure to combustion products is associated with an increased risk of esophageal cancer.	[ "Alcohol", "and", "tobacco", "habits", "have", "been", "identified", "as", "strong", "risk", "factors", "for", "esophageal", "cancer", ".", "Increased", "risks", "of", "esophageal", "cancer", "have", "also", "been", "reported", "to", "be", "associated", "with", "occupational", "exposure", "to", "asbestos", "and", "various", "metals", ",", "among", "vulcanization", "workers", ",", "asphalt", "workers", ",", "and", "workers", "in", "the", "petrochemical", "industry", ".", "Mortality", "and", "cancer", "incidence", "were", "investigated", "in", "a", "series", "of", "studies", "of", "workers", "exposed", "to", "combustion", "by", "-", "products", ",", "i.e", ".", ",", "chimney", "sweeps", ",", "waste", "incinerator", "workers", ",", "gas", "workers", ",", "and", "bus", "garage", "workers", "exposed", "to", "diesel", "exhausts", ".", "The", "SMRs", "for", "esophageal", "cancer", "ranged", "from", "150", "-", "386", "in", "these", "cohorts", ",", "and", "a", "combined", "SMR", "of", "289", "(", "95", "%", "C.I.", "174", "-", "452", ")", "was", "obtained", ".", "Available", "data", "on", "smoking", "habits", "and", "indirect", "indicators", "of", "alcohol", "consumption", "show", "that", "the", "excess", "cannot", "be", "attributed", "solely", "to", "these", "factors", ".", "It", "seems", "likely", "that", "occupational", "exposure", "to", "combustion", "products", "is", "associated", "with", "an", "increased", "risk", "of", "esophageal", "cancer", "." ]	[ "Disease", "Plant" ]
laparoscopic surgery is an umlsterm, optics is an umlsterm, hospital is an umlsterm, operations is an umlsterm, voice is an umlsterm, arm is an umlsterm, optics is an umlsterm, gallbladder is an umlsterm, stomach is an umlsterm, large bowel is an umlsterm, hernia is an umlsterm, operations is an umlsterm, visual field is an umlsterm, arm is an umlsterm, voice is an umlsterm, exact is an umlsterm, operations is an umlsterm, operator is an umlsterm, surgeries is an umlsterm, arm is an umlsterm, operating theater is an umlsterm	DerChirurg.70680837.eng.abstr_task0	Sentence: Currently laparoscopic surgery is limited by several factors . One of them is the precise handling of optics . Up to now , in our hospital 52 laparoscopic operations have been done with a voice - controlled robot arm to handle the optics in gallbladder , stomach , large bowel and hernia operations . The visual field is determined by the surgeon . In all cases handling of the robot arm was precise and the voice response exact and without technical problems . Twenty-nine operations were done by one operator as " solo surgeries " . In 20 further cases there was one assistant . A robot arm can be used successfully without problems by any laparoscopic surgeon in any operating theater . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Currently laparoscopic surgery is limited by several factors . One of them is the precise handling of optics . Up to now , in our hospital 52 laparoscopic operations have been done with a voice - controlled robot arm to handle the optics in gallbladder , stomach , large bowel and hernia operations . The visual field is determined by the surgeon . In all cases handling of the robot arm was precise and the voice response exact and without technical problems . Twenty-nine operations were done by one operator as " solo surgeries " . In 20 further cases there was one assistant . A robot arm can be used successfully without problems by any laparoscopic surgeon in any operating theater .	[ "Currently", "laparoscopic", "surgery", "is", "limited", "by", "several", "factors", ".", "One", "of", "them", "is", "the", "precise", "handling", "of", "optics", ".", "Up", "to", "now", ",", "in", "our", "hospital", "52", "laparoscopic", "operations", "have", "been", "done", "with", "a", "voice", "-", "controlled", "robot", "arm", "to", "handle", "the", "optics", "in", "gallbladder", ",", "stomach", ",", "large", "bowel", "and", "hernia", "operations", ".", "The", "visual", "field", "is", "determined", "by", "the", "surgeon", ".", "In", "all", "cases", "handling", "of", "the", "robot", "arm", "was", "precise", "and", "the", "voice", "response", "exact", "and", "without", "technical", "problems", ".", "Twenty", "-", "nine", "operations", "were", "done", "by", "one", "operator", "as", "\"", "solo", "surgeries", "\"", ".", "In", "20", "further", "cases", "there", "was", "one", "assistant", ".", "A", "robot", "arm", "can", "be", "used", "successfully", "without", "problems", "by", "any", "laparoscopic", "surgeon", "in", "any", "operating", "theater", "." ]	[ "umlsterm" ]
laparoscopic surgery is an umlsterm, optics is an umlsterm, hospital is an umlsterm, operations is an umlsterm, voice is an umlsterm, arm is an umlsterm, optics is an umlsterm, gallbladder is an umlsterm, stomach is an umlsterm, large bowel is an umlsterm, hernia is an umlsterm, operations is an umlsterm, visual field is an umlsterm, arm is an umlsterm, voice is an umlsterm, exact is an umlsterm, operations is an umlsterm, operator is an umlsterm, surgeries is an umlsterm, arm is an umlsterm, operating theater is an umlsterm	DerChirurg.70680837.eng.abstr_task1	Sentence: Currently laparoscopic surgery is limited by several factors . One of them is the precise handling of optics . Up to now , in our hospital 52 laparoscopic operations have been done with a voice - controlled robot arm to handle the optics in gallbladder , stomach , large bowel and hernia operations . The visual field is determined by the surgeon . In all cases handling of the robot arm was precise and the voice response exact and without technical problems . Twenty-nine operations were done by one operator as " solo surgeries " . In 20 further cases there was one assistant . A robot arm can be used successfully without problems by any laparoscopic surgeon in any operating theater . Instructions: please typing these entity words according to sentence: laparoscopic surgery, optics, hospital, operations, voice, arm, optics, gallbladder, stomach, large bowel, hernia, operations, visual field, arm, voice, exact, operations, operator, surgeries, arm, operating theater Options: umlsterm	[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Currently laparoscopic surgery is limited by several factors . One of them is the precise handling of optics . Up to now , in our hospital 52 laparoscopic operations have been done with a voice - controlled robot arm to handle the optics in gallbladder , stomach , large bowel and hernia operations . The visual field is determined by the surgeon . In all cases handling of the robot arm was precise and the voice response exact and without technical problems . Twenty-nine operations were done by one operator as " solo surgeries " . In 20 further cases there was one assistant . A robot arm can be used successfully without problems by any laparoscopic surgeon in any operating theater .	[ "Currently", "laparoscopic", "surgery", "is", "limited", "by", "several", "factors", ".", "One", "of", "them", "is", "the", "precise", "handling", "of", "optics", ".", "Up", "to", "now", ",", "in", "our", "hospital", "52", "laparoscopic", "operations", "have", "been", "done", "with", "a", "voice", "-", "controlled", "robot", "arm", "to", "handle", "the", "optics", "in", "gallbladder", ",", "stomach", ",", "large", "bowel", "and", "hernia", "operations", ".", "The", "visual", "field", "is", "determined", "by", "the", "surgeon", ".", "In", "all", "cases", "handling", "of", "the", "robot", "arm", "was", "precise", "and", "the", "voice", "response", "exact", "and", "without", "technical", "problems", ".", "Twenty", "-", "nine", "operations", "were", "done", "by", "one", "operator", "as", "\"", "solo", "surgeries", "\"", ".", "In", "20", "further", "cases", "there", "was", "one", "assistant", ".", "A", "robot", "arm", "can", "be", "used", "successfully", "without", "problems", "by", "any", "laparoscopic", "surgeon", "in", "any", "operating", "theater", "." ]	[ "umlsterm" ]
laparoscopic surgery, optics, hospital, operations, voice, arm, optics, gallbladder, stomach, large bowel, hernia, operations, visual field, arm, voice, exact, operations, operator, surgeries, arm, operating theater	DerChirurg.70680837.eng.abstr_task2	Sentence: Currently laparoscopic surgery is limited by several factors . One of them is the precise handling of optics . Up to now , in our hospital 52 laparoscopic operations have been done with a voice - controlled robot arm to handle the optics in gallbladder , stomach , large bowel and hernia operations . The visual field is determined by the surgeon . In all cases handling of the robot arm was precise and the voice response exact and without technical problems . Twenty-nine operations were done by one operator as " solo surgeries " . In 20 further cases there was one assistant . A robot arm can be used successfully without problems by any laparoscopic surgeon in any operating theater . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]	Currently laparoscopic surgery is limited by several factors . One of them is the precise handling of optics . Up to now , in our hospital 52 laparoscopic operations have been done with a voice - controlled robot arm to handle the optics in gallbladder , stomach , large bowel and hernia operations . The visual field is determined by the surgeon . In all cases handling of the robot arm was precise and the voice response exact and without technical problems . Twenty-nine operations were done by one operator as " solo surgeries " . In 20 further cases there was one assistant . A robot arm can be used successfully without problems by any laparoscopic surgeon in any operating theater .	[ "Currently", "laparoscopic", "surgery", "is", "limited", "by", "several", "factors", ".", "One", "of", "them", "is", "the", "precise", "handling", "of", "optics", ".", "Up", "to", "now", ",", "in", "our", "hospital", "52", "laparoscopic", "operations", "have", "been", "done", "with", "a", "voice", "-", "controlled", "robot", "arm", "to", "handle", "the", "optics", "in", "gallbladder", ",", "stomach", ",", "large", "bowel", "and", "hernia", "operations", ".", "The", "visual", "field", "is", "determined", "by", "the", "surgeon", ".", "In", "all", "cases", "handling", "of", "the", "robot", "arm", "was", "precise", "and", "the", "voice", "response", "exact", "and", "without", "technical", "problems", ".", "Twenty", "-", "nine", "operations", "were", "done", "by", "one", "operator", "as", "\"", "solo", "surgeries", "\"", ".", "In", "20", "further", "cases", "there", "was", "one", "assistant", ".", "A", "robot", "arm", "can", "be", "used", "successfully", "without", "problems", "by", "any", "laparoscopic", "surgeon", "in", "any", "operating", "theater", "." ]	[ "umlsterm" ]
calcineurin is a GENE-N	16751287_task0	Sentence: Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O" ]	Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin.	[ "Decrease", "in", "density", "of", "INa", "is", "in", "the", "common", "final", "pathway", "to", "heart", "block", "in", "murine", "hearts", "overexpressing", "calcineurin", "." ]	[ "CHEMICAL", "GENE-N" ]
calcineurin is a GENE-N	16751287_task1	Sentence: Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin. Instructions: please typing these entity words according to sentence: calcineurin Options: GENE-N	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O" ]	Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin.	[ "Decrease", "in", "density", "of", "INa", "is", "in", "the", "common", "final", "pathway", "to", "heart", "block", "in", "murine", "hearts", "overexpressing", "calcineurin", "." ]	[ "CHEMICAL", "GENE-N" ]
calcineurin	16751287_task2	Sentence: Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O" ]	Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin.	[ "Decrease", "in", "density", "of", "INa", "is", "in", "the", "common", "final", "pathway", "to", "heart", "block", "in", "murine", "hearts", "overexpressing", "calcineurin", "." ]	[ "CHEMICAL", "GENE-N" ]
Weight loss maintenance is a Outcome_Physical, overweight is a Participant_Condition, ad libitum diets is a Intervention_Physical, high dietary protein ( P ) content is a Intervention_Physical, low glycemic index is a Intervention_Physical, effect is a Outcome_Other, weight loss maintenance is a Outcome_Physical, overweight or obese is a Participant_Condition, adults is a Participant_Age, 256 adults is a Participant_Sample-size, control is a Intervention_Control, change in body weight is a Outcome_Physical, Average weight regain is a Outcome_Physical, regained less weight is a Outcome_Physical, difference in weight regain is a Outcome_Physical, GI on weight regain is a Outcome_Physical, improves weight loss is a Outcome_Physical, overweight and obese is a Participant_Condition	64539_task0	Sentence: Weight loss maintenance in overweight subjects on ad libitum diets with high or low protein content and glycemic index : the DIOGENES trial 12-month results . BACKGROUND A high dietary protein ( P ) content and low glycemic index ( LGI ) have been suggested to be beneficial for weight management , but long-term studies are scarce . OBJECTIVE The DIOGENES randomized clinical trial investigated the effect of P and GI on weight loss maintenance in overweight or obese adults in eight centers across Europe . This study reports the 1-year results in two of the centers that extended the intervention to 1 year . METHOD After an 8-week low-calorie diet ( LCD ) , 256 adults ( body mass index > 27 kg m ( - ) ( 2 ) ) were randomized to five ad libitum diets for 12 months : high P/LGI ( HP/LGI ) , HP/high GI ( HP/HGI ) , low P/LGI ( LP/LGI ) , LP/HGI and a control diet . During the first 6 months , foods were provided for free through a shop system and during the whole 12-month period , subjects received guidance by a dietician . Primary outcome variable was the change in body weight over the 12-month intervention period . RESULTS During the LCD period , subjects lost 11.2 ( 10.8 , 12.0 ) kg ( mean ( 95 % confidence interval ( CI ) ) ) . Average weight regain over the 12-month intervention period was 3.9 ( 95 % CI 3.0-4.8 ) kg . Subjects on the HP diets regained less weight than subjects on the LP diets . The difference in weight regain after 1 year was 2.0 ( 0.4 , 3.6 ) kg ( P=0.017 ) ( completers analysis , N=139 ) or 2.8 ( 1.4 , 4.1 ) kg ( P < 0.001 ) ( intention-to-treat analysis , N=256 ) . No consistent effect of GI on weight regain was found . There were no clinically relevant differences in changes in cardiometabolic risk factors among diet groups . CONCLUSION A higher protein content of an ad libitum diet improves weight loss maintenance in overweight and obese adults over 12 months . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Participant_Condition, Intervention_Control, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O" ]	Weight loss maintenance in overweight subjects on ad libitum diets with high or low protein content and glycemic index : the DIOGENES trial 12-month results . BACKGROUND A high dietary protein ( P ) content and low glycemic index ( LGI ) have been suggested to be beneficial for weight management , but long-term studies are scarce . OBJECTIVE The DIOGENES randomized clinical trial investigated the effect of P and GI on weight loss maintenance in overweight or obese adults in eight centers across Europe . This study reports the 1-year results in two of the centers that extended the intervention to 1 year . METHOD After an 8-week low-calorie diet ( LCD ) , 256 adults ( body mass index > 27 kg m ( - ) ( 2 ) ) were randomized to five ad libitum diets for 12 months : high P/LGI ( HP/LGI ) , HP/high GI ( HP/HGI ) , low P/LGI ( LP/LGI ) , LP/HGI and a control diet . During the first 6 months , foods were provided for free through a shop system and during the whole 12-month period , subjects received guidance by a dietician . Primary outcome variable was the change in body weight over the 12-month intervention period . RESULTS During the LCD period , subjects lost 11.2 ( 10.8 , 12.0 ) kg ( mean ( 95 % confidence interval ( CI ) ) ) . Average weight regain over the 12-month intervention period was 3.9 ( 95 % CI 3.0-4.8 ) kg . Subjects on the HP diets regained less weight than subjects on the LP diets . The difference in weight regain after 1 year was 2.0 ( 0.4 , 3.6 ) kg ( P=0.017 ) ( completers analysis , N=139 ) or 2.8 ( 1.4 , 4.1 ) kg ( P < 0.001 ) ( intention-to-treat analysis , N=256 ) . No consistent effect of GI on weight regain was found . There were no clinically relevant differences in changes in cardiometabolic risk factors among diet groups . CONCLUSION A higher protein content of an ad libitum diet improves weight loss maintenance in overweight and obese adults over 12 months .	[ "Weight", "loss", "maintenance", "in", "overweight", "subjects", "on", "ad", "libitum", "diets", "with", "high", "or", "low", "protein", "content", "and", "glycemic", "index", ":", "the", "DIOGENES", "trial", "12-month", "results", ".", "BACKGROUND", "A", "high", "dietary", "protein", "(", "P", ")", "content", "and", "low", "glycemic", "index", "(", "LGI", ")", "have", "been", "suggested", "to", "be", "beneficial", "for", "weight", "management", ",", "but", "long", "-", "term", "studies", "are", "scarce", ".", "OBJECTIVE", "The", "DIOGENES", "randomized", "clinical", "trial", "investigated", "the", "effect", "of", "P", "and", "GI", "on", "weight", "loss", "maintenance", "in", "overweight", "or", "obese", "adults", "in", "eight", "centers", "across", "Europe", ".", "This", "study", "reports", "the", "1-year", "results", "in", "two", "of", "the", "centers", "that", "extended", "the", "intervention", "to", "1", "year", ".", "METHOD", "After", "an", "8-week", "low", "-", "calorie", "diet", "(", "LCD", ")", ",", "256", "adults", "(", "body", "mass", "index", ">", "27", "kg", "m", "(", "-", ")", "(", "2", ")", ")", "were", "randomized", "to", "five", "ad", "libitum", "diets", "for", "12", "months", ":", "high", "P", "/", "LGI", "(", "HP", "/", "LGI", ")", ",", "HP", "/", "high", "GI", "(", "HP", "/", "HGI", ")", ",", "low", "P", "/", "LGI", "(", "LP", "/", "LGI", ")", ",", "LP", "/", "HGI", "and", "a", "control", "diet", ".", "During", "the", "first", "6", "months", ",", "foods", "were", "provided", "for", "free", "through", "a", "shop", "system", "and", "during", "the", "whole", "12-month", "period", ",", "subjects", "received", "guidance", "by", "a", "dietician", ".", "Primary", "outcome", "variable", "was", "the", "change", "in", "body", "weight", "over", "the", "12-month", "intervention", "period", ".", "RESULTS", "During", "the", "LCD", "period", ",", "subjects", "lost", "11.2", "(", "10.8", ",", "12.0", ")", "kg", "(", "mean", "(", "95", "%", "confidence", "interval", "(", "CI", ")", ")", ")", ".", "Average", "weight", "regain", "over", "the", "12-month", "intervention", "period", "was", "3.9", "(", "95", "%", "CI", "3.0", "-", "4.8", ")", "kg", ".", "Subjects", "on", "the", "HP", "diets", "regained", "less", "weight", "than", "subjects", "on", "the", "LP", "diets", ".", "The", "difference", "in", "weight", "regain", "after", "1", "year", "was", "2.0", "(", "0.4", ",", "3.6", ")", "kg", "(", "P=0.017", ")", "(", "completers", "analysis", ",", "N=139", ")", "or", "2.8", "(", "1.4", ",", "4.1", ")", "kg", "(", "P", "<", "0.001", ")", "(", "intention", "-", "to", "-", "treat", "analysis", ",", "N=256", ")", ".", "No", "consistent", "effect", "of", "GI", "on", "weight", "regain", "was", "found", ".", "There", "were", "no", "clinically", "relevant", "differences", "in", "changes", "in", "cardiometabolic", "risk", "factors", "among", "diet", "groups", ".", "CONCLUSION", "A", "higher", "protein", "content", "of", "an", "ad", "libitum", "diet", "improves", "weight", "loss", "maintenance", "in", "overweight", "and", "obese", "adults", "over", "12", "months", "." ]	[ "Intervention_Physical", "Outcome_Physical", "Participant_Condition", "Participant_Sample-size", "Intervention_Control", "Outcome_Other", "Participant_Age" ]
Weight loss maintenance is a Outcome_Physical, overweight is a Participant_Condition, ad libitum diets is a Intervention_Physical, high dietary protein ( P ) content is a Intervention_Physical, low glycemic index is a Intervention_Physical, effect is a Outcome_Other, weight loss maintenance is a Outcome_Physical, overweight or obese is a Participant_Condition, adults is a Participant_Age, 256 adults is a Participant_Sample-size, control is a Intervention_Control, change in body weight is a Outcome_Physical, Average weight regain is a Outcome_Physical, regained less weight is a Outcome_Physical, difference in weight regain is a Outcome_Physical, GI on weight regain is a Outcome_Physical, improves weight loss is a Outcome_Physical, overweight and obese is a Participant_Condition	64539_task1	Sentence: Weight loss maintenance in overweight subjects on ad libitum diets with high or low protein content and glycemic index : the DIOGENES trial 12-month results . BACKGROUND A high dietary protein ( P ) content and low glycemic index ( LGI ) have been suggested to be beneficial for weight management , but long-term studies are scarce . OBJECTIVE The DIOGENES randomized clinical trial investigated the effect of P and GI on weight loss maintenance in overweight or obese adults in eight centers across Europe . This study reports the 1-year results in two of the centers that extended the intervention to 1 year . METHOD After an 8-week low-calorie diet ( LCD ) , 256 adults ( body mass index > 27 kg m ( - ) ( 2 ) ) were randomized to five ad libitum diets for 12 months : high P/LGI ( HP/LGI ) , HP/high GI ( HP/HGI ) , low P/LGI ( LP/LGI ) , LP/HGI and a control diet . During the first 6 months , foods were provided for free through a shop system and during the whole 12-month period , subjects received guidance by a dietician . Primary outcome variable was the change in body weight over the 12-month intervention period . RESULTS During the LCD period , subjects lost 11.2 ( 10.8 , 12.0 ) kg ( mean ( 95 % confidence interval ( CI ) ) ) . Average weight regain over the 12-month intervention period was 3.9 ( 95 % CI 3.0-4.8 ) kg . Subjects on the HP diets regained less weight than subjects on the LP diets . The difference in weight regain after 1 year was 2.0 ( 0.4 , 3.6 ) kg ( P=0.017 ) ( completers analysis , N=139 ) or 2.8 ( 1.4 , 4.1 ) kg ( P < 0.001 ) ( intention-to-treat analysis , N=256 ) . No consistent effect of GI on weight regain was found . There were no clinically relevant differences in changes in cardiometabolic risk factors among diet groups . CONCLUSION A higher protein content of an ad libitum diet improves weight loss maintenance in overweight and obese adults over 12 months . Instructions: please typing these entity words according to sentence: Weight loss maintenance, overweight, ad libitum diets, high dietary protein ( P ) content, low glycemic index, effect, weight loss maintenance, overweight or obese, adults, 256 adults, control, change in body weight, Average weight regain, regained less weight, difference in weight regain, GI on weight regain, improves weight loss, overweight and obese Options: Intervention_Physical, Participant_Condition, Intervention_Control, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O" ]	Weight loss maintenance in overweight subjects on ad libitum diets with high or low protein content and glycemic index : the DIOGENES trial 12-month results . BACKGROUND A high dietary protein ( P ) content and low glycemic index ( LGI ) have been suggested to be beneficial for weight management , but long-term studies are scarce . OBJECTIVE The DIOGENES randomized clinical trial investigated the effect of P and GI on weight loss maintenance in overweight or obese adults in eight centers across Europe . This study reports the 1-year results in two of the centers that extended the intervention to 1 year . METHOD After an 8-week low-calorie diet ( LCD ) , 256 adults ( body mass index > 27 kg m ( - ) ( 2 ) ) were randomized to five ad libitum diets for 12 months : high P/LGI ( HP/LGI ) , HP/high GI ( HP/HGI ) , low P/LGI ( LP/LGI ) , LP/HGI and a control diet . During the first 6 months , foods were provided for free through a shop system and during the whole 12-month period , subjects received guidance by a dietician . Primary outcome variable was the change in body weight over the 12-month intervention period . RESULTS During the LCD period , subjects lost 11.2 ( 10.8 , 12.0 ) kg ( mean ( 95 % confidence interval ( CI ) ) ) . Average weight regain over the 12-month intervention period was 3.9 ( 95 % CI 3.0-4.8 ) kg . Subjects on the HP diets regained less weight than subjects on the LP diets . The difference in weight regain after 1 year was 2.0 ( 0.4 , 3.6 ) kg ( P=0.017 ) ( completers analysis , N=139 ) or 2.8 ( 1.4 , 4.1 ) kg ( P < 0.001 ) ( intention-to-treat analysis , N=256 ) . No consistent effect of GI on weight regain was found . There were no clinically relevant differences in changes in cardiometabolic risk factors among diet groups . CONCLUSION A higher protein content of an ad libitum diet improves weight loss maintenance in overweight and obese adults over 12 months .	[ "Weight", "loss", "maintenance", "in", "overweight", "subjects", "on", "ad", "libitum", "diets", "with", "high", "or", "low", "protein", "content", "and", "glycemic", "index", ":", "the", "DIOGENES", "trial", "12-month", "results", ".", "BACKGROUND", "A", "high", "dietary", "protein", "(", "P", ")", "content", "and", "low", "glycemic", "index", "(", "LGI", ")", "have", "been", "suggested", "to", "be", "beneficial", "for", "weight", "management", ",", "but", "long", "-", "term", "studies", "are", "scarce", ".", "OBJECTIVE", "The", "DIOGENES", "randomized", "clinical", "trial", "investigated", "the", "effect", "of", "P", "and", "GI", "on", "weight", "loss", "maintenance", "in", "overweight", "or", "obese", "adults", "in", "eight", "centers", "across", "Europe", ".", "This", "study", "reports", "the", "1-year", "results", "in", "two", "of", "the", "centers", "that", "extended", "the", "intervention", "to", "1", "year", ".", "METHOD", "After", "an", "8-week", "low", "-", "calorie", "diet", "(", "LCD", ")", ",", "256", "adults", "(", "body", "mass", "index", ">", "27", "kg", "m", "(", "-", ")", "(", "2", ")", ")", "were", "randomized", "to", "five", "ad", "libitum", "diets", "for", "12", "months", ":", "high", "P", "/", "LGI", "(", "HP", "/", "LGI", ")", ",", "HP", "/", "high", "GI", "(", "HP", "/", "HGI", ")", ",", "low", "P", "/", "LGI", "(", "LP", "/", "LGI", ")", ",", "LP", "/", "HGI", "and", "a", "control", "diet", ".", "During", "the", "first", "6", "months", ",", "foods", "were", "provided", "for", "free", "through", "a", "shop", "system", "and", "during", "the", "whole", "12-month", "period", ",", "subjects", "received", "guidance", "by", "a", "dietician", ".", "Primary", "outcome", "variable", "was", "the", "change", "in", "body", "weight", "over", "the", "12-month", "intervention", "period", ".", "RESULTS", "During", "the", "LCD", "period", ",", "subjects", "lost", "11.2", "(", "10.8", ",", "12.0", ")", "kg", "(", "mean", "(", "95", "%", "confidence", "interval", "(", "CI", ")", ")", ")", ".", "Average", "weight", "regain", "over", "the", "12-month", "intervention", "period", "was", "3.9", "(", "95", "%", "CI", "3.0", "-", "4.8", ")", "kg", ".", "Subjects", "on", "the", "HP", "diets", "regained", "less", "weight", "than", "subjects", "on", "the", "LP", "diets", ".", "The", "difference", "in", "weight", "regain", "after", "1", "year", "was", "2.0", "(", "0.4", ",", "3.6", ")", "kg", "(", "P=0.017", ")", "(", "completers", "analysis", ",", "N=139", ")", "or", "2.8", "(", "1.4", ",", "4.1", ")", "kg", "(", "P", "<", "0.001", ")", "(", "intention", "-", "to", "-", "treat", "analysis", ",", "N=256", ")", ".", "No", "consistent", "effect", "of", "GI", "on", "weight", "regain", "was", "found", ".", "There", "were", "no", "clinically", "relevant", "differences", "in", "changes", "in", "cardiometabolic", "risk", "factors", "among", "diet", "groups", ".", "CONCLUSION", "A", "higher", "protein", "content", "of", "an", "ad", "libitum", "diet", "improves", "weight", "loss", "maintenance", "in", "overweight", "and", "obese", "adults", "over", "12", "months", "." ]	[ "Intervention_Physical", "Outcome_Physical", "Participant_Condition", "Participant_Sample-size", "Intervention_Control", "Outcome_Other", "Participant_Age" ]
Weight loss maintenance, overweight, ad libitum diets, high dietary protein ( P ) content, low glycemic index, effect, weight loss maintenance, overweight or obese, adults, 256 adults, control, change in body weight, Average weight regain, regained less weight, difference in weight regain, GI on weight regain, improves weight loss, overweight and obese	64539_task2	Sentence: Weight loss maintenance in overweight subjects on ad libitum diets with high or low protein content and glycemic index : the DIOGENES trial 12-month results . BACKGROUND A high dietary protein ( P ) content and low glycemic index ( LGI ) have been suggested to be beneficial for weight management , but long-term studies are scarce . OBJECTIVE The DIOGENES randomized clinical trial investigated the effect of P and GI on weight loss maintenance in overweight or obese adults in eight centers across Europe . This study reports the 1-year results in two of the centers that extended the intervention to 1 year . METHOD After an 8-week low-calorie diet ( LCD ) , 256 adults ( body mass index > 27 kg m ( - ) ( 2 ) ) were randomized to five ad libitum diets for 12 months : high P/LGI ( HP/LGI ) , HP/high GI ( HP/HGI ) , low P/LGI ( LP/LGI ) , LP/HGI and a control diet . During the first 6 months , foods were provided for free through a shop system and during the whole 12-month period , subjects received guidance by a dietician . Primary outcome variable was the change in body weight over the 12-month intervention period . RESULTS During the LCD period , subjects lost 11.2 ( 10.8 , 12.0 ) kg ( mean ( 95 % confidence interval ( CI ) ) ) . Average weight regain over the 12-month intervention period was 3.9 ( 95 % CI 3.0-4.8 ) kg . Subjects on the HP diets regained less weight than subjects on the LP diets . The difference in weight regain after 1 year was 2.0 ( 0.4 , 3.6 ) kg ( P=0.017 ) ( completers analysis , N=139 ) or 2.8 ( 1.4 , 4.1 ) kg ( P < 0.001 ) ( intention-to-treat analysis , N=256 ) . No consistent effect of GI on weight regain was found . There were no clinically relevant differences in changes in cardiometabolic risk factors among diet groups . CONCLUSION A higher protein content of an ad libitum diet improves weight loss maintenance in overweight and obese adults over 12 months . Instructions: please extract entity words from the input sentence	[ "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O" ]	Weight loss maintenance in overweight subjects on ad libitum diets with high or low protein content and glycemic index : the DIOGENES trial 12-month results . BACKGROUND A high dietary protein ( P ) content and low glycemic index ( LGI ) have been suggested to be beneficial for weight management , but long-term studies are scarce . OBJECTIVE The DIOGENES randomized clinical trial investigated the effect of P and GI on weight loss maintenance in overweight or obese adults in eight centers across Europe . This study reports the 1-year results in two of the centers that extended the intervention to 1 year . METHOD After an 8-week low-calorie diet ( LCD ) , 256 adults ( body mass index > 27 kg m ( - ) ( 2 ) ) were randomized to five ad libitum diets for 12 months : high P/LGI ( HP/LGI ) , HP/high GI ( HP/HGI ) , low P/LGI ( LP/LGI ) , LP/HGI and a control diet . During the first 6 months , foods were provided for free through a shop system and during the whole 12-month period , subjects received guidance by a dietician . Primary outcome variable was the change in body weight over the 12-month intervention period . RESULTS During the LCD period , subjects lost 11.2 ( 10.8 , 12.0 ) kg ( mean ( 95 % confidence interval ( CI ) ) ) . Average weight regain over the 12-month intervention period was 3.9 ( 95 % CI 3.0-4.8 ) kg . Subjects on the HP diets regained less weight than subjects on the LP diets . The difference in weight regain after 1 year was 2.0 ( 0.4 , 3.6 ) kg ( P=0.017 ) ( completers analysis , N=139 ) or 2.8 ( 1.4 , 4.1 ) kg ( P < 0.001 ) ( intention-to-treat analysis , N=256 ) . No consistent effect of GI on weight regain was found . There were no clinically relevant differences in changes in cardiometabolic risk factors among diet groups . CONCLUSION A higher protein content of an ad libitum diet improves weight loss maintenance in overweight and obese adults over 12 months .	[ "Weight", "loss", "maintenance", "in", "overweight", "subjects", "on", "ad", "libitum", "diets", "with", "high", "or", "low", "protein", "content", "and", "glycemic", "index", ":", "the", "DIOGENES", "trial", "12-month", "results", ".", "BACKGROUND", "A", "high", "dietary", "protein", "(", "P", ")", "content", "and", "low", "glycemic", "index", "(", "LGI", ")", "have", "been", "suggested", "to", "be", "beneficial", "for", "weight", "management", ",", "but", "long", "-", "term", "studies", "are", "scarce", ".", "OBJECTIVE", "The", "DIOGENES", "randomized", "clinical", "trial", "investigated", "the", "effect", "of", "P", "and", "GI", "on", "weight", "loss", "maintenance", "in", "overweight", "or", "obese", "adults", "in", "eight", "centers", "across", "Europe", ".", "This", "study", "reports", "the", "1-year", "results", "in", "two", "of", "the", "centers", "that", "extended", "the", "intervention", "to", "1", "year", ".", "METHOD", "After", "an", "8-week", "low", "-", "calorie", "diet", "(", "LCD", ")", ",", "256", "adults", "(", "body", "mass", "index", ">", "27", "kg", "m", "(", "-", ")", "(", "2", ")", ")", "were", "randomized", "to", "five", "ad", "libitum", "diets", "for", "12", "months", ":", "high", "P", "/", "LGI", "(", "HP", "/", "LGI", ")", ",", "HP", "/", "high", "GI", "(", "HP", "/", "HGI", ")", ",", "low", "P", "/", "LGI", "(", "LP", "/", "LGI", ")", ",", "LP", "/", "HGI", "and", "a", "control", "diet", ".", "During", "the", "first", "6", "months", ",", "foods", "were", "provided", "for", "free", "through", "a", "shop", "system", "and", "during", "the", "whole", "12-month", "period", ",", "subjects", "received", "guidance", "by", "a", "dietician", ".", "Primary", "outcome", "variable", "was", "the", "change", "in", "body", "weight", "over", "the", "12-month", "intervention", "period", ".", "RESULTS", "During", "the", "LCD", "period", ",", "subjects", "lost", "11.2", "(", "10.8", ",", "12.0", ")", "kg", "(", "mean", "(", "95", "%", "confidence", "interval", "(", "CI", ")", ")", ")", ".", "Average", "weight", "regain", "over", "the", "12-month", "intervention", "period", "was", "3.9", "(", "95", "%", "CI", "3.0", "-", "4.8", ")", "kg", ".", "Subjects", "on", "the", "HP", "diets", "regained", "less", "weight", "than", "subjects", "on", "the", "LP", "diets", ".", "The", "difference", "in", "weight", "regain", "after", "1", "year", "was", "2.0", "(", "0.4", ",", "3.6", ")", "kg", "(", "P=0.017", ")", "(", "completers", "analysis", ",", "N=139", ")", "or", "2.8", "(", "1.4", ",", "4.1", ")", "kg", "(", "P", "<", "0.001", ")", "(", "intention", "-", "to", "-", "treat", "analysis", ",", "N=256", ")", ".", "No", "consistent", "effect", "of", "GI", "on", "weight", "regain", "was", "found", ".", "There", "were", "no", "clinically", "relevant", "differences", "in", "changes", "in", "cardiometabolic", "risk", "factors", "among", "diet", "groups", ".", "CONCLUSION", "A", "higher", "protein", "content", "of", "an", "ad", "libitum", "diet", "improves", "weight", "loss", "maintenance", "in", "overweight", "and", "obese", "adults", "over", "12", "months", "." ]	[ "Intervention_Physical", "Outcome_Physical", "Participant_Condition", "Participant_Sample-size", "Intervention_Control", "Outcome_Other", "Participant_Age" ]
tumorchirurgischen is an umlsterm, Beckens is an umlsterm, Mann is an umlsterm, Patienten is an umlsterm, Tumortherapie is an umlsterm, Ejakulation is an umlsterm, medikamentoeser Therapie is an umlsterm, Tumore is an umlsterm, Therapie is an umlsterm, Harnblasen- is an umlsterm, Prostata is an umlsterm, Hodenkarzinoms is an umlsterm, Tumoren is an umlsterm, Neuroanatomie is an umlsterm, Techniken is an umlsterm, Nervenbahnen is an umlsterm, Tumorerkrankung is an umlsterm, Patienten is an umlsterm, Lebensqualitaet is an umlsterm, Ejakulationsstoerungen is an umlsterm, Therapiemodalitaeten is an umlsterm	Reproduktionsmedizin.90150378.ger.abstr_task0	Sentence: Nach tumorchirurgischen Eingriffen im Bauchraum , dem Retroperitoneum und des kleinen Beckens kann es zu einer Schaedigung der Nerven und Gefaesse der Sexualorgane kommen . Infolge hiervon kommt es haeufig zu sexuellen Funktionsstoerungen beim Mann . Da es sich oft um Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter handelt , wird der Praevention solcher Begleiterscheinungen bei der Tumortherapie besondere Bedeutung geschenkt . Eine Beeintraechtigung der Erektion oder Stoerungen der Ejakulation koennen nach operativer , strahlentherapeutischer oder medikamentoeser Therapie verschiedener Tumore auftreten . Haeufig treten sie bei der Therapie des Harnblasen- , Prostata , Hodenkarzinoms oder kolorektalen Tumoren auf . Durch eingehendes Verstaendnis der Neuroanatomie und moderne chirurgische Techniken sind diese Stoerungen heute in einem hohen Prozentsatz vermeidbar . Laesst sich eine Schaedigung der entsprechenden Nervenbahnen aufgrund der erforderlichen Radikalitaet des chirurgischen Eingriffs , um die Tumorerkrankung kurativ zu therapieren , nicht vermeiden , sind sexuelle Funktionsstoerungen fuer diese Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter eine deutliche Einschraenkung der Lebensqualitaet . Sowohl Ejakulationsstoerungen als auch Erektionsstoerungen lassen sich jedoch durch eine Reihe von Therapiemodalitaeten in fast allen Faellen behandeln . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Nach tumorchirurgischen Eingriffen im Bauchraum , dem Retroperitoneum und des kleinen Beckens kann es zu einer Schaedigung der Nerven und Gefaesse der Sexualorgane kommen . Infolge hiervon kommt es haeufig zu sexuellen Funktionsstoerungen beim Mann . Da es sich oft um Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter handelt , wird der Praevention solcher Begleiterscheinungen bei der Tumortherapie besondere Bedeutung geschenkt . Eine Beeintraechtigung der Erektion oder Stoerungen der Ejakulation koennen nach operativer , strahlentherapeutischer oder medikamentoeser Therapie verschiedener Tumore auftreten . Haeufig treten sie bei der Therapie des Harnblasen- , Prostata , Hodenkarzinoms oder kolorektalen Tumoren auf . Durch eingehendes Verstaendnis der Neuroanatomie und moderne chirurgische Techniken sind diese Stoerungen heute in einem hohen Prozentsatz vermeidbar . Laesst sich eine Schaedigung der entsprechenden Nervenbahnen aufgrund der erforderlichen Radikalitaet des chirurgischen Eingriffs , um die Tumorerkrankung kurativ zu therapieren , nicht vermeiden , sind sexuelle Funktionsstoerungen fuer diese Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter eine deutliche Einschraenkung der Lebensqualitaet . Sowohl Ejakulationsstoerungen als auch Erektionsstoerungen lassen sich jedoch durch eine Reihe von Therapiemodalitaeten in fast allen Faellen behandeln .	[ "Nach", "tumorchirurgischen", "Eingriffen", "im", "Bauchraum", ",", "dem", "Retroperitoneum", "und", "des", "kleinen", "Beckens", "kann", "es", "zu", "einer", "Schaedigung", "der", "Nerven", "und", "Gefaesse", "der", "Sexualorgane", "kommen", ".", "Infolge", "hiervon", "kommt", "es", "haeufig", "zu", "sexuellen", "Funktionsstoerungen", "beim", "Mann", ".", "Da", "es", "sich", "oft", "um", "Patienten", "im", "sexuell", "aktiven", "und", "auch", "reproduktionsfaehigen", "Alter", "handelt", ",", "wird", "der", "Praevention", "solcher", "Begleiterscheinungen", "bei", "der", "Tumortherapie", "besondere", "Bedeutung", "geschenkt", ".", "Eine", "Beeintraechtigung", "der", "Erektion", "oder", "Stoerungen", "der", "Ejakulation", "koennen", "nach", "operativer", ",", "strahlentherapeutischer", "oder", "medikamentoeser", "Therapie", "verschiedener", "Tumore", "auftreten", ".", "Haeufig", "treten", "sie", "bei", "der", "Therapie", "des", "Harnblasen-", ",", "Prostata", ",", "Hodenkarzinoms", "oder", "kolorektalen", "Tumoren", "auf", ".", "Durch", "eingehendes", "Verstaendnis", "der", "Neuroanatomie", "und", "moderne", "chirurgische", "Techniken", "sind", "diese", "Stoerungen", "heute", "in", "einem", "hohen", "Prozentsatz", "vermeidbar", ".", "Laesst", "sich", "eine", "Schaedigung", "der", "entsprechenden", "Nervenbahnen", "aufgrund", "der", "erforderlichen", "Radikalitaet", "des", "chirurgischen", "Eingriffs", ",", "um", "die", "Tumorerkrankung", "kurativ", "zu", "therapieren", ",", "nicht", "vermeiden", ",", "sind", "sexuelle", "Funktionsstoerungen", "fuer", "diese", "Patienten", "im", "sexuell", "aktiven", "und", "auch", "reproduktionsfaehigen", "Alter", "eine", "deutliche", "Einschraenkung", "der", "Lebensqualitaet", ".", "Sowohl", "Ejakulationsstoerungen", "als", "auch", "Erektionsstoerungen", "lassen", "sich", "jedoch", "durch", "eine", "Reihe", "von", "Therapiemodalitaeten", "in", "fast", "allen", "Faellen", "behandeln", "." ]	[ "umlsterm" ]
tumorchirurgischen is an umlsterm, Beckens is an umlsterm, Mann is an umlsterm, Patienten is an umlsterm, Tumortherapie is an umlsterm, Ejakulation is an umlsterm, medikamentoeser Therapie is an umlsterm, Tumore is an umlsterm, Therapie is an umlsterm, Harnblasen- is an umlsterm, Prostata is an umlsterm, Hodenkarzinoms is an umlsterm, Tumoren is an umlsterm, Neuroanatomie is an umlsterm, Techniken is an umlsterm, Nervenbahnen is an umlsterm, Tumorerkrankung is an umlsterm, Patienten is an umlsterm, Lebensqualitaet is an umlsterm, Ejakulationsstoerungen is an umlsterm, Therapiemodalitaeten is an umlsterm	Reproduktionsmedizin.90150378.ger.abstr_task1	Sentence: Nach tumorchirurgischen Eingriffen im Bauchraum , dem Retroperitoneum und des kleinen Beckens kann es zu einer Schaedigung der Nerven und Gefaesse der Sexualorgane kommen . Infolge hiervon kommt es haeufig zu sexuellen Funktionsstoerungen beim Mann . Da es sich oft um Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter handelt , wird der Praevention solcher Begleiterscheinungen bei der Tumortherapie besondere Bedeutung geschenkt . Eine Beeintraechtigung der Erektion oder Stoerungen der Ejakulation koennen nach operativer , strahlentherapeutischer oder medikamentoeser Therapie verschiedener Tumore auftreten . Haeufig treten sie bei der Therapie des Harnblasen- , Prostata , Hodenkarzinoms oder kolorektalen Tumoren auf . Durch eingehendes Verstaendnis der Neuroanatomie und moderne chirurgische Techniken sind diese Stoerungen heute in einem hohen Prozentsatz vermeidbar . Laesst sich eine Schaedigung der entsprechenden Nervenbahnen aufgrund der erforderlichen Radikalitaet des chirurgischen Eingriffs , um die Tumorerkrankung kurativ zu therapieren , nicht vermeiden , sind sexuelle Funktionsstoerungen fuer diese Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter eine deutliche Einschraenkung der Lebensqualitaet . Sowohl Ejakulationsstoerungen als auch Erektionsstoerungen lassen sich jedoch durch eine Reihe von Therapiemodalitaeten in fast allen Faellen behandeln . Instructions: please typing these entity words according to sentence: tumorchirurgischen, Beckens, Mann, Patienten, Tumortherapie, Ejakulation, medikamentoeser Therapie, Tumore, Therapie, Harnblasen-, Prostata, Hodenkarzinoms, Tumoren, Neuroanatomie, Techniken, Nervenbahnen, Tumorerkrankung, Patienten, Lebensqualitaet, Ejakulationsstoerungen, Therapiemodalitaeten Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Nach tumorchirurgischen Eingriffen im Bauchraum , dem Retroperitoneum und des kleinen Beckens kann es zu einer Schaedigung der Nerven und Gefaesse der Sexualorgane kommen . Infolge hiervon kommt es haeufig zu sexuellen Funktionsstoerungen beim Mann . Da es sich oft um Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter handelt , wird der Praevention solcher Begleiterscheinungen bei der Tumortherapie besondere Bedeutung geschenkt . Eine Beeintraechtigung der Erektion oder Stoerungen der Ejakulation koennen nach operativer , strahlentherapeutischer oder medikamentoeser Therapie verschiedener Tumore auftreten . Haeufig treten sie bei der Therapie des Harnblasen- , Prostata , Hodenkarzinoms oder kolorektalen Tumoren auf . Durch eingehendes Verstaendnis der Neuroanatomie und moderne chirurgische Techniken sind diese Stoerungen heute in einem hohen Prozentsatz vermeidbar . Laesst sich eine Schaedigung der entsprechenden Nervenbahnen aufgrund der erforderlichen Radikalitaet des chirurgischen Eingriffs , um die Tumorerkrankung kurativ zu therapieren , nicht vermeiden , sind sexuelle Funktionsstoerungen fuer diese Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter eine deutliche Einschraenkung der Lebensqualitaet . Sowohl Ejakulationsstoerungen als auch Erektionsstoerungen lassen sich jedoch durch eine Reihe von Therapiemodalitaeten in fast allen Faellen behandeln .	[ "Nach", "tumorchirurgischen", "Eingriffen", "im", "Bauchraum", ",", "dem", "Retroperitoneum", "und", "des", "kleinen", "Beckens", "kann", "es", "zu", "einer", "Schaedigung", "der", "Nerven", "und", "Gefaesse", "der", "Sexualorgane", "kommen", ".", "Infolge", "hiervon", "kommt", "es", "haeufig", "zu", "sexuellen", "Funktionsstoerungen", "beim", "Mann", ".", "Da", "es", "sich", "oft", "um", "Patienten", "im", "sexuell", "aktiven", "und", "auch", "reproduktionsfaehigen", "Alter", "handelt", ",", "wird", "der", "Praevention", "solcher", "Begleiterscheinungen", "bei", "der", "Tumortherapie", "besondere", "Bedeutung", "geschenkt", ".", "Eine", "Beeintraechtigung", "der", "Erektion", "oder", "Stoerungen", "der", "Ejakulation", "koennen", "nach", "operativer", ",", "strahlentherapeutischer", "oder", "medikamentoeser", "Therapie", "verschiedener", "Tumore", "auftreten", ".", "Haeufig", "treten", "sie", "bei", "der", "Therapie", "des", "Harnblasen-", ",", "Prostata", ",", "Hodenkarzinoms", "oder", "kolorektalen", "Tumoren", "auf", ".", "Durch", "eingehendes", "Verstaendnis", "der", "Neuroanatomie", "und", "moderne", "chirurgische", "Techniken", "sind", "diese", "Stoerungen", "heute", "in", "einem", "hohen", "Prozentsatz", "vermeidbar", ".", "Laesst", "sich", "eine", "Schaedigung", "der", "entsprechenden", "Nervenbahnen", "aufgrund", "der", "erforderlichen", "Radikalitaet", "des", "chirurgischen", "Eingriffs", ",", "um", "die", "Tumorerkrankung", "kurativ", "zu", "therapieren", ",", "nicht", "vermeiden", ",", "sind", "sexuelle", "Funktionsstoerungen", "fuer", "diese", "Patienten", "im", "sexuell", "aktiven", "und", "auch", "reproduktionsfaehigen", "Alter", "eine", "deutliche", "Einschraenkung", "der", "Lebensqualitaet", ".", "Sowohl", "Ejakulationsstoerungen", "als", "auch", "Erektionsstoerungen", "lassen", "sich", "jedoch", "durch", "eine", "Reihe", "von", "Therapiemodalitaeten", "in", "fast", "allen", "Faellen", "behandeln", "." ]	[ "umlsterm" ]
tumorchirurgischen, Beckens, Mann, Patienten, Tumortherapie, Ejakulation, medikamentoeser Therapie, Tumore, Therapie, Harnblasen-, Prostata, Hodenkarzinoms, Tumoren, Neuroanatomie, Techniken, Nervenbahnen, Tumorerkrankung, Patienten, Lebensqualitaet, Ejakulationsstoerungen, Therapiemodalitaeten	Reproduktionsmedizin.90150378.ger.abstr_task2	Sentence: Nach tumorchirurgischen Eingriffen im Bauchraum , dem Retroperitoneum und des kleinen Beckens kann es zu einer Schaedigung der Nerven und Gefaesse der Sexualorgane kommen . Infolge hiervon kommt es haeufig zu sexuellen Funktionsstoerungen beim Mann . Da es sich oft um Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter handelt , wird der Praevention solcher Begleiterscheinungen bei der Tumortherapie besondere Bedeutung geschenkt . Eine Beeintraechtigung der Erektion oder Stoerungen der Ejakulation koennen nach operativer , strahlentherapeutischer oder medikamentoeser Therapie verschiedener Tumore auftreten . Haeufig treten sie bei der Therapie des Harnblasen- , Prostata , Hodenkarzinoms oder kolorektalen Tumoren auf . Durch eingehendes Verstaendnis der Neuroanatomie und moderne chirurgische Techniken sind diese Stoerungen heute in einem hohen Prozentsatz vermeidbar . Laesst sich eine Schaedigung der entsprechenden Nervenbahnen aufgrund der erforderlichen Radikalitaet des chirurgischen Eingriffs , um die Tumorerkrankung kurativ zu therapieren , nicht vermeiden , sind sexuelle Funktionsstoerungen fuer diese Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter eine deutliche Einschraenkung der Lebensqualitaet . Sowohl Ejakulationsstoerungen als auch Erektionsstoerungen lassen sich jedoch durch eine Reihe von Therapiemodalitaeten in fast allen Faellen behandeln . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Nach tumorchirurgischen Eingriffen im Bauchraum , dem Retroperitoneum und des kleinen Beckens kann es zu einer Schaedigung der Nerven und Gefaesse der Sexualorgane kommen . Infolge hiervon kommt es haeufig zu sexuellen Funktionsstoerungen beim Mann . Da es sich oft um Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter handelt , wird der Praevention solcher Begleiterscheinungen bei der Tumortherapie besondere Bedeutung geschenkt . Eine Beeintraechtigung der Erektion oder Stoerungen der Ejakulation koennen nach operativer , strahlentherapeutischer oder medikamentoeser Therapie verschiedener Tumore auftreten . Haeufig treten sie bei der Therapie des Harnblasen- , Prostata , Hodenkarzinoms oder kolorektalen Tumoren auf . Durch eingehendes Verstaendnis der Neuroanatomie und moderne chirurgische Techniken sind diese Stoerungen heute in einem hohen Prozentsatz vermeidbar . Laesst sich eine Schaedigung der entsprechenden Nervenbahnen aufgrund der erforderlichen Radikalitaet des chirurgischen Eingriffs , um die Tumorerkrankung kurativ zu therapieren , nicht vermeiden , sind sexuelle Funktionsstoerungen fuer diese Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter eine deutliche Einschraenkung der Lebensqualitaet . Sowohl Ejakulationsstoerungen als auch Erektionsstoerungen lassen sich jedoch durch eine Reihe von Therapiemodalitaeten in fast allen Faellen behandeln .	[ "Nach", "tumorchirurgischen", "Eingriffen", "im", "Bauchraum", ",", "dem", "Retroperitoneum", "und", "des", "kleinen", "Beckens", "kann", "es", "zu", "einer", "Schaedigung", "der", "Nerven", "und", "Gefaesse", "der", "Sexualorgane", "kommen", ".", "Infolge", "hiervon", "kommt", "es", "haeufig", "zu", "sexuellen", "Funktionsstoerungen", "beim", "Mann", ".", "Da", "es", "sich", "oft", "um", "Patienten", "im", "sexuell", "aktiven", "und", "auch", "reproduktionsfaehigen", "Alter", "handelt", ",", "wird", "der", "Praevention", "solcher", "Begleiterscheinungen", "bei", "der", "Tumortherapie", "besondere", "Bedeutung", "geschenkt", ".", "Eine", "Beeintraechtigung", "der", "Erektion", "oder", "Stoerungen", "der", "Ejakulation", "koennen", "nach", "operativer", ",", "strahlentherapeutischer", "oder", "medikamentoeser", "Therapie", "verschiedener", "Tumore", "auftreten", ".", "Haeufig", "treten", "sie", "bei", "der", "Therapie", "des", "Harnblasen-", ",", "Prostata", ",", "Hodenkarzinoms", "oder", "kolorektalen", "Tumoren", "auf", ".", "Durch", "eingehendes", "Verstaendnis", "der", "Neuroanatomie", "und", "moderne", "chirurgische", "Techniken", "sind", "diese", "Stoerungen", "heute", "in", "einem", "hohen", "Prozentsatz", "vermeidbar", ".", "Laesst", "sich", "eine", "Schaedigung", "der", "entsprechenden", "Nervenbahnen", "aufgrund", "der", "erforderlichen", "Radikalitaet", "des", "chirurgischen", "Eingriffs", ",", "um", "die", "Tumorerkrankung", "kurativ", "zu", "therapieren", ",", "nicht", "vermeiden", ",", "sind", "sexuelle", "Funktionsstoerungen", "fuer", "diese", "Patienten", "im", "sexuell", "aktiven", "und", "auch", "reproduktionsfaehigen", "Alter", "eine", "deutliche", "Einschraenkung", "der", "Lebensqualitaet", ".", "Sowohl", "Ejakulationsstoerungen", "als", "auch", "Erektionsstoerungen", "lassen", "sich", "jedoch", "durch", "eine", "Reihe", "von", "Therapiemodalitaeten", "in", "fast", "allen", "Faellen", "behandeln", "." ]	[ "umlsterm" ]
artery is an umlsterm, regression is an umlsterm, femoral artery is an umlsterm, blood supply is an umlsterm, leg is an umlsterm, femoral artery is an umlsterm, artery is an umlsterm, ischemia is an umlsterm, buttock is an umlsterm, Combined therapy is an umlsterm, catheter is an umlsterm, fibrinolysis is an umlsterm, ligation is an umlsterm, artery is an umlsterm, procedure is an umlsterm, leg is an umlsterm, perfusion is an umlsterm	DerChirurg.90700795.eng.abstr_task0	Sentence: Persistent sciatic artery as a rare entity results from lack of regression of the femoral artery blood supply of the leg and is often combined with an abnormally developed superficial femoral artery . We describe the case of a complete , persistent sciatic artery with peripheral ischemia caused by thrombo-embolism from buttock aneurysmal formation . Combined therapy of catheter fibrinolysis , followed by proximal and distal ligation of sciatic artery and peripheral bypass procedure , restored regular leg perfusion . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]	Persistent sciatic artery as a rare entity results from lack of regression of the femoral artery blood supply of the leg and is often combined with an abnormally developed superficial femoral artery . We describe the case of a complete , persistent sciatic artery with peripheral ischemia caused by thrombo-embolism from buttock aneurysmal formation . Combined therapy of catheter fibrinolysis , followed by proximal and distal ligation of sciatic artery and peripheral bypass procedure , restored regular leg perfusion .	[ "Persistent", "sciatic", "artery", "as", "a", "rare", "entity", "results", "from", "lack", "of", "regression", "of", "the", "femoral", "artery", "blood", "supply", "of", "the", "leg", "and", "is", "often", "combined", "with", "an", "abnormally", "developed", "superficial", "femoral", "artery", ".", "We", "describe", "the", "case", "of", "a", "complete", ",", "persistent", "sciatic", "artery", "with", "peripheral", "ischemia", "caused", "by", "thrombo", "-", "embolism", "from", "buttock", "aneurysmal", "formation", ".", "Combined", "therapy", "of", "catheter", "fibrinolysis", ",", "followed", "by", "proximal", "and", "distal", "ligation", "of", "sciatic", "artery", "and", "peripheral", "bypass", "procedure", ",", "restored", "regular", "leg", "perfusion", "." ]	[ "umlsterm" ]
artery is an umlsterm, regression is an umlsterm, femoral artery is an umlsterm, blood supply is an umlsterm, leg is an umlsterm, femoral artery is an umlsterm, artery is an umlsterm, ischemia is an umlsterm, buttock is an umlsterm, Combined therapy is an umlsterm, catheter is an umlsterm, fibrinolysis is an umlsterm, ligation is an umlsterm, artery is an umlsterm, procedure is an umlsterm, leg is an umlsterm, perfusion is an umlsterm	DerChirurg.90700795.eng.abstr_task1	Sentence: Persistent sciatic artery as a rare entity results from lack of regression of the femoral artery blood supply of the leg and is often combined with an abnormally developed superficial femoral artery . We describe the case of a complete , persistent sciatic artery with peripheral ischemia caused by thrombo-embolism from buttock aneurysmal formation . Combined therapy of catheter fibrinolysis , followed by proximal and distal ligation of sciatic artery and peripheral bypass procedure , restored regular leg perfusion . Instructions: please typing these entity words according to sentence: artery, regression, femoral artery, blood supply, leg, femoral artery, artery, ischemia, buttock, Combined therapy, catheter, fibrinolysis, ligation, artery, procedure, leg, perfusion Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]	Persistent sciatic artery as a rare entity results from lack of regression of the femoral artery blood supply of the leg and is often combined with an abnormally developed superficial femoral artery . We describe the case of a complete , persistent sciatic artery with peripheral ischemia caused by thrombo-embolism from buttock aneurysmal formation . Combined therapy of catheter fibrinolysis , followed by proximal and distal ligation of sciatic artery and peripheral bypass procedure , restored regular leg perfusion .	[ "Persistent", "sciatic", "artery", "as", "a", "rare", "entity", "results", "from", "lack", "of", "regression", "of", "the", "femoral", "artery", "blood", "supply", "of", "the", "leg", "and", "is", "often", "combined", "with", "an", "abnormally", "developed", "superficial", "femoral", "artery", ".", "We", "describe", "the", "case", "of", "a", "complete", ",", "persistent", "sciatic", "artery", "with", "peripheral", "ischemia", "caused", "by", "thrombo", "-", "embolism", "from", "buttock", "aneurysmal", "formation", ".", "Combined", "therapy", "of", "catheter", "fibrinolysis", ",", "followed", "by", "proximal", "and", "distal", "ligation", "of", "sciatic", "artery", "and", "peripheral", "bypass", "procedure", ",", "restored", "regular", "leg", "perfusion", "." ]	[ "umlsterm" ]
artery, regression, femoral artery, blood supply, leg, femoral artery, artery, ischemia, buttock, Combined therapy, catheter, fibrinolysis, ligation, artery, procedure, leg, perfusion	DerChirurg.90700795.eng.abstr_task2	Sentence: Persistent sciatic artery as a rare entity results from lack of regression of the femoral artery blood supply of the leg and is often combined with an abnormally developed superficial femoral artery . We describe the case of a complete , persistent sciatic artery with peripheral ischemia caused by thrombo-embolism from buttock aneurysmal formation . Combined therapy of catheter fibrinolysis , followed by proximal and distal ligation of sciatic artery and peripheral bypass procedure , restored regular leg perfusion . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]	Persistent sciatic artery as a rare entity results from lack of regression of the femoral artery blood supply of the leg and is often combined with an abnormally developed superficial femoral artery . We describe the case of a complete , persistent sciatic artery with peripheral ischemia caused by thrombo-embolism from buttock aneurysmal formation . Combined therapy of catheter fibrinolysis , followed by proximal and distal ligation of sciatic artery and peripheral bypass procedure , restored regular leg perfusion .	[ "Persistent", "sciatic", "artery", "as", "a", "rare", "entity", "results", "from", "lack", "of", "regression", "of", "the", "femoral", "artery", "blood", "supply", "of", "the", "leg", "and", "is", "often", "combined", "with", "an", "abnormally", "developed", "superficial", "femoral", "artery", ".", "We", "describe", "the", "case", "of", "a", "complete", ",", "persistent", "sciatic", "artery", "with", "peripheral", "ischemia", "caused", "by", "thrombo", "-", "embolism", "from", "buttock", "aneurysmal", "formation", ".", "Combined", "therapy", "of", "catheter", "fibrinolysis", ",", "followed", "by", "proximal", "and", "distal", "ligation", "of", "sciatic", "artery", "and", "peripheral", "bypass", "procedure", ",", "restored", "regular", "leg", "perfusion", "." ]	[ "umlsterm" ]
UL5 is a Individual_protein, UL8 is a Individual_protein, UL52 is a Individual_protein, UL9 is a Individual_protein, ICP8 is a Individual_protein, UL29 is a Individual_protein	571_task0	Sentence: We observed that four replication proteins, UL5, UL8 UL52, and UL9, are necessary for the localization of ICP8 (UL29) to prereplicative sites natural infection conditions. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein	[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	We observed that four replication proteins, UL5, UL8 UL52, and UL9, are necessary for the localization of ICP8 (UL29) to prereplicative sites natural infection conditions.	[ "We", "observed", "that", "four", "replication", "proteins", ",", "UL5", ",", "UL8", "UL52", ",", "and", "UL9", ",", "are", "necessary", "for", "the", "localization", "of", "ICP8", "(", "UL29", ")", "to", "prereplicative", "sites", "natural", "infection", "conditions", "." ]	[ "Individual_protein" ]
UL5 is a Individual_protein, UL8 is a Individual_protein, UL52 is a Individual_protein, UL9 is a Individual_protein, ICP8 is a Individual_protein, UL29 is a Individual_protein	571_task1	Sentence: We observed that four replication proteins, UL5, UL8 UL52, and UL9, are necessary for the localization of ICP8 (UL29) to prereplicative sites natural infection conditions. Instructions: please typing these entity words according to sentence: UL5, UL8, UL52, UL9, ICP8, UL29 Options: Individual_protein	[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	We observed that four replication proteins, UL5, UL8 UL52, and UL9, are necessary for the localization of ICP8 (UL29) to prereplicative sites natural infection conditions.	[ "We", "observed", "that", "four", "replication", "proteins", ",", "UL5", ",", "UL8", "UL52", ",", "and", "UL9", ",", "are", "necessary", "for", "the", "localization", "of", "ICP8", "(", "UL29", ")", "to", "prereplicative", "sites", "natural", "infection", "conditions", "." ]	[ "Individual_protein" ]
UL5, UL8, UL52, UL9, ICP8, UL29	571_task2	Sentence: We observed that four replication proteins, UL5, UL8 UL52, and UL9, are necessary for the localization of ICP8 (UL29) to prereplicative sites natural infection conditions. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O" ]	We observed that four replication proteins, UL5, UL8 UL52, and UL9, are necessary for the localization of ICP8 (UL29) to prereplicative sites natural infection conditions.	[ "We", "observed", "that", "four", "replication", "proteins", ",", "UL5", ",", "UL8", "UL52", ",", "and", "UL9", ",", "are", "necessary", "for", "the", "localization", "of", "ICP8", "(", "UL29", ")", "to", "prereplicative", "sites", "natural", "infection", "conditions", "." ]	[ "Individual_protein" ]
Heparin - induzierten is an umlsterm, Thrombozytopenie is an umlsterm, Thrombozyten is an umlsterm, Heparin is an umlsterm, Komplikationen is an umlsterm, Inzidenz is an umlsterm, Heparin is an umlsterm, Patienten is an umlsterm, Amputation is an umlsterm, Extremitaet is an umlsterm, Myokardinfarkt is an umlsterm, Schlaganfall is an umlsterm, Antigen is an umlsterm, Heparin is an umlsterm, Heparin is an umlsterm, Proteinen is an umlsterm, Antikoerper is an umlsterm, Fc - Rezeptor is an umlsterm, Thrombozytenaktivierung is an umlsterm, Thrombozytenaktivierung is an umlsterm, Endotheloberflaeche is an umlsterm, Komplikationen is an umlsterm, Spezifitaet is an umlsterm, endothelstaendigen is an umlsterm, immunvermittelten is an umlsterm, Heparintherapie is an umlsterm, Thrombozytenabfall is an umlsterm, Venen is an umlsterm, Arterien is an umlsterm, Extremitaeten is an umlsterm, Koronargefaesse is an umlsterm, Diagnostik is an umlsterm, Heparin - induzierte is an umlsterm, Behandlung is an umlsterm, Injektion is an umlsterm, Risiko is an umlsterm, Kreuzallergie is an umlsterm, Thrombozytenzahl is an umlsterm, Thrombozytenzahl is an umlsterm, Heparin is an umlsterm, Heparintherapie is an umlsterm, Blutplaettchen is an umlsterm, Heparin - therapie is an umlsterm, Heparintherapie is an umlsterm, Heparintherapie is an umlsterm, Diagnose is an umlsterm, Patienten is an umlsterm, Notfallausweis is an umlsterm, Konzentrationen is an umlsterm, Heparin is an umlsterm	IntensiveMedizin.80350307.ger.abstr_task0	Sentence: Es werden zwei Formen einer Heparin-induzierten Thrombozytopenie ( HIT ) unterschieden , zum einen die durch direkte Interaktion der Thrombozyten mit Heparin bedingte klinisch inapparente HIT , Typ I , zum anderen die immunologisch bedingte , klinisch bedeutsame , mit thromboembolischen Komplikationen einhergehende HIT Typ II . Die Inzidenz der HIT Typ I betraeg ca. 25% . Die HIT Typ II tritt bei ca. 3% der laenger als 5 Tage mit Heparin behandelten Patienten auf . Es handelt sich um eine inten-sivmedizinische , interdisziplinaere Erkrankung mit einer Letalitaet von ca. 20% und weiteren 20% Defektheilungen ( Amputation einer Extremitaet , Myokardinfarkt , Schlaganfall ) . Als Antigen wirkt in der Mehrzahl der Faelle ein Komplex aus Heparin und Plaettchenfaktor 4 ( PF 4 ) , in seltenen Faellen ein Komplex aus Heparin und anderen Proteinen . Die Heparin-PF-4-Komplexe binden mehrere Antikoerper . Durch Bindung an den thrombozytaeren Fc-Rezeptor fuehren die so entstandenen Immunkomplexe zu einer Thrombozytenaktivierung mit nachfolgender PF-4-Ausschuettung. Das durch die immer wieder erneut stattfindende Thrombozytenaktivierung im Ueberschuss vorhandene PF 4 bindet an auf der Endotheloberflaeche befindliche Glucosaminoglykane . Ein wesentlicher pathophysiologischer Mechanismus fuer die Entstehung thromboembo-lischer Komplikationen ist die fehlende Spezifitaet der HIT-Antikoerper . Sie binden sich auch an Komplexe aus endothelstaendigen heparinaehn-lichen Substanzen ( Glucosaminglykane ) und PF 4. Dies fuehrt zu einer immunvermittelten Endothelver-letzung und bedingt ein erhoehtes Thromboserisiko . Die HIT Typ II tritt bei Erstexposition zwischen dem 6. und 20. Tag einer Heparintherapie , bei Reexposition unter Umstaenden innerhalb weniger Stunden auf . Es findet ein Thrombozytenabfall bis auf unter 100 000/µl statt . Typisch sind venoese und/oder arterielle Thromboembolien , vor allem der grossen Venen und Arterien der Extremitaeten , der zerebralen Versorgung und der Koronargefaesse . Fuer die Diagnostik ist neben der typischen Klinik der Nachweis von HIT-Typ-II-Antikoerpern wichtig . Bewaehrt haben sich der Heparin-induzierte Plaettchen-Aktivierungs- ( Hipa- ) Test und der Immunassay nach Amiral et al. ( PF 4/Heparin-ELISA). Das fuer die Behandlung der HIT Typ II neu zugelassene Lepirudin ( Refludan ) weist bei guter Steuerbarkeit ueber die aktivierte partielle Thrombo-plastinzeit ( aPTT ) und sofortigem Wirkungseintritt nach der Injektion kein Risiko einer Kreuzallergie auf . Von besonderer Bedeutung in der Prophylaxe einer HIT Typ II sind regelmaessige Kontrollen der Thrombozytenzahl . So sollte die Thrombozytenzahl bei Erstexposition gegen-ueber Heparin vor und ab dem 5. Tag einer Heparintherapie taeglich einmal kontrolliert werden . Bei Reexposi-tion sollten die Blutplaettchen ebenfalls vor Einleitung der Heparin-therapie , dann aber bereits ab dem 2. Tag , taeglich kontrolliert werden . Unerlaesslich ist es , auf jede ueberfluessige Heparintherapie zu verzichten , eine indizierte Heparintherapie moeglichst auf 5 Tage zu begrenzen , z.B. durch fruehzeitige Einleitung einer oralen Antikoagulation mit Phen-procoumon ( Marcumar ) . Nach Diagnose einer HIT Typ II sollte fuer die betroffenen Patienten ein Notfallausweis ausgestellt werden . Diese Pa-tienten sollten ebenfalls keine Antithrombin-III- oder Prothrombinpraeparate erhalten , da diesen in zum Teil hohen Konzentrationen Heparin zugesetzt ist . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O" ]	Es werden zwei Formen einer Heparin-induzierten Thrombozytopenie ( HIT ) unterschieden , zum einen die durch direkte Interaktion der Thrombozyten mit Heparin bedingte klinisch inapparente HIT , Typ I , zum anderen die immunologisch bedingte , klinisch bedeutsame , mit thromboembolischen Komplikationen einhergehende HIT Typ II . Die Inzidenz der HIT Typ I betraeg ca. 25% . Die HIT Typ II tritt bei ca. 3% der laenger als 5 Tage mit Heparin behandelten Patienten auf . Es handelt sich um eine inten-sivmedizinische , interdisziplinaere Erkrankung mit einer Letalitaet von ca. 20% und weiteren 20% Defektheilungen ( Amputation einer Extremitaet , Myokardinfarkt , Schlaganfall ) . Als Antigen wirkt in der Mehrzahl der Faelle ein Komplex aus Heparin und Plaettchenfaktor 4 ( PF 4 ) , in seltenen Faellen ein Komplex aus Heparin und anderen Proteinen . Die Heparin-PF-4-Komplexe binden mehrere Antikoerper . Durch Bindung an den thrombozytaeren Fc-Rezeptor fuehren die so entstandenen Immunkomplexe zu einer Thrombozytenaktivierung mit nachfolgender PF-4-Ausschuettung. Das durch die immer wieder erneut stattfindende Thrombozytenaktivierung im Ueberschuss vorhandene PF 4 bindet an auf der Endotheloberflaeche befindliche Glucosaminoglykane . Ein wesentlicher pathophysiologischer Mechanismus fuer die Entstehung thromboembo-lischer Komplikationen ist die fehlende Spezifitaet der HIT-Antikoerper . Sie binden sich auch an Komplexe aus endothelstaendigen heparinaehn-lichen Substanzen ( Glucosaminglykane ) und PF 4. Dies fuehrt zu einer immunvermittelten Endothelver-letzung und bedingt ein erhoehtes Thromboserisiko . Die HIT Typ II tritt bei Erstexposition zwischen dem 6. und 20. Tag einer Heparintherapie , bei Reexposition unter Umstaenden innerhalb weniger Stunden auf . Es findet ein Thrombozytenabfall bis auf unter 100 000/µl statt . Typisch sind venoese und/oder arterielle Thromboembolien , vor allem der grossen Venen und Arterien der Extremitaeten , der zerebralen Versorgung und der Koronargefaesse . Fuer die Diagnostik ist neben der typischen Klinik der Nachweis von HIT-Typ-II-Antikoerpern wichtig . Bewaehrt haben sich der Heparin-induzierte Plaettchen-Aktivierungs- ( Hipa- ) Test und der Immunassay nach Amiral et al. ( PF 4/Heparin-ELISA). Das fuer die Behandlung der HIT Typ II neu zugelassene Lepirudin ( Refludan ) weist bei guter Steuerbarkeit ueber die aktivierte partielle Thrombo-plastinzeit ( aPTT ) und sofortigem Wirkungseintritt nach der Injektion kein Risiko einer Kreuzallergie auf . Von besonderer Bedeutung in der Prophylaxe einer HIT Typ II sind regelmaessige Kontrollen der Thrombozytenzahl . So sollte die Thrombozytenzahl bei Erstexposition gegen-ueber Heparin vor und ab dem 5. Tag einer Heparintherapie taeglich einmal kontrolliert werden . Bei Reexposi-tion sollten die Blutplaettchen ebenfalls vor Einleitung der Heparin-therapie , dann aber bereits ab dem 2. Tag , taeglich kontrolliert werden . Unerlaesslich ist es , auf jede ueberfluessige Heparintherapie zu verzichten , eine indizierte Heparintherapie moeglichst auf 5 Tage zu begrenzen , z.B. durch fruehzeitige Einleitung einer oralen Antikoagulation mit Phen-procoumon ( Marcumar ) . Nach Diagnose einer HIT Typ II sollte fuer die betroffenen Patienten ein Notfallausweis ausgestellt werden . Diese Pa-tienten sollten ebenfalls keine Antithrombin-III- oder Prothrombinpraeparate erhalten , da diesen in zum Teil hohen Konzentrationen Heparin zugesetzt ist .	[ "Es", "werden", "zwei", "Formen", "einer", "Heparin", "-", "induzierten", "Thrombozytopenie", "(", "HIT", ")", "unterschieden", ",", "zum", "einen", "die", "durch", "direkte", "Interaktion", "der", "Thrombozyten", "mit", "Heparin", "bedingte", "klinisch", "inapparente", "HIT", ",", "Typ", "I", ",", "zum", "anderen", "die", "immunologisch", "bedingte", ",", "klinisch", "bedeutsame", ",", "mit", "thromboembolischen", "Komplikationen", "einhergehende", "HIT", "Typ", "II", ".", "Die", "Inzidenz", "der", "HIT", "Typ", "I", "betraeg", "ca", ".", "25", "%", ".", "Die", "HIT", "Typ", "II", "tritt", "bei", "ca", ".", "3", "%", "der", "laenger", "als", "5", "Tage", "mit", "Heparin", "behandelten", "Patienten", "auf", ".", "Es", "handelt", "sich", "um", "eine", "inten", "-", "sivmedizinische", ",", "interdisziplinaere", "Erkrankung", "mit", "einer", "Letalitaet", "von", "ca", ".", "20", "%", "und", "weiteren", "20", "%", "Defektheilungen", "(", "Amputation", "einer", "Extremitaet", ",", "Myokardinfarkt", ",", "Schlaganfall", ")", ".", "Als", "Antigen", "wirkt", "in", "der", "Mehrzahl", "der", "Faelle", "ein", "Komplex", "aus", "Heparin", "und", "Plaettchenfaktor", "4", "(", "PF", "4", ")", ",", "in", "seltenen", "Faellen", "ein", "Komplex", "aus", "Heparin", "und", "anderen", "Proteinen", ".", "Die", "Heparin", "-", "PF-4-Komplexe", "binden", "mehrere", "Antikoerper", ".", "Durch", "Bindung", "an", "den", "thrombozytaeren", "Fc", "-", "Rezeptor", "fuehren", "die", "so", "entstandenen", "Immunkomplexe", "zu", "einer", "Thrombozytenaktivierung", "mit", "nachfolgender", "PF-4-Ausschuettung", ".", "Das", "durch", "die", "immer", "wieder", "erneut", "stattfindende", "Thrombozytenaktivierung", "im", "Ueberschuss", "vorhandene", "PF", "4", "bindet", "an", "auf", "der", "Endotheloberflaeche", "befindliche", "Glucosaminoglykane", ".", "Ein", "wesentlicher", "pathophysiologischer", "Mechanismus", "fuer", "die", "Entstehung", "thromboembo", "-", "lischer", "Komplikationen", "ist", "die", "fehlende", "Spezifitaet", "der", "HIT", "-", "Antikoerper", ".", "Sie", "binden", "sich", "auch", "an", "Komplexe", "aus", "endothelstaendigen", "heparinaehn", "-", "lichen", "Substanzen", "(", "Glucosaminglykane", ")", "und", "PF", "4", ".", "Dies", "fuehrt", "zu", "einer", "immunvermittelten", "Endothelver", "-", "letzung", "und", "bedingt", "ein", "erhoehtes", "Thromboserisiko", ".", "Die", "HIT", "Typ", "II", "tritt", "bei", "Erstexposition", "zwischen", "dem", "6", ".", "und", "20", ".", "Tag", "einer", "Heparintherapie", ",", "bei", "Reexposition", "unter", "Umstaenden", "innerhalb", "weniger", "Stunden", "auf", ".", "Es", "findet", "ein", "Thrombozytenabfall", "bis", "auf", "unter", "100", "000/µl", "statt", ".", "Typisch", "sind", "venoese", "und", "/", "oder", "arterielle", "Thromboembolien", ",", "vor", "allem", "der", "grossen", "Venen", "und", "Arterien", "der", "Extremitaeten", ",", "der", "zerebralen", "Versorgung", "und", "der", "Koronargefaesse", ".", "Fuer", "die", "Diagnostik", "ist", "neben", "der", "typischen", "Klinik", "der", "Nachweis", "von", "HIT", "-", "Typ", "-", "II", "-", "Antikoerpern", "wichtig", ".", "Bewaehrt", "haben", "sich", "der", "Heparin", "-", "induzierte", "Plaettchen", "-", "Aktivierungs-", "(", "Hipa-", ")", "Test", "und", "der", "Immunassay", "nach", "Amiral", "et", "al", ".", "(", "PF", "4", "/", "Heparin", "-", "ELISA", ")", ".", "Das", "fuer", "die", "Behandlung", "der", "HIT", "Typ", "II", "neu", "zugelassene", "Lepirudin", "(", "Refludan", ")", "weist", "bei", "guter", "Steuerbarkeit", "ueber", "die", "aktivierte", "partielle", "Thrombo", "-", "plastinzeit", "(", "aPTT", ")", "und", "sofortigem", "Wirkungseintritt", "nach", "der", "Injektion", "kein", "Risiko", "einer", "Kreuzallergie", "auf", ".", "Von", "besonderer", "Bedeutung", "in", "der", "Prophylaxe", "einer", "HIT", "Typ", "II", "sind", "regelmaessige", "Kontrollen", "der", "Thrombozytenzahl", ".", "So", "sollte", "die", "Thrombozytenzahl", "bei", "Erstexposition", "gegen", "-", "ueber", "Heparin", "vor", "und", "ab", "dem", "5", ".", "Tag", "einer", "Heparintherapie", "taeglich", "einmal", "kontrolliert", "werden", ".", "Bei", "Reexposi", "-", "tion", "sollten", "die", "Blutplaettchen", "ebenfalls", "vor", "Einleitung", "der", "Heparin", "-", "therapie", ",", "dann", "aber", "bereits", "ab", "dem", "2", ".", "Tag", ",", "taeglich", "kontrolliert", "werden", ".", "Unerlaesslich", "ist", "es", ",", "auf", "jede", "ueberfluessige", "Heparintherapie", "zu", "verzichten", ",", "eine", "indizierte", "Heparintherapie", "moeglichst", "auf", "5", "Tage", "zu", "begrenzen", ",", "z.", "B.", "durch", "fruehzeitige", "Einleitung", "einer", "oralen", "Antikoagulation", "mit", "Phen", "-", "procoumon", "(", "Marcumar", ")", ".", "Nach", "Diagnose", "einer", "HIT", "Typ", "II", "sollte", "fuer", "die", "betroffenen", "Patienten", "ein", "Notfallausweis", "ausgestellt", "werden", ".", "Diese", "Pa", "-", "tienten", "sollten", "ebenfalls", "keine", "Antithrombin", "-", "III-", "oder", "Prothrombinpraeparate", "erhalten", ",", "da", "diesen", "in", "zum", "Teil", "hohen", "Konzentrationen", "Heparin", "zugesetzt", "ist", "." ]	[ "umlsterm" ]
Heparin - induzierten is an umlsterm, Thrombozytopenie is an umlsterm, Thrombozyten is an umlsterm, Heparin is an umlsterm, Komplikationen is an umlsterm, Inzidenz is an umlsterm, Heparin is an umlsterm, Patienten is an umlsterm, Amputation is an umlsterm, Extremitaet is an umlsterm, Myokardinfarkt is an umlsterm, Schlaganfall is an umlsterm, Antigen is an umlsterm, Heparin is an umlsterm, Heparin is an umlsterm, Proteinen is an umlsterm, Antikoerper is an umlsterm, Fc - Rezeptor is an umlsterm, Thrombozytenaktivierung is an umlsterm, Thrombozytenaktivierung is an umlsterm, Endotheloberflaeche is an umlsterm, Komplikationen is an umlsterm, Spezifitaet is an umlsterm, endothelstaendigen is an umlsterm, immunvermittelten is an umlsterm, Heparintherapie is an umlsterm, Thrombozytenabfall is an umlsterm, Venen is an umlsterm, Arterien is an umlsterm, Extremitaeten is an umlsterm, Koronargefaesse is an umlsterm, Diagnostik is an umlsterm, Heparin - induzierte is an umlsterm, Behandlung is an umlsterm, Injektion is an umlsterm, Risiko is an umlsterm, Kreuzallergie is an umlsterm, Thrombozytenzahl is an umlsterm, Thrombozytenzahl is an umlsterm, Heparin is an umlsterm, Heparintherapie is an umlsterm, Blutplaettchen is an umlsterm, Heparin - therapie is an umlsterm, Heparintherapie is an umlsterm, Heparintherapie is an umlsterm, Diagnose is an umlsterm, Patienten is an umlsterm, Notfallausweis is an umlsterm, Konzentrationen is an umlsterm, Heparin is an umlsterm	IntensiveMedizin.80350307.ger.abstr_task1	Sentence: Es werden zwei Formen einer Heparin-induzierten Thrombozytopenie ( HIT ) unterschieden , zum einen die durch direkte Interaktion der Thrombozyten mit Heparin bedingte klinisch inapparente HIT , Typ I , zum anderen die immunologisch bedingte , klinisch bedeutsame , mit thromboembolischen Komplikationen einhergehende HIT Typ II . Die Inzidenz der HIT Typ I betraeg ca. 25% . Die HIT Typ II tritt bei ca. 3% der laenger als 5 Tage mit Heparin behandelten Patienten auf . Es handelt sich um eine inten-sivmedizinische , interdisziplinaere Erkrankung mit einer Letalitaet von ca. 20% und weiteren 20% Defektheilungen ( Amputation einer Extremitaet , Myokardinfarkt , Schlaganfall ) . Als Antigen wirkt in der Mehrzahl der Faelle ein Komplex aus Heparin und Plaettchenfaktor 4 ( PF 4 ) , in seltenen Faellen ein Komplex aus Heparin und anderen Proteinen . Die Heparin-PF-4-Komplexe binden mehrere Antikoerper . Durch Bindung an den thrombozytaeren Fc-Rezeptor fuehren die so entstandenen Immunkomplexe zu einer Thrombozytenaktivierung mit nachfolgender PF-4-Ausschuettung. Das durch die immer wieder erneut stattfindende Thrombozytenaktivierung im Ueberschuss vorhandene PF 4 bindet an auf der Endotheloberflaeche befindliche Glucosaminoglykane . Ein wesentlicher pathophysiologischer Mechanismus fuer die Entstehung thromboembo-lischer Komplikationen ist die fehlende Spezifitaet der HIT-Antikoerper . Sie binden sich auch an Komplexe aus endothelstaendigen heparinaehn-lichen Substanzen ( Glucosaminglykane ) und PF 4. Dies fuehrt zu einer immunvermittelten Endothelver-letzung und bedingt ein erhoehtes Thromboserisiko . Die HIT Typ II tritt bei Erstexposition zwischen dem 6. und 20. Tag einer Heparintherapie , bei Reexposition unter Umstaenden innerhalb weniger Stunden auf . Es findet ein Thrombozytenabfall bis auf unter 100 000/µl statt . Typisch sind venoese und/oder arterielle Thromboembolien , vor allem der grossen Venen und Arterien der Extremitaeten , der zerebralen Versorgung und der Koronargefaesse . Fuer die Diagnostik ist neben der typischen Klinik der Nachweis von HIT-Typ-II-Antikoerpern wichtig . Bewaehrt haben sich der Heparin-induzierte Plaettchen-Aktivierungs- ( Hipa- ) Test und der Immunassay nach Amiral et al. ( PF 4/Heparin-ELISA). Das fuer die Behandlung der HIT Typ II neu zugelassene Lepirudin ( Refludan ) weist bei guter Steuerbarkeit ueber die aktivierte partielle Thrombo-plastinzeit ( aPTT ) und sofortigem Wirkungseintritt nach der Injektion kein Risiko einer Kreuzallergie auf . Von besonderer Bedeutung in der Prophylaxe einer HIT Typ II sind regelmaessige Kontrollen der Thrombozytenzahl . So sollte die Thrombozytenzahl bei Erstexposition gegen-ueber Heparin vor und ab dem 5. Tag einer Heparintherapie taeglich einmal kontrolliert werden . Bei Reexposi-tion sollten die Blutplaettchen ebenfalls vor Einleitung der Heparin-therapie , dann aber bereits ab dem 2. Tag , taeglich kontrolliert werden . Unerlaesslich ist es , auf jede ueberfluessige Heparintherapie zu verzichten , eine indizierte Heparintherapie moeglichst auf 5 Tage zu begrenzen , z.B. durch fruehzeitige Einleitung einer oralen Antikoagulation mit Phen-procoumon ( Marcumar ) . Nach Diagnose einer HIT Typ II sollte fuer die betroffenen Patienten ein Notfallausweis ausgestellt werden . Diese Pa-tienten sollten ebenfalls keine Antithrombin-III- oder Prothrombinpraeparate erhalten , da diesen in zum Teil hohen Konzentrationen Heparin zugesetzt ist . Instructions: please typing these entity words according to sentence: Heparin - induzierten, Thrombozytopenie, Thrombozyten, Heparin, Komplikationen, Inzidenz, Heparin, Patienten, Amputation, Extremitaet, Myokardinfarkt, Schlaganfall, Antigen, Heparin, Heparin, Proteinen, Antikoerper, Fc - Rezeptor, Thrombozytenaktivierung, Thrombozytenaktivierung, Endotheloberflaeche, Komplikationen, Spezifitaet, endothelstaendigen, immunvermittelten, Heparintherapie, Thrombozytenabfall, Venen, Arterien, Extremitaeten, Koronargefaesse, Diagnostik, Heparin - induzierte, Behandlung, Injektion, Risiko, Kreuzallergie, Thrombozytenzahl, Thrombozytenzahl, Heparin, Heparintherapie, Blutplaettchen, Heparin - therapie, Heparintherapie, Heparintherapie, Diagnose, Patienten, Notfallausweis, Konzentrationen, Heparin Options: umlsterm	[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O" ]	Es werden zwei Formen einer Heparin-induzierten Thrombozytopenie ( HIT ) unterschieden , zum einen die durch direkte Interaktion der Thrombozyten mit Heparin bedingte klinisch inapparente HIT , Typ I , zum anderen die immunologisch bedingte , klinisch bedeutsame , mit thromboembolischen Komplikationen einhergehende HIT Typ II . Die Inzidenz der HIT Typ I betraeg ca. 25% . Die HIT Typ II tritt bei ca. 3% der laenger als 5 Tage mit Heparin behandelten Patienten auf . Es handelt sich um eine inten-sivmedizinische , interdisziplinaere Erkrankung mit einer Letalitaet von ca. 20% und weiteren 20% Defektheilungen ( Amputation einer Extremitaet , Myokardinfarkt , Schlaganfall ) . Als Antigen wirkt in der Mehrzahl der Faelle ein Komplex aus Heparin und Plaettchenfaktor 4 ( PF 4 ) , in seltenen Faellen ein Komplex aus Heparin und anderen Proteinen . Die Heparin-PF-4-Komplexe binden mehrere Antikoerper . Durch Bindung an den thrombozytaeren Fc-Rezeptor fuehren die so entstandenen Immunkomplexe zu einer Thrombozytenaktivierung mit nachfolgender PF-4-Ausschuettung. Das durch die immer wieder erneut stattfindende Thrombozytenaktivierung im Ueberschuss vorhandene PF 4 bindet an auf der Endotheloberflaeche befindliche Glucosaminoglykane . Ein wesentlicher pathophysiologischer Mechanismus fuer die Entstehung thromboembo-lischer Komplikationen ist die fehlende Spezifitaet der HIT-Antikoerper . Sie binden sich auch an Komplexe aus endothelstaendigen heparinaehn-lichen Substanzen ( Glucosaminglykane ) und PF 4. Dies fuehrt zu einer immunvermittelten Endothelver-letzung und bedingt ein erhoehtes Thromboserisiko . Die HIT Typ II tritt bei Erstexposition zwischen dem 6. und 20. Tag einer Heparintherapie , bei Reexposition unter Umstaenden innerhalb weniger Stunden auf . Es findet ein Thrombozytenabfall bis auf unter 100 000/µl statt . Typisch sind venoese und/oder arterielle Thromboembolien , vor allem der grossen Venen und Arterien der Extremitaeten , der zerebralen Versorgung und der Koronargefaesse . Fuer die Diagnostik ist neben der typischen Klinik der Nachweis von HIT-Typ-II-Antikoerpern wichtig . Bewaehrt haben sich der Heparin-induzierte Plaettchen-Aktivierungs- ( Hipa- ) Test und der Immunassay nach Amiral et al. ( PF 4/Heparin-ELISA). Das fuer die Behandlung der HIT Typ II neu zugelassene Lepirudin ( Refludan ) weist bei guter Steuerbarkeit ueber die aktivierte partielle Thrombo-plastinzeit ( aPTT ) und sofortigem Wirkungseintritt nach der Injektion kein Risiko einer Kreuzallergie auf . Von besonderer Bedeutung in der Prophylaxe einer HIT Typ II sind regelmaessige Kontrollen der Thrombozytenzahl . So sollte die Thrombozytenzahl bei Erstexposition gegen-ueber Heparin vor und ab dem 5. Tag einer Heparintherapie taeglich einmal kontrolliert werden . Bei Reexposi-tion sollten die Blutplaettchen ebenfalls vor Einleitung der Heparin-therapie , dann aber bereits ab dem 2. Tag , taeglich kontrolliert werden . Unerlaesslich ist es , auf jede ueberfluessige Heparintherapie zu verzichten , eine indizierte Heparintherapie moeglichst auf 5 Tage zu begrenzen , z.B. durch fruehzeitige Einleitung einer oralen Antikoagulation mit Phen-procoumon ( Marcumar ) . Nach Diagnose einer HIT Typ II sollte fuer die betroffenen Patienten ein Notfallausweis ausgestellt werden . Diese Pa-tienten sollten ebenfalls keine Antithrombin-III- oder Prothrombinpraeparate erhalten , da diesen in zum Teil hohen Konzentrationen Heparin zugesetzt ist .	[ "Es", "werden", "zwei", "Formen", "einer", "Heparin", "-", "induzierten", "Thrombozytopenie", "(", "HIT", ")", "unterschieden", ",", "zum", "einen", "die", "durch", "direkte", "Interaktion", "der", "Thrombozyten", "mit", "Heparin", "bedingte", "klinisch", "inapparente", "HIT", ",", "Typ", "I", ",", "zum", "anderen", "die", "immunologisch", "bedingte", ",", "klinisch", "bedeutsame", ",", "mit", "thromboembolischen", "Komplikationen", "einhergehende", "HIT", "Typ", "II", ".", "Die", "Inzidenz", "der", "HIT", "Typ", "I", "betraeg", "ca", ".", "25", "%", ".", "Die", "HIT", "Typ", "II", "tritt", "bei", "ca", ".", "3", "%", "der", "laenger", "als", "5", "Tage", "mit", "Heparin", "behandelten", "Patienten", "auf", ".", "Es", "handelt", "sich", "um", "eine", "inten", "-", "sivmedizinische", ",", "interdisziplinaere", "Erkrankung", "mit", "einer", "Letalitaet", "von", "ca", ".", "20", "%", "und", "weiteren", "20", "%", "Defektheilungen", "(", "Amputation", "einer", "Extremitaet", ",", "Myokardinfarkt", ",", "Schlaganfall", ")", ".", "Als", "Antigen", "wirkt", "in", "der", "Mehrzahl", "der", "Faelle", "ein", "Komplex", "aus", "Heparin", "und", "Plaettchenfaktor", "4", "(", "PF", "4", ")", ",", "in", "seltenen", "Faellen", "ein", "Komplex", "aus", "Heparin", "und", "anderen", "Proteinen", ".", "Die", "Heparin", "-", "PF-4-Komplexe", "binden", "mehrere", "Antikoerper", ".", "Durch", "Bindung", "an", "den", "thrombozytaeren", "Fc", "-", "Rezeptor", "fuehren", "die", "so", "entstandenen", "Immunkomplexe", "zu", "einer", "Thrombozytenaktivierung", "mit", "nachfolgender", "PF-4-Ausschuettung", ".", "Das", "durch", "die", "immer", "wieder", "erneut", "stattfindende", "Thrombozytenaktivierung", "im", "Ueberschuss", "vorhandene", "PF", "4", "bindet", "an", "auf", "der", "Endotheloberflaeche", "befindliche", "Glucosaminoglykane", ".", "Ein", "wesentlicher", "pathophysiologischer", "Mechanismus", "fuer", "die", "Entstehung", "thromboembo", "-", "lischer", "Komplikationen", "ist", "die", "fehlende", "Spezifitaet", "der", "HIT", "-", "Antikoerper", ".", "Sie", "binden", "sich", "auch", "an", "Komplexe", "aus", "endothelstaendigen", "heparinaehn", "-", "lichen", "Substanzen", "(", "Glucosaminglykane", ")", "und", "PF", "4", ".", "Dies", "fuehrt", "zu", "einer", "immunvermittelten", "Endothelver", "-", "letzung", "und", "bedingt", "ein", "erhoehtes", "Thromboserisiko", ".", "Die", "HIT", "Typ", "II", "tritt", "bei", "Erstexposition", "zwischen", "dem", "6", ".", "und", "20", ".", "Tag", "einer", "Heparintherapie", ",", "bei", "Reexposition", "unter", "Umstaenden", "innerhalb", "weniger", "Stunden", "auf", ".", "Es", "findet", "ein", "Thrombozytenabfall", "bis", "auf", "unter", "100", "000/µl", "statt", ".", "Typisch", "sind", "venoese", "und", "/", "oder", "arterielle", "Thromboembolien", ",", "vor", "allem", "der", "grossen", "Venen", "und", "Arterien", "der", "Extremitaeten", ",", "der", "zerebralen", "Versorgung", "und", "der", "Koronargefaesse", ".", "Fuer", "die", "Diagnostik", "ist", "neben", "der", "typischen", "Klinik", "der", "Nachweis", "von", "HIT", "-", "Typ", "-", "II", "-", "Antikoerpern", "wichtig", ".", "Bewaehrt", "haben", "sich", "der", "Heparin", "-", "induzierte", "Plaettchen", "-", "Aktivierungs-", "(", "Hipa-", ")", "Test", "und", "der", "Immunassay", "nach", "Amiral", "et", "al", ".", "(", "PF", "4", "/", "Heparin", "-", "ELISA", ")", ".", "Das", "fuer", "die", "Behandlung", "der", "HIT", "Typ", "II", "neu", "zugelassene", "Lepirudin", "(", "Refludan", ")", "weist", "bei", "guter", "Steuerbarkeit", "ueber", "die", "aktivierte", "partielle", "Thrombo", "-", "plastinzeit", "(", "aPTT", ")", "und", "sofortigem", "Wirkungseintritt", "nach", "der", "Injektion", "kein", "Risiko", "einer", "Kreuzallergie", "auf", ".", "Von", "besonderer", "Bedeutung", "in", "der", "Prophylaxe", "einer", "HIT", "Typ", "II", "sind", "regelmaessige", "Kontrollen", "der", "Thrombozytenzahl", ".", "So", "sollte", "die", "Thrombozytenzahl", "bei", "Erstexposition", "gegen", "-", "ueber", "Heparin", "vor", "und", "ab", "dem", "5", ".", "Tag", "einer", "Heparintherapie", "taeglich", "einmal", "kontrolliert", "werden", ".", "Bei", "Reexposi", "-", "tion", "sollten", "die", "Blutplaettchen", "ebenfalls", "vor", "Einleitung", "der", "Heparin", "-", "therapie", ",", "dann", "aber", "bereits", "ab", "dem", "2", ".", "Tag", ",", "taeglich", "kontrolliert", "werden", ".", "Unerlaesslich", "ist", "es", ",", "auf", "jede", "ueberfluessige", "Heparintherapie", "zu", "verzichten", ",", "eine", "indizierte", "Heparintherapie", "moeglichst", "auf", "5", "Tage", "zu", "begrenzen", ",", "z.", "B.", "durch", "fruehzeitige", "Einleitung", "einer", "oralen", "Antikoagulation", "mit", "Phen", "-", "procoumon", "(", "Marcumar", ")", ".", "Nach", "Diagnose", "einer", "HIT", "Typ", "II", "sollte", "fuer", "die", "betroffenen", "Patienten", "ein", "Notfallausweis", "ausgestellt", "werden", ".", "Diese", "Pa", "-", "tienten", "sollten", "ebenfalls", "keine", "Antithrombin", "-", "III-", "oder", "Prothrombinpraeparate", "erhalten", ",", "da", "diesen", "in", "zum", "Teil", "hohen", "Konzentrationen", "Heparin", "zugesetzt", "ist", "." ]	[ "umlsterm" ]
Heparin - induzierten, Thrombozytopenie, Thrombozyten, Heparin, Komplikationen, Inzidenz, Heparin, Patienten, Amputation, Extremitaet, Myokardinfarkt, Schlaganfall, Antigen, Heparin, Heparin, Proteinen, Antikoerper, Fc - Rezeptor, Thrombozytenaktivierung, Thrombozytenaktivierung, Endotheloberflaeche, Komplikationen, Spezifitaet, endothelstaendigen, immunvermittelten, Heparintherapie, Thrombozytenabfall, Venen, Arterien, Extremitaeten, Koronargefaesse, Diagnostik, Heparin - induzierte, Behandlung, Injektion, Risiko, Kreuzallergie, Thrombozytenzahl, Thrombozytenzahl, Heparin, Heparintherapie, Blutplaettchen, Heparin - therapie, Heparintherapie, Heparintherapie, Diagnose, Patienten, Notfallausweis, Konzentrationen, Heparin	IntensiveMedizin.80350307.ger.abstr_task2	Sentence: Es werden zwei Formen einer Heparin-induzierten Thrombozytopenie ( HIT ) unterschieden , zum einen die durch direkte Interaktion der Thrombozyten mit Heparin bedingte klinisch inapparente HIT , Typ I , zum anderen die immunologisch bedingte , klinisch bedeutsame , mit thromboembolischen Komplikationen einhergehende HIT Typ II . Die Inzidenz der HIT Typ I betraeg ca. 25% . Die HIT Typ II tritt bei ca. 3% der laenger als 5 Tage mit Heparin behandelten Patienten auf . Es handelt sich um eine inten-sivmedizinische , interdisziplinaere Erkrankung mit einer Letalitaet von ca. 20% und weiteren 20% Defektheilungen ( Amputation einer Extremitaet , Myokardinfarkt , Schlaganfall ) . Als Antigen wirkt in der Mehrzahl der Faelle ein Komplex aus Heparin und Plaettchenfaktor 4 ( PF 4 ) , in seltenen Faellen ein Komplex aus Heparin und anderen Proteinen . Die Heparin-PF-4-Komplexe binden mehrere Antikoerper . Durch Bindung an den thrombozytaeren Fc-Rezeptor fuehren die so entstandenen Immunkomplexe zu einer Thrombozytenaktivierung mit nachfolgender PF-4-Ausschuettung. Das durch die immer wieder erneut stattfindende Thrombozytenaktivierung im Ueberschuss vorhandene PF 4 bindet an auf der Endotheloberflaeche befindliche Glucosaminoglykane . Ein wesentlicher pathophysiologischer Mechanismus fuer die Entstehung thromboembo-lischer Komplikationen ist die fehlende Spezifitaet der HIT-Antikoerper . Sie binden sich auch an Komplexe aus endothelstaendigen heparinaehn-lichen Substanzen ( Glucosaminglykane ) und PF 4. Dies fuehrt zu einer immunvermittelten Endothelver-letzung und bedingt ein erhoehtes Thromboserisiko . Die HIT Typ II tritt bei Erstexposition zwischen dem 6. und 20. Tag einer Heparintherapie , bei Reexposition unter Umstaenden innerhalb weniger Stunden auf . Es findet ein Thrombozytenabfall bis auf unter 100 000/µl statt . Typisch sind venoese und/oder arterielle Thromboembolien , vor allem der grossen Venen und Arterien der Extremitaeten , der zerebralen Versorgung und der Koronargefaesse . Fuer die Diagnostik ist neben der typischen Klinik der Nachweis von HIT-Typ-II-Antikoerpern wichtig . Bewaehrt haben sich der Heparin-induzierte Plaettchen-Aktivierungs- ( Hipa- ) Test und der Immunassay nach Amiral et al. ( PF 4/Heparin-ELISA). Das fuer die Behandlung der HIT Typ II neu zugelassene Lepirudin ( Refludan ) weist bei guter Steuerbarkeit ueber die aktivierte partielle Thrombo-plastinzeit ( aPTT ) und sofortigem Wirkungseintritt nach der Injektion kein Risiko einer Kreuzallergie auf . Von besonderer Bedeutung in der Prophylaxe einer HIT Typ II sind regelmaessige Kontrollen der Thrombozytenzahl . So sollte die Thrombozytenzahl bei Erstexposition gegen-ueber Heparin vor und ab dem 5. Tag einer Heparintherapie taeglich einmal kontrolliert werden . Bei Reexposi-tion sollten die Blutplaettchen ebenfalls vor Einleitung der Heparin-therapie , dann aber bereits ab dem 2. Tag , taeglich kontrolliert werden . Unerlaesslich ist es , auf jede ueberfluessige Heparintherapie zu verzichten , eine indizierte Heparintherapie moeglichst auf 5 Tage zu begrenzen , z.B. durch fruehzeitige Einleitung einer oralen Antikoagulation mit Phen-procoumon ( Marcumar ) . Nach Diagnose einer HIT Typ II sollte fuer die betroffenen Patienten ein Notfallausweis ausgestellt werden . Diese Pa-tienten sollten ebenfalls keine Antithrombin-III- oder Prothrombinpraeparate erhalten , da diesen in zum Teil hohen Konzentrationen Heparin zugesetzt ist . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O" ]	Es werden zwei Formen einer Heparin-induzierten Thrombozytopenie ( HIT ) unterschieden , zum einen die durch direkte Interaktion der Thrombozyten mit Heparin bedingte klinisch inapparente HIT , Typ I , zum anderen die immunologisch bedingte , klinisch bedeutsame , mit thromboembolischen Komplikationen einhergehende HIT Typ II . Die Inzidenz der HIT Typ I betraeg ca. 25% . Die HIT Typ II tritt bei ca. 3% der laenger als 5 Tage mit Heparin behandelten Patienten auf . Es handelt sich um eine inten-sivmedizinische , interdisziplinaere Erkrankung mit einer Letalitaet von ca. 20% und weiteren 20% Defektheilungen ( Amputation einer Extremitaet , Myokardinfarkt , Schlaganfall ) . Als Antigen wirkt in der Mehrzahl der Faelle ein Komplex aus Heparin und Plaettchenfaktor 4 ( PF 4 ) , in seltenen Faellen ein Komplex aus Heparin und anderen Proteinen . Die Heparin-PF-4-Komplexe binden mehrere Antikoerper . Durch Bindung an den thrombozytaeren Fc-Rezeptor fuehren die so entstandenen Immunkomplexe zu einer Thrombozytenaktivierung mit nachfolgender PF-4-Ausschuettung. Das durch die immer wieder erneut stattfindende Thrombozytenaktivierung im Ueberschuss vorhandene PF 4 bindet an auf der Endotheloberflaeche befindliche Glucosaminoglykane . Ein wesentlicher pathophysiologischer Mechanismus fuer die Entstehung thromboembo-lischer Komplikationen ist die fehlende Spezifitaet der HIT-Antikoerper . Sie binden sich auch an Komplexe aus endothelstaendigen heparinaehn-lichen Substanzen ( Glucosaminglykane ) und PF 4. Dies fuehrt zu einer immunvermittelten Endothelver-letzung und bedingt ein erhoehtes Thromboserisiko . Die HIT Typ II tritt bei Erstexposition zwischen dem 6. und 20. Tag einer Heparintherapie , bei Reexposition unter Umstaenden innerhalb weniger Stunden auf . Es findet ein Thrombozytenabfall bis auf unter 100 000/µl statt . Typisch sind venoese und/oder arterielle Thromboembolien , vor allem der grossen Venen und Arterien der Extremitaeten , der zerebralen Versorgung und der Koronargefaesse . Fuer die Diagnostik ist neben der typischen Klinik der Nachweis von HIT-Typ-II-Antikoerpern wichtig . Bewaehrt haben sich der Heparin-induzierte Plaettchen-Aktivierungs- ( Hipa- ) Test und der Immunassay nach Amiral et al. ( PF 4/Heparin-ELISA). Das fuer die Behandlung der HIT Typ II neu zugelassene Lepirudin ( Refludan ) weist bei guter Steuerbarkeit ueber die aktivierte partielle Thrombo-plastinzeit ( aPTT ) und sofortigem Wirkungseintritt nach der Injektion kein Risiko einer Kreuzallergie auf . Von besonderer Bedeutung in der Prophylaxe einer HIT Typ II sind regelmaessige Kontrollen der Thrombozytenzahl . So sollte die Thrombozytenzahl bei Erstexposition gegen-ueber Heparin vor und ab dem 5. Tag einer Heparintherapie taeglich einmal kontrolliert werden . Bei Reexposi-tion sollten die Blutplaettchen ebenfalls vor Einleitung der Heparin-therapie , dann aber bereits ab dem 2. Tag , taeglich kontrolliert werden . Unerlaesslich ist es , auf jede ueberfluessige Heparintherapie zu verzichten , eine indizierte Heparintherapie moeglichst auf 5 Tage zu begrenzen , z.B. durch fruehzeitige Einleitung einer oralen Antikoagulation mit Phen-procoumon ( Marcumar ) . Nach Diagnose einer HIT Typ II sollte fuer die betroffenen Patienten ein Notfallausweis ausgestellt werden . Diese Pa-tienten sollten ebenfalls keine Antithrombin-III- oder Prothrombinpraeparate erhalten , da diesen in zum Teil hohen Konzentrationen Heparin zugesetzt ist .	[ "Es", "werden", "zwei", "Formen", "einer", "Heparin", "-", "induzierten", "Thrombozytopenie", "(", "HIT", ")", "unterschieden", ",", "zum", "einen", "die", "durch", "direkte", "Interaktion", "der", "Thrombozyten", "mit", "Heparin", "bedingte", "klinisch", "inapparente", "HIT", ",", "Typ", "I", ",", "zum", "anderen", "die", "immunologisch", "bedingte", ",", "klinisch", "bedeutsame", ",", "mit", "thromboembolischen", "Komplikationen", "einhergehende", "HIT", "Typ", "II", ".", "Die", "Inzidenz", "der", "HIT", "Typ", "I", "betraeg", "ca", ".", "25", "%", ".", "Die", "HIT", "Typ", "II", "tritt", "bei", "ca", ".", "3", "%", "der", "laenger", "als", "5", "Tage", "mit", "Heparin", "behandelten", "Patienten", "auf", ".", "Es", "handelt", "sich", "um", "eine", "inten", "-", "sivmedizinische", ",", "interdisziplinaere", "Erkrankung", "mit", "einer", "Letalitaet", "von", "ca", ".", "20", "%", "und", "weiteren", "20", "%", "Defektheilungen", "(", "Amputation", "einer", "Extremitaet", ",", "Myokardinfarkt", ",", "Schlaganfall", ")", ".", "Als", "Antigen", "wirkt", "in", "der", "Mehrzahl", "der", "Faelle", "ein", "Komplex", "aus", "Heparin", "und", "Plaettchenfaktor", "4", "(", "PF", "4", ")", ",", "in", "seltenen", "Faellen", "ein", "Komplex", "aus", "Heparin", "und", "anderen", "Proteinen", ".", "Die", "Heparin", "-", "PF-4-Komplexe", "binden", "mehrere", "Antikoerper", ".", "Durch", "Bindung", "an", "den", "thrombozytaeren", "Fc", "-", "Rezeptor", "fuehren", "die", "so", "entstandenen", "Immunkomplexe", "zu", "einer", "Thrombozytenaktivierung", "mit", "nachfolgender", "PF-4-Ausschuettung", ".", "Das", "durch", "die", "immer", "wieder", "erneut", "stattfindende", "Thrombozytenaktivierung", "im", "Ueberschuss", "vorhandene", "PF", "4", "bindet", "an", "auf", "der", "Endotheloberflaeche", "befindliche", "Glucosaminoglykane", ".", "Ein", "wesentlicher", "pathophysiologischer", "Mechanismus", "fuer", "die", "Entstehung", "thromboembo", "-", "lischer", "Komplikationen", "ist", "die", "fehlende", "Spezifitaet", "der", "HIT", "-", "Antikoerper", ".", "Sie", "binden", "sich", "auch", "an", "Komplexe", "aus", "endothelstaendigen", "heparinaehn", "-", "lichen", "Substanzen", "(", "Glucosaminglykane", ")", "und", "PF", "4", ".", "Dies", "fuehrt", "zu", "einer", "immunvermittelten", "Endothelver", "-", "letzung", "und", "bedingt", "ein", "erhoehtes", "Thromboserisiko", ".", "Die", "HIT", "Typ", "II", "tritt", "bei", "Erstexposition", "zwischen", "dem", "6", ".", "und", "20", ".", "Tag", "einer", "Heparintherapie", ",", "bei", "Reexposition", "unter", "Umstaenden", "innerhalb", "weniger", "Stunden", "auf", ".", "Es", "findet", "ein", "Thrombozytenabfall", "bis", "auf", "unter", "100", "000/µl", "statt", ".", "Typisch", "sind", "venoese", "und", "/", "oder", "arterielle", "Thromboembolien", ",", "vor", "allem", "der", "grossen", "Venen", "und", "Arterien", "der", "Extremitaeten", ",", "der", "zerebralen", "Versorgung", "und", "der", "Koronargefaesse", ".", "Fuer", "die", "Diagnostik", "ist", "neben", "der", "typischen", "Klinik", "der", "Nachweis", "von", "HIT", "-", "Typ", "-", "II", "-", "Antikoerpern", "wichtig", ".", "Bewaehrt", "haben", "sich", "der", "Heparin", "-", "induzierte", "Plaettchen", "-", "Aktivierungs-", "(", "Hipa-", ")", "Test", "und", "der", "Immunassay", "nach", "Amiral", "et", "al", ".", "(", "PF", "4", "/", "Heparin", "-", "ELISA", ")", ".", "Das", "fuer", "die", "Behandlung", "der", "HIT", "Typ", "II", "neu", "zugelassene", "Lepirudin", "(", "Refludan", ")", "weist", "bei", "guter", "Steuerbarkeit", "ueber", "die", "aktivierte", "partielle", "Thrombo", "-", "plastinzeit", "(", "aPTT", ")", "und", "sofortigem", "Wirkungseintritt", "nach", "der", "Injektion", "kein", "Risiko", "einer", "Kreuzallergie", "auf", ".", "Von", "besonderer", "Bedeutung", "in", "der", "Prophylaxe", "einer", "HIT", "Typ", "II", "sind", "regelmaessige", "Kontrollen", "der", "Thrombozytenzahl", ".", "So", "sollte", "die", "Thrombozytenzahl", "bei", "Erstexposition", "gegen", "-", "ueber", "Heparin", "vor", "und", "ab", "dem", "5", ".", "Tag", "einer", "Heparintherapie", "taeglich", "einmal", "kontrolliert", "werden", ".", "Bei", "Reexposi", "-", "tion", "sollten", "die", "Blutplaettchen", "ebenfalls", "vor", "Einleitung", "der", "Heparin", "-", "therapie", ",", "dann", "aber", "bereits", "ab", "dem", "2", ".", "Tag", ",", "taeglich", "kontrolliert", "werden", ".", "Unerlaesslich", "ist", "es", ",", "auf", "jede", "ueberfluessige", "Heparintherapie", "zu", "verzichten", ",", "eine", "indizierte", "Heparintherapie", "moeglichst", "auf", "5", "Tage", "zu", "begrenzen", ",", "z.", "B.", "durch", "fruehzeitige", "Einleitung", "einer", "oralen", "Antikoagulation", "mit", "Phen", "-", "procoumon", "(", "Marcumar", ")", ".", "Nach", "Diagnose", "einer", "HIT", "Typ", "II", "sollte", "fuer", "die", "betroffenen", "Patienten", "ein", "Notfallausweis", "ausgestellt", "werden", ".", "Diese", "Pa", "-", "tienten", "sollten", "ebenfalls", "keine", "Antithrombin", "-", "III-", "oder", "Prothrombinpraeparate", "erhalten", ",", "da", "diesen", "in", "zum", "Teil", "hohen", "Konzentrationen", "Heparin", "zugesetzt", "ist", "." ]	[ "umlsterm" ]
interleukin-2 is a Protein, interleukin-2 is a Protein, IL-2 is a Protein, CD4 is a Protein, IL-2 is a Protein, IL-2 is a Protein, NF - AT binding sites is a Entity, CD4 is a Protein, IL-2 is a Protein, CD4 is a Protein	8325322_task0	Sentence: Occurrence of a silencer of the interleukin-2 gene in naive but not in memory resting T helper lymphocytes. In the immune system the first activation of a naive T cell by antigen is a key step in the shaping of the peripheral T cell specificity repertoire and maintenance of self-tolerance. In the present study, analysis of the interleukin-2 (IL-2) gene activation shows that naive human helper T cells (cord blood CD4+ T cells, adult CD4+CD45RO- T cells) regulate IL-2 transcription by a mechanism involving both a silencer and an activator acting on the purine-rich IL-2 promoter elements (NF-AT binding sites). By contrast, memory cells, either in vitro activated helper T cells reverting to a resting state, or CD4+ T (memory) clones, or CD4+CD45RO+ T cells isolated ex vivo, no longer have a silencer. Their IL-2 transcription seems to be controlled solely by the transition from inactive to active functional state of a positive transcription factor binding to these promoter elements as well as its cytoplasmic or nuclear location: in resting memory T cells the activator is located in the cytoplasm and is inactive, whereas in stimulated cells it is functional in promoting transcription and now resides in the nucleus. Thus, the regulation of the gene coding for the main T cell growth factor changes irreversibly after the first encounter of T cells with antigen. It is most likely that the presence of a silencer contributes to the more stringent activation requirements of naive CD4+ T cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O" ]	Occurrence of a silencer of the interleukin-2 gene in naive but not in memory resting T helper lymphocytes. In the immune system the first activation of a naive T cell by antigen is a key step in the shaping of the peripheral T cell specificity repertoire and maintenance of self-tolerance. In the present study, analysis of the interleukin-2 (IL-2) gene activation shows that naive human helper T cells (cord blood CD4+ T cells, adult CD4+CD45RO- T cells) regulate IL-2 transcription by a mechanism involving both a silencer and an activator acting on the purine-rich IL-2 promoter elements (NF-AT binding sites). By contrast, memory cells, either in vitro activated helper T cells reverting to a resting state, or CD4+ T (memory) clones, or CD4+CD45RO+ T cells isolated ex vivo, no longer have a silencer. Their IL-2 transcription seems to be controlled solely by the transition from inactive to active functional state of a positive transcription factor binding to these promoter elements as well as its cytoplasmic or nuclear location: in resting memory T cells the activator is located in the cytoplasm and is inactive, whereas in stimulated cells it is functional in promoting transcription and now resides in the nucleus. Thus, the regulation of the gene coding for the main T cell growth factor changes irreversibly after the first encounter of T cells with antigen. It is most likely that the presence of a silencer contributes to the more stringent activation requirements of naive CD4+ T cells.	[ "Occurrence", "of", "a", "silencer", "of", "the", "interleukin-2", "gene", "in", "naive", "but", "not", "in", "memory", "resting", "T", "helper", "lymphocytes", ".", "\n", "In", "the", "immune", "system", "the", "first", "activation", "of", "a", "naive", "T", "cell", "by", "antigen", "is", "a", "key", "step", "in", "the", "shaping", "of", "the", "peripheral", "T", "cell", "specificity", "repertoire", "and", "maintenance", "of", "self", "-", "tolerance", ".", "In", "the", "present", "study", ",", "analysis", "of", "the", "interleukin-2", "(", "IL-2", ")", "gene", "activation", "shows", "that", "naive", "human", "helper", "T", "cells", "(", "cord", "blood", "CD4", "+", "T", "cells", ",", "adult", "CD4+CD45RO-", "T", "cells", ")", "regulate", "IL-2", "transcription", "by", "a", "mechanism", "involving", "both", "a", "silencer", "and", "an", "activator", "acting", "on", "the", "purine", "-", "rich", "IL-2", "promoter", "elements", "(", "NF", "-", "AT", "binding", "sites", ")", ".", "By", "contrast", ",", "memory", "cells", ",", "either", "in", "vitro", "activated", "helper", "T", "cells", "reverting", "to", "a", "resting", "state", ",", "or", "CD4", "+", "T", "(", "memory", ")", "clones", ",", "or", "CD4+CD45RO+", "T", "cells", "isolated", "ex", "vivo", ",", "no", "longer", "have", "a", "silencer", ".", "Their", "IL-2", "transcription", "seems", "to", "be", "controlled", "solely", "by", "the", "transition", "from", "inactive", "to", "active", "functional", "state", "of", "a", "positive", "transcription", "factor", "binding", "to", "these", "promoter", "elements", "as", "well", "as", "its", "cytoplasmic", "or", "nuclear", "location", ":", "in", "resting", "memory", "T", "cells", "the", "activator", "is", "located", "in", "the", "cytoplasm", "and", "is", "inactive", ",", "whereas", "in", "stimulated", "cells", "it", "is", "functional", "in", "promoting", "transcription", "and", "now", "resides", "in", "the", "nucleus", ".", "Thus", ",", "the", "regulation", "of", "the", "gene", "coding", "for", "the", "main", "T", "cell", "growth", "factor", "changes", "irreversibly", "after", "the", "first", "encounter", "of", "T", "cells", "with", "antigen", ".", "It", "is", "most", "likely", "that", "the", "presence", "of", "a", "silencer", "contributes", "to", "the", "more", "stringent", "activation", "requirements", "of", "naive", "CD4", "+", "T", "cells", "." ]	[ "Entity", "Protein" ]
interleukin-2 is a Protein, interleukin-2 is a Protein, IL-2 is a Protein, CD4 is a Protein, IL-2 is a Protein, IL-2 is a Protein, NF - AT binding sites is a Entity, CD4 is a Protein, IL-2 is a Protein, CD4 is a Protein	8325322_task1	Sentence: Occurrence of a silencer of the interleukin-2 gene in naive but not in memory resting T helper lymphocytes. In the immune system the first activation of a naive T cell by antigen is a key step in the shaping of the peripheral T cell specificity repertoire and maintenance of self-tolerance. In the present study, analysis of the interleukin-2 (IL-2) gene activation shows that naive human helper T cells (cord blood CD4+ T cells, adult CD4+CD45RO- T cells) regulate IL-2 transcription by a mechanism involving both a silencer and an activator acting on the purine-rich IL-2 promoter elements (NF-AT binding sites). By contrast, memory cells, either in vitro activated helper T cells reverting to a resting state, or CD4+ T (memory) clones, or CD4+CD45RO+ T cells isolated ex vivo, no longer have a silencer. Their IL-2 transcription seems to be controlled solely by the transition from inactive to active functional state of a positive transcription factor binding to these promoter elements as well as its cytoplasmic or nuclear location: in resting memory T cells the activator is located in the cytoplasm and is inactive, whereas in stimulated cells it is functional in promoting transcription and now resides in the nucleus. Thus, the regulation of the gene coding for the main T cell growth factor changes irreversibly after the first encounter of T cells with antigen. It is most likely that the presence of a silencer contributes to the more stringent activation requirements of naive CD4+ T cells. Instructions: please typing these entity words according to sentence: interleukin-2, interleukin-2, IL-2, CD4, IL-2, IL-2, NF - AT binding sites, CD4, IL-2, CD4 Options: Entity, Protein	[ "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O" ]	Occurrence of a silencer of the interleukin-2 gene in naive but not in memory resting T helper lymphocytes. In the immune system the first activation of a naive T cell by antigen is a key step in the shaping of the peripheral T cell specificity repertoire and maintenance of self-tolerance. In the present study, analysis of the interleukin-2 (IL-2) gene activation shows that naive human helper T cells (cord blood CD4+ T cells, adult CD4+CD45RO- T cells) regulate IL-2 transcription by a mechanism involving both a silencer and an activator acting on the purine-rich IL-2 promoter elements (NF-AT binding sites). By contrast, memory cells, either in vitro activated helper T cells reverting to a resting state, or CD4+ T (memory) clones, or CD4+CD45RO+ T cells isolated ex vivo, no longer have a silencer. Their IL-2 transcription seems to be controlled solely by the transition from inactive to active functional state of a positive transcription factor binding to these promoter elements as well as its cytoplasmic or nuclear location: in resting memory T cells the activator is located in the cytoplasm and is inactive, whereas in stimulated cells it is functional in promoting transcription and now resides in the nucleus. Thus, the regulation of the gene coding for the main T cell growth factor changes irreversibly after the first encounter of T cells with antigen. It is most likely that the presence of a silencer contributes to the more stringent activation requirements of naive CD4+ T cells.	[ "Occurrence", "of", "a", "silencer", "of", "the", "interleukin-2", "gene", "in", "naive", "but", "not", "in", "memory", "resting", "T", "helper", "lymphocytes", ".", "\n", "In", "the", "immune", "system", "the", "first", "activation", "of", "a", "naive", "T", "cell", "by", "antigen", "is", "a", "key", "step", "in", "the", "shaping", "of", "the", "peripheral", "T", "cell", "specificity", "repertoire", "and", "maintenance", "of", "self", "-", "tolerance", ".", "In", "the", "present", "study", ",", "analysis", "of", "the", "interleukin-2", "(", "IL-2", ")", "gene", "activation", "shows", "that", "naive", "human", "helper", "T", "cells", "(", "cord", "blood", "CD4", "+", "T", "cells", ",", "adult", "CD4+CD45RO-", "T", "cells", ")", "regulate", "IL-2", "transcription", "by", "a", "mechanism", "involving", "both", "a", "silencer", "and", "an", "activator", "acting", "on", "the", "purine", "-", "rich", "IL-2", "promoter", "elements", "(", "NF", "-", "AT", "binding", "sites", ")", ".", "By", "contrast", ",", "memory", "cells", ",", "either", "in", "vitro", "activated", "helper", "T", "cells", "reverting", "to", "a", "resting", "state", ",", "or", "CD4", "+", "T", "(", "memory", ")", "clones", ",", "or", "CD4+CD45RO+", "T", "cells", "isolated", "ex", "vivo", ",", "no", "longer", "have", "a", "silencer", ".", "Their", "IL-2", "transcription", "seems", "to", "be", "controlled", "solely", "by", "the", "transition", "from", "inactive", "to", "active", "functional", "state", "of", "a", "positive", "transcription", "factor", "binding", "to", "these", "promoter", "elements", "as", "well", "as", "its", "cytoplasmic", "or", "nuclear", "location", ":", "in", "resting", "memory", "T", "cells", "the", "activator", "is", "located", "in", "the", "cytoplasm", "and", "is", "inactive", ",", "whereas", "in", "stimulated", "cells", "it", "is", "functional", "in", "promoting", "transcription", "and", "now", "resides", "in", "the", "nucleus", ".", "Thus", ",", "the", "regulation", "of", "the", "gene", "coding", "for", "the", "main", "T", "cell", "growth", "factor", "changes", "irreversibly", "after", "the", "first", "encounter", "of", "T", "cells", "with", "antigen", ".", "It", "is", "most", "likely", "that", "the", "presence", "of", "a", "silencer", "contributes", "to", "the", "more", "stringent", "activation", "requirements", "of", "naive", "CD4", "+", "T", "cells", "." ]	[ "Entity", "Protein" ]
interleukin-2, interleukin-2, IL-2, CD4, IL-2, IL-2, NF - AT binding sites, CD4, IL-2, CD4	8325322_task2	Sentence: Occurrence of a silencer of the interleukin-2 gene in naive but not in memory resting T helper lymphocytes. In the immune system the first activation of a naive T cell by antigen is a key step in the shaping of the peripheral T cell specificity repertoire and maintenance of self-tolerance. In the present study, analysis of the interleukin-2 (IL-2) gene activation shows that naive human helper T cells (cord blood CD4+ T cells, adult CD4+CD45RO- T cells) regulate IL-2 transcription by a mechanism involving both a silencer and an activator acting on the purine-rich IL-2 promoter elements (NF-AT binding sites). By contrast, memory cells, either in vitro activated helper T cells reverting to a resting state, or CD4+ T (memory) clones, or CD4+CD45RO+ T cells isolated ex vivo, no longer have a silencer. Their IL-2 transcription seems to be controlled solely by the transition from inactive to active functional state of a positive transcription factor binding to these promoter elements as well as its cytoplasmic or nuclear location: in resting memory T cells the activator is located in the cytoplasm and is inactive, whereas in stimulated cells it is functional in promoting transcription and now resides in the nucleus. Thus, the regulation of the gene coding for the main T cell growth factor changes irreversibly after the first encounter of T cells with antigen. It is most likely that the presence of a silencer contributes to the more stringent activation requirements of naive CD4+ T cells. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O" ]	Occurrence of a silencer of the interleukin-2 gene in naive but not in memory resting T helper lymphocytes. In the immune system the first activation of a naive T cell by antigen is a key step in the shaping of the peripheral T cell specificity repertoire and maintenance of self-tolerance. In the present study, analysis of the interleukin-2 (IL-2) gene activation shows that naive human helper T cells (cord blood CD4+ T cells, adult CD4+CD45RO- T cells) regulate IL-2 transcription by a mechanism involving both a silencer and an activator acting on the purine-rich IL-2 promoter elements (NF-AT binding sites). By contrast, memory cells, either in vitro activated helper T cells reverting to a resting state, or CD4+ T (memory) clones, or CD4+CD45RO+ T cells isolated ex vivo, no longer have a silencer. Their IL-2 transcription seems to be controlled solely by the transition from inactive to active functional state of a positive transcription factor binding to these promoter elements as well as its cytoplasmic or nuclear location: in resting memory T cells the activator is located in the cytoplasm and is inactive, whereas in stimulated cells it is functional in promoting transcription and now resides in the nucleus. Thus, the regulation of the gene coding for the main T cell growth factor changes irreversibly after the first encounter of T cells with antigen. It is most likely that the presence of a silencer contributes to the more stringent activation requirements of naive CD4+ T cells.	[ "Occurrence", "of", "a", "silencer", "of", "the", "interleukin-2", "gene", "in", "naive", "but", "not", "in", "memory", "resting", "T", "helper", "lymphocytes", ".", "\n", "In", "the", "immune", "system", "the", "first", "activation", "of", "a", "naive", "T", "cell", "by", "antigen", "is", "a", "key", "step", "in", "the", "shaping", "of", "the", "peripheral", "T", "cell", "specificity", "repertoire", "and", "maintenance", "of", "self", "-", "tolerance", ".", "In", "the", "present", "study", ",", "analysis", "of", "the", "interleukin-2", "(", "IL-2", ")", "gene", "activation", "shows", "that", "naive", "human", "helper", "T", "cells", "(", "cord", "blood", "CD4", "+", "T", "cells", ",", "adult", "CD4+CD45RO-", "T", "cells", ")", "regulate", "IL-2", "transcription", "by", "a", "mechanism", "involving", "both", "a", "silencer", "and", "an", "activator", "acting", "on", "the", "purine", "-", "rich", "IL-2", "promoter", "elements", "(", "NF", "-", "AT", "binding", "sites", ")", ".", "By", "contrast", ",", "memory", "cells", ",", "either", "in", "vitro", "activated", "helper", "T", "cells", "reverting", "to", "a", "resting", "state", ",", "or", "CD4", "+", "T", "(", "memory", ")", "clones", ",", "or", "CD4+CD45RO+", "T", "cells", "isolated", "ex", "vivo", ",", "no", "longer", "have", "a", "silencer", ".", "Their", "IL-2", "transcription", "seems", "to", "be", "controlled", "solely", "by", "the", "transition", "from", "inactive", "to", "active", "functional", "state", "of", "a", "positive", "transcription", "factor", "binding", "to", "these", "promoter", "elements", "as", "well", "as", "its", "cytoplasmic", "or", "nuclear", "location", ":", "in", "resting", "memory", "T", "cells", "the", "activator", "is", "located", "in", "the", "cytoplasm", "and", "is", "inactive", ",", "whereas", "in", "stimulated", "cells", "it", "is", "functional", "in", "promoting", "transcription", "and", "now", "resides", "in", "the", "nucleus", ".", "Thus", ",", "the", "regulation", "of", "the", "gene", "coding", "for", "the", "main", "T", "cell", "growth", "factor", "changes", "irreversibly", "after", "the", "first", "encounter", "of", "T", "cells", "with", "antigen", ".", "It", "is", "most", "likely", "that", "the", "presence", "of", "a", "silencer", "contributes", "to", "the", "more", "stringent", "activation", "requirements", "of", "naive", "CD4", "+", "T", "cells", "." ]	[ "Entity", "Protein" ]
ursodeoxycholic acid is a Intervention_Pharmacological, serum liver enzymes is a Outcome_Physical, hepatitis C virus - related chronic liver disease is a Participant_Condition, ursodeoxycholic acid ( UDCA ) is a Intervention_Pharmacological, serum liver enzyme levels [ alanine aminotransferase ( ALT ) and gamma - glutamyl transferase ( GGT ) ] is a Outcome_Physical, 101 is a Participant_Sample-size, no treatment is a Intervention_Control, serum ALT and GGT levels is a Outcome_Physical, ALT values is a Outcome_Physical, mean ALT and GGT levels is a Outcome_Physical, interferon therapy is a Intervention_Pharmacological	82019_task0	Sentence: Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease . OBJECTIVE To study the effect of ursodeoxycholic acid ( UDCA ) on serum liver enzyme levels [ alanine aminotransferase ( ALT ) and gamma-glutamyl transferase ( GGT ) ] in 101 patients with hepatitis C virus-related chronic liver disease . METHODS Forty-nine patients were assigned to receive UDCA ( 450 mg/day ) over a period of 6 months and 52 to receive no treatment . RESULTS In the UDCA group , serum ALT and GGT levels significantly improved . ALT values decreased from pre-treatment levels of 157.0 +/- 62.6 IU/l to 82.5 +/- 46.4 IU/l ( P < 0.05 ) , and GGT fell from 141.3 +/- 86.2 IU/l to 66.0 +/- 49.5 IU/l ( P < 0.001 ) . No significant change occurred in the mean ALT and GGT levels in the control group . CONCLUSION Although our encouraging preliminary results must be validated by double-blind histological trials , UDCA may be an alternative treatment for patients who fail to respond to interferon therapy . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Sample-size	[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O" ]	Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease . OBJECTIVE To study the effect of ursodeoxycholic acid ( UDCA ) on serum liver enzyme levels [ alanine aminotransferase ( ALT ) and gamma-glutamyl transferase ( GGT ) ] in 101 patients with hepatitis C virus-related chronic liver disease . METHODS Forty-nine patients were assigned to receive UDCA ( 450 mg/day ) over a period of 6 months and 52 to receive no treatment . RESULTS In the UDCA group , serum ALT and GGT levels significantly improved . ALT values decreased from pre-treatment levels of 157.0 +/- 62.6 IU/l to 82.5 +/- 46.4 IU/l ( P < 0.05 ) , and GGT fell from 141.3 +/- 86.2 IU/l to 66.0 +/- 49.5 IU/l ( P < 0.001 ) . No significant change occurred in the mean ALT and GGT levels in the control group . CONCLUSION Although our encouraging preliminary results must be validated by double-blind histological trials , UDCA may be an alternative treatment for patients who fail to respond to interferon therapy .	[ "Effects", "of", "ursodeoxycholic", "acid", "on", "serum", "liver", "enzymes", "in", "patients", "with", "hepatitis", "C", "virus", "-", "related", "chronic", "liver", "disease", ".", "OBJECTIVE", "To", "study", "the", "effect", "of", "ursodeoxycholic", "acid", "(", "UDCA", ")", "on", "serum", "liver", "enzyme", "levels", "[", "alanine", "aminotransferase", "(", "ALT", ")", "and", "gamma", "-", "glutamyl", "transferase", "(", "GGT", ")", "]", "in", "101", "patients", "with", "hepatitis", "C", "virus", "-", "related", "chronic", "liver", "disease", ".", "METHODS", "Forty", "-", "nine", "patients", "were", "assigned", "to", "receive", "UDCA", "(", "450", "mg", "/", "day", ")", "over", "a", "period", "of", "6", "months", "and", "52", "to", "receive", "no", "treatment", ".", "RESULTS", "In", "the", "UDCA", "group", ",", "serum", "ALT", "and", "GGT", "levels", "significantly", "improved", ".", "ALT", "values", "decreased", "from", "pre", "-", "treatment", "levels", "of", "157.0", "+", "/-", "62.6", "IU", "/", "l", "to", "82.5", "+", "/-", "46.4", "IU", "/", "l", "(", "P", "<", "0.05", ")", ",", "and", "GGT", "fell", "from", "141.3", "+", "/-", "86.2", "IU", "/", "l", "to", "66.0", "+", "/-", "49.5", "IU", "/", "l", "(", "P", "<", "0.001", ")", ".", "No", "significant", "change", "occurred", "in", "the", "mean", "ALT", "and", "GGT", "levels", "in", "the", "control", "group", ".", "CONCLUSION", "Although", "our", "encouraging", "preliminary", "results", "must", "be", "validated", "by", "double", "-", "blind", "histological", "trials", ",", "UDCA", "may", "be", "an", "alternative", "treatment", "for", "patients", "who", "fail", "to", "respond", "to", "interferon", "therapy", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size" ]
ursodeoxycholic acid is a Intervention_Pharmacological, serum liver enzymes is a Outcome_Physical, hepatitis C virus - related chronic liver disease is a Participant_Condition, ursodeoxycholic acid ( UDCA ) is a Intervention_Pharmacological, serum liver enzyme levels [ alanine aminotransferase ( ALT ) and gamma - glutamyl transferase ( GGT ) ] is a Outcome_Physical, 101 is a Participant_Sample-size, no treatment is a Intervention_Control, serum ALT and GGT levels is a Outcome_Physical, ALT values is a Outcome_Physical, mean ALT and GGT levels is a Outcome_Physical, interferon therapy is a Intervention_Pharmacological	82019_task1	Sentence: Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease . OBJECTIVE To study the effect of ursodeoxycholic acid ( UDCA ) on serum liver enzyme levels [ alanine aminotransferase ( ALT ) and gamma-glutamyl transferase ( GGT ) ] in 101 patients with hepatitis C virus-related chronic liver disease . METHODS Forty-nine patients were assigned to receive UDCA ( 450 mg/day ) over a period of 6 months and 52 to receive no treatment . RESULTS In the UDCA group , serum ALT and GGT levels significantly improved . ALT values decreased from pre-treatment levels of 157.0 +/- 62.6 IU/l to 82.5 +/- 46.4 IU/l ( P < 0.05 ) , and GGT fell from 141.3 +/- 86.2 IU/l to 66.0 +/- 49.5 IU/l ( P < 0.001 ) . No significant change occurred in the mean ALT and GGT levels in the control group . CONCLUSION Although our encouraging preliminary results must be validated by double-blind histological trials , UDCA may be an alternative treatment for patients who fail to respond to interferon therapy . Instructions: please typing these entity words according to sentence: ursodeoxycholic acid, serum liver enzymes, hepatitis C virus - related chronic liver disease, ursodeoxycholic acid ( UDCA ), serum liver enzyme levels [ alanine aminotransferase ( ALT ) and gamma - glutamyl transferase ( GGT ) ], 101, no treatment, serum ALT and GGT levels, ALT values, mean ALT and GGT levels, interferon therapy Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Sample-size	[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O" ]	Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease . OBJECTIVE To study the effect of ursodeoxycholic acid ( UDCA ) on serum liver enzyme levels [ alanine aminotransferase ( ALT ) and gamma-glutamyl transferase ( GGT ) ] in 101 patients with hepatitis C virus-related chronic liver disease . METHODS Forty-nine patients were assigned to receive UDCA ( 450 mg/day ) over a period of 6 months and 52 to receive no treatment . RESULTS In the UDCA group , serum ALT and GGT levels significantly improved . ALT values decreased from pre-treatment levels of 157.0 +/- 62.6 IU/l to 82.5 +/- 46.4 IU/l ( P < 0.05 ) , and GGT fell from 141.3 +/- 86.2 IU/l to 66.0 +/- 49.5 IU/l ( P < 0.001 ) . No significant change occurred in the mean ALT and GGT levels in the control group . CONCLUSION Although our encouraging preliminary results must be validated by double-blind histological trials , UDCA may be an alternative treatment for patients who fail to respond to interferon therapy .	[ "Effects", "of", "ursodeoxycholic", "acid", "on", "serum", "liver", "enzymes", "in", "patients", "with", "hepatitis", "C", "virus", "-", "related", "chronic", "liver", "disease", ".", "OBJECTIVE", "To", "study", "the", "effect", "of", "ursodeoxycholic", "acid", "(", "UDCA", ")", "on", "serum", "liver", "enzyme", "levels", "[", "alanine", "aminotransferase", "(", "ALT", ")", "and", "gamma", "-", "glutamyl", "transferase", "(", "GGT", ")", "]", "in", "101", "patients", "with", "hepatitis", "C", "virus", "-", "related", "chronic", "liver", "disease", ".", "METHODS", "Forty", "-", "nine", "patients", "were", "assigned", "to", "receive", "UDCA", "(", "450", "mg", "/", "day", ")", "over", "a", "period", "of", "6", "months", "and", "52", "to", "receive", "no", "treatment", ".", "RESULTS", "In", "the", "UDCA", "group", ",", "serum", "ALT", "and", "GGT", "levels", "significantly", "improved", ".", "ALT", "values", "decreased", "from", "pre", "-", "treatment", "levels", "of", "157.0", "+", "/-", "62.6", "IU", "/", "l", "to", "82.5", "+", "/-", "46.4", "IU", "/", "l", "(", "P", "<", "0.05", ")", ",", "and", "GGT", "fell", "from", "141.3", "+", "/-", "86.2", "IU", "/", "l", "to", "66.0", "+", "/-", "49.5", "IU", "/", "l", "(", "P", "<", "0.001", ")", ".", "No", "significant", "change", "occurred", "in", "the", "mean", "ALT", "and", "GGT", "levels", "in", "the", "control", "group", ".", "CONCLUSION", "Although", "our", "encouraging", "preliminary", "results", "must", "be", "validated", "by", "double", "-", "blind", "histological", "trials", ",", "UDCA", "may", "be", "an", "alternative", "treatment", "for", "patients", "who", "fail", "to", "respond", "to", "interferon", "therapy", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size" ]
ursodeoxycholic acid, serum liver enzymes, hepatitis C virus - related chronic liver disease, ursodeoxycholic acid ( UDCA ), serum liver enzyme levels [ alanine aminotransferase ( ALT ) and gamma - glutamyl transferase ( GGT ) ], 101, no treatment, serum ALT and GGT levels, ALT values, mean ALT and GGT levels, interferon therapy	82019_task2	Sentence: Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease . OBJECTIVE To study the effect of ursodeoxycholic acid ( UDCA ) on serum liver enzyme levels [ alanine aminotransferase ( ALT ) and gamma-glutamyl transferase ( GGT ) ] in 101 patients with hepatitis C virus-related chronic liver disease . METHODS Forty-nine patients were assigned to receive UDCA ( 450 mg/day ) over a period of 6 months and 52 to receive no treatment . RESULTS In the UDCA group , serum ALT and GGT levels significantly improved . ALT values decreased from pre-treatment levels of 157.0 +/- 62.6 IU/l to 82.5 +/- 46.4 IU/l ( P < 0.05 ) , and GGT fell from 141.3 +/- 86.2 IU/l to 66.0 +/- 49.5 IU/l ( P < 0.001 ) . No significant change occurred in the mean ALT and GGT levels in the control group . CONCLUSION Although our encouraging preliminary results must be validated by double-blind histological trials , UDCA may be an alternative treatment for patients who fail to respond to interferon therapy . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O" ]	Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease . OBJECTIVE To study the effect of ursodeoxycholic acid ( UDCA ) on serum liver enzyme levels [ alanine aminotransferase ( ALT ) and gamma-glutamyl transferase ( GGT ) ] in 101 patients with hepatitis C virus-related chronic liver disease . METHODS Forty-nine patients were assigned to receive UDCA ( 450 mg/day ) over a period of 6 months and 52 to receive no treatment . RESULTS In the UDCA group , serum ALT and GGT levels significantly improved . ALT values decreased from pre-treatment levels of 157.0 +/- 62.6 IU/l to 82.5 +/- 46.4 IU/l ( P < 0.05 ) , and GGT fell from 141.3 +/- 86.2 IU/l to 66.0 +/- 49.5 IU/l ( P < 0.001 ) . No significant change occurred in the mean ALT and GGT levels in the control group . CONCLUSION Although our encouraging preliminary results must be validated by double-blind histological trials , UDCA may be an alternative treatment for patients who fail to respond to interferon therapy .	[ "Effects", "of", "ursodeoxycholic", "acid", "on", "serum", "liver", "enzymes", "in", "patients", "with", "hepatitis", "C", "virus", "-", "related", "chronic", "liver", "disease", ".", "OBJECTIVE", "To", "study", "the", "effect", "of", "ursodeoxycholic", "acid", "(", "UDCA", ")", "on", "serum", "liver", "enzyme", "levels", "[", "alanine", "aminotransferase", "(", "ALT", ")", "and", "gamma", "-", "glutamyl", "transferase", "(", "GGT", ")", "]", "in", "101", "patients", "with", "hepatitis", "C", "virus", "-", "related", "chronic", "liver", "disease", ".", "METHODS", "Forty", "-", "nine", "patients", "were", "assigned", "to", "receive", "UDCA", "(", "450", "mg", "/", "day", ")", "over", "a", "period", "of", "6", "months", "and", "52", "to", "receive", "no", "treatment", ".", "RESULTS", "In", "the", "UDCA", "group", ",", "serum", "ALT", "and", "GGT", "levels", "significantly", "improved", ".", "ALT", "values", "decreased", "from", "pre", "-", "treatment", "levels", "of", "157.0", "+", "/-", "62.6", "IU", "/", "l", "to", "82.5", "+", "/-", "46.4", "IU", "/", "l", "(", "P", "<", "0.05", ")", ",", "and", "GGT", "fell", "from", "141.3", "+", "/-", "86.2", "IU", "/", "l", "to", "66.0", "+", "/-", "49.5", "IU", "/", "l", "(", "P", "<", "0.001", ")", ".", "No", "significant", "change", "occurred", "in", "the", "mean", "ALT", "and", "GGT", "levels", "in", "the", "control", "group", ".", "CONCLUSION", "Although", "our", "encouraging", "preliminary", "results", "must", "be", "validated", "by", "double", "-", "blind", "histological", "trials", ",", "UDCA", "may", "be", "an", "alternative", "treatment", "for", "patients", "who", "fail", "to", "respond", "to", "interferon", "therapy", "." ]	[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size" ]
study design is an umlsterm, radiology is an umlsterm	DerRadiologe.80380241.eng.abstr_task0	Sentence: Purpose : To review important aspects of study design in clinical radiology and to introduce the reader to the requirements of Good Clinical Practice ( GCP ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Purpose : To review important aspects of study design in clinical radiology and to introduce the reader to the requirements of Good Clinical Practice ( GCP ) .	[ "Purpose", ":", "To", "review", "important", "aspects", "of", "study", "design", "in", "clinical", "radiology", "and", "to", "introduce", "the", "reader", "to", "the", "requirements", "of", "Good", "Clinical", "Practice", "(", "GCP", ")", "." ]	[ "umlsterm" ]
study design is an umlsterm, radiology is an umlsterm	DerRadiologe.80380241.eng.abstr_task1	Sentence: Purpose : To review important aspects of study design in clinical radiology and to introduce the reader to the requirements of Good Clinical Practice ( GCP ) . Instructions: please typing these entity words according to sentence: study design, radiology Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Purpose : To review important aspects of study design in clinical radiology and to introduce the reader to the requirements of Good Clinical Practice ( GCP ) .	[ "Purpose", ":", "To", "review", "important", "aspects", "of", "study", "design", "in", "clinical", "radiology", "and", "to", "introduce", "the", "reader", "to", "the", "requirements", "of", "Good", "Clinical", "Practice", "(", "GCP", ")", "." ]	[ "umlsterm" ]
study design, radiology	DerRadiologe.80380241.eng.abstr_task2	Sentence: Purpose : To review important aspects of study design in clinical radiology and to introduce the reader to the requirements of Good Clinical Practice ( GCP ) . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Purpose : To review important aspects of study design in clinical radiology and to introduce the reader to the requirements of Good Clinical Practice ( GCP ) .	[ "Purpose", ":", "To", "review", "important", "aspects", "of", "study", "design", "in", "clinical", "radiology", "and", "to", "introduce", "the", "reader", "to", "the", "requirements", "of", "Good", "Clinical", "Practice", "(", "GCP", ")", "." ]	[ "umlsterm" ]
androgen is a CHEMICAL, androgen receptor is a GENE-Y, AR is a GENE-Y, androgen is a CHEMICAL, androgen is a CHEMICAL, 17alpha - methyltestosterone is a CHEMICAL, 17alpha - MT is a CHEMICAL, vinclozolin is a CHEMICAL, linuron is a CHEMICAL, AR is a GENE-Y, androgen is a CHEMICAL, 17alpha - methyldihydrotestosterone is a CHEMICAL, MDHT is a CHEMICAL, levonorgestrel is a CHEMICAL, norethynodrel is a CHEMICAL, progesterone is a CHEMICAL, o , p'-DDT is a CHEMICAL, dibutylphthalate is a CHEMICAL, DBP is a CHEMICAL, anti - androgen is a CHEMICAL, flutamide is a CHEMICAL, prochloraz is a CHEMICAL, o , p'-DDT is a CHEMICAL, progesterone is a CHEMICAL, norethynodrel is a CHEMICAL, DBP is a CHEMICAL, lactate dehydrogenase is a GENE-N, 17alpha - MT is a CHEMICAL, vinclozolin is a CHEMICAL, o , p'-DDT is a CHEMICAL, DBP is a CHEMICAL, MDHT is a CHEMICAL, 17alpha - MT is a CHEMICAL, levonorgestrel is a CHEMICAL, norethynodrel is a CHEMICAL, Progesterone is a CHEMICAL, DBP is a CHEMICAL, norethynodrel is a CHEMICAL, Progesterone is a CHEMICAL, AR is a GENE-Y	4671_task0	Sentence: Screening for (anti)androgenic properties using a standard operation protocol based on the human stably transfected androgen sensitive PALM cell line. First steps towards validation. Despite more than a decade of research in the field of endocrine active compounds targeting the androgen receptor (AR), and although suitable cell lines can be obtained, no validated human stably transfected androgen sensitive transactivation assay is available. Bayer Schering Pharma (BSP) and the Flemish Institute for Technological Research (VITO), partners within the EU-sponsored 6th framework project ReProTect, made first steps towards such a validation. A standard operation protocol (SOP) developed at BSP based on the androgen sensitive PALM cell line was transferred to VITO and its performance and transferability were thoroughly studied. The investigation followed a generic protocol prepared for all reporter gene assays evaluated within ReProTect, and in both laboratories at least three independent experiments were performed. The highest concentration to be tested was limited to 10 microM, if needed. A few compounds, 17alpha-methyltestosterone (17alpha-MT), vinclozolin and linuron, were studied using a real world scenario, i.e., assuming that their interaction with the AR was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening. All other compounds were tested according to the generic protocol: Compounds screened for agonism were the reference androgen 17alpha-methyldihydrotestosterone (MDHT), levonorgestrel, norethynodrel, progesterone, o,p'-DDT, and dibutylphthalate (DBP), while compounds screened for antagonism were the reference anti-androgen flutamide, prochloraz, o,p'-DDT, progesterone, norethynodrel, and DBP. Cytotoxicity was assessed in parallel as lactate dehydrogenase release. The prescreen classified 17alpha-MT as androgenic, vinclozolin and linuron as anti-androgenic and compounds were tested accordingly. In the absence of cytotoxicity, appropriate androgenic properties of reference and test compounds were detected by both laboratories, o,p'-DDT and DBP had no androgenic activity. Across the two laboratories EC(50)-values for MDHT, 17alpha-MT, and levonorgestrel varied by not more than a factor of 3.4, for norethynodrel by a factor of 9.7. Progesterone effects could not fully be evaluated, as frequently concentration response curves were incomplete. In the absence of cytotoxicity anti-androgenic properties of reference and test compounds were also detected in both laboratories. DBP, the putative negative reference compound, was inactive, norethynodrel rather showed agonistic properties. Progesterone was an antagonist at low concentrations, but agonistic properties were observed in one laboratory at high concentrations. Since the highest test concentration was limited to 10 microM, for some compounds no complete concentration response curves were obtained and estimation of EC(50)-values was less robust. Our data demonstrated that the SOP was transferable, and that the assay was able to rank compounds with strong, weak, and without affinity for the AR and to discriminate agonists and antagonists. The sensitivity of the assay could be improved further, if the limit of solubility or beginning cytotoxicity was chosen as the highest test concentration. The assay avoids the use of tissues from laboratory animals, and thus contributes to the 3R concept. Furthermore, it could be adjusted to an intermediate/high throughput format. On the whole, this PALM assay is a promising candidate for further validation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Screening for (anti)androgenic properties using a standard operation protocol based on the human stably transfected androgen sensitive PALM cell line. First steps towards validation. Despite more than a decade of research in the field of endocrine active compounds targeting the androgen receptor (AR), and although suitable cell lines can be obtained, no validated human stably transfected androgen sensitive transactivation assay is available. Bayer Schering Pharma (BSP) and the Flemish Institute for Technological Research (VITO), partners within the EU-sponsored 6th framework project ReProTect, made first steps towards such a validation. A standard operation protocol (SOP) developed at BSP based on the androgen sensitive PALM cell line was transferred to VITO and its performance and transferability were thoroughly studied. The investigation followed a generic protocol prepared for all reporter gene assays evaluated within ReProTect, and in both laboratories at least three independent experiments were performed. The highest concentration to be tested was limited to 10 microM, if needed. A few compounds, 17alpha-methyltestosterone (17alpha-MT), vinclozolin and linuron, were studied using a real world scenario, i.e., assuming that their interaction with the AR was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening. All other compounds were tested according to the generic protocol: Compounds screened for agonism were the reference androgen 17alpha-methyldihydrotestosterone (MDHT), levonorgestrel, norethynodrel, progesterone, o,p'-DDT, and dibutylphthalate (DBP), while compounds screened for antagonism were the reference anti-androgen flutamide, prochloraz, o,p'-DDT, progesterone, norethynodrel, and DBP. Cytotoxicity was assessed in parallel as lactate dehydrogenase release. The prescreen classified 17alpha-MT as androgenic, vinclozolin and linuron as anti-androgenic and compounds were tested accordingly. In the absence of cytotoxicity, appropriate androgenic properties of reference and test compounds were detected by both laboratories, o,p'-DDT and DBP had no androgenic activity. Across the two laboratories EC(50)-values for MDHT, 17alpha-MT, and levonorgestrel varied by not more than a factor of 3.4, for norethynodrel by a factor of 9.7. Progesterone effects could not fully be evaluated, as frequently concentration response curves were incomplete. In the absence of cytotoxicity anti-androgenic properties of reference and test compounds were also detected in both laboratories. DBP, the putative negative reference compound, was inactive, norethynodrel rather showed agonistic properties. Progesterone was an antagonist at low concentrations, but agonistic properties were observed in one laboratory at high concentrations. Since the highest test concentration was limited to 10 microM, for some compounds no complete concentration response curves were obtained and estimation of EC(50)-values was less robust. Our data demonstrated that the SOP was transferable, and that the assay was able to rank compounds with strong, weak, and without affinity for the AR and to discriminate agonists and antagonists. The sensitivity of the assay could be improved further, if the limit of solubility or beginning cytotoxicity was chosen as the highest test concentration. The assay avoids the use of tissues from laboratory animals, and thus contributes to the 3R concept. Furthermore, it could be adjusted to an intermediate/high throughput format. On the whole, this PALM assay is a promising candidate for further validation.	[ "Screening", "for", "(", "anti)androgenic", "properties", "using", "a", "standard", "operation", "protocol", "based", "on", "the", "human", "stably", "transfected", "androgen", "sensitive", "PALM", "cell", "line", ".", "First", "steps", "towards", "validation", ".", "\n", "Despite", "more", "than", "a", "decade", "of", "research", "in", "the", "field", "of", "endocrine", "active", "compounds", "targeting", "the", "androgen", "receptor", "(", "AR", ")", ",", "and", "although", "suitable", "cell", "lines", "can", "be", "obtained", ",", "no", "validated", "human", "stably", "transfected", "androgen", "sensitive", "transactivation", "assay", "is", "available", ".", "Bayer", "Schering", "Pharma", "(", "BSP", ")", "and", "the", "Flemish", "Institute", "for", "Technological", "Research", "(", "VITO", ")", ",", "partners", "within", "the", "EU", "-", "sponsored", "6th", "framework", "project", "ReProTect", ",", "made", "first", "steps", "towards", "such", "a", "validation", ".", "A", "standard", "operation", "protocol", "(", "SOP", ")", "developed", "at", "BSP", "based", "on", "the", "androgen", "sensitive", "PALM", "cell", "line", "was", "transferred", "to", "VITO", "and", "its", "performance", "and", "transferability", "were", "thoroughly", "studied", ".", "The", "investigation", "followed", "a", "generic", "protocol", "prepared", "for", "all", "reporter", "gene", "assays", "evaluated", "within", "ReProTect", ",", "and", "in", "both", "laboratories", "at", "least", "three", "independent", "experiments", "were", "performed", ".", "The", "highest", "concentration", "to", "be", "tested", "was", "limited", "to", "10", "microM", ",", "if", "needed", ".", "A", "few", "compounds", ",", "17alpha", "-", "methyltestosterone", "(", "17alpha", "-", "MT", ")", ",", "vinclozolin", "and", "linuron", ",", "were", "studied", "using", "a", "real", "world", "scenario", ",", "i.e", ".", ",", "assuming", "that", "their", "interaction", "with", "the", "AR", "was", "not", "known", ":", "A", "prescreening", "for", "agonism", "and", "true", ",", "competitive", "antagonism", "was", "used", "to", "select", "conditions", "such", "as", "the", "appropriate", "mode", "of", "action", ",", "and", "the", "working", "range", "excluding", "cytotoxicity", "for", "the", "final", "screening", ".", "All", "other", "compounds", "were", "tested", "according", "to", "the", "generic", "protocol", ":", "Compounds", "screened", "for", "agonism", "were", "the", "reference", "androgen", "17alpha", "-", "methyldihydrotestosterone", "(", "MDHT", ")", ",", "levonorgestrel", ",", "norethynodrel", ",", "progesterone", ",", "o", ",", "p'-DDT", ",", "and", "dibutylphthalate", "(", "DBP", ")", ",", "while", "compounds", "screened", "for", "antagonism", "were", "the", "reference", "anti", "-", "androgen", "flutamide", ",", "prochloraz", ",", "o", ",", "p'-DDT", ",", "progesterone", ",", "norethynodrel", ",", "and", "DBP", ".", "Cytotoxicity", "was", "assessed", "in", "parallel", "as", "lactate", "dehydrogenase", "release", ".", "The", "prescreen", "classified", "17alpha", "-", "MT", "as", "androgenic", ",", "vinclozolin", "and", "linuron", "as", "anti", "-", "androgenic", "and", "compounds", "were", "tested", "accordingly", ".", "In", "the", "absence", "of", "cytotoxicity", ",", "appropriate", "androgenic", "properties", "of", "reference", "and", "test", "compounds", "were", "detected", "by", "both", "laboratories", ",", "o", ",", "p'-DDT", "and", "DBP", "had", "no", "androgenic", "activity", ".", "Across", "the", "two", "laboratories", "EC(50)-values", "for", "MDHT", ",", "17alpha", "-", "MT", ",", "and", "levonorgestrel", "varied", "by", "not", "more", "than", "a", "factor", "of", "3.4", ",", "for", "norethynodrel", "by", "a", "factor", "of", "9.7", ".", "Progesterone", "effects", "could", "not", "fully", "be", "evaluated", ",", "as", "frequently", "concentration", "response", "curves", "were", "incomplete", ".", "In", "the", "absence", "of", "cytotoxicity", "anti", "-", "androgenic", "properties", "of", "reference", "and", "test", "compounds", "were", "also", "detected", "in", "both", "laboratories", ".", "DBP", ",", "the", "putative", "negative", "reference", "compound", ",", "was", "inactive", ",", "norethynodrel", "rather", "showed", "agonistic", "properties", ".", "Progesterone", "was", "an", "antagonist", "at", "low", "concentrations", ",", "but", "agonistic", "properties", "were", "observed", "in", "one", "laboratory", "at", "high", "concentrations", ".", "Since", "the", "highest", "test", "concentration", "was", "limited", "to", "10", "microM", ",", "for", "some", "compounds", "no", "complete", "concentration", "response", "curves", "were", "obtained", "and", "estimation", "of", "EC(50)-values", "was", "less", "robust", ".", "Our", "data", "demonstrated", "that", "the", "SOP", "was", "transferable", ",", "and", "that", "the", "assay", "was", "able", "to", "rank", "compounds", "with", "strong", ",", "weak", ",", "and", "without", "affinity", "for", "the", "AR", "and", "to", "discriminate", "agonists", "and", "antagonists", ".", "The", "sensitivity", "of", "the", "assay", "could", "be", "improved", "further", ",", "if", "the", "limit", "of", "solubility", "or", "beginning", "cytotoxicity", "was", "chosen", "as", "the", "highest", "test", "concentration", ".", "The", "assay", "avoids", "the", "use", "of", "tissues", "from", "laboratory", "animals", ",", "and", "thus", "contributes", "to", "the", "3R", "concept", ".", "Furthermore", ",", "it", "could", "be", "adjusted", "to", "an", "intermediate", "/", "high", "throughput", "format", ".", "On", "the", "whole", ",", "this", "PALM", "assay", "is", "a", "promising", "candidate", "for", "further", "validation", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
androgen is a CHEMICAL, androgen receptor is a GENE-Y, AR is a GENE-Y, androgen is a CHEMICAL, androgen is a CHEMICAL, 17alpha - methyltestosterone is a CHEMICAL, 17alpha - MT is a CHEMICAL, vinclozolin is a CHEMICAL, linuron is a CHEMICAL, AR is a GENE-Y, androgen is a CHEMICAL, 17alpha - methyldihydrotestosterone is a CHEMICAL, MDHT is a CHEMICAL, levonorgestrel is a CHEMICAL, norethynodrel is a CHEMICAL, progesterone is a CHEMICAL, o , p'-DDT is a CHEMICAL, dibutylphthalate is a CHEMICAL, DBP is a CHEMICAL, anti - androgen is a CHEMICAL, flutamide is a CHEMICAL, prochloraz is a CHEMICAL, o , p'-DDT is a CHEMICAL, progesterone is a CHEMICAL, norethynodrel is a CHEMICAL, DBP is a CHEMICAL, lactate dehydrogenase is a GENE-N, 17alpha - MT is a CHEMICAL, vinclozolin is a CHEMICAL, o , p'-DDT is a CHEMICAL, DBP is a CHEMICAL, MDHT is a CHEMICAL, 17alpha - MT is a CHEMICAL, levonorgestrel is a CHEMICAL, norethynodrel is a CHEMICAL, Progesterone is a CHEMICAL, DBP is a CHEMICAL, norethynodrel is a CHEMICAL, Progesterone is a CHEMICAL, AR is a GENE-Y	4671_task1	Sentence: Screening for (anti)androgenic properties using a standard operation protocol based on the human stably transfected androgen sensitive PALM cell line. First steps towards validation. Despite more than a decade of research in the field of endocrine active compounds targeting the androgen receptor (AR), and although suitable cell lines can be obtained, no validated human stably transfected androgen sensitive transactivation assay is available. Bayer Schering Pharma (BSP) and the Flemish Institute for Technological Research (VITO), partners within the EU-sponsored 6th framework project ReProTect, made first steps towards such a validation. A standard operation protocol (SOP) developed at BSP based on the androgen sensitive PALM cell line was transferred to VITO and its performance and transferability were thoroughly studied. The investigation followed a generic protocol prepared for all reporter gene assays evaluated within ReProTect, and in both laboratories at least three independent experiments were performed. The highest concentration to be tested was limited to 10 microM, if needed. A few compounds, 17alpha-methyltestosterone (17alpha-MT), vinclozolin and linuron, were studied using a real world scenario, i.e., assuming that their interaction with the AR was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening. All other compounds were tested according to the generic protocol: Compounds screened for agonism were the reference androgen 17alpha-methyldihydrotestosterone (MDHT), levonorgestrel, norethynodrel, progesterone, o,p'-DDT, and dibutylphthalate (DBP), while compounds screened for antagonism were the reference anti-androgen flutamide, prochloraz, o,p'-DDT, progesterone, norethynodrel, and DBP. Cytotoxicity was assessed in parallel as lactate dehydrogenase release. The prescreen classified 17alpha-MT as androgenic, vinclozolin and linuron as anti-androgenic and compounds were tested accordingly. In the absence of cytotoxicity, appropriate androgenic properties of reference and test compounds were detected by both laboratories, o,p'-DDT and DBP had no androgenic activity. Across the two laboratories EC(50)-values for MDHT, 17alpha-MT, and levonorgestrel varied by not more than a factor of 3.4, for norethynodrel by a factor of 9.7. Progesterone effects could not fully be evaluated, as frequently concentration response curves were incomplete. In the absence of cytotoxicity anti-androgenic properties of reference and test compounds were also detected in both laboratories. DBP, the putative negative reference compound, was inactive, norethynodrel rather showed agonistic properties. Progesterone was an antagonist at low concentrations, but agonistic properties were observed in one laboratory at high concentrations. Since the highest test concentration was limited to 10 microM, for some compounds no complete concentration response curves were obtained and estimation of EC(50)-values was less robust. Our data demonstrated that the SOP was transferable, and that the assay was able to rank compounds with strong, weak, and without affinity for the AR and to discriminate agonists and antagonists. The sensitivity of the assay could be improved further, if the limit of solubility or beginning cytotoxicity was chosen as the highest test concentration. The assay avoids the use of tissues from laboratory animals, and thus contributes to the 3R concept. Furthermore, it could be adjusted to an intermediate/high throughput format. On the whole, this PALM assay is a promising candidate for further validation. Instructions: please typing these entity words according to sentence: androgen, androgen receptor, AR, androgen, androgen, 17alpha - methyltestosterone, 17alpha - MT, vinclozolin, linuron, AR, androgen, 17alpha - methyldihydrotestosterone, MDHT, levonorgestrel, norethynodrel, progesterone, o , p'-DDT, dibutylphthalate, DBP, anti - androgen, flutamide, prochloraz, o , p'-DDT, progesterone, norethynodrel, DBP, lactate dehydrogenase, 17alpha - MT, vinclozolin, o , p'-DDT, DBP, MDHT, 17alpha - MT, levonorgestrel, norethynodrel, Progesterone, DBP, norethynodrel, Progesterone, AR Options: GENE-N, GENE-Y, CHEMICAL	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Screening for (anti)androgenic properties using a standard operation protocol based on the human stably transfected androgen sensitive PALM cell line. First steps towards validation. Despite more than a decade of research in the field of endocrine active compounds targeting the androgen receptor (AR), and although suitable cell lines can be obtained, no validated human stably transfected androgen sensitive transactivation assay is available. Bayer Schering Pharma (BSP) and the Flemish Institute for Technological Research (VITO), partners within the EU-sponsored 6th framework project ReProTect, made first steps towards such a validation. A standard operation protocol (SOP) developed at BSP based on the androgen sensitive PALM cell line was transferred to VITO and its performance and transferability were thoroughly studied. The investigation followed a generic protocol prepared for all reporter gene assays evaluated within ReProTect, and in both laboratories at least three independent experiments were performed. The highest concentration to be tested was limited to 10 microM, if needed. A few compounds, 17alpha-methyltestosterone (17alpha-MT), vinclozolin and linuron, were studied using a real world scenario, i.e., assuming that their interaction with the AR was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening. All other compounds were tested according to the generic protocol: Compounds screened for agonism were the reference androgen 17alpha-methyldihydrotestosterone (MDHT), levonorgestrel, norethynodrel, progesterone, o,p'-DDT, and dibutylphthalate (DBP), while compounds screened for antagonism were the reference anti-androgen flutamide, prochloraz, o,p'-DDT, progesterone, norethynodrel, and DBP. Cytotoxicity was assessed in parallel as lactate dehydrogenase release. The prescreen classified 17alpha-MT as androgenic, vinclozolin and linuron as anti-androgenic and compounds were tested accordingly. In the absence of cytotoxicity, appropriate androgenic properties of reference and test compounds were detected by both laboratories, o,p'-DDT and DBP had no androgenic activity. Across the two laboratories EC(50)-values for MDHT, 17alpha-MT, and levonorgestrel varied by not more than a factor of 3.4, for norethynodrel by a factor of 9.7. Progesterone effects could not fully be evaluated, as frequently concentration response curves were incomplete. In the absence of cytotoxicity anti-androgenic properties of reference and test compounds were also detected in both laboratories. DBP, the putative negative reference compound, was inactive, norethynodrel rather showed agonistic properties. Progesterone was an antagonist at low concentrations, but agonistic properties were observed in one laboratory at high concentrations. Since the highest test concentration was limited to 10 microM, for some compounds no complete concentration response curves were obtained and estimation of EC(50)-values was less robust. Our data demonstrated that the SOP was transferable, and that the assay was able to rank compounds with strong, weak, and without affinity for the AR and to discriminate agonists and antagonists. The sensitivity of the assay could be improved further, if the limit of solubility or beginning cytotoxicity was chosen as the highest test concentration. The assay avoids the use of tissues from laboratory animals, and thus contributes to the 3R concept. Furthermore, it could be adjusted to an intermediate/high throughput format. On the whole, this PALM assay is a promising candidate for further validation.	[ "Screening", "for", "(", "anti)androgenic", "properties", "using", "a", "standard", "operation", "protocol", "based", "on", "the", "human", "stably", "transfected", "androgen", "sensitive", "PALM", "cell", "line", ".", "First", "steps", "towards", "validation", ".", "\n", "Despite", "more", "than", "a", "decade", "of", "research", "in", "the", "field", "of", "endocrine", "active", "compounds", "targeting", "the", "androgen", "receptor", "(", "AR", ")", ",", "and", "although", "suitable", "cell", "lines", "can", "be", "obtained", ",", "no", "validated", "human", "stably", "transfected", "androgen", "sensitive", "transactivation", "assay", "is", "available", ".", "Bayer", "Schering", "Pharma", "(", "BSP", ")", "and", "the", "Flemish", "Institute", "for", "Technological", "Research", "(", "VITO", ")", ",", "partners", "within", "the", "EU", "-", "sponsored", "6th", "framework", "project", "ReProTect", ",", "made", "first", "steps", "towards", "such", "a", "validation", ".", "A", "standard", "operation", "protocol", "(", "SOP", ")", "developed", "at", "BSP", "based", "on", "the", "androgen", "sensitive", "PALM", "cell", "line", "was", "transferred", "to", "VITO", "and", "its", "performance", "and", "transferability", "were", "thoroughly", "studied", ".", "The", "investigation", "followed", "a", "generic", "protocol", "prepared", "for", "all", "reporter", "gene", "assays", "evaluated", "within", "ReProTect", ",", "and", "in", "both", "laboratories", "at", "least", "three", "independent", "experiments", "were", "performed", ".", "The", "highest", "concentration", "to", "be", "tested", "was", "limited", "to", "10", "microM", ",", "if", "needed", ".", "A", "few", "compounds", ",", "17alpha", "-", "methyltestosterone", "(", "17alpha", "-", "MT", ")", ",", "vinclozolin", "and", "linuron", ",", "were", "studied", "using", "a", "real", "world", "scenario", ",", "i.e", ".", ",", "assuming", "that", "their", "interaction", "with", "the", "AR", "was", "not", "known", ":", "A", "prescreening", "for", "agonism", "and", "true", ",", "competitive", "antagonism", "was", "used", "to", "select", "conditions", "such", "as", "the", "appropriate", "mode", "of", "action", ",", "and", "the", "working", "range", "excluding", "cytotoxicity", "for", "the", "final", "screening", ".", "All", "other", "compounds", "were", "tested", "according", "to", "the", "generic", "protocol", ":", "Compounds", "screened", "for", "agonism", "were", "the", "reference", "androgen", "17alpha", "-", "methyldihydrotestosterone", "(", "MDHT", ")", ",", "levonorgestrel", ",", "norethynodrel", ",", "progesterone", ",", "o", ",", "p'-DDT", ",", "and", "dibutylphthalate", "(", "DBP", ")", ",", "while", "compounds", "screened", "for", "antagonism", "were", "the", "reference", "anti", "-", "androgen", "flutamide", ",", "prochloraz", ",", "o", ",", "p'-DDT", ",", "progesterone", ",", "norethynodrel", ",", "and", "DBP", ".", "Cytotoxicity", "was", "assessed", "in", "parallel", "as", "lactate", "dehydrogenase", "release", ".", "The", "prescreen", "classified", "17alpha", "-", "MT", "as", "androgenic", ",", "vinclozolin", "and", "linuron", "as", "anti", "-", "androgenic", "and", "compounds", "were", "tested", "accordingly", ".", "In", "the", "absence", "of", "cytotoxicity", ",", "appropriate", "androgenic", "properties", "of", "reference", "and", "test", "compounds", "were", "detected", "by", "both", "laboratories", ",", "o", ",", "p'-DDT", "and", "DBP", "had", "no", "androgenic", "activity", ".", "Across", "the", "two", "laboratories", "EC(50)-values", "for", "MDHT", ",", "17alpha", "-", "MT", ",", "and", "levonorgestrel", "varied", "by", "not", "more", "than", "a", "factor", "of", "3.4", ",", "for", "norethynodrel", "by", "a", "factor", "of", "9.7", ".", "Progesterone", "effects", "could", "not", "fully", "be", "evaluated", ",", "as", "frequently", "concentration", "response", "curves", "were", "incomplete", ".", "In", "the", "absence", "of", "cytotoxicity", "anti", "-", "androgenic", "properties", "of", "reference", "and", "test", "compounds", "were", "also", "detected", "in", "both", "laboratories", ".", "DBP", ",", "the", "putative", "negative", "reference", "compound", ",", "was", "inactive", ",", "norethynodrel", "rather", "showed", "agonistic", "properties", ".", "Progesterone", "was", "an", "antagonist", "at", "low", "concentrations", ",", "but", "agonistic", "properties", "were", "observed", "in", "one", "laboratory", "at", "high", "concentrations", ".", "Since", "the", "highest", "test", "concentration", "was", "limited", "to", "10", "microM", ",", "for", "some", "compounds", "no", "complete", "concentration", "response", "curves", "were", "obtained", "and", "estimation", "of", "EC(50)-values", "was", "less", "robust", ".", "Our", "data", "demonstrated", "that", "the", "SOP", "was", "transferable", ",", "and", "that", "the", "assay", "was", "able", "to", "rank", "compounds", "with", "strong", ",", "weak", ",", "and", "without", "affinity", "for", "the", "AR", "and", "to", "discriminate", "agonists", "and", "antagonists", ".", "The", "sensitivity", "of", "the", "assay", "could", "be", "improved", "further", ",", "if", "the", "limit", "of", "solubility", "or", "beginning", "cytotoxicity", "was", "chosen", "as", "the", "highest", "test", "concentration", ".", "The", "assay", "avoids", "the", "use", "of", "tissues", "from", "laboratory", "animals", ",", "and", "thus", "contributes", "to", "the", "3R", "concept", ".", "Furthermore", ",", "it", "could", "be", "adjusted", "to", "an", "intermediate", "/", "high", "throughput", "format", ".", "On", "the", "whole", ",", "this", "PALM", "assay", "is", "a", "promising", "candidate", "for", "further", "validation", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
androgen, androgen receptor, AR, androgen, androgen, 17alpha - methyltestosterone, 17alpha - MT, vinclozolin, linuron, AR, androgen, 17alpha - methyldihydrotestosterone, MDHT, levonorgestrel, norethynodrel, progesterone, o , p'-DDT, dibutylphthalate, DBP, anti - androgen, flutamide, prochloraz, o , p'-DDT, progesterone, norethynodrel, DBP, lactate dehydrogenase, 17alpha - MT, vinclozolin, o , p'-DDT, DBP, MDHT, 17alpha - MT, levonorgestrel, norethynodrel, Progesterone, DBP, norethynodrel, Progesterone, AR	4671_task2	Sentence: Screening for (anti)androgenic properties using a standard operation protocol based on the human stably transfected androgen sensitive PALM cell line. First steps towards validation. Despite more than a decade of research in the field of endocrine active compounds targeting the androgen receptor (AR), and although suitable cell lines can be obtained, no validated human stably transfected androgen sensitive transactivation assay is available. Bayer Schering Pharma (BSP) and the Flemish Institute for Technological Research (VITO), partners within the EU-sponsored 6th framework project ReProTect, made first steps towards such a validation. A standard operation protocol (SOP) developed at BSP based on the androgen sensitive PALM cell line was transferred to VITO and its performance and transferability were thoroughly studied. The investigation followed a generic protocol prepared for all reporter gene assays evaluated within ReProTect, and in both laboratories at least three independent experiments were performed. The highest concentration to be tested was limited to 10 microM, if needed. A few compounds, 17alpha-methyltestosterone (17alpha-MT), vinclozolin and linuron, were studied using a real world scenario, i.e., assuming that their interaction with the AR was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening. All other compounds were tested according to the generic protocol: Compounds screened for agonism were the reference androgen 17alpha-methyldihydrotestosterone (MDHT), levonorgestrel, norethynodrel, progesterone, o,p'-DDT, and dibutylphthalate (DBP), while compounds screened for antagonism were the reference anti-androgen flutamide, prochloraz, o,p'-DDT, progesterone, norethynodrel, and DBP. Cytotoxicity was assessed in parallel as lactate dehydrogenase release. The prescreen classified 17alpha-MT as androgenic, vinclozolin and linuron as anti-androgenic and compounds were tested accordingly. In the absence of cytotoxicity, appropriate androgenic properties of reference and test compounds were detected by both laboratories, o,p'-DDT and DBP had no androgenic activity. Across the two laboratories EC(50)-values for MDHT, 17alpha-MT, and levonorgestrel varied by not more than a factor of 3.4, for norethynodrel by a factor of 9.7. Progesterone effects could not fully be evaluated, as frequently concentration response curves were incomplete. In the absence of cytotoxicity anti-androgenic properties of reference and test compounds were also detected in both laboratories. DBP, the putative negative reference compound, was inactive, norethynodrel rather showed agonistic properties. Progesterone was an antagonist at low concentrations, but agonistic properties were observed in one laboratory at high concentrations. Since the highest test concentration was limited to 10 microM, for some compounds no complete concentration response curves were obtained and estimation of EC(50)-values was less robust. Our data demonstrated that the SOP was transferable, and that the assay was able to rank compounds with strong, weak, and without affinity for the AR and to discriminate agonists and antagonists. The sensitivity of the assay could be improved further, if the limit of solubility or beginning cytotoxicity was chosen as the highest test concentration. The assay avoids the use of tissues from laboratory animals, and thus contributes to the 3R concept. Furthermore, it could be adjusted to an intermediate/high throughput format. On the whole, this PALM assay is a promising candidate for further validation. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Screening for (anti)androgenic properties using a standard operation protocol based on the human stably transfected androgen sensitive PALM cell line. First steps towards validation. Despite more than a decade of research in the field of endocrine active compounds targeting the androgen receptor (AR), and although suitable cell lines can be obtained, no validated human stably transfected androgen sensitive transactivation assay is available. Bayer Schering Pharma (BSP) and the Flemish Institute for Technological Research (VITO), partners within the EU-sponsored 6th framework project ReProTect, made first steps towards such a validation. A standard operation protocol (SOP) developed at BSP based on the androgen sensitive PALM cell line was transferred to VITO and its performance and transferability were thoroughly studied. The investigation followed a generic protocol prepared for all reporter gene assays evaluated within ReProTect, and in both laboratories at least three independent experiments were performed. The highest concentration to be tested was limited to 10 microM, if needed. A few compounds, 17alpha-methyltestosterone (17alpha-MT), vinclozolin and linuron, were studied using a real world scenario, i.e., assuming that their interaction with the AR was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening. All other compounds were tested according to the generic protocol: Compounds screened for agonism were the reference androgen 17alpha-methyldihydrotestosterone (MDHT), levonorgestrel, norethynodrel, progesterone, o,p'-DDT, and dibutylphthalate (DBP), while compounds screened for antagonism were the reference anti-androgen flutamide, prochloraz, o,p'-DDT, progesterone, norethynodrel, and DBP. Cytotoxicity was assessed in parallel as lactate dehydrogenase release. The prescreen classified 17alpha-MT as androgenic, vinclozolin and linuron as anti-androgenic and compounds were tested accordingly. In the absence of cytotoxicity, appropriate androgenic properties of reference and test compounds were detected by both laboratories, o,p'-DDT and DBP had no androgenic activity. Across the two laboratories EC(50)-values for MDHT, 17alpha-MT, and levonorgestrel varied by not more than a factor of 3.4, for norethynodrel by a factor of 9.7. Progesterone effects could not fully be evaluated, as frequently concentration response curves were incomplete. In the absence of cytotoxicity anti-androgenic properties of reference and test compounds were also detected in both laboratories. DBP, the putative negative reference compound, was inactive, norethynodrel rather showed agonistic properties. Progesterone was an antagonist at low concentrations, but agonistic properties were observed in one laboratory at high concentrations. Since the highest test concentration was limited to 10 microM, for some compounds no complete concentration response curves were obtained and estimation of EC(50)-values was less robust. Our data demonstrated that the SOP was transferable, and that the assay was able to rank compounds with strong, weak, and without affinity for the AR and to discriminate agonists and antagonists. The sensitivity of the assay could be improved further, if the limit of solubility or beginning cytotoxicity was chosen as the highest test concentration. The assay avoids the use of tissues from laboratory animals, and thus contributes to the 3R concept. Furthermore, it could be adjusted to an intermediate/high throughput format. On the whole, this PALM assay is a promising candidate for further validation.	[ "Screening", "for", "(", "anti)androgenic", "properties", "using", "a", "standard", "operation", "protocol", "based", "on", "the", "human", "stably", "transfected", "androgen", "sensitive", "PALM", "cell", "line", ".", "First", "steps", "towards", "validation", ".", "\n", "Despite", "more", "than", "a", "decade", "of", "research", "in", "the", "field", "of", "endocrine", "active", "compounds", "targeting", "the", "androgen", "receptor", "(", "AR", ")", ",", "and", "although", "suitable", "cell", "lines", "can", "be", "obtained", ",", "no", "validated", "human", "stably", "transfected", "androgen", "sensitive", "transactivation", "assay", "is", "available", ".", "Bayer", "Schering", "Pharma", "(", "BSP", ")", "and", "the", "Flemish", "Institute", "for", "Technological", "Research", "(", "VITO", ")", ",", "partners", "within", "the", "EU", "-", "sponsored", "6th", "framework", "project", "ReProTect", ",", "made", "first", "steps", "towards", "such", "a", "validation", ".", "A", "standard", "operation", "protocol", "(", "SOP", ")", "developed", "at", "BSP", "based", "on", "the", "androgen", "sensitive", "PALM", "cell", "line", "was", "transferred", "to", "VITO", "and", "its", "performance", "and", "transferability", "were", "thoroughly", "studied", ".", "The", "investigation", "followed", "a", "generic", "protocol", "prepared", "for", "all", "reporter", "gene", "assays", "evaluated", "within", "ReProTect", ",", "and", "in", "both", "laboratories", "at", "least", "three", "independent", "experiments", "were", "performed", ".", "The", "highest", "concentration", "to", "be", "tested", "was", "limited", "to", "10", "microM", ",", "if", "needed", ".", "A", "few", "compounds", ",", "17alpha", "-", "methyltestosterone", "(", "17alpha", "-", "MT", ")", ",", "vinclozolin", "and", "linuron", ",", "were", "studied", "using", "a", "real", "world", "scenario", ",", "i.e", ".", ",", "assuming", "that", "their", "interaction", "with", "the", "AR", "was", "not", "known", ":", "A", "prescreening", "for", "agonism", "and", "true", ",", "competitive", "antagonism", "was", "used", "to", "select", "conditions", "such", "as", "the", "appropriate", "mode", "of", "action", ",", "and", "the", "working", "range", "excluding", "cytotoxicity", "for", "the", "final", "screening", ".", "All", "other", "compounds", "were", "tested", "according", "to", "the", "generic", "protocol", ":", "Compounds", "screened", "for", "agonism", "were", "the", "reference", "androgen", "17alpha", "-", "methyldihydrotestosterone", "(", "MDHT", ")", ",", "levonorgestrel", ",", "norethynodrel", ",", "progesterone", ",", "o", ",", "p'-DDT", ",", "and", "dibutylphthalate", "(", "DBP", ")", ",", "while", "compounds", "screened", "for", "antagonism", "were", "the", "reference", "anti", "-", "androgen", "flutamide", ",", "prochloraz", ",", "o", ",", "p'-DDT", ",", "progesterone", ",", "norethynodrel", ",", "and", "DBP", ".", "Cytotoxicity", "was", "assessed", "in", "parallel", "as", "lactate", "dehydrogenase", "release", ".", "The", "prescreen", "classified", "17alpha", "-", "MT", "as", "androgenic", ",", "vinclozolin", "and", "linuron", "as", "anti", "-", "androgenic", "and", "compounds", "were", "tested", "accordingly", ".", "In", "the", "absence", "of", "cytotoxicity", ",", "appropriate", "androgenic", "properties", "of", "reference", "and", "test", "compounds", "were", "detected", "by", "both", "laboratories", ",", "o", ",", "p'-DDT", "and", "DBP", "had", "no", "androgenic", "activity", ".", "Across", "the", "two", "laboratories", "EC(50)-values", "for", "MDHT", ",", "17alpha", "-", "MT", ",", "and", "levonorgestrel", "varied", "by", "not", "more", "than", "a", "factor", "of", "3.4", ",", "for", "norethynodrel", "by", "a", "factor", "of", "9.7", ".", "Progesterone", "effects", "could", "not", "fully", "be", "evaluated", ",", "as", "frequently", "concentration", "response", "curves", "were", "incomplete", ".", "In", "the", "absence", "of", "cytotoxicity", "anti", "-", "androgenic", "properties", "of", "reference", "and", "test", "compounds", "were", "also", "detected", "in", "both", "laboratories", ".", "DBP", ",", "the", "putative", "negative", "reference", "compound", ",", "was", "inactive", ",", "norethynodrel", "rather", "showed", "agonistic", "properties", ".", "Progesterone", "was", "an", "antagonist", "at", "low", "concentrations", ",", "but", "agonistic", "properties", "were", "observed", "in", "one", "laboratory", "at", "high", "concentrations", ".", "Since", "the", "highest", "test", "concentration", "was", "limited", "to", "10", "microM", ",", "for", "some", "compounds", "no", "complete", "concentration", "response", "curves", "were", "obtained", "and", "estimation", "of", "EC(50)-values", "was", "less", "robust", ".", "Our", "data", "demonstrated", "that", "the", "SOP", "was", "transferable", ",", "and", "that", "the", "assay", "was", "able", "to", "rank", "compounds", "with", "strong", ",", "weak", ",", "and", "without", "affinity", "for", "the", "AR", "and", "to", "discriminate", "agonists", "and", "antagonists", ".", "The", "sensitivity", "of", "the", "assay", "could", "be", "improved", "further", ",", "if", "the", "limit", "of", "solubility", "or", "beginning", "cytotoxicity", "was", "chosen", "as", "the", "highest", "test", "concentration", ".", "The", "assay", "avoids", "the", "use", "of", "tissues", "from", "laboratory", "animals", ",", "and", "thus", "contributes", "to", "the", "3R", "concept", ".", "Furthermore", ",", "it", "could", "be", "adjusted", "to", "an", "intermediate", "/", "high", "throughput", "format", ".", "On", "the", "whole", ",", "this", "PALM", "assay", "is", "a", "promising", "candidate", "for", "further", "validation", "." ]	[ "CHEMICAL", "GENE-N", "GENE-Y" ]
Gram - positive is a Phenotype, Actinobacteria is a Microorganism, Corynebacterium casei is a Microorganism, C. variabile is a Microorganism, cheese from dairy A is a Habitat, Brachybacterium alimentarum is a Microorganism, Brevibacterium is a Microorganism, cheeses from the farmhouses is a Habitat, dairies is a Habitat, B. permense is a Microorganism, cheese from dairy A is a Habitat, B. linens is a Microorganism, cheese from dairy B is a Habitat, B. aurantiacum is a Microorganism, dairy is a Habitat, Brevibacterium spp . is a Microorganism, dairy is a Habitat, coagulase negative is a Phenotype, staphylococci is a Microorganism, Staphylococcus saprophyticus is a Microorganism, cheeses from dairies B is a Habitat, Staph . equorum is a Microorganism, cheeses from dairies C is a Habitat, Gram - negative is a Phenotype, Proteus vulgaris is a Microorganism, Alcaligenes faecalis is a Microorganism, dairy is a Habitat, surface yeast microbiota is a Habitat, yeast surface microbiota is a Habitat, farmhouse cheeses is a Habitat, cheese is a Habitat, industrial dairy is a Habitat, dairy is a Habitat, cheese from dairy A is a Habitat, Yarrowia lipolytica is a Microorganism, Scopulariopsis brevicaulis is a Microorganism, yeast microbiota is a Habitat, cheese from dairy B is a Habitat, Geotrichum spp . is a Microorganism, Kluyveromyces marxianus is a Microorganism, Debaryomyces hansenii is a Microorganism, cheese from dairy C is a Habitat, D. hansenii is a Microorganism, Geothrichum spp . is a Microorganism, cheese from dairy D is a Habitat, D. hansenii is a Microorganism	101_task0	Sentence: Most species were Gram-positive Actinobacteria with Corynebacterium casei and/or C. variabile as the predominant (Table 4). Additionally, the cheese from dairy A was dominated by high of numbers of Brachybacterium alimentarum. Various Brevibacterium species were found on the cheeses from the farmhouses (dairies A, B and C). B. permense was found on the cheese from dairy A, B. linens was found on the cheese from dairy B and B. aurantiacum was found on the cheese from dairy C. Brevibacterium spp. could not be isolated on the cheese from dairy D. Furthermore, a number of coagulase negative staphylococci were found, i.e., Staphylococcus saprophyticus on the cheeses from dairies B and D, and Staph. equorum on the cheeses from dairies C and D. Finally, a number of Gram-negative bacteria species including Proteus vulgaris and Alcaligenes faecalis was found on the cheese from dairy C.Figure 3 shows the grouping of the surface yeast microbiota. The yeast surface microbiota on the three farmhouse cheeses consisted of two to four groups, whereas the cheese produced at the industrial dairy (dairy D) consisted of only one single group. The cheese from dairy A was equally dominated by Yarrowia lipolytica and Scopulariopsis brevicaulis. The yeast microbiota on cheese from dairy B was primarily dominated by Geotrichum spp., however, Kluyveromyces marxianus and Debaryomyces hansenii were additionally found in minor amounts. The cheese from dairy C was dominated by D. hansenii followed by a minor group of Geothrichum spp. Finally, the cheese from dairy D was entirely dominated by D. hansenii. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Microorganism, Phenotype, Habitat	[ "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "B-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "B-Microorganism", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O" ]	Most species were Gram-positive Actinobacteria with Corynebacterium casei and/or C. variabile as the predominant (Table 4). Additionally, the cheese from dairy A was dominated by high of numbers of Brachybacterium alimentarum. Various Brevibacterium species were found on the cheeses from the farmhouses (dairies A, B and C). B. permense was found on the cheese from dairy A, B. linens was found on the cheese from dairy B and B. aurantiacum was found on the cheese from dairy C. Brevibacterium spp. could not be isolated on the cheese from dairy D. Furthermore, a number of coagulase negative staphylococci were found, i.e., Staphylococcus saprophyticus on the cheeses from dairies B and D, and Staph. equorum on the cheeses from dairies C and D. Finally, a number of Gram-negative bacteria species including Proteus vulgaris and Alcaligenes faecalis was found on the cheese from dairy C.Figure 3 shows the grouping of the surface yeast microbiota. The yeast surface microbiota on the three farmhouse cheeses consisted of two to four groups, whereas the cheese produced at the industrial dairy (dairy D) consisted of only one single group. The cheese from dairy A was equally dominated by Yarrowia lipolytica and Scopulariopsis brevicaulis. The yeast microbiota on cheese from dairy B was primarily dominated by Geotrichum spp., however, Kluyveromyces marxianus and Debaryomyces hansenii were additionally found in minor amounts. The cheese from dairy C was dominated by D. hansenii followed by a minor group of Geothrichum spp. Finally, the cheese from dairy D was entirely dominated by D. hansenii.	[ "Most", "species", "were", "Gram", "-", "positive", "Actinobacteria", "with", "Corynebacterium", "casei", "and", "/", "or", "C.", "variabile", "as", "the", "predominant", "(", "Table", "4", ")", ".", "Additionally", ",", "the", "cheese", "from", "dairy", "A", "was", "dominated", "by", "high", "of", "numbers", "of", "Brachybacterium", "alimentarum", ".", "Various", "Brevibacterium", "species", "were", "found", "on", "the", "cheeses", "from", "the", "farmhouses", "(", "dairies", "A", ",", "B", "and", "C", ")", ".", "B.", "permense", "was", "found", "on", "the", "cheese", "from", "dairy", "A", ",", "B.", "linens", "was", "found", "on", "the", "cheese", "from", "dairy", "B", "and", "B.", "aurantiacum", "was", "found", "on", "the", "cheese", "from", "dairy", "C.", "Brevibacterium", " ", "spp", ".", "could", "not", "be", "isolated", "on", "the", "cheese", "from", "dairy", "D.", "Furthermore", ",", "a", " ", "number", "of", "coagulase", "negative", "staphylococci", "were", "found", ",", "i.e", ".", ",", "Staphylococcus", "saprophyticus", "on", "the", "cheeses", "from", "dairies", "B", "and", "D", ",", "and", "Staph", ".", "equorum", "on", "the", "cheeses", "from", "dairies", "C", "and", "D.", "Finally", ",", "a", "number", "of", "Gram", "-", "negative", "bacteria", "species", "including", "Proteus", "vulgaris", "and", "Alcaligenes", "faecalis", "was", "found", "on", "the", "cheese", "from", "dairy", "C.Figure", "3", " ", "shows", "the", "grouping", "of", "the", "surface", "yeast", "microbiota", ".", "The", "yeast", "surface", " ", "microbiota", "on", "the", "three", "farmhouse", "cheeses", "consisted", "of", "two", "to", "four", " ", "groups", ",", "whereas", "the", "cheese", "produced", "at", "the", "industrial", "dairy", "(", "dairy", "D", ")", " ", "consisted", "of", "only", "one", "single", "group", ".", "The", "cheese", "from", "dairy", "A", "was", "equally", " ", "dominated", "by", "Yarrowia", "lipolytica", "and", "Scopulariopsis", "brevicaulis", ".", "The", "yeast", "microbiota", "on", "cheese", "from", "dairy", "B", "was", "primarily", "dominated", "by", "Geotrichum", "spp", ".", ",", "however", ",", "Kluyveromyces", "marxianus", "and", "Debaryomyces", "hansenii", "were", "additionally", "found", "in", "minor", "amounts", ".", "The", "cheese", "from", "dairy", "C", "was", "dominated", "by", "D.", "hansenii", "followed", "by", "a", "minor", "group", "of", "Geothrichum", "spp", ".", "Finally", ",", "the", "cheese", "from", "dairy", "D", "was", "entirely", "dominated", "by", "D.", "hansenii", "." ]	[ "Microorganism", "Habitat", "Phenotype" ]
Gram - positive is a Phenotype, Actinobacteria is a Microorganism, Corynebacterium casei is a Microorganism, C. variabile is a Microorganism, cheese from dairy A is a Habitat, Brachybacterium alimentarum is a Microorganism, Brevibacterium is a Microorganism, cheeses from the farmhouses is a Habitat, dairies is a Habitat, B. permense is a Microorganism, cheese from dairy A is a Habitat, B. linens is a Microorganism, cheese from dairy B is a Habitat, B. aurantiacum is a Microorganism, dairy is a Habitat, Brevibacterium spp . is a Microorganism, dairy is a Habitat, coagulase negative is a Phenotype, staphylococci is a Microorganism, Staphylococcus saprophyticus is a Microorganism, cheeses from dairies B is a Habitat, Staph . equorum is a Microorganism, cheeses from dairies C is a Habitat, Gram - negative is a Phenotype, Proteus vulgaris is a Microorganism, Alcaligenes faecalis is a Microorganism, dairy is a Habitat, surface yeast microbiota is a Habitat, yeast surface microbiota is a Habitat, farmhouse cheeses is a Habitat, cheese is a Habitat, industrial dairy is a Habitat, dairy is a Habitat, cheese from dairy A is a Habitat, Yarrowia lipolytica is a Microorganism, Scopulariopsis brevicaulis is a Microorganism, yeast microbiota is a Habitat, cheese from dairy B is a Habitat, Geotrichum spp . is a Microorganism, Kluyveromyces marxianus is a Microorganism, Debaryomyces hansenii is a Microorganism, cheese from dairy C is a Habitat, D. hansenii is a Microorganism, Geothrichum spp . is a Microorganism, cheese from dairy D is a Habitat, D. hansenii is a Microorganism	101_task1	Sentence: Most species were Gram-positive Actinobacteria with Corynebacterium casei and/or C. variabile as the predominant (Table 4). Additionally, the cheese from dairy A was dominated by high of numbers of Brachybacterium alimentarum. Various Brevibacterium species were found on the cheeses from the farmhouses (dairies A, B and C). B. permense was found on the cheese from dairy A, B. linens was found on the cheese from dairy B and B. aurantiacum was found on the cheese from dairy C. Brevibacterium spp. could not be isolated on the cheese from dairy D. Furthermore, a number of coagulase negative staphylococci were found, i.e., Staphylococcus saprophyticus on the cheeses from dairies B and D, and Staph. equorum on the cheeses from dairies C and D. Finally, a number of Gram-negative bacteria species including Proteus vulgaris and Alcaligenes faecalis was found on the cheese from dairy C.Figure 3 shows the grouping of the surface yeast microbiota. The yeast surface microbiota on the three farmhouse cheeses consisted of two to four groups, whereas the cheese produced at the industrial dairy (dairy D) consisted of only one single group. The cheese from dairy A was equally dominated by Yarrowia lipolytica and Scopulariopsis brevicaulis. The yeast microbiota on cheese from dairy B was primarily dominated by Geotrichum spp., however, Kluyveromyces marxianus and Debaryomyces hansenii were additionally found in minor amounts. The cheese from dairy C was dominated by D. hansenii followed by a minor group of Geothrichum spp. Finally, the cheese from dairy D was entirely dominated by D. hansenii. Instructions: please typing these entity words according to sentence: Gram - positive, Actinobacteria, Corynebacterium casei, C. variabile, cheese from dairy A, Brachybacterium alimentarum, Brevibacterium, cheeses from the farmhouses, dairies, B. permense, cheese from dairy A, B. linens, cheese from dairy B, B. aurantiacum, dairy, Brevibacterium spp ., dairy, coagulase negative, staphylococci, Staphylococcus saprophyticus, cheeses from dairies B, Staph . equorum, cheeses from dairies C, Gram - negative, Proteus vulgaris, Alcaligenes faecalis, dairy, surface yeast microbiota, yeast surface microbiota, farmhouse cheeses, cheese, industrial dairy, dairy, cheese from dairy A, Yarrowia lipolytica, Scopulariopsis brevicaulis, yeast microbiota, cheese from dairy B, Geotrichum spp ., Kluyveromyces marxianus, Debaryomyces hansenii, cheese from dairy C, D. hansenii, Geothrichum spp ., cheese from dairy D, D. hansenii Options: Microorganism, Phenotype, Habitat	[ "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "B-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "B-Microorganism", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O" ]	Most species were Gram-positive Actinobacteria with Corynebacterium casei and/or C. variabile as the predominant (Table 4). Additionally, the cheese from dairy A was dominated by high of numbers of Brachybacterium alimentarum. Various Brevibacterium species were found on the cheeses from the farmhouses (dairies A, B and C). B. permense was found on the cheese from dairy A, B. linens was found on the cheese from dairy B and B. aurantiacum was found on the cheese from dairy C. Brevibacterium spp. could not be isolated on the cheese from dairy D. Furthermore, a number of coagulase negative staphylococci were found, i.e., Staphylococcus saprophyticus on the cheeses from dairies B and D, and Staph. equorum on the cheeses from dairies C and D. Finally, a number of Gram-negative bacteria species including Proteus vulgaris and Alcaligenes faecalis was found on the cheese from dairy C.Figure 3 shows the grouping of the surface yeast microbiota. The yeast surface microbiota on the three farmhouse cheeses consisted of two to four groups, whereas the cheese produced at the industrial dairy (dairy D) consisted of only one single group. The cheese from dairy A was equally dominated by Yarrowia lipolytica and Scopulariopsis brevicaulis. The yeast microbiota on cheese from dairy B was primarily dominated by Geotrichum spp., however, Kluyveromyces marxianus and Debaryomyces hansenii were additionally found in minor amounts. The cheese from dairy C was dominated by D. hansenii followed by a minor group of Geothrichum spp. Finally, the cheese from dairy D was entirely dominated by D. hansenii.	[ "Most", "species", "were", "Gram", "-", "positive", "Actinobacteria", "with", "Corynebacterium", "casei", "and", "/", "or", "C.", "variabile", "as", "the", "predominant", "(", "Table", "4", ")", ".", "Additionally", ",", "the", "cheese", "from", "dairy", "A", "was", "dominated", "by", "high", "of", "numbers", "of", "Brachybacterium", "alimentarum", ".", "Various", "Brevibacterium", "species", "were", "found", "on", "the", "cheeses", "from", "the", "farmhouses", "(", "dairies", "A", ",", "B", "and", "C", ")", ".", "B.", "permense", "was", "found", "on", "the", "cheese", "from", "dairy", "A", ",", "B.", "linens", "was", "found", "on", "the", "cheese", "from", "dairy", "B", "and", "B.", "aurantiacum", "was", "found", "on", "the", "cheese", "from", "dairy", "C.", "Brevibacterium", " ", "spp", ".", "could", "not", "be", "isolated", "on", "the", "cheese", "from", "dairy", "D.", "Furthermore", ",", "a", " ", "number", "of", "coagulase", "negative", "staphylococci", "were", "found", ",", "i.e", ".", ",", "Staphylococcus", "saprophyticus", "on", "the", "cheeses", "from", "dairies", "B", "and", "D", ",", "and", "Staph", ".", "equorum", "on", "the", "cheeses", "from", "dairies", "C", "and", "D.", "Finally", ",", "a", "number", "of", "Gram", "-", "negative", "bacteria", "species", "including", "Proteus", "vulgaris", "and", "Alcaligenes", "faecalis", "was", "found", "on", "the", "cheese", "from", "dairy", "C.Figure", "3", " ", "shows", "the", "grouping", "of", "the", "surface", "yeast", "microbiota", ".", "The", "yeast", "surface", " ", "microbiota", "on", "the", "three", "farmhouse", "cheeses", "consisted", "of", "two", "to", "four", " ", "groups", ",", "whereas", "the", "cheese", "produced", "at", "the", "industrial", "dairy", "(", "dairy", "D", ")", " ", "consisted", "of", "only", "one", "single", "group", ".", "The", "cheese", "from", "dairy", "A", "was", "equally", " ", "dominated", "by", "Yarrowia", "lipolytica", "and", "Scopulariopsis", "brevicaulis", ".", "The", "yeast", "microbiota", "on", "cheese", "from", "dairy", "B", "was", "primarily", "dominated", "by", "Geotrichum", "spp", ".", ",", "however", ",", "Kluyveromyces", "marxianus", "and", "Debaryomyces", "hansenii", "were", "additionally", "found", "in", "minor", "amounts", ".", "The", "cheese", "from", "dairy", "C", "was", "dominated", "by", "D.", "hansenii", "followed", "by", "a", "minor", "group", "of", "Geothrichum", "spp", ".", "Finally", ",", "the", "cheese", "from", "dairy", "D", "was", "entirely", "dominated", "by", "D.", "hansenii", "." ]	[ "Microorganism", "Habitat", "Phenotype" ]

Perfusion is an umlsterm, Peptids is an umlsterm, Endothelin-1 is an umlsterm, ANP is an umlsterm, Haemodynamik is an umlsterm, Patienten is an umlsterm, angeborenen is an umlsterm, pulmonaler Hypertension is an umlsterm, Stickstoffmonoxid is an umlsterm, NO - Synthase is an umlsterm, ANP is an umlsterm, Guanosinmonophosphat is an umlsterm, Sauerstoff is an umlsterm, Patienten is an umlsterm, pulmonaler Hypertension is an umlsterm, Patienten is an umlsterm, pulmonaler Hypertension is an umlsterm, Feedback - Mechanismus is an umlsterm, ANP is an umlsterm, ET-1 is an umlsterm, ANP is an umlsterm, Vasodilatation is an umlsterm, Sauerstoff is an umlsterm

ZfuerKardiologie.00890100.ger.abstr_task1

Sentence: Die pulmonale Perfusion wird von vasokonstriktorischen und vasodilatatorischen Faktoren reguliert . Ziel der Studie war es , den Einfluss des vasokonstriktorischen Peptids Endothelin-1 ( ET-1) und des vasodilatatorischen atrialen natriuretischen Peptis ( ANP ) auf die pulmonale Haemodynamik bei Patienten mit angeborenen Shuntvitien und konsekutiver pulmonaler Hypertension zu untersuchen . Sowohl Stickstoffmonoxid ( NO ) , das von einer konstitutiven endothelialen NO-Synthase ( eNOS ) gebildet wird , als auch ANP entfalten ihre vasodilatatorische Wirkung durch den intrazellulaeren Botenstoff ( second messenger zyklisches Guanosinmonophosphat ( ) cGMP ) . Sauerstoff ist ein Kofaktor der eNOS und ein bedeutsamer pulmonaler Vasodilatator bei Patienten mit pulmonaler Hypertension . Es wurde ueberprueft , ob bei Patienten mit pulmonaler Hypertension ein Feedback-Mechanismus zwischen ANP und ET-1 besteht und inwieweit die cGMP-Produktion von der Stimulation durch ANP abhaengt . Darueber hinaus sollte untersucht werden , ob das Phaenomen einer pulmonalen Vasodilatation durch Sauerstoff mit Aenderungen der ET-1- oder cGMP-Plasmaspiegel einhergeht . Instructions: please typing these entity words according to sentence: Perfusion, Peptids, Endothelin-1, ANP, Haemodynamik, Patienten, angeborenen, pulmonaler Hypertension, Stickstoffmonoxid, NO - Synthase, ANP, Guanosinmonophosphat, Sauerstoff, Patienten, pulmonaler Hypertension, Patienten, pulmonaler Hypertension, Feedback - Mechanismus, ANP, ET-1, ANP, Vasodilatation, Sauerstoff Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die pulmonale Perfusion wird von vasokonstriktorischen und vasodilatatorischen Faktoren reguliert . Ziel der Studie war es , den Einfluss des vasokonstriktorischen Peptids Endothelin-1 ( ET-1) und des vasodilatatorischen atrialen natriuretischen Peptis ( ANP ) auf die pulmonale Haemodynamik bei Patienten mit angeborenen Shuntvitien und konsekutiver pulmonaler Hypertension zu untersuchen . Sowohl Stickstoffmonoxid ( NO ) , das von einer konstitutiven endothelialen NO-Synthase ( eNOS ) gebildet wird , als auch ANP entfalten ihre vasodilatatorische Wirkung durch den intrazellulaeren Botenstoff ( second messenger zyklisches Guanosinmonophosphat ( ) cGMP ) . Sauerstoff ist ein Kofaktor der eNOS und ein bedeutsamer pulmonaler Vasodilatator bei Patienten mit pulmonaler Hypertension . Es wurde ueberprueft , ob bei Patienten mit pulmonaler Hypertension ein Feedback-Mechanismus zwischen ANP und ET-1 besteht und inwieweit die cGMP-Produktion von der Stimulation durch ANP abhaengt . Darueber hinaus sollte untersucht werden , ob das Phaenomen einer pulmonalen Vasodilatation durch Sauerstoff mit Aenderungen der ET-1- oder cGMP-Plasmaspiegel einhergeht .

[ "Die", "pulmonale", "Perfusion", "wird", "von", "vasokonstriktorischen", "und", "vasodilatatorischen", "Faktoren", "reguliert", ".", "Ziel", "der", "Studie", "war", "es", ",", "den", "Einfluss", "des", "vasokonstriktorischen", "Peptids", "Endothelin-1", "(", "ET-1", ")", "und", "des", "vasodilatatorischen", "atrialen", "natriuretischen", "Peptis", "(", "ANP", ")", "auf", "die", "pulmonale", "Haemodynamik", "bei", "Patienten", "mit", "angeborenen", "Shuntvitien", "und", "konsekutiver", "pulmonaler", "Hypertension", "zu", "untersuchen", ".", "Sowohl", "Stickstoffmonoxid", "(", "NO", ")", ",", "das", "von", "einer", "konstitutiven", "endothelialen", "NO", "-", "Synthase", "(", "eNOS", ")", "gebildet", "wird", ",", "als", "auch", "ANP", "entfalten", "ihre", "vasodilatatorische", "Wirkung", "durch", "den", "intrazellulaeren", "Botenstoff", "(", "second", "messenger", "zyklisches", "Guanosinmonophosphat", "(", ")", "cGMP", ")", ".", "Sauerstoff", "ist", "ein", "Kofaktor", "der", "eNOS", "und", "ein", "bedeutsamer", "pulmonaler", "Vasodilatator", "bei", "Patienten", "mit", "pulmonaler", "Hypertension", ".", "Es", "wurde", "ueberprueft", ",", "ob", "bei", "Patienten", "mit", "pulmonaler", "Hypertension", "ein", "Feedback", "-", "Mechanismus", "zwischen", "ANP", "und", "ET-1", "besteht", "und", "inwieweit", "die", "cGMP", "-", "Produktion", "von", "der", "Stimulation", "durch", "ANP", "abhaengt", ".", "Darueber", "hinaus", "sollte", "untersucht", "werden", ",", "ob", "das", "Phaenomen", "einer", "pulmonalen", "Vasodilatation", "durch", "Sauerstoff", "mit", "Aenderungen", "der", "ET-1-", "oder", "cGMP", "-", "Plasmaspiegel", "einhergeht", "." ]

[ "umlsterm" ]

Perfusion, Peptids, Endothelin-1, ANP, Haemodynamik, Patienten, angeborenen, pulmonaler Hypertension, Stickstoffmonoxid, NO - Synthase, ANP, Guanosinmonophosphat, Sauerstoff, Patienten, pulmonaler Hypertension, Patienten, pulmonaler Hypertension, Feedback - Mechanismus, ANP, ET-1, ANP, Vasodilatation, Sauerstoff

ZfuerKardiologie.00890100.ger.abstr_task2

Sentence: Die pulmonale Perfusion wird von vasokonstriktorischen und vasodilatatorischen Faktoren reguliert . Ziel der Studie war es , den Einfluss des vasokonstriktorischen Peptids Endothelin-1 ( ET-1) und des vasodilatatorischen atrialen natriuretischen Peptis ( ANP ) auf die pulmonale Haemodynamik bei Patienten mit angeborenen Shuntvitien und konsekutiver pulmonaler Hypertension zu untersuchen . Sowohl Stickstoffmonoxid ( NO ) , das von einer konstitutiven endothelialen NO-Synthase ( eNOS ) gebildet wird , als auch ANP entfalten ihre vasodilatatorische Wirkung durch den intrazellulaeren Botenstoff ( second messenger zyklisches Guanosinmonophosphat ( ) cGMP ) . Sauerstoff ist ein Kofaktor der eNOS und ein bedeutsamer pulmonaler Vasodilatator bei Patienten mit pulmonaler Hypertension . Es wurde ueberprueft , ob bei Patienten mit pulmonaler Hypertension ein Feedback-Mechanismus zwischen ANP und ET-1 besteht und inwieweit die cGMP-Produktion von der Stimulation durch ANP abhaengt . Darueber hinaus sollte untersucht werden , ob das Phaenomen einer pulmonalen Vasodilatation durch Sauerstoff mit Aenderungen der ET-1- oder cGMP-Plasmaspiegel einhergeht . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Die pulmonale Perfusion wird von vasokonstriktorischen und vasodilatatorischen Faktoren reguliert . Ziel der Studie war es , den Einfluss des vasokonstriktorischen Peptids Endothelin-1 ( ET-1) und des vasodilatatorischen atrialen natriuretischen Peptis ( ANP ) auf die pulmonale Haemodynamik bei Patienten mit angeborenen Shuntvitien und konsekutiver pulmonaler Hypertension zu untersuchen . Sowohl Stickstoffmonoxid ( NO ) , das von einer konstitutiven endothelialen NO-Synthase ( eNOS ) gebildet wird , als auch ANP entfalten ihre vasodilatatorische Wirkung durch den intrazellulaeren Botenstoff ( second messenger zyklisches Guanosinmonophosphat ( ) cGMP ) . Sauerstoff ist ein Kofaktor der eNOS und ein bedeutsamer pulmonaler Vasodilatator bei Patienten mit pulmonaler Hypertension . Es wurde ueberprueft , ob bei Patienten mit pulmonaler Hypertension ein Feedback-Mechanismus zwischen ANP und ET-1 besteht und inwieweit die cGMP-Produktion von der Stimulation durch ANP abhaengt . Darueber hinaus sollte untersucht werden , ob das Phaenomen einer pulmonalen Vasodilatation durch Sauerstoff mit Aenderungen der ET-1- oder cGMP-Plasmaspiegel einhergeht .

[ "Die", "pulmonale", "Perfusion", "wird", "von", "vasokonstriktorischen", "und", "vasodilatatorischen", "Faktoren", "reguliert", ".", "Ziel", "der", "Studie", "war", "es", ",", "den", "Einfluss", "des", "vasokonstriktorischen", "Peptids", "Endothelin-1", "(", "ET-1", ")", "und", "des", "vasodilatatorischen", "atrialen", "natriuretischen", "Peptis", "(", "ANP", ")", "auf", "die", "pulmonale", "Haemodynamik", "bei", "Patienten", "mit", "angeborenen", "Shuntvitien", "und", "konsekutiver", "pulmonaler", "Hypertension", "zu", "untersuchen", ".", "Sowohl", "Stickstoffmonoxid", "(", "NO", ")", ",", "das", "von", "einer", "konstitutiven", "endothelialen", "NO", "-", "Synthase", "(", "eNOS", ")", "gebildet", "wird", ",", "als", "auch", "ANP", "entfalten", "ihre", "vasodilatatorische", "Wirkung", "durch", "den", "intrazellulaeren", "Botenstoff", "(", "second", "messenger", "zyklisches", "Guanosinmonophosphat", "(", ")", "cGMP", ")", ".", "Sauerstoff", "ist", "ein", "Kofaktor", "der", "eNOS", "und", "ein", "bedeutsamer", "pulmonaler", "Vasodilatator", "bei", "Patienten", "mit", "pulmonaler", "Hypertension", ".", "Es", "wurde", "ueberprueft", ",", "ob", "bei", "Patienten", "mit", "pulmonaler", "Hypertension", "ein", "Feedback", "-", "Mechanismus", "zwischen", "ANP", "und", "ET-1", "besteht", "und", "inwieweit", "die", "cGMP", "-", "Produktion", "von", "der", "Stimulation", "durch", "ANP", "abhaengt", ".", "Darueber", "hinaus", "sollte", "untersucht", "werden", ",", "ob", "das", "Phaenomen", "einer", "pulmonalen", "Vasodilatation", "durch", "Sauerstoff", "mit", "Aenderungen", "der", "ET-1-", "oder", "cGMP", "-", "Plasmaspiegel", "einhergeht", "." ]

[ "umlsterm" ]

nanocrystalline hydroxyapatite paste is a Intervention_Pharmacological, nanocrystalline hydroxyapatite ( nano - HA ) bone graft substitute is a Intervention_Pharmacological, Probing bone levels ( PBL ) is a Outcome_Physical, probing pocket depths ( PPD ) is a Outcome_Physical, Healing is a Outcome_Physical, in mean PPD is a Outcome_Physical, PPD reduction is a Outcome_Physical

41534_task0

Sentence: Clinical effects of nanocrystalline hydroxyapatite paste in the treatment of intrabony periodontal defects : a randomized controlled clinical study . The purpose of the present randomized controlled clinical study was to compare the clinical outcomes of papilla preservation flap surgery with or without the application of a novel nanocrystalline hydroxyapatite ( nano-HA ) bone graft substitute . Fourteen patients with paired intrabony periodontal defects of ≥ 4 mm participated in this split-mouth design study . The defects in each subject were randomly selected to receive nano-HA paste in conjunction with papilla preservation flaps or papilla preservation flaps alone . Probing bone levels ( PBL ) from a customized acrylic stent and probing pocket depths ( PPD ) were measured at baseline and again 6 months following surgery . No differences in any of the investigated parameters were observed at baseline between the two groups . Healing was uneventful in all patients . Both treatments resulted in significant improvements between baseline and 6 months ( p < 0.05 ) . At 6 months after therapy , the sites treated with nano-HA paste showed a reduction in mean PPD from 8.3 ± 1.2 to 4.0 ± 1.1 mm and a gain in PBL of 4.3 ± 1.4 mm , whereas in the control group , the mean PPD changed from 7.9 ± 1.2 mm to 5.0 ± 1.2 mm and PBL gain was 2.6 ± 1.4 mm . Results demonstrated statistically greater PPD reduction and PBL gain ( p < 0.05 ) in the test group as compared with the control group . In conclusion , after 6 months , the treatment of intrabony periodontal defects with a nano-HA paste leads to significantly improved clinical outcomes when compared with papilla preservation flap surgery alone . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Physical

[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Clinical effects of nanocrystalline hydroxyapatite paste in the treatment of intrabony periodontal defects : a randomized controlled clinical study . The purpose of the present randomized controlled clinical study was to compare the clinical outcomes of papilla preservation flap surgery with or without the application of a novel nanocrystalline hydroxyapatite ( nano-HA ) bone graft substitute . Fourteen patients with paired intrabony periodontal defects of ≥ 4 mm participated in this split-mouth design study . The defects in each subject were randomly selected to receive nano-HA paste in conjunction with papilla preservation flaps or papilla preservation flaps alone . Probing bone levels ( PBL ) from a customized acrylic stent and probing pocket depths ( PPD ) were measured at baseline and again 6 months following surgery . No differences in any of the investigated parameters were observed at baseline between the two groups . Healing was uneventful in all patients . Both treatments resulted in significant improvements between baseline and 6 months ( p < 0.05 ) . At 6 months after therapy , the sites treated with nano-HA paste showed a reduction in mean PPD from 8.3 ± 1.2 to 4.0 ± 1.1 mm and a gain in PBL of 4.3 ± 1.4 mm , whereas in the control group , the mean PPD changed from 7.9 ± 1.2 mm to 5.0 ± 1.2 mm and PBL gain was 2.6 ± 1.4 mm . Results demonstrated statistically greater PPD reduction and PBL gain ( p < 0.05 ) in the test group as compared with the control group . In conclusion , after 6 months , the treatment of intrabony periodontal defects with a nano-HA paste leads to significantly improved clinical outcomes when compared with papilla preservation flap surgery alone .

[ "Clinical", "effects", "of", "nanocrystalline", "hydroxyapatite", "paste", "in", "the", "treatment", "of", "intrabony", "periodontal", "defects", ":", "a", "randomized", "controlled", "clinical", "study", ".", "The", "purpose", "of", "the", "present", "randomized", "controlled", "clinical", "study", "was", "to", "compare", "the", "clinical", "outcomes", "of", "papilla", "preservation", "flap", "surgery", "with", "or", "without", "the", "application", "of", "a", "novel", "nanocrystalline", "hydroxyapatite", "(", "nano", "-", "HA", ")", "bone", "graft", "substitute", ".", "Fourteen", "patients", "with", "paired", "intrabony", "periodontal", "defects", "of", "≥", "4", "mm", "participated", "in", "this", "split", "-", "mouth", "design", "study", ".", "The", "defects", "in", "each", "subject", "were", "randomly", "selected", "to", "receive", "nano", "-", "HA", "paste", "in", "conjunction", "with", "papilla", "preservation", "flaps", "or", "papilla", "preservation", "flaps", "alone", ".", "Probing", "bone", "levels", "(", "PBL", ")", "from", "a", "customized", "acrylic", "stent", "and", "probing", "pocket", "depths", "(", "PPD", ")", "were", "measured", "at", "baseline", "and", "again", "6", "months", "following", "surgery", ".", "No", "differences", "in", "any", "of", "the", "investigated", "parameters", "were", "observed", "at", "baseline", "between", "the", "two", "groups", ".", "Healing", "was", "uneventful", "in", "all", "patients", ".", "Both", "treatments", "resulted", "in", "significant", "improvements", "between", "baseline", "and", "6", "months", "(", "p", "<", "0.05", ")", ".", "At", "6", "months", "after", "therapy", ",", "the", "sites", "treated", "with", "nano", "-", "HA", "paste", "showed", "a", "reduction", "in", "mean", "PPD", "from", "8.3", "±", "1.2", "to", "4.0", "±", "1.1", "mm", "and", "a", "gain", "in", "PBL", "of", "4.3", "±", "1.4", "mm", ",", "whereas", "in", "the", "control", "group", ",", "the", "mean", "PPD", "changed", "from", "7.9", "±", "1.2", "mm", "to", "5.0", "±", "1.2", "mm", "and", "PBL", "gain", "was", "2.6", "±", "1.4", "mm", ".", "Results", "demonstrated", "statistically", "greater", "PPD", "reduction", "and", "PBL", "gain", "(", "p", "<", "0.05", ")", "in", "the", "test", "group", "as", "compared", "with", "the", "control", "group", ".", "In", "conclusion", ",", "after", "6", "months", ",", "the", "treatment", "of", "intrabony", "periodontal", "defects", "with", "a", "nano", "-", "HA", "paste", "leads", "to", "significantly", "improved", "clinical", "outcomes", "when", "compared", "with", "papilla", "preservation", "flap", "surgery", "alone", "." ]

[ "Intervention_Pharmacological", "Outcome_Physical" ]

nanocrystalline hydroxyapatite paste is a Intervention_Pharmacological, nanocrystalline hydroxyapatite ( nano - HA ) bone graft substitute is a Intervention_Pharmacological, Probing bone levels ( PBL ) is a Outcome_Physical, probing pocket depths ( PPD ) is a Outcome_Physical, Healing is a Outcome_Physical, in mean PPD is a Outcome_Physical, PPD reduction is a Outcome_Physical

41534_task1

Sentence: Clinical effects of nanocrystalline hydroxyapatite paste in the treatment of intrabony periodontal defects : a randomized controlled clinical study . The purpose of the present randomized controlled clinical study was to compare the clinical outcomes of papilla preservation flap surgery with or without the application of a novel nanocrystalline hydroxyapatite ( nano-HA ) bone graft substitute . Fourteen patients with paired intrabony periodontal defects of ≥ 4 mm participated in this split-mouth design study . The defects in each subject were randomly selected to receive nano-HA paste in conjunction with papilla preservation flaps or papilla preservation flaps alone . Probing bone levels ( PBL ) from a customized acrylic stent and probing pocket depths ( PPD ) were measured at baseline and again 6 months following surgery . No differences in any of the investigated parameters were observed at baseline between the two groups . Healing was uneventful in all patients . Both treatments resulted in significant improvements between baseline and 6 months ( p < 0.05 ) . At 6 months after therapy , the sites treated with nano-HA paste showed a reduction in mean PPD from 8.3 ± 1.2 to 4.0 ± 1.1 mm and a gain in PBL of 4.3 ± 1.4 mm , whereas in the control group , the mean PPD changed from 7.9 ± 1.2 mm to 5.0 ± 1.2 mm and PBL gain was 2.6 ± 1.4 mm . Results demonstrated statistically greater PPD reduction and PBL gain ( p < 0.05 ) in the test group as compared with the control group . In conclusion , after 6 months , the treatment of intrabony periodontal defects with a nano-HA paste leads to significantly improved clinical outcomes when compared with papilla preservation flap surgery alone . Instructions: please typing these entity words according to sentence: nanocrystalline hydroxyapatite paste, nanocrystalline hydroxyapatite ( nano - HA ) bone graft substitute, Probing bone levels ( PBL ), probing pocket depths ( PPD ), Healing, in mean PPD, PPD reduction Options: Intervention_Pharmacological, Outcome_Physical

[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Clinical effects of nanocrystalline hydroxyapatite paste in the treatment of intrabony periodontal defects : a randomized controlled clinical study . The purpose of the present randomized controlled clinical study was to compare the clinical outcomes of papilla preservation flap surgery with or without the application of a novel nanocrystalline hydroxyapatite ( nano-HA ) bone graft substitute . Fourteen patients with paired intrabony periodontal defects of ≥ 4 mm participated in this split-mouth design study . The defects in each subject were randomly selected to receive nano-HA paste in conjunction with papilla preservation flaps or papilla preservation flaps alone . Probing bone levels ( PBL ) from a customized acrylic stent and probing pocket depths ( PPD ) were measured at baseline and again 6 months following surgery . No differences in any of the investigated parameters were observed at baseline between the two groups . Healing was uneventful in all patients . Both treatments resulted in significant improvements between baseline and 6 months ( p < 0.05 ) . At 6 months after therapy , the sites treated with nano-HA paste showed a reduction in mean PPD from 8.3 ± 1.2 to 4.0 ± 1.1 mm and a gain in PBL of 4.3 ± 1.4 mm , whereas in the control group , the mean PPD changed from 7.9 ± 1.2 mm to 5.0 ± 1.2 mm and PBL gain was 2.6 ± 1.4 mm . Results demonstrated statistically greater PPD reduction and PBL gain ( p < 0.05 ) in the test group as compared with the control group . In conclusion , after 6 months , the treatment of intrabony periodontal defects with a nano-HA paste leads to significantly improved clinical outcomes when compared with papilla preservation flap surgery alone .

[ "Clinical", "effects", "of", "nanocrystalline", "hydroxyapatite", "paste", "in", "the", "treatment", "of", "intrabony", "periodontal", "defects", ":", "a", "randomized", "controlled", "clinical", "study", ".", "The", "purpose", "of", "the", "present", "randomized", "controlled", "clinical", "study", "was", "to", "compare", "the", "clinical", "outcomes", "of", "papilla", "preservation", "flap", "surgery", "with", "or", "without", "the", "application", "of", "a", "novel", "nanocrystalline", "hydroxyapatite", "(", "nano", "-", "HA", ")", "bone", "graft", "substitute", ".", "Fourteen", "patients", "with", "paired", "intrabony", "periodontal", "defects", "of", "≥", "4", "mm", "participated", "in", "this", "split", "-", "mouth", "design", "study", ".", "The", "defects", "in", "each", "subject", "were", "randomly", "selected", "to", "receive", "nano", "-", "HA", "paste", "in", "conjunction", "with", "papilla", "preservation", "flaps", "or", "papilla", "preservation", "flaps", "alone", ".", "Probing", "bone", "levels", "(", "PBL", ")", "from", "a", "customized", "acrylic", "stent", "and", "probing", "pocket", "depths", "(", "PPD", ")", "were", "measured", "at", "baseline", "and", "again", "6", "months", "following", "surgery", ".", "No", "differences", "in", "any", "of", "the", "investigated", "parameters", "were", "observed", "at", "baseline", "between", "the", "two", "groups", ".", "Healing", "was", "uneventful", "in", "all", "patients", ".", "Both", "treatments", "resulted", "in", "significant", "improvements", "between", "baseline", "and", "6", "months", "(", "p", "<", "0.05", ")", ".", "At", "6", "months", "after", "therapy", ",", "the", "sites", "treated", "with", "nano", "-", "HA", "paste", "showed", "a", "reduction", "in", "mean", "PPD", "from", "8.3", "±", "1.2", "to", "4.0", "±", "1.1", "mm", "and", "a", "gain", "in", "PBL", "of", "4.3", "±", "1.4", "mm", ",", "whereas", "in", "the", "control", "group", ",", "the", "mean", "PPD", "changed", "from", "7.9", "±", "1.2", "mm", "to", "5.0", "±", "1.2", "mm", "and", "PBL", "gain", "was", "2.6", "±", "1.4", "mm", ".", "Results", "demonstrated", "statistically", "greater", "PPD", "reduction", "and", "PBL", "gain", "(", "p", "<", "0.05", ")", "in", "the", "test", "group", "as", "compared", "with", "the", "control", "group", ".", "In", "conclusion", ",", "after", "6", "months", ",", "the", "treatment", "of", "intrabony", "periodontal", "defects", "with", "a", "nano", "-", "HA", "paste", "leads", "to", "significantly", "improved", "clinical", "outcomes", "when", "compared", "with", "papilla", "preservation", "flap", "surgery", "alone", "." ]

[ "Intervention_Pharmacological", "Outcome_Physical" ]

nanocrystalline hydroxyapatite paste, nanocrystalline hydroxyapatite ( nano - HA ) bone graft substitute, Probing bone levels ( PBL ), probing pocket depths ( PPD ), Healing, in mean PPD, PPD reduction

41534_task2

Sentence: Clinical effects of nanocrystalline hydroxyapatite paste in the treatment of intrabony periodontal defects : a randomized controlled clinical study . The purpose of the present randomized controlled clinical study was to compare the clinical outcomes of papilla preservation flap surgery with or without the application of a novel nanocrystalline hydroxyapatite ( nano-HA ) bone graft substitute . Fourteen patients with paired intrabony periodontal defects of ≥ 4 mm participated in this split-mouth design study . The defects in each subject were randomly selected to receive nano-HA paste in conjunction with papilla preservation flaps or papilla preservation flaps alone . Probing bone levels ( PBL ) from a customized acrylic stent and probing pocket depths ( PPD ) were measured at baseline and again 6 months following surgery . No differences in any of the investigated parameters were observed at baseline between the two groups . Healing was uneventful in all patients . Both treatments resulted in significant improvements between baseline and 6 months ( p < 0.05 ) . At 6 months after therapy , the sites treated with nano-HA paste showed a reduction in mean PPD from 8.3 ± 1.2 to 4.0 ± 1.1 mm and a gain in PBL of 4.3 ± 1.4 mm , whereas in the control group , the mean PPD changed from 7.9 ± 1.2 mm to 5.0 ± 1.2 mm and PBL gain was 2.6 ± 1.4 mm . Results demonstrated statistically greater PPD reduction and PBL gain ( p < 0.05 ) in the test group as compared with the control group . In conclusion , after 6 months , the treatment of intrabony periodontal defects with a nano-HA paste leads to significantly improved clinical outcomes when compared with papilla preservation flap surgery alone . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Clinical effects of nanocrystalline hydroxyapatite paste in the treatment of intrabony periodontal defects : a randomized controlled clinical study . The purpose of the present randomized controlled clinical study was to compare the clinical outcomes of papilla preservation flap surgery with or without the application of a novel nanocrystalline hydroxyapatite ( nano-HA ) bone graft substitute . Fourteen patients with paired intrabony periodontal defects of ≥ 4 mm participated in this split-mouth design study . The defects in each subject were randomly selected to receive nano-HA paste in conjunction with papilla preservation flaps or papilla preservation flaps alone . Probing bone levels ( PBL ) from a customized acrylic stent and probing pocket depths ( PPD ) were measured at baseline and again 6 months following surgery . No differences in any of the investigated parameters were observed at baseline between the two groups . Healing was uneventful in all patients . Both treatments resulted in significant improvements between baseline and 6 months ( p < 0.05 ) . At 6 months after therapy , the sites treated with nano-HA paste showed a reduction in mean PPD from 8.3 ± 1.2 to 4.0 ± 1.1 mm and a gain in PBL of 4.3 ± 1.4 mm , whereas in the control group , the mean PPD changed from 7.9 ± 1.2 mm to 5.0 ± 1.2 mm and PBL gain was 2.6 ± 1.4 mm . Results demonstrated statistically greater PPD reduction and PBL gain ( p < 0.05 ) in the test group as compared with the control group . In conclusion , after 6 months , the treatment of intrabony periodontal defects with a nano-HA paste leads to significantly improved clinical outcomes when compared with papilla preservation flap surgery alone .

[ "Clinical", "effects", "of", "nanocrystalline", "hydroxyapatite", "paste", "in", "the", "treatment", "of", "intrabony", "periodontal", "defects", ":", "a", "randomized", "controlled", "clinical", "study", ".", "The", "purpose", "of", "the", "present", "randomized", "controlled", "clinical", "study", "was", "to", "compare", "the", "clinical", "outcomes", "of", "papilla", "preservation", "flap", "surgery", "with", "or", "without", "the", "application", "of", "a", "novel", "nanocrystalline", "hydroxyapatite", "(", "nano", "-", "HA", ")", "bone", "graft", "substitute", ".", "Fourteen", "patients", "with", "paired", "intrabony", "periodontal", "defects", "of", "≥", "4", "mm", "participated", "in", "this", "split", "-", "mouth", "design", "study", ".", "The", "defects", "in", "each", "subject", "were", "randomly", "selected", "to", "receive", "nano", "-", "HA", "paste", "in", "conjunction", "with", "papilla", "preservation", "flaps", "or", "papilla", "preservation", "flaps", "alone", ".", "Probing", "bone", "levels", "(", "PBL", ")", "from", "a", "customized", "acrylic", "stent", "and", "probing", "pocket", "depths", "(", "PPD", ")", "were", "measured", "at", "baseline", "and", "again", "6", "months", "following", "surgery", ".", "No", "differences", "in", "any", "of", "the", "investigated", "parameters", "were", "observed", "at", "baseline", "between", "the", "two", "groups", ".", "Healing", "was", "uneventful", "in", "all", "patients", ".", "Both", "treatments", "resulted", "in", "significant", "improvements", "between", "baseline", "and", "6", "months", "(", "p", "<", "0.05", ")", ".", "At", "6", "months", "after", "therapy", ",", "the", "sites", "treated", "with", "nano", "-", "HA", "paste", "showed", "a", "reduction", "in", "mean", "PPD", "from", "8.3", "±", "1.2", "to", "4.0", "±", "1.1", "mm", "and", "a", "gain", "in", "PBL", "of", "4.3", "±", "1.4", "mm", ",", "whereas", "in", "the", "control", "group", ",", "the", "mean", "PPD", "changed", "from", "7.9", "±", "1.2", "mm", "to", "5.0", "±", "1.2", "mm", "and", "PBL", "gain", "was", "2.6", "±", "1.4", "mm", ".", "Results", "demonstrated", "statistically", "greater", "PPD", "reduction", "and", "PBL", "gain", "(", "p", "<", "0.05", ")", "in", "the", "test", "group", "as", "compared", "with", "the", "control", "group", ".", "In", "conclusion", ",", "after", "6", "months", ",", "the", "treatment", "of", "intrabony", "periodontal", "defects", "with", "a", "nano", "-", "HA", "paste", "leads", "to", "significantly", "improved", "clinical", "outcomes", "when", "compared", "with", "papilla", "preservation", "flap", "surgery", "alone", "." ]

[ "Intervention_Pharmacological", "Outcome_Physical" ]

antifungal agents is a GROUP, ketoconazole is a DRUG, itraconazole is a DRUG, Nafazodone is a DRUG, fluvoxamine is a DRUG, cimetidine is a DRUG, Xanax is a BRAND, Fluoxetine is a DRUG, OCs is a GROUP, sertraline is a DRUG, diltiazem is a DRUG, macrolide antibiotics is a GROUP

Adinazolam_ddi_task0

Sentence: Co-administration with antifungal agents such as ketoconazole or itraconazole is not recommended. Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction). Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics (exercise caution). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GROUP, BRAND, DRUG

[ "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-BRAND", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O" ]

Co-administration with antifungal agents such as ketoconazole or itraconazole is not recommended. Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction). Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics (exercise caution).

[ "Co", "-", "administration", "with", "antifungal", "agents", "such", "as", "ketoconazole", "or", "itraconazole", "is", "not", "recommended", ".", "Nafazodone", ",", "fluvoxamine", ",", "cimetidine", "(", "consider", "Xanax", "dose", "reduction", ")", ".", "Fluoxetine", ",", "OCs", ",", "sertraline", ",", "diltiazem", ",", "macrolide", "antibiotics", "(", "exercise", "caution", ")", "." ]

[ "GROUP", "DRUG", "BRAND" ]

antifungal agents is a GROUP, ketoconazole is a DRUG, itraconazole is a DRUG, Nafazodone is a DRUG, fluvoxamine is a DRUG, cimetidine is a DRUG, Xanax is a BRAND, Fluoxetine is a DRUG, OCs is a GROUP, sertraline is a DRUG, diltiazem is a DRUG, macrolide antibiotics is a GROUP

Adinazolam_ddi_task1

Sentence: Co-administration with antifungal agents such as ketoconazole or itraconazole is not recommended. Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction). Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics (exercise caution). Instructions: please typing these entity words according to sentence: antifungal agents, ketoconazole, itraconazole, Nafazodone, fluvoxamine, cimetidine, Xanax, Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics Options: GROUP, BRAND, DRUG

[ "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-BRAND", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O" ]

Co-administration with antifungal agents such as ketoconazole or itraconazole is not recommended. Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction). Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics (exercise caution).

[ "Co", "-", "administration", "with", "antifungal", "agents", "such", "as", "ketoconazole", "or", "itraconazole", "is", "not", "recommended", ".", "Nafazodone", ",", "fluvoxamine", ",", "cimetidine", "(", "consider", "Xanax", "dose", "reduction", ")", ".", "Fluoxetine", ",", "OCs", ",", "sertraline", ",", "diltiazem", ",", "macrolide", "antibiotics", "(", "exercise", "caution", ")", "." ]

[ "GROUP", "DRUG", "BRAND" ]

antifungal agents, ketoconazole, itraconazole, Nafazodone, fluvoxamine, cimetidine, Xanax, Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics

Adinazolam_ddi_task2

Sentence: Co-administration with antifungal agents such as ketoconazole or itraconazole is not recommended. Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction). Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics (exercise caution). Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-GROUP", "I-GROUP", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "B-BRAND", "O", "O", "O", "O", "B-DRUG", "O", "B-GROUP", "O", "B-DRUG", "O", "B-DRUG", "O", "B-GROUP", "I-GROUP", "O", "O", "O", "O", "O" ]

Co-administration with antifungal agents such as ketoconazole or itraconazole is not recommended. Nafazodone, fluvoxamine, cimetidine (consider Xanax dose reduction). Fluoxetine, OCs, sertraline, diltiazem, macrolide antibiotics (exercise caution).

[ "Co", "-", "administration", "with", "antifungal", "agents", "such", "as", "ketoconazole", "or", "itraconazole", "is", "not", "recommended", ".", "Nafazodone", ",", "fluvoxamine", ",", "cimetidine", "(", "consider", "Xanax", "dose", "reduction", ")", ".", "Fluoxetine", ",", "OCs", ",", "sertraline", ",", "diltiazem", ",", "macrolide", "antibiotics", "(", "exercise", "caution", ")", "." ]

[ "GROUP", "DRUG", "BRAND" ]

modulation of the soleus H - reflex is a Outcome_Physical, rhythmical arm swing is a Intervention_Physical, rhythmic arm swing is a Intervention_Physical, depression of the soleus H - reflex is a Outcome_Physical, ipsilateral is a Participant_Condition, soleus H - reflex depression is a Outcome_Physical, ipsilateral backward arm swing is a Intervention_Physical, ipsilateral arm forward swing is a Intervention_Physical, ipsilateral arm swing is a Intervention_Physical

5688_task0

Sentence: Phase-dependent modulation of the soleus H-reflex during rhythmical arm swing in humans . The purpose of this study is to investigate modulation of the soleus H-reflex during rhythmic arm swing in humans . Significant depression of the soleus H-reflex was observed when subjects swung their ipsilateral arms or both arms reciprocally during testing . The degree of soleus H-reflex depression appeared directly proportional to the speed of the arm swing . This depression was observed in the conditioning-testing intervals of 400 , 500 , and 600 msec during the ipsilateral backward arm swing and at the onset of the ipsilateral arm forward swing . This phase of depression partially overlapped the phase of depression of the soleus H-reflex during walking . However , the pattern of modulation during arm swing was not exactly the same as that during walking . Therefore , we concluded that the ipsilateral arm swing may partially affect the depression of the soleus H-reflex during the arm swing phase of walking but is not responsible for depression of the soleus H-reflex throughout the entire walking cycle . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Outcome_Physical, Participant_Condition

[ "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Phase-dependent modulation of the soleus H-reflex during rhythmical arm swing in humans . The purpose of this study is to investigate modulation of the soleus H-reflex during rhythmic arm swing in humans . Significant depression of the soleus H-reflex was observed when subjects swung their ipsilateral arms or both arms reciprocally during testing . The degree of soleus H-reflex depression appeared directly proportional to the speed of the arm swing . This depression was observed in the conditioning-testing intervals of 400 , 500 , and 600 msec during the ipsilateral backward arm swing and at the onset of the ipsilateral arm forward swing . This phase of depression partially overlapped the phase of depression of the soleus H-reflex during walking . However , the pattern of modulation during arm swing was not exactly the same as that during walking . Therefore , we concluded that the ipsilateral arm swing may partially affect the depression of the soleus H-reflex during the arm swing phase of walking but is not responsible for depression of the soleus H-reflex throughout the entire walking cycle .

[ "Phase", "-", "dependent", "modulation", "of", "the", "soleus", "H", "-", "reflex", "during", "rhythmical", "arm", "swing", "in", "humans", ".", "The", "purpose", "of", "this", "study", "is", "to", "investigate", "modulation", "of", "the", "soleus", "H", "-", "reflex", "during", "rhythmic", "arm", "swing", "in", "humans", ".", "Significant", "depression", "of", "the", "soleus", "H", "-", "reflex", "was", "observed", "when", "subjects", "swung", "their", "ipsilateral", "arms", "or", "both", "arms", "reciprocally", "during", "testing", ".", "The", "degree", "of", "soleus", "H", "-", "reflex", "depression", "appeared", "directly", "proportional", "to", "the", "speed", "of", "the", "arm", "swing", ".", "This", "depression", "was", "observed", "in", "the", "conditioning", "-", "testing", "intervals", "of", "400", ",", "500", ",", "and", "600", "msec", "during", "the", "ipsilateral", "backward", "arm", "swing", "and", "at", "the", "onset", "of", "the", "ipsilateral", "arm", "forward", "swing", ".", "This", "phase", "of", "depression", "partially", "overlapped", "the", "phase", "of", "depression", "of", "the", "soleus", "H", "-", "reflex", "during", "walking", ".", "However", ",", "the", "pattern", "of", "modulation", "during", "arm", "swing", "was", "not", "exactly", "the", "same", "as", "that", "during", "walking", ".", "Therefore", ",", "we", "concluded", "that", "the", "ipsilateral", "arm", "swing", "may", "partially", "affect", "the", "depression", "of", "the", "soleus", "H", "-", "reflex", "during", "the", "arm", "swing", "phase", "of", "walking", "but", "is", "not", "responsible", "for", "depression", "of", "the", "soleus", "H", "-", "reflex", "throughout", "the", "entire", "walking", "cycle", "." ]

[ "Outcome_Physical", "Intervention_Physical", "Participant_Condition" ]

modulation of the soleus H - reflex is a Outcome_Physical, rhythmical arm swing is a Intervention_Physical, rhythmic arm swing is a Intervention_Physical, depression of the soleus H - reflex is a Outcome_Physical, ipsilateral is a Participant_Condition, soleus H - reflex depression is a Outcome_Physical, ipsilateral backward arm swing is a Intervention_Physical, ipsilateral arm forward swing is a Intervention_Physical, ipsilateral arm swing is a Intervention_Physical

5688_task1

Sentence: Phase-dependent modulation of the soleus H-reflex during rhythmical arm swing in humans . The purpose of this study is to investigate modulation of the soleus H-reflex during rhythmic arm swing in humans . Significant depression of the soleus H-reflex was observed when subjects swung their ipsilateral arms or both arms reciprocally during testing . The degree of soleus H-reflex depression appeared directly proportional to the speed of the arm swing . This depression was observed in the conditioning-testing intervals of 400 , 500 , and 600 msec during the ipsilateral backward arm swing and at the onset of the ipsilateral arm forward swing . This phase of depression partially overlapped the phase of depression of the soleus H-reflex during walking . However , the pattern of modulation during arm swing was not exactly the same as that during walking . Therefore , we concluded that the ipsilateral arm swing may partially affect the depression of the soleus H-reflex during the arm swing phase of walking but is not responsible for depression of the soleus H-reflex throughout the entire walking cycle . Instructions: please typing these entity words according to sentence: modulation of the soleus H - reflex, rhythmical arm swing, rhythmic arm swing, depression of the soleus H - reflex, ipsilateral, soleus H - reflex depression, ipsilateral backward arm swing, ipsilateral arm forward swing, ipsilateral arm swing Options: Intervention_Physical, Outcome_Physical, Participant_Condition

[ "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Phase-dependent modulation of the soleus H-reflex during rhythmical arm swing in humans . The purpose of this study is to investigate modulation of the soleus H-reflex during rhythmic arm swing in humans . Significant depression of the soleus H-reflex was observed when subjects swung their ipsilateral arms or both arms reciprocally during testing . The degree of soleus H-reflex depression appeared directly proportional to the speed of the arm swing . This depression was observed in the conditioning-testing intervals of 400 , 500 , and 600 msec during the ipsilateral backward arm swing and at the onset of the ipsilateral arm forward swing . This phase of depression partially overlapped the phase of depression of the soleus H-reflex during walking . However , the pattern of modulation during arm swing was not exactly the same as that during walking . Therefore , we concluded that the ipsilateral arm swing may partially affect the depression of the soleus H-reflex during the arm swing phase of walking but is not responsible for depression of the soleus H-reflex throughout the entire walking cycle .

[ "Phase", "-", "dependent", "modulation", "of", "the", "soleus", "H", "-", "reflex", "during", "rhythmical", "arm", "swing", "in", "humans", ".", "The", "purpose", "of", "this", "study", "is", "to", "investigate", "modulation", "of", "the", "soleus", "H", "-", "reflex", "during", "rhythmic", "arm", "swing", "in", "humans", ".", "Significant", "depression", "of", "the", "soleus", "H", "-", "reflex", "was", "observed", "when", "subjects", "swung", "their", "ipsilateral", "arms", "or", "both", "arms", "reciprocally", "during", "testing", ".", "The", "degree", "of", "soleus", "H", "-", "reflex", "depression", "appeared", "directly", "proportional", "to", "the", "speed", "of", "the", "arm", "swing", ".", "This", "depression", "was", "observed", "in", "the", "conditioning", "-", "testing", "intervals", "of", "400", ",", "500", ",", "and", "600", "msec", "during", "the", "ipsilateral", "backward", "arm", "swing", "and", "at", "the", "onset", "of", "the", "ipsilateral", "arm", "forward", "swing", ".", "This", "phase", "of", "depression", "partially", "overlapped", "the", "phase", "of", "depression", "of", "the", "soleus", "H", "-", "reflex", "during", "walking", ".", "However", ",", "the", "pattern", "of", "modulation", "during", "arm", "swing", "was", "not", "exactly", "the", "same", "as", "that", "during", "walking", ".", "Therefore", ",", "we", "concluded", "that", "the", "ipsilateral", "arm", "swing", "may", "partially", "affect", "the", "depression", "of", "the", "soleus", "H", "-", "reflex", "during", "the", "arm", "swing", "phase", "of", "walking", "but", "is", "not", "responsible", "for", "depression", "of", "the", "soleus", "H", "-", "reflex", "throughout", "the", "entire", "walking", "cycle", "." ]

[ "Outcome_Physical", "Intervention_Physical", "Participant_Condition" ]

modulation of the soleus H - reflex, rhythmical arm swing, rhythmic arm swing, depression of the soleus H - reflex, ipsilateral, soleus H - reflex depression, ipsilateral backward arm swing, ipsilateral arm forward swing, ipsilateral arm swing

5688_task2

Sentence: Phase-dependent modulation of the soleus H-reflex during rhythmical arm swing in humans . The purpose of this study is to investigate modulation of the soleus H-reflex during rhythmic arm swing in humans . Significant depression of the soleus H-reflex was observed when subjects swung their ipsilateral arms or both arms reciprocally during testing . The degree of soleus H-reflex depression appeared directly proportional to the speed of the arm swing . This depression was observed in the conditioning-testing intervals of 400 , 500 , and 600 msec during the ipsilateral backward arm swing and at the onset of the ipsilateral arm forward swing . This phase of depression partially overlapped the phase of depression of the soleus H-reflex during walking . However , the pattern of modulation during arm swing was not exactly the same as that during walking . Therefore , we concluded that the ipsilateral arm swing may partially affect the depression of the soleus H-reflex during the arm swing phase of walking but is not responsible for depression of the soleus H-reflex throughout the entire walking cycle . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Phase-dependent modulation of the soleus H-reflex during rhythmical arm swing in humans . The purpose of this study is to investigate modulation of the soleus H-reflex during rhythmic arm swing in humans . Significant depression of the soleus H-reflex was observed when subjects swung their ipsilateral arms or both arms reciprocally during testing . The degree of soleus H-reflex depression appeared directly proportional to the speed of the arm swing . This depression was observed in the conditioning-testing intervals of 400 , 500 , and 600 msec during the ipsilateral backward arm swing and at the onset of the ipsilateral arm forward swing . This phase of depression partially overlapped the phase of depression of the soleus H-reflex during walking . However , the pattern of modulation during arm swing was not exactly the same as that during walking . Therefore , we concluded that the ipsilateral arm swing may partially affect the depression of the soleus H-reflex during the arm swing phase of walking but is not responsible for depression of the soleus H-reflex throughout the entire walking cycle .

[ "Phase", "-", "dependent", "modulation", "of", "the", "soleus", "H", "-", "reflex", "during", "rhythmical", "arm", "swing", "in", "humans", ".", "The", "purpose", "of", "this", "study", "is", "to", "investigate", "modulation", "of", "the", "soleus", "H", "-", "reflex", "during", "rhythmic", "arm", "swing", "in", "humans", ".", "Significant", "depression", "of", "the", "soleus", "H", "-", "reflex", "was", "observed", "when", "subjects", "swung", "their", "ipsilateral", "arms", "or", "both", "arms", "reciprocally", "during", "testing", ".", "The", "degree", "of", "soleus", "H", "-", "reflex", "depression", "appeared", "directly", "proportional", "to", "the", "speed", "of", "the", "arm", "swing", ".", "This", "depression", "was", "observed", "in", "the", "conditioning", "-", "testing", "intervals", "of", "400", ",", "500", ",", "and", "600", "msec", "during", "the", "ipsilateral", "backward", "arm", "swing", "and", "at", "the", "onset", "of", "the", "ipsilateral", "arm", "forward", "swing", ".", "This", "phase", "of", "depression", "partially", "overlapped", "the", "phase", "of", "depression", "of", "the", "soleus", "H", "-", "reflex", "during", "walking", ".", "However", ",", "the", "pattern", "of", "modulation", "during", "arm", "swing", "was", "not", "exactly", "the", "same", "as", "that", "during", "walking", ".", "Therefore", ",", "we", "concluded", "that", "the", "ipsilateral", "arm", "swing", "may", "partially", "affect", "the", "depression", "of", "the", "soleus", "H", "-", "reflex", "during", "the", "arm", "swing", "phase", "of", "walking", "but", "is", "not", "responsible", "for", "depression", "of", "the", "soleus", "H", "-", "reflex", "throughout", "the", "entire", "walking", "cycle", "." ]

[ "Outcome_Physical", "Intervention_Physical", "Participant_Condition" ]

Protein - tyrosine kinase activation is an other_name, lipopolysaccharide induction is an other_name, interleukin 1beta is a protein_molecule, NFkappaB activation is an other_name, NFkappaB nuclear translocation is an other_name

20977_task0

Sentence: Protein-tyrosine kinase activation is required for lipopolysaccharide induction of interleukin 1beta and NFkappaB activation, but not NFkappaB nuclear translocation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein_molecule, other_name

[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "B-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]

Protein-tyrosine kinase activation is required for lipopolysaccharide induction of interleukin 1beta and NFkappaB activation, but not NFkappaB nuclear translocation.

[ "Protein", "-", "tyrosine", "kinase", "activation", "is", "required", "for", "lipopolysaccharide", "induction", "of", "interleukin", "1beta", "and", "NFkappaB", "activation", ",", "but", "not", "NFkappaB", "nuclear", "translocation", "." ]

[ "other_name", "protein_molecule", "cell_line", "protein_family_or_group", "lipid", "cell_type", "protein_complex", "amino_acid_monomer" ]

Protein - tyrosine kinase activation is an other_name, lipopolysaccharide induction is an other_name, interleukin 1beta is a protein_molecule, NFkappaB activation is an other_name, NFkappaB nuclear translocation is an other_name

20977_task1

Sentence: Protein-tyrosine kinase activation is required for lipopolysaccharide induction of interleukin 1beta and NFkappaB activation, but not NFkappaB nuclear translocation. Instructions: please typing these entity words according to sentence: Protein - tyrosine kinase activation, lipopolysaccharide induction, interleukin 1beta, NFkappaB activation, NFkappaB nuclear translocation Options: protein_molecule, other_name

[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "B-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]

Protein-tyrosine kinase activation is required for lipopolysaccharide induction of interleukin 1beta and NFkappaB activation, but not NFkappaB nuclear translocation.

[ "Protein", "-", "tyrosine", "kinase", "activation", "is", "required", "for", "lipopolysaccharide", "induction", "of", "interleukin", "1beta", "and", "NFkappaB", "activation", ",", "but", "not", "NFkappaB", "nuclear", "translocation", "." ]

[ "other_name", "protein_molecule", "cell_line", "protein_family_or_group", "lipid", "cell_type", "protein_complex", "amino_acid_monomer" ]

Protein - tyrosine kinase activation, lipopolysaccharide induction, interleukin 1beta, NFkappaB activation, NFkappaB nuclear translocation

20977_task2

Sentence: Protein-tyrosine kinase activation is required for lipopolysaccharide induction of interleukin 1beta and NFkappaB activation, but not NFkappaB nuclear translocation. Instructions: please extract entity words from the input sentence

[ "B-other_name", "I-other_name", "I-other_name", "I-other_name", "I-other_name", "O", "O", "O", "B-other_name", "I-other_name", "O", "B-protein_molecule", "I-protein_molecule", "O", "B-other_name", "I-other_name", "O", "O", "O", "B-other_name", "I-other_name", "I-other_name", "O" ]

Protein-tyrosine kinase activation is required for lipopolysaccharide induction of interleukin 1beta and NFkappaB activation, but not NFkappaB nuclear translocation.

[ "Protein", "-", "tyrosine", "kinase", "activation", "is", "required", "for", "lipopolysaccharide", "induction", "of", "interleukin", "1beta", "and", "NFkappaB", "activation", ",", "but", "not", "NFkappaB", "nuclear", "translocation", "." ]

[ "other_name", "protein_molecule", "cell_line", "protein_family_or_group", "lipid", "cell_type", "protein_complex", "amino_acid_monomer" ]

SST is an intervention, labeling anger is an outcome, LA is an intervention

1041_task0

Sentence: After the 6-month training period , the SST Group made fewer errors in labeling anger on adult faces , whereas error rates in the LA Group remained stable . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: intervention, outcome

[ "O", "O", "O", "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O" ]

After the 6-month training period , the SST Group made fewer errors in labeling anger on adult faces , whereas error rates in the LA Group remained stable .

[ "After", "the", "6-month", "training", "period", ",", "the", "SST", "Group", "made", "fewer", "errors", "in", "labeling", "anger", "on", "adult", "faces", ",", "whereas", "error", "rates", "in", "the", "LA", "Group", "remained", "stable", "." ]

[ "outcome", "intervention" ]

SST is an intervention, labeling anger is an outcome, LA is an intervention

1041_task1

Sentence: After the 6-month training period , the SST Group made fewer errors in labeling anger on adult faces , whereas error rates in the LA Group remained stable . Instructions: please typing these entity words according to sentence: SST, labeling anger, LA Options: intervention, outcome

[ "O", "O", "O", "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O" ]

After the 6-month training period , the SST Group made fewer errors in labeling anger on adult faces , whereas error rates in the LA Group remained stable .

[ "After", "the", "6-month", "training", "period", ",", "the", "SST", "Group", "made", "fewer", "errors", "in", "labeling", "anger", "on", "adult", "faces", ",", "whereas", "error", "rates", "in", "the", "LA", "Group", "remained", "stable", "." ]

[ "outcome", "intervention" ]

SST, labeling anger, LA

1041_task2

Sentence: After the 6-month training period , the SST Group made fewer errors in labeling anger on adult faces , whereas error rates in the LA Group remained stable . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O", "O", "B-outcome", "I-outcome", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-intervention", "O", "O", "O", "O" ]

After the 6-month training period , the SST Group made fewer errors in labeling anger on adult faces , whereas error rates in the LA Group remained stable .

[ "After", "the", "6-month", "training", "period", ",", "the", "SST", "Group", "made", "fewer", "errors", "in", "labeling", "anger", "on", "adult", "faces", ",", "whereas", "error", "rates", "in", "the", "LA", "Group", "remained", "stable", "." ]

[ "outcome", "intervention" ]

aim is an umlsterm, patients is an umlsterm, preeclampsia is an umlsterm, t - PA is an umlsterm, PAI-1 is an umlsterm, human is an umlsterm, cells is an umlsterm, human is an umlsterm, endothelium is an umlsterm, cells is an umlsterm, umbilical veins is an umlsterm, patients is an umlsterm, HELLP syndrome is an umlsterm, patients is an umlsterm, preeclampsia is an umlsterm, patients is an umlsterm, women is an umlsterm, controls is an umlsterm, t - PA is an umlsterm, PAI-1 is an umlsterm, ELISA is an umlsterm, cell cultures is an umlsterm, t - PA is an umlsterm, patients is an umlsterm, preeclampsia is an umlsterm, HELLP syndrome is an umlsterm, control group is an umlsterm, PAI-1 is an umlsterm, cell cultures is an umlsterm, t - PA is an umlsterm, PAI-1 is an umlsterm, patients is an umlsterm, preeclampsia is an umlsterm, HELLP syndrome is an umlsterm, t - PA is an umlsterm, PAI-1 is an umlsterm, human is an umlsterm, endothelium is an umlsterm, cells is an umlsterm, patients is an umlsterm, sign is an umlsterm, cell is an umlsterm

PerinatalMedizin.60080079.eng.abstr_task0

Sentence: The aim of our study was to investigate the influence that serum of patients with preeclampsia has on t-PA and PAI-1 expression from human endothelial cells . For this purpose , we cultured human endothelium cells , gained from umbilical veins , for 24 h with sera of 7 patients with HELLP syndrome and 12 patients with preeclampsia . The sera of 12 normotensive pregnant patients and 9 non-pregnant women were used as controls . We then determined t-PA and PAI-1 levels by ELISA , both in the maternal serum and in the supernatant of the endothelial cell cultures . While t-PA levels were significantly higher in the serum of patients with preeclampsia and HELLP syndrome than in the control group ( median : 8.0 ng/ml and 6.2 ng/ml vs 3.9 ng/ml and 3.1 ng/ml ) , levels of PAI-1 did not show any significant disparity among the different groups . The supernatant of the endothelial cell cultures demonstrated significantly elevated levels of both t-PA ( P 0.001 ) and PAI-1 ( P 0.01 ) when stimulated with serum gained from patients with preeclampsia or HELLP syndrome . The increased expression of t-PA and PAI-1 from human endothelium cells after stimulation with the serum of preeclamptic patients must be considered as a sign of increased endothelial cell activation . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O" ]

The aim of our study was to investigate the influence that serum of patients with preeclampsia has on t-PA and PAI-1 expression from human endothelial cells . For this purpose , we cultured human endothelium cells , gained from umbilical veins , for 24 h with sera of 7 patients with HELLP syndrome and 12 patients with preeclampsia . The sera of 12 normotensive pregnant patients and 9 non-pregnant women were used as controls . We then determined t-PA and PAI-1 levels by ELISA , both in the maternal serum and in the supernatant of the endothelial cell cultures . While t-PA levels were significantly higher in the serum of patients with preeclampsia and HELLP syndrome than in the control group ( median : 8.0 ng/ml and 6.2 ng/ml vs 3.9 ng/ml and 3.1 ng/ml ) , levels of PAI-1 did not show any significant disparity among the different groups . The supernatant of the endothelial cell cultures demonstrated significantly elevated levels of both t-PA ( P 0.001 ) and PAI-1 ( P 0.01 ) when stimulated with serum gained from patients with preeclampsia or HELLP syndrome . The increased expression of t-PA and PAI-1 from human endothelium cells after stimulation with the serum of preeclamptic patients must be considered as a sign of increased endothelial cell activation .

[ "The", "aim", "of", "our", "study", "was", "to", "investigate", "the", "influence", "that", "serum", "of", "patients", "with", "preeclampsia", "has", "on", "t", "-", "PA", "and", "PAI-1", "expression", "from", "human", "endothelial", "cells", ".", "For", "this", "purpose", ",", "we", "cultured", "human", "endothelium", "cells", ",", "gained", "from", "umbilical", "veins", ",", "for", "24", "h", "with", "sera", "of", "7", "patients", "with", "HELLP", "syndrome", "and", "12", "patients", "with", "preeclampsia", ".", "The", "sera", "of", "12", "normotensive", "pregnant", "patients", "and", "9", "non", "-", "pregnant", "women", "were", "used", "as", "controls", ".", "We", "then", "determined", "t", "-", "PA", "and", "PAI-1", "levels", "by", "ELISA", ",", "both", "in", "the", "maternal", "serum", "and", "in", "the", "supernatant", "of", "the", "endothelial", "cell", "cultures", ".", "While", "t", "-", "PA", "levels", "were", "significantly", "higher", "in", "the", "serum", "of", "patients", "with", "preeclampsia", "and", "HELLP", "syndrome", "than", "in", "the", "control", "group", "(", "median", ":", "8.0", "ng", "/", "ml", "and", "6.2", "ng", "/", "ml", "vs", "3.9", "ng", "/", "ml", "and", "3.1", "ng", "/", "ml", ")", ",", "levels", "of", "PAI-1", "did", "not", "show", "any", "significant", "disparity", "among", "the", "different", "groups", ".", "The", "supernatant", "of", "the", "endothelial", "cell", "cultures", "demonstrated", "significantly", "elevated", "levels", "of", "both", "t", "-", "PA", "(", "P", "0.001", ")", "and", "PAI-1", "(", "P", "0.01", ")", "when", "stimulated", "with", "serum", "gained", "from", "patients", "with", "preeclampsia", "or", "HELLP", "syndrome", ".", "The", "increased", "expression", "of", "t", "-", "PA", "and", "PAI-1", "from", "human", "endothelium", "cells", "after", "stimulation", "with", "the", "serum", "of", "preeclamptic", "patients", "must", "be", "considered", "as", "a", "sign", "of", "increased", "endothelial", "cell", "activation", "." ]

[ "umlsterm" ]

aim is an umlsterm, patients is an umlsterm, preeclampsia is an umlsterm, t - PA is an umlsterm, PAI-1 is an umlsterm, human is an umlsterm, cells is an umlsterm, human is an umlsterm, endothelium is an umlsterm, cells is an umlsterm, umbilical veins is an umlsterm, patients is an umlsterm, HELLP syndrome is an umlsterm, patients is an umlsterm, preeclampsia is an umlsterm, patients is an umlsterm, women is an umlsterm, controls is an umlsterm, t - PA is an umlsterm, PAI-1 is an umlsterm, ELISA is an umlsterm, cell cultures is an umlsterm, t - PA is an umlsterm, patients is an umlsterm, preeclampsia is an umlsterm, HELLP syndrome is an umlsterm, control group is an umlsterm, PAI-1 is an umlsterm, cell cultures is an umlsterm, t - PA is an umlsterm, PAI-1 is an umlsterm, patients is an umlsterm, preeclampsia is an umlsterm, HELLP syndrome is an umlsterm, t - PA is an umlsterm, PAI-1 is an umlsterm, human is an umlsterm, endothelium is an umlsterm, cells is an umlsterm, patients is an umlsterm, sign is an umlsterm, cell is an umlsterm

PerinatalMedizin.60080079.eng.abstr_task1

Sentence: The aim of our study was to investigate the influence that serum of patients with preeclampsia has on t-PA and PAI-1 expression from human endothelial cells . For this purpose , we cultured human endothelium cells , gained from umbilical veins , for 24 h with sera of 7 patients with HELLP syndrome and 12 patients with preeclampsia . The sera of 12 normotensive pregnant patients and 9 non-pregnant women were used as controls . We then determined t-PA and PAI-1 levels by ELISA , both in the maternal serum and in the supernatant of the endothelial cell cultures . While t-PA levels were significantly higher in the serum of patients with preeclampsia and HELLP syndrome than in the control group ( median : 8.0 ng/ml and 6.2 ng/ml vs 3.9 ng/ml and 3.1 ng/ml ) , levels of PAI-1 did not show any significant disparity among the different groups . The supernatant of the endothelial cell cultures demonstrated significantly elevated levels of both t-PA ( P 0.001 ) and PAI-1 ( P 0.01 ) when stimulated with serum gained from patients with preeclampsia or HELLP syndrome . The increased expression of t-PA and PAI-1 from human endothelium cells after stimulation with the serum of preeclamptic patients must be considered as a sign of increased endothelial cell activation . Instructions: please typing these entity words according to sentence: aim, patients, preeclampsia, t - PA, PAI-1, human, cells, human, endothelium, cells, umbilical veins, patients, HELLP syndrome, patients, preeclampsia, patients, women, controls, t - PA, PAI-1, ELISA, cell cultures, t - PA, patients, preeclampsia, HELLP syndrome, control group, PAI-1, cell cultures, t - PA, PAI-1, patients, preeclampsia, HELLP syndrome, t - PA, PAI-1, human, endothelium, cells, patients, sign, cell Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O" ]

The aim of our study was to investigate the influence that serum of patients with preeclampsia has on t-PA and PAI-1 expression from human endothelial cells . For this purpose , we cultured human endothelium cells , gained from umbilical veins , for 24 h with sera of 7 patients with HELLP syndrome and 12 patients with preeclampsia . The sera of 12 normotensive pregnant patients and 9 non-pregnant women were used as controls . We then determined t-PA and PAI-1 levels by ELISA , both in the maternal serum and in the supernatant of the endothelial cell cultures . While t-PA levels were significantly higher in the serum of patients with preeclampsia and HELLP syndrome than in the control group ( median : 8.0 ng/ml and 6.2 ng/ml vs 3.9 ng/ml and 3.1 ng/ml ) , levels of PAI-1 did not show any significant disparity among the different groups . The supernatant of the endothelial cell cultures demonstrated significantly elevated levels of both t-PA ( P 0.001 ) and PAI-1 ( P 0.01 ) when stimulated with serum gained from patients with preeclampsia or HELLP syndrome . The increased expression of t-PA and PAI-1 from human endothelium cells after stimulation with the serum of preeclamptic patients must be considered as a sign of increased endothelial cell activation .

[ "The", "aim", "of", "our", "study", "was", "to", "investigate", "the", "influence", "that", "serum", "of", "patients", "with", "preeclampsia", "has", "on", "t", "-", "PA", "and", "PAI-1", "expression", "from", "human", "endothelial", "cells", ".", "For", "this", "purpose", ",", "we", "cultured", "human", "endothelium", "cells", ",", "gained", "from", "umbilical", "veins", ",", "for", "24", "h", "with", "sera", "of", "7", "patients", "with", "HELLP", "syndrome", "and", "12", "patients", "with", "preeclampsia", ".", "The", "sera", "of", "12", "normotensive", "pregnant", "patients", "and", "9", "non", "-", "pregnant", "women", "were", "used", "as", "controls", ".", "We", "then", "determined", "t", "-", "PA", "and", "PAI-1", "levels", "by", "ELISA", ",", "both", "in", "the", "maternal", "serum", "and", "in", "the", "supernatant", "of", "the", "endothelial", "cell", "cultures", ".", "While", "t", "-", "PA", "levels", "were", "significantly", "higher", "in", "the", "serum", "of", "patients", "with", "preeclampsia", "and", "HELLP", "syndrome", "than", "in", "the", "control", "group", "(", "median", ":", "8.0", "ng", "/", "ml", "and", "6.2", "ng", "/", "ml", "vs", "3.9", "ng", "/", "ml", "and", "3.1", "ng", "/", "ml", ")", ",", "levels", "of", "PAI-1", "did", "not", "show", "any", "significant", "disparity", "among", "the", "different", "groups", ".", "The", "supernatant", "of", "the", "endothelial", "cell", "cultures", "demonstrated", "significantly", "elevated", "levels", "of", "both", "t", "-", "PA", "(", "P", "0.001", ")", "and", "PAI-1", "(", "P", "0.01", ")", "when", "stimulated", "with", "serum", "gained", "from", "patients", "with", "preeclampsia", "or", "HELLP", "syndrome", ".", "The", "increased", "expression", "of", "t", "-", "PA", "and", "PAI-1", "from", "human", "endothelium", "cells", "after", "stimulation", "with", "the", "serum", "of", "preeclamptic", "patients", "must", "be", "considered", "as", "a", "sign", "of", "increased", "endothelial", "cell", "activation", "." ]

[ "umlsterm" ]

aim, patients, preeclampsia, t - PA, PAI-1, human, cells, human, endothelium, cells, umbilical veins, patients, HELLP syndrome, patients, preeclampsia, patients, women, controls, t - PA, PAI-1, ELISA, cell cultures, t - PA, patients, preeclampsia, HELLP syndrome, control group, PAI-1, cell cultures, t - PA, PAI-1, patients, preeclampsia, HELLP syndrome, t - PA, PAI-1, human, endothelium, cells, patients, sign, cell

PerinatalMedizin.60080079.eng.abstr_task2

Sentence: The aim of our study was to investigate the influence that serum of patients with preeclampsia has on t-PA and PAI-1 expression from human endothelial cells . For this purpose , we cultured human endothelium cells , gained from umbilical veins , for 24 h with sera of 7 patients with HELLP syndrome and 12 patients with preeclampsia . The sera of 12 normotensive pregnant patients and 9 non-pregnant women were used as controls . We then determined t-PA and PAI-1 levels by ELISA , both in the maternal serum and in the supernatant of the endothelial cell cultures . While t-PA levels were significantly higher in the serum of patients with preeclampsia and HELLP syndrome than in the control group ( median : 8.0 ng/ml and 6.2 ng/ml vs 3.9 ng/ml and 3.1 ng/ml ) , levels of PAI-1 did not show any significant disparity among the different groups . The supernatant of the endothelial cell cultures demonstrated significantly elevated levels of both t-PA ( P 0.001 ) and PAI-1 ( P 0.01 ) when stimulated with serum gained from patients with preeclampsia or HELLP syndrome . The increased expression of t-PA and PAI-1 from human endothelium cells after stimulation with the serum of preeclamptic patients must be considered as a sign of increased endothelial cell activation . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O" ]

The aim of our study was to investigate the influence that serum of patients with preeclampsia has on t-PA and PAI-1 expression from human endothelial cells . For this purpose , we cultured human endothelium cells , gained from umbilical veins , for 24 h with sera of 7 patients with HELLP syndrome and 12 patients with preeclampsia . The sera of 12 normotensive pregnant patients and 9 non-pregnant women were used as controls . We then determined t-PA and PAI-1 levels by ELISA , both in the maternal serum and in the supernatant of the endothelial cell cultures . While t-PA levels were significantly higher in the serum of patients with preeclampsia and HELLP syndrome than in the control group ( median : 8.0 ng/ml and 6.2 ng/ml vs 3.9 ng/ml and 3.1 ng/ml ) , levels of PAI-1 did not show any significant disparity among the different groups . The supernatant of the endothelial cell cultures demonstrated significantly elevated levels of both t-PA ( P 0.001 ) and PAI-1 ( P 0.01 ) when stimulated with serum gained from patients with preeclampsia or HELLP syndrome . The increased expression of t-PA and PAI-1 from human endothelium cells after stimulation with the serum of preeclamptic patients must be considered as a sign of increased endothelial cell activation .

[ "The", "aim", "of", "our", "study", "was", "to", "investigate", "the", "influence", "that", "serum", "of", "patients", "with", "preeclampsia", "has", "on", "t", "-", "PA", "and", "PAI-1", "expression", "from", "human", "endothelial", "cells", ".", "For", "this", "purpose", ",", "we", "cultured", "human", "endothelium", "cells", ",", "gained", "from", "umbilical", "veins", ",", "for", "24", "h", "with", "sera", "of", "7", "patients", "with", "HELLP", "syndrome", "and", "12", "patients", "with", "preeclampsia", ".", "The", "sera", "of", "12", "normotensive", "pregnant", "patients", "and", "9", "non", "-", "pregnant", "women", "were", "used", "as", "controls", ".", "We", "then", "determined", "t", "-", "PA", "and", "PAI-1", "levels", "by", "ELISA", ",", "both", "in", "the", "maternal", "serum", "and", "in", "the", "supernatant", "of", "the", "endothelial", "cell", "cultures", ".", "While", "t", "-", "PA", "levels", "were", "significantly", "higher", "in", "the", "serum", "of", "patients", "with", "preeclampsia", "and", "HELLP", "syndrome", "than", "in", "the", "control", "group", "(", "median", ":", "8.0", "ng", "/", "ml", "and", "6.2", "ng", "/", "ml", "vs", "3.9", "ng", "/", "ml", "and", "3.1", "ng", "/", "ml", ")", ",", "levels", "of", "PAI-1", "did", "not", "show", "any", "significant", "disparity", "among", "the", "different", "groups", ".", "The", "supernatant", "of", "the", "endothelial", "cell", "cultures", "demonstrated", "significantly", "elevated", "levels", "of", "both", "t", "-", "PA", "(", "P", "0.001", ")", "and", "PAI-1", "(", "P", "0.01", ")", "when", "stimulated", "with", "serum", "gained", "from", "patients", "with", "preeclampsia", "or", "HELLP", "syndrome", ".", "The", "increased", "expression", "of", "t", "-", "PA", "and", "PAI-1", "from", "human", "endothelium", "cells", "after", "stimulation", "with", "the", "serum", "of", "preeclamptic", "patients", "must", "be", "considered", "as", "a", "sign", "of", "increased", "endothelial", "cell", "activation", "." ]

[ "umlsterm" ]

loxapine is a DRUG, lorazepam is a DRUG, loxapine is a DRUG, loxapine is a DRUG

Loxapine_ddi_task0

Sentence: There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam. The risk of using loxapine in combination with CNS-active drugs has not been systematically evaluated. Therefore, caution is advised if the concomitant administration of loxapine and CNS-active drugs is required. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: DRUG

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O" ]

There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam. The risk of using loxapine in combination with CNS-active drugs has not been systematically evaluated. Therefore, caution is advised if the concomitant administration of loxapine and CNS-active drugs is required.

[ "There", "have", "been", "rare", "reports", "of", "significant", "respiratory", "depression", ",", "stupor", "and", "/", "or", "hypotension", "with", "the", "concomitant", "use", "of", "loxapine", "and", "lorazepam", ".", "The", "risk", "of", "using", "loxapine", "in", "combination", "with", "CNS", "-", "active", "drugs", "has", "not", "been", "systematically", "evaluated", ".", "Therefore", ",", "caution", "is", "advised", "if", "the", "concomitant", "administration", "of", "loxapine", "and", "CNS", "-", "active", "drugs", "is", "required", "." ]

[ "DRUG" ]

loxapine is a DRUG, lorazepam is a DRUG, loxapine is a DRUG, loxapine is a DRUG

Loxapine_ddi_task1

Sentence: There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam. The risk of using loxapine in combination with CNS-active drugs has not been systematically evaluated. Therefore, caution is advised if the concomitant administration of loxapine and CNS-active drugs is required. Instructions: please typing these entity words according to sentence: loxapine, lorazepam, loxapine, loxapine Options: DRUG

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O" ]

There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam. The risk of using loxapine in combination with CNS-active drugs has not been systematically evaluated. Therefore, caution is advised if the concomitant administration of loxapine and CNS-active drugs is required.

[ "There", "have", "been", "rare", "reports", "of", "significant", "respiratory", "depression", ",", "stupor", "and", "/", "or", "hypotension", "with", "the", "concomitant", "use", "of", "loxapine", "and", "lorazepam", ".", "The", "risk", "of", "using", "loxapine", "in", "combination", "with", "CNS", "-", "active", "drugs", "has", "not", "been", "systematically", "evaluated", ".", "Therefore", ",", "caution", "is", "advised", "if", "the", "concomitant", "administration", "of", "loxapine", "and", "CNS", "-", "active", "drugs", "is", "required", "." ]

[ "DRUG" ]

loxapine, lorazepam, loxapine, loxapine

Loxapine_ddi_task2

Sentence: There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam. The risk of using loxapine in combination with CNS-active drugs has not been systematically evaluated. Therefore, caution is advised if the concomitant administration of loxapine and CNS-active drugs is required. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "B-DRUG", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-DRUG", "O", "O", "O", "O", "O", "O", "O", "O" ]

There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of loxapine and lorazepam. The risk of using loxapine in combination with CNS-active drugs has not been systematically evaluated. Therefore, caution is advised if the concomitant administration of loxapine and CNS-active drugs is required.

[ "There", "have", "been", "rare", "reports", "of", "significant", "respiratory", "depression", ",", "stupor", "and", "/", "or", "hypotension", "with", "the", "concomitant", "use", "of", "loxapine", "and", "lorazepam", ".", "The", "risk", "of", "using", "loxapine", "in", "combination", "with", "CNS", "-", "active", "drugs", "has", "not", "been", "systematically", "evaluated", ".", "Therefore", ",", "caution", "is", "advised", "if", "the", "concomitant", "administration", "of", "loxapine", "and", "CNS", "-", "active", "drugs", "is", "required", "." ]

[ "DRUG" ]

biopterin is a CHEMICAL

10464780_task0

Sentence: [The relation between metabolism of biopterin and dystonia-parkinsonism]. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O" ]

[The relation between metabolism of biopterin and dystonia-parkinsonism].

[ "[", "The", "relation", "between", "metabolism", "of", "biopterin", "and", "dystonia", "-", "parkinsonism", "]", "." ]

[ "GENE-Y", "CHEMICAL" ]

biopterin is a CHEMICAL

10464780_task1

Sentence: [The relation between metabolism of biopterin and dystonia-parkinsonism]. Instructions: please typing these entity words according to sentence: biopterin Options: CHEMICAL

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O" ]

[The relation between metabolism of biopterin and dystonia-parkinsonism].

[ "[", "The", "relation", "between", "metabolism", "of", "biopterin", "and", "dystonia", "-", "parkinsonism", "]", "." ]

[ "GENE-Y", "CHEMICAL" ]

biopterin

10464780_task2

Sentence: [The relation between metabolism of biopterin and dystonia-parkinsonism]. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O" ]

[The relation between metabolism of biopterin and dystonia-parkinsonism].

[ "[", "The", "relation", "between", "metabolism", "of", "biopterin", "and", "dystonia", "-", "parkinsonism", "]", "." ]

[ "GENE-Y", "CHEMICAL" ]

Tumor is a MORFOLOGIA_NEOPLASIA, carcinoma intraductal de alto grado is a MORFOLOGIA_NEOPLASIA, metástasis de acenocarcinoma is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, Carcinoma intraductal is a MORFOLOGIA_NEOPLASIA, cT4dNxM0 is a MORFOLOGIA_NEOPLASIA, carcinoma is a MORFOLOGIA_NEOPLASIA, metastásicas is a MORFOLOGIA_NEOPLASIA

81_task0

Sentence: Anamnesis Mujer de 51 años, sin alergias medicamentosas conocidas. No antecedentes médicos de interés. Intervenida de lesión benigna de la mama derecha y quistectomía en la trompa de Falopio. Fumadora de 1 paquete/día. No embarazos. Menarquia a los 10 años y menopausia a los 46 años. Acude a su médico de cabecera por una lesión eritematosa e inflamatoria en la mama izquierda, orientada como mastitis, para la que se pauta tratamiento antibiótico. Exploración física Estable hemodinámicamente. ECOG 0. ACP: dentro de la normalidad. Tumor inflamatorio que ocupa los cuatro cuadrantes de la mama izquierda, con mayor afectación inflamatoria en ambos cuadrantes inferiores. No adenopatías palpables axilares ni supraclaviculares. Pruebas complementarias Se inicia estudio de manera ambulatoria, con la realización de las siguientes pruebas complementarias: » Mamografía (27/6/14): engrosamiento difuso de la piel de la mama izquierda. Marcado aumento de la reticulación del tejido graso subcutáneo. BIRADS 0. » Resonancia magnética (RM) (3/7/14): notable asimetría. Mama izquierda con engrosamiento de la piel, el pezón y la areola. Presencia de un ganglio linfático de 14 mm en la axila izquierda. » Biopsia ecodirigida con resultado anatomopatológico: carcinoma intraductal de alto grado, con necrosis y microcalcificaciones. Receptores hormonales (RH) negativos, HER2 positivo, Ki-67 27% » PAAF axilar: compatible con metástasis de acenocarcinoma » Se solicitan una TC toracoabdominal (TC TA) y una gamagrafía ósea (GGO), que descartan metástasis. » Se solicita una ventriculografía isotópica para la valoración de la función cardíaca previa al tratamiento con antraciclina (FEV 62%). Diagnóstico Carcinoma intraductal de mama izquierda, cT4dNxM0 (estadio III), RH-, HER2+, Ki-67 27%. Tratamiento Paciente candidata a quimioterapia neoadyuvante; se inicia en agosto de 2014 con esquema antraciclina + taxanos + trastuzumab + pertuzumab. Evolución La paciente realiza cuatro ciclos de quimioterapia con el esquema arriba indicado, presentando como complicación durante este período neutropenia grado 3. El 28 de octubre de 2014 acude a consulta para continuar el tratamiento. Clínicamente, presenta astenia grado 3, con aparición de eritema en el surco intermamario. Se solicita punch de la lesión, con positividad para carcinoma de origen mamario, RH-, HER2+, por lo tanto se trata de una progresión local en el curso de la neoadyuvancia. Valorada por Cirugía, que descarta cirugía de rescate por extensa afectación cutánea, se realiza un nuevo estudio de estadificación con TC TA y GGO, sin lesiones metastásicas. Valorado el caso en comité de mama, se decide cambio a segunda línea con capecitabina + lapatinib. Actualmente, la paciente ha realizado seis ciclos, con total desaparición de la lesión inflamatoria en la mama, y con RM sin captaciones patológicas nodulares focales ni adenopatías de tamaño patológico a nivel axilar, ni en las cadenas mamarias internas. Actualmente está en espera de mastectomía radical y posterior tratamiento con radioterapia local. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Mujer de 51 años, sin alergias medicamentosas conocidas. No antecedentes médicos de interés. Intervenida de lesión benigna de la mama derecha y quistectomía en la trompa de Falopio. Fumadora de 1 paquete/día. No embarazos. Menarquia a los 10 años y menopausia a los 46 años. Acude a su médico de cabecera por una lesión eritematosa e inflamatoria en la mama izquierda, orientada como mastitis, para la que se pauta tratamiento antibiótico. Exploración física Estable hemodinámicamente. ECOG 0. ACP: dentro de la normalidad. Tumor inflamatorio que ocupa los cuatro cuadrantes de la mama izquierda, con mayor afectación inflamatoria en ambos cuadrantes inferiores. No adenopatías palpables axilares ni supraclaviculares. Pruebas complementarias Se inicia estudio de manera ambulatoria, con la realización de las siguientes pruebas complementarias: » Mamografía (27/6/14): engrosamiento difuso de la piel de la mama izquierda. Marcado aumento de la reticulación del tejido graso subcutáneo. BIRADS 0. » Resonancia magnética (RM) (3/7/14): notable asimetría. Mama izquierda con engrosamiento de la piel, el pezón y la areola. Presencia de un ganglio linfático de 14 mm en la axila izquierda. » Biopsia ecodirigida con resultado anatomopatológico: carcinoma intraductal de alto grado, con necrosis y microcalcificaciones. Receptores hormonales (RH) negativos, HER2 positivo, Ki-67 27% » PAAF axilar: compatible con metástasis de acenocarcinoma » Se solicitan una TC toracoabdominal (TC TA) y una gamagrafía ósea (GGO), que descartan metástasis. » Se solicita una ventriculografía isotópica para la valoración de la función cardíaca previa al tratamiento con antraciclina (FEV 62%). Diagnóstico Carcinoma intraductal de mama izquierda, cT4dNxM0 (estadio III), RH-, HER2+, Ki-67 27%. Tratamiento Paciente candidata a quimioterapia neoadyuvante; se inicia en agosto de 2014 con esquema antraciclina + taxanos + trastuzumab + pertuzumab. Evolución La paciente realiza cuatro ciclos de quimioterapia con el esquema arriba indicado, presentando como complicación durante este período neutropenia grado 3. El 28 de octubre de 2014 acude a consulta para continuar el tratamiento. Clínicamente, presenta astenia grado 3, con aparición de eritema en el surco intermamario. Se solicita punch de la lesión, con positividad para carcinoma de origen mamario, RH-, HER2+, por lo tanto se trata de una progresión local en el curso de la neoadyuvancia. Valorada por Cirugía, que descarta cirugía de rescate por extensa afectación cutánea, se realiza un nuevo estudio de estadificación con TC TA y GGO, sin lesiones metastásicas. Valorado el caso en comité de mama, se decide cambio a segunda línea con capecitabina + lapatinib. Actualmente, la paciente ha realizado seis ciclos, con total desaparición de la lesión inflamatoria en la mama, y con RM sin captaciones patológicas nodulares focales ni adenopatías de tamaño patológico a nivel axilar, ni en las cadenas mamarias internas. Actualmente está en espera de mastectomía radical y posterior tratamiento con radioterapia local.

[ "Anamnesis", "\n", "Mujer", "de", "51", "años", ",", "sin", "alergias", "medicamentosas", "conocidas", ".", "No", "antecedentes", "médicos", "de", "interés", ".", "\n", "Intervenida", "de", "lesión", "benigna", "de", "la", "mama", "derecha", "y", "quistectomía", "en", "la", "trompa", "de", "Falopio", ".", "Fumadora", "de", "1", "paquete", "/", "día", ".", "No", "embarazos", ".", "Menarquia", "a", "los", "10", "años", "y", "menopausia", "a", "los", "46", "años", ".", "\n\n", "Acude", "a", "su", "médico", "de", "cabecera", "por", "una", "lesión", "eritematosa", "e", "inflamatoria", "en", "la", "mama", "izquierda", ",", "orientada", "como", "mastitis", ",", "para", "la", "que", "se", "pauta", "tratamiento", "antibiótico", ".", "\n\n", "Exploración", "física", "\n", "Estable", "hemodinámicamente", ".", "ECOG", "0", ".", "ACP", ":", "dentro", "de", "la", "normalidad", ".", "Tumor", "inflamatorio", "que", "ocupa", "los", "cuatro", "cuadrantes", "de", "la", "mama", "izquierda", ",", "con", "mayor", "afectación", "inflamatoria", "en", "ambos", "cuadrantes", "inferiores", ".", "No", "adenopatías", "palpables", "axilares", "ni", "supraclaviculares", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "inicia", "estudio", "de", "manera", "ambulatoria", ",", "con", "la", "realización", "de", "las", "siguientes", "pruebas", "complementarias", ":", "\n", "»", "Mamografía", "(", "27/6/14", "):", "engrosamiento", "difuso", "de", "la", "piel", "de", "la", "mama", "izquierda", ".", "Marcado", "aumento", "de", "la", "reticulación", "del", "tejido", "graso", "subcutáneo", ".", "BIRADS", "0", ".", "\n", "»", "Resonancia", "magnética", "(", "RM", ")", "(", "3/7/14", "):", "notable", "asimetría", ".", "Mama", "izquierda", "con", "engrosamiento", "de", "la", "piel", ",", "el", "pezón", "y", "la", "areola", ".", "Presencia", "de", "un", "ganglio", "linfático", "de", "14", "mm", "en", "la", "axila", "izquierda", ".", "\n", "»", "Biopsia", "ecodirigida", "con", "resultado", "anatomopatológico", ":", "carcinoma", "intraductal", "de", "alto", "grado", ",", "con", "necrosis", "y", "microcalcificaciones", ".", "Receptores", "hormonales", "(", "RH", ")", "negativos", ",", "HER2", "positivo", ",", "Ki-67", "27", "%", "\n", "»", "PAAF", "axilar", ":", "compatible", "con", "metástasis", "de", "acenocarcinoma", "\n", "»", "Se", "solicitan", "una", "TC", "toracoabdominal", "(", "TC", "TA", ")", "y", "una", "gamagrafía", "ósea", "(", "GGO", ")", ",", "que", "descartan", "metástasis", ".", "\n", "»", "Se", "solicita", "una", "ventriculografía", "isotópica", "para", "la", "valoración", "de", "la", "función", "cardíaca", "previa", "al", "tratamiento", "con", "antraciclina", "(", "FEV", "62", "%", ")", ".", "\n\n", "Diagnóstico", "\n", "Carcinoma", "intraductal", "de", "mama", "izquierda", ",", "cT4dNxM0", "(", "estadio", "III", ")", ",", "RH-", ",", "HER2", "+", ",", "Ki-67", "27", "%", ".", "\n\n", "Tratamiento", "\n", "Paciente", "candidata", "a", "quimioterapia", "neoadyuvante", ";", "se", "inicia", "en", "agosto", "de", "2014", "con", "esquema", "antraciclina", "+", "taxanos", "+", "trastuzumab", "+", "pertuzumab", ".", "\n\n", "Evolución", "\n", "La", "paciente", "realiza", "cuatro", "ciclos", "de", "quimioterapia", "con", "el", "esquema", "arriba", "indicado", ",", "presentando", "como", "complicación", "durante", "este", "período", "neutropenia", "grado", "3", ".", "El", "28", "de", "octubre", "de", "2014", "acude", "a", "consulta", "para", "continuar", "el", "tratamiento", ".", "Clínicamente", ",", "presenta", "astenia", "grado", "3", ",", "con", "aparición", "de", "eritema", "en", "el", "surco", "intermamario", ".", "Se", "solicita", "punch", "de", "la", "lesión", ",", "con", "positividad", "para", "carcinoma", "de", "origen", "mamario", ",", "RH-", ",", "HER2", "+", ",", "por", "lo", "tanto", "se", "trata", "de", "una", "progresión", "local", "en", "el", "curso", "de", "la", "neoadyuvancia", ".", "Valorada", "por", "Cirugía", ",", "que", "descarta", "cirugía", "de", "rescate", "por", "extensa", "afectación", "cutánea", ",", "se", "realiza", "un", "nuevo", "estudio", "de", "estadificación", "con", "TC", "TA", "y", "GGO", ",", "sin", "lesiones", "metastásicas", ".", "Valorado", "el", "caso", "en", "comité", "de", "mama", ",", "se", "decide", "cambio", "a", "segunda", "línea", "con", "capecitabina", "+", "lapatinib", ".", "Actualmente", ",", "la", "paciente", "ha", "realizado", "seis", "ciclos", ",", "con", "total", "desaparición", "de", "la", "lesión", "inflamatoria", "en", "la", "mama", ",", "y", "con", "RM", "sin", "captaciones", "patológicas", "nodulares", "focales", "ni", "adenopatías", "de", "tamaño", "patológico", "a", "nivel", "axilar", ",", "ni", "en", "las", "cadenas", "mamarias", "internas", ".", "Actualmente", "está", "en", "espera", "de", "mastectomía", "radical", "y", "posterior", "tratamiento", "con", "radioterapia", "local", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

Tumor is a MORFOLOGIA_NEOPLASIA, carcinoma intraductal de alto grado is a MORFOLOGIA_NEOPLASIA, metástasis de acenocarcinoma is a MORFOLOGIA_NEOPLASIA, metástasis is a MORFOLOGIA_NEOPLASIA, Carcinoma intraductal is a MORFOLOGIA_NEOPLASIA, cT4dNxM0 is a MORFOLOGIA_NEOPLASIA, carcinoma is a MORFOLOGIA_NEOPLASIA, metastásicas is a MORFOLOGIA_NEOPLASIA

81_task1

Sentence: Anamnesis Mujer de 51 años, sin alergias medicamentosas conocidas. No antecedentes médicos de interés. Intervenida de lesión benigna de la mama derecha y quistectomía en la trompa de Falopio. Fumadora de 1 paquete/día. No embarazos. Menarquia a los 10 años y menopausia a los 46 años. Acude a su médico de cabecera por una lesión eritematosa e inflamatoria en la mama izquierda, orientada como mastitis, para la que se pauta tratamiento antibiótico. Exploración física Estable hemodinámicamente. ECOG 0. ACP: dentro de la normalidad. Tumor inflamatorio que ocupa los cuatro cuadrantes de la mama izquierda, con mayor afectación inflamatoria en ambos cuadrantes inferiores. No adenopatías palpables axilares ni supraclaviculares. Pruebas complementarias Se inicia estudio de manera ambulatoria, con la realización de las siguientes pruebas complementarias: » Mamografía (27/6/14): engrosamiento difuso de la piel de la mama izquierda. Marcado aumento de la reticulación del tejido graso subcutáneo. BIRADS 0. » Resonancia magnética (RM) (3/7/14): notable asimetría. Mama izquierda con engrosamiento de la piel, el pezón y la areola. Presencia de un ganglio linfático de 14 mm en la axila izquierda. » Biopsia ecodirigida con resultado anatomopatológico: carcinoma intraductal de alto grado, con necrosis y microcalcificaciones. Receptores hormonales (RH) negativos, HER2 positivo, Ki-67 27% » PAAF axilar: compatible con metástasis de acenocarcinoma » Se solicitan una TC toracoabdominal (TC TA) y una gamagrafía ósea (GGO), que descartan metástasis. » Se solicita una ventriculografía isotópica para la valoración de la función cardíaca previa al tratamiento con antraciclina (FEV 62%). Diagnóstico Carcinoma intraductal de mama izquierda, cT4dNxM0 (estadio III), RH-, HER2+, Ki-67 27%. Tratamiento Paciente candidata a quimioterapia neoadyuvante; se inicia en agosto de 2014 con esquema antraciclina + taxanos + trastuzumab + pertuzumab. Evolución La paciente realiza cuatro ciclos de quimioterapia con el esquema arriba indicado, presentando como complicación durante este período neutropenia grado 3. El 28 de octubre de 2014 acude a consulta para continuar el tratamiento. Clínicamente, presenta astenia grado 3, con aparición de eritema en el surco intermamario. Se solicita punch de la lesión, con positividad para carcinoma de origen mamario, RH-, HER2+, por lo tanto se trata de una progresión local en el curso de la neoadyuvancia. Valorada por Cirugía, que descarta cirugía de rescate por extensa afectación cutánea, se realiza un nuevo estudio de estadificación con TC TA y GGO, sin lesiones metastásicas. Valorado el caso en comité de mama, se decide cambio a segunda línea con capecitabina + lapatinib. Actualmente, la paciente ha realizado seis ciclos, con total desaparición de la lesión inflamatoria en la mama, y con RM sin captaciones patológicas nodulares focales ni adenopatías de tamaño patológico a nivel axilar, ni en las cadenas mamarias internas. Actualmente está en espera de mastectomía radical y posterior tratamiento con radioterapia local. Instructions: please typing these entity words according to sentence: Tumor, carcinoma intraductal de alto grado, metástasis de acenocarcinoma, metástasis, Carcinoma intraductal, cT4dNxM0, carcinoma, metastásicas Options: MORFOLOGIA_NEOPLASIA

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Mujer de 51 años, sin alergias medicamentosas conocidas. No antecedentes médicos de interés. Intervenida de lesión benigna de la mama derecha y quistectomía en la trompa de Falopio. Fumadora de 1 paquete/día. No embarazos. Menarquia a los 10 años y menopausia a los 46 años. Acude a su médico de cabecera por una lesión eritematosa e inflamatoria en la mama izquierda, orientada como mastitis, para la que se pauta tratamiento antibiótico. Exploración física Estable hemodinámicamente. ECOG 0. ACP: dentro de la normalidad. Tumor inflamatorio que ocupa los cuatro cuadrantes de la mama izquierda, con mayor afectación inflamatoria en ambos cuadrantes inferiores. No adenopatías palpables axilares ni supraclaviculares. Pruebas complementarias Se inicia estudio de manera ambulatoria, con la realización de las siguientes pruebas complementarias: » Mamografía (27/6/14): engrosamiento difuso de la piel de la mama izquierda. Marcado aumento de la reticulación del tejido graso subcutáneo. BIRADS 0. » Resonancia magnética (RM) (3/7/14): notable asimetría. Mama izquierda con engrosamiento de la piel, el pezón y la areola. Presencia de un ganglio linfático de 14 mm en la axila izquierda. » Biopsia ecodirigida con resultado anatomopatológico: carcinoma intraductal de alto grado, con necrosis y microcalcificaciones. Receptores hormonales (RH) negativos, HER2 positivo, Ki-67 27% » PAAF axilar: compatible con metástasis de acenocarcinoma » Se solicitan una TC toracoabdominal (TC TA) y una gamagrafía ósea (GGO), que descartan metástasis. » Se solicita una ventriculografía isotópica para la valoración de la función cardíaca previa al tratamiento con antraciclina (FEV 62%). Diagnóstico Carcinoma intraductal de mama izquierda, cT4dNxM0 (estadio III), RH-, HER2+, Ki-67 27%. Tratamiento Paciente candidata a quimioterapia neoadyuvante; se inicia en agosto de 2014 con esquema antraciclina + taxanos + trastuzumab + pertuzumab. Evolución La paciente realiza cuatro ciclos de quimioterapia con el esquema arriba indicado, presentando como complicación durante este período neutropenia grado 3. El 28 de octubre de 2014 acude a consulta para continuar el tratamiento. Clínicamente, presenta astenia grado 3, con aparición de eritema en el surco intermamario. Se solicita punch de la lesión, con positividad para carcinoma de origen mamario, RH-, HER2+, por lo tanto se trata de una progresión local en el curso de la neoadyuvancia. Valorada por Cirugía, que descarta cirugía de rescate por extensa afectación cutánea, se realiza un nuevo estudio de estadificación con TC TA y GGO, sin lesiones metastásicas. Valorado el caso en comité de mama, se decide cambio a segunda línea con capecitabina + lapatinib. Actualmente, la paciente ha realizado seis ciclos, con total desaparición de la lesión inflamatoria en la mama, y con RM sin captaciones patológicas nodulares focales ni adenopatías de tamaño patológico a nivel axilar, ni en las cadenas mamarias internas. Actualmente está en espera de mastectomía radical y posterior tratamiento con radioterapia local.

[ "Anamnesis", "\n", "Mujer", "de", "51", "años", ",", "sin", "alergias", "medicamentosas", "conocidas", ".", "No", "antecedentes", "médicos", "de", "interés", ".", "\n", "Intervenida", "de", "lesión", "benigna", "de", "la", "mama", "derecha", "y", "quistectomía", "en", "la", "trompa", "de", "Falopio", ".", "Fumadora", "de", "1", "paquete", "/", "día", ".", "No", "embarazos", ".", "Menarquia", "a", "los", "10", "años", "y", "menopausia", "a", "los", "46", "años", ".", "\n\n", "Acude", "a", "su", "médico", "de", "cabecera", "por", "una", "lesión", "eritematosa", "e", "inflamatoria", "en", "la", "mama", "izquierda", ",", "orientada", "como", "mastitis", ",", "para", "la", "que", "se", "pauta", "tratamiento", "antibiótico", ".", "\n\n", "Exploración", "física", "\n", "Estable", "hemodinámicamente", ".", "ECOG", "0", ".", "ACP", ":", "dentro", "de", "la", "normalidad", ".", "Tumor", "inflamatorio", "que", "ocupa", "los", "cuatro", "cuadrantes", "de", "la", "mama", "izquierda", ",", "con", "mayor", "afectación", "inflamatoria", "en", "ambos", "cuadrantes", "inferiores", ".", "No", "adenopatías", "palpables", "axilares", "ni", "supraclaviculares", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "inicia", "estudio", "de", "manera", "ambulatoria", ",", "con", "la", "realización", "de", "las", "siguientes", "pruebas", "complementarias", ":", "\n", "»", "Mamografía", "(", "27/6/14", "):", "engrosamiento", "difuso", "de", "la", "piel", "de", "la", "mama", "izquierda", ".", "Marcado", "aumento", "de", "la", "reticulación", "del", "tejido", "graso", "subcutáneo", ".", "BIRADS", "0", ".", "\n", "»", "Resonancia", "magnética", "(", "RM", ")", "(", "3/7/14", "):", "notable", "asimetría", ".", "Mama", "izquierda", "con", "engrosamiento", "de", "la", "piel", ",", "el", "pezón", "y", "la", "areola", ".", "Presencia", "de", "un", "ganglio", "linfático", "de", "14", "mm", "en", "la", "axila", "izquierda", ".", "\n", "»", "Biopsia", "ecodirigida", "con", "resultado", "anatomopatológico", ":", "carcinoma", "intraductal", "de", "alto", "grado", ",", "con", "necrosis", "y", "microcalcificaciones", ".", "Receptores", "hormonales", "(", "RH", ")", "negativos", ",", "HER2", "positivo", ",", "Ki-67", "27", "%", "\n", "»", "PAAF", "axilar", ":", "compatible", "con", "metástasis", "de", "acenocarcinoma", "\n", "»", "Se", "solicitan", "una", "TC", "toracoabdominal", "(", "TC", "TA", ")", "y", "una", "gamagrafía", "ósea", "(", "GGO", ")", ",", "que", "descartan", "metástasis", ".", "\n", "»", "Se", "solicita", "una", "ventriculografía", "isotópica", "para", "la", "valoración", "de", "la", "función", "cardíaca", "previa", "al", "tratamiento", "con", "antraciclina", "(", "FEV", "62", "%", ")", ".", "\n\n", "Diagnóstico", "\n", "Carcinoma", "intraductal", "de", "mama", "izquierda", ",", "cT4dNxM0", "(", "estadio", "III", ")", ",", "RH-", ",", "HER2", "+", ",", "Ki-67", "27", "%", ".", "\n\n", "Tratamiento", "\n", "Paciente", "candidata", "a", "quimioterapia", "neoadyuvante", ";", "se", "inicia", "en", "agosto", "de", "2014", "con", "esquema", "antraciclina", "+", "taxanos", "+", "trastuzumab", "+", "pertuzumab", ".", "\n\n", "Evolución", "\n", "La", "paciente", "realiza", "cuatro", "ciclos", "de", "quimioterapia", "con", "el", "esquema", "arriba", "indicado", ",", "presentando", "como", "complicación", "durante", "este", "período", "neutropenia", "grado", "3", ".", "El", "28", "de", "octubre", "de", "2014", "acude", "a", "consulta", "para", "continuar", "el", "tratamiento", ".", "Clínicamente", ",", "presenta", "astenia", "grado", "3", ",", "con", "aparición", "de", "eritema", "en", "el", "surco", "intermamario", ".", "Se", "solicita", "punch", "de", "la", "lesión", ",", "con", "positividad", "para", "carcinoma", "de", "origen", "mamario", ",", "RH-", ",", "HER2", "+", ",", "por", "lo", "tanto", "se", "trata", "de", "una", "progresión", "local", "en", "el", "curso", "de", "la", "neoadyuvancia", ".", "Valorada", "por", "Cirugía", ",", "que", "descarta", "cirugía", "de", "rescate", "por", "extensa", "afectación", "cutánea", ",", "se", "realiza", "un", "nuevo", "estudio", "de", "estadificación", "con", "TC", "TA", "y", "GGO", ",", "sin", "lesiones", "metastásicas", ".", "Valorado", "el", "caso", "en", "comité", "de", "mama", ",", "se", "decide", "cambio", "a", "segunda", "línea", "con", "capecitabina", "+", "lapatinib", ".", "Actualmente", ",", "la", "paciente", "ha", "realizado", "seis", "ciclos", ",", "con", "total", "desaparición", "de", "la", "lesión", "inflamatoria", "en", "la", "mama", ",", "y", "con", "RM", "sin", "captaciones", "patológicas", "nodulares", "focales", "ni", "adenopatías", "de", "tamaño", "patológico", "a", "nivel", "axilar", ",", "ni", "en", "las", "cadenas", "mamarias", "internas", ".", "Actualmente", "está", "en", "espera", "de", "mastectomía", "radical", "y", "posterior", "tratamiento", "con", "radioterapia", "local", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

Tumor, carcinoma intraductal de alto grado, metástasis de acenocarcinoma, metástasis, Carcinoma intraductal, cT4dNxM0, carcinoma, metastásicas

81_task2

Sentence: Anamnesis Mujer de 51 años, sin alergias medicamentosas conocidas. No antecedentes médicos de interés. Intervenida de lesión benigna de la mama derecha y quistectomía en la trompa de Falopio. Fumadora de 1 paquete/día. No embarazos. Menarquia a los 10 años y menopausia a los 46 años. Acude a su médico de cabecera por una lesión eritematosa e inflamatoria en la mama izquierda, orientada como mastitis, para la que se pauta tratamiento antibiótico. Exploración física Estable hemodinámicamente. ECOG 0. ACP: dentro de la normalidad. Tumor inflamatorio que ocupa los cuatro cuadrantes de la mama izquierda, con mayor afectación inflamatoria en ambos cuadrantes inferiores. No adenopatías palpables axilares ni supraclaviculares. Pruebas complementarias Se inicia estudio de manera ambulatoria, con la realización de las siguientes pruebas complementarias: » Mamografía (27/6/14): engrosamiento difuso de la piel de la mama izquierda. Marcado aumento de la reticulación del tejido graso subcutáneo. BIRADS 0. » Resonancia magnética (RM) (3/7/14): notable asimetría. Mama izquierda con engrosamiento de la piel, el pezón y la areola. Presencia de un ganglio linfático de 14 mm en la axila izquierda. » Biopsia ecodirigida con resultado anatomopatológico: carcinoma intraductal de alto grado, con necrosis y microcalcificaciones. Receptores hormonales (RH) negativos, HER2 positivo, Ki-67 27% » PAAF axilar: compatible con metástasis de acenocarcinoma » Se solicitan una TC toracoabdominal (TC TA) y una gamagrafía ósea (GGO), que descartan metástasis. » Se solicita una ventriculografía isotópica para la valoración de la función cardíaca previa al tratamiento con antraciclina (FEV 62%). Diagnóstico Carcinoma intraductal de mama izquierda, cT4dNxM0 (estadio III), RH-, HER2+, Ki-67 27%. Tratamiento Paciente candidata a quimioterapia neoadyuvante; se inicia en agosto de 2014 con esquema antraciclina + taxanos + trastuzumab + pertuzumab. Evolución La paciente realiza cuatro ciclos de quimioterapia con el esquema arriba indicado, presentando como complicación durante este período neutropenia grado 3. El 28 de octubre de 2014 acude a consulta para continuar el tratamiento. Clínicamente, presenta astenia grado 3, con aparición de eritema en el surco intermamario. Se solicita punch de la lesión, con positividad para carcinoma de origen mamario, RH-, HER2+, por lo tanto se trata de una progresión local en el curso de la neoadyuvancia. Valorada por Cirugía, que descarta cirugía de rescate por extensa afectación cutánea, se realiza un nuevo estudio de estadificación con TC TA y GGO, sin lesiones metastásicas. Valorado el caso en comité de mama, se decide cambio a segunda línea con capecitabina + lapatinib. Actualmente, la paciente ha realizado seis ciclos, con total desaparición de la lesión inflamatoria en la mama, y con RM sin captaciones patológicas nodulares focales ni adenopatías de tamaño patológico a nivel axilar, ni en las cadenas mamarias internas. Actualmente está en espera de mastectomía radical y posterior tratamiento con radioterapia local. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "I-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-MORFOLOGIA_NEOPLASIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Anamnesis Mujer de 51 años, sin alergias medicamentosas conocidas. No antecedentes médicos de interés. Intervenida de lesión benigna de la mama derecha y quistectomía en la trompa de Falopio. Fumadora de 1 paquete/día. No embarazos. Menarquia a los 10 años y menopausia a los 46 años. Acude a su médico de cabecera por una lesión eritematosa e inflamatoria en la mama izquierda, orientada como mastitis, para la que se pauta tratamiento antibiótico. Exploración física Estable hemodinámicamente. ECOG 0. ACP: dentro de la normalidad. Tumor inflamatorio que ocupa los cuatro cuadrantes de la mama izquierda, con mayor afectación inflamatoria en ambos cuadrantes inferiores. No adenopatías palpables axilares ni supraclaviculares. Pruebas complementarias Se inicia estudio de manera ambulatoria, con la realización de las siguientes pruebas complementarias: » Mamografía (27/6/14): engrosamiento difuso de la piel de la mama izquierda. Marcado aumento de la reticulación del tejido graso subcutáneo. BIRADS 0. » Resonancia magnética (RM) (3/7/14): notable asimetría. Mama izquierda con engrosamiento de la piel, el pezón y la areola. Presencia de un ganglio linfático de 14 mm en la axila izquierda. » Biopsia ecodirigida con resultado anatomopatológico: carcinoma intraductal de alto grado, con necrosis y microcalcificaciones. Receptores hormonales (RH) negativos, HER2 positivo, Ki-67 27% » PAAF axilar: compatible con metástasis de acenocarcinoma » Se solicitan una TC toracoabdominal (TC TA) y una gamagrafía ósea (GGO), que descartan metástasis. » Se solicita una ventriculografía isotópica para la valoración de la función cardíaca previa al tratamiento con antraciclina (FEV 62%). Diagnóstico Carcinoma intraductal de mama izquierda, cT4dNxM0 (estadio III), RH-, HER2+, Ki-67 27%. Tratamiento Paciente candidata a quimioterapia neoadyuvante; se inicia en agosto de 2014 con esquema antraciclina + taxanos + trastuzumab + pertuzumab. Evolución La paciente realiza cuatro ciclos de quimioterapia con el esquema arriba indicado, presentando como complicación durante este período neutropenia grado 3. El 28 de octubre de 2014 acude a consulta para continuar el tratamiento. Clínicamente, presenta astenia grado 3, con aparición de eritema en el surco intermamario. Se solicita punch de la lesión, con positividad para carcinoma de origen mamario, RH-, HER2+, por lo tanto se trata de una progresión local en el curso de la neoadyuvancia. Valorada por Cirugía, que descarta cirugía de rescate por extensa afectación cutánea, se realiza un nuevo estudio de estadificación con TC TA y GGO, sin lesiones metastásicas. Valorado el caso en comité de mama, se decide cambio a segunda línea con capecitabina + lapatinib. Actualmente, la paciente ha realizado seis ciclos, con total desaparición de la lesión inflamatoria en la mama, y con RM sin captaciones patológicas nodulares focales ni adenopatías de tamaño patológico a nivel axilar, ni en las cadenas mamarias internas. Actualmente está en espera de mastectomía radical y posterior tratamiento con radioterapia local.

[ "Anamnesis", "\n", "Mujer", "de", "51", "años", ",", "sin", "alergias", "medicamentosas", "conocidas", ".", "No", "antecedentes", "médicos", "de", "interés", ".", "\n", "Intervenida", "de", "lesión", "benigna", "de", "la", "mama", "derecha", "y", "quistectomía", "en", "la", "trompa", "de", "Falopio", ".", "Fumadora", "de", "1", "paquete", "/", "día", ".", "No", "embarazos", ".", "Menarquia", "a", "los", "10", "años", "y", "menopausia", "a", "los", "46", "años", ".", "\n\n", "Acude", "a", "su", "médico", "de", "cabecera", "por", "una", "lesión", "eritematosa", "e", "inflamatoria", "en", "la", "mama", "izquierda", ",", "orientada", "como", "mastitis", ",", "para", "la", "que", "se", "pauta", "tratamiento", "antibiótico", ".", "\n\n", "Exploración", "física", "\n", "Estable", "hemodinámicamente", ".", "ECOG", "0", ".", "ACP", ":", "dentro", "de", "la", "normalidad", ".", "Tumor", "inflamatorio", "que", "ocupa", "los", "cuatro", "cuadrantes", "de", "la", "mama", "izquierda", ",", "con", "mayor", "afectación", "inflamatoria", "en", "ambos", "cuadrantes", "inferiores", ".", "No", "adenopatías", "palpables", "axilares", "ni", "supraclaviculares", ".", "\n\n", "Pruebas", "complementarias", "\n", "Se", "inicia", "estudio", "de", "manera", "ambulatoria", ",", "con", "la", "realización", "de", "las", "siguientes", "pruebas", "complementarias", ":", "\n", "»", "Mamografía", "(", "27/6/14", "):", "engrosamiento", "difuso", "de", "la", "piel", "de", "la", "mama", "izquierda", ".", "Marcado", "aumento", "de", "la", "reticulación", "del", "tejido", "graso", "subcutáneo", ".", "BIRADS", "0", ".", "\n", "»", "Resonancia", "magnética", "(", "RM", ")", "(", "3/7/14", "):", "notable", "asimetría", ".", "Mama", "izquierda", "con", "engrosamiento", "de", "la", "piel", ",", "el", "pezón", "y", "la", "areola", ".", "Presencia", "de", "un", "ganglio", "linfático", "de", "14", "mm", "en", "la", "axila", "izquierda", ".", "\n", "»", "Biopsia", "ecodirigida", "con", "resultado", "anatomopatológico", ":", "carcinoma", "intraductal", "de", "alto", "grado", ",", "con", "necrosis", "y", "microcalcificaciones", ".", "Receptores", "hormonales", "(", "RH", ")", "negativos", ",", "HER2", "positivo", ",", "Ki-67", "27", "%", "\n", "»", "PAAF", "axilar", ":", "compatible", "con", "metástasis", "de", "acenocarcinoma", "\n", "»", "Se", "solicitan", "una", "TC", "toracoabdominal", "(", "TC", "TA", ")", "y", "una", "gamagrafía", "ósea", "(", "GGO", ")", ",", "que", "descartan", "metástasis", ".", "\n", "»", "Se", "solicita", "una", "ventriculografía", "isotópica", "para", "la", "valoración", "de", "la", "función", "cardíaca", "previa", "al", "tratamiento", "con", "antraciclina", "(", "FEV", "62", "%", ")", ".", "\n\n", "Diagnóstico", "\n", "Carcinoma", "intraductal", "de", "mama", "izquierda", ",", "cT4dNxM0", "(", "estadio", "III", ")", ",", "RH-", ",", "HER2", "+", ",", "Ki-67", "27", "%", ".", "\n\n", "Tratamiento", "\n", "Paciente", "candidata", "a", "quimioterapia", "neoadyuvante", ";", "se", "inicia", "en", "agosto", "de", "2014", "con", "esquema", "antraciclina", "+", "taxanos", "+", "trastuzumab", "+", "pertuzumab", ".", "\n\n", "Evolución", "\n", "La", "paciente", "realiza", "cuatro", "ciclos", "de", "quimioterapia", "con", "el", "esquema", "arriba", "indicado", ",", "presentando", "como", "complicación", "durante", "este", "período", "neutropenia", "grado", "3", ".", "El", "28", "de", "octubre", "de", "2014", "acude", "a", "consulta", "para", "continuar", "el", "tratamiento", ".", "Clínicamente", ",", "presenta", "astenia", "grado", "3", ",", "con", "aparición", "de", "eritema", "en", "el", "surco", "intermamario", ".", "Se", "solicita", "punch", "de", "la", "lesión", ",", "con", "positividad", "para", "carcinoma", "de", "origen", "mamario", ",", "RH-", ",", "HER2", "+", ",", "por", "lo", "tanto", "se", "trata", "de", "una", "progresión", "local", "en", "el", "curso", "de", "la", "neoadyuvancia", ".", "Valorada", "por", "Cirugía", ",", "que", "descarta", "cirugía", "de", "rescate", "por", "extensa", "afectación", "cutánea", ",", "se", "realiza", "un", "nuevo", "estudio", "de", "estadificación", "con", "TC", "TA", "y", "GGO", ",", "sin", "lesiones", "metastásicas", ".", "Valorado", "el", "caso", "en", "comité", "de", "mama", ",", "se", "decide", "cambio", "a", "segunda", "línea", "con", "capecitabina", "+", "lapatinib", ".", "Actualmente", ",", "la", "paciente", "ha", "realizado", "seis", "ciclos", ",", "con", "total", "desaparición", "de", "la", "lesión", "inflamatoria", "en", "la", "mama", ",", "y", "con", "RM", "sin", "captaciones", "patológicas", "nodulares", "focales", "ni", "adenopatías", "de", "tamaño", "patológico", "a", "nivel", "axilar", ",", "ni", "en", "las", "cadenas", "mamarias", "internas", ".", "Actualmente", "está", "en", "espera", "de", "mastectomía", "radical", "y", "posterior", "tratamiento", "con", "radioterapia", "local", "." ]

[ "MORFOLOGIA_NEOPLASIA" ]

Blind versus open approach to laparoscopic cholecystectomy : is a Intervention_Surgical, 150 is a Participant_Sample-size, gallbladder lithiasis is a Participant_Condition, laparoscopy is a Participant_Condition, rate of complications is a Outcome_Adverse-effects, mortality is a Outcome_Mortality, Major complications is a Outcome_Adverse-effects, Minor complications is a Outcome_Adverse-effects, achievement of pneumoperitoneum is a Outcome_Physical, open laparoscopic technique is a Intervention_Surgical, blind approach is a Intervention_Physical

92964_task0

Sentence: Blind versus open approach to laparoscopic cholecystectomy : a randomized study . Intraabdominal structures may be damaged during blind introduction of the first trocar for laparoscopic operations . In this study , 150 patients with gallbladder lithiasis who underwent laparoscopy were randomly assigned to two groups , a blind ( V group ) or an open ( H group ) , in order to compare the results and the rate of complications . No mortality was observed . Major complications occurred in 3/75 ( 4 % ) patients of the V group and in 1/75 ( 1.3 % ) patient of the H group ( p < 0.05 ) . Minor complications occurred in 5/75 ( 6.7 % ) patients of either group . The achievement of pneumoperitoneum required 4.5+/-0.4 min in the V group and 3.2+/-0.2 min in the H group ( p < 0.05 ) . The open laparoscopic technique is safer and faster than the blind approach ; therefore , it is proposed that this approach be routinely used in all laparoscopic procedures . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Outcome_Adverse-effects, Intervention_Physical, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Intervention_Surgical

[ "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Blind versus open approach to laparoscopic cholecystectomy : a randomized study . Intraabdominal structures may be damaged during blind introduction of the first trocar for laparoscopic operations . In this study , 150 patients with gallbladder lithiasis who underwent laparoscopy were randomly assigned to two groups , a blind ( V group ) or an open ( H group ) , in order to compare the results and the rate of complications . No mortality was observed . Major complications occurred in 3/75 ( 4 % ) patients of the V group and in 1/75 ( 1.3 % ) patient of the H group ( p < 0.05 ) . Minor complications occurred in 5/75 ( 6.7 % ) patients of either group . The achievement of pneumoperitoneum required 4.5+/-0.4 min in the V group and 3.2+/-0.2 min in the H group ( p < 0.05 ) . The open laparoscopic technique is safer and faster than the blind approach ; therefore , it is proposed that this approach be routinely used in all laparoscopic procedures .

[ "Blind", "versus", "open", "approach", "to", "laparoscopic", "cholecystectomy", ":", "a", "randomized", "study", ".", "Intraabdominal", "structures", "may", "be", "damaged", "during", "blind", "introduction", "of", "the", "first", "trocar", "for", "laparoscopic", "operations", ".", "In", "this", "study", ",", "150", "patients", "with", "gallbladder", "lithiasis", "who", "underwent", "laparoscopy", "were", "randomly", "assigned", "to", "two", "groups", ",", "a", "blind", "(", "V", "group", ")", "or", "an", "open", "(", "H", "group", ")", ",", "in", "order", "to", "compare", "the", "results", "and", "the", "rate", "of", "complications", ".", "No", "mortality", "was", "observed", ".", "Major", "complications", "occurred", "in", "3/75", "(", "4", "%", ")", "patients", "of", "the", "V", "group", "and", "in", "1/75", "(", "1.3", "%", ")", "patient", "of", "the", "H", "group", "(", "p", "<", "0.05", ")", ".", "Minor", "complications", "occurred", "in", "5/75", "(", "6.7", "%", ")", "patients", "of", "either", "group", ".", "The", "achievement", "of", "pneumoperitoneum", "required", "4.5+/-0.4", "min", "in", "the", "V", "group", "and", "3.2+/-0.2", "min", "in", "the", "H", "group", "(", "p", "<", "0.05", ")", ".", "The", "open", "laparoscopic", "technique", "is", "safer", "and", "faster", "than", "the", "blind", "approach", ";", "therefore", ",", "it", "is", "proposed", "that", "this", "approach", "be", "routinely", "used", "in", "all", "laparoscopic", "procedures", "." ]

[ "Intervention_Surgical", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Condition", "Intervention_Physical", "Outcome_Mortality", "Participant_Sample-size" ]

Blind versus open approach to laparoscopic cholecystectomy : is a Intervention_Surgical, 150 is a Participant_Sample-size, gallbladder lithiasis is a Participant_Condition, laparoscopy is a Participant_Condition, rate of complications is a Outcome_Adverse-effects, mortality is a Outcome_Mortality, Major complications is a Outcome_Adverse-effects, Minor complications is a Outcome_Adverse-effects, achievement of pneumoperitoneum is a Outcome_Physical, open laparoscopic technique is a Intervention_Surgical, blind approach is a Intervention_Physical

92964_task1

Sentence: Blind versus open approach to laparoscopic cholecystectomy : a randomized study . Intraabdominal structures may be damaged during blind introduction of the first trocar for laparoscopic operations . In this study , 150 patients with gallbladder lithiasis who underwent laparoscopy were randomly assigned to two groups , a blind ( V group ) or an open ( H group ) , in order to compare the results and the rate of complications . No mortality was observed . Major complications occurred in 3/75 ( 4 % ) patients of the V group and in 1/75 ( 1.3 % ) patient of the H group ( p < 0.05 ) . Minor complications occurred in 5/75 ( 6.7 % ) patients of either group . The achievement of pneumoperitoneum required 4.5+/-0.4 min in the V group and 3.2+/-0.2 min in the H group ( p < 0.05 ) . The open laparoscopic technique is safer and faster than the blind approach ; therefore , it is proposed that this approach be routinely used in all laparoscopic procedures . Instructions: please typing these entity words according to sentence: Blind versus open approach to laparoscopic cholecystectomy :, 150, gallbladder lithiasis, laparoscopy, rate of complications, mortality, Major complications, Minor complications, achievement of pneumoperitoneum, open laparoscopic technique, blind approach Options: Outcome_Adverse-effects, Intervention_Physical, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Intervention_Surgical

[ "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Blind versus open approach to laparoscopic cholecystectomy : a randomized study . Intraabdominal structures may be damaged during blind introduction of the first trocar for laparoscopic operations . In this study , 150 patients with gallbladder lithiasis who underwent laparoscopy were randomly assigned to two groups , a blind ( V group ) or an open ( H group ) , in order to compare the results and the rate of complications . No mortality was observed . Major complications occurred in 3/75 ( 4 % ) patients of the V group and in 1/75 ( 1.3 % ) patient of the H group ( p < 0.05 ) . Minor complications occurred in 5/75 ( 6.7 % ) patients of either group . The achievement of pneumoperitoneum required 4.5+/-0.4 min in the V group and 3.2+/-0.2 min in the H group ( p < 0.05 ) . The open laparoscopic technique is safer and faster than the blind approach ; therefore , it is proposed that this approach be routinely used in all laparoscopic procedures .

[ "Blind", "versus", "open", "approach", "to", "laparoscopic", "cholecystectomy", ":", "a", "randomized", "study", ".", "Intraabdominal", "structures", "may", "be", "damaged", "during", "blind", "introduction", "of", "the", "first", "trocar", "for", "laparoscopic", "operations", ".", "In", "this", "study", ",", "150", "patients", "with", "gallbladder", "lithiasis", "who", "underwent", "laparoscopy", "were", "randomly", "assigned", "to", "two", "groups", ",", "a", "blind", "(", "V", "group", ")", "or", "an", "open", "(", "H", "group", ")", ",", "in", "order", "to", "compare", "the", "results", "and", "the", "rate", "of", "complications", ".", "No", "mortality", "was", "observed", ".", "Major", "complications", "occurred", "in", "3/75", "(", "4", "%", ")", "patients", "of", "the", "V", "group", "and", "in", "1/75", "(", "1.3", "%", ")", "patient", "of", "the", "H", "group", "(", "p", "<", "0.05", ")", ".", "Minor", "complications", "occurred", "in", "5/75", "(", "6.7", "%", ")", "patients", "of", "either", "group", ".", "The", "achievement", "of", "pneumoperitoneum", "required", "4.5+/-0.4", "min", "in", "the", "V", "group", "and", "3.2+/-0.2", "min", "in", "the", "H", "group", "(", "p", "<", "0.05", ")", ".", "The", "open", "laparoscopic", "technique", "is", "safer", "and", "faster", "than", "the", "blind", "approach", ";", "therefore", ",", "it", "is", "proposed", "that", "this", "approach", "be", "routinely", "used", "in", "all", "laparoscopic", "procedures", "." ]

[ "Intervention_Surgical", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Condition", "Intervention_Physical", "Outcome_Mortality", "Participant_Sample-size" ]

Blind versus open approach to laparoscopic cholecystectomy :, 150, gallbladder lithiasis, laparoscopy, rate of complications, mortality, Major complications, Minor complications, achievement of pneumoperitoneum, open laparoscopic technique, blind approach

92964_task2

Sentence: Blind versus open approach to laparoscopic cholecystectomy : a randomized study . Intraabdominal structures may be damaged during blind introduction of the first trocar for laparoscopic operations . In this study , 150 patients with gallbladder lithiasis who underwent laparoscopy were randomly assigned to two groups , a blind ( V group ) or an open ( H group ) , in order to compare the results and the rate of complications . No mortality was observed . Major complications occurred in 3/75 ( 4 % ) patients of the V group and in 1/75 ( 1.3 % ) patient of the H group ( p < 0.05 ) . Minor complications occurred in 5/75 ( 6.7 % ) patients of either group . The achievement of pneumoperitoneum required 4.5+/-0.4 min in the V group and 3.2+/-0.2 min in the H group ( p < 0.05 ) . The open laparoscopic technique is safer and faster than the blind approach ; therefore , it is proposed that this approach be routinely used in all laparoscopic procedures . Instructions: please extract entity words from the input sentence

[ "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "B-Outcome_Mortality", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Surgical", "I-Intervention_Surgical", "I-Intervention_Surgical", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Blind versus open approach to laparoscopic cholecystectomy : a randomized study . Intraabdominal structures may be damaged during blind introduction of the first trocar for laparoscopic operations . In this study , 150 patients with gallbladder lithiasis who underwent laparoscopy were randomly assigned to two groups , a blind ( V group ) or an open ( H group ) , in order to compare the results and the rate of complications . No mortality was observed . Major complications occurred in 3/75 ( 4 % ) patients of the V group and in 1/75 ( 1.3 % ) patient of the H group ( p < 0.05 ) . Minor complications occurred in 5/75 ( 6.7 % ) patients of either group . The achievement of pneumoperitoneum required 4.5+/-0.4 min in the V group and 3.2+/-0.2 min in the H group ( p < 0.05 ) . The open laparoscopic technique is safer and faster than the blind approach ; therefore , it is proposed that this approach be routinely used in all laparoscopic procedures .

[ "Blind", "versus", "open", "approach", "to", "laparoscopic", "cholecystectomy", ":", "a", "randomized", "study", ".", "Intraabdominal", "structures", "may", "be", "damaged", "during", "blind", "introduction", "of", "the", "first", "trocar", "for", "laparoscopic", "operations", ".", "In", "this", "study", ",", "150", "patients", "with", "gallbladder", "lithiasis", "who", "underwent", "laparoscopy", "were", "randomly", "assigned", "to", "two", "groups", ",", "a", "blind", "(", "V", "group", ")", "or", "an", "open", "(", "H", "group", ")", ",", "in", "order", "to", "compare", "the", "results", "and", "the", "rate", "of", "complications", ".", "No", "mortality", "was", "observed", ".", "Major", "complications", "occurred", "in", "3/75", "(", "4", "%", ")", "patients", "of", "the", "V", "group", "and", "in", "1/75", "(", "1.3", "%", ")", "patient", "of", "the", "H", "group", "(", "p", "<", "0.05", ")", ".", "Minor", "complications", "occurred", "in", "5/75", "(", "6.7", "%", ")", "patients", "of", "either", "group", ".", "The", "achievement", "of", "pneumoperitoneum", "required", "4.5+/-0.4", "min", "in", "the", "V", "group", "and", "3.2+/-0.2", "min", "in", "the", "H", "group", "(", "p", "<", "0.05", ")", ".", "The", "open", "laparoscopic", "technique", "is", "safer", "and", "faster", "than", "the", "blind", "approach", ";", "therefore", ",", "it", "is", "proposed", "that", "this", "approach", "be", "routinely", "used", "in", "all", "laparoscopic", "procedures", "." ]

[ "Intervention_Surgical", "Outcome_Physical", "Outcome_Adverse-effects", "Participant_Condition", "Intervention_Physical", "Outcome_Mortality", "Participant_Sample-size" ]

PSA is a PROTEINAS, marlex is a NORMALIZABLES

8_task0

Sentence: Varón de 65 años que consultaba por un síndrome obstructivo infravesical junto con una tumoración blanda en el hemiescroto derecho, que disminuía de tamaño durante la micción. A la exploración física destacaba la presencia de una bolsa escrotal derecha aumentada de tamaño y de una hernia inguinal reductible. Al tacto rectal destacaba una próstata de tamaño medio, bilobulada y de características adenomatosas. Dentro de las exploraciones complementarias se realizó un PSA total que fue normal, una ecografía vesico-prostática que puso de manifiesto una próstata de 57 gramos y una ecografía testicular con una imagen sugestiva de herniación vesical. Finalmente, la cistografía retrógrada nos mostró la presencia de una hernia vesical masiva en hemiescroto derecho. El tratamiento fue quirúrgico y consistió en la resección de la porción herniada de la vejiga que era para peritoneal y una corrección de la hernia inguinal con malla de marlex. En un segundo tiempo se realizo una RTU de próstata. Controlado a los seis meses el paciente permanece asintomático. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: NORMALIZABLES, PROTEINAS

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Varón de 65 años que consultaba por un síndrome obstructivo infravesical junto con una tumoración blanda en el hemiescroto derecho, que disminuía de tamaño durante la micción. A la exploración física destacaba la presencia de una bolsa escrotal derecha aumentada de tamaño y de una hernia inguinal reductible. Al tacto rectal destacaba una próstata de tamaño medio, bilobulada y de características adenomatosas. Dentro de las exploraciones complementarias se realizó un PSA total que fue normal, una ecografía vesico-prostática que puso de manifiesto una próstata de 57 gramos y una ecografía testicular con una imagen sugestiva de herniación vesical. Finalmente, la cistografía retrógrada nos mostró la presencia de una hernia vesical masiva en hemiescroto derecho. El tratamiento fue quirúrgico y consistió en la resección de la porción herniada de la vejiga que era para peritoneal y una corrección de la hernia inguinal con malla de marlex. En un segundo tiempo se realizo una RTU de próstata. Controlado a los seis meses el paciente permanece asintomático.

[ "Varón", "de", "65", "años", "que", "consultaba", "por", "un", "síndrome", "obstructivo", "infravesical", "junto", "con", "una", "tumoración", "blanda", "en", "el", "hemiescroto", "derecho", ",", "que", "disminuía", "de", "tamaño", "durante", "la", "micción", ".", "\n", "A", "la", "exploración", "física", "destacaba", "la", "presencia", "de", "una", "bolsa", "escrotal", "derecha", "aumentada", "de", "tamaño", "y", "de", "una", "hernia", "inguinal", "reductible", ".", "Al", "tacto", "rectal", "destacaba", "una", "próstata", "de", "tamaño", "medio", ",", "bilobulada", "y", "de", "características", "adenomatosas", ".", "\n", "Dentro", "de", "las", "exploraciones", "complementarias", "se", "realizó", "un", "PSA", "total", "que", "fue", "normal", ",", "una", "ecografía", "vesico", "-", "prostática", "que", "puso", "de", "manifiesto", "una", "próstata", "de", "57", "gramos", "y", "una", "ecografía", "testicular", "con", "una", "imagen", "sugestiva", "de", "herniación", "vesical", ".", "\n\n", "Finalmente", ",", "la", "cistografía", "retrógrada", "nos", "mostró", "la", "presencia", "de", "una", "hernia", "vesical", "masiva", "en", "hemiescroto", "derecho", ".", "\n\n", "El", "tratamiento", "fue", "quirúrgico", "y", "consistió", "en", "la", "resección", "de", "la", "porción", "herniada", "de", "la", "vejiga", "que", "era", "para", "peritoneal", "y", "una", "corrección", "de", "la", "hernia", "inguinal", "con", "malla", "de", "marlex", ".", "En", "un", "segundo", "tiempo", "se", "realizo", "una", "RTU", "de", "próstata", ".", "\n", "Controlado", "a", "los", "seis", "meses", "el", "paciente", "permanece", "asintomático", ".", "\n" ]

[ "NORMALIZABLES", "PROTEINAS" ]

PSA is a PROTEINAS, marlex is a NORMALIZABLES

8_task1

Sentence: Varón de 65 años que consultaba por un síndrome obstructivo infravesical junto con una tumoración blanda en el hemiescroto derecho, que disminuía de tamaño durante la micción. A la exploración física destacaba la presencia de una bolsa escrotal derecha aumentada de tamaño y de una hernia inguinal reductible. Al tacto rectal destacaba una próstata de tamaño medio, bilobulada y de características adenomatosas. Dentro de las exploraciones complementarias se realizó un PSA total que fue normal, una ecografía vesico-prostática que puso de manifiesto una próstata de 57 gramos y una ecografía testicular con una imagen sugestiva de herniación vesical. Finalmente, la cistografía retrógrada nos mostró la presencia de una hernia vesical masiva en hemiescroto derecho. El tratamiento fue quirúrgico y consistió en la resección de la porción herniada de la vejiga que era para peritoneal y una corrección de la hernia inguinal con malla de marlex. En un segundo tiempo se realizo una RTU de próstata. Controlado a los seis meses el paciente permanece asintomático. Instructions: please typing these entity words according to sentence: PSA, marlex Options: NORMALIZABLES, PROTEINAS

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Varón de 65 años que consultaba por un síndrome obstructivo infravesical junto con una tumoración blanda en el hemiescroto derecho, que disminuía de tamaño durante la micción. A la exploración física destacaba la presencia de una bolsa escrotal derecha aumentada de tamaño y de una hernia inguinal reductible. Al tacto rectal destacaba una próstata de tamaño medio, bilobulada y de características adenomatosas. Dentro de las exploraciones complementarias se realizó un PSA total que fue normal, una ecografía vesico-prostática que puso de manifiesto una próstata de 57 gramos y una ecografía testicular con una imagen sugestiva de herniación vesical. Finalmente, la cistografía retrógrada nos mostró la presencia de una hernia vesical masiva en hemiescroto derecho. El tratamiento fue quirúrgico y consistió en la resección de la porción herniada de la vejiga que era para peritoneal y una corrección de la hernia inguinal con malla de marlex. En un segundo tiempo se realizo una RTU de próstata. Controlado a los seis meses el paciente permanece asintomático.

[ "Varón", "de", "65", "años", "que", "consultaba", "por", "un", "síndrome", "obstructivo", "infravesical", "junto", "con", "una", "tumoración", "blanda", "en", "el", "hemiescroto", "derecho", ",", "que", "disminuía", "de", "tamaño", "durante", "la", "micción", ".", "\n", "A", "la", "exploración", "física", "destacaba", "la", "presencia", "de", "una", "bolsa", "escrotal", "derecha", "aumentada", "de", "tamaño", "y", "de", "una", "hernia", "inguinal", "reductible", ".", "Al", "tacto", "rectal", "destacaba", "una", "próstata", "de", "tamaño", "medio", ",", "bilobulada", "y", "de", "características", "adenomatosas", ".", "\n", "Dentro", "de", "las", "exploraciones", "complementarias", "se", "realizó", "un", "PSA", "total", "que", "fue", "normal", ",", "una", "ecografía", "vesico", "-", "prostática", "que", "puso", "de", "manifiesto", "una", "próstata", "de", "57", "gramos", "y", "una", "ecografía", "testicular", "con", "una", "imagen", "sugestiva", "de", "herniación", "vesical", ".", "\n\n", "Finalmente", ",", "la", "cistografía", "retrógrada", "nos", "mostró", "la", "presencia", "de", "una", "hernia", "vesical", "masiva", "en", "hemiescroto", "derecho", ".", "\n\n", "El", "tratamiento", "fue", "quirúrgico", "y", "consistió", "en", "la", "resección", "de", "la", "porción", "herniada", "de", "la", "vejiga", "que", "era", "para", "peritoneal", "y", "una", "corrección", "de", "la", "hernia", "inguinal", "con", "malla", "de", "marlex", ".", "En", "un", "segundo", "tiempo", "se", "realizo", "una", "RTU", "de", "próstata", ".", "\n", "Controlado", "a", "los", "seis", "meses", "el", "paciente", "permanece", "asintomático", ".", "\n" ]

[ "NORMALIZABLES", "PROTEINAS" ]

PSA, marlex

8_task2

Sentence: Varón de 65 años que consultaba por un síndrome obstructivo infravesical junto con una tumoración blanda en el hemiescroto derecho, que disminuía de tamaño durante la micción. A la exploración física destacaba la presencia de una bolsa escrotal derecha aumentada de tamaño y de una hernia inguinal reductible. Al tacto rectal destacaba una próstata de tamaño medio, bilobulada y de características adenomatosas. Dentro de las exploraciones complementarias se realizó un PSA total que fue normal, una ecografía vesico-prostática que puso de manifiesto una próstata de 57 gramos y una ecografía testicular con una imagen sugestiva de herniación vesical. Finalmente, la cistografía retrógrada nos mostró la presencia de una hernia vesical masiva en hemiescroto derecho. El tratamiento fue quirúrgico y consistió en la resección de la porción herniada de la vejiga que era para peritoneal y una corrección de la hernia inguinal con malla de marlex. En un segundo tiempo se realizo una RTU de próstata. Controlado a los seis meses el paciente permanece asintomático. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-PROTEINAS", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NORMALIZABLES", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Varón de 65 años que consultaba por un síndrome obstructivo infravesical junto con una tumoración blanda en el hemiescroto derecho, que disminuía de tamaño durante la micción. A la exploración física destacaba la presencia de una bolsa escrotal derecha aumentada de tamaño y de una hernia inguinal reductible. Al tacto rectal destacaba una próstata de tamaño medio, bilobulada y de características adenomatosas. Dentro de las exploraciones complementarias se realizó un PSA total que fue normal, una ecografía vesico-prostática que puso de manifiesto una próstata de 57 gramos y una ecografía testicular con una imagen sugestiva de herniación vesical. Finalmente, la cistografía retrógrada nos mostró la presencia de una hernia vesical masiva en hemiescroto derecho. El tratamiento fue quirúrgico y consistió en la resección de la porción herniada de la vejiga que era para peritoneal y una corrección de la hernia inguinal con malla de marlex. En un segundo tiempo se realizo una RTU de próstata. Controlado a los seis meses el paciente permanece asintomático.

[ "Varón", "de", "65", "años", "que", "consultaba", "por", "un", "síndrome", "obstructivo", "infravesical", "junto", "con", "una", "tumoración", "blanda", "en", "el", "hemiescroto", "derecho", ",", "que", "disminuía", "de", "tamaño", "durante", "la", "micción", ".", "\n", "A", "la", "exploración", "física", "destacaba", "la", "presencia", "de", "una", "bolsa", "escrotal", "derecha", "aumentada", "de", "tamaño", "y", "de", "una", "hernia", "inguinal", "reductible", ".", "Al", "tacto", "rectal", "destacaba", "una", "próstata", "de", "tamaño", "medio", ",", "bilobulada", "y", "de", "características", "adenomatosas", ".", "\n", "Dentro", "de", "las", "exploraciones", "complementarias", "se", "realizó", "un", "PSA", "total", "que", "fue", "normal", ",", "una", "ecografía", "vesico", "-", "prostática", "que", "puso", "de", "manifiesto", "una", "próstata", "de", "57", "gramos", "y", "una", "ecografía", "testicular", "con", "una", "imagen", "sugestiva", "de", "herniación", "vesical", ".", "\n\n", "Finalmente", ",", "la", "cistografía", "retrógrada", "nos", "mostró", "la", "presencia", "de", "una", "hernia", "vesical", "masiva", "en", "hemiescroto", "derecho", ".", "\n\n", "El", "tratamiento", "fue", "quirúrgico", "y", "consistió", "en", "la", "resección", "de", "la", "porción", "herniada", "de", "la", "vejiga", "que", "era", "para", "peritoneal", "y", "una", "corrección", "de", "la", "hernia", "inguinal", "con", "malla", "de", "marlex", ".", "En", "un", "segundo", "tiempo", "se", "realizo", "una", "RTU", "de", "próstata", ".", "\n", "Controlado", "a", "los", "seis", "meses", "el", "paciente", "permanece", "asintomático", ".", "\n" ]

[ "NORMALIZABLES", "PROTEINAS" ]

benzenesulfonamide is a CHEMICAL, carbonic anhydrase IX is a GENE-Y

23234246_task0

Sentence: Synthesis and SAR of novel Re/99mTc-labeled benzenesulfonamide carbonic anhydrase IX inhibitors for molecular imaging of tumor hypoxia. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]

Synthesis and SAR of novel Re/99mTc-labeled benzenesulfonamide carbonic anhydrase IX inhibitors for molecular imaging of tumor hypoxia.

[ "Synthesis", "and", "SAR", "of", "novel", "Re/99mTc", "-", "labeled", "benzenesulfonamide", "carbonic", "anhydrase", "IX", "inhibitors", "for", "molecular", "imaging", "of", "tumor", "hypoxia", "." ]

[ "CHEMICAL", "GENE-Y" ]

benzenesulfonamide is a CHEMICAL, carbonic anhydrase IX is a GENE-Y

23234246_task1

Sentence: Synthesis and SAR of novel Re/99mTc-labeled benzenesulfonamide carbonic anhydrase IX inhibitors for molecular imaging of tumor hypoxia. Instructions: please typing these entity words according to sentence: benzenesulfonamide, carbonic anhydrase IX Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]

Synthesis and SAR of novel Re/99mTc-labeled benzenesulfonamide carbonic anhydrase IX inhibitors for molecular imaging of tumor hypoxia.

[ "Synthesis", "and", "SAR", "of", "novel", "Re/99mTc", "-", "labeled", "benzenesulfonamide", "carbonic", "anhydrase", "IX", "inhibitors", "for", "molecular", "imaging", "of", "tumor", "hypoxia", "." ]

[ "CHEMICAL", "GENE-Y" ]

benzenesulfonamide, carbonic anhydrase IX

23234246_task2

Sentence: Synthesis and SAR of novel Re/99mTc-labeled benzenesulfonamide carbonic anhydrase IX inhibitors for molecular imaging of tumor hypoxia. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O" ]

Synthesis and SAR of novel Re/99mTc-labeled benzenesulfonamide carbonic anhydrase IX inhibitors for molecular imaging of tumor hypoxia.

[ "Synthesis", "and", "SAR", "of", "novel", "Re/99mTc", "-", "labeled", "benzenesulfonamide", "carbonic", "anhydrase", "IX", "inhibitors", "for", "molecular", "imaging", "of", "tumor", "hypoxia", "." ]

[ "CHEMICAL", "GENE-Y" ]

dystonia is an umlsterm, panic attacks is an umlsterm, treatment is an umlsterm, pathology is an umlsterm, medication is an umlsterm, objective is an umlsterm, analysis is an umlsterm, movement disorder is an umlsterm, myoclonus is an umlsterm, medication is an umlsterm, Nefadozone is an umlsterm, myoclonus is an umlsterm, frequency is an umlsterm, panic attacks is an umlsterm

DerNervenarzt.00710839.eng.abstr_task0

Sentence: We report a case of autosomal dominantly inherited dystonia and panic attacks to discuss successful treatment of a common serotonergic pathology with medication . The objective analysis of the movement disorder was done by Optotrak©. First we demonstrate a reduction of the myoclonus by L-5-hydroxytryptophan, which inhibits after 11 months . After changing the medication to Nefadozone , the myoclonus and the frequency of panic attacks were reduced . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]

We report a case of autosomal dominantly inherited dystonia and panic attacks to discuss successful treatment of a common serotonergic pathology with medication . The objective analysis of the movement disorder was done by Optotrak©. First we demonstrate a reduction of the myoclonus by L-5-hydroxytryptophan, which inhibits after 11 months . After changing the medication to Nefadozone , the myoclonus and the frequency of panic attacks were reduced .

[ "We", "report", "a", "case", "of", "autosomal", "dominantly", "inherited", "dystonia", "and", "panic", "attacks", "to", "discuss", "successful", "treatment", "of", "a", "common", "serotonergic", "pathology", "with", "medication", ".", "The", "objective", "analysis", "of", "the", "movement", "disorder", "was", "done", "by", "Optotrak", "©", ".", "First", "we", "demonstrate", "a", "reduction", "of", "the", "myoclonus", "by", "L-5-hydroxytryptophan", ",", "which", "inhibits", "after", "11", "months", ".", "After", "changing", "the", "medication", "to", "Nefadozone", ",", "the", "myoclonus", "and", "the", "frequency", "of", "panic", "attacks", "were", "reduced", "." ]

[ "umlsterm" ]

dystonia is an umlsterm, panic attacks is an umlsterm, treatment is an umlsterm, pathology is an umlsterm, medication is an umlsterm, objective is an umlsterm, analysis is an umlsterm, movement disorder is an umlsterm, myoclonus is an umlsterm, medication is an umlsterm, Nefadozone is an umlsterm, myoclonus is an umlsterm, frequency is an umlsterm, panic attacks is an umlsterm

DerNervenarzt.00710839.eng.abstr_task1

Sentence: We report a case of autosomal dominantly inherited dystonia and panic attacks to discuss successful treatment of a common serotonergic pathology with medication . The objective analysis of the movement disorder was done by Optotrak©. First we demonstrate a reduction of the myoclonus by L-5-hydroxytryptophan, which inhibits after 11 months . After changing the medication to Nefadozone , the myoclonus and the frequency of panic attacks were reduced . Instructions: please typing these entity words according to sentence: dystonia, panic attacks, treatment, pathology, medication, objective, analysis, movement disorder, myoclonus, medication, Nefadozone, myoclonus, frequency, panic attacks Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]

We report a case of autosomal dominantly inherited dystonia and panic attacks to discuss successful treatment of a common serotonergic pathology with medication . The objective analysis of the movement disorder was done by Optotrak©. First we demonstrate a reduction of the myoclonus by L-5-hydroxytryptophan, which inhibits after 11 months . After changing the medication to Nefadozone , the myoclonus and the frequency of panic attacks were reduced .

[ "We", "report", "a", "case", "of", "autosomal", "dominantly", "inherited", "dystonia", "and", "panic", "attacks", "to", "discuss", "successful", "treatment", "of", "a", "common", "serotonergic", "pathology", "with", "medication", ".", "The", "objective", "analysis", "of", "the", "movement", "disorder", "was", "done", "by", "Optotrak", "©", ".", "First", "we", "demonstrate", "a", "reduction", "of", "the", "myoclonus", "by", "L-5-hydroxytryptophan", ",", "which", "inhibits", "after", "11", "months", ".", "After", "changing", "the", "medication", "to", "Nefadozone", ",", "the", "myoclonus", "and", "the", "frequency", "of", "panic", "attacks", "were", "reduced", "." ]

[ "umlsterm" ]

dystonia, panic attacks, treatment, pathology, medication, objective, analysis, movement disorder, myoclonus, medication, Nefadozone, myoclonus, frequency, panic attacks

DerNervenarzt.00710839.eng.abstr_task2

Sentence: We report a case of autosomal dominantly inherited dystonia and panic attacks to discuss successful treatment of a common serotonergic pathology with medication . The objective analysis of the movement disorder was done by Optotrak©. First we demonstrate a reduction of the myoclonus by L-5-hydroxytryptophan, which inhibits after 11 months . After changing the medication to Nefadozone , the myoclonus and the frequency of panic attacks were reduced . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O" ]

We report a case of autosomal dominantly inherited dystonia and panic attacks to discuss successful treatment of a common serotonergic pathology with medication . The objective analysis of the movement disorder was done by Optotrak©. First we demonstrate a reduction of the myoclonus by L-5-hydroxytryptophan, which inhibits after 11 months . After changing the medication to Nefadozone , the myoclonus and the frequency of panic attacks were reduced .

[ "We", "report", "a", "case", "of", "autosomal", "dominantly", "inherited", "dystonia", "and", "panic", "attacks", "to", "discuss", "successful", "treatment", "of", "a", "common", "serotonergic", "pathology", "with", "medication", ".", "The", "objective", "analysis", "of", "the", "movement", "disorder", "was", "done", "by", "Optotrak", "©", ".", "First", "we", "demonstrate", "a", "reduction", "of", "the", "myoclonus", "by", "L-5-hydroxytryptophan", ",", "which", "inhibits", "after", "11", "months", ".", "After", "changing", "the", "medication", "to", "Nefadozone", ",", "the", "myoclonus", "and", "the", "frequency", "of", "panic", "attacks", "were", "reduced", "." ]

[ "umlsterm" ]

phosphodiesterase-5 is a GENE-Y, vardenafil is a CHEMICAL, sildenafil is a CHEMICAL

17959709_task0

Sentence: Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O" ]

Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil.

[ "Conformational", "variations", "of", "both", "phosphodiesterase-5", "and", "inhibitors", "provide", "the", "structural", "basis", "for", "the", "physiological", "effects", "of", "vardenafil", "and", "sildenafil", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

phosphodiesterase-5 is a GENE-Y, vardenafil is a CHEMICAL, sildenafil is a CHEMICAL

17959709_task1

Sentence: Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Instructions: please typing these entity words according to sentence: phosphodiesterase-5, vardenafil, sildenafil Options: GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O" ]

Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil.

[ "Conformational", "variations", "of", "both", "phosphodiesterase-5", "and", "inhibitors", "provide", "the", "structural", "basis", "for", "the", "physiological", "effects", "of", "vardenafil", "and", "sildenafil", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

phosphodiesterase-5, vardenafil, sildenafil

17959709_task2

Sentence: Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O" ]

Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil.

[ "Conformational", "variations", "of", "both", "phosphodiesterase-5", "and", "inhibitors", "provide", "the", "structural", "basis", "for", "the", "physiological", "effects", "of", "vardenafil", "and", "sildenafil", "." ]

[ "GENE-N", "GENE-Y", "CHEMICAL" ]

Tissue - type plasminogen activator is a GENE-Y, cytokine is a GENE-N, matrix metalloproteinase-9 is a GENE-Y, Tissue - type plasminogen activator is a GENE-Y, tPA is a GENE-Y, serine protease is a GENE-N, plasmin is a GENE-Y, matrix metalloproteinase-9 is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, tPA is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, tPA is a GENE-Y, low density lipoprotein receptor - related protein-1 is a GENE-Y, LRP-1 is a GENE-Y, LRP-1 is a GENE-Y, LRP-1 is a GENE-Y, tPA is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, tyrosine is a CHEMICAL, LRP-1 is a GENE-Y, Mek1 is a GENE-Y, Erk-1 and -2 is a GENE-N, Erk-1/2 is a GENE-N, Mek1 is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, constitutively activated Mek1 is a GENE-Y, Erk-1/2 is a GENE-N, MMP-9 is a GENE-Y, tPA is a GENE-Y, LRP-1 is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, cytokine is a GENE-N, LRP-1 is a GENE-Y, tyrosine is a CHEMICAL

25458_task0

Sentence: Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. Tissue-type plasminogen activator (tPA), a serine protease well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts. However, exactly how tPA transduces its signal into the nucleus to control gene expression is unknown. This study investigated the mechanism by which tPA induces MMP-9 gene expression. Both wild-type and non-enzymatic mutant tPA were found to induce MMP-9 expression in rat kidney interstitial fibroblasts (NRK-49F), indicating that the actions of tPA are independent of its proteolytic activity. tPA bound to the low density lipoprotein receptor-related protein-1 (LRP-1) in NRK-49F cells, and this binding was competitively abrogated by the LRP-1 antagonist, the receptor-associated protein. In mouse embryonic fibroblasts (PEA-13) lacking LRP-1, tPA failed to induce MMP-9 expression. Furthermore, tPA induced rapid tyrosine phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream Erk-1 and -2. Blockade of Erk-1/2 activation by the Mek1 inhibitor abolished MMP-9 induction by tPA in NRK-49F cells. Conversely, overexpression of constitutively activated Mek1 induced Erk-1/2 phosphorylation and MMP-9 expression. In mouse obstructed kidney, tPA, LRP-1, and MMP-9 were concomitantly induced in the renal interstitium. Collectively, these results suggest that besides its classical proteolytic activity, tPA acts as a cytokine that binds to the cell membrane receptor LRP-1, induces its tyrosine phosphorylation, and triggers intracellular signal transduction, thereby inducing specific gene expression in renal interstitial fibroblasts. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL, GENE-Y, GENE-N

[ "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. Tissue-type plasminogen activator (tPA), a serine protease well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts. However, exactly how tPA transduces its signal into the nucleus to control gene expression is unknown. This study investigated the mechanism by which tPA induces MMP-9 gene expression. Both wild-type and non-enzymatic mutant tPA were found to induce MMP-9 expression in rat kidney interstitial fibroblasts (NRK-49F), indicating that the actions of tPA are independent of its proteolytic activity. tPA bound to the low density lipoprotein receptor-related protein-1 (LRP-1) in NRK-49F cells, and this binding was competitively abrogated by the LRP-1 antagonist, the receptor-associated protein. In mouse embryonic fibroblasts (PEA-13) lacking LRP-1, tPA failed to induce MMP-9 expression. Furthermore, tPA induced rapid tyrosine phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream Erk-1 and -2. Blockade of Erk-1/2 activation by the Mek1 inhibitor abolished MMP-9 induction by tPA in NRK-49F cells. Conversely, overexpression of constitutively activated Mek1 induced Erk-1/2 phosphorylation and MMP-9 expression. In mouse obstructed kidney, tPA, LRP-1, and MMP-9 were concomitantly induced in the renal interstitium. Collectively, these results suggest that besides its classical proteolytic activity, tPA acts as a cytokine that binds to the cell membrane receptor LRP-1, induces its tyrosine phosphorylation, and triggers intracellular signal transduction, thereby inducing specific gene expression in renal interstitial fibroblasts.

[ "Tissue", "-", "type", "plasminogen", "activator", "acts", "as", "a", "cytokine", "that", "triggers", "intracellular", "signal", "transduction", "and", "induces", "matrix", "metalloproteinase-9", "gene", "expression", ".", "\n", "Tissue", "-", "type", "plasminogen", "activator", "(", "tPA", ")", ",", "a", "serine", "protease", "well", "known", "for", "generating", "plasmin", ",", "has", "been", "demonstrated", "to", "induce", "matrix", "metalloproteinase-9", "(", "MMP-9", ")", "gene", "expression", "and", "protein", "secretion", "in", "renal", "interstitial", "fibroblasts", ".", "However", ",", "exactly", "how", "tPA", "transduces", "its", "signal", "into", "the", "nucleus", "to", "control", "gene", "expression", "is", "unknown", ".", "This", "study", "investigated", "the", "mechanism", "by", "which", "tPA", "induces", "MMP-9", "gene", "expression", ".", "Both", "wild", "-", "type", "and", "non", "-", "enzymatic", "mutant", "tPA", "were", "found", "to", "induce", "MMP-9", "expression", "in", "rat", "kidney", "interstitial", "fibroblasts", "(", "NRK-49F", ")", ",", "indicating", "that", "the", "actions", "of", "tPA", "are", "independent", "of", "its", "proteolytic", "activity", ".", "tPA", "bound", "to", "the", "low", "density", "lipoprotein", "receptor", "-", "related", "protein-1", "(", "LRP-1", ")", "in", "NRK-49F", "cells", ",", "and", "this", "binding", "was", "competitively", "abrogated", "by", "the", "LRP-1", "antagonist", ",", "the", "receptor", "-", "associated", "protein", ".", "In", "mouse", "embryonic", "fibroblasts", "(", "PEA-13", ")", "lacking", "LRP-1", ",", "tPA", "failed", "to", "induce", "MMP-9", "expression", ".", "Furthermore", ",", "tPA", "induced", "rapid", "tyrosine", "phosphorylation", "on", "the", "beta", "subunit", "of", "LRP-1", ",", "which", "was", "followed", "by", "the", "activation", "of", "Mek1", "and", "its", "downstream", "Erk-1", "and", "-2", ".", "Blockade", "of", "Erk-1/2", "activation", "by", "the", "Mek1", "inhibitor", "abolished", "MMP-9", "induction", "by", "tPA", "in", "NRK-49F", "cells", ".", "Conversely", ",", "overexpression", "of", "constitutively", "activated", "Mek1", "induced", "Erk-1/2", "phosphorylation", "and", "MMP-9", "expression", ".", "In", "mouse", "obstructed", "kidney", ",", "tPA", ",", "LRP-1", ",", "and", "MMP-9", "were", "concomitantly", "induced", "in", "the", "renal", "interstitium", ".", "Collectively", ",", "these", "results", "suggest", "that", "besides", "its", "classical", "proteolytic", "activity", ",", "tPA", "acts", "as", "a", "cytokine", "that", "binds", "to", "the", "cell", "membrane", "receptor", "LRP-1", ",", "induces", "its", "tyrosine", "phosphorylation", ",", "and", "triggers", "intracellular", "signal", "transduction", ",", "thereby", "inducing", "specific", "gene", "expression", "in", "renal", "interstitial", "fibroblasts", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

Tissue - type plasminogen activator is a GENE-Y, cytokine is a GENE-N, matrix metalloproteinase-9 is a GENE-Y, Tissue - type plasminogen activator is a GENE-Y, tPA is a GENE-Y, serine protease is a GENE-N, plasmin is a GENE-Y, matrix metalloproteinase-9 is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, tPA is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, tPA is a GENE-Y, low density lipoprotein receptor - related protein-1 is a GENE-Y, LRP-1 is a GENE-Y, LRP-1 is a GENE-Y, LRP-1 is a GENE-Y, tPA is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, tyrosine is a CHEMICAL, LRP-1 is a GENE-Y, Mek1 is a GENE-Y, Erk-1 and -2 is a GENE-N, Erk-1/2 is a GENE-N, Mek1 is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, constitutively activated Mek1 is a GENE-Y, Erk-1/2 is a GENE-N, MMP-9 is a GENE-Y, tPA is a GENE-Y, LRP-1 is a GENE-Y, MMP-9 is a GENE-Y, tPA is a GENE-Y, cytokine is a GENE-N, LRP-1 is a GENE-Y, tyrosine is a CHEMICAL

25458_task1

Sentence: Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. Tissue-type plasminogen activator (tPA), a serine protease well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts. However, exactly how tPA transduces its signal into the nucleus to control gene expression is unknown. This study investigated the mechanism by which tPA induces MMP-9 gene expression. Both wild-type and non-enzymatic mutant tPA were found to induce MMP-9 expression in rat kidney interstitial fibroblasts (NRK-49F), indicating that the actions of tPA are independent of its proteolytic activity. tPA bound to the low density lipoprotein receptor-related protein-1 (LRP-1) in NRK-49F cells, and this binding was competitively abrogated by the LRP-1 antagonist, the receptor-associated protein. In mouse embryonic fibroblasts (PEA-13) lacking LRP-1, tPA failed to induce MMP-9 expression. Furthermore, tPA induced rapid tyrosine phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream Erk-1 and -2. Blockade of Erk-1/2 activation by the Mek1 inhibitor abolished MMP-9 induction by tPA in NRK-49F cells. Conversely, overexpression of constitutively activated Mek1 induced Erk-1/2 phosphorylation and MMP-9 expression. In mouse obstructed kidney, tPA, LRP-1, and MMP-9 were concomitantly induced in the renal interstitium. Collectively, these results suggest that besides its classical proteolytic activity, tPA acts as a cytokine that binds to the cell membrane receptor LRP-1, induces its tyrosine phosphorylation, and triggers intracellular signal transduction, thereby inducing specific gene expression in renal interstitial fibroblasts. Instructions: please typing these entity words according to sentence: Tissue - type plasminogen activator, cytokine, matrix metalloproteinase-9, Tissue - type plasminogen activator, tPA, serine protease, plasmin, matrix metalloproteinase-9, MMP-9, tPA, tPA, MMP-9, tPA, MMP-9, tPA, tPA, low density lipoprotein receptor - related protein-1, LRP-1, LRP-1, LRP-1, tPA, MMP-9, tPA, tyrosine, LRP-1, Mek1, Erk-1 and -2, Erk-1/2, Mek1, MMP-9, tPA, constitutively activated Mek1, Erk-1/2, MMP-9, tPA, LRP-1, MMP-9, tPA, cytokine, LRP-1, tyrosine Options: CHEMICAL, GENE-Y, GENE-N

[ "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. Tissue-type plasminogen activator (tPA), a serine protease well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts. However, exactly how tPA transduces its signal into the nucleus to control gene expression is unknown. This study investigated the mechanism by which tPA induces MMP-9 gene expression. Both wild-type and non-enzymatic mutant tPA were found to induce MMP-9 expression in rat kidney interstitial fibroblasts (NRK-49F), indicating that the actions of tPA are independent of its proteolytic activity. tPA bound to the low density lipoprotein receptor-related protein-1 (LRP-1) in NRK-49F cells, and this binding was competitively abrogated by the LRP-1 antagonist, the receptor-associated protein. In mouse embryonic fibroblasts (PEA-13) lacking LRP-1, tPA failed to induce MMP-9 expression. Furthermore, tPA induced rapid tyrosine phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream Erk-1 and -2. Blockade of Erk-1/2 activation by the Mek1 inhibitor abolished MMP-9 induction by tPA in NRK-49F cells. Conversely, overexpression of constitutively activated Mek1 induced Erk-1/2 phosphorylation and MMP-9 expression. In mouse obstructed kidney, tPA, LRP-1, and MMP-9 were concomitantly induced in the renal interstitium. Collectively, these results suggest that besides its classical proteolytic activity, tPA acts as a cytokine that binds to the cell membrane receptor LRP-1, induces its tyrosine phosphorylation, and triggers intracellular signal transduction, thereby inducing specific gene expression in renal interstitial fibroblasts.

[ "Tissue", "-", "type", "plasminogen", "activator", "acts", "as", "a", "cytokine", "that", "triggers", "intracellular", "signal", "transduction", "and", "induces", "matrix", "metalloproteinase-9", "gene", "expression", ".", "\n", "Tissue", "-", "type", "plasminogen", "activator", "(", "tPA", ")", ",", "a", "serine", "protease", "well", "known", "for", "generating", "plasmin", ",", "has", "been", "demonstrated", "to", "induce", "matrix", "metalloproteinase-9", "(", "MMP-9", ")", "gene", "expression", "and", "protein", "secretion", "in", "renal", "interstitial", "fibroblasts", ".", "However", ",", "exactly", "how", "tPA", "transduces", "its", "signal", "into", "the", "nucleus", "to", "control", "gene", "expression", "is", "unknown", ".", "This", "study", "investigated", "the", "mechanism", "by", "which", "tPA", "induces", "MMP-9", "gene", "expression", ".", "Both", "wild", "-", "type", "and", "non", "-", "enzymatic", "mutant", "tPA", "were", "found", "to", "induce", "MMP-9", "expression", "in", "rat", "kidney", "interstitial", "fibroblasts", "(", "NRK-49F", ")", ",", "indicating", "that", "the", "actions", "of", "tPA", "are", "independent", "of", "its", "proteolytic", "activity", ".", "tPA", "bound", "to", "the", "low", "density", "lipoprotein", "receptor", "-", "related", "protein-1", "(", "LRP-1", ")", "in", "NRK-49F", "cells", ",", "and", "this", "binding", "was", "competitively", "abrogated", "by", "the", "LRP-1", "antagonist", ",", "the", "receptor", "-", "associated", "protein", ".", "In", "mouse", "embryonic", "fibroblasts", "(", "PEA-13", ")", "lacking", "LRP-1", ",", "tPA", "failed", "to", "induce", "MMP-9", "expression", ".", "Furthermore", ",", "tPA", "induced", "rapid", "tyrosine", "phosphorylation", "on", "the", "beta", "subunit", "of", "LRP-1", ",", "which", "was", "followed", "by", "the", "activation", "of", "Mek1", "and", "its", "downstream", "Erk-1", "and", "-2", ".", "Blockade", "of", "Erk-1/2", "activation", "by", "the", "Mek1", "inhibitor", "abolished", "MMP-9", "induction", "by", "tPA", "in", "NRK-49F", "cells", ".", "Conversely", ",", "overexpression", "of", "constitutively", "activated", "Mek1", "induced", "Erk-1/2", "phosphorylation", "and", "MMP-9", "expression", ".", "In", "mouse", "obstructed", "kidney", ",", "tPA", ",", "LRP-1", ",", "and", "MMP-9", "were", "concomitantly", "induced", "in", "the", "renal", "interstitium", ".", "Collectively", ",", "these", "results", "suggest", "that", "besides", "its", "classical", "proteolytic", "activity", ",", "tPA", "acts", "as", "a", "cytokine", "that", "binds", "to", "the", "cell", "membrane", "receptor", "LRP-1", ",", "induces", "its", "tyrosine", "phosphorylation", ",", "and", "triggers", "intracellular", "signal", "transduction", ",", "thereby", "inducing", "specific", "gene", "expression", "in", "renal", "interstitial", "fibroblasts", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

Tissue - type plasminogen activator, cytokine, matrix metalloproteinase-9, Tissue - type plasminogen activator, tPA, serine protease, plasmin, matrix metalloproteinase-9, MMP-9, tPA, tPA, MMP-9, tPA, MMP-9, tPA, tPA, low density lipoprotein receptor - related protein-1, LRP-1, LRP-1, LRP-1, tPA, MMP-9, tPA, tyrosine, LRP-1, Mek1, Erk-1 and -2, Erk-1/2, Mek1, MMP-9, tPA, constitutively activated Mek1, Erk-1/2, MMP-9, tPA, LRP-1, MMP-9, tPA, cytokine, LRP-1, tyrosine

25458_task2

Sentence: Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. Tissue-type plasminogen activator (tPA), a serine protease well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts. However, exactly how tPA transduces its signal into the nucleus to control gene expression is unknown. This study investigated the mechanism by which tPA induces MMP-9 gene expression. Both wild-type and non-enzymatic mutant tPA were found to induce MMP-9 expression in rat kidney interstitial fibroblasts (NRK-49F), indicating that the actions of tPA are independent of its proteolytic activity. tPA bound to the low density lipoprotein receptor-related protein-1 (LRP-1) in NRK-49F cells, and this binding was competitively abrogated by the LRP-1 antagonist, the receptor-associated protein. In mouse embryonic fibroblasts (PEA-13) lacking LRP-1, tPA failed to induce MMP-9 expression. Furthermore, tPA induced rapid tyrosine phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream Erk-1 and -2. Blockade of Erk-1/2 activation by the Mek1 inhibitor abolished MMP-9 induction by tPA in NRK-49F cells. Conversely, overexpression of constitutively activated Mek1 induced Erk-1/2 phosphorylation and MMP-9 expression. In mouse obstructed kidney, tPA, LRP-1, and MMP-9 were concomitantly induced in the renal interstitium. Collectively, these results suggest that besides its classical proteolytic activity, tPA acts as a cytokine that binds to the cell membrane receptor LRP-1, induces its tyrosine phosphorylation, and triggers intracellular signal transduction, thereby inducing specific gene expression in renal interstitial fibroblasts. Instructions: please extract entity words from the input sentence

[ "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "I-GENE-N", "I-GENE-N", "O", "O", "O", "B-GENE-N", "O", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "I-GENE-Y", "O", "B-GENE-N", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "B-GENE-Y", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-GENE-N", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. Tissue-type plasminogen activator (tPA), a serine protease well known for generating plasmin, has been demonstrated to induce matrix metalloproteinase-9 (MMP-9) gene expression and protein secretion in renal interstitial fibroblasts. However, exactly how tPA transduces its signal into the nucleus to control gene expression is unknown. This study investigated the mechanism by which tPA induces MMP-9 gene expression. Both wild-type and non-enzymatic mutant tPA were found to induce MMP-9 expression in rat kidney interstitial fibroblasts (NRK-49F), indicating that the actions of tPA are independent of its proteolytic activity. tPA bound to the low density lipoprotein receptor-related protein-1 (LRP-1) in NRK-49F cells, and this binding was competitively abrogated by the LRP-1 antagonist, the receptor-associated protein. In mouse embryonic fibroblasts (PEA-13) lacking LRP-1, tPA failed to induce MMP-9 expression. Furthermore, tPA induced rapid tyrosine phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream Erk-1 and -2. Blockade of Erk-1/2 activation by the Mek1 inhibitor abolished MMP-9 induction by tPA in NRK-49F cells. Conversely, overexpression of constitutively activated Mek1 induced Erk-1/2 phosphorylation and MMP-9 expression. In mouse obstructed kidney, tPA, LRP-1, and MMP-9 were concomitantly induced in the renal interstitium. Collectively, these results suggest that besides its classical proteolytic activity, tPA acts as a cytokine that binds to the cell membrane receptor LRP-1, induces its tyrosine phosphorylation, and triggers intracellular signal transduction, thereby inducing specific gene expression in renal interstitial fibroblasts.

[ "Tissue", "-", "type", "plasminogen", "activator", "acts", "as", "a", "cytokine", "that", "triggers", "intracellular", "signal", "transduction", "and", "induces", "matrix", "metalloproteinase-9", "gene", "expression", ".", "\n", "Tissue", "-", "type", "plasminogen", "activator", "(", "tPA", ")", ",", "a", "serine", "protease", "well", "known", "for", "generating", "plasmin", ",", "has", "been", "demonstrated", "to", "induce", "matrix", "metalloproteinase-9", "(", "MMP-9", ")", "gene", "expression", "and", "protein", "secretion", "in", "renal", "interstitial", "fibroblasts", ".", "However", ",", "exactly", "how", "tPA", "transduces", "its", "signal", "into", "the", "nucleus", "to", "control", "gene", "expression", "is", "unknown", ".", "This", "study", "investigated", "the", "mechanism", "by", "which", "tPA", "induces", "MMP-9", "gene", "expression", ".", "Both", "wild", "-", "type", "and", "non", "-", "enzymatic", "mutant", "tPA", "were", "found", "to", "induce", "MMP-9", "expression", "in", "rat", "kidney", "interstitial", "fibroblasts", "(", "NRK-49F", ")", ",", "indicating", "that", "the", "actions", "of", "tPA", "are", "independent", "of", "its", "proteolytic", "activity", ".", "tPA", "bound", "to", "the", "low", "density", "lipoprotein", "receptor", "-", "related", "protein-1", "(", "LRP-1", ")", "in", "NRK-49F", "cells", ",", "and", "this", "binding", "was", "competitively", "abrogated", "by", "the", "LRP-1", "antagonist", ",", "the", "receptor", "-", "associated", "protein", ".", "In", "mouse", "embryonic", "fibroblasts", "(", "PEA-13", ")", "lacking", "LRP-1", ",", "tPA", "failed", "to", "induce", "MMP-9", "expression", ".", "Furthermore", ",", "tPA", "induced", "rapid", "tyrosine", "phosphorylation", "on", "the", "beta", "subunit", "of", "LRP-1", ",", "which", "was", "followed", "by", "the", "activation", "of", "Mek1", "and", "its", "downstream", "Erk-1", "and", "-2", ".", "Blockade", "of", "Erk-1/2", "activation", "by", "the", "Mek1", "inhibitor", "abolished", "MMP-9", "induction", "by", "tPA", "in", "NRK-49F", "cells", ".", "Conversely", ",", "overexpression", "of", "constitutively", "activated", "Mek1", "induced", "Erk-1/2", "phosphorylation", "and", "MMP-9", "expression", ".", "In", "mouse", "obstructed", "kidney", ",", "tPA", ",", "LRP-1", ",", "and", "MMP-9", "were", "concomitantly", "induced", "in", "the", "renal", "interstitium", ".", "Collectively", ",", "these", "results", "suggest", "that", "besides", "its", "classical", "proteolytic", "activity", ",", "tPA", "acts", "as", "a", "cytokine", "that", "binds", "to", "the", "cell", "membrane", "receptor", "LRP-1", ",", "induces", "its", "tyrosine", "phosphorylation", ",", "and", "triggers", "intracellular", "signal", "transduction", ",", "thereby", "inducing", "specific", "gene", "expression", "in", "renal", "interstitial", "fibroblasts", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

Kraniofaziale Fehlbildungen is an umlsterm, Schaedelnaehten is an umlsterm, Hirn- is an umlsterm, Gesichtsschaedels is an umlsterm, Therapieansaetze is an umlsterm, Technik is an umlsterm, Operationstechnik is an umlsterm, Operationstechniken is an umlsterm, Techniken is an umlsterm, Tumorchirurgie is an umlsterm, Traumatologie is an umlsterm

MundKieferGesichtschirurgie.0004s068.ger.abstr_task0

Sentence: Kraniofaziale Fehlbildungen entstehen ueberwiegend durch die vorzeitige Verknoecherung von Schaedelnaehten . Je nach Nahtbefall resultieren daraus mehr oder weniger ausgepraegte Deformationen des Hirn- und Gesichtsschaedels , die sowohl zu einer funktionellen als auch zu einer aesthetischen Beeintraechtigung fuehren . Die Aetiopathogenese ist noch weitgehend ungeklaert . In den vergangenen 100 Jahren wurden verschiedene Therapieansaetze entwickelt , wobei Tessier mit der Technik des frontoorbitalen Advancements der entscheidende Fortschritt gelang . Aufbauend auf dieser Operationstechnik wurden bis heute zahlreiche Verbesserungen eingebracht . Mit den heutigen Operationstechniken ist es moeglich , praktisch alle Schaedelfehlbildungen zu therapieren . Gleichzeitig konnten durch diese Techniken auch Fortschritte in der Tumorchirurgie und der Traumatologie erzielt werden . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]

Kraniofaziale Fehlbildungen entstehen ueberwiegend durch die vorzeitige Verknoecherung von Schaedelnaehten . Je nach Nahtbefall resultieren daraus mehr oder weniger ausgepraegte Deformationen des Hirn- und Gesichtsschaedels , die sowohl zu einer funktionellen als auch zu einer aesthetischen Beeintraechtigung fuehren . Die Aetiopathogenese ist noch weitgehend ungeklaert . In den vergangenen 100 Jahren wurden verschiedene Therapieansaetze entwickelt , wobei Tessier mit der Technik des frontoorbitalen Advancements der entscheidende Fortschritt gelang . Aufbauend auf dieser Operationstechnik wurden bis heute zahlreiche Verbesserungen eingebracht . Mit den heutigen Operationstechniken ist es moeglich , praktisch alle Schaedelfehlbildungen zu therapieren . Gleichzeitig konnten durch diese Techniken auch Fortschritte in der Tumorchirurgie und der Traumatologie erzielt werden .

[ "Kraniofaziale", "Fehlbildungen", "entstehen", "ueberwiegend", "durch", "die", "vorzeitige", "Verknoecherung", "von", "Schaedelnaehten", ".", "Je", "nach", "Nahtbefall", "resultieren", "daraus", "mehr", "oder", "weniger", "ausgepraegte", "Deformationen", "des", "Hirn-", "und", "Gesichtsschaedels", ",", "die", "sowohl", "zu", "einer", "funktionellen", "als", "auch", "zu", "einer", "aesthetischen", "Beeintraechtigung", "fuehren", ".", "Die", "Aetiopathogenese", "ist", "noch", "weitgehend", "ungeklaert", ".", "In", "den", "vergangenen", "100", "Jahren", "wurden", "verschiedene", "Therapieansaetze", "entwickelt", ",", "wobei", "Tessier", "mit", "der", "Technik", "des", "frontoorbitalen", "Advancements", "der", "entscheidende", "Fortschritt", "gelang", ".", "Aufbauend", "auf", "dieser", "Operationstechnik", "wurden", "bis", "heute", "zahlreiche", "Verbesserungen", "eingebracht", ".", "Mit", "den", "heutigen", "Operationstechniken", "ist", "es", "moeglich", ",", "praktisch", "alle", "Schaedelfehlbildungen", "zu", "therapieren", ".", "Gleichzeitig", "konnten", "durch", "diese", "Techniken", "auch", "Fortschritte", "in", "der", "Tumorchirurgie", "und", "der", "Traumatologie", "erzielt", "werden", "." ]

[ "umlsterm" ]

Kraniofaziale Fehlbildungen is an umlsterm, Schaedelnaehten is an umlsterm, Hirn- is an umlsterm, Gesichtsschaedels is an umlsterm, Therapieansaetze is an umlsterm, Technik is an umlsterm, Operationstechnik is an umlsterm, Operationstechniken is an umlsterm, Techniken is an umlsterm, Tumorchirurgie is an umlsterm, Traumatologie is an umlsterm

MundKieferGesichtschirurgie.0004s068.ger.abstr_task1

Sentence: Kraniofaziale Fehlbildungen entstehen ueberwiegend durch die vorzeitige Verknoecherung von Schaedelnaehten . Je nach Nahtbefall resultieren daraus mehr oder weniger ausgepraegte Deformationen des Hirn- und Gesichtsschaedels , die sowohl zu einer funktionellen als auch zu einer aesthetischen Beeintraechtigung fuehren . Die Aetiopathogenese ist noch weitgehend ungeklaert . In den vergangenen 100 Jahren wurden verschiedene Therapieansaetze entwickelt , wobei Tessier mit der Technik des frontoorbitalen Advancements der entscheidende Fortschritt gelang . Aufbauend auf dieser Operationstechnik wurden bis heute zahlreiche Verbesserungen eingebracht . Mit den heutigen Operationstechniken ist es moeglich , praktisch alle Schaedelfehlbildungen zu therapieren . Gleichzeitig konnten durch diese Techniken auch Fortschritte in der Tumorchirurgie und der Traumatologie erzielt werden . Instructions: please typing these entity words according to sentence: Kraniofaziale Fehlbildungen, Schaedelnaehten, Hirn-, Gesichtsschaedels, Therapieansaetze, Technik, Operationstechnik, Operationstechniken, Techniken, Tumorchirurgie, Traumatologie Options: umlsterm

[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]

Kraniofaziale Fehlbildungen entstehen ueberwiegend durch die vorzeitige Verknoecherung von Schaedelnaehten . Je nach Nahtbefall resultieren daraus mehr oder weniger ausgepraegte Deformationen des Hirn- und Gesichtsschaedels , die sowohl zu einer funktionellen als auch zu einer aesthetischen Beeintraechtigung fuehren . Die Aetiopathogenese ist noch weitgehend ungeklaert . In den vergangenen 100 Jahren wurden verschiedene Therapieansaetze entwickelt , wobei Tessier mit der Technik des frontoorbitalen Advancements der entscheidende Fortschritt gelang . Aufbauend auf dieser Operationstechnik wurden bis heute zahlreiche Verbesserungen eingebracht . Mit den heutigen Operationstechniken ist es moeglich , praktisch alle Schaedelfehlbildungen zu therapieren . Gleichzeitig konnten durch diese Techniken auch Fortschritte in der Tumorchirurgie und der Traumatologie erzielt werden .

[ "Kraniofaziale", "Fehlbildungen", "entstehen", "ueberwiegend", "durch", "die", "vorzeitige", "Verknoecherung", "von", "Schaedelnaehten", ".", "Je", "nach", "Nahtbefall", "resultieren", "daraus", "mehr", "oder", "weniger", "ausgepraegte", "Deformationen", "des", "Hirn-", "und", "Gesichtsschaedels", ",", "die", "sowohl", "zu", "einer", "funktionellen", "als", "auch", "zu", "einer", "aesthetischen", "Beeintraechtigung", "fuehren", ".", "Die", "Aetiopathogenese", "ist", "noch", "weitgehend", "ungeklaert", ".", "In", "den", "vergangenen", "100", "Jahren", "wurden", "verschiedene", "Therapieansaetze", "entwickelt", ",", "wobei", "Tessier", "mit", "der", "Technik", "des", "frontoorbitalen", "Advancements", "der", "entscheidende", "Fortschritt", "gelang", ".", "Aufbauend", "auf", "dieser", "Operationstechnik", "wurden", "bis", "heute", "zahlreiche", "Verbesserungen", "eingebracht", ".", "Mit", "den", "heutigen", "Operationstechniken", "ist", "es", "moeglich", ",", "praktisch", "alle", "Schaedelfehlbildungen", "zu", "therapieren", ".", "Gleichzeitig", "konnten", "durch", "diese", "Techniken", "auch", "Fortschritte", "in", "der", "Tumorchirurgie", "und", "der", "Traumatologie", "erzielt", "werden", "." ]

[ "umlsterm" ]

Kraniofaziale Fehlbildungen, Schaedelnaehten, Hirn-, Gesichtsschaedels, Therapieansaetze, Technik, Operationstechnik, Operationstechniken, Techniken, Tumorchirurgie, Traumatologie

MundKieferGesichtschirurgie.0004s068.ger.abstr_task2

Sentence: Kraniofaziale Fehlbildungen entstehen ueberwiegend durch die vorzeitige Verknoecherung von Schaedelnaehten . Je nach Nahtbefall resultieren daraus mehr oder weniger ausgepraegte Deformationen des Hirn- und Gesichtsschaedels , die sowohl zu einer funktionellen als auch zu einer aesthetischen Beeintraechtigung fuehren . Die Aetiopathogenese ist noch weitgehend ungeklaert . In den vergangenen 100 Jahren wurden verschiedene Therapieansaetze entwickelt , wobei Tessier mit der Technik des frontoorbitalen Advancements der entscheidende Fortschritt gelang . Aufbauend auf dieser Operationstechnik wurden bis heute zahlreiche Verbesserungen eingebracht . Mit den heutigen Operationstechniken ist es moeglich , praktisch alle Schaedelfehlbildungen zu therapieren . Gleichzeitig konnten durch diese Techniken auch Fortschritte in der Tumorchirurgie und der Traumatologie erzielt werden . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O" ]

Kraniofaziale Fehlbildungen entstehen ueberwiegend durch die vorzeitige Verknoecherung von Schaedelnaehten . Je nach Nahtbefall resultieren daraus mehr oder weniger ausgepraegte Deformationen des Hirn- und Gesichtsschaedels , die sowohl zu einer funktionellen als auch zu einer aesthetischen Beeintraechtigung fuehren . Die Aetiopathogenese ist noch weitgehend ungeklaert . In den vergangenen 100 Jahren wurden verschiedene Therapieansaetze entwickelt , wobei Tessier mit der Technik des frontoorbitalen Advancements der entscheidende Fortschritt gelang . Aufbauend auf dieser Operationstechnik wurden bis heute zahlreiche Verbesserungen eingebracht . Mit den heutigen Operationstechniken ist es moeglich , praktisch alle Schaedelfehlbildungen zu therapieren . Gleichzeitig konnten durch diese Techniken auch Fortschritte in der Tumorchirurgie und der Traumatologie erzielt werden .

[ "Kraniofaziale", "Fehlbildungen", "entstehen", "ueberwiegend", "durch", "die", "vorzeitige", "Verknoecherung", "von", "Schaedelnaehten", ".", "Je", "nach", "Nahtbefall", "resultieren", "daraus", "mehr", "oder", "weniger", "ausgepraegte", "Deformationen", "des", "Hirn-", "und", "Gesichtsschaedels", ",", "die", "sowohl", "zu", "einer", "funktionellen", "als", "auch", "zu", "einer", "aesthetischen", "Beeintraechtigung", "fuehren", ".", "Die", "Aetiopathogenese", "ist", "noch", "weitgehend", "ungeklaert", ".", "In", "den", "vergangenen", "100", "Jahren", "wurden", "verschiedene", "Therapieansaetze", "entwickelt", ",", "wobei", "Tessier", "mit", "der", "Technik", "des", "frontoorbitalen", "Advancements", "der", "entscheidende", "Fortschritt", "gelang", ".", "Aufbauend", "auf", "dieser", "Operationstechnik", "wurden", "bis", "heute", "zahlreiche", "Verbesserungen", "eingebracht", ".", "Mit", "den", "heutigen", "Operationstechniken", "ist", "es", "moeglich", ",", "praktisch", "alle", "Schaedelfehlbildungen", "zu", "therapieren", ".", "Gleichzeitig", "konnten", "durch", "diese", "Techniken", "auch", "Fortschritte", "in", "der", "Tumorchirurgie", "und", "der", "Traumatologie", "erzielt", "werden", "." ]

[ "umlsterm" ]

N - acetyl cysteine is a CHEMICAL, NAC is a CHEMICAL, organosulfur is a CHEMICAL

23578993_task0

Sentence: Effect of N-acetyl cysteine (NAC), an organosulfur compound from Allium plants, on experimentally induced hepatic prefibrogenic events in wistar rat. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of N-acetyl cysteine (NAC), an organosulfur compound from Allium plants, on experimentally induced hepatic prefibrogenic events in wistar rat.

[ "Effect", "of", "N", "-", "acetyl", "cysteine", "(", "NAC", ")", ",", "an", "organosulfur", "compound", "from", "Allium", "plants", ",", "on", "experimentally", "induced", "hepatic", "prefibrogenic", "events", "in", "wistar", "rat", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

N - acetyl cysteine is a CHEMICAL, NAC is a CHEMICAL, organosulfur is a CHEMICAL

23578993_task1

Sentence: Effect of N-acetyl cysteine (NAC), an organosulfur compound from Allium plants, on experimentally induced hepatic prefibrogenic events in wistar rat. Instructions: please typing these entity words according to sentence: N - acetyl cysteine, NAC, organosulfur Options: CHEMICAL

[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of N-acetyl cysteine (NAC), an organosulfur compound from Allium plants, on experimentally induced hepatic prefibrogenic events in wistar rat.

[ "Effect", "of", "N", "-", "acetyl", "cysteine", "(", "NAC", ")", ",", "an", "organosulfur", "compound", "from", "Allium", "plants", ",", "on", "experimentally", "induced", "hepatic", "prefibrogenic", "events", "in", "wistar", "rat", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

N - acetyl cysteine, NAC, organosulfur

23578993_task2

Sentence: Effect of N-acetyl cysteine (NAC), an organosulfur compound from Allium plants, on experimentally induced hepatic prefibrogenic events in wistar rat. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of N-acetyl cysteine (NAC), an organosulfur compound from Allium plants, on experimentally induced hepatic prefibrogenic events in wistar rat.

[ "Effect", "of", "N", "-", "acetyl", "cysteine", "(", "NAC", ")", ",", "an", "organosulfur", "compound", "from", "Allium", "plants", ",", "on", "experimentally", "induced", "hepatic", "prefibrogenic", "events", "in", "wistar", "rat", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

CG beta is a protein, subunit is a protein, CG beta alpha is a protein, FSH beta is a protein

HPRD50.d2_task0

Sentence: We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "B-protein", "O", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "I-protein", "O" ]

We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer

[ "We", "tested", "this", "point", "by", "cotransfecting", "CHO", "cells", "with", "the", "genes", "encoding", "F", "beta", "alpha", "and", "the", "CG", "beta", "subunit", "or", "the", "CG", "beta", "alpha", "and", "FSH", "beta", "monomer" ]

[ "protein" ]

CG beta is a protein, subunit is a protein, CG beta alpha is a protein, FSH beta is a protein

HPRD50.d2_task1

Sentence: We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer Instructions: please typing these entity words according to sentence: CG beta, subunit, CG beta alpha, FSH beta Options: protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "B-protein", "O", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "I-protein", "O" ]

We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer

[ "We", "tested", "this", "point", "by", "cotransfecting", "CHO", "cells", "with", "the", "genes", "encoding", "F", "beta", "alpha", "and", "the", "CG", "beta", "subunit", "or", "the", "CG", "beta", "alpha", "and", "FSH", "beta", "monomer" ]

[ "protein" ]

CG beta, subunit, CG beta alpha, FSH beta

HPRD50.d2_task2

Sentence: We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "B-protein", "O", "O", "B-protein", "I-protein", "I-protein", "O", "B-protein", "I-protein", "O" ]

We tested this point by cotransfecting CHO cells with the genes encoding F beta alpha and the CG beta subunit or the CG beta alpha and FSH beta monomer

[ "We", "tested", "this", "point", "by", "cotransfecting", "CHO", "cells", "with", "the", "genes", "encoding", "F", "beta", "alpha", "and", "the", "CG", "beta", "subunit", "or", "the", "CG", "beta", "alpha", "and", "FSH", "beta", "monomer" ]

[ "protein" ]

carbon is a CHEMICAL

23301860_task0

Sentence: Single-walled carbon nanotube surface control of complement recognition and activation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: CHEMICAL

[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Single-walled carbon nanotube surface control of complement recognition and activation.

[ "Single", "-", "walled", "carbon", "nanotube", "surface", "control", "of", "complement", "recognition", "and", "activation", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

carbon is a CHEMICAL

23301860_task1

Sentence: Single-walled carbon nanotube surface control of complement recognition and activation. Instructions: please typing these entity words according to sentence: carbon Options: CHEMICAL

[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Single-walled carbon nanotube surface control of complement recognition and activation.

[ "Single", "-", "walled", "carbon", "nanotube", "surface", "control", "of", "complement", "recognition", "and", "activation", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

carbon

23301860_task2

Sentence: Single-walled carbon nanotube surface control of complement recognition and activation. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Single-walled carbon nanotube surface control of complement recognition and activation.

[ "Single", "-", "walled", "carbon", "nanotube", "surface", "control", "of", "complement", "recognition", "and", "activation", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

adult is an umlsterm, hyperkinetic syndrome is an umlsterm, attention is an umlsterm, disorder is an umlsterm, Germany is an umlsterm, children is an umlsterm, symptoms is an umlsterm, adults is an umlsterm, syndrome is an umlsterm, symptoms is an umlsterm, hyperactivity is an umlsterm, Retrospective is an umlsterm, diagnosis is an umlsterm, emotional disturbances is an umlsterm, stress is an umlsterm, adults is an umlsterm, symptoms is an umlsterm, learning disorders is an umlsterm, dyslexia is an umlsterm, dysgraphia is an umlsterm, differential diagnosis is an umlsterm, anxiety is an umlsterm, antisocial personality disorders is an umlsterm, comorbidity is an umlsterm, transmission is an umlsterm, findings is an umlsterm, neurotransmitters is an umlsterm, treatment is an umlsterm, pemoline is an umlsterm, tricyclic antidepressants is an umlsterm, beta blockers is an umlsterm, bupropion is an umlsterm, fluoxetine is an umlsterm, venlafaxine is an umlsterm

DerNervenarzt.80690543.eng.abstr_task0

Sentence: The clinical picture of adult hyperkinetic syndrome ( HKS ) or attention deficit/hyperactivity disorder is nearly unknown in Germany . It can be estimated , that approximately one third of affected children also show symptoms as adults . In the combined type of the syndrome symptoms of inattention as well as of hyperactivity and impulsivity are present , a predominantly inattentive or hyperactive-impulsive type is possible . Retrospective diagnosis of HKS in childhood can be difficult . Disorganization , emotional disturbances and stress intolerance are common in adults with HKS as well as residual symptoms of learning disorders like dyslexia , dyscalculia and dysgraphia . In differential diagnosis especially affective , anxiety and antisocial personality disorders have to be considered , for which on the other side a frequent comorbidity with HKS is known . There is strong evidence for genetic transmission . Neurobiological findings revealed dysregulation of neurotransmitters . For treatment stimulants as pemoline and methamphetamin are effective , in addition tricyclic antidepressants or beta blockers ; positive effects are probable for moclobemide , bupropion , fluoxetine and venlafaxine . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

The clinical picture of adult hyperkinetic syndrome ( HKS ) or attention deficit/hyperactivity disorder is nearly unknown in Germany . It can be estimated , that approximately one third of affected children also show symptoms as adults . In the combined type of the syndrome symptoms of inattention as well as of hyperactivity and impulsivity are present , a predominantly inattentive or hyperactive-impulsive type is possible . Retrospective diagnosis of HKS in childhood can be difficult . Disorganization , emotional disturbances and stress intolerance are common in adults with HKS as well as residual symptoms of learning disorders like dyslexia , dyscalculia and dysgraphia . In differential diagnosis especially affective , anxiety and antisocial personality disorders have to be considered , for which on the other side a frequent comorbidity with HKS is known . There is strong evidence for genetic transmission . Neurobiological findings revealed dysregulation of neurotransmitters . For treatment stimulants as pemoline and methamphetamin are effective , in addition tricyclic antidepressants or beta blockers ; positive effects are probable for moclobemide , bupropion , fluoxetine and venlafaxine .

[ "The", "clinical", "picture", "of", "adult", "hyperkinetic", "syndrome", "(", "HKS", ")", "or", "attention", "deficit", "/", "hyperactivity", "disorder", "is", "nearly", "unknown", "in", "Germany", ".", "It", "can", "be", "estimated", ",", "that", "approximately", "one", "third", "of", "affected", "children", "also", "show", "symptoms", "as", "adults", ".", "In", "the", "combined", "type", "of", "the", "syndrome", "symptoms", "of", "inattention", "as", "well", "as", "of", "hyperactivity", "and", "impulsivity", "are", "present", ",", "a", "predominantly", "inattentive", "or", "hyperactive", "-", "impulsive", "type", "is", "possible", ".", "Retrospective", "diagnosis", "of", "HKS", "in", "childhood", "can", "be", "difficult", ".", "Disorganization", ",", "emotional", "disturbances", "and", "stress", "intolerance", "are", "common", "in", "adults", "with", "HKS", "as", "well", "as", "residual", "symptoms", "of", "learning", "disorders", "like", "dyslexia", ",", "dyscalculia", "and", "dysgraphia", ".", "In", "differential", "diagnosis", "especially", "affective", ",", "anxiety", "and", "antisocial", "personality", "disorders", "have", "to", "be", "considered", ",", "for", "which", "on", "the", "other", "side", "a", "frequent", "comorbidity", "with", "HKS", "is", "known", ".", "There", "is", "strong", "evidence", "for", "genetic", "transmission", ".", "Neurobiological", "findings", "revealed", "dysregulation", "of", "neurotransmitters", ".", "For", "treatment", "stimulants", "as", "pemoline", "and", "methamphetamin", "are", "effective", ",", "in", "addition", "tricyclic", "antidepressants", "or", "beta", "blockers", ";", "positive", "effects", "are", "probable", "for", "moclobemide", ",", "bupropion", ",", "fluoxetine", "and", "venlafaxine", "." ]

[ "umlsterm" ]

adult is an umlsterm, hyperkinetic syndrome is an umlsterm, attention is an umlsterm, disorder is an umlsterm, Germany is an umlsterm, children is an umlsterm, symptoms is an umlsterm, adults is an umlsterm, syndrome is an umlsterm, symptoms is an umlsterm, hyperactivity is an umlsterm, Retrospective is an umlsterm, diagnosis is an umlsterm, emotional disturbances is an umlsterm, stress is an umlsterm, adults is an umlsterm, symptoms is an umlsterm, learning disorders is an umlsterm, dyslexia is an umlsterm, dysgraphia is an umlsterm, differential diagnosis is an umlsterm, anxiety is an umlsterm, antisocial personality disorders is an umlsterm, comorbidity is an umlsterm, transmission is an umlsterm, findings is an umlsterm, neurotransmitters is an umlsterm, treatment is an umlsterm, pemoline is an umlsterm, tricyclic antidepressants is an umlsterm, beta blockers is an umlsterm, bupropion is an umlsterm, fluoxetine is an umlsterm, venlafaxine is an umlsterm

DerNervenarzt.80690543.eng.abstr_task1

Sentence: The clinical picture of adult hyperkinetic syndrome ( HKS ) or attention deficit/hyperactivity disorder is nearly unknown in Germany . It can be estimated , that approximately one third of affected children also show symptoms as adults . In the combined type of the syndrome symptoms of inattention as well as of hyperactivity and impulsivity are present , a predominantly inattentive or hyperactive-impulsive type is possible . Retrospective diagnosis of HKS in childhood can be difficult . Disorganization , emotional disturbances and stress intolerance are common in adults with HKS as well as residual symptoms of learning disorders like dyslexia , dyscalculia and dysgraphia . In differential diagnosis especially affective , anxiety and antisocial personality disorders have to be considered , for which on the other side a frequent comorbidity with HKS is known . There is strong evidence for genetic transmission . Neurobiological findings revealed dysregulation of neurotransmitters . For treatment stimulants as pemoline and methamphetamin are effective , in addition tricyclic antidepressants or beta blockers ; positive effects are probable for moclobemide , bupropion , fluoxetine and venlafaxine . Instructions: please typing these entity words according to sentence: adult, hyperkinetic syndrome, attention, disorder, Germany, children, symptoms, adults, syndrome, symptoms, hyperactivity, Retrospective, diagnosis, emotional disturbances, stress, adults, symptoms, learning disorders, dyslexia, dysgraphia, differential diagnosis, anxiety, antisocial personality disorders, comorbidity, transmission, findings, neurotransmitters, treatment, pemoline, tricyclic antidepressants, beta blockers, bupropion, fluoxetine, venlafaxine Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

The clinical picture of adult hyperkinetic syndrome ( HKS ) or attention deficit/hyperactivity disorder is nearly unknown in Germany . It can be estimated , that approximately one third of affected children also show symptoms as adults . In the combined type of the syndrome symptoms of inattention as well as of hyperactivity and impulsivity are present , a predominantly inattentive or hyperactive-impulsive type is possible . Retrospective diagnosis of HKS in childhood can be difficult . Disorganization , emotional disturbances and stress intolerance are common in adults with HKS as well as residual symptoms of learning disorders like dyslexia , dyscalculia and dysgraphia . In differential diagnosis especially affective , anxiety and antisocial personality disorders have to be considered , for which on the other side a frequent comorbidity with HKS is known . There is strong evidence for genetic transmission . Neurobiological findings revealed dysregulation of neurotransmitters . For treatment stimulants as pemoline and methamphetamin are effective , in addition tricyclic antidepressants or beta blockers ; positive effects are probable for moclobemide , bupropion , fluoxetine and venlafaxine .

[ "The", "clinical", "picture", "of", "adult", "hyperkinetic", "syndrome", "(", "HKS", ")", "or", "attention", "deficit", "/", "hyperactivity", "disorder", "is", "nearly", "unknown", "in", "Germany", ".", "It", "can", "be", "estimated", ",", "that", "approximately", "one", "third", "of", "affected", "children", "also", "show", "symptoms", "as", "adults", ".", "In", "the", "combined", "type", "of", "the", "syndrome", "symptoms", "of", "inattention", "as", "well", "as", "of", "hyperactivity", "and", "impulsivity", "are", "present", ",", "a", "predominantly", "inattentive", "or", "hyperactive", "-", "impulsive", "type", "is", "possible", ".", "Retrospective", "diagnosis", "of", "HKS", "in", "childhood", "can", "be", "difficult", ".", "Disorganization", ",", "emotional", "disturbances", "and", "stress", "intolerance", "are", "common", "in", "adults", "with", "HKS", "as", "well", "as", "residual", "symptoms", "of", "learning", "disorders", "like", "dyslexia", ",", "dyscalculia", "and", "dysgraphia", ".", "In", "differential", "diagnosis", "especially", "affective", ",", "anxiety", "and", "antisocial", "personality", "disorders", "have", "to", "be", "considered", ",", "for", "which", "on", "the", "other", "side", "a", "frequent", "comorbidity", "with", "HKS", "is", "known", ".", "There", "is", "strong", "evidence", "for", "genetic", "transmission", ".", "Neurobiological", "findings", "revealed", "dysregulation", "of", "neurotransmitters", ".", "For", "treatment", "stimulants", "as", "pemoline", "and", "methamphetamin", "are", "effective", ",", "in", "addition", "tricyclic", "antidepressants", "or", "beta", "blockers", ";", "positive", "effects", "are", "probable", "for", "moclobemide", ",", "bupropion", ",", "fluoxetine", "and", "venlafaxine", "." ]

[ "umlsterm" ]

adult, hyperkinetic syndrome, attention, disorder, Germany, children, symptoms, adults, syndrome, symptoms, hyperactivity, Retrospective, diagnosis, emotional disturbances, stress, adults, symptoms, learning disorders, dyslexia, dysgraphia, differential diagnosis, anxiety, antisocial personality disorders, comorbidity, transmission, findings, neurotransmitters, treatment, pemoline, tricyclic antidepressants, beta blockers, bupropion, fluoxetine, venlafaxine

DerNervenarzt.80690543.eng.abstr_task2

Sentence: The clinical picture of adult hyperkinetic syndrome ( HKS ) or attention deficit/hyperactivity disorder is nearly unknown in Germany . It can be estimated , that approximately one third of affected children also show symptoms as adults . In the combined type of the syndrome symptoms of inattention as well as of hyperactivity and impulsivity are present , a predominantly inattentive or hyperactive-impulsive type is possible . Retrospective diagnosis of HKS in childhood can be difficult . Disorganization , emotional disturbances and stress intolerance are common in adults with HKS as well as residual symptoms of learning disorders like dyslexia , dyscalculia and dysgraphia . In differential diagnosis especially affective , anxiety and antisocial personality disorders have to be considered , for which on the other side a frequent comorbidity with HKS is known . There is strong evidence for genetic transmission . Neurobiological findings revealed dysregulation of neurotransmitters . For treatment stimulants as pemoline and methamphetamin are effective , in addition tricyclic antidepressants or beta blockers ; positive effects are probable for moclobemide , bupropion , fluoxetine and venlafaxine . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

The clinical picture of adult hyperkinetic syndrome ( HKS ) or attention deficit/hyperactivity disorder is nearly unknown in Germany . It can be estimated , that approximately one third of affected children also show symptoms as adults . In the combined type of the syndrome symptoms of inattention as well as of hyperactivity and impulsivity are present , a predominantly inattentive or hyperactive-impulsive type is possible . Retrospective diagnosis of HKS in childhood can be difficult . Disorganization , emotional disturbances and stress intolerance are common in adults with HKS as well as residual symptoms of learning disorders like dyslexia , dyscalculia and dysgraphia . In differential diagnosis especially affective , anxiety and antisocial personality disorders have to be considered , for which on the other side a frequent comorbidity with HKS is known . There is strong evidence for genetic transmission . Neurobiological findings revealed dysregulation of neurotransmitters . For treatment stimulants as pemoline and methamphetamin are effective , in addition tricyclic antidepressants or beta blockers ; positive effects are probable for moclobemide , bupropion , fluoxetine and venlafaxine .

[ "The", "clinical", "picture", "of", "adult", "hyperkinetic", "syndrome", "(", "HKS", ")", "or", "attention", "deficit", "/", "hyperactivity", "disorder", "is", "nearly", "unknown", "in", "Germany", ".", "It", "can", "be", "estimated", ",", "that", "approximately", "one", "third", "of", "affected", "children", "also", "show", "symptoms", "as", "adults", ".", "In", "the", "combined", "type", "of", "the", "syndrome", "symptoms", "of", "inattention", "as", "well", "as", "of", "hyperactivity", "and", "impulsivity", "are", "present", ",", "a", "predominantly", "inattentive", "or", "hyperactive", "-", "impulsive", "type", "is", "possible", ".", "Retrospective", "diagnosis", "of", "HKS", "in", "childhood", "can", "be", "difficult", ".", "Disorganization", ",", "emotional", "disturbances", "and", "stress", "intolerance", "are", "common", "in", "adults", "with", "HKS", "as", "well", "as", "residual", "symptoms", "of", "learning", "disorders", "like", "dyslexia", ",", "dyscalculia", "and", "dysgraphia", ".", "In", "differential", "diagnosis", "especially", "affective", ",", "anxiety", "and", "antisocial", "personality", "disorders", "have", "to", "be", "considered", ",", "for", "which", "on", "the", "other", "side", "a", "frequent", "comorbidity", "with", "HKS", "is", "known", ".", "There", "is", "strong", "evidence", "for", "genetic", "transmission", ".", "Neurobiological", "findings", "revealed", "dysregulation", "of", "neurotransmitters", ".", "For", "treatment", "stimulants", "as", "pemoline", "and", "methamphetamin", "are", "effective", ",", "in", "addition", "tricyclic", "antidepressants", "or", "beta", "blockers", ";", "positive", "effects", "are", "probable", "for", "moclobemide", ",", "bupropion", ",", "fluoxetine", "and", "venlafaxine", "." ]

[ "umlsterm" ]

tobacco is a Plant, esophageal cancer is a Disease, esophageal cancer is a Disease, cancer is a Disease, esophageal cancer is a Disease, esophageal cancer is a Disease

8357273_task0

Sentence: Alcohol and tobacco habits have been identified as strong risk factors for esophageal cancer. Increased risks of esophageal cancer have also been reported to be associated with occupational exposure to asbestos and various metals, among vulcanization workers, asphalt workers, and workers in the petrochemical industry. Mortality and cancer incidence were investigated in a series of studies of workers exposed to combustion by-products, i.e., chimney sweeps, waste incinerator workers, gas workers, and bus garage workers exposed to diesel exhausts. The SMRs for esophageal cancer ranged from 150-386 in these cohorts, and a combined SMR of 289 (95% C.I. 174-452) was obtained. Available data on smoking habits and indirect indicators of alcohol consumption show that the excess cannot be attributed solely to these factors. It seems likely that occupational exposure to combustion products is associated with an increased risk of esophageal cancer. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Disease, Plant

[ "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O" ]

Alcohol and tobacco habits have been identified as strong risk factors for esophageal cancer. Increased risks of esophageal cancer have also been reported to be associated with occupational exposure to asbestos and various metals, among vulcanization workers, asphalt workers, and workers in the petrochemical industry. Mortality and cancer incidence were investigated in a series of studies of workers exposed to combustion by-products, i.e., chimney sweeps, waste incinerator workers, gas workers, and bus garage workers exposed to diesel exhausts. The SMRs for esophageal cancer ranged from 150-386 in these cohorts, and a combined SMR of 289 (95% C.I. 174-452) was obtained. Available data on smoking habits and indirect indicators of alcohol consumption show that the excess cannot be attributed solely to these factors. It seems likely that occupational exposure to combustion products is associated with an increased risk of esophageal cancer.

[ "Alcohol", "and", "tobacco", "habits", "have", "been", "identified", "as", "strong", "risk", "factors", "for", "esophageal", "cancer", ".", "Increased", "risks", "of", "esophageal", "cancer", "have", "also", "been", "reported", "to", "be", "associated", "with", "occupational", "exposure", "to", "asbestos", "and", "various", "metals", ",", "among", "vulcanization", "workers", ",", "asphalt", "workers", ",", "and", "workers", "in", "the", "petrochemical", "industry", ".", "Mortality", "and", "cancer", "incidence", "were", "investigated", "in", "a", "series", "of", "studies", "of", "workers", "exposed", "to", "combustion", "by", "-", "products", ",", "i.e", ".", ",", "chimney", "sweeps", ",", "waste", "incinerator", "workers", ",", "gas", "workers", ",", "and", "bus", "garage", "workers", "exposed", "to", "diesel", "exhausts", ".", "The", "SMRs", "for", "esophageal", "cancer", "ranged", "from", "150", "-", "386", "in", "these", "cohorts", ",", "and", "a", "combined", "SMR", "of", "289", "(", "95", "%", "C.I.", "174", "-", "452", ")", "was", "obtained", ".", "Available", "data", "on", "smoking", "habits", "and", "indirect", "indicators", "of", "alcohol", "consumption", "show", "that", "the", "excess", "cannot", "be", "attributed", "solely", "to", "these", "factors", ".", "It", "seems", "likely", "that", "occupational", "exposure", "to", "combustion", "products", "is", "associated", "with", "an", "increased", "risk", "of", "esophageal", "cancer", "." ]

[ "Disease", "Plant" ]

tobacco is a Plant, esophageal cancer is a Disease, esophageal cancer is a Disease, cancer is a Disease, esophageal cancer is a Disease, esophageal cancer is a Disease

8357273_task1

Sentence: Alcohol and tobacco habits have been identified as strong risk factors for esophageal cancer. Increased risks of esophageal cancer have also been reported to be associated with occupational exposure to asbestos and various metals, among vulcanization workers, asphalt workers, and workers in the petrochemical industry. Mortality and cancer incidence were investigated in a series of studies of workers exposed to combustion by-products, i.e., chimney sweeps, waste incinerator workers, gas workers, and bus garage workers exposed to diesel exhausts. The SMRs for esophageal cancer ranged from 150-386 in these cohorts, and a combined SMR of 289 (95% C.I. 174-452) was obtained. Available data on smoking habits and indirect indicators of alcohol consumption show that the excess cannot be attributed solely to these factors. It seems likely that occupational exposure to combustion products is associated with an increased risk of esophageal cancer. Instructions: please typing these entity words according to sentence: tobacco, esophageal cancer, esophageal cancer, cancer, esophageal cancer, esophageal cancer Options: Disease, Plant

[ "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O" ]

Alcohol and tobacco habits have been identified as strong risk factors for esophageal cancer. Increased risks of esophageal cancer have also been reported to be associated with occupational exposure to asbestos and various metals, among vulcanization workers, asphalt workers, and workers in the petrochemical industry. Mortality and cancer incidence were investigated in a series of studies of workers exposed to combustion by-products, i.e., chimney sweeps, waste incinerator workers, gas workers, and bus garage workers exposed to diesel exhausts. The SMRs for esophageal cancer ranged from 150-386 in these cohorts, and a combined SMR of 289 (95% C.I. 174-452) was obtained. Available data on smoking habits and indirect indicators of alcohol consumption show that the excess cannot be attributed solely to these factors. It seems likely that occupational exposure to combustion products is associated with an increased risk of esophageal cancer.

[ "Alcohol", "and", "tobacco", "habits", "have", "been", "identified", "as", "strong", "risk", "factors", "for", "esophageal", "cancer", ".", "Increased", "risks", "of", "esophageal", "cancer", "have", "also", "been", "reported", "to", "be", "associated", "with", "occupational", "exposure", "to", "asbestos", "and", "various", "metals", ",", "among", "vulcanization", "workers", ",", "asphalt", "workers", ",", "and", "workers", "in", "the", "petrochemical", "industry", ".", "Mortality", "and", "cancer", "incidence", "were", "investigated", "in", "a", "series", "of", "studies", "of", "workers", "exposed", "to", "combustion", "by", "-", "products", ",", "i.e", ".", ",", "chimney", "sweeps", ",", "waste", "incinerator", "workers", ",", "gas", "workers", ",", "and", "bus", "garage", "workers", "exposed", "to", "diesel", "exhausts", ".", "The", "SMRs", "for", "esophageal", "cancer", "ranged", "from", "150", "-", "386", "in", "these", "cohorts", ",", "and", "a", "combined", "SMR", "of", "289", "(", "95", "%", "C.I.", "174", "-", "452", ")", "was", "obtained", ".", "Available", "data", "on", "smoking", "habits", "and", "indirect", "indicators", "of", "alcohol", "consumption", "show", "that", "the", "excess", "cannot", "be", "attributed", "solely", "to", "these", "factors", ".", "It", "seems", "likely", "that", "occupational", "exposure", "to", "combustion", "products", "is", "associated", "with", "an", "increased", "risk", "of", "esophageal", "cancer", "." ]

[ "Disease", "Plant" ]

tobacco, esophageal cancer, esophageal cancer, cancer, esophageal cancer, esophageal cancer

8357273_task2

Sentence: Alcohol and tobacco habits have been identified as strong risk factors for esophageal cancer. Increased risks of esophageal cancer have also been reported to be associated with occupational exposure to asbestos and various metals, among vulcanization workers, asphalt workers, and workers in the petrochemical industry. Mortality and cancer incidence were investigated in a series of studies of workers exposed to combustion by-products, i.e., chimney sweeps, waste incinerator workers, gas workers, and bus garage workers exposed to diesel exhausts. The SMRs for esophageal cancer ranged from 150-386 in these cohorts, and a combined SMR of 289 (95% C.I. 174-452) was obtained. Available data on smoking habits and indirect indicators of alcohol consumption show that the excess cannot be attributed solely to these factors. It seems likely that occupational exposure to combustion products is associated with an increased risk of esophageal cancer. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Plant", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Disease", "I-Disease", "O" ]

Alcohol and tobacco habits have been identified as strong risk factors for esophageal cancer. Increased risks of esophageal cancer have also been reported to be associated with occupational exposure to asbestos and various metals, among vulcanization workers, asphalt workers, and workers in the petrochemical industry. Mortality and cancer incidence were investigated in a series of studies of workers exposed to combustion by-products, i.e., chimney sweeps, waste incinerator workers, gas workers, and bus garage workers exposed to diesel exhausts. The SMRs for esophageal cancer ranged from 150-386 in these cohorts, and a combined SMR of 289 (95% C.I. 174-452) was obtained. Available data on smoking habits and indirect indicators of alcohol consumption show that the excess cannot be attributed solely to these factors. It seems likely that occupational exposure to combustion products is associated with an increased risk of esophageal cancer.

[ "Alcohol", "and", "tobacco", "habits", "have", "been", "identified", "as", "strong", "risk", "factors", "for", "esophageal", "cancer", ".", "Increased", "risks", "of", "esophageal", "cancer", "have", "also", "been", "reported", "to", "be", "associated", "with", "occupational", "exposure", "to", "asbestos", "and", "various", "metals", ",", "among", "vulcanization", "workers", ",", "asphalt", "workers", ",", "and", "workers", "in", "the", "petrochemical", "industry", ".", "Mortality", "and", "cancer", "incidence", "were", "investigated", "in", "a", "series", "of", "studies", "of", "workers", "exposed", "to", "combustion", "by", "-", "products", ",", "i.e", ".", ",", "chimney", "sweeps", ",", "waste", "incinerator", "workers", ",", "gas", "workers", ",", "and", "bus", "garage", "workers", "exposed", "to", "diesel", "exhausts", ".", "The", "SMRs", "for", "esophageal", "cancer", "ranged", "from", "150", "-", "386", "in", "these", "cohorts", ",", "and", "a", "combined", "SMR", "of", "289", "(", "95", "%", "C.I.", "174", "-", "452", ")", "was", "obtained", ".", "Available", "data", "on", "smoking", "habits", "and", "indirect", "indicators", "of", "alcohol", "consumption", "show", "that", "the", "excess", "cannot", "be", "attributed", "solely", "to", "these", "factors", ".", "It", "seems", "likely", "that", "occupational", "exposure", "to", "combustion", "products", "is", "associated", "with", "an", "increased", "risk", "of", "esophageal", "cancer", "." ]

[ "Disease", "Plant" ]

laparoscopic surgery is an umlsterm, optics is an umlsterm, hospital is an umlsterm, operations is an umlsterm, voice is an umlsterm, arm is an umlsterm, optics is an umlsterm, gallbladder is an umlsterm, stomach is an umlsterm, large bowel is an umlsterm, hernia is an umlsterm, operations is an umlsterm, visual field is an umlsterm, arm is an umlsterm, voice is an umlsterm, exact is an umlsterm, operations is an umlsterm, operator is an umlsterm, surgeries is an umlsterm, arm is an umlsterm, operating theater is an umlsterm

DerChirurg.70680837.eng.abstr_task0

Sentence: Currently laparoscopic surgery is limited by several factors . One of them is the precise handling of optics . Up to now , in our hospital 52 laparoscopic operations have been done with a voice - controlled robot arm to handle the optics in gallbladder , stomach , large bowel and hernia operations . The visual field is determined by the surgeon . In all cases handling of the robot arm was precise and the voice response exact and without technical problems . Twenty-nine operations were done by one operator as " solo surgeries " . In 20 further cases there was one assistant . A robot arm can be used successfully without problems by any laparoscopic surgeon in any operating theater . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Currently laparoscopic surgery is limited by several factors . One of them is the precise handling of optics . Up to now , in our hospital 52 laparoscopic operations have been done with a voice - controlled robot arm to handle the optics in gallbladder , stomach , large bowel and hernia operations . The visual field is determined by the surgeon . In all cases handling of the robot arm was precise and the voice response exact and without technical problems . Twenty-nine operations were done by one operator as " solo surgeries " . In 20 further cases there was one assistant . A robot arm can be used successfully without problems by any laparoscopic surgeon in any operating theater .

[ "Currently", "laparoscopic", "surgery", "is", "limited", "by", "several", "factors", ".", "One", "of", "them", "is", "the", "precise", "handling", "of", "optics", ".", "Up", "to", "now", ",", "in", "our", "hospital", "52", "laparoscopic", "operations", "have", "been", "done", "with", "a", "voice", "-", "controlled", "robot", "arm", "to", "handle", "the", "optics", "in", "gallbladder", ",", "stomach", ",", "large", "bowel", "and", "hernia", "operations", ".", "The", "visual", "field", "is", "determined", "by", "the", "surgeon", ".", "In", "all", "cases", "handling", "of", "the", "robot", "arm", "was", "precise", "and", "the", "voice", "response", "exact", "and", "without", "technical", "problems", ".", "Twenty", "-", "nine", "operations", "were", "done", "by", "one", "operator", "as", "\"", "solo", "surgeries", "\"", ".", "In", "20", "further", "cases", "there", "was", "one", "assistant", ".", "A", "robot", "arm", "can", "be", "used", "successfully", "without", "problems", "by", "any", "laparoscopic", "surgeon", "in", "any", "operating", "theater", "." ]

[ "umlsterm" ]

laparoscopic surgery is an umlsterm, optics is an umlsterm, hospital is an umlsterm, operations is an umlsterm, voice is an umlsterm, arm is an umlsterm, optics is an umlsterm, gallbladder is an umlsterm, stomach is an umlsterm, large bowel is an umlsterm, hernia is an umlsterm, operations is an umlsterm, visual field is an umlsterm, arm is an umlsterm, voice is an umlsterm, exact is an umlsterm, operations is an umlsterm, operator is an umlsterm, surgeries is an umlsterm, arm is an umlsterm, operating theater is an umlsterm

DerChirurg.70680837.eng.abstr_task1

Sentence: Currently laparoscopic surgery is limited by several factors . One of them is the precise handling of optics . Up to now , in our hospital 52 laparoscopic operations have been done with a voice - controlled robot arm to handle the optics in gallbladder , stomach , large bowel and hernia operations . The visual field is determined by the surgeon . In all cases handling of the robot arm was precise and the voice response exact and without technical problems . Twenty-nine operations were done by one operator as " solo surgeries " . In 20 further cases there was one assistant . A robot arm can be used successfully without problems by any laparoscopic surgeon in any operating theater . Instructions: please typing these entity words according to sentence: laparoscopic surgery, optics, hospital, operations, voice, arm, optics, gallbladder, stomach, large bowel, hernia, operations, visual field, arm, voice, exact, operations, operator, surgeries, arm, operating theater Options: umlsterm

[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Currently laparoscopic surgery is limited by several factors . One of them is the precise handling of optics . Up to now , in our hospital 52 laparoscopic operations have been done with a voice - controlled robot arm to handle the optics in gallbladder , stomach , large bowel and hernia operations . The visual field is determined by the surgeon . In all cases handling of the robot arm was precise and the voice response exact and without technical problems . Twenty-nine operations were done by one operator as " solo surgeries " . In 20 further cases there was one assistant . A robot arm can be used successfully without problems by any laparoscopic surgeon in any operating theater .

[ "Currently", "laparoscopic", "surgery", "is", "limited", "by", "several", "factors", ".", "One", "of", "them", "is", "the", "precise", "handling", "of", "optics", ".", "Up", "to", "now", ",", "in", "our", "hospital", "52", "laparoscopic", "operations", "have", "been", "done", "with", "a", "voice", "-", "controlled", "robot", "arm", "to", "handle", "the", "optics", "in", "gallbladder", ",", "stomach", ",", "large", "bowel", "and", "hernia", "operations", ".", "The", "visual", "field", "is", "determined", "by", "the", "surgeon", ".", "In", "all", "cases", "handling", "of", "the", "robot", "arm", "was", "precise", "and", "the", "voice", "response", "exact", "and", "without", "technical", "problems", ".", "Twenty", "-", "nine", "operations", "were", "done", "by", "one", "operator", "as", "\"", "solo", "surgeries", "\"", ".", "In", "20", "further", "cases", "there", "was", "one", "assistant", ".", "A", "robot", "arm", "can", "be", "used", "successfully", "without", "problems", "by", "any", "laparoscopic", "surgeon", "in", "any", "operating", "theater", "." ]

[ "umlsterm" ]

laparoscopic surgery, optics, hospital, operations, voice, arm, optics, gallbladder, stomach, large bowel, hernia, operations, visual field, arm, voice, exact, operations, operator, surgeries, arm, operating theater

DerChirurg.70680837.eng.abstr_task2

Sentence: Currently laparoscopic surgery is limited by several factors . One of them is the precise handling of optics . Up to now , in our hospital 52 laparoscopic operations have been done with a voice - controlled robot arm to handle the optics in gallbladder , stomach , large bowel and hernia operations . The visual field is determined by the surgeon . In all cases handling of the robot arm was precise and the voice response exact and without technical problems . Twenty-nine operations were done by one operator as " solo surgeries " . In 20 further cases there was one assistant . A robot arm can be used successfully without problems by any laparoscopic surgeon in any operating theater . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O" ]

Currently laparoscopic surgery is limited by several factors . One of them is the precise handling of optics . Up to now , in our hospital 52 laparoscopic operations have been done with a voice - controlled robot arm to handle the optics in gallbladder , stomach , large bowel and hernia operations . The visual field is determined by the surgeon . In all cases handling of the robot arm was precise and the voice response exact and without technical problems . Twenty-nine operations were done by one operator as " solo surgeries " . In 20 further cases there was one assistant . A robot arm can be used successfully without problems by any laparoscopic surgeon in any operating theater .

[ "Currently", "laparoscopic", "surgery", "is", "limited", "by", "several", "factors", ".", "One", "of", "them", "is", "the", "precise", "handling", "of", "optics", ".", "Up", "to", "now", ",", "in", "our", "hospital", "52", "laparoscopic", "operations", "have", "been", "done", "with", "a", "voice", "-", "controlled", "robot", "arm", "to", "handle", "the", "optics", "in", "gallbladder", ",", "stomach", ",", "large", "bowel", "and", "hernia", "operations", ".", "The", "visual", "field", "is", "determined", "by", "the", "surgeon", ".", "In", "all", "cases", "handling", "of", "the", "robot", "arm", "was", "precise", "and", "the", "voice", "response", "exact", "and", "without", "technical", "problems", ".", "Twenty", "-", "nine", "operations", "were", "done", "by", "one", "operator", "as", "\"", "solo", "surgeries", "\"", ".", "In", "20", "further", "cases", "there", "was", "one", "assistant", ".", "A", "robot", "arm", "can", "be", "used", "successfully", "without", "problems", "by", "any", "laparoscopic", "surgeon", "in", "any", "operating", "theater", "." ]

[ "umlsterm" ]

calcineurin is a GENE-N

16751287_task0

Sentence: Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O" ]

Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin.

[ "Decrease", "in", "density", "of", "INa", "is", "in", "the", "common", "final", "pathway", "to", "heart", "block", "in", "murine", "hearts", "overexpressing", "calcineurin", "." ]

[ "CHEMICAL", "GENE-N" ]

calcineurin is a GENE-N

16751287_task1

Sentence: Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin. Instructions: please typing these entity words according to sentence: calcineurin Options: GENE-N

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O" ]

Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin.

[ "Decrease", "in", "density", "of", "INa", "is", "in", "the", "common", "final", "pathway", "to", "heart", "block", "in", "murine", "hearts", "overexpressing", "calcineurin", "." ]

[ "CHEMICAL", "GENE-N" ]

calcineurin

16751287_task2

Sentence: Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "O" ]

Decrease in density of INa is in the common final pathway to heart block in murine hearts overexpressing calcineurin.

[ "Decrease", "in", "density", "of", "INa", "is", "in", "the", "common", "final", "pathway", "to", "heart", "block", "in", "murine", "hearts", "overexpressing", "calcineurin", "." ]

[ "CHEMICAL", "GENE-N" ]

Weight loss maintenance is a Outcome_Physical, overweight is a Participant_Condition, ad libitum diets is a Intervention_Physical, high dietary protein ( P ) content is a Intervention_Physical, low glycemic index is a Intervention_Physical, effect is a Outcome_Other, weight loss maintenance is a Outcome_Physical, overweight or obese is a Participant_Condition, adults is a Participant_Age, 256 adults is a Participant_Sample-size, control is a Intervention_Control, change in body weight is a Outcome_Physical, Average weight regain is a Outcome_Physical, regained less weight is a Outcome_Physical, difference in weight regain is a Outcome_Physical, GI on weight regain is a Outcome_Physical, improves weight loss is a Outcome_Physical, overweight and obese is a Participant_Condition

64539_task0

Sentence: Weight loss maintenance in overweight subjects on ad libitum diets with high or low protein content and glycemic index : the DIOGENES trial 12-month results . BACKGROUND A high dietary protein ( P ) content and low glycemic index ( LGI ) have been suggested to be beneficial for weight management , but long-term studies are scarce . OBJECTIVE The DIOGENES randomized clinical trial investigated the effect of P and GI on weight loss maintenance in overweight or obese adults in eight centers across Europe . This study reports the 1-year results in two of the centers that extended the intervention to 1 year . METHOD After an 8-week low-calorie diet ( LCD ) , 256 adults ( body mass index > 27 kg m ( - ) ( 2 ) ) were randomized to five ad libitum diets for 12 months : high P/LGI ( HP/LGI ) , HP/high GI ( HP/HGI ) , low P/LGI ( LP/LGI ) , LP/HGI and a control diet . During the first 6 months , foods were provided for free through a shop system and during the whole 12-month period , subjects received guidance by a dietician . Primary outcome variable was the change in body weight over the 12-month intervention period . RESULTS During the LCD period , subjects lost 11.2 ( 10.8 , 12.0 ) kg ( mean ( 95 % confidence interval ( CI ) ) ) . Average weight regain over the 12-month intervention period was 3.9 ( 95 % CI 3.0-4.8 ) kg . Subjects on the HP diets regained less weight than subjects on the LP diets . The difference in weight regain after 1 year was 2.0 ( 0.4 , 3.6 ) kg ( P=0.017 ) ( completers analysis , N=139 ) or 2.8 ( 1.4 , 4.1 ) kg ( P < 0.001 ) ( intention-to-treat analysis , N=256 ) . No consistent effect of GI on weight regain was found . There were no clinically relevant differences in changes in cardiometabolic risk factors among diet groups . CONCLUSION A higher protein content of an ad libitum diet improves weight loss maintenance in overweight and obese adults over 12 months . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Physical, Participant_Condition, Intervention_Control, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O" ]

Weight loss maintenance in overweight subjects on ad libitum diets with high or low protein content and glycemic index : the DIOGENES trial 12-month results . BACKGROUND A high dietary protein ( P ) content and low glycemic index ( LGI ) have been suggested to be beneficial for weight management , but long-term studies are scarce . OBJECTIVE The DIOGENES randomized clinical trial investigated the effect of P and GI on weight loss maintenance in overweight or obese adults in eight centers across Europe . This study reports the 1-year results in two of the centers that extended the intervention to 1 year . METHOD After an 8-week low-calorie diet ( LCD ) , 256 adults ( body mass index > 27 kg m ( - ) ( 2 ) ) were randomized to five ad libitum diets for 12 months : high P/LGI ( HP/LGI ) , HP/high GI ( HP/HGI ) , low P/LGI ( LP/LGI ) , LP/HGI and a control diet . During the first 6 months , foods were provided for free through a shop system and during the whole 12-month period , subjects received guidance by a dietician . Primary outcome variable was the change in body weight over the 12-month intervention period . RESULTS During the LCD period , subjects lost 11.2 ( 10.8 , 12.0 ) kg ( mean ( 95 % confidence interval ( CI ) ) ) . Average weight regain over the 12-month intervention period was 3.9 ( 95 % CI 3.0-4.8 ) kg . Subjects on the HP diets regained less weight than subjects on the LP diets . The difference in weight regain after 1 year was 2.0 ( 0.4 , 3.6 ) kg ( P=0.017 ) ( completers analysis , N=139 ) or 2.8 ( 1.4 , 4.1 ) kg ( P < 0.001 ) ( intention-to-treat analysis , N=256 ) . No consistent effect of GI on weight regain was found . There were no clinically relevant differences in changes in cardiometabolic risk factors among diet groups . CONCLUSION A higher protein content of an ad libitum diet improves weight loss maintenance in overweight and obese adults over 12 months .

[ "Weight", "loss", "maintenance", "in", "overweight", "subjects", "on", "ad", "libitum", "diets", "with", "high", "or", "low", "protein", "content", "and", "glycemic", "index", ":", "the", "DIOGENES", "trial", "12-month", "results", ".", "BACKGROUND", "A", "high", "dietary", "protein", "(", "P", ")", "content", "and", "low", "glycemic", "index", "(", "LGI", ")", "have", "been", "suggested", "to", "be", "beneficial", "for", "weight", "management", ",", "but", "long", "-", "term", "studies", "are", "scarce", ".", "OBJECTIVE", "The", "DIOGENES", "randomized", "clinical", "trial", "investigated", "the", "effect", "of", "P", "and", "GI", "on", "weight", "loss", "maintenance", "in", "overweight", "or", "obese", "adults", "in", "eight", "centers", "across", "Europe", ".", "This", "study", "reports", "the", "1-year", "results", "in", "two", "of", "the", "centers", "that", "extended", "the", "intervention", "to", "1", "year", ".", "METHOD", "After", "an", "8-week", "low", "-", "calorie", "diet", "(", "LCD", ")", ",", "256", "adults", "(", "body", "mass", "index", ">", "27", "kg", "m", "(", "-", ")", "(", "2", ")", ")", "were", "randomized", "to", "five", "ad", "libitum", "diets", "for", "12", "months", ":", "high", "P", "/", "LGI", "(", "HP", "/", "LGI", ")", ",", "HP", "/", "high", "GI", "(", "HP", "/", "HGI", ")", ",", "low", "P", "/", "LGI", "(", "LP", "/", "LGI", ")", ",", "LP", "/", "HGI", "and", "a", "control", "diet", ".", "During", "the", "first", "6", "months", ",", "foods", "were", "provided", "for", "free", "through", "a", "shop", "system", "and", "during", "the", "whole", "12-month", "period", ",", "subjects", "received", "guidance", "by", "a", "dietician", ".", "Primary", "outcome", "variable", "was", "the", "change", "in", "body", "weight", "over", "the", "12-month", "intervention", "period", ".", "RESULTS", "During", "the", "LCD", "period", ",", "subjects", "lost", "11.2", "(", "10.8", ",", "12.0", ")", "kg", "(", "mean", "(", "95", "%", "confidence", "interval", "(", "CI", ")", ")", ")", ".", "Average", "weight", "regain", "over", "the", "12-month", "intervention", "period", "was", "3.9", "(", "95", "%", "CI", "3.0", "-", "4.8", ")", "kg", ".", "Subjects", "on", "the", "HP", "diets", "regained", "less", "weight", "than", "subjects", "on", "the", "LP", "diets", ".", "The", "difference", "in", "weight", "regain", "after", "1", "year", "was", "2.0", "(", "0.4", ",", "3.6", ")", "kg", "(", "P=0.017", ")", "(", "completers", "analysis", ",", "N=139", ")", "or", "2.8", "(", "1.4", ",", "4.1", ")", "kg", "(", "P", "<", "0.001", ")", "(", "intention", "-", "to", "-", "treat", "analysis", ",", "N=256", ")", ".", "No", "consistent", "effect", "of", "GI", "on", "weight", "regain", "was", "found", ".", "There", "were", "no", "clinically", "relevant", "differences", "in", "changes", "in", "cardiometabolic", "risk", "factors", "among", "diet", "groups", ".", "CONCLUSION", "A", "higher", "protein", "content", "of", "an", "ad", "libitum", "diet", "improves", "weight", "loss", "maintenance", "in", "overweight", "and", "obese", "adults", "over", "12", "months", "." ]

[ "Intervention_Physical", "Outcome_Physical", "Participant_Condition", "Participant_Sample-size", "Intervention_Control", "Outcome_Other", "Participant_Age" ]

Weight loss maintenance is a Outcome_Physical, overweight is a Participant_Condition, ad libitum diets is a Intervention_Physical, high dietary protein ( P ) content is a Intervention_Physical, low glycemic index is a Intervention_Physical, effect is a Outcome_Other, weight loss maintenance is a Outcome_Physical, overweight or obese is a Participant_Condition, adults is a Participant_Age, 256 adults is a Participant_Sample-size, control is a Intervention_Control, change in body weight is a Outcome_Physical, Average weight regain is a Outcome_Physical, regained less weight is a Outcome_Physical, difference in weight regain is a Outcome_Physical, GI on weight regain is a Outcome_Physical, improves weight loss is a Outcome_Physical, overweight and obese is a Participant_Condition

64539_task1

Sentence: Weight loss maintenance in overweight subjects on ad libitum diets with high or low protein content and glycemic index : the DIOGENES trial 12-month results . BACKGROUND A high dietary protein ( P ) content and low glycemic index ( LGI ) have been suggested to be beneficial for weight management , but long-term studies are scarce . OBJECTIVE The DIOGENES randomized clinical trial investigated the effect of P and GI on weight loss maintenance in overweight or obese adults in eight centers across Europe . This study reports the 1-year results in two of the centers that extended the intervention to 1 year . METHOD After an 8-week low-calorie diet ( LCD ) , 256 adults ( body mass index > 27 kg m ( - ) ( 2 ) ) were randomized to five ad libitum diets for 12 months : high P/LGI ( HP/LGI ) , HP/high GI ( HP/HGI ) , low P/LGI ( LP/LGI ) , LP/HGI and a control diet . During the first 6 months , foods were provided for free through a shop system and during the whole 12-month period , subjects received guidance by a dietician . Primary outcome variable was the change in body weight over the 12-month intervention period . RESULTS During the LCD period , subjects lost 11.2 ( 10.8 , 12.0 ) kg ( mean ( 95 % confidence interval ( CI ) ) ) . Average weight regain over the 12-month intervention period was 3.9 ( 95 % CI 3.0-4.8 ) kg . Subjects on the HP diets regained less weight than subjects on the LP diets . The difference in weight regain after 1 year was 2.0 ( 0.4 , 3.6 ) kg ( P=0.017 ) ( completers analysis , N=139 ) or 2.8 ( 1.4 , 4.1 ) kg ( P < 0.001 ) ( intention-to-treat analysis , N=256 ) . No consistent effect of GI on weight regain was found . There were no clinically relevant differences in changes in cardiometabolic risk factors among diet groups . CONCLUSION A higher protein content of an ad libitum diet improves weight loss maintenance in overweight and obese adults over 12 months . Instructions: please typing these entity words according to sentence: Weight loss maintenance, overweight, ad libitum diets, high dietary protein ( P ) content, low glycemic index, effect, weight loss maintenance, overweight or obese, adults, 256 adults, control, change in body weight, Average weight regain, regained less weight, difference in weight regain, GI on weight regain, improves weight loss, overweight and obese Options: Intervention_Physical, Participant_Condition, Intervention_Control, Participant_Age, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O" ]

Weight loss maintenance in overweight subjects on ad libitum diets with high or low protein content and glycemic index : the DIOGENES trial 12-month results . BACKGROUND A high dietary protein ( P ) content and low glycemic index ( LGI ) have been suggested to be beneficial for weight management , but long-term studies are scarce . OBJECTIVE The DIOGENES randomized clinical trial investigated the effect of P and GI on weight loss maintenance in overweight or obese adults in eight centers across Europe . This study reports the 1-year results in two of the centers that extended the intervention to 1 year . METHOD After an 8-week low-calorie diet ( LCD ) , 256 adults ( body mass index > 27 kg m ( - ) ( 2 ) ) were randomized to five ad libitum diets for 12 months : high P/LGI ( HP/LGI ) , HP/high GI ( HP/HGI ) , low P/LGI ( LP/LGI ) , LP/HGI and a control diet . During the first 6 months , foods were provided for free through a shop system and during the whole 12-month period , subjects received guidance by a dietician . Primary outcome variable was the change in body weight over the 12-month intervention period . RESULTS During the LCD period , subjects lost 11.2 ( 10.8 , 12.0 ) kg ( mean ( 95 % confidence interval ( CI ) ) ) . Average weight regain over the 12-month intervention period was 3.9 ( 95 % CI 3.0-4.8 ) kg . Subjects on the HP diets regained less weight than subjects on the LP diets . The difference in weight regain after 1 year was 2.0 ( 0.4 , 3.6 ) kg ( P=0.017 ) ( completers analysis , N=139 ) or 2.8 ( 1.4 , 4.1 ) kg ( P < 0.001 ) ( intention-to-treat analysis , N=256 ) . No consistent effect of GI on weight regain was found . There were no clinically relevant differences in changes in cardiometabolic risk factors among diet groups . CONCLUSION A higher protein content of an ad libitum diet improves weight loss maintenance in overweight and obese adults over 12 months .

[ "Weight", "loss", "maintenance", "in", "overweight", "subjects", "on", "ad", "libitum", "diets", "with", "high", "or", "low", "protein", "content", "and", "glycemic", "index", ":", "the", "DIOGENES", "trial", "12-month", "results", ".", "BACKGROUND", "A", "high", "dietary", "protein", "(", "P", ")", "content", "and", "low", "glycemic", "index", "(", "LGI", ")", "have", "been", "suggested", "to", "be", "beneficial", "for", "weight", "management", ",", "but", "long", "-", "term", "studies", "are", "scarce", ".", "OBJECTIVE", "The", "DIOGENES", "randomized", "clinical", "trial", "investigated", "the", "effect", "of", "P", "and", "GI", "on", "weight", "loss", "maintenance", "in", "overweight", "or", "obese", "adults", "in", "eight", "centers", "across", "Europe", ".", "This", "study", "reports", "the", "1-year", "results", "in", "two", "of", "the", "centers", "that", "extended", "the", "intervention", "to", "1", "year", ".", "METHOD", "After", "an", "8-week", "low", "-", "calorie", "diet", "(", "LCD", ")", ",", "256", "adults", "(", "body", "mass", "index", ">", "27", "kg", "m", "(", "-", ")", "(", "2", ")", ")", "were", "randomized", "to", "five", "ad", "libitum", "diets", "for", "12", "months", ":", "high", "P", "/", "LGI", "(", "HP", "/", "LGI", ")", ",", "HP", "/", "high", "GI", "(", "HP", "/", "HGI", ")", ",", "low", "P", "/", "LGI", "(", "LP", "/", "LGI", ")", ",", "LP", "/", "HGI", "and", "a", "control", "diet", ".", "During", "the", "first", "6", "months", ",", "foods", "were", "provided", "for", "free", "through", "a", "shop", "system", "and", "during", "the", "whole", "12-month", "period", ",", "subjects", "received", "guidance", "by", "a", "dietician", ".", "Primary", "outcome", "variable", "was", "the", "change", "in", "body", "weight", "over", "the", "12-month", "intervention", "period", ".", "RESULTS", "During", "the", "LCD", "period", ",", "subjects", "lost", "11.2", "(", "10.8", ",", "12.0", ")", "kg", "(", "mean", "(", "95", "%", "confidence", "interval", "(", "CI", ")", ")", ")", ".", "Average", "weight", "regain", "over", "the", "12-month", "intervention", "period", "was", "3.9", "(", "95", "%", "CI", "3.0", "-", "4.8", ")", "kg", ".", "Subjects", "on", "the", "HP", "diets", "regained", "less", "weight", "than", "subjects", "on", "the", "LP", "diets", ".", "The", "difference", "in", "weight", "regain", "after", "1", "year", "was", "2.0", "(", "0.4", ",", "3.6", ")", "kg", "(", "P=0.017", ")", "(", "completers", "analysis", ",", "N=139", ")", "or", "2.8", "(", "1.4", ",", "4.1", ")", "kg", "(", "P", "<", "0.001", ")", "(", "intention", "-", "to", "-", "treat", "analysis", ",", "N=256", ")", ".", "No", "consistent", "effect", "of", "GI", "on", "weight", "regain", "was", "found", ".", "There", "were", "no", "clinically", "relevant", "differences", "in", "changes", "in", "cardiometabolic", "risk", "factors", "among", "diet", "groups", ".", "CONCLUSION", "A", "higher", "protein", "content", "of", "an", "ad", "libitum", "diet", "improves", "weight", "loss", "maintenance", "in", "overweight", "and", "obese", "adults", "over", "12", "months", "." ]

[ "Intervention_Physical", "Outcome_Physical", "Participant_Condition", "Participant_Sample-size", "Intervention_Control", "Outcome_Other", "Participant_Age" ]

Weight loss maintenance, overweight, ad libitum diets, high dietary protein ( P ) content, low glycemic index, effect, weight loss maintenance, overweight or obese, adults, 256 adults, control, change in body weight, Average weight regain, regained less weight, difference in weight regain, GI on weight regain, improves weight loss, overweight and obese

64539_task2

Sentence: Weight loss maintenance in overweight subjects on ad libitum diets with high or low protein content and glycemic index : the DIOGENES trial 12-month results . BACKGROUND A high dietary protein ( P ) content and low glycemic index ( LGI ) have been suggested to be beneficial for weight management , but long-term studies are scarce . OBJECTIVE The DIOGENES randomized clinical trial investigated the effect of P and GI on weight loss maintenance in overweight or obese adults in eight centers across Europe . This study reports the 1-year results in two of the centers that extended the intervention to 1 year . METHOD After an 8-week low-calorie diet ( LCD ) , 256 adults ( body mass index > 27 kg m ( - ) ( 2 ) ) were randomized to five ad libitum diets for 12 months : high P/LGI ( HP/LGI ) , HP/high GI ( HP/HGI ) , low P/LGI ( LP/LGI ) , LP/HGI and a control diet . During the first 6 months , foods were provided for free through a shop system and during the whole 12-month period , subjects received guidance by a dietician . Primary outcome variable was the change in body weight over the 12-month intervention period . RESULTS During the LCD period , subjects lost 11.2 ( 10.8 , 12.0 ) kg ( mean ( 95 % confidence interval ( CI ) ) ) . Average weight regain over the 12-month intervention period was 3.9 ( 95 % CI 3.0-4.8 ) kg . Subjects on the HP diets regained less weight than subjects on the LP diets . The difference in weight regain after 1 year was 2.0 ( 0.4 , 3.6 ) kg ( P=0.017 ) ( completers analysis , N=139 ) or 2.8 ( 1.4 , 4.1 ) kg ( P < 0.001 ) ( intention-to-treat analysis , N=256 ) . No consistent effect of GI on weight regain was found . There were no clinically relevant differences in changes in cardiometabolic risk factors among diet groups . CONCLUSION A higher protein content of an ad libitum diet improves weight loss maintenance in overweight and obese adults over 12 months . Instructions: please extract entity words from the input sentence

[ "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "B-Participant_Age", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O" ]

Weight loss maintenance in overweight subjects on ad libitum diets with high or low protein content and glycemic index : the DIOGENES trial 12-month results . BACKGROUND A high dietary protein ( P ) content and low glycemic index ( LGI ) have been suggested to be beneficial for weight management , but long-term studies are scarce . OBJECTIVE The DIOGENES randomized clinical trial investigated the effect of P and GI on weight loss maintenance in overweight or obese adults in eight centers across Europe . This study reports the 1-year results in two of the centers that extended the intervention to 1 year . METHOD After an 8-week low-calorie diet ( LCD ) , 256 adults ( body mass index > 27 kg m ( - ) ( 2 ) ) were randomized to five ad libitum diets for 12 months : high P/LGI ( HP/LGI ) , HP/high GI ( HP/HGI ) , low P/LGI ( LP/LGI ) , LP/HGI and a control diet . During the first 6 months , foods were provided for free through a shop system and during the whole 12-month period , subjects received guidance by a dietician . Primary outcome variable was the change in body weight over the 12-month intervention period . RESULTS During the LCD period , subjects lost 11.2 ( 10.8 , 12.0 ) kg ( mean ( 95 % confidence interval ( CI ) ) ) . Average weight regain over the 12-month intervention period was 3.9 ( 95 % CI 3.0-4.8 ) kg . Subjects on the HP diets regained less weight than subjects on the LP diets . The difference in weight regain after 1 year was 2.0 ( 0.4 , 3.6 ) kg ( P=0.017 ) ( completers analysis , N=139 ) or 2.8 ( 1.4 , 4.1 ) kg ( P < 0.001 ) ( intention-to-treat analysis , N=256 ) . No consistent effect of GI on weight regain was found . There were no clinically relevant differences in changes in cardiometabolic risk factors among diet groups . CONCLUSION A higher protein content of an ad libitum diet improves weight loss maintenance in overweight and obese adults over 12 months .

[ "Weight", "loss", "maintenance", "in", "overweight", "subjects", "on", "ad", "libitum", "diets", "with", "high", "or", "low", "protein", "content", "and", "glycemic", "index", ":", "the", "DIOGENES", "trial", "12-month", "results", ".", "BACKGROUND", "A", "high", "dietary", "protein", "(", "P", ")", "content", "and", "low", "glycemic", "index", "(", "LGI", ")", "have", "been", "suggested", "to", "be", "beneficial", "for", "weight", "management", ",", "but", "long", "-", "term", "studies", "are", "scarce", ".", "OBJECTIVE", "The", "DIOGENES", "randomized", "clinical", "trial", "investigated", "the", "effect", "of", "P", "and", "GI", "on", "weight", "loss", "maintenance", "in", "overweight", "or", "obese", "adults", "in", "eight", "centers", "across", "Europe", ".", "This", "study", "reports", "the", "1-year", "results", "in", "two", "of", "the", "centers", "that", "extended", "the", "intervention", "to", "1", "year", ".", "METHOD", "After", "an", "8-week", "low", "-", "calorie", "diet", "(", "LCD", ")", ",", "256", "adults", "(", "body", "mass", "index", ">", "27", "kg", "m", "(", "-", ")", "(", "2", ")", ")", "were", "randomized", "to", "five", "ad", "libitum", "diets", "for", "12", "months", ":", "high", "P", "/", "LGI", "(", "HP", "/", "LGI", ")", ",", "HP", "/", "high", "GI", "(", "HP", "/", "HGI", ")", ",", "low", "P", "/", "LGI", "(", "LP", "/", "LGI", ")", ",", "LP", "/", "HGI", "and", "a", "control", "diet", ".", "During", "the", "first", "6", "months", ",", "foods", "were", "provided", "for", "free", "through", "a", "shop", "system", "and", "during", "the", "whole", "12-month", "period", ",", "subjects", "received", "guidance", "by", "a", "dietician", ".", "Primary", "outcome", "variable", "was", "the", "change", "in", "body", "weight", "over", "the", "12-month", "intervention", "period", ".", "RESULTS", "During", "the", "LCD", "period", ",", "subjects", "lost", "11.2", "(", "10.8", ",", "12.0", ")", "kg", "(", "mean", "(", "95", "%", "confidence", "interval", "(", "CI", ")", ")", ")", ".", "Average", "weight", "regain", "over", "the", "12-month", "intervention", "period", "was", "3.9", "(", "95", "%", "CI", "3.0", "-", "4.8", ")", "kg", ".", "Subjects", "on", "the", "HP", "diets", "regained", "less", "weight", "than", "subjects", "on", "the", "LP", "diets", ".", "The", "difference", "in", "weight", "regain", "after", "1", "year", "was", "2.0", "(", "0.4", ",", "3.6", ")", "kg", "(", "P=0.017", ")", "(", "completers", "analysis", ",", "N=139", ")", "or", "2.8", "(", "1.4", ",", "4.1", ")", "kg", "(", "P", "<", "0.001", ")", "(", "intention", "-", "to", "-", "treat", "analysis", ",", "N=256", ")", ".", "No", "consistent", "effect", "of", "GI", "on", "weight", "regain", "was", "found", ".", "There", "were", "no", "clinically", "relevant", "differences", "in", "changes", "in", "cardiometabolic", "risk", "factors", "among", "diet", "groups", ".", "CONCLUSION", "A", "higher", "protein", "content", "of", "an", "ad", "libitum", "diet", "improves", "weight", "loss", "maintenance", "in", "overweight", "and", "obese", "adults", "over", "12", "months", "." ]

[ "Intervention_Physical", "Outcome_Physical", "Participant_Condition", "Participant_Sample-size", "Intervention_Control", "Outcome_Other", "Participant_Age" ]

tumorchirurgischen is an umlsterm, Beckens is an umlsterm, Mann is an umlsterm, Patienten is an umlsterm, Tumortherapie is an umlsterm, Ejakulation is an umlsterm, medikamentoeser Therapie is an umlsterm, Tumore is an umlsterm, Therapie is an umlsterm, Harnblasen- is an umlsterm, Prostata is an umlsterm, Hodenkarzinoms is an umlsterm, Tumoren is an umlsterm, Neuroanatomie is an umlsterm, Techniken is an umlsterm, Nervenbahnen is an umlsterm, Tumorerkrankung is an umlsterm, Patienten is an umlsterm, Lebensqualitaet is an umlsterm, Ejakulationsstoerungen is an umlsterm, Therapiemodalitaeten is an umlsterm

Reproduktionsmedizin.90150378.ger.abstr_task0

Sentence: Nach tumorchirurgischen Eingriffen im Bauchraum , dem Retroperitoneum und des kleinen Beckens kann es zu einer Schaedigung der Nerven und Gefaesse der Sexualorgane kommen . Infolge hiervon kommt es haeufig zu sexuellen Funktionsstoerungen beim Mann . Da es sich oft um Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter handelt , wird der Praevention solcher Begleiterscheinungen bei der Tumortherapie besondere Bedeutung geschenkt . Eine Beeintraechtigung der Erektion oder Stoerungen der Ejakulation koennen nach operativer , strahlentherapeutischer oder medikamentoeser Therapie verschiedener Tumore auftreten . Haeufig treten sie bei der Therapie des Harnblasen- , Prostata , Hodenkarzinoms oder kolorektalen Tumoren auf . Durch eingehendes Verstaendnis der Neuroanatomie und moderne chirurgische Techniken sind diese Stoerungen heute in einem hohen Prozentsatz vermeidbar . Laesst sich eine Schaedigung der entsprechenden Nervenbahnen aufgrund der erforderlichen Radikalitaet des chirurgischen Eingriffs , um die Tumorerkrankung kurativ zu therapieren , nicht vermeiden , sind sexuelle Funktionsstoerungen fuer diese Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter eine deutliche Einschraenkung der Lebensqualitaet . Sowohl Ejakulationsstoerungen als auch Erektionsstoerungen lassen sich jedoch durch eine Reihe von Therapiemodalitaeten in fast allen Faellen behandeln . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Nach tumorchirurgischen Eingriffen im Bauchraum , dem Retroperitoneum und des kleinen Beckens kann es zu einer Schaedigung der Nerven und Gefaesse der Sexualorgane kommen . Infolge hiervon kommt es haeufig zu sexuellen Funktionsstoerungen beim Mann . Da es sich oft um Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter handelt , wird der Praevention solcher Begleiterscheinungen bei der Tumortherapie besondere Bedeutung geschenkt . Eine Beeintraechtigung der Erektion oder Stoerungen der Ejakulation koennen nach operativer , strahlentherapeutischer oder medikamentoeser Therapie verschiedener Tumore auftreten . Haeufig treten sie bei der Therapie des Harnblasen- , Prostata , Hodenkarzinoms oder kolorektalen Tumoren auf . Durch eingehendes Verstaendnis der Neuroanatomie und moderne chirurgische Techniken sind diese Stoerungen heute in einem hohen Prozentsatz vermeidbar . Laesst sich eine Schaedigung der entsprechenden Nervenbahnen aufgrund der erforderlichen Radikalitaet des chirurgischen Eingriffs , um die Tumorerkrankung kurativ zu therapieren , nicht vermeiden , sind sexuelle Funktionsstoerungen fuer diese Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter eine deutliche Einschraenkung der Lebensqualitaet . Sowohl Ejakulationsstoerungen als auch Erektionsstoerungen lassen sich jedoch durch eine Reihe von Therapiemodalitaeten in fast allen Faellen behandeln .

[ "Nach", "tumorchirurgischen", "Eingriffen", "im", "Bauchraum", ",", "dem", "Retroperitoneum", "und", "des", "kleinen", "Beckens", "kann", "es", "zu", "einer", "Schaedigung", "der", "Nerven", "und", "Gefaesse", "der", "Sexualorgane", "kommen", ".", "Infolge", "hiervon", "kommt", "es", "haeufig", "zu", "sexuellen", "Funktionsstoerungen", "beim", "Mann", ".", "Da", "es", "sich", "oft", "um", "Patienten", "im", "sexuell", "aktiven", "und", "auch", "reproduktionsfaehigen", "Alter", "handelt", ",", "wird", "der", "Praevention", "solcher", "Begleiterscheinungen", "bei", "der", "Tumortherapie", "besondere", "Bedeutung", "geschenkt", ".", "Eine", "Beeintraechtigung", "der", "Erektion", "oder", "Stoerungen", "der", "Ejakulation", "koennen", "nach", "operativer", ",", "strahlentherapeutischer", "oder", "medikamentoeser", "Therapie", "verschiedener", "Tumore", "auftreten", ".", "Haeufig", "treten", "sie", "bei", "der", "Therapie", "des", "Harnblasen-", ",", "Prostata", ",", "Hodenkarzinoms", "oder", "kolorektalen", "Tumoren", "auf", ".", "Durch", "eingehendes", "Verstaendnis", "der", "Neuroanatomie", "und", "moderne", "chirurgische", "Techniken", "sind", "diese", "Stoerungen", "heute", "in", "einem", "hohen", "Prozentsatz", "vermeidbar", ".", "Laesst", "sich", "eine", "Schaedigung", "der", "entsprechenden", "Nervenbahnen", "aufgrund", "der", "erforderlichen", "Radikalitaet", "des", "chirurgischen", "Eingriffs", ",", "um", "die", "Tumorerkrankung", "kurativ", "zu", "therapieren", ",", "nicht", "vermeiden", ",", "sind", "sexuelle", "Funktionsstoerungen", "fuer", "diese", "Patienten", "im", "sexuell", "aktiven", "und", "auch", "reproduktionsfaehigen", "Alter", "eine", "deutliche", "Einschraenkung", "der", "Lebensqualitaet", ".", "Sowohl", "Ejakulationsstoerungen", "als", "auch", "Erektionsstoerungen", "lassen", "sich", "jedoch", "durch", "eine", "Reihe", "von", "Therapiemodalitaeten", "in", "fast", "allen", "Faellen", "behandeln", "." ]

[ "umlsterm" ]

tumorchirurgischen is an umlsterm, Beckens is an umlsterm, Mann is an umlsterm, Patienten is an umlsterm, Tumortherapie is an umlsterm, Ejakulation is an umlsterm, medikamentoeser Therapie is an umlsterm, Tumore is an umlsterm, Therapie is an umlsterm, Harnblasen- is an umlsterm, Prostata is an umlsterm, Hodenkarzinoms is an umlsterm, Tumoren is an umlsterm, Neuroanatomie is an umlsterm, Techniken is an umlsterm, Nervenbahnen is an umlsterm, Tumorerkrankung is an umlsterm, Patienten is an umlsterm, Lebensqualitaet is an umlsterm, Ejakulationsstoerungen is an umlsterm, Therapiemodalitaeten is an umlsterm

Reproduktionsmedizin.90150378.ger.abstr_task1

Sentence: Nach tumorchirurgischen Eingriffen im Bauchraum , dem Retroperitoneum und des kleinen Beckens kann es zu einer Schaedigung der Nerven und Gefaesse der Sexualorgane kommen . Infolge hiervon kommt es haeufig zu sexuellen Funktionsstoerungen beim Mann . Da es sich oft um Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter handelt , wird der Praevention solcher Begleiterscheinungen bei der Tumortherapie besondere Bedeutung geschenkt . Eine Beeintraechtigung der Erektion oder Stoerungen der Ejakulation koennen nach operativer , strahlentherapeutischer oder medikamentoeser Therapie verschiedener Tumore auftreten . Haeufig treten sie bei der Therapie des Harnblasen- , Prostata , Hodenkarzinoms oder kolorektalen Tumoren auf . Durch eingehendes Verstaendnis der Neuroanatomie und moderne chirurgische Techniken sind diese Stoerungen heute in einem hohen Prozentsatz vermeidbar . Laesst sich eine Schaedigung der entsprechenden Nervenbahnen aufgrund der erforderlichen Radikalitaet des chirurgischen Eingriffs , um die Tumorerkrankung kurativ zu therapieren , nicht vermeiden , sind sexuelle Funktionsstoerungen fuer diese Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter eine deutliche Einschraenkung der Lebensqualitaet . Sowohl Ejakulationsstoerungen als auch Erektionsstoerungen lassen sich jedoch durch eine Reihe von Therapiemodalitaeten in fast allen Faellen behandeln . Instructions: please typing these entity words according to sentence: tumorchirurgischen, Beckens, Mann, Patienten, Tumortherapie, Ejakulation, medikamentoeser Therapie, Tumore, Therapie, Harnblasen-, Prostata, Hodenkarzinoms, Tumoren, Neuroanatomie, Techniken, Nervenbahnen, Tumorerkrankung, Patienten, Lebensqualitaet, Ejakulationsstoerungen, Therapiemodalitaeten Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Nach tumorchirurgischen Eingriffen im Bauchraum , dem Retroperitoneum und des kleinen Beckens kann es zu einer Schaedigung der Nerven und Gefaesse der Sexualorgane kommen . Infolge hiervon kommt es haeufig zu sexuellen Funktionsstoerungen beim Mann . Da es sich oft um Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter handelt , wird der Praevention solcher Begleiterscheinungen bei der Tumortherapie besondere Bedeutung geschenkt . Eine Beeintraechtigung der Erektion oder Stoerungen der Ejakulation koennen nach operativer , strahlentherapeutischer oder medikamentoeser Therapie verschiedener Tumore auftreten . Haeufig treten sie bei der Therapie des Harnblasen- , Prostata , Hodenkarzinoms oder kolorektalen Tumoren auf . Durch eingehendes Verstaendnis der Neuroanatomie und moderne chirurgische Techniken sind diese Stoerungen heute in einem hohen Prozentsatz vermeidbar . Laesst sich eine Schaedigung der entsprechenden Nervenbahnen aufgrund der erforderlichen Radikalitaet des chirurgischen Eingriffs , um die Tumorerkrankung kurativ zu therapieren , nicht vermeiden , sind sexuelle Funktionsstoerungen fuer diese Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter eine deutliche Einschraenkung der Lebensqualitaet . Sowohl Ejakulationsstoerungen als auch Erektionsstoerungen lassen sich jedoch durch eine Reihe von Therapiemodalitaeten in fast allen Faellen behandeln .

[ "Nach", "tumorchirurgischen", "Eingriffen", "im", "Bauchraum", ",", "dem", "Retroperitoneum", "und", "des", "kleinen", "Beckens", "kann", "es", "zu", "einer", "Schaedigung", "der", "Nerven", "und", "Gefaesse", "der", "Sexualorgane", "kommen", ".", "Infolge", "hiervon", "kommt", "es", "haeufig", "zu", "sexuellen", "Funktionsstoerungen", "beim", "Mann", ".", "Da", "es", "sich", "oft", "um", "Patienten", "im", "sexuell", "aktiven", "und", "auch", "reproduktionsfaehigen", "Alter", "handelt", ",", "wird", "der", "Praevention", "solcher", "Begleiterscheinungen", "bei", "der", "Tumortherapie", "besondere", "Bedeutung", "geschenkt", ".", "Eine", "Beeintraechtigung", "der", "Erektion", "oder", "Stoerungen", "der", "Ejakulation", "koennen", "nach", "operativer", ",", "strahlentherapeutischer", "oder", "medikamentoeser", "Therapie", "verschiedener", "Tumore", "auftreten", ".", "Haeufig", "treten", "sie", "bei", "der", "Therapie", "des", "Harnblasen-", ",", "Prostata", ",", "Hodenkarzinoms", "oder", "kolorektalen", "Tumoren", "auf", ".", "Durch", "eingehendes", "Verstaendnis", "der", "Neuroanatomie", "und", "moderne", "chirurgische", "Techniken", "sind", "diese", "Stoerungen", "heute", "in", "einem", "hohen", "Prozentsatz", "vermeidbar", ".", "Laesst", "sich", "eine", "Schaedigung", "der", "entsprechenden", "Nervenbahnen", "aufgrund", "der", "erforderlichen", "Radikalitaet", "des", "chirurgischen", "Eingriffs", ",", "um", "die", "Tumorerkrankung", "kurativ", "zu", "therapieren", ",", "nicht", "vermeiden", ",", "sind", "sexuelle", "Funktionsstoerungen", "fuer", "diese", "Patienten", "im", "sexuell", "aktiven", "und", "auch", "reproduktionsfaehigen", "Alter", "eine", "deutliche", "Einschraenkung", "der", "Lebensqualitaet", ".", "Sowohl", "Ejakulationsstoerungen", "als", "auch", "Erektionsstoerungen", "lassen", "sich", "jedoch", "durch", "eine", "Reihe", "von", "Therapiemodalitaeten", "in", "fast", "allen", "Faellen", "behandeln", "." ]

[ "umlsterm" ]

tumorchirurgischen, Beckens, Mann, Patienten, Tumortherapie, Ejakulation, medikamentoeser Therapie, Tumore, Therapie, Harnblasen-, Prostata, Hodenkarzinoms, Tumoren, Neuroanatomie, Techniken, Nervenbahnen, Tumorerkrankung, Patienten, Lebensqualitaet, Ejakulationsstoerungen, Therapiemodalitaeten

Reproduktionsmedizin.90150378.ger.abstr_task2

Sentence: Nach tumorchirurgischen Eingriffen im Bauchraum , dem Retroperitoneum und des kleinen Beckens kann es zu einer Schaedigung der Nerven und Gefaesse der Sexualorgane kommen . Infolge hiervon kommt es haeufig zu sexuellen Funktionsstoerungen beim Mann . Da es sich oft um Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter handelt , wird der Praevention solcher Begleiterscheinungen bei der Tumortherapie besondere Bedeutung geschenkt . Eine Beeintraechtigung der Erektion oder Stoerungen der Ejakulation koennen nach operativer , strahlentherapeutischer oder medikamentoeser Therapie verschiedener Tumore auftreten . Haeufig treten sie bei der Therapie des Harnblasen- , Prostata , Hodenkarzinoms oder kolorektalen Tumoren auf . Durch eingehendes Verstaendnis der Neuroanatomie und moderne chirurgische Techniken sind diese Stoerungen heute in einem hohen Prozentsatz vermeidbar . Laesst sich eine Schaedigung der entsprechenden Nervenbahnen aufgrund der erforderlichen Radikalitaet des chirurgischen Eingriffs , um die Tumorerkrankung kurativ zu therapieren , nicht vermeiden , sind sexuelle Funktionsstoerungen fuer diese Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter eine deutliche Einschraenkung der Lebensqualitaet . Sowohl Ejakulationsstoerungen als auch Erektionsstoerungen lassen sich jedoch durch eine Reihe von Therapiemodalitaeten in fast allen Faellen behandeln . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Nach tumorchirurgischen Eingriffen im Bauchraum , dem Retroperitoneum und des kleinen Beckens kann es zu einer Schaedigung der Nerven und Gefaesse der Sexualorgane kommen . Infolge hiervon kommt es haeufig zu sexuellen Funktionsstoerungen beim Mann . Da es sich oft um Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter handelt , wird der Praevention solcher Begleiterscheinungen bei der Tumortherapie besondere Bedeutung geschenkt . Eine Beeintraechtigung der Erektion oder Stoerungen der Ejakulation koennen nach operativer , strahlentherapeutischer oder medikamentoeser Therapie verschiedener Tumore auftreten . Haeufig treten sie bei der Therapie des Harnblasen- , Prostata , Hodenkarzinoms oder kolorektalen Tumoren auf . Durch eingehendes Verstaendnis der Neuroanatomie und moderne chirurgische Techniken sind diese Stoerungen heute in einem hohen Prozentsatz vermeidbar . Laesst sich eine Schaedigung der entsprechenden Nervenbahnen aufgrund der erforderlichen Radikalitaet des chirurgischen Eingriffs , um die Tumorerkrankung kurativ zu therapieren , nicht vermeiden , sind sexuelle Funktionsstoerungen fuer diese Patienten im sexuell aktiven und auch reproduktionsfaehigen Alter eine deutliche Einschraenkung der Lebensqualitaet . Sowohl Ejakulationsstoerungen als auch Erektionsstoerungen lassen sich jedoch durch eine Reihe von Therapiemodalitaeten in fast allen Faellen behandeln .

[ "Nach", "tumorchirurgischen", "Eingriffen", "im", "Bauchraum", ",", "dem", "Retroperitoneum", "und", "des", "kleinen", "Beckens", "kann", "es", "zu", "einer", "Schaedigung", "der", "Nerven", "und", "Gefaesse", "der", "Sexualorgane", "kommen", ".", "Infolge", "hiervon", "kommt", "es", "haeufig", "zu", "sexuellen", "Funktionsstoerungen", "beim", "Mann", ".", "Da", "es", "sich", "oft", "um", "Patienten", "im", "sexuell", "aktiven", "und", "auch", "reproduktionsfaehigen", "Alter", "handelt", ",", "wird", "der", "Praevention", "solcher", "Begleiterscheinungen", "bei", "der", "Tumortherapie", "besondere", "Bedeutung", "geschenkt", ".", "Eine", "Beeintraechtigung", "der", "Erektion", "oder", "Stoerungen", "der", "Ejakulation", "koennen", "nach", "operativer", ",", "strahlentherapeutischer", "oder", "medikamentoeser", "Therapie", "verschiedener", "Tumore", "auftreten", ".", "Haeufig", "treten", "sie", "bei", "der", "Therapie", "des", "Harnblasen-", ",", "Prostata", ",", "Hodenkarzinoms", "oder", "kolorektalen", "Tumoren", "auf", ".", "Durch", "eingehendes", "Verstaendnis", "der", "Neuroanatomie", "und", "moderne", "chirurgische", "Techniken", "sind", "diese", "Stoerungen", "heute", "in", "einem", "hohen", "Prozentsatz", "vermeidbar", ".", "Laesst", "sich", "eine", "Schaedigung", "der", "entsprechenden", "Nervenbahnen", "aufgrund", "der", "erforderlichen", "Radikalitaet", "des", "chirurgischen", "Eingriffs", ",", "um", "die", "Tumorerkrankung", "kurativ", "zu", "therapieren", ",", "nicht", "vermeiden", ",", "sind", "sexuelle", "Funktionsstoerungen", "fuer", "diese", "Patienten", "im", "sexuell", "aktiven", "und", "auch", "reproduktionsfaehigen", "Alter", "eine", "deutliche", "Einschraenkung", "der", "Lebensqualitaet", ".", "Sowohl", "Ejakulationsstoerungen", "als", "auch", "Erektionsstoerungen", "lassen", "sich", "jedoch", "durch", "eine", "Reihe", "von", "Therapiemodalitaeten", "in", "fast", "allen", "Faellen", "behandeln", "." ]

[ "umlsterm" ]

artery is an umlsterm, regression is an umlsterm, femoral artery is an umlsterm, blood supply is an umlsterm, leg is an umlsterm, femoral artery is an umlsterm, artery is an umlsterm, ischemia is an umlsterm, buttock is an umlsterm, Combined therapy is an umlsterm, catheter is an umlsterm, fibrinolysis is an umlsterm, ligation is an umlsterm, artery is an umlsterm, procedure is an umlsterm, leg is an umlsterm, perfusion is an umlsterm

DerChirurg.90700795.eng.abstr_task0

Sentence: Persistent sciatic artery as a rare entity results from lack of regression of the femoral artery blood supply of the leg and is often combined with an abnormally developed superficial femoral artery . We describe the case of a complete , persistent sciatic artery with peripheral ischemia caused by thrombo-embolism from buttock aneurysmal formation . Combined therapy of catheter fibrinolysis , followed by proximal and distal ligation of sciatic artery and peripheral bypass procedure , restored regular leg perfusion . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]

Persistent sciatic artery as a rare entity results from lack of regression of the femoral artery blood supply of the leg and is often combined with an abnormally developed superficial femoral artery . We describe the case of a complete , persistent sciatic artery with peripheral ischemia caused by thrombo-embolism from buttock aneurysmal formation . Combined therapy of catheter fibrinolysis , followed by proximal and distal ligation of sciatic artery and peripheral bypass procedure , restored regular leg perfusion .

[ "Persistent", "sciatic", "artery", "as", "a", "rare", "entity", "results", "from", "lack", "of", "regression", "of", "the", "femoral", "artery", "blood", "supply", "of", "the", "leg", "and", "is", "often", "combined", "with", "an", "abnormally", "developed", "superficial", "femoral", "artery", ".", "We", "describe", "the", "case", "of", "a", "complete", ",", "persistent", "sciatic", "artery", "with", "peripheral", "ischemia", "caused", "by", "thrombo", "-", "embolism", "from", "buttock", "aneurysmal", "formation", ".", "Combined", "therapy", "of", "catheter", "fibrinolysis", ",", "followed", "by", "proximal", "and", "distal", "ligation", "of", "sciatic", "artery", "and", "peripheral", "bypass", "procedure", ",", "restored", "regular", "leg", "perfusion", "." ]

[ "umlsterm" ]

artery is an umlsterm, regression is an umlsterm, femoral artery is an umlsterm, blood supply is an umlsterm, leg is an umlsterm, femoral artery is an umlsterm, artery is an umlsterm, ischemia is an umlsterm, buttock is an umlsterm, Combined therapy is an umlsterm, catheter is an umlsterm, fibrinolysis is an umlsterm, ligation is an umlsterm, artery is an umlsterm, procedure is an umlsterm, leg is an umlsterm, perfusion is an umlsterm

DerChirurg.90700795.eng.abstr_task1

Sentence: Persistent sciatic artery as a rare entity results from lack of regression of the femoral artery blood supply of the leg and is often combined with an abnormally developed superficial femoral artery . We describe the case of a complete , persistent sciatic artery with peripheral ischemia caused by thrombo-embolism from buttock aneurysmal formation . Combined therapy of catheter fibrinolysis , followed by proximal and distal ligation of sciatic artery and peripheral bypass procedure , restored regular leg perfusion . Instructions: please typing these entity words according to sentence: artery, regression, femoral artery, blood supply, leg, femoral artery, artery, ischemia, buttock, Combined therapy, catheter, fibrinolysis, ligation, artery, procedure, leg, perfusion Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]

Persistent sciatic artery as a rare entity results from lack of regression of the femoral artery blood supply of the leg and is often combined with an abnormally developed superficial femoral artery . We describe the case of a complete , persistent sciatic artery with peripheral ischemia caused by thrombo-embolism from buttock aneurysmal formation . Combined therapy of catheter fibrinolysis , followed by proximal and distal ligation of sciatic artery and peripheral bypass procedure , restored regular leg perfusion .

[ "Persistent", "sciatic", "artery", "as", "a", "rare", "entity", "results", "from", "lack", "of", "regression", "of", "the", "femoral", "artery", "blood", "supply", "of", "the", "leg", "and", "is", "often", "combined", "with", "an", "abnormally", "developed", "superficial", "femoral", "artery", ".", "We", "describe", "the", "case", "of", "a", "complete", ",", "persistent", "sciatic", "artery", "with", "peripheral", "ischemia", "caused", "by", "thrombo", "-", "embolism", "from", "buttock", "aneurysmal", "formation", ".", "Combined", "therapy", "of", "catheter", "fibrinolysis", ",", "followed", "by", "proximal", "and", "distal", "ligation", "of", "sciatic", "artery", "and", "peripheral", "bypass", "procedure", ",", "restored", "regular", "leg", "perfusion", "." ]

[ "umlsterm" ]

artery, regression, femoral artery, blood supply, leg, femoral artery, artery, ischemia, buttock, Combined therapy, catheter, fibrinolysis, ligation, artery, procedure, leg, perfusion

DerChirurg.90700795.eng.abstr_task2

Sentence: Persistent sciatic artery as a rare entity results from lack of regression of the femoral artery blood supply of the leg and is often combined with an abnormally developed superficial femoral artery . We describe the case of a complete , persistent sciatic artery with peripheral ischemia caused by thrombo-embolism from buttock aneurysmal formation . Combined therapy of catheter fibrinolysis , followed by proximal and distal ligation of sciatic artery and peripheral bypass procedure , restored regular leg perfusion . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O" ]

Persistent sciatic artery as a rare entity results from lack of regression of the femoral artery blood supply of the leg and is often combined with an abnormally developed superficial femoral artery . We describe the case of a complete , persistent sciatic artery with peripheral ischemia caused by thrombo-embolism from buttock aneurysmal formation . Combined therapy of catheter fibrinolysis , followed by proximal and distal ligation of sciatic artery and peripheral bypass procedure , restored regular leg perfusion .

[ "Persistent", "sciatic", "artery", "as", "a", "rare", "entity", "results", "from", "lack", "of", "regression", "of", "the", "femoral", "artery", "blood", "supply", "of", "the", "leg", "and", "is", "often", "combined", "with", "an", "abnormally", "developed", "superficial", "femoral", "artery", ".", "We", "describe", "the", "case", "of", "a", "complete", ",", "persistent", "sciatic", "artery", "with", "peripheral", "ischemia", "caused", "by", "thrombo", "-", "embolism", "from", "buttock", "aneurysmal", "formation", ".", "Combined", "therapy", "of", "catheter", "fibrinolysis", ",", "followed", "by", "proximal", "and", "distal", "ligation", "of", "sciatic", "artery", "and", "peripheral", "bypass", "procedure", ",", "restored", "regular", "leg", "perfusion", "." ]

[ "umlsterm" ]

UL5 is a Individual_protein, UL8 is a Individual_protein, UL52 is a Individual_protein, UL9 is a Individual_protein, ICP8 is a Individual_protein, UL29 is a Individual_protein

571_task0

Sentence: We observed that four replication proteins, UL5, UL8 UL52, and UL9, are necessary for the localization of ICP8 (UL29) to prereplicative sites natural infection conditions. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Individual_protein

[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

We observed that four replication proteins, UL5, UL8 UL52, and UL9, are necessary for the localization of ICP8 (UL29) to prereplicative sites natural infection conditions.

[ "We", "observed", "that", "four", "replication", "proteins", ",", "UL5", ",", "UL8", "UL52", ",", "and", "UL9", ",", "are", "necessary", "for", "the", "localization", "of", "ICP8", "(", "UL29", ")", "to", "prereplicative", "sites", "natural", "infection", "conditions", "." ]

[ "Individual_protein" ]

UL5 is a Individual_protein, UL8 is a Individual_protein, UL52 is a Individual_protein, UL9 is a Individual_protein, ICP8 is a Individual_protein, UL29 is a Individual_protein

571_task1

Sentence: We observed that four replication proteins, UL5, UL8 UL52, and UL9, are necessary for the localization of ICP8 (UL29) to prereplicative sites natural infection conditions. Instructions: please typing these entity words according to sentence: UL5, UL8, UL52, UL9, ICP8, UL29 Options: Individual_protein

[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

We observed that four replication proteins, UL5, UL8 UL52, and UL9, are necessary for the localization of ICP8 (UL29) to prereplicative sites natural infection conditions.

[ "We", "observed", "that", "four", "replication", "proteins", ",", "UL5", ",", "UL8", "UL52", ",", "and", "UL9", ",", "are", "necessary", "for", "the", "localization", "of", "ICP8", "(", "UL29", ")", "to", "prereplicative", "sites", "natural", "infection", "conditions", "." ]

[ "Individual_protein" ]

UL5, UL8, UL52, UL9, ICP8, UL29

571_task2

Sentence: We observed that four replication proteins, UL5, UL8 UL52, and UL9, are necessary for the localization of ICP8 (UL29) to prereplicative sites natural infection conditions. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "B-Individual_protein", "O", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "B-Individual_protein", "O", "B-Individual_protein", "O", "O", "O", "O", "O", "O", "O", "O" ]

We observed that four replication proteins, UL5, UL8 UL52, and UL9, are necessary for the localization of ICP8 (UL29) to prereplicative sites natural infection conditions.

[ "We", "observed", "that", "four", "replication", "proteins", ",", "UL5", ",", "UL8", "UL52", ",", "and", "UL9", ",", "are", "necessary", "for", "the", "localization", "of", "ICP8", "(", "UL29", ")", "to", "prereplicative", "sites", "natural", "infection", "conditions", "." ]

[ "Individual_protein" ]

Heparin - induzierten is an umlsterm, Thrombozytopenie is an umlsterm, Thrombozyten is an umlsterm, Heparin is an umlsterm, Komplikationen is an umlsterm, Inzidenz is an umlsterm, Heparin is an umlsterm, Patienten is an umlsterm, Amputation is an umlsterm, Extremitaet is an umlsterm, Myokardinfarkt is an umlsterm, Schlaganfall is an umlsterm, Antigen is an umlsterm, Heparin is an umlsterm, Heparin is an umlsterm, Proteinen is an umlsterm, Antikoerper is an umlsterm, Fc - Rezeptor is an umlsterm, Thrombozytenaktivierung is an umlsterm, Thrombozytenaktivierung is an umlsterm, Endotheloberflaeche is an umlsterm, Komplikationen is an umlsterm, Spezifitaet is an umlsterm, endothelstaendigen is an umlsterm, immunvermittelten is an umlsterm, Heparintherapie is an umlsterm, Thrombozytenabfall is an umlsterm, Venen is an umlsterm, Arterien is an umlsterm, Extremitaeten is an umlsterm, Koronargefaesse is an umlsterm, Diagnostik is an umlsterm, Heparin - induzierte is an umlsterm, Behandlung is an umlsterm, Injektion is an umlsterm, Risiko is an umlsterm, Kreuzallergie is an umlsterm, Thrombozytenzahl is an umlsterm, Thrombozytenzahl is an umlsterm, Heparin is an umlsterm, Heparintherapie is an umlsterm, Blutplaettchen is an umlsterm, Heparin - therapie is an umlsterm, Heparintherapie is an umlsterm, Heparintherapie is an umlsterm, Diagnose is an umlsterm, Patienten is an umlsterm, Notfallausweis is an umlsterm, Konzentrationen is an umlsterm, Heparin is an umlsterm

IntensiveMedizin.80350307.ger.abstr_task0

Sentence: Es werden zwei Formen einer Heparin-induzierten Thrombozytopenie ( HIT ) unterschieden , zum einen die durch direkte Interaktion der Thrombozyten mit Heparin bedingte klinisch inapparente HIT , Typ I , zum anderen die immunologisch bedingte , klinisch bedeutsame , mit thromboembolischen Komplikationen einhergehende HIT Typ II . Die Inzidenz der HIT Typ I betraeg ca. 25% . Die HIT Typ II tritt bei ca. 3% der laenger als 5 Tage mit Heparin behandelten Patienten auf . Es handelt sich um eine inten-sivmedizinische , interdisziplinaere Erkrankung mit einer Letalitaet von ca. 20% und weiteren 20% Defektheilungen ( Amputation einer Extremitaet , Myokardinfarkt , Schlaganfall ) . Als Antigen wirkt in der Mehrzahl der Faelle ein Komplex aus Heparin und Plaettchenfaktor 4 ( PF 4 ) , in seltenen Faellen ein Komplex aus Heparin und anderen Proteinen . Die Heparin-PF-4-Komplexe binden mehrere Antikoerper . Durch Bindung an den thrombozytaeren Fc-Rezeptor fuehren die so entstandenen Immunkomplexe zu einer Thrombozytenaktivierung mit nachfolgender PF-4-Ausschuettung. Das durch die immer wieder erneut stattfindende Thrombozytenaktivierung im Ueberschuss vorhandene PF 4 bindet an auf der Endotheloberflaeche befindliche Glucosaminoglykane . Ein wesentlicher pathophysiologischer Mechanismus fuer die Entstehung thromboembo-lischer Komplikationen ist die fehlende Spezifitaet der HIT-Antikoerper . Sie binden sich auch an Komplexe aus endothelstaendigen heparinaehn-lichen Substanzen ( Glucosaminglykane ) und PF 4. Dies fuehrt zu einer immunvermittelten Endothelver-letzung und bedingt ein erhoehtes Thromboserisiko . Die HIT Typ II tritt bei Erstexposition zwischen dem 6. und 20. Tag einer Heparintherapie , bei Reexposition unter Umstaenden innerhalb weniger Stunden auf . Es findet ein Thrombozytenabfall bis auf unter 100 000/µl statt . Typisch sind venoese und/oder arterielle Thromboembolien , vor allem der grossen Venen und Arterien der Extremitaeten , der zerebralen Versorgung und der Koronargefaesse . Fuer die Diagnostik ist neben der typischen Klinik der Nachweis von HIT-Typ-II-Antikoerpern wichtig . Bewaehrt haben sich der Heparin-induzierte Plaettchen-Aktivierungs- ( Hipa- ) Test und der Immunassay nach Amiral et al. ( PF 4/Heparin-ELISA). Das fuer die Behandlung der HIT Typ II neu zugelassene Lepirudin ( Refludan ) weist bei guter Steuerbarkeit ueber die aktivierte partielle Thrombo-plastinzeit ( aPTT ) und sofortigem Wirkungseintritt nach der Injektion kein Risiko einer Kreuzallergie auf . Von besonderer Bedeutung in der Prophylaxe einer HIT Typ II sind regelmaessige Kontrollen der Thrombozytenzahl . So sollte die Thrombozytenzahl bei Erstexposition gegen-ueber Heparin vor und ab dem 5. Tag einer Heparintherapie taeglich einmal kontrolliert werden . Bei Reexposi-tion sollten die Blutplaettchen ebenfalls vor Einleitung der Heparin-therapie , dann aber bereits ab dem 2. Tag , taeglich kontrolliert werden . Unerlaesslich ist es , auf jede ueberfluessige Heparintherapie zu verzichten , eine indizierte Heparintherapie moeglichst auf 5 Tage zu begrenzen , z.B. durch fruehzeitige Einleitung einer oralen Antikoagulation mit Phen-procoumon ( Marcumar ) . Nach Diagnose einer HIT Typ II sollte fuer die betroffenen Patienten ein Notfallausweis ausgestellt werden . Diese Pa-tienten sollten ebenfalls keine Antithrombin-III- oder Prothrombinpraeparate erhalten , da diesen in zum Teil hohen Konzentrationen Heparin zugesetzt ist . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O" ]

Es werden zwei Formen einer Heparin-induzierten Thrombozytopenie ( HIT ) unterschieden , zum einen die durch direkte Interaktion der Thrombozyten mit Heparin bedingte klinisch inapparente HIT , Typ I , zum anderen die immunologisch bedingte , klinisch bedeutsame , mit thromboembolischen Komplikationen einhergehende HIT Typ II . Die Inzidenz der HIT Typ I betraeg ca. 25% . Die HIT Typ II tritt bei ca. 3% der laenger als 5 Tage mit Heparin behandelten Patienten auf . Es handelt sich um eine inten-sivmedizinische , interdisziplinaere Erkrankung mit einer Letalitaet von ca. 20% und weiteren 20% Defektheilungen ( Amputation einer Extremitaet , Myokardinfarkt , Schlaganfall ) . Als Antigen wirkt in der Mehrzahl der Faelle ein Komplex aus Heparin und Plaettchenfaktor 4 ( PF 4 ) , in seltenen Faellen ein Komplex aus Heparin und anderen Proteinen . Die Heparin-PF-4-Komplexe binden mehrere Antikoerper . Durch Bindung an den thrombozytaeren Fc-Rezeptor fuehren die so entstandenen Immunkomplexe zu einer Thrombozytenaktivierung mit nachfolgender PF-4-Ausschuettung. Das durch die immer wieder erneut stattfindende Thrombozytenaktivierung im Ueberschuss vorhandene PF 4 bindet an auf der Endotheloberflaeche befindliche Glucosaminoglykane . Ein wesentlicher pathophysiologischer Mechanismus fuer die Entstehung thromboembo-lischer Komplikationen ist die fehlende Spezifitaet der HIT-Antikoerper . Sie binden sich auch an Komplexe aus endothelstaendigen heparinaehn-lichen Substanzen ( Glucosaminglykane ) und PF 4. Dies fuehrt zu einer immunvermittelten Endothelver-letzung und bedingt ein erhoehtes Thromboserisiko . Die HIT Typ II tritt bei Erstexposition zwischen dem 6. und 20. Tag einer Heparintherapie , bei Reexposition unter Umstaenden innerhalb weniger Stunden auf . Es findet ein Thrombozytenabfall bis auf unter 100 000/µl statt . Typisch sind venoese und/oder arterielle Thromboembolien , vor allem der grossen Venen und Arterien der Extremitaeten , der zerebralen Versorgung und der Koronargefaesse . Fuer die Diagnostik ist neben der typischen Klinik der Nachweis von HIT-Typ-II-Antikoerpern wichtig . Bewaehrt haben sich der Heparin-induzierte Plaettchen-Aktivierungs- ( Hipa- ) Test und der Immunassay nach Amiral et al. ( PF 4/Heparin-ELISA). Das fuer die Behandlung der HIT Typ II neu zugelassene Lepirudin ( Refludan ) weist bei guter Steuerbarkeit ueber die aktivierte partielle Thrombo-plastinzeit ( aPTT ) und sofortigem Wirkungseintritt nach der Injektion kein Risiko einer Kreuzallergie auf . Von besonderer Bedeutung in der Prophylaxe einer HIT Typ II sind regelmaessige Kontrollen der Thrombozytenzahl . So sollte die Thrombozytenzahl bei Erstexposition gegen-ueber Heparin vor und ab dem 5. Tag einer Heparintherapie taeglich einmal kontrolliert werden . Bei Reexposi-tion sollten die Blutplaettchen ebenfalls vor Einleitung der Heparin-therapie , dann aber bereits ab dem 2. Tag , taeglich kontrolliert werden . Unerlaesslich ist es , auf jede ueberfluessige Heparintherapie zu verzichten , eine indizierte Heparintherapie moeglichst auf 5 Tage zu begrenzen , z.B. durch fruehzeitige Einleitung einer oralen Antikoagulation mit Phen-procoumon ( Marcumar ) . Nach Diagnose einer HIT Typ II sollte fuer die betroffenen Patienten ein Notfallausweis ausgestellt werden . Diese Pa-tienten sollten ebenfalls keine Antithrombin-III- oder Prothrombinpraeparate erhalten , da diesen in zum Teil hohen Konzentrationen Heparin zugesetzt ist .

[ "Es", "werden", "zwei", "Formen", "einer", "Heparin", "-", "induzierten", "Thrombozytopenie", "(", "HIT", ")", "unterschieden", ",", "zum", "einen", "die", "durch", "direkte", "Interaktion", "der", "Thrombozyten", "mit", "Heparin", "bedingte", "klinisch", "inapparente", "HIT", ",", "Typ", "I", ",", "zum", "anderen", "die", "immunologisch", "bedingte", ",", "klinisch", "bedeutsame", ",", "mit", "thromboembolischen", "Komplikationen", "einhergehende", "HIT", "Typ", "II", ".", "Die", "Inzidenz", "der", "HIT", "Typ", "I", "betraeg", "ca", ".", "25", "%", ".", "Die", "HIT", "Typ", "II", "tritt", "bei", "ca", ".", "3", "%", "der", "laenger", "als", "5", "Tage", "mit", "Heparin", "behandelten", "Patienten", "auf", ".", "Es", "handelt", "sich", "um", "eine", "inten", "-", "sivmedizinische", ",", "interdisziplinaere", "Erkrankung", "mit", "einer", "Letalitaet", "von", "ca", ".", "20", "%", "und", "weiteren", "20", "%", "Defektheilungen", "(", "Amputation", "einer", "Extremitaet", ",", "Myokardinfarkt", ",", "Schlaganfall", ")", ".", "Als", "Antigen", "wirkt", "in", "der", "Mehrzahl", "der", "Faelle", "ein", "Komplex", "aus", "Heparin", "und", "Plaettchenfaktor", "4", "(", "PF", "4", ")", ",", "in", "seltenen", "Faellen", "ein", "Komplex", "aus", "Heparin", "und", "anderen", "Proteinen", ".", "Die", "Heparin", "-", "PF-4-Komplexe", "binden", "mehrere", "Antikoerper", ".", "Durch", "Bindung", "an", "den", "thrombozytaeren", "Fc", "-", "Rezeptor", "fuehren", "die", "so", "entstandenen", "Immunkomplexe", "zu", "einer", "Thrombozytenaktivierung", "mit", "nachfolgender", "PF-4-Ausschuettung", ".", "Das", "durch", "die", "immer", "wieder", "erneut", "stattfindende", "Thrombozytenaktivierung", "im", "Ueberschuss", "vorhandene", "PF", "4", "bindet", "an", "auf", "der", "Endotheloberflaeche", "befindliche", "Glucosaminoglykane", ".", "Ein", "wesentlicher", "pathophysiologischer", "Mechanismus", "fuer", "die", "Entstehung", "thromboembo", "-", "lischer", "Komplikationen", "ist", "die", "fehlende", "Spezifitaet", "der", "HIT", "-", "Antikoerper", ".", "Sie", "binden", "sich", "auch", "an", "Komplexe", "aus", "endothelstaendigen", "heparinaehn", "-", "lichen", "Substanzen", "(", "Glucosaminglykane", ")", "und", "PF", "4", ".", "Dies", "fuehrt", "zu", "einer", "immunvermittelten", "Endothelver", "-", "letzung", "und", "bedingt", "ein", "erhoehtes", "Thromboserisiko", ".", "Die", "HIT", "Typ", "II", "tritt", "bei", "Erstexposition", "zwischen", "dem", "6", ".", "und", "20", ".", "Tag", "einer", "Heparintherapie", ",", "bei", "Reexposition", "unter", "Umstaenden", "innerhalb", "weniger", "Stunden", "auf", ".", "Es", "findet", "ein", "Thrombozytenabfall", "bis", "auf", "unter", "100", "000/µl", "statt", ".", "Typisch", "sind", "venoese", "und", "/", "oder", "arterielle", "Thromboembolien", ",", "vor", "allem", "der", "grossen", "Venen", "und", "Arterien", "der", "Extremitaeten", ",", "der", "zerebralen", "Versorgung", "und", "der", "Koronargefaesse", ".", "Fuer", "die", "Diagnostik", "ist", "neben", "der", "typischen", "Klinik", "der", "Nachweis", "von", "HIT", "-", "Typ", "-", "II", "-", "Antikoerpern", "wichtig", ".", "Bewaehrt", "haben", "sich", "der", "Heparin", "-", "induzierte", "Plaettchen", "-", "Aktivierungs-", "(", "Hipa-", ")", "Test", "und", "der", "Immunassay", "nach", "Amiral", "et", "al", ".", "(", "PF", "4", "/", "Heparin", "-", "ELISA", ")", ".", "Das", "fuer", "die", "Behandlung", "der", "HIT", "Typ", "II", "neu", "zugelassene", "Lepirudin", "(", "Refludan", ")", "weist", "bei", "guter", "Steuerbarkeit", "ueber", "die", "aktivierte", "partielle", "Thrombo", "-", "plastinzeit", "(", "aPTT", ")", "und", "sofortigem", "Wirkungseintritt", "nach", "der", "Injektion", "kein", "Risiko", "einer", "Kreuzallergie", "auf", ".", "Von", "besonderer", "Bedeutung", "in", "der", "Prophylaxe", "einer", "HIT", "Typ", "II", "sind", "regelmaessige", "Kontrollen", "der", "Thrombozytenzahl", ".", "So", "sollte", "die", "Thrombozytenzahl", "bei", "Erstexposition", "gegen", "-", "ueber", "Heparin", "vor", "und", "ab", "dem", "5", ".", "Tag", "einer", "Heparintherapie", "taeglich", "einmal", "kontrolliert", "werden", ".", "Bei", "Reexposi", "-", "tion", "sollten", "die", "Blutplaettchen", "ebenfalls", "vor", "Einleitung", "der", "Heparin", "-", "therapie", ",", "dann", "aber", "bereits", "ab", "dem", "2", ".", "Tag", ",", "taeglich", "kontrolliert", "werden", ".", "Unerlaesslich", "ist", "es", ",", "auf", "jede", "ueberfluessige", "Heparintherapie", "zu", "verzichten", ",", "eine", "indizierte", "Heparintherapie", "moeglichst", "auf", "5", "Tage", "zu", "begrenzen", ",", "z.", "B.", "durch", "fruehzeitige", "Einleitung", "einer", "oralen", "Antikoagulation", "mit", "Phen", "-", "procoumon", "(", "Marcumar", ")", ".", "Nach", "Diagnose", "einer", "HIT", "Typ", "II", "sollte", "fuer", "die", "betroffenen", "Patienten", "ein", "Notfallausweis", "ausgestellt", "werden", ".", "Diese", "Pa", "-", "tienten", "sollten", "ebenfalls", "keine", "Antithrombin", "-", "III-", "oder", "Prothrombinpraeparate", "erhalten", ",", "da", "diesen", "in", "zum", "Teil", "hohen", "Konzentrationen", "Heparin", "zugesetzt", "ist", "." ]

[ "umlsterm" ]

Heparin - induzierten is an umlsterm, Thrombozytopenie is an umlsterm, Thrombozyten is an umlsterm, Heparin is an umlsterm, Komplikationen is an umlsterm, Inzidenz is an umlsterm, Heparin is an umlsterm, Patienten is an umlsterm, Amputation is an umlsterm, Extremitaet is an umlsterm, Myokardinfarkt is an umlsterm, Schlaganfall is an umlsterm, Antigen is an umlsterm, Heparin is an umlsterm, Heparin is an umlsterm, Proteinen is an umlsterm, Antikoerper is an umlsterm, Fc - Rezeptor is an umlsterm, Thrombozytenaktivierung is an umlsterm, Thrombozytenaktivierung is an umlsterm, Endotheloberflaeche is an umlsterm, Komplikationen is an umlsterm, Spezifitaet is an umlsterm, endothelstaendigen is an umlsterm, immunvermittelten is an umlsterm, Heparintherapie is an umlsterm, Thrombozytenabfall is an umlsterm, Venen is an umlsterm, Arterien is an umlsterm, Extremitaeten is an umlsterm, Koronargefaesse is an umlsterm, Diagnostik is an umlsterm, Heparin - induzierte is an umlsterm, Behandlung is an umlsterm, Injektion is an umlsterm, Risiko is an umlsterm, Kreuzallergie is an umlsterm, Thrombozytenzahl is an umlsterm, Thrombozytenzahl is an umlsterm, Heparin is an umlsterm, Heparintherapie is an umlsterm, Blutplaettchen is an umlsterm, Heparin - therapie is an umlsterm, Heparintherapie is an umlsterm, Heparintherapie is an umlsterm, Diagnose is an umlsterm, Patienten is an umlsterm, Notfallausweis is an umlsterm, Konzentrationen is an umlsterm, Heparin is an umlsterm

IntensiveMedizin.80350307.ger.abstr_task1

Sentence: Es werden zwei Formen einer Heparin-induzierten Thrombozytopenie ( HIT ) unterschieden , zum einen die durch direkte Interaktion der Thrombozyten mit Heparin bedingte klinisch inapparente HIT , Typ I , zum anderen die immunologisch bedingte , klinisch bedeutsame , mit thromboembolischen Komplikationen einhergehende HIT Typ II . Die Inzidenz der HIT Typ I betraeg ca. 25% . Die HIT Typ II tritt bei ca. 3% der laenger als 5 Tage mit Heparin behandelten Patienten auf . Es handelt sich um eine inten-sivmedizinische , interdisziplinaere Erkrankung mit einer Letalitaet von ca. 20% und weiteren 20% Defektheilungen ( Amputation einer Extremitaet , Myokardinfarkt , Schlaganfall ) . Als Antigen wirkt in der Mehrzahl der Faelle ein Komplex aus Heparin und Plaettchenfaktor 4 ( PF 4 ) , in seltenen Faellen ein Komplex aus Heparin und anderen Proteinen . Die Heparin-PF-4-Komplexe binden mehrere Antikoerper . Durch Bindung an den thrombozytaeren Fc-Rezeptor fuehren die so entstandenen Immunkomplexe zu einer Thrombozytenaktivierung mit nachfolgender PF-4-Ausschuettung. Das durch die immer wieder erneut stattfindende Thrombozytenaktivierung im Ueberschuss vorhandene PF 4 bindet an auf der Endotheloberflaeche befindliche Glucosaminoglykane . Ein wesentlicher pathophysiologischer Mechanismus fuer die Entstehung thromboembo-lischer Komplikationen ist die fehlende Spezifitaet der HIT-Antikoerper . Sie binden sich auch an Komplexe aus endothelstaendigen heparinaehn-lichen Substanzen ( Glucosaminglykane ) und PF 4. Dies fuehrt zu einer immunvermittelten Endothelver-letzung und bedingt ein erhoehtes Thromboserisiko . Die HIT Typ II tritt bei Erstexposition zwischen dem 6. und 20. Tag einer Heparintherapie , bei Reexposition unter Umstaenden innerhalb weniger Stunden auf . Es findet ein Thrombozytenabfall bis auf unter 100 000/µl statt . Typisch sind venoese und/oder arterielle Thromboembolien , vor allem der grossen Venen und Arterien der Extremitaeten , der zerebralen Versorgung und der Koronargefaesse . Fuer die Diagnostik ist neben der typischen Klinik der Nachweis von HIT-Typ-II-Antikoerpern wichtig . Bewaehrt haben sich der Heparin-induzierte Plaettchen-Aktivierungs- ( Hipa- ) Test und der Immunassay nach Amiral et al. ( PF 4/Heparin-ELISA). Das fuer die Behandlung der HIT Typ II neu zugelassene Lepirudin ( Refludan ) weist bei guter Steuerbarkeit ueber die aktivierte partielle Thrombo-plastinzeit ( aPTT ) und sofortigem Wirkungseintritt nach der Injektion kein Risiko einer Kreuzallergie auf . Von besonderer Bedeutung in der Prophylaxe einer HIT Typ II sind regelmaessige Kontrollen der Thrombozytenzahl . So sollte die Thrombozytenzahl bei Erstexposition gegen-ueber Heparin vor und ab dem 5. Tag einer Heparintherapie taeglich einmal kontrolliert werden . Bei Reexposi-tion sollten die Blutplaettchen ebenfalls vor Einleitung der Heparin-therapie , dann aber bereits ab dem 2. Tag , taeglich kontrolliert werden . Unerlaesslich ist es , auf jede ueberfluessige Heparintherapie zu verzichten , eine indizierte Heparintherapie moeglichst auf 5 Tage zu begrenzen , z.B. durch fruehzeitige Einleitung einer oralen Antikoagulation mit Phen-procoumon ( Marcumar ) . Nach Diagnose einer HIT Typ II sollte fuer die betroffenen Patienten ein Notfallausweis ausgestellt werden . Diese Pa-tienten sollten ebenfalls keine Antithrombin-III- oder Prothrombinpraeparate erhalten , da diesen in zum Teil hohen Konzentrationen Heparin zugesetzt ist . Instructions: please typing these entity words according to sentence: Heparin - induzierten, Thrombozytopenie, Thrombozyten, Heparin, Komplikationen, Inzidenz, Heparin, Patienten, Amputation, Extremitaet, Myokardinfarkt, Schlaganfall, Antigen, Heparin, Heparin, Proteinen, Antikoerper, Fc - Rezeptor, Thrombozytenaktivierung, Thrombozytenaktivierung, Endotheloberflaeche, Komplikationen, Spezifitaet, endothelstaendigen, immunvermittelten, Heparintherapie, Thrombozytenabfall, Venen, Arterien, Extremitaeten, Koronargefaesse, Diagnostik, Heparin - induzierte, Behandlung, Injektion, Risiko, Kreuzallergie, Thrombozytenzahl, Thrombozytenzahl, Heparin, Heparintherapie, Blutplaettchen, Heparin - therapie, Heparintherapie, Heparintherapie, Diagnose, Patienten, Notfallausweis, Konzentrationen, Heparin Options: umlsterm

[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O" ]

Es werden zwei Formen einer Heparin-induzierten Thrombozytopenie ( HIT ) unterschieden , zum einen die durch direkte Interaktion der Thrombozyten mit Heparin bedingte klinisch inapparente HIT , Typ I , zum anderen die immunologisch bedingte , klinisch bedeutsame , mit thromboembolischen Komplikationen einhergehende HIT Typ II . Die Inzidenz der HIT Typ I betraeg ca. 25% . Die HIT Typ II tritt bei ca. 3% der laenger als 5 Tage mit Heparin behandelten Patienten auf . Es handelt sich um eine inten-sivmedizinische , interdisziplinaere Erkrankung mit einer Letalitaet von ca. 20% und weiteren 20% Defektheilungen ( Amputation einer Extremitaet , Myokardinfarkt , Schlaganfall ) . Als Antigen wirkt in der Mehrzahl der Faelle ein Komplex aus Heparin und Plaettchenfaktor 4 ( PF 4 ) , in seltenen Faellen ein Komplex aus Heparin und anderen Proteinen . Die Heparin-PF-4-Komplexe binden mehrere Antikoerper . Durch Bindung an den thrombozytaeren Fc-Rezeptor fuehren die so entstandenen Immunkomplexe zu einer Thrombozytenaktivierung mit nachfolgender PF-4-Ausschuettung. Das durch die immer wieder erneut stattfindende Thrombozytenaktivierung im Ueberschuss vorhandene PF 4 bindet an auf der Endotheloberflaeche befindliche Glucosaminoglykane . Ein wesentlicher pathophysiologischer Mechanismus fuer die Entstehung thromboembo-lischer Komplikationen ist die fehlende Spezifitaet der HIT-Antikoerper . Sie binden sich auch an Komplexe aus endothelstaendigen heparinaehn-lichen Substanzen ( Glucosaminglykane ) und PF 4. Dies fuehrt zu einer immunvermittelten Endothelver-letzung und bedingt ein erhoehtes Thromboserisiko . Die HIT Typ II tritt bei Erstexposition zwischen dem 6. und 20. Tag einer Heparintherapie , bei Reexposition unter Umstaenden innerhalb weniger Stunden auf . Es findet ein Thrombozytenabfall bis auf unter 100 000/µl statt . Typisch sind venoese und/oder arterielle Thromboembolien , vor allem der grossen Venen und Arterien der Extremitaeten , der zerebralen Versorgung und der Koronargefaesse . Fuer die Diagnostik ist neben der typischen Klinik der Nachweis von HIT-Typ-II-Antikoerpern wichtig . Bewaehrt haben sich der Heparin-induzierte Plaettchen-Aktivierungs- ( Hipa- ) Test und der Immunassay nach Amiral et al. ( PF 4/Heparin-ELISA). Das fuer die Behandlung der HIT Typ II neu zugelassene Lepirudin ( Refludan ) weist bei guter Steuerbarkeit ueber die aktivierte partielle Thrombo-plastinzeit ( aPTT ) und sofortigem Wirkungseintritt nach der Injektion kein Risiko einer Kreuzallergie auf . Von besonderer Bedeutung in der Prophylaxe einer HIT Typ II sind regelmaessige Kontrollen der Thrombozytenzahl . So sollte die Thrombozytenzahl bei Erstexposition gegen-ueber Heparin vor und ab dem 5. Tag einer Heparintherapie taeglich einmal kontrolliert werden . Bei Reexposi-tion sollten die Blutplaettchen ebenfalls vor Einleitung der Heparin-therapie , dann aber bereits ab dem 2. Tag , taeglich kontrolliert werden . Unerlaesslich ist es , auf jede ueberfluessige Heparintherapie zu verzichten , eine indizierte Heparintherapie moeglichst auf 5 Tage zu begrenzen , z.B. durch fruehzeitige Einleitung einer oralen Antikoagulation mit Phen-procoumon ( Marcumar ) . Nach Diagnose einer HIT Typ II sollte fuer die betroffenen Patienten ein Notfallausweis ausgestellt werden . Diese Pa-tienten sollten ebenfalls keine Antithrombin-III- oder Prothrombinpraeparate erhalten , da diesen in zum Teil hohen Konzentrationen Heparin zugesetzt ist .

[ "Es", "werden", "zwei", "Formen", "einer", "Heparin", "-", "induzierten", "Thrombozytopenie", "(", "HIT", ")", "unterschieden", ",", "zum", "einen", "die", "durch", "direkte", "Interaktion", "der", "Thrombozyten", "mit", "Heparin", "bedingte", "klinisch", "inapparente", "HIT", ",", "Typ", "I", ",", "zum", "anderen", "die", "immunologisch", "bedingte", ",", "klinisch", "bedeutsame", ",", "mit", "thromboembolischen", "Komplikationen", "einhergehende", "HIT", "Typ", "II", ".", "Die", "Inzidenz", "der", "HIT", "Typ", "I", "betraeg", "ca", ".", "25", "%", ".", "Die", "HIT", "Typ", "II", "tritt", "bei", "ca", ".", "3", "%", "der", "laenger", "als", "5", "Tage", "mit", "Heparin", "behandelten", "Patienten", "auf", ".", "Es", "handelt", "sich", "um", "eine", "inten", "-", "sivmedizinische", ",", "interdisziplinaere", "Erkrankung", "mit", "einer", "Letalitaet", "von", "ca", ".", "20", "%", "und", "weiteren", "20", "%", "Defektheilungen", "(", "Amputation", "einer", "Extremitaet", ",", "Myokardinfarkt", ",", "Schlaganfall", ")", ".", "Als", "Antigen", "wirkt", "in", "der", "Mehrzahl", "der", "Faelle", "ein", "Komplex", "aus", "Heparin", "und", "Plaettchenfaktor", "4", "(", "PF", "4", ")", ",", "in", "seltenen", "Faellen", "ein", "Komplex", "aus", "Heparin", "und", "anderen", "Proteinen", ".", "Die", "Heparin", "-", "PF-4-Komplexe", "binden", "mehrere", "Antikoerper", ".", "Durch", "Bindung", "an", "den", "thrombozytaeren", "Fc", "-", "Rezeptor", "fuehren", "die", "so", "entstandenen", "Immunkomplexe", "zu", "einer", "Thrombozytenaktivierung", "mit", "nachfolgender", "PF-4-Ausschuettung", ".", "Das", "durch", "die", "immer", "wieder", "erneut", "stattfindende", "Thrombozytenaktivierung", "im", "Ueberschuss", "vorhandene", "PF", "4", "bindet", "an", "auf", "der", "Endotheloberflaeche", "befindliche", "Glucosaminoglykane", ".", "Ein", "wesentlicher", "pathophysiologischer", "Mechanismus", "fuer", "die", "Entstehung", "thromboembo", "-", "lischer", "Komplikationen", "ist", "die", "fehlende", "Spezifitaet", "der", "HIT", "-", "Antikoerper", ".", "Sie", "binden", "sich", "auch", "an", "Komplexe", "aus", "endothelstaendigen", "heparinaehn", "-", "lichen", "Substanzen", "(", "Glucosaminglykane", ")", "und", "PF", "4", ".", "Dies", "fuehrt", "zu", "einer", "immunvermittelten", "Endothelver", "-", "letzung", "und", "bedingt", "ein", "erhoehtes", "Thromboserisiko", ".", "Die", "HIT", "Typ", "II", "tritt", "bei", "Erstexposition", "zwischen", "dem", "6", ".", "und", "20", ".", "Tag", "einer", "Heparintherapie", ",", "bei", "Reexposition", "unter", "Umstaenden", "innerhalb", "weniger", "Stunden", "auf", ".", "Es", "findet", "ein", "Thrombozytenabfall", "bis", "auf", "unter", "100", "000/µl", "statt", ".", "Typisch", "sind", "venoese", "und", "/", "oder", "arterielle", "Thromboembolien", ",", "vor", "allem", "der", "grossen", "Venen", "und", "Arterien", "der", "Extremitaeten", ",", "der", "zerebralen", "Versorgung", "und", "der", "Koronargefaesse", ".", "Fuer", "die", "Diagnostik", "ist", "neben", "der", "typischen", "Klinik", "der", "Nachweis", "von", "HIT", "-", "Typ", "-", "II", "-", "Antikoerpern", "wichtig", ".", "Bewaehrt", "haben", "sich", "der", "Heparin", "-", "induzierte", "Plaettchen", "-", "Aktivierungs-", "(", "Hipa-", ")", "Test", "und", "der", "Immunassay", "nach", "Amiral", "et", "al", ".", "(", "PF", "4", "/", "Heparin", "-", "ELISA", ")", ".", "Das", "fuer", "die", "Behandlung", "der", "HIT", "Typ", "II", "neu", "zugelassene", "Lepirudin", "(", "Refludan", ")", "weist", "bei", "guter", "Steuerbarkeit", "ueber", "die", "aktivierte", "partielle", "Thrombo", "-", "plastinzeit", "(", "aPTT", ")", "und", "sofortigem", "Wirkungseintritt", "nach", "der", "Injektion", "kein", "Risiko", "einer", "Kreuzallergie", "auf", ".", "Von", "besonderer", "Bedeutung", "in", "der", "Prophylaxe", "einer", "HIT", "Typ", "II", "sind", "regelmaessige", "Kontrollen", "der", "Thrombozytenzahl", ".", "So", "sollte", "die", "Thrombozytenzahl", "bei", "Erstexposition", "gegen", "-", "ueber", "Heparin", "vor", "und", "ab", "dem", "5", ".", "Tag", "einer", "Heparintherapie", "taeglich", "einmal", "kontrolliert", "werden", ".", "Bei", "Reexposi", "-", "tion", "sollten", "die", "Blutplaettchen", "ebenfalls", "vor", "Einleitung", "der", "Heparin", "-", "therapie", ",", "dann", "aber", "bereits", "ab", "dem", "2", ".", "Tag", ",", "taeglich", "kontrolliert", "werden", ".", "Unerlaesslich", "ist", "es", ",", "auf", "jede", "ueberfluessige", "Heparintherapie", "zu", "verzichten", ",", "eine", "indizierte", "Heparintherapie", "moeglichst", "auf", "5", "Tage", "zu", "begrenzen", ",", "z.", "B.", "durch", "fruehzeitige", "Einleitung", "einer", "oralen", "Antikoagulation", "mit", "Phen", "-", "procoumon", "(", "Marcumar", ")", ".", "Nach", "Diagnose", "einer", "HIT", "Typ", "II", "sollte", "fuer", "die", "betroffenen", "Patienten", "ein", "Notfallausweis", "ausgestellt", "werden", ".", "Diese", "Pa", "-", "tienten", "sollten", "ebenfalls", "keine", "Antithrombin", "-", "III-", "oder", "Prothrombinpraeparate", "erhalten", ",", "da", "diesen", "in", "zum", "Teil", "hohen", "Konzentrationen", "Heparin", "zugesetzt", "ist", "." ]

[ "umlsterm" ]

Heparin - induzierten, Thrombozytopenie, Thrombozyten, Heparin, Komplikationen, Inzidenz, Heparin, Patienten, Amputation, Extremitaet, Myokardinfarkt, Schlaganfall, Antigen, Heparin, Heparin, Proteinen, Antikoerper, Fc - Rezeptor, Thrombozytenaktivierung, Thrombozytenaktivierung, Endotheloberflaeche, Komplikationen, Spezifitaet, endothelstaendigen, immunvermittelten, Heparintherapie, Thrombozytenabfall, Venen, Arterien, Extremitaeten, Koronargefaesse, Diagnostik, Heparin - induzierte, Behandlung, Injektion, Risiko, Kreuzallergie, Thrombozytenzahl, Thrombozytenzahl, Heparin, Heparintherapie, Blutplaettchen, Heparin - therapie, Heparintherapie, Heparintherapie, Diagnose, Patienten, Notfallausweis, Konzentrationen, Heparin

IntensiveMedizin.80350307.ger.abstr_task2

Sentence: Es werden zwei Formen einer Heparin-induzierten Thrombozytopenie ( HIT ) unterschieden , zum einen die durch direkte Interaktion der Thrombozyten mit Heparin bedingte klinisch inapparente HIT , Typ I , zum anderen die immunologisch bedingte , klinisch bedeutsame , mit thromboembolischen Komplikationen einhergehende HIT Typ II . Die Inzidenz der HIT Typ I betraeg ca. 25% . Die HIT Typ II tritt bei ca. 3% der laenger als 5 Tage mit Heparin behandelten Patienten auf . Es handelt sich um eine inten-sivmedizinische , interdisziplinaere Erkrankung mit einer Letalitaet von ca. 20% und weiteren 20% Defektheilungen ( Amputation einer Extremitaet , Myokardinfarkt , Schlaganfall ) . Als Antigen wirkt in der Mehrzahl der Faelle ein Komplex aus Heparin und Plaettchenfaktor 4 ( PF 4 ) , in seltenen Faellen ein Komplex aus Heparin und anderen Proteinen . Die Heparin-PF-4-Komplexe binden mehrere Antikoerper . Durch Bindung an den thrombozytaeren Fc-Rezeptor fuehren die so entstandenen Immunkomplexe zu einer Thrombozytenaktivierung mit nachfolgender PF-4-Ausschuettung. Das durch die immer wieder erneut stattfindende Thrombozytenaktivierung im Ueberschuss vorhandene PF 4 bindet an auf der Endotheloberflaeche befindliche Glucosaminoglykane . Ein wesentlicher pathophysiologischer Mechanismus fuer die Entstehung thromboembo-lischer Komplikationen ist die fehlende Spezifitaet der HIT-Antikoerper . Sie binden sich auch an Komplexe aus endothelstaendigen heparinaehn-lichen Substanzen ( Glucosaminglykane ) und PF 4. Dies fuehrt zu einer immunvermittelten Endothelver-letzung und bedingt ein erhoehtes Thromboserisiko . Die HIT Typ II tritt bei Erstexposition zwischen dem 6. und 20. Tag einer Heparintherapie , bei Reexposition unter Umstaenden innerhalb weniger Stunden auf . Es findet ein Thrombozytenabfall bis auf unter 100 000/µl statt . Typisch sind venoese und/oder arterielle Thromboembolien , vor allem der grossen Venen und Arterien der Extremitaeten , der zerebralen Versorgung und der Koronargefaesse . Fuer die Diagnostik ist neben der typischen Klinik der Nachweis von HIT-Typ-II-Antikoerpern wichtig . Bewaehrt haben sich der Heparin-induzierte Plaettchen-Aktivierungs- ( Hipa- ) Test und der Immunassay nach Amiral et al. ( PF 4/Heparin-ELISA). Das fuer die Behandlung der HIT Typ II neu zugelassene Lepirudin ( Refludan ) weist bei guter Steuerbarkeit ueber die aktivierte partielle Thrombo-plastinzeit ( aPTT ) und sofortigem Wirkungseintritt nach der Injektion kein Risiko einer Kreuzallergie auf . Von besonderer Bedeutung in der Prophylaxe einer HIT Typ II sind regelmaessige Kontrollen der Thrombozytenzahl . So sollte die Thrombozytenzahl bei Erstexposition gegen-ueber Heparin vor und ab dem 5. Tag einer Heparintherapie taeglich einmal kontrolliert werden . Bei Reexposi-tion sollten die Blutplaettchen ebenfalls vor Einleitung der Heparin-therapie , dann aber bereits ab dem 2. Tag , taeglich kontrolliert werden . Unerlaesslich ist es , auf jede ueberfluessige Heparintherapie zu verzichten , eine indizierte Heparintherapie moeglichst auf 5 Tage zu begrenzen , z.B. durch fruehzeitige Einleitung einer oralen Antikoagulation mit Phen-procoumon ( Marcumar ) . Nach Diagnose einer HIT Typ II sollte fuer die betroffenen Patienten ein Notfallausweis ausgestellt werden . Diese Pa-tienten sollten ebenfalls keine Antithrombin-III- oder Prothrombinpraeparate erhalten , da diesen in zum Teil hohen Konzentrationen Heparin zugesetzt ist . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O" ]

Es werden zwei Formen einer Heparin-induzierten Thrombozytopenie ( HIT ) unterschieden , zum einen die durch direkte Interaktion der Thrombozyten mit Heparin bedingte klinisch inapparente HIT , Typ I , zum anderen die immunologisch bedingte , klinisch bedeutsame , mit thromboembolischen Komplikationen einhergehende HIT Typ II . Die Inzidenz der HIT Typ I betraeg ca. 25% . Die HIT Typ II tritt bei ca. 3% der laenger als 5 Tage mit Heparin behandelten Patienten auf . Es handelt sich um eine inten-sivmedizinische , interdisziplinaere Erkrankung mit einer Letalitaet von ca. 20% und weiteren 20% Defektheilungen ( Amputation einer Extremitaet , Myokardinfarkt , Schlaganfall ) . Als Antigen wirkt in der Mehrzahl der Faelle ein Komplex aus Heparin und Plaettchenfaktor 4 ( PF 4 ) , in seltenen Faellen ein Komplex aus Heparin und anderen Proteinen . Die Heparin-PF-4-Komplexe binden mehrere Antikoerper . Durch Bindung an den thrombozytaeren Fc-Rezeptor fuehren die so entstandenen Immunkomplexe zu einer Thrombozytenaktivierung mit nachfolgender PF-4-Ausschuettung. Das durch die immer wieder erneut stattfindende Thrombozytenaktivierung im Ueberschuss vorhandene PF 4 bindet an auf der Endotheloberflaeche befindliche Glucosaminoglykane . Ein wesentlicher pathophysiologischer Mechanismus fuer die Entstehung thromboembo-lischer Komplikationen ist die fehlende Spezifitaet der HIT-Antikoerper . Sie binden sich auch an Komplexe aus endothelstaendigen heparinaehn-lichen Substanzen ( Glucosaminglykane ) und PF 4. Dies fuehrt zu einer immunvermittelten Endothelver-letzung und bedingt ein erhoehtes Thromboserisiko . Die HIT Typ II tritt bei Erstexposition zwischen dem 6. und 20. Tag einer Heparintherapie , bei Reexposition unter Umstaenden innerhalb weniger Stunden auf . Es findet ein Thrombozytenabfall bis auf unter 100 000/µl statt . Typisch sind venoese und/oder arterielle Thromboembolien , vor allem der grossen Venen und Arterien der Extremitaeten , der zerebralen Versorgung und der Koronargefaesse . Fuer die Diagnostik ist neben der typischen Klinik der Nachweis von HIT-Typ-II-Antikoerpern wichtig . Bewaehrt haben sich der Heparin-induzierte Plaettchen-Aktivierungs- ( Hipa- ) Test und der Immunassay nach Amiral et al. ( PF 4/Heparin-ELISA). Das fuer die Behandlung der HIT Typ II neu zugelassene Lepirudin ( Refludan ) weist bei guter Steuerbarkeit ueber die aktivierte partielle Thrombo-plastinzeit ( aPTT ) und sofortigem Wirkungseintritt nach der Injektion kein Risiko einer Kreuzallergie auf . Von besonderer Bedeutung in der Prophylaxe einer HIT Typ II sind regelmaessige Kontrollen der Thrombozytenzahl . So sollte die Thrombozytenzahl bei Erstexposition gegen-ueber Heparin vor und ab dem 5. Tag einer Heparintherapie taeglich einmal kontrolliert werden . Bei Reexposi-tion sollten die Blutplaettchen ebenfalls vor Einleitung der Heparin-therapie , dann aber bereits ab dem 2. Tag , taeglich kontrolliert werden . Unerlaesslich ist es , auf jede ueberfluessige Heparintherapie zu verzichten , eine indizierte Heparintherapie moeglichst auf 5 Tage zu begrenzen , z.B. durch fruehzeitige Einleitung einer oralen Antikoagulation mit Phen-procoumon ( Marcumar ) . Nach Diagnose einer HIT Typ II sollte fuer die betroffenen Patienten ein Notfallausweis ausgestellt werden . Diese Pa-tienten sollten ebenfalls keine Antithrombin-III- oder Prothrombinpraeparate erhalten , da diesen in zum Teil hohen Konzentrationen Heparin zugesetzt ist .

[ "Es", "werden", "zwei", "Formen", "einer", "Heparin", "-", "induzierten", "Thrombozytopenie", "(", "HIT", ")", "unterschieden", ",", "zum", "einen", "die", "durch", "direkte", "Interaktion", "der", "Thrombozyten", "mit", "Heparin", "bedingte", "klinisch", "inapparente", "HIT", ",", "Typ", "I", ",", "zum", "anderen", "die", "immunologisch", "bedingte", ",", "klinisch", "bedeutsame", ",", "mit", "thromboembolischen", "Komplikationen", "einhergehende", "HIT", "Typ", "II", ".", "Die", "Inzidenz", "der", "HIT", "Typ", "I", "betraeg", "ca", ".", "25", "%", ".", "Die", "HIT", "Typ", "II", "tritt", "bei", "ca", ".", "3", "%", "der", "laenger", "als", "5", "Tage", "mit", "Heparin", "behandelten", "Patienten", "auf", ".", "Es", "handelt", "sich", "um", "eine", "inten", "-", "sivmedizinische", ",", "interdisziplinaere", "Erkrankung", "mit", "einer", "Letalitaet", "von", "ca", ".", "20", "%", "und", "weiteren", "20", "%", "Defektheilungen", "(", "Amputation", "einer", "Extremitaet", ",", "Myokardinfarkt", ",", "Schlaganfall", ")", ".", "Als", "Antigen", "wirkt", "in", "der", "Mehrzahl", "der", "Faelle", "ein", "Komplex", "aus", "Heparin", "und", "Plaettchenfaktor", "4", "(", "PF", "4", ")", ",", "in", "seltenen", "Faellen", "ein", "Komplex", "aus", "Heparin", "und", "anderen", "Proteinen", ".", "Die", "Heparin", "-", "PF-4-Komplexe", "binden", "mehrere", "Antikoerper", ".", "Durch", "Bindung", "an", "den", "thrombozytaeren", "Fc", "-", "Rezeptor", "fuehren", "die", "so", "entstandenen", "Immunkomplexe", "zu", "einer", "Thrombozytenaktivierung", "mit", "nachfolgender", "PF-4-Ausschuettung", ".", "Das", "durch", "die", "immer", "wieder", "erneut", "stattfindende", "Thrombozytenaktivierung", "im", "Ueberschuss", "vorhandene", "PF", "4", "bindet", "an", "auf", "der", "Endotheloberflaeche", "befindliche", "Glucosaminoglykane", ".", "Ein", "wesentlicher", "pathophysiologischer", "Mechanismus", "fuer", "die", "Entstehung", "thromboembo", "-", "lischer", "Komplikationen", "ist", "die", "fehlende", "Spezifitaet", "der", "HIT", "-", "Antikoerper", ".", "Sie", "binden", "sich", "auch", "an", "Komplexe", "aus", "endothelstaendigen", "heparinaehn", "-", "lichen", "Substanzen", "(", "Glucosaminglykane", ")", "und", "PF", "4", ".", "Dies", "fuehrt", "zu", "einer", "immunvermittelten", "Endothelver", "-", "letzung", "und", "bedingt", "ein", "erhoehtes", "Thromboserisiko", ".", "Die", "HIT", "Typ", "II", "tritt", "bei", "Erstexposition", "zwischen", "dem", "6", ".", "und", "20", ".", "Tag", "einer", "Heparintherapie", ",", "bei", "Reexposition", "unter", "Umstaenden", "innerhalb", "weniger", "Stunden", "auf", ".", "Es", "findet", "ein", "Thrombozytenabfall", "bis", "auf", "unter", "100", "000/µl", "statt", ".", "Typisch", "sind", "venoese", "und", "/", "oder", "arterielle", "Thromboembolien", ",", "vor", "allem", "der", "grossen", "Venen", "und", "Arterien", "der", "Extremitaeten", ",", "der", "zerebralen", "Versorgung", "und", "der", "Koronargefaesse", ".", "Fuer", "die", "Diagnostik", "ist", "neben", "der", "typischen", "Klinik", "der", "Nachweis", "von", "HIT", "-", "Typ", "-", "II", "-", "Antikoerpern", "wichtig", ".", "Bewaehrt", "haben", "sich", "der", "Heparin", "-", "induzierte", "Plaettchen", "-", "Aktivierungs-", "(", "Hipa-", ")", "Test", "und", "der", "Immunassay", "nach", "Amiral", "et", "al", ".", "(", "PF", "4", "/", "Heparin", "-", "ELISA", ")", ".", "Das", "fuer", "die", "Behandlung", "der", "HIT", "Typ", "II", "neu", "zugelassene", "Lepirudin", "(", "Refludan", ")", "weist", "bei", "guter", "Steuerbarkeit", "ueber", "die", "aktivierte", "partielle", "Thrombo", "-", "plastinzeit", "(", "aPTT", ")", "und", "sofortigem", "Wirkungseintritt", "nach", "der", "Injektion", "kein", "Risiko", "einer", "Kreuzallergie", "auf", ".", "Von", "besonderer", "Bedeutung", "in", "der", "Prophylaxe", "einer", "HIT", "Typ", "II", "sind", "regelmaessige", "Kontrollen", "der", "Thrombozytenzahl", ".", "So", "sollte", "die", "Thrombozytenzahl", "bei", "Erstexposition", "gegen", "-", "ueber", "Heparin", "vor", "und", "ab", "dem", "5", ".", "Tag", "einer", "Heparintherapie", "taeglich", "einmal", "kontrolliert", "werden", ".", "Bei", "Reexposi", "-", "tion", "sollten", "die", "Blutplaettchen", "ebenfalls", "vor", "Einleitung", "der", "Heparin", "-", "therapie", ",", "dann", "aber", "bereits", "ab", "dem", "2", ".", "Tag", ",", "taeglich", "kontrolliert", "werden", ".", "Unerlaesslich", "ist", "es", ",", "auf", "jede", "ueberfluessige", "Heparintherapie", "zu", "verzichten", ",", "eine", "indizierte", "Heparintherapie", "moeglichst", "auf", "5", "Tage", "zu", "begrenzen", ",", "z.", "B.", "durch", "fruehzeitige", "Einleitung", "einer", "oralen", "Antikoagulation", "mit", "Phen", "-", "procoumon", "(", "Marcumar", ")", ".", "Nach", "Diagnose", "einer", "HIT", "Typ", "II", "sollte", "fuer", "die", "betroffenen", "Patienten", "ein", "Notfallausweis", "ausgestellt", "werden", ".", "Diese", "Pa", "-", "tienten", "sollten", "ebenfalls", "keine", "Antithrombin", "-", "III-", "oder", "Prothrombinpraeparate", "erhalten", ",", "da", "diesen", "in", "zum", "Teil", "hohen", "Konzentrationen", "Heparin", "zugesetzt", "ist", "." ]

[ "umlsterm" ]

interleukin-2 is a Protein, interleukin-2 is a Protein, IL-2 is a Protein, CD4 is a Protein, IL-2 is a Protein, IL-2 is a Protein, NF - AT binding sites is a Entity, CD4 is a Protein, IL-2 is a Protein, CD4 is a Protein

8325322_task0

Sentence: Occurrence of a silencer of the interleukin-2 gene in naive but not in memory resting T helper lymphocytes. In the immune system the first activation of a naive T cell by antigen is a key step in the shaping of the peripheral T cell specificity repertoire and maintenance of self-tolerance. In the present study, analysis of the interleukin-2 (IL-2) gene activation shows that naive human helper T cells (cord blood CD4+ T cells, adult CD4+CD45RO- T cells) regulate IL-2 transcription by a mechanism involving both a silencer and an activator acting on the purine-rich IL-2 promoter elements (NF-AT binding sites). By contrast, memory cells, either in vitro activated helper T cells reverting to a resting state, or CD4+ T (memory) clones, or CD4+CD45RO+ T cells isolated ex vivo, no longer have a silencer. Their IL-2 transcription seems to be controlled solely by the transition from inactive to active functional state of a positive transcription factor binding to these promoter elements as well as its cytoplasmic or nuclear location: in resting memory T cells the activator is located in the cytoplasm and is inactive, whereas in stimulated cells it is functional in promoting transcription and now resides in the nucleus. Thus, the regulation of the gene coding for the main T cell growth factor changes irreversibly after the first encounter of T cells with antigen. It is most likely that the presence of a silencer contributes to the more stringent activation requirements of naive CD4+ T cells. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O" ]

Occurrence of a silencer of the interleukin-2 gene in naive but not in memory resting T helper lymphocytes. In the immune system the first activation of a naive T cell by antigen is a key step in the shaping of the peripheral T cell specificity repertoire and maintenance of self-tolerance. In the present study, analysis of the interleukin-2 (IL-2) gene activation shows that naive human helper T cells (cord blood CD4+ T cells, adult CD4+CD45RO- T cells) regulate IL-2 transcription by a mechanism involving both a silencer and an activator acting on the purine-rich IL-2 promoter elements (NF-AT binding sites). By contrast, memory cells, either in vitro activated helper T cells reverting to a resting state, or CD4+ T (memory) clones, or CD4+CD45RO+ T cells isolated ex vivo, no longer have a silencer. Their IL-2 transcription seems to be controlled solely by the transition from inactive to active functional state of a positive transcription factor binding to these promoter elements as well as its cytoplasmic or nuclear location: in resting memory T cells the activator is located in the cytoplasm and is inactive, whereas in stimulated cells it is functional in promoting transcription and now resides in the nucleus. Thus, the regulation of the gene coding for the main T cell growth factor changes irreversibly after the first encounter of T cells with antigen. It is most likely that the presence of a silencer contributes to the more stringent activation requirements of naive CD4+ T cells.

[ "Occurrence", "of", "a", "silencer", "of", "the", "interleukin-2", "gene", "in", "naive", "but", "not", "in", "memory", "resting", "T", "helper", "lymphocytes", ".", "\n", "In", "the", "immune", "system", "the", "first", "activation", "of", "a", "naive", "T", "cell", "by", "antigen", "is", "a", "key", "step", "in", "the", "shaping", "of", "the", "peripheral", "T", "cell", "specificity", "repertoire", "and", "maintenance", "of", "self", "-", "tolerance", ".", "In", "the", "present", "study", ",", "analysis", "of", "the", "interleukin-2", "(", "IL-2", ")", "gene", "activation", "shows", "that", "naive", "human", "helper", "T", "cells", "(", "cord", "blood", "CD4", "+", "T", "cells", ",", "adult", "CD4+CD45RO-", "T", "cells", ")", "regulate", "IL-2", "transcription", "by", "a", "mechanism", "involving", "both", "a", "silencer", "and", "an", "activator", "acting", "on", "the", "purine", "-", "rich", "IL-2", "promoter", "elements", "(", "NF", "-", "AT", "binding", "sites", ")", ".", "By", "contrast", ",", "memory", "cells", ",", "either", "in", "vitro", "activated", "helper", "T", "cells", "reverting", "to", "a", "resting", "state", ",", "or", "CD4", "+", "T", "(", "memory", ")", "clones", ",", "or", "CD4+CD45RO+", "T", "cells", "isolated", "ex", "vivo", ",", "no", "longer", "have", "a", "silencer", ".", "Their", "IL-2", "transcription", "seems", "to", "be", "controlled", "solely", "by", "the", "transition", "from", "inactive", "to", "active", "functional", "state", "of", "a", "positive", "transcription", "factor", "binding", "to", "these", "promoter", "elements", "as", "well", "as", "its", "cytoplasmic", "or", "nuclear", "location", ":", "in", "resting", "memory", "T", "cells", "the", "activator", "is", "located", "in", "the", "cytoplasm", "and", "is", "inactive", ",", "whereas", "in", "stimulated", "cells", "it", "is", "functional", "in", "promoting", "transcription", "and", "now", "resides", "in", "the", "nucleus", ".", "Thus", ",", "the", "regulation", "of", "the", "gene", "coding", "for", "the", "main", "T", "cell", "growth", "factor", "changes", "irreversibly", "after", "the", "first", "encounter", "of", "T", "cells", "with", "antigen", ".", "It", "is", "most", "likely", "that", "the", "presence", "of", "a", "silencer", "contributes", "to", "the", "more", "stringent", "activation", "requirements", "of", "naive", "CD4", "+", "T", "cells", "." ]

[ "Entity", "Protein" ]

interleukin-2 is a Protein, interleukin-2 is a Protein, IL-2 is a Protein, CD4 is a Protein, IL-2 is a Protein, IL-2 is a Protein, NF - AT binding sites is a Entity, CD4 is a Protein, IL-2 is a Protein, CD4 is a Protein

8325322_task1

Sentence: Occurrence of a silencer of the interleukin-2 gene in naive but not in memory resting T helper lymphocytes. In the immune system the first activation of a naive T cell by antigen is a key step in the shaping of the peripheral T cell specificity repertoire and maintenance of self-tolerance. In the present study, analysis of the interleukin-2 (IL-2) gene activation shows that naive human helper T cells (cord blood CD4+ T cells, adult CD4+CD45RO- T cells) regulate IL-2 transcription by a mechanism involving both a silencer and an activator acting on the purine-rich IL-2 promoter elements (NF-AT binding sites). By contrast, memory cells, either in vitro activated helper T cells reverting to a resting state, or CD4+ T (memory) clones, or CD4+CD45RO+ T cells isolated ex vivo, no longer have a silencer. Their IL-2 transcription seems to be controlled solely by the transition from inactive to active functional state of a positive transcription factor binding to these promoter elements as well as its cytoplasmic or nuclear location: in resting memory T cells the activator is located in the cytoplasm and is inactive, whereas in stimulated cells it is functional in promoting transcription and now resides in the nucleus. Thus, the regulation of the gene coding for the main T cell growth factor changes irreversibly after the first encounter of T cells with antigen. It is most likely that the presence of a silencer contributes to the more stringent activation requirements of naive CD4+ T cells. Instructions: please typing these entity words according to sentence: interleukin-2, interleukin-2, IL-2, CD4, IL-2, IL-2, NF - AT binding sites, CD4, IL-2, CD4 Options: Entity, Protein

[ "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O" ]

Occurrence of a silencer of the interleukin-2 gene in naive but not in memory resting T helper lymphocytes. In the immune system the first activation of a naive T cell by antigen is a key step in the shaping of the peripheral T cell specificity repertoire and maintenance of self-tolerance. In the present study, analysis of the interleukin-2 (IL-2) gene activation shows that naive human helper T cells (cord blood CD4+ T cells, adult CD4+CD45RO- T cells) regulate IL-2 transcription by a mechanism involving both a silencer and an activator acting on the purine-rich IL-2 promoter elements (NF-AT binding sites). By contrast, memory cells, either in vitro activated helper T cells reverting to a resting state, or CD4+ T (memory) clones, or CD4+CD45RO+ T cells isolated ex vivo, no longer have a silencer. Their IL-2 transcription seems to be controlled solely by the transition from inactive to active functional state of a positive transcription factor binding to these promoter elements as well as its cytoplasmic or nuclear location: in resting memory T cells the activator is located in the cytoplasm and is inactive, whereas in stimulated cells it is functional in promoting transcription and now resides in the nucleus. Thus, the regulation of the gene coding for the main T cell growth factor changes irreversibly after the first encounter of T cells with antigen. It is most likely that the presence of a silencer contributes to the more stringent activation requirements of naive CD4+ T cells.

[ "Occurrence", "of", "a", "silencer", "of", "the", "interleukin-2", "gene", "in", "naive", "but", "not", "in", "memory", "resting", "T", "helper", "lymphocytes", ".", "\n", "In", "the", "immune", "system", "the", "first", "activation", "of", "a", "naive", "T", "cell", "by", "antigen", "is", "a", "key", "step", "in", "the", "shaping", "of", "the", "peripheral", "T", "cell", "specificity", "repertoire", "and", "maintenance", "of", "self", "-", "tolerance", ".", "In", "the", "present", "study", ",", "analysis", "of", "the", "interleukin-2", "(", "IL-2", ")", "gene", "activation", "shows", "that", "naive", "human", "helper", "T", "cells", "(", "cord", "blood", "CD4", "+", "T", "cells", ",", "adult", "CD4+CD45RO-", "T", "cells", ")", "regulate", "IL-2", "transcription", "by", "a", "mechanism", "involving", "both", "a", "silencer", "and", "an", "activator", "acting", "on", "the", "purine", "-", "rich", "IL-2", "promoter", "elements", "(", "NF", "-", "AT", "binding", "sites", ")", ".", "By", "contrast", ",", "memory", "cells", ",", "either", "in", "vitro", "activated", "helper", "T", "cells", "reverting", "to", "a", "resting", "state", ",", "or", "CD4", "+", "T", "(", "memory", ")", "clones", ",", "or", "CD4+CD45RO+", "T", "cells", "isolated", "ex", "vivo", ",", "no", "longer", "have", "a", "silencer", ".", "Their", "IL-2", "transcription", "seems", "to", "be", "controlled", "solely", "by", "the", "transition", "from", "inactive", "to", "active", "functional", "state", "of", "a", "positive", "transcription", "factor", "binding", "to", "these", "promoter", "elements", "as", "well", "as", "its", "cytoplasmic", "or", "nuclear", "location", ":", "in", "resting", "memory", "T", "cells", "the", "activator", "is", "located", "in", "the", "cytoplasm", "and", "is", "inactive", ",", "whereas", "in", "stimulated", "cells", "it", "is", "functional", "in", "promoting", "transcription", "and", "now", "resides", "in", "the", "nucleus", ".", "Thus", ",", "the", "regulation", "of", "the", "gene", "coding", "for", "the", "main", "T", "cell", "growth", "factor", "changes", "irreversibly", "after", "the", "first", "encounter", "of", "T", "cells", "with", "antigen", ".", "It", "is", "most", "likely", "that", "the", "presence", "of", "a", "silencer", "contributes", "to", "the", "more", "stringent", "activation", "requirements", "of", "naive", "CD4", "+", "T", "cells", "." ]

[ "Entity", "Protein" ]

interleukin-2, interleukin-2, IL-2, CD4, IL-2, IL-2, NF - AT binding sites, CD4, IL-2, CD4

8325322_task2

Sentence: Occurrence of a silencer of the interleukin-2 gene in naive but not in memory resting T helper lymphocytes. In the immune system the first activation of a naive T cell by antigen is a key step in the shaping of the peripheral T cell specificity repertoire and maintenance of self-tolerance. In the present study, analysis of the interleukin-2 (IL-2) gene activation shows that naive human helper T cells (cord blood CD4+ T cells, adult CD4+CD45RO- T cells) regulate IL-2 transcription by a mechanism involving both a silencer and an activator acting on the purine-rich IL-2 promoter elements (NF-AT binding sites). By contrast, memory cells, either in vitro activated helper T cells reverting to a resting state, or CD4+ T (memory) clones, or CD4+CD45RO+ T cells isolated ex vivo, no longer have a silencer. Their IL-2 transcription seems to be controlled solely by the transition from inactive to active functional state of a positive transcription factor binding to these promoter elements as well as its cytoplasmic or nuclear location: in resting memory T cells the activator is located in the cytoplasm and is inactive, whereas in stimulated cells it is functional in promoting transcription and now resides in the nucleus. Thus, the regulation of the gene coding for the main T cell growth factor changes irreversibly after the first encounter of T cells with antigen. It is most likely that the presence of a silencer contributes to the more stringent activation requirements of naive CD4+ T cells. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "B-Entity", "I-Entity", "I-Entity", "I-Entity", "I-Entity", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O" ]

Occurrence of a silencer of the interleukin-2 gene in naive but not in memory resting T helper lymphocytes. In the immune system the first activation of a naive T cell by antigen is a key step in the shaping of the peripheral T cell specificity repertoire and maintenance of self-tolerance. In the present study, analysis of the interleukin-2 (IL-2) gene activation shows that naive human helper T cells (cord blood CD4+ T cells, adult CD4+CD45RO- T cells) regulate IL-2 transcription by a mechanism involving both a silencer and an activator acting on the purine-rich IL-2 promoter elements (NF-AT binding sites). By contrast, memory cells, either in vitro activated helper T cells reverting to a resting state, or CD4+ T (memory) clones, or CD4+CD45RO+ T cells isolated ex vivo, no longer have a silencer. Their IL-2 transcription seems to be controlled solely by the transition from inactive to active functional state of a positive transcription factor binding to these promoter elements as well as its cytoplasmic or nuclear location: in resting memory T cells the activator is located in the cytoplasm and is inactive, whereas in stimulated cells it is functional in promoting transcription and now resides in the nucleus. Thus, the regulation of the gene coding for the main T cell growth factor changes irreversibly after the first encounter of T cells with antigen. It is most likely that the presence of a silencer contributes to the more stringent activation requirements of naive CD4+ T cells.

[ "Occurrence", "of", "a", "silencer", "of", "the", "interleukin-2", "gene", "in", "naive", "but", "not", "in", "memory", "resting", "T", "helper", "lymphocytes", ".", "\n", "In", "the", "immune", "system", "the", "first", "activation", "of", "a", "naive", "T", "cell", "by", "antigen", "is", "a", "key", "step", "in", "the", "shaping", "of", "the", "peripheral", "T", "cell", "specificity", "repertoire", "and", "maintenance", "of", "self", "-", "tolerance", ".", "In", "the", "present", "study", ",", "analysis", "of", "the", "interleukin-2", "(", "IL-2", ")", "gene", "activation", "shows", "that", "naive", "human", "helper", "T", "cells", "(", "cord", "blood", "CD4", "+", "T", "cells", ",", "adult", "CD4+CD45RO-", "T", "cells", ")", "regulate", "IL-2", "transcription", "by", "a", "mechanism", "involving", "both", "a", "silencer", "and", "an", "activator", "acting", "on", "the", "purine", "-", "rich", "IL-2", "promoter", "elements", "(", "NF", "-", "AT", "binding", "sites", ")", ".", "By", "contrast", ",", "memory", "cells", ",", "either", "in", "vitro", "activated", "helper", "T", "cells", "reverting", "to", "a", "resting", "state", ",", "or", "CD4", "+", "T", "(", "memory", ")", "clones", ",", "or", "CD4+CD45RO+", "T", "cells", "isolated", "ex", "vivo", ",", "no", "longer", "have", "a", "silencer", ".", "Their", "IL-2", "transcription", "seems", "to", "be", "controlled", "solely", "by", "the", "transition", "from", "inactive", "to", "active", "functional", "state", "of", "a", "positive", "transcription", "factor", "binding", "to", "these", "promoter", "elements", "as", "well", "as", "its", "cytoplasmic", "or", "nuclear", "location", ":", "in", "resting", "memory", "T", "cells", "the", "activator", "is", "located", "in", "the", "cytoplasm", "and", "is", "inactive", ",", "whereas", "in", "stimulated", "cells", "it", "is", "functional", "in", "promoting", "transcription", "and", "now", "resides", "in", "the", "nucleus", ".", "Thus", ",", "the", "regulation", "of", "the", "gene", "coding", "for", "the", "main", "T", "cell", "growth", "factor", "changes", "irreversibly", "after", "the", "first", "encounter", "of", "T", "cells", "with", "antigen", ".", "It", "is", "most", "likely", "that", "the", "presence", "of", "a", "silencer", "contributes", "to", "the", "more", "stringent", "activation", "requirements", "of", "naive", "CD4", "+", "T", "cells", "." ]

[ "Entity", "Protein" ]

ursodeoxycholic acid is a Intervention_Pharmacological, serum liver enzymes is a Outcome_Physical, hepatitis C virus - related chronic liver disease is a Participant_Condition, ursodeoxycholic acid ( UDCA ) is a Intervention_Pharmacological, serum liver enzyme levels [ alanine aminotransferase ( ALT ) and gamma - glutamyl transferase ( GGT ) ] is a Outcome_Physical, 101 is a Participant_Sample-size, no treatment is a Intervention_Control, serum ALT and GGT levels is a Outcome_Physical, ALT values is a Outcome_Physical, mean ALT and GGT levels is a Outcome_Physical, interferon therapy is a Intervention_Pharmacological

82019_task0

Sentence: Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease . OBJECTIVE To study the effect of ursodeoxycholic acid ( UDCA ) on serum liver enzyme levels [ alanine aminotransferase ( ALT ) and gamma-glutamyl transferase ( GGT ) ] in 101 patients with hepatitis C virus-related chronic liver disease . METHODS Forty-nine patients were assigned to receive UDCA ( 450 mg/day ) over a period of 6 months and 52 to receive no treatment . RESULTS In the UDCA group , serum ALT and GGT levels significantly improved . ALT values decreased from pre-treatment levels of 157.0 +/- 62.6 IU/l to 82.5 +/- 46.4 IU/l ( P < 0.05 ) , and GGT fell from 141.3 +/- 86.2 IU/l to 66.0 +/- 49.5 IU/l ( P < 0.001 ) . No significant change occurred in the mean ALT and GGT levels in the control group . CONCLUSION Although our encouraging preliminary results must be validated by double-blind histological trials , UDCA may be an alternative treatment for patients who fail to respond to interferon therapy . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Sample-size

[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O" ]

Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease . OBJECTIVE To study the effect of ursodeoxycholic acid ( UDCA ) on serum liver enzyme levels [ alanine aminotransferase ( ALT ) and gamma-glutamyl transferase ( GGT ) ] in 101 patients with hepatitis C virus-related chronic liver disease . METHODS Forty-nine patients were assigned to receive UDCA ( 450 mg/day ) over a period of 6 months and 52 to receive no treatment . RESULTS In the UDCA group , serum ALT and GGT levels significantly improved . ALT values decreased from pre-treatment levels of 157.0 +/- 62.6 IU/l to 82.5 +/- 46.4 IU/l ( P < 0.05 ) , and GGT fell from 141.3 +/- 86.2 IU/l to 66.0 +/- 49.5 IU/l ( P < 0.001 ) . No significant change occurred in the mean ALT and GGT levels in the control group . CONCLUSION Although our encouraging preliminary results must be validated by double-blind histological trials , UDCA may be an alternative treatment for patients who fail to respond to interferon therapy .

[ "Effects", "of", "ursodeoxycholic", "acid", "on", "serum", "liver", "enzymes", "in", "patients", "with", "hepatitis", "C", "virus", "-", "related", "chronic", "liver", "disease", ".", "OBJECTIVE", "To", "study", "the", "effect", "of", "ursodeoxycholic", "acid", "(", "UDCA", ")", "on", "serum", "liver", "enzyme", "levels", "[", "alanine", "aminotransferase", "(", "ALT", ")", "and", "gamma", "-", "glutamyl", "transferase", "(", "GGT", ")", "]", "in", "101", "patients", "with", "hepatitis", "C", "virus", "-", "related", "chronic", "liver", "disease", ".", "METHODS", "Forty", "-", "nine", "patients", "were", "assigned", "to", "receive", "UDCA", "(", "450", "mg", "/", "day", ")", "over", "a", "period", "of", "6", "months", "and", "52", "to", "receive", "no", "treatment", ".", "RESULTS", "In", "the", "UDCA", "group", ",", "serum", "ALT", "and", "GGT", "levels", "significantly", "improved", ".", "ALT", "values", "decreased", "from", "pre", "-", "treatment", "levels", "of", "157.0", "+", "/-", "62.6", "IU", "/", "l", "to", "82.5", "+", "/-", "46.4", "IU", "/", "l", "(", "P", "<", "0.05", ")", ",", "and", "GGT", "fell", "from", "141.3", "+", "/-", "86.2", "IU", "/", "l", "to", "66.0", "+", "/-", "49.5", "IU", "/", "l", "(", "P", "<", "0.001", ")", ".", "No", "significant", "change", "occurred", "in", "the", "mean", "ALT", "and", "GGT", "levels", "in", "the", "control", "group", ".", "CONCLUSION", "Although", "our", "encouraging", "preliminary", "results", "must", "be", "validated", "by", "double", "-", "blind", "histological", "trials", ",", "UDCA", "may", "be", "an", "alternative", "treatment", "for", "patients", "who", "fail", "to", "respond", "to", "interferon", "therapy", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size" ]

ursodeoxycholic acid is a Intervention_Pharmacological, serum liver enzymes is a Outcome_Physical, hepatitis C virus - related chronic liver disease is a Participant_Condition, ursodeoxycholic acid ( UDCA ) is a Intervention_Pharmacological, serum liver enzyme levels [ alanine aminotransferase ( ALT ) and gamma - glutamyl transferase ( GGT ) ] is a Outcome_Physical, 101 is a Participant_Sample-size, no treatment is a Intervention_Control, serum ALT and GGT levels is a Outcome_Physical, ALT values is a Outcome_Physical, mean ALT and GGT levels is a Outcome_Physical, interferon therapy is a Intervention_Pharmacological

82019_task1

Sentence: Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease . OBJECTIVE To study the effect of ursodeoxycholic acid ( UDCA ) on serum liver enzyme levels [ alanine aminotransferase ( ALT ) and gamma-glutamyl transferase ( GGT ) ] in 101 patients with hepatitis C virus-related chronic liver disease . METHODS Forty-nine patients were assigned to receive UDCA ( 450 mg/day ) over a period of 6 months and 52 to receive no treatment . RESULTS In the UDCA group , serum ALT and GGT levels significantly improved . ALT values decreased from pre-treatment levels of 157.0 +/- 62.6 IU/l to 82.5 +/- 46.4 IU/l ( P < 0.05 ) , and GGT fell from 141.3 +/- 86.2 IU/l to 66.0 +/- 49.5 IU/l ( P < 0.001 ) . No significant change occurred in the mean ALT and GGT levels in the control group . CONCLUSION Although our encouraging preliminary results must be validated by double-blind histological trials , UDCA may be an alternative treatment for patients who fail to respond to interferon therapy . Instructions: please typing these entity words according to sentence: ursodeoxycholic acid, serum liver enzymes, hepatitis C virus - related chronic liver disease, ursodeoxycholic acid ( UDCA ), serum liver enzyme levels [ alanine aminotransferase ( ALT ) and gamma - glutamyl transferase ( GGT ) ], 101, no treatment, serum ALT and GGT levels, ALT values, mean ALT and GGT levels, interferon therapy Options: Intervention_Pharmacological, Intervention_Control, Participant_Condition, Outcome_Physical, Participant_Sample-size

[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O" ]

Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease . OBJECTIVE To study the effect of ursodeoxycholic acid ( UDCA ) on serum liver enzyme levels [ alanine aminotransferase ( ALT ) and gamma-glutamyl transferase ( GGT ) ] in 101 patients with hepatitis C virus-related chronic liver disease . METHODS Forty-nine patients were assigned to receive UDCA ( 450 mg/day ) over a period of 6 months and 52 to receive no treatment . RESULTS In the UDCA group , serum ALT and GGT levels significantly improved . ALT values decreased from pre-treatment levels of 157.0 +/- 62.6 IU/l to 82.5 +/- 46.4 IU/l ( P < 0.05 ) , and GGT fell from 141.3 +/- 86.2 IU/l to 66.0 +/- 49.5 IU/l ( P < 0.001 ) . No significant change occurred in the mean ALT and GGT levels in the control group . CONCLUSION Although our encouraging preliminary results must be validated by double-blind histological trials , UDCA may be an alternative treatment for patients who fail to respond to interferon therapy .

[ "Effects", "of", "ursodeoxycholic", "acid", "on", "serum", "liver", "enzymes", "in", "patients", "with", "hepatitis", "C", "virus", "-", "related", "chronic", "liver", "disease", ".", "OBJECTIVE", "To", "study", "the", "effect", "of", "ursodeoxycholic", "acid", "(", "UDCA", ")", "on", "serum", "liver", "enzyme", "levels", "[", "alanine", "aminotransferase", "(", "ALT", ")", "and", "gamma", "-", "glutamyl", "transferase", "(", "GGT", ")", "]", "in", "101", "patients", "with", "hepatitis", "C", "virus", "-", "related", "chronic", "liver", "disease", ".", "METHODS", "Forty", "-", "nine", "patients", "were", "assigned", "to", "receive", "UDCA", "(", "450", "mg", "/", "day", ")", "over", "a", "period", "of", "6", "months", "and", "52", "to", "receive", "no", "treatment", ".", "RESULTS", "In", "the", "UDCA", "group", ",", "serum", "ALT", "and", "GGT", "levels", "significantly", "improved", ".", "ALT", "values", "decreased", "from", "pre", "-", "treatment", "levels", "of", "157.0", "+", "/-", "62.6", "IU", "/", "l", "to", "82.5", "+", "/-", "46.4", "IU", "/", "l", "(", "P", "<", "0.05", ")", ",", "and", "GGT", "fell", "from", "141.3", "+", "/-", "86.2", "IU", "/", "l", "to", "66.0", "+", "/-", "49.5", "IU", "/", "l", "(", "P", "<", "0.001", ")", ".", "No", "significant", "change", "occurred", "in", "the", "mean", "ALT", "and", "GGT", "levels", "in", "the", "control", "group", ".", "CONCLUSION", "Although", "our", "encouraging", "preliminary", "results", "must", "be", "validated", "by", "double", "-", "blind", "histological", "trials", ",", "UDCA", "may", "be", "an", "alternative", "treatment", "for", "patients", "who", "fail", "to", "respond", "to", "interferon", "therapy", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size" ]

ursodeoxycholic acid, serum liver enzymes, hepatitis C virus - related chronic liver disease, ursodeoxycholic acid ( UDCA ), serum liver enzyme levels [ alanine aminotransferase ( ALT ) and gamma - glutamyl transferase ( GGT ) ], 101, no treatment, serum ALT and GGT levels, ALT values, mean ALT and GGT levels, interferon therapy

82019_task2

Sentence: Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease . OBJECTIVE To study the effect of ursodeoxycholic acid ( UDCA ) on serum liver enzyme levels [ alanine aminotransferase ( ALT ) and gamma-glutamyl transferase ( GGT ) ] in 101 patients with hepatitis C virus-related chronic liver disease . METHODS Forty-nine patients were assigned to receive UDCA ( 450 mg/day ) over a period of 6 months and 52 to receive no treatment . RESULTS In the UDCA group , serum ALT and GGT levels significantly improved . ALT values decreased from pre-treatment levels of 157.0 +/- 62.6 IU/l to 82.5 +/- 46.4 IU/l ( P < 0.05 ) , and GGT fell from 141.3 +/- 86.2 IU/l to 66.0 +/- 49.5 IU/l ( P < 0.001 ) . No significant change occurred in the mean ALT and GGT levels in the control group . CONCLUSION Although our encouraging preliminary results must be validated by double-blind histological trials , UDCA may be an alternative treatment for patients who fail to respond to interferon therapy . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Control", "I-Intervention_Control", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O" ]

Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease . OBJECTIVE To study the effect of ursodeoxycholic acid ( UDCA ) on serum liver enzyme levels [ alanine aminotransferase ( ALT ) and gamma-glutamyl transferase ( GGT ) ] in 101 patients with hepatitis C virus-related chronic liver disease . METHODS Forty-nine patients were assigned to receive UDCA ( 450 mg/day ) over a period of 6 months and 52 to receive no treatment . RESULTS In the UDCA group , serum ALT and GGT levels significantly improved . ALT values decreased from pre-treatment levels of 157.0 +/- 62.6 IU/l to 82.5 +/- 46.4 IU/l ( P < 0.05 ) , and GGT fell from 141.3 +/- 86.2 IU/l to 66.0 +/- 49.5 IU/l ( P < 0.001 ) . No significant change occurred in the mean ALT and GGT levels in the control group . CONCLUSION Although our encouraging preliminary results must be validated by double-blind histological trials , UDCA may be an alternative treatment for patients who fail to respond to interferon therapy .

[ "Effects", "of", "ursodeoxycholic", "acid", "on", "serum", "liver", "enzymes", "in", "patients", "with", "hepatitis", "C", "virus", "-", "related", "chronic", "liver", "disease", ".", "OBJECTIVE", "To", "study", "the", "effect", "of", "ursodeoxycholic", "acid", "(", "UDCA", ")", "on", "serum", "liver", "enzyme", "levels", "[", "alanine", "aminotransferase", "(", "ALT", ")", "and", "gamma", "-", "glutamyl", "transferase", "(", "GGT", ")", "]", "in", "101", "patients", "with", "hepatitis", "C", "virus", "-", "related", "chronic", "liver", "disease", ".", "METHODS", "Forty", "-", "nine", "patients", "were", "assigned", "to", "receive", "UDCA", "(", "450", "mg", "/", "day", ")", "over", "a", "period", "of", "6", "months", "and", "52", "to", "receive", "no", "treatment", ".", "RESULTS", "In", "the", "UDCA", "group", ",", "serum", "ALT", "and", "GGT", "levels", "significantly", "improved", ".", "ALT", "values", "decreased", "from", "pre", "-", "treatment", "levels", "of", "157.0", "+", "/-", "62.6", "IU", "/", "l", "to", "82.5", "+", "/-", "46.4", "IU", "/", "l", "(", "P", "<", "0.05", ")", ",", "and", "GGT", "fell", "from", "141.3", "+", "/-", "86.2", "IU", "/", "l", "to", "66.0", "+", "/-", "49.5", "IU", "/", "l", "(", "P", "<", "0.001", ")", ".", "No", "significant", "change", "occurred", "in", "the", "mean", "ALT", "and", "GGT", "levels", "in", "the", "control", "group", ".", "CONCLUSION", "Although", "our", "encouraging", "preliminary", "results", "must", "be", "validated", "by", "double", "-", "blind", "histological", "trials", ",", "UDCA", "may", "be", "an", "alternative", "treatment", "for", "patients", "who", "fail", "to", "respond", "to", "interferon", "therapy", "." ]

[ "Outcome_Physical", "Participant_Condition", "Intervention_Pharmacological", "Intervention_Control", "Participant_Sample-size" ]

study design is an umlsterm, radiology is an umlsterm

DerRadiologe.80380241.eng.abstr_task0

Sentence: Purpose : To review important aspects of study design in clinical radiology and to introduce the reader to the requirements of Good Clinical Practice ( GCP ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Purpose : To review important aspects of study design in clinical radiology and to introduce the reader to the requirements of Good Clinical Practice ( GCP ) .

[ "Purpose", ":", "To", "review", "important", "aspects", "of", "study", "design", "in", "clinical", "radiology", "and", "to", "introduce", "the", "reader", "to", "the", "requirements", "of", "Good", "Clinical", "Practice", "(", "GCP", ")", "." ]

[ "umlsterm" ]

study design is an umlsterm, radiology is an umlsterm

DerRadiologe.80380241.eng.abstr_task1

Sentence: Purpose : To review important aspects of study design in clinical radiology and to introduce the reader to the requirements of Good Clinical Practice ( GCP ) . Instructions: please typing these entity words according to sentence: study design, radiology Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Purpose : To review important aspects of study design in clinical radiology and to introduce the reader to the requirements of Good Clinical Practice ( GCP ) .

[ "Purpose", ":", "To", "review", "important", "aspects", "of", "study", "design", "in", "clinical", "radiology", "and", "to", "introduce", "the", "reader", "to", "the", "requirements", "of", "Good", "Clinical", "Practice", "(", "GCP", ")", "." ]

[ "umlsterm" ]

study design, radiology

DerRadiologe.80380241.eng.abstr_task2

Sentence: Purpose : To review important aspects of study design in clinical radiology and to introduce the reader to the requirements of Good Clinical Practice ( GCP ) . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Purpose : To review important aspects of study design in clinical radiology and to introduce the reader to the requirements of Good Clinical Practice ( GCP ) .

[ "Purpose", ":", "To", "review", "important", "aspects", "of", "study", "design", "in", "clinical", "radiology", "and", "to", "introduce", "the", "reader", "to", "the", "requirements", "of", "Good", "Clinical", "Practice", "(", "GCP", ")", "." ]

[ "umlsterm" ]

androgen is a CHEMICAL, androgen receptor is a GENE-Y, AR is a GENE-Y, androgen is a CHEMICAL, androgen is a CHEMICAL, 17alpha - methyltestosterone is a CHEMICAL, 17alpha - MT is a CHEMICAL, vinclozolin is a CHEMICAL, linuron is a CHEMICAL, AR is a GENE-Y, androgen is a CHEMICAL, 17alpha - methyldihydrotestosterone is a CHEMICAL, MDHT is a CHEMICAL, levonorgestrel is a CHEMICAL, norethynodrel is a CHEMICAL, progesterone is a CHEMICAL, o , p'-DDT is a CHEMICAL, dibutylphthalate is a CHEMICAL, DBP is a CHEMICAL, anti - androgen is a CHEMICAL, flutamide is a CHEMICAL, prochloraz is a CHEMICAL, o , p'-DDT is a CHEMICAL, progesterone is a CHEMICAL, norethynodrel is a CHEMICAL, DBP is a CHEMICAL, lactate dehydrogenase is a GENE-N, 17alpha - MT is a CHEMICAL, vinclozolin is a CHEMICAL, o , p'-DDT is a CHEMICAL, DBP is a CHEMICAL, MDHT is a CHEMICAL, 17alpha - MT is a CHEMICAL, levonorgestrel is a CHEMICAL, norethynodrel is a CHEMICAL, Progesterone is a CHEMICAL, DBP is a CHEMICAL, norethynodrel is a CHEMICAL, Progesterone is a CHEMICAL, AR is a GENE-Y

4671_task0

Sentence: Screening for (anti)androgenic properties using a standard operation protocol based on the human stably transfected androgen sensitive PALM cell line. First steps towards validation. Despite more than a decade of research in the field of endocrine active compounds targeting the androgen receptor (AR), and although suitable cell lines can be obtained, no validated human stably transfected androgen sensitive transactivation assay is available. Bayer Schering Pharma (BSP) and the Flemish Institute for Technological Research (VITO), partners within the EU-sponsored 6th framework project ReProTect, made first steps towards such a validation. A standard operation protocol (SOP) developed at BSP based on the androgen sensitive PALM cell line was transferred to VITO and its performance and transferability were thoroughly studied. The investigation followed a generic protocol prepared for all reporter gene assays evaluated within ReProTect, and in both laboratories at least three independent experiments were performed. The highest concentration to be tested was limited to 10 microM, if needed. A few compounds, 17alpha-methyltestosterone (17alpha-MT), vinclozolin and linuron, were studied using a real world scenario, i.e., assuming that their interaction with the AR was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening. All other compounds were tested according to the generic protocol: Compounds screened for agonism were the reference androgen 17alpha-methyldihydrotestosterone (MDHT), levonorgestrel, norethynodrel, progesterone, o,p'-DDT, and dibutylphthalate (DBP), while compounds screened for antagonism were the reference anti-androgen flutamide, prochloraz, o,p'-DDT, progesterone, norethynodrel, and DBP. Cytotoxicity was assessed in parallel as lactate dehydrogenase release. The prescreen classified 17alpha-MT as androgenic, vinclozolin and linuron as anti-androgenic and compounds were tested accordingly. In the absence of cytotoxicity, appropriate androgenic properties of reference and test compounds were detected by both laboratories, o,p'-DDT and DBP had no androgenic activity. Across the two laboratories EC(50)-values for MDHT, 17alpha-MT, and levonorgestrel varied by not more than a factor of 3.4, for norethynodrel by a factor of 9.7. Progesterone effects could not fully be evaluated, as frequently concentration response curves were incomplete. In the absence of cytotoxicity anti-androgenic properties of reference and test compounds were also detected in both laboratories. DBP, the putative negative reference compound, was inactive, norethynodrel rather showed agonistic properties. Progesterone was an antagonist at low concentrations, but agonistic properties were observed in one laboratory at high concentrations. Since the highest test concentration was limited to 10 microM, for some compounds no complete concentration response curves were obtained and estimation of EC(50)-values was less robust. Our data demonstrated that the SOP was transferable, and that the assay was able to rank compounds with strong, weak, and without affinity for the AR and to discriminate agonists and antagonists. The sensitivity of the assay could be improved further, if the limit of solubility or beginning cytotoxicity was chosen as the highest test concentration. The assay avoids the use of tissues from laboratory animals, and thus contributes to the 3R concept. Furthermore, it could be adjusted to an intermediate/high throughput format. On the whole, this PALM assay is a promising candidate for further validation. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Screening for (anti)androgenic properties using a standard operation protocol based on the human stably transfected androgen sensitive PALM cell line. First steps towards validation. Despite more than a decade of research in the field of endocrine active compounds targeting the androgen receptor (AR), and although suitable cell lines can be obtained, no validated human stably transfected androgen sensitive transactivation assay is available. Bayer Schering Pharma (BSP) and the Flemish Institute for Technological Research (VITO), partners within the EU-sponsored 6th framework project ReProTect, made first steps towards such a validation. A standard operation protocol (SOP) developed at BSP based on the androgen sensitive PALM cell line was transferred to VITO and its performance and transferability were thoroughly studied. The investigation followed a generic protocol prepared for all reporter gene assays evaluated within ReProTect, and in both laboratories at least three independent experiments were performed. The highest concentration to be tested was limited to 10 microM, if needed. A few compounds, 17alpha-methyltestosterone (17alpha-MT), vinclozolin and linuron, were studied using a real world scenario, i.e., assuming that their interaction with the AR was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening. All other compounds were tested according to the generic protocol: Compounds screened for agonism were the reference androgen 17alpha-methyldihydrotestosterone (MDHT), levonorgestrel, norethynodrel, progesterone, o,p'-DDT, and dibutylphthalate (DBP), while compounds screened for antagonism were the reference anti-androgen flutamide, prochloraz, o,p'-DDT, progesterone, norethynodrel, and DBP. Cytotoxicity was assessed in parallel as lactate dehydrogenase release. The prescreen classified 17alpha-MT as androgenic, vinclozolin and linuron as anti-androgenic and compounds were tested accordingly. In the absence of cytotoxicity, appropriate androgenic properties of reference and test compounds were detected by both laboratories, o,p'-DDT and DBP had no androgenic activity. Across the two laboratories EC(50)-values for MDHT, 17alpha-MT, and levonorgestrel varied by not more than a factor of 3.4, for norethynodrel by a factor of 9.7. Progesterone effects could not fully be evaluated, as frequently concentration response curves were incomplete. In the absence of cytotoxicity anti-androgenic properties of reference and test compounds were also detected in both laboratories. DBP, the putative negative reference compound, was inactive, norethynodrel rather showed agonistic properties. Progesterone was an antagonist at low concentrations, but agonistic properties were observed in one laboratory at high concentrations. Since the highest test concentration was limited to 10 microM, for some compounds no complete concentration response curves were obtained and estimation of EC(50)-values was less robust. Our data demonstrated that the SOP was transferable, and that the assay was able to rank compounds with strong, weak, and without affinity for the AR and to discriminate agonists and antagonists. The sensitivity of the assay could be improved further, if the limit of solubility or beginning cytotoxicity was chosen as the highest test concentration. The assay avoids the use of tissues from laboratory animals, and thus contributes to the 3R concept. Furthermore, it could be adjusted to an intermediate/high throughput format. On the whole, this PALM assay is a promising candidate for further validation.

[ "Screening", "for", "(", "anti)androgenic", "properties", "using", "a", "standard", "operation", "protocol", "based", "on", "the", "human", "stably", "transfected", "androgen", "sensitive", "PALM", "cell", "line", ".", "First", "steps", "towards", "validation", ".", "\n", "Despite", "more", "than", "a", "decade", "of", "research", "in", "the", "field", "of", "endocrine", "active", "compounds", "targeting", "the", "androgen", "receptor", "(", "AR", ")", ",", "and", "although", "suitable", "cell", "lines", "can", "be", "obtained", ",", "no", "validated", "human", "stably", "transfected", "androgen", "sensitive", "transactivation", "assay", "is", "available", ".", "Bayer", "Schering", "Pharma", "(", "BSP", ")", "and", "the", "Flemish", "Institute", "for", "Technological", "Research", "(", "VITO", ")", ",", "partners", "within", "the", "EU", "-", "sponsored", "6th", "framework", "project", "ReProTect", ",", "made", "first", "steps", "towards", "such", "a", "validation", ".", "A", "standard", "operation", "protocol", "(", "SOP", ")", "developed", "at", "BSP", "based", "on", "the", "androgen", "sensitive", "PALM", "cell", "line", "was", "transferred", "to", "VITO", "and", "its", "performance", "and", "transferability", "were", "thoroughly", "studied", ".", "The", "investigation", "followed", "a", "generic", "protocol", "prepared", "for", "all", "reporter", "gene", "assays", "evaluated", "within", "ReProTect", ",", "and", "in", "both", "laboratories", "at", "least", "three", "independent", "experiments", "were", "performed", ".", "The", "highest", "concentration", "to", "be", "tested", "was", "limited", "to", "10", "microM", ",", "if", "needed", ".", "A", "few", "compounds", ",", "17alpha", "-", "methyltestosterone", "(", "17alpha", "-", "MT", ")", ",", "vinclozolin", "and", "linuron", ",", "were", "studied", "using", "a", "real", "world", "scenario", ",", "i.e", ".", ",", "assuming", "that", "their", "interaction", "with", "the", "AR", "was", "not", "known", ":", "A", "prescreening", "for", "agonism", "and", "true", ",", "competitive", "antagonism", "was", "used", "to", "select", "conditions", "such", "as", "the", "appropriate", "mode", "of", "action", ",", "and", "the", "working", "range", "excluding", "cytotoxicity", "for", "the", "final", "screening", ".", "All", "other", "compounds", "were", "tested", "according", "to", "the", "generic", "protocol", ":", "Compounds", "screened", "for", "agonism", "were", "the", "reference", "androgen", "17alpha", "-", "methyldihydrotestosterone", "(", "MDHT", ")", ",", "levonorgestrel", ",", "norethynodrel", ",", "progesterone", ",", "o", ",", "p'-DDT", ",", "and", "dibutylphthalate", "(", "DBP", ")", ",", "while", "compounds", "screened", "for", "antagonism", "were", "the", "reference", "anti", "-", "androgen", "flutamide", ",", "prochloraz", ",", "o", ",", "p'-DDT", ",", "progesterone", ",", "norethynodrel", ",", "and", "DBP", ".", "Cytotoxicity", "was", "assessed", "in", "parallel", "as", "lactate", "dehydrogenase", "release", ".", "The", "prescreen", "classified", "17alpha", "-", "MT", "as", "androgenic", ",", "vinclozolin", "and", "linuron", "as", "anti", "-", "androgenic", "and", "compounds", "were", "tested", "accordingly", ".", "In", "the", "absence", "of", "cytotoxicity", ",", "appropriate", "androgenic", "properties", "of", "reference", "and", "test", "compounds", "were", "detected", "by", "both", "laboratories", ",", "o", ",", "p'-DDT", "and", "DBP", "had", "no", "androgenic", "activity", ".", "Across", "the", "two", "laboratories", "EC(50)-values", "for", "MDHT", ",", "17alpha", "-", "MT", ",", "and", "levonorgestrel", "varied", "by", "not", "more", "than", "a", "factor", "of", "3.4", ",", "for", "norethynodrel", "by", "a", "factor", "of", "9.7", ".", "Progesterone", "effects", "could", "not", "fully", "be", "evaluated", ",", "as", "frequently", "concentration", "response", "curves", "were", "incomplete", ".", "In", "the", "absence", "of", "cytotoxicity", "anti", "-", "androgenic", "properties", "of", "reference", "and", "test", "compounds", "were", "also", "detected", "in", "both", "laboratories", ".", "DBP", ",", "the", "putative", "negative", "reference", "compound", ",", "was", "inactive", ",", "norethynodrel", "rather", "showed", "agonistic", "properties", ".", "Progesterone", "was", "an", "antagonist", "at", "low", "concentrations", ",", "but", "agonistic", "properties", "were", "observed", "in", "one", "laboratory", "at", "high", "concentrations", ".", "Since", "the", "highest", "test", "concentration", "was", "limited", "to", "10", "microM", ",", "for", "some", "compounds", "no", "complete", "concentration", "response", "curves", "were", "obtained", "and", "estimation", "of", "EC(50)-values", "was", "less", "robust", ".", "Our", "data", "demonstrated", "that", "the", "SOP", "was", "transferable", ",", "and", "that", "the", "assay", "was", "able", "to", "rank", "compounds", "with", "strong", ",", "weak", ",", "and", "without", "affinity", "for", "the", "AR", "and", "to", "discriminate", "agonists", "and", "antagonists", ".", "The", "sensitivity", "of", "the", "assay", "could", "be", "improved", "further", ",", "if", "the", "limit", "of", "solubility", "or", "beginning", "cytotoxicity", "was", "chosen", "as", "the", "highest", "test", "concentration", ".", "The", "assay", "avoids", "the", "use", "of", "tissues", "from", "laboratory", "animals", ",", "and", "thus", "contributes", "to", "the", "3R", "concept", ".", "Furthermore", ",", "it", "could", "be", "adjusted", "to", "an", "intermediate", "/", "high", "throughput", "format", ".", "On", "the", "whole", ",", "this", "PALM", "assay", "is", "a", "promising", "candidate", "for", "further", "validation", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

androgen is a CHEMICAL, androgen receptor is a GENE-Y, AR is a GENE-Y, androgen is a CHEMICAL, androgen is a CHEMICAL, 17alpha - methyltestosterone is a CHEMICAL, 17alpha - MT is a CHEMICAL, vinclozolin is a CHEMICAL, linuron is a CHEMICAL, AR is a GENE-Y, androgen is a CHEMICAL, 17alpha - methyldihydrotestosterone is a CHEMICAL, MDHT is a CHEMICAL, levonorgestrel is a CHEMICAL, norethynodrel is a CHEMICAL, progesterone is a CHEMICAL, o , p'-DDT is a CHEMICAL, dibutylphthalate is a CHEMICAL, DBP is a CHEMICAL, anti - androgen is a CHEMICAL, flutamide is a CHEMICAL, prochloraz is a CHEMICAL, o , p'-DDT is a CHEMICAL, progesterone is a CHEMICAL, norethynodrel is a CHEMICAL, DBP is a CHEMICAL, lactate dehydrogenase is a GENE-N, 17alpha - MT is a CHEMICAL, vinclozolin is a CHEMICAL, o , p'-DDT is a CHEMICAL, DBP is a CHEMICAL, MDHT is a CHEMICAL, 17alpha - MT is a CHEMICAL, levonorgestrel is a CHEMICAL, norethynodrel is a CHEMICAL, Progesterone is a CHEMICAL, DBP is a CHEMICAL, norethynodrel is a CHEMICAL, Progesterone is a CHEMICAL, AR is a GENE-Y

4671_task1

Sentence: Screening for (anti)androgenic properties using a standard operation protocol based on the human stably transfected androgen sensitive PALM cell line. First steps towards validation. Despite more than a decade of research in the field of endocrine active compounds targeting the androgen receptor (AR), and although suitable cell lines can be obtained, no validated human stably transfected androgen sensitive transactivation assay is available. Bayer Schering Pharma (BSP) and the Flemish Institute for Technological Research (VITO), partners within the EU-sponsored 6th framework project ReProTect, made first steps towards such a validation. A standard operation protocol (SOP) developed at BSP based on the androgen sensitive PALM cell line was transferred to VITO and its performance and transferability were thoroughly studied. The investigation followed a generic protocol prepared for all reporter gene assays evaluated within ReProTect, and in both laboratories at least three independent experiments were performed. The highest concentration to be tested was limited to 10 microM, if needed. A few compounds, 17alpha-methyltestosterone (17alpha-MT), vinclozolin and linuron, were studied using a real world scenario, i.e., assuming that their interaction with the AR was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening. All other compounds were tested according to the generic protocol: Compounds screened for agonism were the reference androgen 17alpha-methyldihydrotestosterone (MDHT), levonorgestrel, norethynodrel, progesterone, o,p'-DDT, and dibutylphthalate (DBP), while compounds screened for antagonism were the reference anti-androgen flutamide, prochloraz, o,p'-DDT, progesterone, norethynodrel, and DBP. Cytotoxicity was assessed in parallel as lactate dehydrogenase release. The prescreen classified 17alpha-MT as androgenic, vinclozolin and linuron as anti-androgenic and compounds were tested accordingly. In the absence of cytotoxicity, appropriate androgenic properties of reference and test compounds were detected by both laboratories, o,p'-DDT and DBP had no androgenic activity. Across the two laboratories EC(50)-values for MDHT, 17alpha-MT, and levonorgestrel varied by not more than a factor of 3.4, for norethynodrel by a factor of 9.7. Progesterone effects could not fully be evaluated, as frequently concentration response curves were incomplete. In the absence of cytotoxicity anti-androgenic properties of reference and test compounds were also detected in both laboratories. DBP, the putative negative reference compound, was inactive, norethynodrel rather showed agonistic properties. Progesterone was an antagonist at low concentrations, but agonistic properties were observed in one laboratory at high concentrations. Since the highest test concentration was limited to 10 microM, for some compounds no complete concentration response curves were obtained and estimation of EC(50)-values was less robust. Our data demonstrated that the SOP was transferable, and that the assay was able to rank compounds with strong, weak, and without affinity for the AR and to discriminate agonists and antagonists. The sensitivity of the assay could be improved further, if the limit of solubility or beginning cytotoxicity was chosen as the highest test concentration. The assay avoids the use of tissues from laboratory animals, and thus contributes to the 3R concept. Furthermore, it could be adjusted to an intermediate/high throughput format. On the whole, this PALM assay is a promising candidate for further validation. Instructions: please typing these entity words according to sentence: androgen, androgen receptor, AR, androgen, androgen, 17alpha - methyltestosterone, 17alpha - MT, vinclozolin, linuron, AR, androgen, 17alpha - methyldihydrotestosterone, MDHT, levonorgestrel, norethynodrel, progesterone, o , p'-DDT, dibutylphthalate, DBP, anti - androgen, flutamide, prochloraz, o , p'-DDT, progesterone, norethynodrel, DBP, lactate dehydrogenase, 17alpha - MT, vinclozolin, o , p'-DDT, DBP, MDHT, 17alpha - MT, levonorgestrel, norethynodrel, Progesterone, DBP, norethynodrel, Progesterone, AR Options: GENE-N, GENE-Y, CHEMICAL

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Screening for (anti)androgenic properties using a standard operation protocol based on the human stably transfected androgen sensitive PALM cell line. First steps towards validation. Despite more than a decade of research in the field of endocrine active compounds targeting the androgen receptor (AR), and although suitable cell lines can be obtained, no validated human stably transfected androgen sensitive transactivation assay is available. Bayer Schering Pharma (BSP) and the Flemish Institute for Technological Research (VITO), partners within the EU-sponsored 6th framework project ReProTect, made first steps towards such a validation. A standard operation protocol (SOP) developed at BSP based on the androgen sensitive PALM cell line was transferred to VITO and its performance and transferability were thoroughly studied. The investigation followed a generic protocol prepared for all reporter gene assays evaluated within ReProTect, and in both laboratories at least three independent experiments were performed. The highest concentration to be tested was limited to 10 microM, if needed. A few compounds, 17alpha-methyltestosterone (17alpha-MT), vinclozolin and linuron, were studied using a real world scenario, i.e., assuming that their interaction with the AR was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening. All other compounds were tested according to the generic protocol: Compounds screened for agonism were the reference androgen 17alpha-methyldihydrotestosterone (MDHT), levonorgestrel, norethynodrel, progesterone, o,p'-DDT, and dibutylphthalate (DBP), while compounds screened for antagonism were the reference anti-androgen flutamide, prochloraz, o,p'-DDT, progesterone, norethynodrel, and DBP. Cytotoxicity was assessed in parallel as lactate dehydrogenase release. The prescreen classified 17alpha-MT as androgenic, vinclozolin and linuron as anti-androgenic and compounds were tested accordingly. In the absence of cytotoxicity, appropriate androgenic properties of reference and test compounds were detected by both laboratories, o,p'-DDT and DBP had no androgenic activity. Across the two laboratories EC(50)-values for MDHT, 17alpha-MT, and levonorgestrel varied by not more than a factor of 3.4, for norethynodrel by a factor of 9.7. Progesterone effects could not fully be evaluated, as frequently concentration response curves were incomplete. In the absence of cytotoxicity anti-androgenic properties of reference and test compounds were also detected in both laboratories. DBP, the putative negative reference compound, was inactive, norethynodrel rather showed agonistic properties. Progesterone was an antagonist at low concentrations, but agonistic properties were observed in one laboratory at high concentrations. Since the highest test concentration was limited to 10 microM, for some compounds no complete concentration response curves were obtained and estimation of EC(50)-values was less robust. Our data demonstrated that the SOP was transferable, and that the assay was able to rank compounds with strong, weak, and without affinity for the AR and to discriminate agonists and antagonists. The sensitivity of the assay could be improved further, if the limit of solubility or beginning cytotoxicity was chosen as the highest test concentration. The assay avoids the use of tissues from laboratory animals, and thus contributes to the 3R concept. Furthermore, it could be adjusted to an intermediate/high throughput format. On the whole, this PALM assay is a promising candidate for further validation.

[ "Screening", "for", "(", "anti)androgenic", "properties", "using", "a", "standard", "operation", "protocol", "based", "on", "the", "human", "stably", "transfected", "androgen", "sensitive", "PALM", "cell", "line", ".", "First", "steps", "towards", "validation", ".", "\n", "Despite", "more", "than", "a", "decade", "of", "research", "in", "the", "field", "of", "endocrine", "active", "compounds", "targeting", "the", "androgen", "receptor", "(", "AR", ")", ",", "and", "although", "suitable", "cell", "lines", "can", "be", "obtained", ",", "no", "validated", "human", "stably", "transfected", "androgen", "sensitive", "transactivation", "assay", "is", "available", ".", "Bayer", "Schering", "Pharma", "(", "BSP", ")", "and", "the", "Flemish", "Institute", "for", "Technological", "Research", "(", "VITO", ")", ",", "partners", "within", "the", "EU", "-", "sponsored", "6th", "framework", "project", "ReProTect", ",", "made", "first", "steps", "towards", "such", "a", "validation", ".", "A", "standard", "operation", "protocol", "(", "SOP", ")", "developed", "at", "BSP", "based", "on", "the", "androgen", "sensitive", "PALM", "cell", "line", "was", "transferred", "to", "VITO", "and", "its", "performance", "and", "transferability", "were", "thoroughly", "studied", ".", "The", "investigation", "followed", "a", "generic", "protocol", "prepared", "for", "all", "reporter", "gene", "assays", "evaluated", "within", "ReProTect", ",", "and", "in", "both", "laboratories", "at", "least", "three", "independent", "experiments", "were", "performed", ".", "The", "highest", "concentration", "to", "be", "tested", "was", "limited", "to", "10", "microM", ",", "if", "needed", ".", "A", "few", "compounds", ",", "17alpha", "-", "methyltestosterone", "(", "17alpha", "-", "MT", ")", ",", "vinclozolin", "and", "linuron", ",", "were", "studied", "using", "a", "real", "world", "scenario", ",", "i.e", ".", ",", "assuming", "that", "their", "interaction", "with", "the", "AR", "was", "not", "known", ":", "A", "prescreening", "for", "agonism", "and", "true", ",", "competitive", "antagonism", "was", "used", "to", "select", "conditions", "such", "as", "the", "appropriate", "mode", "of", "action", ",", "and", "the", "working", "range", "excluding", "cytotoxicity", "for", "the", "final", "screening", ".", "All", "other", "compounds", "were", "tested", "according", "to", "the", "generic", "protocol", ":", "Compounds", "screened", "for", "agonism", "were", "the", "reference", "androgen", "17alpha", "-", "methyldihydrotestosterone", "(", "MDHT", ")", ",", "levonorgestrel", ",", "norethynodrel", ",", "progesterone", ",", "o", ",", "p'-DDT", ",", "and", "dibutylphthalate", "(", "DBP", ")", ",", "while", "compounds", "screened", "for", "antagonism", "were", "the", "reference", "anti", "-", "androgen", "flutamide", ",", "prochloraz", ",", "o", ",", "p'-DDT", ",", "progesterone", ",", "norethynodrel", ",", "and", "DBP", ".", "Cytotoxicity", "was", "assessed", "in", "parallel", "as", "lactate", "dehydrogenase", "release", ".", "The", "prescreen", "classified", "17alpha", "-", "MT", "as", "androgenic", ",", "vinclozolin", "and", "linuron", "as", "anti", "-", "androgenic", "and", "compounds", "were", "tested", "accordingly", ".", "In", "the", "absence", "of", "cytotoxicity", ",", "appropriate", "androgenic", "properties", "of", "reference", "and", "test", "compounds", "were", "detected", "by", "both", "laboratories", ",", "o", ",", "p'-DDT", "and", "DBP", "had", "no", "androgenic", "activity", ".", "Across", "the", "two", "laboratories", "EC(50)-values", "for", "MDHT", ",", "17alpha", "-", "MT", ",", "and", "levonorgestrel", "varied", "by", "not", "more", "than", "a", "factor", "of", "3.4", ",", "for", "norethynodrel", "by", "a", "factor", "of", "9.7", ".", "Progesterone", "effects", "could", "not", "fully", "be", "evaluated", ",", "as", "frequently", "concentration", "response", "curves", "were", "incomplete", ".", "In", "the", "absence", "of", "cytotoxicity", "anti", "-", "androgenic", "properties", "of", "reference", "and", "test", "compounds", "were", "also", "detected", "in", "both", "laboratories", ".", "DBP", ",", "the", "putative", "negative", "reference", "compound", ",", "was", "inactive", ",", "norethynodrel", "rather", "showed", "agonistic", "properties", ".", "Progesterone", "was", "an", "antagonist", "at", "low", "concentrations", ",", "but", "agonistic", "properties", "were", "observed", "in", "one", "laboratory", "at", "high", "concentrations", ".", "Since", "the", "highest", "test", "concentration", "was", "limited", "to", "10", "microM", ",", "for", "some", "compounds", "no", "complete", "concentration", "response", "curves", "were", "obtained", "and", "estimation", "of", "EC(50)-values", "was", "less", "robust", ".", "Our", "data", "demonstrated", "that", "the", "SOP", "was", "transferable", ",", "and", "that", "the", "assay", "was", "able", "to", "rank", "compounds", "with", "strong", ",", "weak", ",", "and", "without", "affinity", "for", "the", "AR", "and", "to", "discriminate", "agonists", "and", "antagonists", ".", "The", "sensitivity", "of", "the", "assay", "could", "be", "improved", "further", ",", "if", "the", "limit", "of", "solubility", "or", "beginning", "cytotoxicity", "was", "chosen", "as", "the", "highest", "test", "concentration", ".", "The", "assay", "avoids", "the", "use", "of", "tissues", "from", "laboratory", "animals", ",", "and", "thus", "contributes", "to", "the", "3R", "concept", ".", "Furthermore", ",", "it", "could", "be", "adjusted", "to", "an", "intermediate", "/", "high", "throughput", "format", ".", "On", "the", "whole", ",", "this", "PALM", "assay", "is", "a", "promising", "candidate", "for", "further", "validation", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

androgen, androgen receptor, AR, androgen, androgen, 17alpha - methyltestosterone, 17alpha - MT, vinclozolin, linuron, AR, androgen, 17alpha - methyldihydrotestosterone, MDHT, levonorgestrel, norethynodrel, progesterone, o , p'-DDT, dibutylphthalate, DBP, anti - androgen, flutamide, prochloraz, o , p'-DDT, progesterone, norethynodrel, DBP, lactate dehydrogenase, 17alpha - MT, vinclozolin, o , p'-DDT, DBP, MDHT, 17alpha - MT, levonorgestrel, norethynodrel, Progesterone, DBP, norethynodrel, Progesterone, AR

4671_task2

Sentence: Screening for (anti)androgenic properties using a standard operation protocol based on the human stably transfected androgen sensitive PALM cell line. First steps towards validation. Despite more than a decade of research in the field of endocrine active compounds targeting the androgen receptor (AR), and although suitable cell lines can be obtained, no validated human stably transfected androgen sensitive transactivation assay is available. Bayer Schering Pharma (BSP) and the Flemish Institute for Technological Research (VITO), partners within the EU-sponsored 6th framework project ReProTect, made first steps towards such a validation. A standard operation protocol (SOP) developed at BSP based on the androgen sensitive PALM cell line was transferred to VITO and its performance and transferability were thoroughly studied. The investigation followed a generic protocol prepared for all reporter gene assays evaluated within ReProTect, and in both laboratories at least three independent experiments were performed. The highest concentration to be tested was limited to 10 microM, if needed. A few compounds, 17alpha-methyltestosterone (17alpha-MT), vinclozolin and linuron, were studied using a real world scenario, i.e., assuming that their interaction with the AR was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening. All other compounds were tested according to the generic protocol: Compounds screened for agonism were the reference androgen 17alpha-methyldihydrotestosterone (MDHT), levonorgestrel, norethynodrel, progesterone, o,p'-DDT, and dibutylphthalate (DBP), while compounds screened for antagonism were the reference anti-androgen flutamide, prochloraz, o,p'-DDT, progesterone, norethynodrel, and DBP. Cytotoxicity was assessed in parallel as lactate dehydrogenase release. The prescreen classified 17alpha-MT as androgenic, vinclozolin and linuron as anti-androgenic and compounds were tested accordingly. In the absence of cytotoxicity, appropriate androgenic properties of reference and test compounds were detected by both laboratories, o,p'-DDT and DBP had no androgenic activity. Across the two laboratories EC(50)-values for MDHT, 17alpha-MT, and levonorgestrel varied by not more than a factor of 3.4, for norethynodrel by a factor of 9.7. Progesterone effects could not fully be evaluated, as frequently concentration response curves were incomplete. In the absence of cytotoxicity anti-androgenic properties of reference and test compounds were also detected in both laboratories. DBP, the putative negative reference compound, was inactive, norethynodrel rather showed agonistic properties. Progesterone was an antagonist at low concentrations, but agonistic properties were observed in one laboratory at high concentrations. Since the highest test concentration was limited to 10 microM, for some compounds no complete concentration response curves were obtained and estimation of EC(50)-values was less robust. Our data demonstrated that the SOP was transferable, and that the assay was able to rank compounds with strong, weak, and without affinity for the AR and to discriminate agonists and antagonists. The sensitivity of the assay could be improved further, if the limit of solubility or beginning cytotoxicity was chosen as the highest test concentration. The assay avoids the use of tissues from laboratory animals, and thus contributes to the 3R concept. Furthermore, it could be adjusted to an intermediate/high throughput format. On the whole, this PALM assay is a promising candidate for further validation. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "I-GENE-Y", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "B-CHEMICAL", "I-CHEMICAL", "I-CHEMICAL", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-GENE-Y", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Screening for (anti)androgenic properties using a standard operation protocol based on the human stably transfected androgen sensitive PALM cell line. First steps towards validation. Despite more than a decade of research in the field of endocrine active compounds targeting the androgen receptor (AR), and although suitable cell lines can be obtained, no validated human stably transfected androgen sensitive transactivation assay is available. Bayer Schering Pharma (BSP) and the Flemish Institute for Technological Research (VITO), partners within the EU-sponsored 6th framework project ReProTect, made first steps towards such a validation. A standard operation protocol (SOP) developed at BSP based on the androgen sensitive PALM cell line was transferred to VITO and its performance and transferability were thoroughly studied. The investigation followed a generic protocol prepared for all reporter gene assays evaluated within ReProTect, and in both laboratories at least three independent experiments were performed. The highest concentration to be tested was limited to 10 microM, if needed. A few compounds, 17alpha-methyltestosterone (17alpha-MT), vinclozolin and linuron, were studied using a real world scenario, i.e., assuming that their interaction with the AR was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening. All other compounds were tested according to the generic protocol: Compounds screened for agonism were the reference androgen 17alpha-methyldihydrotestosterone (MDHT), levonorgestrel, norethynodrel, progesterone, o,p'-DDT, and dibutylphthalate (DBP), while compounds screened for antagonism were the reference anti-androgen flutamide, prochloraz, o,p'-DDT, progesterone, norethynodrel, and DBP. Cytotoxicity was assessed in parallel as lactate dehydrogenase release. The prescreen classified 17alpha-MT as androgenic, vinclozolin and linuron as anti-androgenic and compounds were tested accordingly. In the absence of cytotoxicity, appropriate androgenic properties of reference and test compounds were detected by both laboratories, o,p'-DDT and DBP had no androgenic activity. Across the two laboratories EC(50)-values for MDHT, 17alpha-MT, and levonorgestrel varied by not more than a factor of 3.4, for norethynodrel by a factor of 9.7. Progesterone effects could not fully be evaluated, as frequently concentration response curves were incomplete. In the absence of cytotoxicity anti-androgenic properties of reference and test compounds were also detected in both laboratories. DBP, the putative negative reference compound, was inactive, norethynodrel rather showed agonistic properties. Progesterone was an antagonist at low concentrations, but agonistic properties were observed in one laboratory at high concentrations. Since the highest test concentration was limited to 10 microM, for some compounds no complete concentration response curves were obtained and estimation of EC(50)-values was less robust. Our data demonstrated that the SOP was transferable, and that the assay was able to rank compounds with strong, weak, and without affinity for the AR and to discriminate agonists and antagonists. The sensitivity of the assay could be improved further, if the limit of solubility or beginning cytotoxicity was chosen as the highest test concentration. The assay avoids the use of tissues from laboratory animals, and thus contributes to the 3R concept. Furthermore, it could be adjusted to an intermediate/high throughput format. On the whole, this PALM assay is a promising candidate for further validation.

[ "Screening", "for", "(", "anti)androgenic", "properties", "using", "a", "standard", "operation", "protocol", "based", "on", "the", "human", "stably", "transfected", "androgen", "sensitive", "PALM", "cell", "line", ".", "First", "steps", "towards", "validation", ".", "\n", "Despite", "more", "than", "a", "decade", "of", "research", "in", "the", "field", "of", "endocrine", "active", "compounds", "targeting", "the", "androgen", "receptor", "(", "AR", ")", ",", "and", "although", "suitable", "cell", "lines", "can", "be", "obtained", ",", "no", "validated", "human", "stably", "transfected", "androgen", "sensitive", "transactivation", "assay", "is", "available", ".", "Bayer", "Schering", "Pharma", "(", "BSP", ")", "and", "the", "Flemish", "Institute", "for", "Technological", "Research", "(", "VITO", ")", ",", "partners", "within", "the", "EU", "-", "sponsored", "6th", "framework", "project", "ReProTect", ",", "made", "first", "steps", "towards", "such", "a", "validation", ".", "A", "standard", "operation", "protocol", "(", "SOP", ")", "developed", "at", "BSP", "based", "on", "the", "androgen", "sensitive", "PALM", "cell", "line", "was", "transferred", "to", "VITO", "and", "its", "performance", "and", "transferability", "were", "thoroughly", "studied", ".", "The", "investigation", "followed", "a", "generic", "protocol", "prepared", "for", "all", "reporter", "gene", "assays", "evaluated", "within", "ReProTect", ",", "and", "in", "both", "laboratories", "at", "least", "three", "independent", "experiments", "were", "performed", ".", "The", "highest", "concentration", "to", "be", "tested", "was", "limited", "to", "10", "microM", ",", "if", "needed", ".", "A", "few", "compounds", ",", "17alpha", "-", "methyltestosterone", "(", "17alpha", "-", "MT", ")", ",", "vinclozolin", "and", "linuron", ",", "were", "studied", "using", "a", "real", "world", "scenario", ",", "i.e", ".", ",", "assuming", "that", "their", "interaction", "with", "the", "AR", "was", "not", "known", ":", "A", "prescreening", "for", "agonism", "and", "true", ",", "competitive", "antagonism", "was", "used", "to", "select", "conditions", "such", "as", "the", "appropriate", "mode", "of", "action", ",", "and", "the", "working", "range", "excluding", "cytotoxicity", "for", "the", "final", "screening", ".", "All", "other", "compounds", "were", "tested", "according", "to", "the", "generic", "protocol", ":", "Compounds", "screened", "for", "agonism", "were", "the", "reference", "androgen", "17alpha", "-", "methyldihydrotestosterone", "(", "MDHT", ")", ",", "levonorgestrel", ",", "norethynodrel", ",", "progesterone", ",", "o", ",", "p'-DDT", ",", "and", "dibutylphthalate", "(", "DBP", ")", ",", "while", "compounds", "screened", "for", "antagonism", "were", "the", "reference", "anti", "-", "androgen", "flutamide", ",", "prochloraz", ",", "o", ",", "p'-DDT", ",", "progesterone", ",", "norethynodrel", ",", "and", "DBP", ".", "Cytotoxicity", "was", "assessed", "in", "parallel", "as", "lactate", "dehydrogenase", "release", ".", "The", "prescreen", "classified", "17alpha", "-", "MT", "as", "androgenic", ",", "vinclozolin", "and", "linuron", "as", "anti", "-", "androgenic", "and", "compounds", "were", "tested", "accordingly", ".", "In", "the", "absence", "of", "cytotoxicity", ",", "appropriate", "androgenic", "properties", "of", "reference", "and", "test", "compounds", "were", "detected", "by", "both", "laboratories", ",", "o", ",", "p'-DDT", "and", "DBP", "had", "no", "androgenic", "activity", ".", "Across", "the", "two", "laboratories", "EC(50)-values", "for", "MDHT", ",", "17alpha", "-", "MT", ",", "and", "levonorgestrel", "varied", "by", "not", "more", "than", "a", "factor", "of", "3.4", ",", "for", "norethynodrel", "by", "a", "factor", "of", "9.7", ".", "Progesterone", "effects", "could", "not", "fully", "be", "evaluated", ",", "as", "frequently", "concentration", "response", "curves", "were", "incomplete", ".", "In", "the", "absence", "of", "cytotoxicity", "anti", "-", "androgenic", "properties", "of", "reference", "and", "test", "compounds", "were", "also", "detected", "in", "both", "laboratories", ".", "DBP", ",", "the", "putative", "negative", "reference", "compound", ",", "was", "inactive", ",", "norethynodrel", "rather", "showed", "agonistic", "properties", ".", "Progesterone", "was", "an", "antagonist", "at", "low", "concentrations", ",", "but", "agonistic", "properties", "were", "observed", "in", "one", "laboratory", "at", "high", "concentrations", ".", "Since", "the", "highest", "test", "concentration", "was", "limited", "to", "10", "microM", ",", "for", "some", "compounds", "no", "complete", "concentration", "response", "curves", "were", "obtained", "and", "estimation", "of", "EC(50)-values", "was", "less", "robust", ".", "Our", "data", "demonstrated", "that", "the", "SOP", "was", "transferable", ",", "and", "that", "the", "assay", "was", "able", "to", "rank", "compounds", "with", "strong", ",", "weak", ",", "and", "without", "affinity", "for", "the", "AR", "and", "to", "discriminate", "agonists", "and", "antagonists", ".", "The", "sensitivity", "of", "the", "assay", "could", "be", "improved", "further", ",", "if", "the", "limit", "of", "solubility", "or", "beginning", "cytotoxicity", "was", "chosen", "as", "the", "highest", "test", "concentration", ".", "The", "assay", "avoids", "the", "use", "of", "tissues", "from", "laboratory", "animals", ",", "and", "thus", "contributes", "to", "the", "3R", "concept", ".", "Furthermore", ",", "it", "could", "be", "adjusted", "to", "an", "intermediate", "/", "high", "throughput", "format", ".", "On", "the", "whole", ",", "this", "PALM", "assay", "is", "a", "promising", "candidate", "for", "further", "validation", "." ]

[ "CHEMICAL", "GENE-N", "GENE-Y" ]

Gram - positive is a Phenotype, Actinobacteria is a Microorganism, Corynebacterium casei is a Microorganism, C. variabile is a Microorganism, cheese from dairy A is a Habitat, Brachybacterium alimentarum is a Microorganism, Brevibacterium is a Microorganism, cheeses from the farmhouses is a Habitat, dairies is a Habitat, B. permense is a Microorganism, cheese from dairy A is a Habitat, B. linens is a Microorganism, cheese from dairy B is a Habitat, B. aurantiacum is a Microorganism, dairy is a Habitat, Brevibacterium spp . is a Microorganism, dairy is a Habitat, coagulase negative is a Phenotype, staphylococci is a Microorganism, Staphylococcus saprophyticus is a Microorganism, cheeses from dairies B is a Habitat, Staph . equorum is a Microorganism, cheeses from dairies C is a Habitat, Gram - negative is a Phenotype, Proteus vulgaris is a Microorganism, Alcaligenes faecalis is a Microorganism, dairy is a Habitat, surface yeast microbiota is a Habitat, yeast surface microbiota is a Habitat, farmhouse cheeses is a Habitat, cheese is a Habitat, industrial dairy is a Habitat, dairy is a Habitat, cheese from dairy A is a Habitat, Yarrowia lipolytica is a Microorganism, Scopulariopsis brevicaulis is a Microorganism, yeast microbiota is a Habitat, cheese from dairy B is a Habitat, Geotrichum spp . is a Microorganism, Kluyveromyces marxianus is a Microorganism, Debaryomyces hansenii is a Microorganism, cheese from dairy C is a Habitat, D. hansenii is a Microorganism, Geothrichum spp . is a Microorganism, cheese from dairy D is a Habitat, D. hansenii is a Microorganism

101_task0

Sentence: Most species were Gram-positive Actinobacteria with Corynebacterium casei and/or C. variabile as the predominant (Table 4). Additionally, the cheese from dairy A was dominated by high of numbers of Brachybacterium alimentarum. Various Brevibacterium species were found on the cheeses from the farmhouses (dairies A, B and C). B. permense was found on the cheese from dairy A, B. linens was found on the cheese from dairy B and B. aurantiacum was found on the cheese from dairy C. Brevibacterium spp. could not be isolated on the cheese from dairy D. Furthermore, a number of coagulase negative staphylococci were found, i.e., Staphylococcus saprophyticus on the cheeses from dairies B and D, and Staph. equorum on the cheeses from dairies C and D. Finally, a number of Gram-negative bacteria species including Proteus vulgaris and Alcaligenes faecalis was found on the cheese from dairy C.Figure 3 shows the grouping of the surface yeast microbiota. The yeast surface microbiota on the three farmhouse cheeses consisted of two to four groups, whereas the cheese produced at the industrial dairy (dairy D) consisted of only one single group. The cheese from dairy A was equally dominated by Yarrowia lipolytica and Scopulariopsis brevicaulis. The yeast microbiota on cheese from dairy B was primarily dominated by Geotrichum spp., however, Kluyveromyces marxianus and Debaryomyces hansenii were additionally found in minor amounts. The cheese from dairy C was dominated by D. hansenii followed by a minor group of Geothrichum spp. Finally, the cheese from dairy D was entirely dominated by D. hansenii. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Microorganism, Phenotype, Habitat

[ "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "B-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "B-Microorganism", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O" ]

Most species were Gram-positive Actinobacteria with Corynebacterium casei and/or C. variabile as the predominant (Table 4). Additionally, the cheese from dairy A was dominated by high of numbers of Brachybacterium alimentarum. Various Brevibacterium species were found on the cheeses from the farmhouses (dairies A, B and C). B. permense was found on the cheese from dairy A, B. linens was found on the cheese from dairy B and B. aurantiacum was found on the cheese from dairy C. Brevibacterium spp. could not be isolated on the cheese from dairy D. Furthermore, a number of coagulase negative staphylococci were found, i.e., Staphylococcus saprophyticus on the cheeses from dairies B and D, and Staph. equorum on the cheeses from dairies C and D. Finally, a number of Gram-negative bacteria species including Proteus vulgaris and Alcaligenes faecalis was found on the cheese from dairy C.Figure 3 shows the grouping of the surface yeast microbiota. The yeast surface microbiota on the three farmhouse cheeses consisted of two to four groups, whereas the cheese produced at the industrial dairy (dairy D) consisted of only one single group. The cheese from dairy A was equally dominated by Yarrowia lipolytica and Scopulariopsis brevicaulis. The yeast microbiota on cheese from dairy B was primarily dominated by Geotrichum spp., however, Kluyveromyces marxianus and Debaryomyces hansenii were additionally found in minor amounts. The cheese from dairy C was dominated by D. hansenii followed by a minor group of Geothrichum spp. Finally, the cheese from dairy D was entirely dominated by D. hansenii.

[ "Most", "species", "were", "Gram", "-", "positive", "Actinobacteria", "with", "Corynebacterium", "casei", "and", "/", "or", "C.", "variabile", "as", "the", "predominant", "(", "Table", "4", ")", ".", "Additionally", ",", "the", "cheese", "from", "dairy", "A", "was", "dominated", "by", "high", "of", "numbers", "of", "Brachybacterium", "alimentarum", ".", "Various", "Brevibacterium", "species", "were", "found", "on", "the", "cheeses", "from", "the", "farmhouses", "(", "dairies", "A", ",", "B", "and", "C", ")", ".", "B.", "permense", "was", "found", "on", "the", "cheese", "from", "dairy", "A", ",", "B.", "linens", "was", "found", "on", "the", "cheese", "from", "dairy", "B", "and", "B.", "aurantiacum", "was", "found", "on", "the", "cheese", "from", "dairy", "C.", "Brevibacterium", " ", "spp", ".", "could", "not", "be", "isolated", "on", "the", "cheese", "from", "dairy", "D.", "Furthermore", ",", "a", " ", "number", "of", "coagulase", "negative", "staphylococci", "were", "found", ",", "i.e", ".", ",", "Staphylococcus", "saprophyticus", "on", "the", "cheeses", "from", "dairies", "B", "and", "D", ",", "and", "Staph", ".", "equorum", "on", "the", "cheeses", "from", "dairies", "C", "and", "D.", "Finally", ",", "a", "number", "of", "Gram", "-", "negative", "bacteria", "species", "including", "Proteus", "vulgaris", "and", "Alcaligenes", "faecalis", "was", "found", "on", "the", "cheese", "from", "dairy", "C.Figure", "3", " ", "shows", "the", "grouping", "of", "the", "surface", "yeast", "microbiota", ".", "The", "yeast", "surface", " ", "microbiota", "on", "the", "three", "farmhouse", "cheeses", "consisted", "of", "two", "to", "four", " ", "groups", ",", "whereas", "the", "cheese", "produced", "at", "the", "industrial", "dairy", "(", "dairy", "D", ")", " ", "consisted", "of", "only", "one", "single", "group", ".", "The", "cheese", "from", "dairy", "A", "was", "equally", " ", "dominated", "by", "Yarrowia", "lipolytica", "and", "Scopulariopsis", "brevicaulis", ".", "The", "yeast", "microbiota", "on", "cheese", "from", "dairy", "B", "was", "primarily", "dominated", "by", "Geotrichum", "spp", ".", ",", "however", ",", "Kluyveromyces", "marxianus", "and", "Debaryomyces", "hansenii", "were", "additionally", "found", "in", "minor", "amounts", ".", "The", "cheese", "from", "dairy", "C", "was", "dominated", "by", "D.", "hansenii", "followed", "by", "a", "minor", "group", "of", "Geothrichum", "spp", ".", "Finally", ",", "the", "cheese", "from", "dairy", "D", "was", "entirely", "dominated", "by", "D.", "hansenii", "." ]

[ "Microorganism", "Habitat", "Phenotype" ]

Gram - positive is a Phenotype, Actinobacteria is a Microorganism, Corynebacterium casei is a Microorganism, C. variabile is a Microorganism, cheese from dairy A is a Habitat, Brachybacterium alimentarum is a Microorganism, Brevibacterium is a Microorganism, cheeses from the farmhouses is a Habitat, dairies is a Habitat, B. permense is a Microorganism, cheese from dairy A is a Habitat, B. linens is a Microorganism, cheese from dairy B is a Habitat, B. aurantiacum is a Microorganism, dairy is a Habitat, Brevibacterium spp . is a Microorganism, dairy is a Habitat, coagulase negative is a Phenotype, staphylococci is a Microorganism, Staphylococcus saprophyticus is a Microorganism, cheeses from dairies B is a Habitat, Staph . equorum is a Microorganism, cheeses from dairies C is a Habitat, Gram - negative is a Phenotype, Proteus vulgaris is a Microorganism, Alcaligenes faecalis is a Microorganism, dairy is a Habitat, surface yeast microbiota is a Habitat, yeast surface microbiota is a Habitat, farmhouse cheeses is a Habitat, cheese is a Habitat, industrial dairy is a Habitat, dairy is a Habitat, cheese from dairy A is a Habitat, Yarrowia lipolytica is a Microorganism, Scopulariopsis brevicaulis is a Microorganism, yeast microbiota is a Habitat, cheese from dairy B is a Habitat, Geotrichum spp . is a Microorganism, Kluyveromyces marxianus is a Microorganism, Debaryomyces hansenii is a Microorganism, cheese from dairy C is a Habitat, D. hansenii is a Microorganism, Geothrichum spp . is a Microorganism, cheese from dairy D is a Habitat, D. hansenii is a Microorganism

101_task1

Sentence: Most species were Gram-positive Actinobacteria with Corynebacterium casei and/or C. variabile as the predominant (Table 4). Additionally, the cheese from dairy A was dominated by high of numbers of Brachybacterium alimentarum. Various Brevibacterium species were found on the cheeses from the farmhouses (dairies A, B and C). B. permense was found on the cheese from dairy A, B. linens was found on the cheese from dairy B and B. aurantiacum was found on the cheese from dairy C. Brevibacterium spp. could not be isolated on the cheese from dairy D. Furthermore, a number of coagulase negative staphylococci were found, i.e., Staphylococcus saprophyticus on the cheeses from dairies B and D, and Staph. equorum on the cheeses from dairies C and D. Finally, a number of Gram-negative bacteria species including Proteus vulgaris and Alcaligenes faecalis was found on the cheese from dairy C.Figure 3 shows the grouping of the surface yeast microbiota. The yeast surface microbiota on the three farmhouse cheeses consisted of two to four groups, whereas the cheese produced at the industrial dairy (dairy D) consisted of only one single group. The cheese from dairy A was equally dominated by Yarrowia lipolytica and Scopulariopsis brevicaulis. The yeast microbiota on cheese from dairy B was primarily dominated by Geotrichum spp., however, Kluyveromyces marxianus and Debaryomyces hansenii were additionally found in minor amounts. The cheese from dairy C was dominated by D. hansenii followed by a minor group of Geothrichum spp. Finally, the cheese from dairy D was entirely dominated by D. hansenii. Instructions: please typing these entity words according to sentence: Gram - positive, Actinobacteria, Corynebacterium casei, C. variabile, cheese from dairy A, Brachybacterium alimentarum, Brevibacterium, cheeses from the farmhouses, dairies, B. permense, cheese from dairy A, B. linens, cheese from dairy B, B. aurantiacum, dairy, Brevibacterium spp ., dairy, coagulase negative, staphylococci, Staphylococcus saprophyticus, cheeses from dairies B, Staph . equorum, cheeses from dairies C, Gram - negative, Proteus vulgaris, Alcaligenes faecalis, dairy, surface yeast microbiota, yeast surface microbiota, farmhouse cheeses, cheese, industrial dairy, dairy, cheese from dairy A, Yarrowia lipolytica, Scopulariopsis brevicaulis, yeast microbiota, cheese from dairy B, Geotrichum spp ., Kluyveromyces marxianus, Debaryomyces hansenii, cheese from dairy C, D. hansenii, Geothrichum spp ., cheese from dairy D, D. hansenii Options: Microorganism, Phenotype, Habitat

[ "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "B-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "B-Microorganism", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "B-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "B-Habitat", "I-Habitat", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "I-Microorganism", "O", "O", "O", "B-Habitat", "I-Habitat", "I-Habitat", "I-Habitat", "O", "O", "O", "O", "B-Microorganism", "I-Microorganism", "O" ]

Most species were Gram-positive Actinobacteria with Corynebacterium casei and/or C. variabile as the predominant (Table 4). Additionally, the cheese from dairy A was dominated by high of numbers of Brachybacterium alimentarum. Various Brevibacterium species were found on the cheeses from the farmhouses (dairies A, B and C). B. permense was found on the cheese from dairy A, B. linens was found on the cheese from dairy B and B. aurantiacum was found on the cheese from dairy C. Brevibacterium spp. could not be isolated on the cheese from dairy D. Furthermore, a number of coagulase negative staphylococci were found, i.e., Staphylococcus saprophyticus on the cheeses from dairies B and D, and Staph. equorum on the cheeses from dairies C and D. Finally, a number of Gram-negative bacteria species including Proteus vulgaris and Alcaligenes faecalis was found on the cheese from dairy C.Figure 3 shows the grouping of the surface yeast microbiota. The yeast surface microbiota on the three farmhouse cheeses consisted of two to four groups, whereas the cheese produced at the industrial dairy (dairy D) consisted of only one single group. The cheese from dairy A was equally dominated by Yarrowia lipolytica and Scopulariopsis brevicaulis. The yeast microbiota on cheese from dairy B was primarily dominated by Geotrichum spp., however, Kluyveromyces marxianus and Debaryomyces hansenii were additionally found in minor amounts. The cheese from dairy C was dominated by D. hansenii followed by a minor group of Geothrichum spp. Finally, the cheese from dairy D was entirely dominated by D. hansenii.

[ "Most", "species", "were", "Gram", "-", "positive", "Actinobacteria", "with", "Corynebacterium", "casei", "and", "/", "or", "C.", "variabile", "as", "the", "predominant", "(", "Table", "4", ")", ".", "Additionally", ",", "the", "cheese", "from", "dairy", "A", "was", "dominated", "by", "high", "of", "numbers", "of", "Brachybacterium", "alimentarum", ".", "Various", "Brevibacterium", "species", "were", "found", "on", "the", "cheeses", "from", "the", "farmhouses", "(", "dairies", "A", ",", "B", "and", "C", ")", ".", "B.", "permense", "was", "found", "on", "the", "cheese", "from", "dairy", "A", ",", "B.", "linens", "was", "found", "on", "the", "cheese", "from", "dairy", "B", "and", "B.", "aurantiacum", "was", "found", "on", "the", "cheese", "from", "dairy", "C.", "Brevibacterium", " ", "spp", ".", "could", "not", "be", "isolated", "on", "the", "cheese", "from", "dairy", "D.", "Furthermore", ",", "a", " ", "number", "of", "coagulase", "negative", "staphylococci", "were", "found", ",", "i.e", ".", ",", "Staphylococcus", "saprophyticus", "on", "the", "cheeses", "from", "dairies", "B", "and", "D", ",", "and", "Staph", ".", "equorum", "on", "the", "cheeses", "from", "dairies", "C", "and", "D.", "Finally", ",", "a", "number", "of", "Gram", "-", "negative", "bacteria", "species", "including", "Proteus", "vulgaris", "and", "Alcaligenes", "faecalis", "was", "found", "on", "the", "cheese", "from", "dairy", "C.Figure", "3", " ", "shows", "the", "grouping", "of", "the", "surface", "yeast", "microbiota", ".", "The", "yeast", "surface", " ", "microbiota", "on", "the", "three", "farmhouse", "cheeses", "consisted", "of", "two", "to", "four", " ", "groups", ",", "whereas", "the", "cheese", "produced", "at", "the", "industrial", "dairy", "(", "dairy", "D", ")", " ", "consisted", "of", "only", "one", "single", "group", ".", "The", "cheese", "from", "dairy", "A", "was", "equally", " ", "dominated", "by", "Yarrowia", "lipolytica", "and", "Scopulariopsis", "brevicaulis", ".", "The", "yeast", "microbiota", "on", "cheese", "from", "dairy", "B", "was", "primarily", "dominated", "by", "Geotrichum", "spp", ".", ",", "however", ",", "Kluyveromyces", "marxianus", "and", "Debaryomyces", "hansenii", "were", "additionally", "found", "in", "minor", "amounts", ".", "The", "cheese", "from", "dairy", "C", "was", "dominated", "by", "D.", "hansenii", "followed", "by", "a", "minor", "group", "of", "Geothrichum", "spp", ".", "Finally", ",", "the", "cheese", "from", "dairy", "D", "was", "entirely", "dominated", "by", "D.", "hansenii", "." ]

[ "Microorganism", "Habitat", "Phenotype" ]